<SEC-DOCUMENT>0001628280-24-010725.txt : 20240313
<SEC-HEADER>0001628280-24-010725.hdr.sgml : 20240313
<ACCEPTANCE-DATETIME>20240312211411
ACCESSION NUMBER:		0001628280-24-010725
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		114
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240313
DATE AS OF CHANGE:		20240312

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		24744328

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>cpix-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cpix="http://www.cumberlandpharma.com/20231231" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2023" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cpix-20231231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-21">True</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-22">False</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-23">0001087294</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" id="f-24">Non-accelerated Filer</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-month-day-year" id="f-25">12/31/2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-26">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-27">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-28">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-29">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-30">TRUE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-31">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-32">No</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-33">No</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-34">Yes</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-35">Yes</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" id="f-36">--12-31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cpix-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManufacturedProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManufacturedProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:HongKongWinHealthPharmaGroupCoLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">cpix:CumberlandEmergingTechnologiesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>cpix:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cpix:AccountsReceivableAllowancesByComponentAxis">cpix:ChargebacksCashDiscountsAndDamagedGoodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-27</xbrli:startDate><xbrli:endDate>2021-12-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:WinHealthInvestmentSingaporeLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:MartinS.BrownJr.sLawFirmMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:MartinS.BrownJr.sLawFirmMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:ProductAssetsAndGlobalRightsVibativMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:ProductAssetsAndGlobalRightsVibativMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:ProductAssetsAndGlobalRightsVibativMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:ProductAssetsAndGlobalRightsVibativMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:ProductAssetsAndGlobalRightsVibativMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:ProductAssetsAndGlobalRightsVibativMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:ProductAssetsAndGlobalRightsVibativMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:ProductAssetsAndGlobalRightsVibativMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:U.S.ProductAssetRightsSancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:U.S.ProductAssetRightsSancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:U.S.ProductAssetRightsSancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:U.S.ProductAssetRightsSancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:U.S.ProductAssetRightsSancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:U.S.ProductAssetRightsSancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:U.S.ProductAssetRightsSancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:U.S.ProductAssetRightsSancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:U.S.ProductAssetRightsSancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:U.S.ProductAssetRightsSancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicGroupBVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:MethotrexateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-01</xbrli:startDate><xbrli:endDate>2016-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicGroupBVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:MethotrexateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-01</xbrli:startDate><xbrli:endDate>2016-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicGroupBVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:MethotrexateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-27</xbrli:startDate><xbrli:endDate>2019-11-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicGroupBVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:MethotrexateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicGroupBVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:MethotrexateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicGroupBVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-12</xbrli:startDate><xbrli:endDate>2022-07-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicGroupBVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductKristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductKristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductVibativMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductVibativMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductSancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductSancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductCaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductCaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductAcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductAcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductOmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductOmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductVaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductVaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductRediTrexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductRediTrexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VibativMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="payment"><xbrli:measure>cpix:payment</xbrli:measure></xbrli:unit><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:FederalGrantProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:FederalGrantProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VibativMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:PublicUtilitiesInventoryRawMaterialsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VibativMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:PublicUtilitiesInventoryRawMaterialsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VibativMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:FinishedGoodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VibativMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:FinishedGoodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:PublicUtilitiesInventoryRawMaterialsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:PublicUtilitiesInventoryRawMaterialsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:PublicUtilitiesInventoryRawMaterialsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:PublicUtilitiesInventoryRawMaterialsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:FinishedGoodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:FinishedGoodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:PublicUtilitiesInventoryRawMaterialsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:SancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:PublicUtilitiesInventoryRawMaterialsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:SancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:PublicUtilitiesInventoryRawMaterialsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:StudyDrugMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:PublicUtilitiesInventoryRawMaterialsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:StudyDrugMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:StudyDrugMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:FinishedGoodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:StudyDrugMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:FinishedGoodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VibativMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:ActivePharmaceuticalIngredientAPIAndWorkInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cpix:ProductAndLicenseRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cpix:ProductAndLicenseRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-05</xbrli:startDate><xbrli:endDate>2023-09-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-05</xbrli:startDate><xbrli:endDate>2023-09-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-08-09</xbrli:startDate><xbrli:endDate>2009-08-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2010-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:IndefiniteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:IndefiniteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cpix:FederalAndStateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cpix:FederalAndStateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cpix:FederalAndStateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="plan"><xbrli:measure>cpix:plan</xbrli:measure></xbrli:unit><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cpix:LongTermIncentiveCompensationPlan2007Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cpix:DirectorsIncentivePlan2007Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:NonprincipalOwnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:NonprincipalOwnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cpix:BroadwestLeaseFiveYearRenewalOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="renewalterm"><xbrli:measure>cpix:renewalTerm</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerSqft"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NephronPharmaceuticalsCorporationNephronMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:A1600WestEndAvenuePartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:A1600WestEndAvenuePartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:Customer12And3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:Customer12And3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="supplier"><xbrli:measure>cpix:supplier</xbrli:measure></xbrli:unit><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:U.S.ProductAssetRightsSancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cpix:CollaborativeArrangementMilestonePaymentThresholdAxis">cpix:Within30DaysOfFirstSNDAFilingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cpix:CollaborativeArrangementMilestonePaymentThresholdAxis">cpix:FollowingApprovalOfFirstSNDAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i3928a3425fef4184806511a3516ffab1_1"></div><div style="min-height:36pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________________________________________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="padding-left:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">December 31, 2023</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">CUMBERLAND PHARMACEUTICALS INC</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:26pt;font-weight:700;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A <ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Tennessee</ix:nonNumeric> Corporation</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IRS Employer Identification No. <ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-5">62-1765329</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commission file number&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-33637</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">1600 West End Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">Suite 1300</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">Nashville</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-10">Tennessee</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">37203</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">615</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">255-0068</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.666%"><tr><td style="width:1.0%"/><td style="width:37.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.922%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.003%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.540%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Title of each class</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trading Symbol(s)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Name of each exchange on which registered</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-14">Common Stock, $0.00 par value per share</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-15">CPIX</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-16">Nasdaq Global Select Market</ix:nonNumeric></span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Securities registered pursuant to Section 12(g) of the Act:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">None</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. is not a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. &#160;&#160;&#160;&#160;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. is required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months, and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. is a non-accelerated filer and a smaller reporting company as defined in Rule&#160;12b-2 of the Exchange Act and is not a shell company.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. has not filed a report on and attestation to its management's assessment of  the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared and issued its audit report.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value of common stock held by non-affiliates as of June&#160;30, 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="f-17">12,061,328</ix:nonFraction>. The number of shares of the registrant&#8217;s Common Stock, no par value, outstanding as of March&#160;8, 2024 was <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-18">14,176,529</ix:nonFraction>.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-19">&#9744;</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:2pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-20" escape="true"><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain information required in Part III of Form 10-K is incorporated by reference from the registrant&#8217;s Proxy Statement for its 2024 annual meeting of shareholders.</span></div></ix:nonNumeric><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i3928a3425fef4184806511a3516ffab1_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Index</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"/><td style="width:77.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.387%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Page Number</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_10">PART I</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_10">1</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_13">Item&#160;1: Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_13">1</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_76">Item&#160;1A: Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_76">34</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_94">Item&#160;1B: Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_94">56</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_1247">Item 1C. Cybersecurity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_1247">56</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_97">Item&#160;2: Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_97">57</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_100">Item&#160;3: Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_100">57</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_103">Item&#160;4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_103">57</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_106">PART II</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_106">57</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_109">Item 5: Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_109">57</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_112">Item&#160;6: Reserved</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_112">59</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_115">Item&#160;7: Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_115">59</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_136">Item&#160;7A: Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_136">70</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_139">Item&#160;8: Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_139">71</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_142">Item&#160;9: Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_142">71</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_145">Item&#160;9A: Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_145">71</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_148">Item&#160;9B: Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_148">72</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_151">Item 9C: Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_151">73</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_154">PART III</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_154">73</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_157">PART IV</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_157">74</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_160">Item&#160;15: Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_157">74</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_163">Item 16: Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_163">78</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_166">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_166">79</a></span></div></td></tr></table></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i3928a3425fef4184806511a3516ffab1_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i3928a3425fef4184806511a3516ffab1_13"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;1. Business.</span></div><div id="i3928a3425fef4184806511a3516ffab1_16"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE COMPANY</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;our&#8221;), is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. We are dedicated to providing innovative products that improve the quality of care for patients and address poorly met medical needs.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary target markets are hospital acute care, gastroenterology and oncology. These medical specialties are characterized by relatively concentrated prescriber bases that we believe can be served effectively by small, targeted sales forces. We promote our approved products through our hospital, field and oncology sales divisions in the United States while we continue to build a network of international partners to register and provide our medicines to patients in their countries. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of brands approved for marketing by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) includes:</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Acetadote</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">acetylcysteine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) injection, for the treatment of acetaminophen poisoning; </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Caldolor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ibuprofen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) injection, for the treatment of pain and fever;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Kristalose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">lactulose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for oral solution, a prescription laxative, for the treatment of constipation;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Omeclamox</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-Pak</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">omeprazole, clarithromycin, amoxicillin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) oral, for the treatment of Helicobacter pylori (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">H. pylori</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) infection and related duodenal ulcer disease;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.15pt">Sancuso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">granisetron)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Vaprisol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">conivaptan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Vibativ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">telavancin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to these commercial brands, we have Phase II clinical programs underway evaluating our ifetroban product candidate in 1) Systemic Sclerosis (&#8220;SSc&#8221;) or scleroderma, a debilitating autoimmune disorder characterized by diffuse fibrosis of the skin and internal organs, 2) patients with cardiomyopathy associated with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Duchenne Muscular Dystrophy </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;DMD&#8221;), a rare, fatal, genetic neuromuscular disease results in deterioration of the skeletal, heart and lung muscles and 3) patients with Idiopathic Pulmonary Fibrosis (&#8220;IPF&#8221;), the most common form of progressive fibrosing interstitial lung disease. Investigational new study applications have been cleared by the FDA enabling us to launch clinical studies in each of these areas. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has built core competencies for the acquisition, development and commercialization of pharmaceutical products in the U.S. &#8211; and we believe we can leverage this existing infrastructure to support our continued growth. Our management team consists of pharmaceutical industry veterans with experience in business development, product development, regulatory, manufacturing, sales, marketing and finance.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business development team identifies, evaluates, and negotiates product acquisition, licensing and co- promotion agreements. Our product development team creates proprietary formulations, manages our clinical studies, prepares our FDA submissions and staffs our medical call center. Our quality and manufacturing professionals oversee the manufacturing, release and shipment of our products. Our marketing and sales organization is responsible for our commercial activities, and we work closely with our distribution partners to ensure the availability and delivery of our products.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i3928a3425fef4184806511a3516ffab1_19"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Mission</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year we took a fresh look at our mission statement and refined it to better capture the spirit of what we do each day at Cumberland. Our mission is now: working together to provide unique products that improve the quality of patient care.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing this statement, we considered several factors.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First, we wanted our mission to address the constituencies we serve, which include patients in need of care, as well as health care providers, our employees, shareholders, partners and community.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also sought to reflect Cumberland&#8217;s culture, where teamwork is prized, emphasized and expected &#8211; in order to achieve our goals.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Next, it needed to demonstrate our focus on developing, acquiring and distributing differentiated brands.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">And finally, we wanted to emphasize that the patient is at the core of everything we do. Our collective efforts are directed at providing unique products that serve as better alternatives for poorly met medical needs.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sustainability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Metrics</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued our inaugural Sustainability Report in 2019, detailing Cumberland&#8217;s activities pertaining to our environmental, social and governance matters, and we remain committed to sustainability and to maintaining transparency of our corporate operations. As one of the largest biopharmaceutical companies founded and headquartered in the Mid-South, we hold ourselves to the highest standards of ethical practices and understand the importance of recognizing and addressing our impact on our constituents, our community and the environment.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2023 sustainability metrics reveal that during that year we provided 3 million patient doses of our products, while safely disposing of nearly 6,000 pounds of expired and damaged products. We had no product recalls and no clinical trials terminated due to failure to practice good clinical standards.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we also highlighted our investment in our employees through our continuing education programs, employee development initiatives and employee recognition awards. We reported that women represented 44% of Cumberland&#8217;s workforce &#8211; and 15% of our employees were minorities.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our sustainability initiatives, we will continue to identify and address critical industry issues, monitor relevant guidelines and utilize best practices.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional Information</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in 1999 and have been headquartered in Nashville, Tennessee since inception. During 2009, we completed an initial public offering of our common shares and listing on the Nasdaq stock exchange. Our website address is </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.cumberlandpharma.com</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Annual Reports (on Form 10-K), Quarterly Reports (on Form 10-Q), Current Reports (on Form 8-K) and all material press releases are available on our website as soon as reasonably practicable after their filing with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). These filings are also available to the public at </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.sec.gov.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRODUCTS</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.794%"><tr><td style="width:1.0%"/><td style="width:30.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:51.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.975%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetaminophen Poisoning</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pain and Fever</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic and Acute Constipation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Pak</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">H. pylori Infection and Related Duodenal Ulcer Disease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nausea and Vomiting Associated with Chemotherapy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euvolemic and Hypervolemic Hyponatremia</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Serious Bacterial Infections</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed</span></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acetadote</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acetadote is an intravenous formulation of N-acetylcysteine, indicated for the treatment of liver toxicity associated with acetaminophen poisoning. Cumberland developed and obtained U.S. FDA approval for Acetadote, and then introduced the product through our hospital sales force. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acetadote is typically used in hospital emergency departments to prevent or lessen potential liver damage resulting from an overdose of acetaminophen, a common ingredient in many over-the-counter and prescription pain- relieving and fever-reducing products. Acetaminophen overdose continues to be a leading cause of poisonings reported by hospital emergency departments in the U.S., and Acetadote has become a standard of care for treating this potentially life-threatening condition.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acetadote received U.S. FDA approval as an orphan drug, which provided seven years of marketing exclusivity from the date of approval. That exclusivity has since expired.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the FDA&#8217;s approval of Acetadote, we committed to certain post-marketing activities for the product. Completion of our first Phase IV commitment resulted in the FDA&#8217;s approval of expanded labeling for the product for use in pediatric patients. Completion of our second Phase IV commitment resulted in further revised labeling for the product with FDA approval of additional safety data.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Completion of our third and final Phase IV commitment culminated in the FDA&#8217;s approval of a new formulation for the product. The next generation formulation contains no ethylene diamine tetracetic acid (&#8220;EDTA&#8221;) or other stabilization agent, chelating agent or preservative. Cumberland introduced this new Acetadote formulation replacing the original form of the product which we no longer manufacture.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA subsequently approved updated labeling for Acetadote revising the product&#8217;s indication and providing new dosing guidance for specific patient populations. As a result, dosing guidance is now included for patients weighing over 100 kg, and new language was added to alert health care providers that, in certain clinical situations, therapy should be extended for some patients.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States Patent and Trademark Office (the &#8220;USPTO&#8221;) issued us a series of patents associated with our Acetadote product. These patents are discussed in Part I, Item I &#8211; &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business - Trademarks and Patents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; &#8211; of this Form 10-K. The FDA has approved several abbreviated new drug applications (&#8220;ANDA&#8221;) filed by various generics companies referencing Acetadote. Those products all possess the old formulation containing EDTA.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into an agreement with Perrigo Company resulting in the distribution of our Authorized Generic acetylcysteine injection (our &#8220;Authorized Generic&#8221;) product. Both Acetadote and our Authorized Generic utilize the new, EDTA-free formulation.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An Illinois judge issued a final ruling in favor of Cumberland Pharmaceuticals Inc. in a patent case associated with Acetadote. By ruling in Cumberland&#8217;s favor, the court upheld the validity of the patent that encompasses our EDTA-free formulation. The court also granted a permanent injunction preventing challengers from marketing a generic version of our proprietary Acetadote product formulation before the expiration of Cumberland&#8217;s patent in </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">August 2025. An Appeals Court affirmed the District Court ruling in the Company&#8217;s favor upholding Cumberland&#8217;s Acetadote patent and expressly rejected the validity challenge.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, we continued to distribute our Acetadote brand, however our Authorized Generic product is now distributed through Padagis US LLC (formerly a division of Perrigo Company).</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Caldolor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caldolor, our intravenous formulation of ibuprofen, was the first injectable product approved in the U.S. for the treatment of both pain and fever. We conducted a series of clinical studies in over 900 adult patients to develop the data to support our FDA submission for the product&#8217;s registration. Following a priority review, the FDA approved Caldolor for marketing in the U.S.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A non-steroidal anti-inflammatory drug (&#8220;NSAID&#8221;), the product was indicated for use in adults as a sole treatment for the management of mild to moderate pain and for the management of moderate to severe pain as an adjunct to opioid analgesics. It was also the first FDA-approved intravenous therapy for treating fever.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We then launched Caldolor and continue to promote the product in the U.S. through our hospital sales force.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed a series of Phase IV studies to gather additional data to support our Caldolor product. Those clinical trials involved another 1,000 adult and pediatric patients. These studies included data on a shortened infusion time and pre-surgical administration of the product. To address our Phase IV commitment to the FDA, these studies also included evaluation of the product for the reduction of fever in hospitalized children and the treatment of pain in children undergoing tonsillectomy surgeries.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We then received FDA approval for the use of Caldolor in pediatric patients 6 months of age and older. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2018, we completed and filed the application for FDA approval of a next generation Caldolor product featuring an improved presentation and formulation which was approved in January 2019. The new, premixed presentation provides health care professionals a formulation that is easy to administer, helping manage the treatment of patient pain and fever, while reducing opioid consumption. It is provided in a pre-mixed bag containing 800 mg of ibuprofen in a 200 mL patented low sodium formulation for injection that is ready to use. It is the first and only FDA-approved pre-mixed bag of ibuprofen. Caldolor is still available as an 800 mg/8mL single&#8211;dose vial for dilution in addition to the ready-to-use bag. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FDA approved our submission to expand the labeling for Caldolor to include administration of the product prior to surgery. During our clinical studies we found that the product delivered its best results when dosed prior to surgery, reducing both patient pain as well as their need for opiates. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, we distributed both the vial and the ready-to-use premixed bag presentations of Caldolor. We also announced an agreement with PiSA Pharmaceutical for the registration and commercialization of Caldolor in Mexico. Under the terms of the agreement, Cumberland will be responsible for providing the product dossier and supplies. PiSA will be responsible for obtaining regulatory approval for the product in Mexico and introducing it to the new market. PiSA expects to provide the product in both 400- and 800-milligram vials.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, the FDA approved expanded labeling for Caldolor to include use in infants 3 to 6 months old. The safety and efficacy of Caldolor has now been established for the treatment of pain and fever in pediatric patients aged 3 months and older. With this newly approved labeling, Caldolor is the only non-opioid product approved to treat pain in infants that is delivered through injection.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in 2023, we announced the publication of positive results from a clinical study investigating the safety and pharmacokinetics of Caldolor in infants. Published in the journal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pediatric Drugs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the results support the FDA&#8217;s approval of Caldolor in patients 3 to 6 months of age. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we reported that we expect Caldolor will be eligible for special Medicare reimbursement under the new Non-Opioids Prevent Addiction in the Nation Act (the &#8220;NOPAIN Act&#8221;), which was enacted as part of the Consolidated Appropriations Act of 2023. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NOPAIN Act requires Medicare to provide separate and more favorable reimbursement for non-opioid products that are used to manage pain during surgeries conducted in hospital outpatient departments or ambulatory surgical centers. In the Medicare Hospital Outpatient Prospective Payment System Proposed Rule, the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) requested that manufacturers with potentially applicable non-opioid products submit comments and supporting clinical evidence regarding products that should be eligible for separate payment. We submitted a comment letter along with the requisite clinical information to the CMS in September of 2023 explaining why Caldolor should be included and separately reimbursed.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We now await further information from CMS expected this year, including the potential new reimbursement level for Caldolor. The Act is scheduled to go into effect in early 2025 and will initially apply to those products that are furnished between January 1st, 2025 and January 1st, 2028.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kristalose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kristalose is a prescription laxative administered orally for the treatment of acute and chronic constipation. An innovative, dry powder crystalline formulation of lactulose, Kristalose is designed to enhance patient acceptance and compliance. It is the only prescription laxative available in pre-measured powder packets.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kristalose dissolves easily in 4 ounces of water, offering patients a virtually taste-free, grit-free and essentially calorie-free alternative to lactulose syrups. We conducted a preference study which indicated that 77% of patients surveyed prefer the taste, consistency and portability of Kristalose over similar products in syrup forms.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired the assets and exclusive rights to Kristalose through a series of transactions, then assembled a dedicated field sales force which re-launched the product as a Cumberland brand. We directed our sales efforts to physicians who are the most prolific writers of prescription laxatives, including gastroenterologists and internists. We supplemented this personal promotion with telemarketing campaigns to expand our reach and support of the product. Using preference data as a cornerstone of our marketing efforts, we repositioned the brand, enhancing patient affordability through a coupon program and expanded managed care coverage for the product.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We added a co-promotion partner, Poly Pharmaceuticals, who is promoting Kristalose to physician targets not covered by our field sales forces. We then added another partner, Foxland Pharmaceuticals, Inc., who is repackaging Kristalose and featuring it with additional new physician targets.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Kristalose award-winning marketing campaign was refreshed for 2022 to support increased engagement with our customers. We also expanded patient support for the brand &#8211; and it was added to the GoodRx platform in 2022.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, we continued to support Kristalose through our field sales force as well as our partnerships with Poly Pharmaceuticals and Foxland Pharmaceuticals, Inc. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have found that the brand performs best in states where we have Medicaid coverage. New York state recently added Kristalose to its Medicaid formulary, and we are implementing a special initiative to increase our presence and share of voice in the state. We believe that this new coverage is contributing to the growth of the product.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Omeclamox</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">-Pak</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many ulcers of the gastrointestinal tract are caused by an infection from the Helicobacter pylori (&#8220;H. pylori&#8221;) bacterium. Omeclamox-Pak is a branded prescription product used for the treatment of these infections and the related duodenal ulcer disease. This innovative product combines three well-known and widely prescribed medications: omeprazole, clarithromycin and amoxicillin.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Omeclamox-Pak was the first FDA-approved triple therapy combination medication to contain omeprazole as the proton pump inhibitor, which works to decrease the amount of acid the stomach produces. Clarithromycin and amoxicillin are both antibiotic agents that hinder the growth of the H. pylori bacteria. Interaction of these agents allows the stomach lining to heal effectively. The medications are packaged together on convenient daily dosing cards, making it simple to follow the twice a day dosing before meals.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired the assets and exclusive rights to Omeclamox-Pak through a series of transactions and re-launched the product as a Cumberland brand supported by our field sales force.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The packager for Omeclamox-Pak encountered financial difficulties in 2020 due to the impact of COVID-19, and their operations are currently suspended. As a result, we depleted our inventory of the product and notified the FDA that the product is currently unavailable. That facility is now under new ownership and new management. We are awaiting resumption of their operations, while also exploring other alternatives to restart the product&#8217;s packaging.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the delay in identifying a packager for Omeclamox-Pak, as a precaution, the Company has taken a non-cash write down of the related intangible asset of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="f-37">3.3</ix:nonFraction> million.  The financial statements reflect this adjustment.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sancuso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of 2021, we entered into an agreement with Kyowa Kirin to acquire the U.S. assets and rights to Sancuso (granisetron transdermal system), an FDA-approved oncology supportive care medicine. This transaction closed in January 2022.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sancuso is the first and only FDA-approved prescription patch for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment for their cancer. The active drug in Sancuso, granisetron, slowly dissolves in the thin layer of adhesive that sticks to the patient&#8217;s skin and is released into their bloodstream over several days, working continuously to prevent chemotherapy-induced nausea and vomiting (&#8220;CINV&#8221;). It is applied 24 to 48 hours before receiving chemotherapy and can prevent CINV for up to five consecutive days. Alternative oral treatments must be taken several times (day and night) to deliver the same therapeutic doses.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2022, we assumed full commercial responsibility for the product in the U.S. &#8211; including its marketing, promotion, distribution, manufacturing and medical support activities. Kyowa Kirin retains international rights, continuing to deliver the product to address oncology patients&#8217; needs throughout the rest of the world. In January 2022, we began shipments of the product and formed a new sales force, Cumberland Oncology, to support the brand. During 2023, we completed the transition of Sancuso from Kyowa Kirin to Cumberland, including the NDA transfer, and expanded our oncology sales division to further support the brand. We also successfully transferred manufacture of the product to a new facility. Following FDA approval of that site, we have now received new supplies of Cumberland-packaged product, which we will begin shipping this year.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vaprisol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired the assets and rights to Vaprisol, a prescription brand indicated to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia. It is one of two branded prescription products indicated for the treatment of hyponatremia, and the only intravenously administered branded treatment.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hyponatremia, an imbalance of serum sodium to body water, is the most common electrolyte disorder among hospitalized patients. These electrolyte disturbances occur when the sodium ion concentration in the plasma is lower than normal and are often associated with a variety of critical care conditions including congestive heart failure, liver failure, kidney failure and pneumonia. Vaprisol raises serum sodium to appropriate levels and promotes free water secretion. Our Vaprisol product has a proven day-one response rate to normalize serum sodium levels in hyponatremic patients and move them out of the Intensive Care Unit as efficiently as possible.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vaprisol is supported by our hospital sales division. Demand for the product increased in 2020 during the pandemic, and we worked to support the expanded use of the product in hospitals and clinics during the health care crisis. During 2021, we shipped all remaining inventory of the product and notified the FDA that supplies of the product are not currently available. We have since transferred the product&#8217;s manufacturing to a new facility. Our new manufacturing partner is working with the FDA to address several Form 483 and warning letter issues in a timely manner. Meanwhile, we have been working with them to support a special, interim supply of compounded product for critically ill patients, which we introduced to the market in late 2023 and will begin selling in early 2024. We then expect to file for the approval to manufacture branded Vaprisol once all FDA issues at the new site are resolved.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vibativ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the Company announced an agreement to acquire the Vibativ assets and assume global responsibility for the brand including the related marketing, distribution, manufacturing and regulatory activities. In early 2021, we introduced the Cumberland-packaged product, which is supported by our hospital sales force.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vibativ is a patented, FDA-approved injectable anti-infective. It is designed to treat serious infections due to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Staphylococcus aureus (&#8220;S. Aureus") </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and other Gram-positive bacteria, including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Methicillin-resistant Staphylococcus aureus (&#8220;MRSA&#8221;) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Methicillin-sensitive Staphylococcus aureus (&#8220;MSSA&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Vibativ addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vibativ can serve as a potentially life-saving treatment in patients with hospital-acquired and ventilator-associated pneumonia resulting from infections including the flu, RSV and COVID-19.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pneumonia caused by secondary bacterial infections is common among patients with viral respiratory infections. Research shows that hospital-acquired pneumonia (&#8220;HAP&#8221;) and ventilator-associated pneumonia (&#8220;VAP&#8221;) have historically accounted for 22% of common hospital-acquired infections. MSSA and MRSA are important disease-causing pathogens in these cases.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While many recently introduced antibiotics are quickly losing the battle to fight the bacteria they were designed to kill because those bacteria have become drug-resistant, Vibativ was specifically designed to kill drug-resistant bacteria. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The molecule of an existing antibiotic to which bacteria had developed a resistance, vancomycin, was altered by adding a lipophilic (fat-loving) component and a hydrophilic (water-loving) component. The lipophilic addition increases Vibativ&#8217;s ability to penetrate the cell wall and inhibits the formation of new cell walls (the development of new and/or additional cell walls is the most common way that bacteria become resistant to drugs). The hydrophilic addition increases Vibativ&#8217;s penetration into tissue &#8211; so it is able to attack infections that are not reachable by other antibiotics. In comparison to vancomycin, Vibativ is 32 times more potent against MRSA strains when tested under in vitro conditions. Further, in clinical trials, Vibativ demonstrated superior cure rates of patients with hospital-acquired bacterial pneumonia.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we announced a new publication in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antimicrobial Agents and Chemotherapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> detailing the results of the first clinical study investigating the safety and pharmacokinetics of our Vibativ product in children 2 to 17 years of age. The results of the study suggest that a single dose of Vibativ is safe in children and they experience reduced exposure to Vibativ, compared with the same body weight-based dosing in adults.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we remain focused on promoting Vibativ in the U.S. market, we are building a network of other established companies to bring Vibativ to patients in their countries and territories. In 2022, we announced a new partnership with Saudi Arabia-based Tabuk Pharmaceutical to introduce Vibativ into the Middle East. The arrangement provides Tabuk exclusive rights to distribute Vibativ in Saudi Arabia and Jordan, with the option to expand into other countries in the region. Additionally, D.B. Pharm, our partner in South Korea who also distributes Caldolor, is awaiting the approval of Vibativ in their country.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Meanwhile, our Vibativ partner for the Chinese market, SciClone Pharmaceuticals, had their approval application in China accepted for review in September 2021. We have since been supporting SciClone and their requests associated with review of that submission. They are working toward the approval and believe that there is significant potential for Vibativ in their country.</span></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PIPELINE</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ifetroban Clinical Studies</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ifetroban is a selective thromboxane-prostanoid receptor (&#8220;TPr&#8221;) antagonist dosed in nearly 1,400 subjects and found to be safe and well tolerated in healthy volunteers and various patient populations. We have been evaluating our ifetroban product candidate in a series of clinical studies. We have three Phase II clinical programs underway evaluating our ifetroban product candidate in 1)  Systemic Sclerosis or scleroderma, a debilitating autoimmune disorder characterized by diffuse fibrosis of the skin and internal organs, 2) patients with cardiomyopathy associated with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Duchenne Muscular Dystrophy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a rare, fatal, genetic neuromuscular disease results in deterioration of the skeletal, heart and lung muscles and 3) patients with Idiopathic Pulmonary Fibrosis, the most common form of progressive fibrosing interstitial lung disease. Investigational new study applications have been cleared by the FDA enabling us to launch clinical studies in each of these areas.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also completed a pilot Phase II study involving 1) patients suffering from Hepatorenal Syndrome, a life-threatening condition involving liver and kidney failure 2) patients with Portal Hypertension associated with chronic liver disease and 3) patients with Aspirin-Exacerbated Respiratory Disease, a severe form of asthma. There were no significant safety issues identified with the use of ifetroban in these patients.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional pilot studies of ifetroban are underway, including several investigator-initiated trials. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are awaiting results from the studies underway before deciding on the best development path for the registration of ifetroban, our first new chemical entity.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is more information about the clinical programs in which we are evaluating ifetroban:</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Systemic Sclerosis (&#8220;SSc&#8221;)</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have initiated the clinical development of ifetroban oral capsules under the brand name Vasculan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Systemic sclerosis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, also called scleroderma. It&#8217;s a debilitating autoimmune disorder characterized by diffuse fibrosis of the skin and internal organs, including the heart, as well as vascular dysfunction. SSc has a high morbidity and the highest case-specific mortality of any rheumatic disorder, with 50% of patients dying or developing major internal organ complications within three years of diagnosis. Although several medications are used to treat the skin disease associated with SSc, there is no universally effective treatment to improve the function of affected internal organs including the cardiovascular system.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiac involvement associated with SSc is often underestimated due to its subtle and atypical presentation. Despite the cardiovascular events associated with its elevated mortality at later stages of the disease, overt signs are suggestive of advance disease including myocardial or pericardial inflammation, heart failure and pulmonary arterial hypertension (&#8220;PAH&#8221;). </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Vanderbilt collaborators completed preclinical studies demonstrating TPr blockade with ifetroban prevents cardiac fibrosis and can restore cardiac function in animal models of PAH.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA cleared our IND application to evaluate 12 months of oral ifetroban (Vasculan) in a 34-subject phase II trial entitled, A </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase II Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients with Diffuse Cutaneous Systemic Sclerosis or Systemic Sclerosis-Associated Pulmonary Arterial Hypertension. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This study is well underway and includes patients with diffuse cutaneous SSc, as well as those with pulmonary arterial hypertension associated with their SSc.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Duchenne Muscular Dystrophy (&#8220;DMD&#8221;)</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also initiated the clinical development of oral ifetroban under the brand name Dyscorban</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of cardiomyopathy associated with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Duchenne Muscular Dystrophy, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a rare and fatal disease caused by a genetic defect which leads to inexorable muscle damage. Cardiomyopathy is the leading cause of death in DMD patients. TPr and its ligand, isoprostanes, are found to have increased in DMD patients.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical studies by our Vanderbilt collaborators demonstrated TPr blockade by ifetroban prevented cardiac dysfunction and improved mortality in several animal models of muscular dystrophy. These results, published in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Journal of the American Heart Association, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">suggest TPr activation contributes to DMD cardiomyopathy and blockade with ifetroban may serve as a novel therapeutic for DMD patients.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA cleared Cumberland&#8217;s IND application to evaluate 12 months of oral ifetroban (Dyscorban) in a Phase II study entitled, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study with an Open-Label Extension to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects with Duchenne Muscular Dystrophy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. With medical centers across the U.S. screening patients, our clinical study is enrolling those with 48 ambulatory and non-ambulatory DMD, 7 years of age and older with stable cardiac function.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland was awarded just over $1 million in federal funding to support this clinical trial, which is the first DMD clinical study awarded FDA Orphan Product Development funding. As a result of the COVID-19 pandemic and its global impact on clinical research in 2020, the FDA awarded a supplemental grant in support of our Phase II DMD study.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Idiopathic Pulmonary Fibrosis (&#8220;IPF&#8221;)</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, our Board of Directors approved a new clinical program for the use of ifetroban to treat </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Progressive Fibrosing Interstitial Lung Diseases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;PF-ILDs&#8221;). Nonclinical studies are complete, and the resulting manuscript was prepared and submitted for publication in 2021.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, we announced that the FDA cleared the IND application for a Phase II study in patients with Idiopathic Pulmonary Fibrosis, the most common form of progressive fibrosing interstitial lung disease. As a result, we are in the process of initiating our FIGHTING FIBROSIS trial designed to enroll 128 patients in over 20 medical centers of excellence across the U.S. This Phase II clinical trial will study the safety, tolerability and efficacy of oral ifetroban in patients with IPF. Recent studies have shown ifetroban can both prevent and enhance resolution of lung fibrosis in multiple preclinical models.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Ifetroban Programs</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also completed a pilot Phase II study involving 1) patients suffering from Hepatorenal Syndrome, a life-threatening condition involving liver and kidney failure 2) patients with Portal Hypertension associated with chronic liver disease and 3) patients with Aspirin-Exacerbated Respiratory Disease, a severe form of asthma. There were no significant safety issues identified with the use of ifetroban in these patients. Additional pilot studies of ifetroban are underway, including several investigator-initiated trials.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our plan going forward is to complete each of our Company-sponsored studies, analyze their final data, announce top-line results and decide on the best development path for the registration of ifetroban, which we continue to believe has the potential to benefit many patients with orphan diseases that represent unmet medical needs.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FDA Fee Waivers</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, the FDA informed us that it had granted two barrier-to-innovation waivers that would result in refunds totaling approximately $2.8 million that we had previously paid for prescription drug program fees.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA granted each waiver after concluding that Cumberland met the statutory criteria based on the innovation associated with its ifetroban clinical development programs, as the funds could be better used to advance those studies. We received both refunds in June 2023.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i3928a3425fef4184806511a3516ffab1_22"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GROWTH STRATEGY</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland&#8217;s growth strategy involves maximizing the potential of our existing brands while continuing to build a portfolio of differentiated products. We currently feature seven products approved by the FDA in the United States. We are also continuing to explore international partnerships to bring our medicines to patients in other countries. Additionally, we look for opportunities to expand our products into additional patient populations through clinical trials, new presentations and our support of select, investigator-initiated studies. We actively pursue opportunities to acquire additional marketed products as well as late-stage development product candidates in our target medical specialties. Our clinical team is developing a pipeline of new product candidates to address poorly met medical needs.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are supplementing these activities with the earlier-stage drug development at Cumberland Emerging Technologies (&#8220;CET&#8221;), our majority-owned subsidiary. CET partners with academic research institutions to identify and support the progress of promising new product candidates, which Cumberland could further develop and commercialize. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, we are seeking long-term, sustainable growth by:</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Supporting and expanding the use of our marketed products. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to evaluate our products following their FDA approval to determine if additional clinical data could expand their market and use. For example, we have secured pediatric approval of Acetadote and Caldolor and expanded the labeling for both brands accordingly. We also added pre-surgery dosing for Caldolor, and recently included newborns to the patients who can benefit from the product. We will continue to explore such opportunities to bring our products to new patient populations.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Selectively adding complementary brands. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our product development activities, we are also seeking to acquire products or late-stage development product candidates to continue to build a portfolio of complementary brands. We focus on under-promoted, FDA-approved drugs as well as late-stage development products that can improve patient care. We will continue to target product acquisition candidates that are competitively differentiated, have valuable intellectual property or other protective features, and allow us to leverage our existing infrastructure. Our acquisitions of Vibativ and Sancuso are examples of the implementation of this strategy.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Progressing our clinical pipeline and incubating future product opportunities at CET.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe it is important to build a pipeline of innovative new product opportunities, as we are doing through our ifetroban Phase II development programs. We are also supplementing our acquisitions and late-stage development activities with early-stage drug development activities with CET.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Leveraging our infrastructure through co-promotion partnerships. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our commercial infrastructure can help drive prescription volume and product sales. We look for strategic partners that can complement our capabilities and enhance opportunities for our brands. For example, our co-promotion partnerships have allowed us to expand the support for Kristalose and Sancuso across the U.S.     </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Building an international contribution to our business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have established our own commercial capabilities, including three sales divisions, to cover the U.S. market for our products. We are also building a network of select international partners to register our products and make them available to patients in their countries. We will continue to develop and expand our network of international partners while supporting our partners&#8217; registration and commercialization efforts in their respective territories. The acquisition of Vibativ resulted in several new international partners and market opportunities.</span></div><div style="margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Managing our operations with financial discipline.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We continually work to manage our expenses in line with our revenues to deliver positive cash flow from operations. We remain in a strong financial position, with favorable gross margins and a strong balance sheet. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i3928a3425fef4184806511a3516ffab1_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SALES AND MARKETING</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland&#8217;s sales and marketing team has broad industry experience in selling branded pharmaceuticals. Our sales and marketing executives direct our national marketing campaigns and maintain key national account relationships. They also manage our dedicated hospital, field and oncology sales forces, which are comprised of approximately 60 sales professionals.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Hospital market:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We promote Caldolor, Vaprisol, Acetadote and Vibativ through our dedicated hospital sales division. This organization targets key hospitals across the U.S. and is comprised of sales professionals with substantial experience in the hospital market. Independent market data continues to indicate that the majority of pharmaceutical promotional spending is directed toward large, outpatient markets on drugs intended for chronic use rather than short-term, hospital use. </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the hospital market is under-served and highly concentrated, and that it can be penetrated effectively by a small, dedicated sales force without large-scale promotional activity. Our established position in the hospital market provided the rationale for adding Vibativ as our first infectious disease product that complements our hospital product line. Our strategy has been to focus our hospital sales team on select, high-priority accounts. </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Gastroenterology market:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We promote Kristalose and Omeclamox-Pak through a dedicated field sales team addressing a targeted group of physicians who are large prescribers of the products. Because the market for gastrointestinal diseases is broad in patient scope, yet relatively narrow in physician base, we believe it provides opportunities that can be penetrated with a modest-sized sales force. We also believe that we can increase market share for these products through our sales and marketing activities.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Oncology market: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2022, we formed a new oncology sales force to promote our Sancuso brand. This organization targets key oncologists and clinics across the U.S. and is comprised of both inside and field-based sales professionals. During 2023, we expanded the sales division as we work to deliver Sancuso to cancer patients, helping them tolerate their chemotherapy treatments. The division is comprised of 12 individuals, including four inside reps. This group can be expanded through additional personnel or augmented through co-promotion partners.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial executives conduct ongoing analyses to evaluate marketing campaigns and promotional programs in support of our brands. The evaluations include development of product profiles, testing of the profiles against the needs of the market, determining what additional product information or development work is needed to effectively market the products and preparing financial forecasts. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize professional branding and packaging as well as promotional items to support our products, including direct mail, sales brochures, journal advertising, educational and reminder leave-behinds, patient educational pieces, coupons and product sampling. We also regularly attend select medical meetings and trade shows to expand the awareness of our products. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our national accounts team is responsible for key large buyers and related marketing programs. This team maintains relationships with our wholesaler customers as well as with third-party payors, such as group purchasing organizations, pharmacy benefit managers, hospital buying groups, outpatient centers, state and federal government purchasers, and health insurance companies. </span></div><div id="i3928a3425fef4184806511a3516ffab1_28"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MATERIAL CUSTOMERS</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary customers are wholesale pharmaceutical distributors in the United States. Total revenue by customer for each customer representing 10% or more of consolidated gross revenues are summarized below for the year ended December&#160;31, 2023:</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:53.240%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.764%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.826%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.764%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i3928a3425fef4184806511a3516ffab1_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTERNATIONAL PARTNERSHIPS</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established our own capabilities to support the commercialization of our products in the U.S. Our international strategy is to identify and partner with other companies that have the appropriate capabilities to support our products in their respective countries. We have entered into a series of agreements to establish an international network, which is summarized in the table below and includes information on our primary partners:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"/><td style="width:29.334%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.123%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.608%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International Partner</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Territory</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phebra Pty Ltd</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote &amp; Caldolor</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D.B. Pharm Korea Co., Ltd.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sandor Medicaids Pvt. Ltd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R-Pharm JSC</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia and CIS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tabuk Pharmaceuticals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saudi Arabia and Jordan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PiSA Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registration</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SciClone Pharmaceuticals, Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China and Hong Kong</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D.B. Pharm Korea Co., Ltd.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol &amp; Vibativ</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registration</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WinHealth Pharma Group Co.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China and Hong Kong</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our international commercialization agreements include a license to one or more Cumberland products for a specific territory as noted in the table above. We seek partners who have the local infrastructure to support the registration and commercialization of our products in their territory. </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our agreements our partners are responsible for:</span></div><div style="margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Seeking regulatory approvals for the products;</span></div><div style="margin-top:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Launching the brand;</span></div><div style="margin-top:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Managing the ongoing marketing, sales and product distribution; </span></div><div style="margin-top:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Addressing the ongoing regulatory requirements in the international territories;</span></div><div style="margin-top:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Remitting any upfront, regulatory and sales milestone payments; </span></div><div style="margin-top:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Providing the transfer price for supplies of the product; and</span></div><div style="margin-top:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Calculating and paying any royalties, as applicable. </span></div><div style="margin-top:8pt;padding-left:22.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Our responsibilities include:</span></div><div style="margin-top:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Providing a dossier of relevant information to support product registration;</span></div><div style="margin-top:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Maintaining our intellectual property associated with the product;</span></div><div style="margin-top:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Sharing our marketing strategy, experience and materials for the brand; and</span></div><div style="margin-top:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Manufacturing and providing the finished product for sale.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, we worked to support our existing international partners, conclude unproductive arrangements and  identify new companies to represent our products in select additional territories. </span></div><div id="i3928a3425fef4184806511a3516ffab1_34"></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BUSINESS DEVELOPMENT</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have had an active business development initiative focused on acquiring rights to marketed products and product candidates that fit our strategy and target markets. We source business development opportunities through our international network of advisory firms and individual pharmaceutical industry and medical advisors. A multi-disciplinary internal management team reviews these opportunities on a regular basis using a group of selection criteria. We have historically focused on product opportunities that are a strategic fit with our commercial organization, development expertise and medical focus, employing a variety of transaction structures.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have continued to build our product portfolio of complementary, niche brands largely through product acquisitions and late-stage development of product candidates.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary targets are under-promoted, FDA - approved drugs with existing brand recognition and late-stage development product candidates that address unmet or poorly met medical needs in the hospital acute care, gastroenterology and oncology markets. We believe that by focusing mainly on approved or late-stage products, we can minimize the significant risk, cost and time associated with drug development.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to strategically review our brands, pipeline and capabilities, as well as our international partners. We believe that it is prudent to continually evaluate our product portfolio, partners, and organization in order to ensure a proper focus and the needed supporting capabilities.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International Partners</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">D.B. Pharm Korea Co., Ltd. (&#8220;D.B. Pharm&#8221;) has licensed our Caldolor product for the South Korean market, and they obtained regulatory approval for Caldolor in their country. During 2023, D.B. Pharm continued to purchase supplies of Caldolor and distributed the brand in South Korea. We have also entered into agreements with D.B. Pharm to register and commercialize our Vaprisol and Vibativ brands in their country. During 2022, we worked with them to prepare the submissions for the approval of each brand there. They are currently awaiting the approval of Vibativ in their country.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have executed a license and distribution agreement with HongKong WinHealth Pharma Group Co. Limited (&#8220;WinHealth&#8221;) for our Caldolor and Acetadote brands in China and Hong Kong. Under the terms of the agreement, WinHealth will provide development milestone payments and purchase supplies of the products following their registration in China.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also entered into a strategic alliance agreement with WinHealth to explore future business opportunities that will further the mission and goals of each organization. Founded in Hangzhou, China and currently headquartered in Hong Kong, WinHealth has developed a wide breadth of capabilities, including drug licensing, product development and registration, and has established a strong network of distribution and sales promotional capabilities for the Chinese market. WinHealth has established partnerships with international companies that include Boehringer-Ingelheim, Janssen, Novartis, Pfizer and Roche, generating several hundred million dollars in sales annually.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we entered into an agreement with WinHealth Investment (Singapore) Ltd. creating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">WHC Biopharmaceuticals, Pte. Ltd</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The joint venture will focus on acquiring, developing, registering, and commercializing development stage and commercial stage biopharmaceuticals for China, Hong Kong and other Asian markets.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R-Pharma JSC (&#8220;R Pharma&#8221;) has licensed our Vibativ product for a territory that includes Russia and a number of adjacent countries in Eastern Europe. R-Pharma is one of the leading multinational pharmaceutical organizations based in Russia. Headquartered in Moscow and focusing on a wide breadth of therapeutic areas in the specialty and hospital care markets, R-Pharma generates $1 billion in annual revenue. R-Pharma has registered Vibativ in Russia and during 2023, continued to purchase supplies of the product for that market. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SciClone Pharmaceuticals (Holdings) Limited (&#8220;SciClone&#8221;) has licensed our Vibativ product for sale and distribution in China and several adjacent countries. In February 2021, SciClone completed an initial public offering and listing of their shares on the Hong Kong stock exchange. In June 2021, SciClone submitted an application to the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chinese regulatory authority for the approval of Vibativ in that country. In October 2021, SciClone informed us that the filing was accepted by the regulatory agency for review. We have since been supporting SciClone and their requests associated with review of that submission. They are working toward the approval, responding to regulatory inquiries, and believe that there is significant potential for Vibativ in their country.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we established distribution for our Vibativ product in the Middle East through a partnership with Tabuk Pharmaceutical Manufacturing Company (&#8220;Tabuk&#8221;). Through our partnership, Tabuk will introduce the product in Saudi Arabia, Jordan and potentially other countries in the Middle East. They are currently updating their product approval in Saudi Arabia with new manufacturing information.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, we announced an agreement with PiSA Pharmaceutical for the registration and commercialization of Caldolor in Mexico. Under the terms of the agreement, Cumberland will be responsible for providing the product dossier and supplies. PiSA will be responsible for obtaining regulatory approval for the product in Mexico and introducing it to the new market. They are currently preparing their submission for the approval of Caldolor in their country.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Poly Co-Promotion Agreement</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a co-promotion arrangement with Poly Pharmaceuticals, Inc. (&#8220;Poly&#8221;) for our Kristalose product in 2017. Poly is a privately held U.S. specialty pharmaceutical company that is featuring Kristalose to an expanded number of physicians. Poly&#8217;s sales organization is more than doubling the number of nationwide physicians that are reached with the Kristalose brand message. In 2019, we extended our co-promotion arrangement with Poly.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2R and Foxland Agreements</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we entered into another co-promotion arrangement related to our Kristalose product. We have agreements with 2R Investments, LLC and with Foxland Pharmaceuticals, Inc. (&#8220;Foxland&#8221;) to package, distribute and promote an unbranded generic form of our Kristalose product to physician targets that we do not cover. We renewed our agreement with Foxland in 2022.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nordic License Agreement</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, we entered into an amendment to our agreement with Nordic Pharma (&#8220;Nordic&#8221;) that addressed the responsibilities and financial arrangements regarding our license to Nordic&#8217;s methotrexate line of products for the U.S. Our line of prefilled methotrexate syringes, marketed under the brand name RediTrex in the U.S., was covered by the license. As of July 1, 2023, Nordic has assumed responsibility for the product in the U.S.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the return of the license, Nordic will provide us with a royalty on their future sales of the products through April 2035. The companies will continue to collaborate on any transition and the ongoing commercialization of the product line.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland transferred the marketing authorization associated with the RediTrex product line to Nordic. They returned the 180,000 shares we issued to them that were associated with the license and refunded the $1 million we paid them following the brand&#8217;s approval in the U.S. Nordic has also issued a credit note in favor of Cumberland in the amount of $1 million for the unpaid milestone payment due from us which was associated with our launch of the product line.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CET University Collaboration Agreements</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through CET, we collaborate with a select group of academic research institutions located in the Mid-South region of the U.S. to identify, co-develop and seek grant funding for promising biomedical technologies emerging from those research institutions. CET is collaborating with Vanderbilt University and other regional academic research institutions and has entered into a series of agreements to access and collaborate on the development of innovative product candidates. These arrangements enable CET to team with university-based researchers to advance their scientific discoveries and breakthroughs by designing new product candidates to improve patient care and address unmet medical needs. CET has been able to help secure federal small business grant funding to support these various projects.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CET has also established and manages the Nashville </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Life Sciences Center</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which serves as an incubator for Middle Tennessee&#8217;s emerging biomedical industry. The Life Sciences Center provides offices, laboratory space, and equipment to early-stage companies looking to develop their technologies and products. We maintain the Cumberland Pharmaceuticals formulation and testing laboratory at the CET Life Sciences Center.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nearly 30 life science companies exist today because of CET, including a vibrant group of current tenants at the Life Sciences Center as well as a growing number of successful graduates.</span></div><div id="i3928a3425fef4184806511a3516ffab1_1253"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CLINICAL AND REGULATORY AFFAIRS</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have in-house capabilities for the management of our clinical, professional and regulatory affairs. Our team develops and manages our clinical trials, prepares regulatory submissions, manages ongoing product-related regulatory responsibilities and manages our medical information call center. Team members have been responsible for devising the regulatory and clinical strategies for all our products as well as obtaining FDA approvals for Acetadote and Caldolor brands.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Development</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical development personnel are responsible for: </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">creating clinical development strategies; </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">designing, implementing and monitoring our clinical trials;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">creating case report forms and other study-related documents; and</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analyzing efficacy and safety data obtained from clinical trials for subsequent submissions and approval of new drugs.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory and Quality Affairs</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal regulatory and quality affairs team is responsible for: </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preparing and submitting INDs for clearance to begin patient studies;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preparing and submitting NDAs and fulfilling post-approval marketing commitments; </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining investigational and marketing applications through the submission of appropriate reports; </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submitting supplemental applications for additional label indications, product line extensions and manufacturing improvements;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">evaluating regulatory risk profiles for product acquisition candidates, including compliance with manufacturing, labeling, distribution and marketing regulations;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">monitoring applicable third-party service providers for quality and compliance with current Good Manufacturing Practices (&#8220;GMPs&#8221;), Good Laboratory Practices (&#8220;GLPs&#8221;), and Good Clinical Practices (&#8220;GCPs&#8221;), and performing periodic audits of such vendors; and</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining systems for document control, product and process change control and customer complaints. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div id="i3928a3425fef4184806511a3516ffab1_40"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROFESSIONAL AND MEDICAL AFFAIRS</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our medical team provides in-house medical information support for our marketed products. This includes interacting directly with health care professionals to address any product or medical inquiries through our medical information call center and medical science liaisons. In addition to coordinating the call center, our clinical/regulatory group generates medical information letters, provides informational memos to our sales forces and assists with ongoing training for the sales forces.</span></div><div id="i3928a3425fef4184806511a3516ffab1_43"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CLINICAL DEVELOPMENT AND STUDY RESULTS </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vibativ Clinical Manuscripts</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vibativ is a patented, FDA-approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, Cumberland announced a new study published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antimicrobial Agents and Chemotherapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> detailing the results of the first clinical study investigating the safety and pharmacokinetics of our Vibativ (telavancin) product in children 2 to 17 years of age. The study found a single 10 mg/kg dose of Vibativ was safe with no serious adverse events or renal concerns. Drug exposure to Vibativ was lower in children compared with the same body weight-based dosing in adults. The study suggests Vibativ is a safe and viable option for pediatric patients ages 2 to 17 who require systemic antibiotics for the treatment of a known or suspected bacterial infection, including those with MRSA or another </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">S. aureus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> pathogen. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Caldolor Newborn Study and Clinical Manuscripts</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We previously received FDA approval for the use of Caldolor in pediatric patients 6 months of age and older. Caldolor is the first and only injectable NSAID approved for use in children.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We then initiated a study to collect data on the use of Caldolor in children ranging in age from birth up to 6 months of age. Enrollment in that multi-center study was completed in 2019, and topline results were announced in 2020, indicating that</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caldolor was well tolerated in this patient population, with no safety concerns noted. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, we announced the FDA approval of Caldolor in pediatric patients 3 to 6 months of age. With this newly approved labeling, Caldolor is the only non-opioid injectable product approved to treat pain in infants that is delivered through injection. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in June 2023, we shared the positive results from a clinical study investigating the safety and pharmacokinetics of Caldolor in newborns, published in the journal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pediatric Drugs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The clinical study evaluated the safety and drug exposure profile of Caldolor in 24 hospitalized infants between the ages of 1 and 6 months who required treatment for pain or fever. Of the 24 patients included in the study, three were under 3 months of age, and the remaining 21 patients were 3 to 6 months of age. Twenty patients received a single dose, and four patients received multiple doses. In this study, single and multiple 10 mg/kg doses of Caldolor were reported safe, with no drug-related adverse events or renal concerns. Drug exposure following a single dose of Caldolor in infants 1 to 6 months of age was similar to what was previously reported in older children. The results of this study support the growing body of evidence that demonstrates Caldolor is a safe therapeutic option available to practitioners for the treatment of fever and pain in infants, children and adults.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ifetroban Phase II Studies</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been evaluating our ifetroban product candidate in a series of clinical studies. We have three Phase II clinical programs underway evaluating our ifetroban product candidate in 1)  Systemic Sclerosis or scleroderma, a debilitating autoimmune disorder characterized by diffuse fibrosis of the skin and internal organs, 2) patients with cardiomyopathy associated with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Duchenne Muscular Dystrophy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a rare, fatal, genetic neuromuscular disease results in deterioration of the skeletal, heart and lung muscles and 3) patients with Idiopathic Pulmonary Fibrosis, the most </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common form of progressive fibrosing interstitial lung disease. Investigational new study applications have been cleared by the FDA enabling us to launch clinical studies in each of these areas.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also completed a pilot Phase II study involving 1) patients suffering from Hepatorenal Syndrome, a life-threatening condition involving liver and kidney failure 2) patients with Portal Hypertension associated with chronic liver disease and 3) patients with Aspirin-Exacerbated Respiratory Disease, a severe form of asthma. There</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">no</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">safety</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">identified</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">use</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ifetroban</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patients.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional pilot studies of ifetroban are underway, including several investigator-initiated trials. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are awaiting results from the studies underway before deciding on the best development path for the registration of ifetroban, our first new chemical entity.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Testing Program</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland entered into a non-clinical evaluation agreement, to test one of our products against bacterial strains and subsequently, in vivo animal models utilizing the preclinical services program funded by the Division of Microbiology and Infectious Diseases (&#8220;DMID&#8221;), part of the National Institute of Allergy and Infectious Diseases (&#8220;NIAID&#8221;),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an institute of the National Institutes of Health (&#8220;NIH&#8221;), which is part of the Department of Health and Human Services (&#8220;HHS&#8221;), an agency of the U.S. government. The NIAID contractors completed these studies and prepared a manuscript for submission to a scientific journal for publication.</span></div><div id="i3928a3425fef4184806511a3516ffab1_46"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CORPORATE DEVELOPMENT</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cumberland Pharma Foundation</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have formed the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cumberland Pharma Foundation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the &#8220;Foundation&#8221;) to provide the ongoing philanthropic endeavors of Cumberland Pharmaceuticals Inc.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Foundation was formed as an independent, nonprofit corporation designed to qualify as a tax-exempt organization pursuant to Section 501(a) of the Internal Revenue Code. The Foundation&#8217;s Board of Directors is comprised of Cumberland Pharmaceuticals executives who are responsible for overseeing the Foundation&#8217;s ongoing activities, including charitable contributions.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We initially provided a grant of 50,000 shares of our common stock to the Foundation. The shares will address the ongoing financial needs of the Foundation, with most of the shares expected to be held for the opportunity to realize long-term appreciation to support the Foundation&#8217;s future.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Foundation maintains independent financial statements and its contributions will not impact the financial statements of Cumberland Pharmaceuticals. Initial annual grants by the Foundation have been and remain consistent with the historic level of contributions made by Cumberland Pharmaceuticals. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cumberland Health and Wellness Political Action Committee</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also formed the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cumberland Health and Wellness Political Action Committee </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the &#8220;PAC&#8221;). The objective of the PAC is to support candidates and policies that are consistent with Cumberland&#8217;s mission of advancing patient care. The PAC&#8217;s activities are held at a local, state, and federal level and conducted in a bi-partisan manner. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial committee membership is comprised of Cumberland Pharmaceuticals employees. The PAC received initial funding from us, and future funding will include voluntary individual contributions from Cumberland Pharmaceuticals directors and employees.</span></div><div id="i3928a3425fef4184806511a3516ffab1_49"></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANUFACTURING AND DISTRIBUTION</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We partner with third parties for certain non-core, capital-intensive capabilities, including the manufacturing and distribution of our products. We manage these third-party relationships and are responsible for the quality review and release of each lot of our products.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acetadote</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an agreement with one manufacturer, who provided commercial supplies of Acetadote in 2023. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Caldolor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have agreements with multiple manufacturers for the supply of Caldolor and during 2023, we obtained commercial supplies from three of these manufacturers for our international and domestic Caldolor requirements. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kristalose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an agreement for the purchase of Kristalose API with an international supplier. We also had manufacturing arrangements with a packager who provided finished supplies of the product for commercial and sampling purposes during 2023. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Omeclamox</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">-Pak</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The packager for Omeclamox-Pak encountered financial difficulties in 2020 due to the impact of COVID-19, and their operations are currently suspended. As a result, we depleted our inventory of the product and notified the FDA that the product is currently unavailable. That facility is now under new ownership and new management. We are awaiting resumption of their operations, while also exploring other alternatives to restart the product&#8217;s packaging.  With uncertain future cash flows, the Board of Directors approved the write-down of the intangible assets related to the product.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sancuso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the acquisition of Sancuso, we obtained an initial supply of finished goods inventory. The agreement with the manufacturer of Sancuso was assigned to us and there were additional goods supplied to us during 2022. The production was moved to one of the manufacturer&#8217;s other facilities. During 2022, that new facility was approved by the FDA to manufacture and supply Sancuso. We received supplies of the product from the new facility in 2023 and will begin shipping the Cumberland-packaged product during 2024.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaprisol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the acquisition of Vaprisol, we obtained a significant existing supply of raw material inventory. We reached an agreement during 2020 with a new manufacturer to provide us with long-term supplies of the product. We subsequently completed the transfer of the product&#8217;s manufacturing to the new facility in 2021. We informed the FDA that supplies of the product are not currently available and are awaiting approval for that new facility. Our new manufacturing partner is working with the FDA to address several Form 483 and warning letter issues in a timely manner. Meanwhile, we have been working with them to support a special, interim supply of compounded product for critically ill patients, which we introduced to the market in late 2023 and will begin selling in early 2024. We then expect to file for the approval to manufacture branded Vaprisol once all FDA issues at the new site are resolved. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vibativ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our acquisition of Vibativ, we obtained a multi-year supply of raw material, work in process and finished goods inventory. As a result of the agreement, we are now responsible for the future manufacturing of the product. We completed the transfer of the product&#8217;s manufacturing activities to a new supplier and received FDA approval for that facility.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distribution</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Like many pharmaceutical companies, we engage a third-party with appropriate facilities and logistical expertise to support the U.S. distribution of our products. In 2023, Cardinal Health Specialty Solutions exclusively handled our U.S. product logistics activities, including warehousing, shipping, and various other customer activities. Our primary customers are the wholesalers of pharmaceuticals who provide our products to hospitals, clinics and retail pharmacies in the U.S.</span></div><div id="i3928a3425fef4184806511a3516ffab1_52"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PATENTS, TRADEMARKS AND OTHER INTELLECTUAL PROPRIETARY RIGHTS</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own the trademarks for each of our branded pharmaceutical products as well as for our corporate name and logo. We have applied for trademark registration for other various names and logos. Over time, we intend to maintain registrations on trademarks that remain valuable to our business.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to protect our products from competition through a combination of patents, trademarks, trade secrets, FDA exclusivity and contractual restrictions on disclosure. Proprietary rights, including patents, are an important element of our business. We seek to protect our proprietary information by requiring our employees, consultants, contractors and other advisors to execute agreements providing for protection of our confidential information upon commencement of their employment or engagement. We also require confidentiality agreements from entities to which we provide our confidential information or materials.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acetadote</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We developed a new formulation of Acetadote (acetylcysteine) injection as part of a Phase IV commitment in response to a request by the FDA to evaluate the reduction of ethylene diamine tetraacetic acid (&#8220;EDTA&#8221;) from the product&#8217;s formulation. In April 2012, the USPTO issued U.S. Patent number 8,148,356 (the &#8220;356 Acetadote Patent&#8221;) which is assigned to us. The claims of the 356 Acetadote Patent encompass the new Acetadote formulation and include composition of matter claims. Following its issuance, the 356 Acetadote Patent was listed in the FDA Orange Book. The 356 Acetadote Patent is scheduled to expire in May 2026, which includes a 270-day patent term adjustment granted by the USPTO.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the issuance of the 356 Acetadote Patent, we received separate Paragraph IV certification notices from InnoPharma, Inc. (&#8220;InnoPharma&#8221;), Paddock Laboratories, LLC (&#8220;Paddock&#8221;), Mylan Institutional LLC (&#8220;Mylan&#8221;), Sagent Agila LLC (&#8220;Sagent&#8221;) and Perrigo Company (&#8220;Perrigo&#8221;) challenging the 356 Acetadote Patent on the basis of non-infringement and/or invalidity. We responded by filing five separate infringement lawsuits, in the appropriate United States District Courts, to contest each of the challenges. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 12, 2012, we entered into a Settlement Agreement (the &#8220;Settlement Agreement&#8221;) with Paddock and Perrigo to resolve the challenges and the pending litigation with those two companies.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2013, the United States District Courts filed opinions granting Sagent&#8217;s and InnoPharma&#8217;s motions to dismiss our suits and we agreed not to file an appeal or motion to reconsider, thereby resolving the challenges and the pending litigation with those two companies. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Settlement Agreement, Paddock and Perrigo admit that the 356 Acetadote Patent is valid and enforceable and that any Paddock or Perrigo generic version of Acetadote (with or without EDTA) would infringe upon the 356 Acetadote Patent. In addition, Paddock and Perrigo will not challenge the validity, enforceability, ownership or patentability of the 356 Acetadote Patent through its expiration currently scheduled for May 2026. On November 12, 2012, in connection with the execution of the Settlement Agreement, we entered into a License and Supply Agreement with Paddock and Perrigo (the &#8220;License and Supply Agreement&#8221;).  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the License and Supply Agreement, if a third party receives final approval from the FDA for an ANDA to sell a generic Acetadote product and such third party made such generic version available for purchase in commercial quantities in the United States, we are to supply Perrigo with an Authorized Generic version of our Acetadote product.   </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 18, 2012, we also submitted a Citizen Petition to the FDA requesting that the FDA refrain from approving any applications for acetylcysteine injection that contain EDTA, based in part on the FDA&#8217;s request that we evaluate the reduction or removal of EDTA from our original Acetadote formulation.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 7, 2012, the FDA responded to the Citizen Petition denying our request and on November 8, 2012, we learned that the FDA approved the ANDA referencing Acetadote filed by InnoPharma, Inc. We brought suit against the FDA contesting the FDA&#8217;s decision to approve the InnoPharma generic on November 13, 2012. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2013, the United States District Court filed an opinion granting a summary judgment in favor of the FDA regarding this suit.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, during 2012 the FDA approved the ANDA referencing Acetadote filed by InnoPharma, Inc. Upon this condition, in accordance with the License and Supply agreement with Perrigo, we began to supply Perrigo with our Authorized Generic. On January 7, 2013, Perrigo announced initial distribution of our Authorized Generic acetylcysteine injection product.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 19, 2013, the USPTO issued U.S. Patent number 8,399,445 (the &#8220;445 Acetadote Patent&#8221;) which is assigned to us. The claims of the 445 Acetadote Patent encompass the use of the 200 mg/ml Acetadote formulation to treat patients with acetaminophen overdose. On April 8, 2013, the 445 Acetadote Patent was listed in the FDA Orange Book. The 445 Acetadote Patent is scheduled to expire in August 2025. Following the issuance of the 445 Acetadote Patent we received separate Paragraph IV certification notices from Perrigo, Sagent Pharmaceuticals, Inc., and Mylan challenging the 445 Acetadote Patent on the basis of non-infringement, unenforceability and/or invalidity.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 10, 2013, we became aware of a Paragraph IV certification notice from Akorn, Inc. challenging the 445 Acetadote Patent and the 356 Acetadote Patent on the basis of non-infringement. On July 12, 2013, we filed a lawsuit for infringement of the 356 Acetadote Patent against Akorn, Inc. in United States District Court.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 18, 2014, the USPTO issued U.S. Patent number 8,653,061 (the &#8220;061 Acetadote Patent&#8221;) which is assigned to us. The claims of the 061 Acetadote Patent encompass the use of the 200 mg/ml Acetadote formulation to treat patients with acetaminophen overdose. Following its issuance, the 061 Acetadote Patent was listed in the FDA Orange Book. The 061 Acetadote Patent is scheduled to expire in August 2025.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 13, 2014, the USPTO issued U.S. Patent number 8,722,738 (the &#8220;738 Acetadote Patent&#8221;) which is assigned to us. The claims of the 738 Acetadote Patent encompass administration methods of acetylcysteine injection, without specification of the presence or lack of EDTA in the injection. Following its issuance, the 738 Acetadote Patent was listed in the FDA Orange Book and it is scheduled to expire in April 2032.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 11, 2014 and March 3, 2015, we became aware of Paragraph IV certification notices from Aurobindo Pharma Limited and Zydus Pharmaceuticals (USA) Inc., respectively, challenging the 356, 445, 061 and 738 Acetadote Patents on the basis of non-infringement.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 10, 2015, the USPTO issued U.S. Patent number 8,952,065 (the &#8220;065 Acetadote Patent&#8221;) which is assigned to us. The claims of the 065 Acetadote Patent encompass the use of the 200 mg/ml Acetadote formulation to treat patients with acute liver failure. The 065 Acetadote Patent is scheduled to expire in August 2025.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2015, the United States District Court for the Northern District of Illinois, Eastern Division (&#8220;District Court&#8221;) ruled in our favor in our lawsuit against Mylan for infringement of the 445 Acetadote Patent. The opinion upheld our 445 Acetadote Patent and expressly rejected Mylan&#8217;s validity challenge. The District Court ruled that Mylan is liable to us for infringement of the 445 Acetadote patent in light of Mylan&#8217;s Abbreviated New Drug Application in which Mylan sought to market a generic version of Acetadote.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 17, 2015, the District Court entered an order enjoining Mylan and its affiliates from selling or using its generic version of Acetadote until August 2025, the date of expiration of the 445 Acetadote Patent. On October 30, 2015, Mylan filed a notice of appeal to the U.S. Court of Appeals for the Federal Circuit (the &#8220;Appeals Court&#8221;).</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 3, 2016, the USPTO issued U.S. Patent number 9,327,028 (the &#8220;028 Acetadote Patent&#8221;) which is assigned to us. The claims of the 028 Acetadote Patent encompass administration methods of acetylcysteine injection, without specification of the presence or lack of EDTA in the injection. Following its issuance, the 028 Acetadote Patent was listed in the FDA Orange Book and it is scheduled to expire in July 2031.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 26, 2017, the Appeals Court affirmed the District Court ruling in our favor in our lawsuit against Mylan for infringement of the 445 Acetadote Patent. The Appeals Court opinion affirmed the District Court&#8217;s ruling upholding our 445 Acetadote Patent and expressly rejected Mylan&#8217;s validity challenge.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 3, 2017, we became aware of a Paragraph IV certification notice from Exela Pharma Sciences, LLC challenging the 356, 445, 061, 738 and 028 Acetadote Patents on the basis of non-infringement.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Caldolor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an exclusive, worldwide license to clinical data for intravenous ibuprofen from Vanderbilt University, in consideration for royalty obligations related to Caldolor. During 2014, we obtained additional patents for the brand. On May 27, 2014, the USPTO issued U.S. Patent number 8,735,452 (the &#8220;452 Caldolor Patent&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which is assigned to us. The claims of the 452 Caldolor Patent encompass methods of treating pain using intravenous ibuprofen. Following its issuance, the 452 Caldolor Patent was listed in the FDA Orange Book and is scheduled to expire in September 2029.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 28, 2014, the USPTO issued U.S. Patent number 8,871,810 (the &#8220;810 Caldolor Patent&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which is assigned to us. The claims of the 810 Caldolor Patent encompass methods of treating pain using intravenous ibuprofen. Following its issuance, the 810 Caldolor Patent was listed in the FDA Orange Book and is scheduled to expire in September 2029. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2015, we obtained four additional patents for Caldolor. On July 7, 2015, the USPTO issued U.S. Patent number&#8217;s 9,072,710 (the &#8220;710 Caldolor Patent&#8221;) and 9,072,661 (the &#8220;661 Caldolor Patent&#8221;) which are assigned to us. The claims of the 710 Caldolor Patent and the 661 Caldolor Patent include composition and methods of treating pain, inflammation and fever using intravenous ibuprofen. These Caldolor Patents are listed in the FDA Orange Book and are scheduled to expire in March 2032. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2015, the USPTO issued U.S. Patent No. 9,012,508 (the &#8220;508 Caldolor Patent&#8221;) which is assigned to us.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The claims of the 508 Caldolor Patent include methods of treating pain using intravenous ibuprofen. Following its issuance, the 508 Caldolor Patent was listed in the FDA Orange Book and is scheduled to expire in September 2030. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 25, 2015, the USPTO issued U.S. Patent number 9,114,068 (the &#8220;068 Caldolor Patent&#8221;) which is assigned to us. The claims of the 068 Caldolor Patent include methods of treating pain using intravenous ibuprofen. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following its issuance, the 068 Caldolor Patent was listed in the FDA Orange Book and is scheduled to expire in September 2029. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 22, 2015, the USPTO issued U.S. Patent number 9,138,404 (the &#8220;404 Caldolor Patent&#8221;) which is assigned to us. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The claims of the 404 Caldolor Patent include methods of treating pain in critically ill patients with intravenous ibuprofen. Following its issuance, the 404 Caldolor Patent was listed in the FDA Orange Book and is scheduled to expire in September 2029.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 29, 2016, the USPTO issued U.S. Patent number 9,295,639 (the &#8220;639 Caldolor Patent&#8221;) which is assigned to us. The claims of the 639 Caldolor Patent include methods of treating pain in critically ill patients with intravenous ibuprofen. Following its issuance, the 639 Caldolor Patent was listed in the FDA Orange Book and is scheduled to expire in September 2029. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 16, 2017, the USPTO issued U.S. Patent number 9,649,284 (the &#8220;284 Caldolor Patent&#8221;) which is assigned to us. The claims of the 284 Caldolor Patent include methods of treating pain in critically ill patients with intravenous ibuprofen. Following its issuance, the 284 Caldolor Patent was listed in the FDA Orange Book and is scheduled to expire in September 2029. We also have additional patent applications related to Caldolor  pending with the USPTO.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vibativ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own numerous U.S. patents and related international patents for Vibativ. These patents were acquired in our November 2018 acquisition of certain product rights, intellectual property and related assets of Vibativ from Theravance. Two Vibativ patents are listed in the FDA Orange Book. U.S. Patent number 7,531,623 (the &#8220;623 Vibativ Patent&#8221;) is scheduled to expire in January 2027 and includes composition of matter claims that encompass the Vibativ drug substance as well as methods for preparing the Vibativ drug substance. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sancuso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the owner of U.S. Patent number 7,608,282 (the &#8220;282 Sancuso Patent&#8221;) for Sancuso. This patent was acquired in our December 2021 acquisition, which closed in January 2022. The patent is of certain product rights, intellectual property and related assets of Sancuso from Kyowa Kirin, Inc. The 282 Sancuso Patent is listed in the FDA Orange Book and is scheduled to expire in January 2025. The 282 Sancuso Patent includes composition of matter claims that encompass the Sancuso drug product as well as methods of using Sancuso for treatment and/or prophylaxis.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Remaining Products</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no issued patents for our Vaprisol, Omeclamox-Pak or Kristalose products. We have multiple granted patents relating to our ifetroban products and patent applications pending with the USPTO.</span></div><div id="i3928a3425fef4184806511a3516ffab1_55"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMPETITION</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical industry is characterized by intense competition and rapid innovation. Our continued success in developing and commercializing pharmaceutical products will depend, in part, upon our ability to compete against existing and future products in our target markets. Competitive factors directly affecting our markets include but are not limited to: </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product attributes such as efficacy, safety, ease-of-use and cost-effectiveness; </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">brand awareness and recognition driven by sales, marketing and distribution capabilities; </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">intellectual property and other exclusivity rights; </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability of resources to build and maintain developmental and commercial capabilities; </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful business development activities; </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">extent of third-party reimbursements, insurance coverage; and </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment of advantageous collaborations to conduct development, manufacturing or commercialization efforts.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of our competitors possess research and development and sales and marketing capabilities as well as financial resources greater than ours. These competitors, in addition to emerging companies and academic research institutions, may be developing, or in the future could develop, new technologies that could compete with our current and future products or render our products obsolete.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products face competition from other branded products, generics, and alternate medical treatments. Our task is to position each brand to feature its competitive advantages, implement a well thought out marketing plan and provide focused sales, field based medical and other tactical support. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acetadote</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acetadote is our injectable formulation of N-acetylcysteine </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NAC&#8221;) for the treatment of acetaminophen overdose. NAC is accepted worldwide as the standard of care for acetaminophen overdose. Our competitors in the acetaminophen overdose market are those companies selling orally administered NAC including, but not limited to, Geneva Pharmaceuticals, Inc., Bedford Laboratories division of Hikma Pharmaceuticals, Roxane Laboratories, Inc., InnoPharma Inc. and Hospira Inc.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2012, InnoPharma Inc. was granted approval by the FDA to distribute their generic form of the old formulation of Acetadote containing EDTA. In late 2012, we entered into the Settlement Agreement with Paddock and Perrigo that included the right to distribute our Authorized Generic Acetadote injection product. Our branded Acetadote now competes with both the EDTA free Authorized Generic Acetadote distributed by Paddock and Perrigo along with generic Acetadote products that contain EDTA. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers of the old Acetadote formulation include: Akorn, AuroMedics Pharma, Fresenius Kabi and Sagent Pharmaceuticals. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Caldolor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caldolor is marketed for the treatment of pain and fever, primarily in a hospital or surgery center setting. A variety of other products address the acute pain market:</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Morphine, the most commonly used product for the treatment of acute, post-operative pain, is manufactured and distributed by several generic pharmaceutical companies;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Other generic injectable opioids, including fentanyl, meperidine and hydromorphone, address this market;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ketorolac tromethamine (brand name Toradol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), an injectable NSAID, is also manufactured and distributed by several generic pharmaceutical companies;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">IV acetaminophen (brand name Ofirmev</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an injectable analgesic product is sold by Mallinckrodt plc, and there are also generic versions from different manufacturers available;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bupivacaine and meloxicam extended release solution (brand name Zynrelef</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), is a dual-acting anesthetic for postoperative pain sold by Heron Therapeutics;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Oliceridine injection (brand name Olinvyk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), is an opioid agonist, a new chemical entity in the acute surgical postoperative pain market, sold by Trevena, Inc.;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bupivacaine injectable suspension (brand name Exparel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), product sold by Pacira Pharmaceuticals, Inc., along with two additional bupivacaine products, Xaracoll and Posimir,which were more recently approved; and</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Acetaminophen and ibuprofen combination injection (brand name Combogesic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), is a combination of acetaminophen and ibuprofen approved by the U.S. FDA in October 2023, and is sold by Hikma Pharmaceuticals PLC.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of other product candidates in development to treat acute pain including injectable NSAIDs, novel opioids, new formulations of existing therapies and extended release anesthetics. We believe non-narcotic analgesics for the treatment of post-surgical pain are the primary potential competitors to Caldolor.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the injectable analgesic products above, many companies are developing analgesics for specific indications such as migraine and neuropathic pain, oral extended-release forms of existing narcotic and non-narcotic products, as well as those with new methods of delivery such as transdermal. We are not aware of any approved injectable products indicated for the treatment of fever in the U.S. other than Caldolor and Ofirmev. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are, however, numerous drugs available to physicians to reduce fevers in hospital settings via oral and rectal administration to the patient, including ibuprofen, acetaminophen and aspirin. These drugs are manufactured by numerous pharmaceutical companies.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kristalose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kristalose is a dry powder crystalline prescription formulation of lactulose indicated for the treatment of constipation. The U.S. constipation therapy market includes various prescription and over the counter, or OTC, products. The branded prescription products which we believe are our primary competitors are:</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Lubiproston (brand name Amitiza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), an oral product indicated for the treatment of chronic  idiopathic constipation, irritable bowel syndrome with constipation in adults, is manufactured and sold by Mallinckrodt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceuticals.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Naloxegol (brand name Movantik</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), an oral product indicated for the treatment of opioid-induced constipation in adults with chronic non-cancer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pain. It was acquired by RedHill Biopharma in the first quarter of 2020. </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Linaclotide (brand name Linzess</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), an oral product indicated for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. It is sold by Allergan, Inc. and Ironwood Pharmaceuticals, Inc.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Plecanatide (brand name Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), an oral product indicated for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. It is sold by Synergy Pharmaceuticals.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Generic and branded liquid lactulose products are marketed by a number of pharmaceutical companies.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Lactitol for oral solution (brand name Pizensy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), an oral, osmotic laxative indicated  for the treatment of chronic idiopathic constipation.  It is distributed by Braintree Laboratories, Inc. and was recently approved by the FDA.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are several hundred OTC products used to treat constipation marketed by numerous pharmaceutical and consumer health companies. MiraLax (polyethylene glycol 3350), previously a prescription product, was indicated for the treatment of constipation and manufactured and marketed by Bayer. MiraLax was converted to an OTC product in February 2007 and recently, the FDA rescinded the approval of the generic prescription polyethylene glycol 3350 products.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sancuso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sancuso is the only transdermal patch FDA approved for the management of chemotherapy induced nausea and vomiting (&#8220;CINV&#8221;). Each patch delivers up to five days of treatment with granisetron, a standard of care for CINV, through the skin. Recommended treatment suggests the patch be applied 24 to 48 hours prior to chemotherapy treatment and remain in place for five days.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While there are no other transdermal products available to treat CINV, there is a large number of generic and branded oral products as well as a limited number of injectables. Cumberland considers the oral branded products to be the most important competition including Akynzeo; Emend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Oral (manufactured by Merck); Varubi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> branded NK1 receptor antagonist sold by Tesaro Inc. a division of GSK); Zuplenz</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  (a branded version of Ondansetron marketed by Par Pharmaceuticals, Inc.) and Kytril</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (a branded version of injectable granisetron hydrochloride manufactured by Roche Pharmaceuticals Inc.).</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vaprisol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vaprisol is a patented, prescription brand indicated to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia. The product was developed and registered by Astellas and then launched in 2006. It is one of two branded prescription products indicated for the treatment of hyponatremia, and the first and only intravenously administered branded treatment. The other competing product is Samsca</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(an oral tolvaptan product sold by Otsuka Pharmaceutical Company).  There are also several generic versions of tolvaptan sold by other companies.</span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vibativ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vibativ is a potent, once-daily, injectable antibiotic for the treatment of certain gram-positive infections. Vibativ is approved for the treatment of complicated skin and skin structure infections and hospital-acquired or ventilator-associated bacterial pneumonia caused by susceptible isolates of Staphylococcus aureus when alternative treatments are not suitable. There are several generic and branded antibiotics that compete for these indications. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major generic competitors are vancomycin, linezolid, and daptomycin. Vancomycin is by far the most widely used agent. Newer branded agents are also available including:</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Ceftaroline fosamil (brand name Teflaro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ), an injectable antibiotic manufactured and sold by</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allergan;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Dalbavancin (brand name Dalvance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ), an injectable antibiotic manufactured and sold by</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allergan; and</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Oritavancin (brand name Orbactiv</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ), an injectable antibiotic manufactured and sold by</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Melinta</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also aware of a number of other novel antibiotics that are currently in development. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Antibiotic drug selection is based both on an empiric and susceptibility proven basis. In the hospital setting, cost is an important factor which favors the use of generic agents if they are effective. Newer agents are often reserved for two reasons: they are valuable in the treatment of patients that fail to respond to generics and it is considered good practice to conserve the use of these agents to reduce the risk of resistance.antimicrobial resistance, which is considered a global public health threat by the Center for Disease Control and Prevention (&#8220;CDC&#8221;). </span></div><div id="i3928a3425fef4184806511a3516ffab1_58"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GOVERNMENT REGULATION</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of new pharmaceutical products can be a long, expensive and risky process. There is no assurance we will obtain successful study results or secure the needed market approvals for our pipeline product candidates. Governmental authorities in the U.S. and other countries extensively regulate the research, development, testing, manufacturing, distribution, marketing and sale of pharmaceutical products. For more information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Risks Relating to Government Regulation"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part I, Item 1A of this Form 10-K. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the FDA under the Federal Food, Drug, and Cosmetic Act, (&#8220;FDCA&#8221;), the Public Health Service Act, and other federal statutes and regulations, subjects pharmaceutical products to rigorous review. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending New Drug Applications (&#8220;NDAs&#8221;) or biologics license applications, (&#8220;BLAs&#8221;), warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, and criminal prosecution.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, our manufacturers and contract research organizations may also be subject to regulations under other federal, state and local laws, including the Occupational Safety and Health Act, (&#8220;OSHA&#8221;), the Resource Conservation and Recovery Act, the Clean Air Act and import, export and customs regulations as well as the laws and regulations of other countries.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FDA Approval Process</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA is a regulatory agency within the Department of Health and Human Services. One of their key responsibilities is to regulate the safety and effectiveness of drugs sold in the United States. The FDA manages this responsibility in two phases: pre-approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(pre-market) and post approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(post-market). The FDA reviews manufacturers' applications to market drugs in the United States; a drug may not be sold unless it has FDA approval. The FDA continues its oversight of drug safety and effectiveness as long as the drug is on the market.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To market a prescription drug in the United States, a manufacturer needs FDA approval. To get that approval, the manufacturer must demonstrate the drug's safety and effectiveness according to criteria specified in law and agency regulations, ensure that its manufacturing plant passes FDA inspection, and obtain FDA approval for the drug's labeling, a term that includes all written material about the drug, including, for example, packaging, prescribing information for physicians and patient brochures.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The progression to drug approval begins before FDA involvement. First, scientists work in the laboratory to discover and develop a new compound. Next, basic safety questions are answered by nonclinical testing with animals and then, a drug or biotechnology company develops a prototype drug. That company must seek clearance from the FDA by way of an IND application to test the product with human subjects. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Those tests, called clinical trials, are carried out sequentially in Phase I, II, and III studies, which involve increasing numbers of subjects. The manufacturer then compiles the resulting data and analyses in an NDA. The FDA reviews the NDA with three major concerns: (1) safety and effectiveness in the drug's proposed use; (2) appropriateness of the proposed labeling; and (3) adequacy of manufacturing methods to assure the drug's identity, strength, quality and purity.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and associated regulations detail the requirements at each step. The FDA uses a few special mechanisms to expedite drug development and the review process when a drug might address an unmet need or a serious disease or condition. Those mechanisms include accelerated approval, fast track and priority reviews and the newer designation, breakthrough therapy.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sponsor of the drug typically conducts human clinical trials in three sequential phases, but the phases may overlap. Phase I clinical trials are generally conducted in a small number of healthy volunteers, primarily to collect and assess pharmacokinetics and safety data at one or more dosages prior to proceeding into patients. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Phase II clinical trials, the sponsor evaluates the early efficacy of the product in short term trials on the targeted indication and identifies possible adverse effects and safety risks in a patient population. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase III clinical trials typically involve testing for patients in long term trials examining safety and clinical efficacy in an expanded population at geographically-dispersed test sites.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA requires that clinical trials be conducted in accordance with the FDA&#8217;s Good Clinical Practice (&#8220;GCP&#8221;) requirements. The FDA may order the partial, temporary or permanent discontinuation of a clinical trial at any time or impose other sanctions if it believes that the clinical trial is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. The institutional review board ("IRB"), or ethics committee (outside of the U.S.), of each clinical site generally must approve the clinical trial design and patient informed consent and may also impose other conditions or require the clinical trial at that site to be halted, either temporarily or permanently, for failure to comply with the IRB's requirements.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of the nonclinical and clinical trials, together with detailed information on the manufacturing and composition of the product and proposed labeling, are submitted to the FDA in the form of an NDA for marketing approval. The NDA undergoes a 60-day validation review period before it is accepted for filing. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the NDA is found to be incomplete, it will not be accepted. Once the NDA is validated and accepted for filing, the FDA begins an in-depth review of the NDA. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under policies agreed to by the FDA under the Prescription Drug User Fee Act, or PDUFA (currently PDUFA VII - effective September 30, 2022), the FDA has a target timeline of 10 months in which to complete its initial review of a standard NDA and respond to the applicant. The review process and the PDUFA goal date may be extended by two months to address deficiencies, or by three months if the FDA requests or if the NDA sponsor otherwise provides additional information or clarification regarding information already provided in the submission at any time during the review clock period. If the FDA&#8217;s evaluations of the NDA and the clinical and manufacturing procedures and facilities are favorable and meet all regulations, the FDA will issue an approval letter. Priority review is reserved for drugs that represent a &#8220;significant improvement in safety or efficacy&#8221; over existing treatments. The FDA endeavors to complete priority reviews in six months.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the NDA meets with FDA approval, a letter will be sent out indicating approval and final labeling recommendations. If not, a complete response letter will be sent to applicants indicating that the review cycle for an application is complete and that the application is not ready for approval. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The complete response letter will describe the specific deficiencies that the agency has identified in an application and what changes must be made before the application can be approved, with no implication regarding </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">whether the application will ultimately be approved. An approval letter authorizes commercial marketing of the drug for the proposed indication(s) under study. While the FDA&#8217;s PDUFA 2021 Performance Report showed a continued increase in the percentage of first-cycle approval letters for new molecular entities rising from 56% for FY 2009 to 84% for FY 2023, we cannot be certain that timely first-cycle approvals will be maintained by the FDA.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the time and cost of completing these steps and obtaining FDA approval can vary dramatically depending on the drug, it can take many years and cost millions of dollars for a novel drug.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section 505(b) New Drug Applications</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An NDA may be submitted under different methods, a 505(b)(1), 505(b)(2) or 505(j). Section 505(b) provides for the submission of an NDA to support the approval of a drug. Upon approval, a drug may be marketed only for the FDA-approved indication(s) in the approved dosage form. Further clinical trials may be necessary to gain approval for the use of the product for any additional indications or dosage forms. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA also requires post market safety surveillance reporting to monitor the side effects of the drug, which may result in withdrawal of approval after marketing begins if significant adverse safety findings are found.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 505(b)(1), or the &#8216;full&#8217; NDA, is used for new chemical entities (&#8220;NCEs&#8221;) and requires full clinical and nonclinical development of a compound. Marketing exclusivity assigned to a 505(b)(1) approval is five years. A 505(b)(2) NDA permits the submission of an NDA where at least some of the information required for approval comes from studies not conducted by or for the applicant using previously reported safety and efficacy data, and for which the applicant has not obtained a right of reference. Generally new studies are required to provide data on the proposed change. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some examples of products that may be allowed to follow a 505(b)(2) path to approval are drugs that have a new dosage form, strength, route of administration, formulation or indication or combination drugs. Marketing exclusivity for a 505(b)(2) submission is three years. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both 505 (b)(1) and (b)(2) are eligible for seven years of exclusivity for orphan drugs and/or six months for pediatric exclusivity. Any marketing exclusivity is independent of patent exclusivity. We successfully secured FDA approvals for Acetadote in January 2004 and for Caldolor in June 2009 pursuant to the 505(b)(2) pathway. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan drug designation</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Orphan Drug Act of 1983 (the &#8220;Orphan Drug Act&#8221;) encourages manufacturers to seek approval of products intended to treat &#8220;rare diseases and conditions&#8221; with a prevalence of fewer than 200,000 patients in the U.S. or for which there is no reasonable expectation of recovering the development costs for the product. For products that receive orphan drug designation by the FDA, the Orphan Drug Act provides tax credits for clinical research, FDA assistance with protocol design, eligibility for FDA grants to fund clinical studies, waiver of the FDA application fee and a period of seven years of marketing exclusivity for the product following FDA marketing approval. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acetadote received orphan drug designation in October 2001 and in 2004 the FDA approved the product to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen. Acetadote was entitled to marketing exclusivity until January 2011 for the treatment of this approved indication.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section 505(j) abbreviated new drug applications</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An abbreviated new drug application (&#8220;ANDA&#8221;) is a type of NDA where approval of a generic drug is based on demonstrating comparability to an innovator drug product (the Reference Listed Drug, or RLD). Applications are "abbreviated" because they generally do not include pre-clinical and clinical data to establish safety and effectiveness. Generics must demonstrate that the product is bioequivalent (i.e., performs in the same manner and is comparable to the 'innovator' product in active ingredient, dosage form, strength, route of administration, labeling, quality, performance characteristics and intended use). </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbreviated applications may be submitted for drug products that are the same as a listed drug and must be identical in active ingredient(s), form, strength, route of administration and in conditions of use (non-exclusive uses). Products are declared suitable based on a suitability petition to the FDA. If the petition is approved, the sponsor may then submit the ANDA.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Hatch-Waxman Act</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Drug Price Competition and Patent Term Restoration Act, informally known as the &#8220;Hatch-Waxman Act&#8221;, is a 1984 United States federal law that established the modern system of generic drugs. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Hatch-Waxman Act amended the Federal Food, Drug, and Cosmetic Act. Section 505(j) 21 U.S.C. 355(j) sets forth the process by which would-be marketers of generic drugs can file ANDAs to seek FDA approval of the generic. Section 505(j)(2)(A)(vii)(IV), the so-called Paragraph IV, allows 180-day exclusivity to companies that are the "first-to-file" an ANDA against holders of patents for branded counterparts.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These Hatch-Waxman Act amendments grant generic manufacturers the ability to mount a validity challenge without incurring the cost of entry or risking enormous damages flowing from any possible infringement. The Hatch-Waxman Act essentially redistributes the relative risk assessments and explains the flow of settlement funds and their magnitude. The Hatch-Waxman Act gives generics considerable leverage in patent litigation.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health care legislation</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2010, former President Obama signed into law the Patient Protection and Affordable Care Act, (&#8220;PPACA&#8221;). On March 30, 2010, the Health Care and Education Reconciliation Act of 2010 (&#8220;HCERA&#8221;), was enacted into law, which modified the revenue provisions of the PPACA. The PPACA as amended by the HCERA constitutes the healthcare reform legislation. The following highlights certain provisions of the legislation that may affect us.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmaceutical Industry Fee: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in calendar-year 2011, an annual fee was imposed on pharmaceutical manufacturers and importers that sell branded prescription drugs to specified government programs (e.g., Medicare Part D, Medicare Part B, Medicaid, Department of Veterans Affairs programs, Department of Defense programs and TRICARE). </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual fee is allocated to companies based on their previous calendar-year market share using sales data that the government agencies that purchase the pharmaceuticals will provide to the Treasury Department. Although we participate in governmental programs that subject us to this fee, our sales volume in such programs is less than $10 million, with the first $5 million of sales being exempt from the fee. This fee has not had a material impact and is not expected to have a material impact on our results of operations.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, PDUFA imposes annual program fees. An applicant will be assessed annual prescription drug program fees for prescription drug products, incurring a fee for each strength of a drug product. An applicant may not be assessed more than five prescription drug program fees for a fiscal year for prescription drug products identified in a single approved application.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Physician Payments Sunshine Act: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PPACA also includes provisions known as the Physician Payments Sunshine Act (&#8220;Sunshine Act&#8221;), which requires manufacturers of pharmaceuticals and medical devices covered under Medicare and Medicaid to record any transfers of value to physicians and teaching hospitals and to report this data to the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;), for aggregation and subsequent public disclosure. Under the Sunshine Act, beginning August 1, 2013, we have collected data regarding reportable transfers of value and have reported such data to CMS. Failure to report appropriate data may result in civil or criminal fines and/or penalties. In addition to the Federal Sunshine Act, similar reporting requirements have also been enacted on the state level requiring transparency of interactions with health care professionals.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medicaid Rebate Rate:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the Medicaid Drug Rebate program we currently are required to provide rebates for covered outpatient drugs that are dispensed to Medicaid beneficiaries. In addition, we also are required to participate in the Public Health Service&#8217;s 340B drug pricing program, which requires us to agree to </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">charge no more than a designated ceiling price for covered outpatient drugs that are dispensed to community health clinics and other entities that receive health services grants from the Public Health Service, as well as hospitals that serve a disproportionate share of low-income patients.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Serialization:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In November of 2013, the FDA passed the Drug Supply Chain Security Act (&#8220;DSCSA&#8221;). The DSCSA was created to strengthen the security of the drug distribution supply chain by adding controls such as a national pharmaceutical track and trace system and establishing national standards for licensing of prescription drug wholesale distributors and third-party logistics providers. DSCSA requires trading partners, including manufacturers, repackagers, wholesale distributors and dispensers to provide transaction information to subsequent purchasers for certain prescription drugs. We have taken necessary steps to implement this program and are in compliance with all requirements.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Century Cures Act:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The 21st Century Cures Act (&#8220;Cures Act&#8221;), signed into law on December 13, 2016, is designed to help accelerate medical product development and bring new innovations and advances to patients who need them faster and more efficiently. The law builds on the FDA&#8217;s ongoing work to incorporate the perspectives of patients into the development of drugs, biological products and devices in the FDA&#8217;s decision-making process. The Cures Act enhances the FDA&#8217;s ability to modernize clinical trial designs and clinical outcome assessments, which will speed the development and review of novel medical products, including medical countermeasures.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, the Cures Act enables us to work with the FDA in the development of new biomarkers, clinical outcome assessments, surrogate endpoints and patient reported outcomes. It allows for the use of data summaries (rather than full clinical trials for approval) as well as the use of real-world evidence to support approval of new indications of approved medical products, or to help satisfy post-approval study requirements for marketed products.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Build Back Better Act and Other Proposed Legislation:  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Build Back Better Act (&#8220;BBBA&#8221;) was introduced in the 117</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Congress and included provisions that were intended to lower the price of prescription drugs, including granting the Medicare program the authority to negotiate prescription drug prices and imposing tax penalties on drug manufacturers if the price of drugs increases too rapidly. Ultimately the BBBA was not enacted, however, future legislative initiatives are likely to include provisions targeted at containing costs in the prescription drug market.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Post Approval Activities</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a drug is on the U.S. market (following FDA approval of the NDA), the FDA continues to address drug production, distribution and use. FDA activities are based on ensuring drug safety and effectiveness. They address product integrity, labeling, reporting of research and adverse events, surveillance, drug studies, risk management, information dissemination, off-label use, physician advertising and direct-to-consumer advertising.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we amend the NDA for an FDA approved product, such as adding safety or efficacy labeling claims, promoting those new claims, making certain manufacturing changes or product enhancements, we will need FDA review and approval before the change can be implemented. While physicians may use products for indications that have not been approved by the FDA, we may not label or promote the product for an indication that has not been approved. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securing FDA approval for new indications, product enhancements and manufacturing and labeling changes may require us to conduct additional clinical trials under the FDA&#8217;s IND regulations. Even if such studies are conducted, they are still subject to the same requirements and timelines as an original NDA.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA continuously gathers information about possible adverse reactions to the products it has approved for use. The FDA requires all manufacturers to report adverse events. It also provides a procedure for consumers and physicians to voluntarily report their concerns about drugs. The agency collects those reports through MedWatch and uses its FDA Adverse Event Reporting System (FAERS) to store and analyze them. Because some events may occur after the use of a drug for reasons unrelated to the product, the FDA reviews the events to assess which ones may indicate a problem with that particular drug. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">They then use information gleaned from the surveillance data to determine a course of action. They might recommend a change in drug labeling to alert users to a potential problem, or perhaps, require the manufacturer to study the observed association between the drug and the adverse event.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state and federal laws have been applied to restrict certain marketing practices in the pharmaceutical industry in recent years. These laws include anti-kickback statutes and false claims statutes. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal health care program anti-kickback statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any health care item or service reimbursable under Medicare, Medicaid or other federally financed health care programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers and prescribers, purchasers or formulary managers. Violations of the anti-kickback statute are punishable by imprisonment, criminal fines, civil monetary penalties and exclusion from participation in federal health care programs.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to these U.S. laws, we are subject to similar laws that govern our marketing practices and financial arrangements with health care providers and otherwise are intended to prohibit illicit kickbacks and bribery, including the Foreign Corrupt Practices Act.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Federal False Claims Act</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal false claims laws prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to have a false claim paid. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of pharmaceutical and other health care companies have been prosecuted under these laws for allegedly inflating drug prices they report to pricing services, which in turn were used by the government to set Medicare and Medicaid reimbursement rates, and for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HIPAA and Other Data Protection Laws</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, we and our collaborators are subject to numerous federal and state privacy and security laws and regulations, including the Health Insurance Portability and Accountability Act of 1996. These laws include obligations related to protecting the privacy and security of health-related personal information, such as information that we may obtain through the clinical trial process. In addition, similar laws and regulations exist in Europe and other jurisdictions, including the European Union&#8217;s General Data Protection Regulation.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ICH - International Committee on Harmonization</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the U.S., our ability to market our products will depend on receiving marketing authorizations from the appropriate regulatory authorities. The International Committee on Harmonization (&#8220;ICH&#8221;) provides a set of standards that most regulatory authorities adhere to (e.g. U.S., Europe, and Japan) allowing greater harmonization in the interpretation and application of technical guidelines and requirements for pharmaceutical product registration, thereby reducing or obviating duplication of testing carried out during the research and development of new human medicines. Regulatory harmonization offers many direct benefits to both regulatory authorities and the pharmaceutical industry with beneficial impact for the protection of public health.</span></div><div id="i3928a3425fef4184806511a3516ffab1_61"></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ENVIRONMENTAL MATTERS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to federal, state and local environmental laws and regulations and we believe that our operations comply with such regulations. We anticipate that the effects of compliance with federal, state and local laws and regulations relating to the discharge of materials into the environment will not have any material effect on our capital expenditures, earnings or competitive position.  </span></div><div id="i3928a3425fef4184806511a3516ffab1_64"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SEASONALITY</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no significant seasonal aspects to our business.</span></div><div id="i3928a3425fef4184806511a3516ffab1_67"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BACKLOG</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the relatively short lead-time required to fill orders for our products, backlog of orders is not considered material to our business.</span></div><div id="i3928a3425fef4184806511a3516ffab1_70"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EMPLOYEES</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had 91 employees. We believe that our future will depend in part on our continued ability to attract, hire, and retain qualified personnel, including hospital oncology and field sales personnel in particular. To that end, we work with qualified search firms to identify talent, we measure and adjust compensation levels to remain competitive and we work closely with team members to support their success.</span></div><div id="i3928a3425fef4184806511a3516ffab1_73"></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make statements in this Annual Report on Form&#160;10-K that are &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statement of historical facts may be forward-looking statements. In particular, forward-looking statements include, among other things, statements regarding our intent, belief or expectations, and can be identified by the use of terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;estimate,&#8221; &#8220;should,&#8221; &#8220;seek,&#8221; &#8220;anticipate&#8221; and other comparable terms or the negative thereof. In addition, we, through our senior management, from time to time make forward-looking oral and written public statements concerning our expected future operations and other developments. While forward-looking statements reflect our good-faith beliefs and best judgment based upon current information, they are not guarantees of future performance and are subject to known and unknown risks and uncertainties, including those mentioned in Item&#160;1A, &#8220;Risk Factors,&#8221; Item&#160;7, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and elsewhere in this Form&#160;10-K. Accordingly, investors are cautioned not to place undue reliance on any forward-looking statements. Actual results may differ materially from the expectations contained in the forward-looking statements as a result of various factors. Such factors include, but are not limited to:</span></div><div style="margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The possible or assumed future results of operations, including the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; </span></div><div style="margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The impact of macroeconomic conditions, including inflationary pressures, rising interest rates, general economic slowdown or a recession, changes in monetary policy, volatile market conditions, financial institution instability, as well as geopolitical instability and the ongoing conflicts outside the U.S., on our operations;</span></div><div style="margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our competitive position and competitors, including the size and growth potential of the markets for our products and product candidates;</span></div><div style="margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The success, cost and timing of our product acquisition and development activities and clinical trials; and our ability to successfully commercialize our product candidates;</span></div><div style="margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product efficacy or safety concerns, whether or not based on scientific evidence, resulting in product withdrawals, recalls, regulatory action on the part of the FDA (or international counterparts) or declining sales;</span></div><div style="margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The performance of our third-party suppliers and manufacturers which impacts our supply chain and could create business shutdowns or product shortages; and the retention of key scientific and management personnel;</span></div><div style="margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The impact on our business, financial condition and results of operations from the effects of a pandemic or the outbreak of an infectious disease in the United States and worldwide and resulting governmental and societal responses;</span></div><div style="margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Challenges to our patents and the introduction of generic versions of our products and product candidates, which could negatively impact our ability to commercialize and sell our products and product candidates and decrease sales a result of market exclusivity;</span></div><div style="margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in reimbursement available to us, including changes in Medicare and Medicaid payment levels and availability of third-party insurance coverage and the effects of future legislation or regulations, including changes to regulatory approval of new products, licensing and patent rights, environmental protection and possible drug re-importation legislation;</span></div><div style="margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Interruptions and breaches of our computer and communications systems, and those of our vendors, including computer viruses, hacking and cyber-attacks, that could impair our ability to conduct business and communicate internally and with our customers, or result in the theft of trade secrets or other misappropriation of assets, or otherwise compromise privacy of sensitive information belonging to us, our customers or other business partners; and </span></div><div style="margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Issuance of new or revised accounting standards by the Financial Accounting Standards Board and the Securities and Exchange Commission. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The list above contains many, but not all, of the factors that could impact our ability to achieve results described in any forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider this list to be a complete statement of all potential risks and uncertainties. For more information about the risks, uncertainties, and other factors that could affect our future results, please refer to Item 1A, Risk Factors, included herein.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">33</span></div></div></div><div id="i3928a3425fef4184806511a3516ffab1_76"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div id="i3928a3425fef4184806511a3516ffab1_1276"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;1A. Risk Factors.</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risk Factor Summary</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. You should carefully consider all information in this Annual Report on Form 10-K prior to investing in our common stock. These risks are discussed more fully in the section titled &#8220;Risk Factors.&#8221; These risks and uncertainties include, but are not limited to, the following:</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Global and national conditions and events, including, but not limited to, rising interest rates, increased inflation, supply chain disruptions, labor conditions, pandemics and public health crises and international conflict, may adversely affect our business, revenues, results of operations and financial condition.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to implement strategies to enhance our performance could have a material adverse effect on our business, results of operations and financial conditions.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to perform depends on keeping and hiring exceptionally talented management and employees, and our failure to do so could have a material adverse effect on our business, revenues, results of operations and financial condition.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our success depends, in part, on our ability to successfully obtain or retain high-performing third-party performers on commercially acceptable terms, and the failure to do so can have a material adverse effect on our business, financial conditions and results of operations.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business is subject to stringent government regulations, it must adhere to numerous complex pieces of legislation, and all of our products face regulatory challenges.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business depends on the successful protection of our intellectual property rights and our product candidates becoming approved by regulatory agencies, commercially viable, and accepted by the market.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business faces a serious financial risk if generic products that compete with any of our branded pharmaceutical products are approved and sold because sales of our products will be adversely-affected and our business may not recover the capital costs of bringing that product to market.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business faces an inherent risk of product liability lawsuits related to the testing of our product candidates and the commercial sale of our products, and if we cannot successfully defend ourselves against the product liability claim, we may incur substantial liabilities.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may attempt to develop internationally and license our products globally, as well as invest in other businesses or joint ventures, all of which may be unsuccessful, divert our management&#8217;s attention and harm our operating results and prospects. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk factors described below and throughout this report should be carefully considered and could materially affect our business. There are also risks that are not presently known or not presently material, as well as the other information set forth in this report that could materially affect our business. In addition, in our periodic filings with the SEC, press releases and other statements, we discuss estimates and projections regarding our future performance and business outlook. By their nature, such &#8220;forward-looking statements&#8221; involve known and unknown risks, uncertainties and other factors that in some cases are out of our control. For a further discussion of forward-looking statements, please refer to the section entitled &#8220;Special Note Regarding Forward-Looking Statements.&#8221; These factors could cause our actual results to differ materially from our historical results or our present expectations and projections. These risk factors and uncertainties include, but are not limited to the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO OUR BUSINESS</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Global and national economic conditions and events, including, but not limited to increased inflation, rising interest rates, supply chain disruptions, labor conditions, pandemics and public health crises and international conflicts, could affect our future access to liquidity and materially adversely affect our results of operations and financial condition.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our business and results of operations could be adversely affected by changes in global or national economic conditions. These conditions include, but are not limited to, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increased inflation, high and rising interest rates, supply chain disruptions, labor conditions, the negative impacts from pandemics and public health crises (including any lingering or recurring adverse impacts from the COVID-19 pandemic) and the negative impacts resulting from the ongoing conflicts in Eastern Europe and the Middle East. These conditions have had a significant adverse impact on economic and market conditions around the world, including the United States. While the economic impact brought by, and the duration of, such global events is difficult to assess or predict, such events could result in additional disruption of global financial markets, reducing our ability to access capital in the future, which could negatively affect our liquidity in the future and in ways that cannot be predicted potentially including a prolonged recessionary environment in the United States. In the longer term, there could be significant new regulatory actions and other events that could limit our activities and investment opportunities or change the functioning of the capital markets, and there is the possibility of a severe worldwide economic downturn. Inflation rates have increased recently to levels not seen in decades. If our costs, in particular costs related to clinical trial expenses and/or employee-related expenses, were to become subject to significant inflationary pressures, it may adversely impact our business, operating results and financial condition. In response to inflationary pressures, the Federal Reserve raised interest rates in 2022 and 2023, and these increases may continue in 2024 and beyond. Increases in interest rates, especially if coupled with reduced government spending and volatility in financial markets, may further increase economic uncertainty and heighten these risks. Although we do not believe that inflation has had a material impact on our financial position or results of operations to date, we may experience increases in the near future (especially if inflation rates continue to rise) on our operating costs, including our labor costs and research and development costs, due to supply chain constraints, ongoing effects of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the COVID-19 pandemic, the ongoing conflicts in Eastern Europe and the Middle East and employee availability and wage increases.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An adverse development regarding our products could have a material and adverse impact on our future revenues and profitability.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product portfolio currently includes seven brands: Acetadote, Caldolor, Kristalose, Vaprisol, Omeclamox-Pak, Vibativ and Sancuso. A product contamination or other safety or regulatory issues, such as a failure to meet certain FDA reporting requirements involving our products, could negatively impact us and possibly lead to a product recall. In addition, changes impacting any of our products in areas such as competition, lack of market acceptance or demand, government regulation, intellectual property, reimbursement and manufacturing could have an adverse impact on our future revenues and profitability including:</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in intellectual property protection available for our products or competing treatments; </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any unfavorable publicity concerning us, our products, or the markets for these products such as information concerning product contamination or other safety issues in any of our product markets, whether or not directly involving our products;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Perception by physicians and other members of the healthcare community of the safety or efficacy of our products or competing products;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulatory developments related to our marketing and promotional practices or the manufacture or continued use of our products;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The prices of our products relative to other drugs or competing treatments;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The impact of current or additional generic competitors;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The availability and level of third-party reimbursement for sales of our products;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The continued availability of adequate supplies of our products to meet demand:</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Weakened demand for our products; and</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unforeseen or serious adverse effects outside of those specified in current product labeling being attributed to any of our approved products.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acetadote may be used to treat acetaminophen overdoses. The FDA has previously requested prescribers and manufacturers of prescription combination products that contain acetaminophen to limit the amount of acetaminophen to no more than 325 milligrams (mg) in each tablet or capsule. The FDA requested this action to protect consumers from the risk of severe liver damage which can result from excess acetaminophen which may reduce the number of acetaminophen overdoses which could result in a lower demand for Acetadote. If the demand for Acetadote decreases, it could have an adverse impact on our future revenues and profitability.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of Caldolor is dependent on many third-parties, including physicians, pharmacists, hospital pharmacy and therapeutics committees, or P&amp;T committees, suppliers and distributors, all of whom we have little or no control over. We expect Caldolor to continue to be administered primarily to hospital and surgery center patients who are unable to receive oral therapies for the treatment of pain or fever. Before we can distribute Caldolor to any new hospital customers, Caldolor must be approved for addition to the hospitals&#8217; formulary lists by their P&amp;T committees. A hospital&#8217;s P&amp;T committee generally governs all matters pertaining to the use of medications within the institution, including review of medication formulary data and recommendations of drugs to the medical staff. We cannot guarantee that we will be successful in getting the approvals we need from enough P&amp;T committees to be able to optimize hospital sales of Caldolor. Even if we obtain hospital approval for Caldolor, we must still convince individual hospital physicians to prescribe Caldolor repeatedly. The commercial success of Caldolor also depends on our ability to coordinate supply, distribution, marketing, sales and education efforts. As with our other products, if Caldolor is not accepted in the marketplace, it could have an adverse impact on our future revenues and profitability.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to review and approve new products and otherwise affect the FDA&#8217;s ability to perform routine functions. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs or modifications to approved drugs to be reviewed and/or approved by necessary government agencies. Such disruptions could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If any manufacturer or partner we rely upon fails to supply our products in the amounts we require on a timely basis, or fails to comply with stringent regulations applicable to pharmaceutical drug manufacturers, we may be unable to meet demand for our products and may lose potential revenues.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not manufacture any of our products, and we do not currently plan to develop any capacity to do so. Our dependence upon third parties for the manufacture of our products could adversely affect our profit margins or our ability to develop and deliver products on a timely and competitive basis. If for any reason we are unable to obtain or retain third-party manufacturers on commercially acceptable terms, we may not be able to sell our products as planned. Furthermore, if we encounter delays or difficulties with contract manufacturers in producing our products, the distribution, marketing and subsequent sales of these products could be adversely affected. A long-term inability to meet demand for our products could result in impairment of our brands overall future and the carrying value of the assets associated with our brands. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acetadote:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have an agreement with one manufacturer to provide commercial supply of Acetadote. If this manufacturer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is unable to produce marketable inventory in sufficient quantities, in the agreed upon time period, we could suffer an inability to meet demand for Acetadote.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Caldolor:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  We have agreements with multiple manufacturers for the supply of Caldolor. If the manufacturers of Caldolor are unable to produce marketable inventory in sufficient quantities, in the agreed upon time period, we could suffer an inability to meet demand for Caldolor.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kristalose:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The active pharmaceutical ingredient for Kristalose is manufactured at a single facility through a complex process. It would be particularly difficult to find a new manufacturer of the Kristalose active pharmaceutical ingredient on an expedited basis. We have manufacturing relationship with one packager who provided finished supplies of Kristalose  for commercial and sampling purposes during 2022. If the manufacturing or packaging facilities are unable to produce useable or marketable inventory in sufficient quantities, in the agreed upon time period, we could suffer an inability to meet demand for Kristalose.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Omeclamox-Pak:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our packager for  Omeclamox-Pak  encountered financial difficulties due to the impact of COVID-19, and their operations are currently suspended. Cumberland is awaiting resumption of those operations while also exploring other alternatives to restart the product&#8217;s packaging. In October 2020, we informed the FDA of a shortage of Omeclamox-Pak which continues. If we are unable to obtain marketable inventory in the future, we could continue to suffer an inability to meet demand for Omeclamox-Pak.  With uncertain future cash flows, the Board of Directors approved the write-down of the intangible assets related to the product.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaprisol:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2018, the manufacturer of Vaprisol informed us that they would no longer be able to provide the product following the manufacturing of one final batch which is providing us with a multi-year supply. We are currently working with a new manufacturer to provide us with long term supplies of the product. In February 2022, we notified the FDA of a shortage of Vaprisol. If we are unable to produce additional marketable inventory in sufficient quantities, in the required  time frame, we could suffer an inability to meet demand for Vaprisol.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vibativ:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Through our acquisition of Vibativ, we acquired a multi-year supply of raw material, work in process and finished goods inventory. In 2020, we completed the transfer of Vibativ manufacturing activities to a new supplier. If we are unable to continue to obtain marketable inventory in sufficient quantities, in the agreed upon time period, we could suffer an inability to meet demand for Vibativ.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sancuso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: As part of the acquisition of Sancuso in January 2022, we obtained an initial supply of finished goods inventory and work in progress. On December 6, 2022, we received notification from Kyowa Kirin, Inc. that the FDA approved a supplemental new drug application associated with a new site at Kindeva Drug Delivery L.P., for the manufacturing and primary packaging of the Sancuso brand.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, all manufacturers of our products and product candidates must comply with current good manufacturing practices, ("GMPs"), enforced by the FDA through its facilities inspection program. These requirements include quality control, quality assurance, and the maintenance of records and documentation. Manufacturers of our products must be unable to comply with GMP requirements and with other FDA, state, and foreign regulatory requirements.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no control over our manufacturers&#8217; compliance with these regulations and standards. If our third-party manufacturers do not comply with these requirements, we could be subject to fines and civil penalties; suspension of production or distribution; suspension or delay in product approval; product seizure or recall; and withdrawal of product approval.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on a variety of other third parties. If these third parties fail to perform as we expect, our operations could be disrupted and our financial results could suffer.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a relatively small internal infrastructure. We rely on a variety of third parties, in addition to our manufacturers, to help us operate our business. If these third parties do not continue to provide services to us, or collaborate with us, we might not be able to obtain others who can serve these functions. This could disrupt our business operations, increase our operating expenses or otherwise adversely affect our operating results. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, we depend and will continue to depend upon independent investigators and collaborators, such as universities, medical institutions, contract research organizations (CROs) and strategic partners to conduct our preclinical and clinical trials. We negotiate budgets and contracts with CROs and study sites, which may result in delays to our development timelines and increased costs. We will rely heavily on these third parties over the course of our clinical trials, and we control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with applicable protocol, legal, regulatory and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with Good Clinical Practice (GCPs), which are regulations and guidelines enforced by </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the FDA and comparable foreign regulatory authorities for therapeutic candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, such regulatory authorities will determine that any of our clinical trials comply with the GCP regulations. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws. Any third parties conducting our clinical trials are not and will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our ongoing preclinical, clinical and nonclinical programs. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, these third parties may have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical studies or other drug development activities, which could affect their performance. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our therapeutic candidates. As a result, our financial results and the commercial prospects for our therapeutic candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed. If any of our relationships with trial sites, or any CRO that we may use in the future, terminates, we may not be able to enter into arrangements with alternative trial sites or CROs or do so on commercially reasonable terms. Switching or adding third parties to conduct our clinical trials involves substantial cost and requires extensive management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Competitive pressures could reduce our revenues and profits.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical industry is intensely competitive. Our strategy is to target differentiated products in specialized markets. However, this strategy does not relieve us from competitive pressures and can entail distinct competitive risks. Certain of our competitors do not aggressively promote their products in our markets. An increase in promotional activity in our markets could result in large shifts in market share, adversely impacting us.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors may sell or develop drugs that are more effective and useful or less costly than ours, and they may be more successful in manufacturing and marketing their products. Many of our competitors have significantly greater financial and marketing resources than we do. Additional competitors may enter our markets.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical industry is characterized by constant and significant investment in new product development, which can result in rapid technological change. The introduction of new products could substantially reduce our market share or render our products obsolete. The selling prices of pharmaceutical products tend to decline as competition increases, through new product introduction or otherwise, which could reduce our revenues and profitability.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If generic products that compete with any of our branded pharmaceutical products are approved and sold, sales of our products will be adversely affected.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generic equivalents for branded pharmaceutical products are typically sold at lower costs than the branded products. The regulatory approval process in the United States exempts generic products from costly and time-consuming clinical trials to demonstrate their safety and efficacy and rely instead on the safety and efficacy of prior products, manufacturers of generic products can invest far less in research and development. After the introduction of a competing generic product, a significant percentage of the prescriptions previously written for the branded product are often written for the generic version. In addition, legislation enacted in most U.S. states allows or, in some instances mandates, that a pharmacist dispense an available generic equivalent when filling a prescription for a branded product, in the absence of specific instructions from the prescribing physician. Governmental and private healthcare payors also emphasize substitution of branded pharmaceuticals with less expensive generic equivalents. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the provisions of the Hatch-Waxman Act, manufacturers of branded products often bring lawsuits to enforce their patent rights against generic products released prior to the expiration of branded products&#8217; patents, but it is possible for generic manufacturers to offer generic products while such litigation is pending. As a result, branded products typically experience a significant loss in revenues following the introduction of a competing generic product, even if subject to an existing patent. Our branded pharmaceutical products are or may become subject to competition from generic equivalents because there is no proprietary protection for some of the branded pharmaceutical products we sell, because our patent protection expires or because our patent protection is not sufficiently broad or enforceable. In addition, we may not be successful in our efforts to extend the proprietary protection afforded our branded products through the development and commercialization of proprietary product improvements. Competition from generic equivalents could result in a decrease in revenues of our branded pharmaceuticals or result in a material impairment of our intangible assets or the acceleration of amortization on our non-impaired intangible assets and may have a material adverse impact on our revenues, financial condition, results of operations and cash flows.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any attempt by us to expand the potential market for any of our products is subject to limitations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expansion of the market for our products may be subject to certain limitations. In the past, these limitations have included FDA required Phase IV commitments. We may also experience delays associated with future required Phase IV clinical studies potentially resulting from, among other factors, difficulty enrolling patients. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to identify and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA. Subject enrollment, a significant factor in the timeline of clinical trials, is affected by many factors including the size and characteristics of the patient population, the proximity of patients to clinical sites, the eligibility and exclusion criteria for the trial, the design of the clinical trial, the risk that enrolled patients will not complete a clinical trial, our ability to recruit clinical trial investigators with the appropriate competencies and experience, our ability to obtain and maintain patient consents, patient referral practices of physicians, ability to monitor patients adequately during and after treatment, competing clinical trials and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating as well as any product candidates under development. We will be required to identify and enroll a sufficient number of subjects for each of our clinical trials. Delays that may result from difficulty enrolling patients could impact our ability to explore opportunities for label expansion and limit our ability to bring our products to new patient populations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have largely obtained regulatory approval to market our products in the United States. Not all foreign jurisdictions may represent attractive opportunities for our products due to pricing, competitive, regulatory or other factors. In certain foreign jurisdictions, we have licensed the right to market some of our products to third parties. These third parties are responsible for seeking and maintaining regulatory approval for the products in their respective jurisdictions. We have no control over these third parties and cannot be sure that marketing approval for our products will be obtained outside the United States.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future growth depends on our ability to identify, acquire rights and successfully integrate new brands into our operations. If we do not successfully identify and acquire rights to products or if we do not successfully integrate acquired product brands into our operations, our growth opportunities may be limited.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have added six products to our portfolio of brands through acquisitions. Our business strategy is to continue to acquire rights to FDA-approved products as well as pharmaceutical product candidates in the late stages of development. We do not plan to conduct basic research or preclinical product development, except to the extent of our investment in CET. As compared to large multi-national pharmaceutical companies, we have limited resources to acquire third-party products, businesses and technologies and integrate them into our current infrastructure. Many acquisition opportunities involve competition among several potential purchasers including large multi-national pharmaceutical companies and other competitors that have access to greater financial resources than we do. With future acquisitions, we may face financial and operational risks and uncertainties. We may not be able to engage in future product acquisitions, and those we do complete may not be beneficial to us in the long term.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, other products in development may encounter unforeseen issues during their clinical trials. Any unforeseen issues or lack of FDA approval will negatively affect marketing and development plans for those products.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to successfully integrate the marketing, sale and distribution of any other potential products into our current infrastructure or if they require significantly greater resources than originally anticipated, we may face financial and operational risks and uncertainties. If we are unable to successfully integrate any acquired brands, both current and future, these product acquisitions may not be beneficial to us in the long term.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ifetroban product candidates have not been approved for sale and may never be successfully commercialized.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that a portion of our future revenue growth may come from sales of our ifetroban product candidates. However, none of these products have been approved by the FDA for marketing, and these product candidates are still subject to risks associated with their development. Drug development is a long, expensive and inherently uncertain process with a high risk of failure at every stage of development, and results of earlier studies and trials may not be predictive of future trial results</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has cleared our IND's for the ifetroban product candidates as we evaluate them as treatments for these conditions. Delays in the enrollment and completion of the clinical studies could significantly delay commercial launch and affect our product development costs. Moreover, results from the clinical studies may not be favorable.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if they are eventually developed and approved by the FDA, they may never gain significant acceptance in the marketplace and therefore never generate substantial revenue or profits for us. Physicians may determine that existing drugs are adequate to address patients&#8217; needs. The extent to which these product candidates will be reimbursed by the U.S. government or third-party payors is also currently unknown.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the foregoing and other factors, we do not know the extent to which our product candidates will contribute to our future growth.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to maintain, train and build an effective sales and marketing infrastructure, we will not be able to commercialize and grow our products and product candidates successfully.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we grow, we may not be able to secure sales personnel or organizations that are adequate in number or expertise to successfully market and sell our products. This risk would be accentuated if we acquire products in areas outside of our current focus areas since our sales forces specialize in our existing areas. If we are unable to expand our sales and marketing capability, train our sales force effectively or provide any other capabilities necessary to commercialize our products and product candidates, we will need to contract with third parties to market and sell our products. We must train our employees on proper regulatory compliance, including, but not limited to, &#8220;fair balance&#8221; promotion of our products and anti-kickback laws. If we are unable to establish and maintain compliant and adequate sales and marketing capabilities, we may not be able to increase our product revenue, may generate increased expenses and may experience regulatory compliance issues.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If governmental or third-party payors do not provide adequate reimbursement for our products, our revenue and prospects for profitability may be limited.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial success depends, in part, on the availability of adequate reimbursement from third-party healthcare payors. Such third-party payors include governmental health programs such as Medicare and Medicaid, managed care providers and private health insurers. Third-party payors are increasingly challenging the pricing of medical products and services, while governments continue to propose and pass legislation designed to reduce the cost of healthcare. Adoption of such legislation could further limit reimbursement for pharmaceuticals. In addition, as part of the Inflation Reduction Act legislation, provisions intended to lower the price of prescription drugs, including permitting Medicare to negotiate the price of prescription drugs once they have been on the market for a fixed number of years, and imposing a tax penalty on drug manufacturers if the price of their drugs increase faster than the rate of inflation. At this time no assurances can be given that these measures, or subsequent legislative proposals, will not have an adverse effect on our revenues in the future. Future cost control initiatives, legislation, and regulations could decrease the price that we receive for our products, which would limit our revenue and profitability.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, reimbursement practices of third-party payors might preclude us from achieving market acceptance for our products or maintaining price levels sufficient to realize an appropriate return on our investment in product acquisition and development. If we cannot obtain adequate reimbursement levels, our business, financial condition and results of operations would be materially and adversely affected.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our employees have been trained to submit accurate and correct pricing information to payors. If, despite the training, our employees provide incorrect or fraudulent information, then we will be subject to various administrative and judicial investigations and litigation.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8220;Formulary&#8221; practices of third-party payors could adversely affect our competitive position.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many managed healthcare organizations control the pharmaceutical products included on their formulary lists. Having products listed on these formulary lists creates competition among pharmaceutical companies which, in turn, has created a trend of downward pricing pressure in our industry. In addition, many managed care organizations are pursuing various ways to reduce pharmaceutical costs and are considering formulary contracts primarily with those pharmaceutical companies that can offer a full line of products for a given therapy sector or disease state. Our products might not be included on the formulary lists of managed care organizations, and downward pricing pressure in our industry generally could negatively impact our operations.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Continued consolidation of distributor networks in the pharmaceutical industry as well as increases in retailer concentration may limit our ability to profitably sell our products.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell most of our products to large pharmaceutical wholesalers, who in turn sell to hospitals, surgery centers and retail pharmacies. The distribution network for pharmaceutical products has become increasingly consolidated in recent years. Further consolidation or financial difficulties could also cause our customers to reduce the amounts of our products that they purchase, adversely impacting our business, financial condition and results of operations.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our CET joint initiative may not result in our gaining access to commercially viable products.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CET joint initiative with Vanderbilt University, WinHealth and Tennessee Technology Development Corporation is designed to help us investigate, in a cost-effective manner, early-stage products and technologies. However, we may never gain access to commercially viable products from CET for a variety of reasons, including:</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CET investigates early-stage products, which have risk of failure prior to FDA approval and commercialization;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In some programs, we do not have pre-set rights to product candidates developed by CET. We would need to agree with CET and its collaborators on the terms of any product licensed or acquired by us;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely principally on government grants to fund CET&#8217;s research and development programs. If these grants were no longer available, we or our co-owners might be unable or unwilling to fund CET operations at current levels or at all;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may become involved in disputes with our co-owners regarding CET policy or operations, such as how best to deploy CET assets or which product opportunities to pursue. Disagreement could disrupt or halt product development; and</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CET may disagree with one of the various universities with which CET is collaborating on research. A disagreement could disrupt or halt product development.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on our key personnel, the loss of whom would adversely affect our operations. If we fail to attract and retain the talent required for our business, our business will be materially harmed.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a relatively small company, and we depend to a great extent on principal members of our management, scientific staff, and sales representatives and managers. If we lose the services of any key personnel, in particular, A.J. Kazimi, our Chief Executive Officer, or other members of senior management it could have a material adverse effect on our business prospects. Mr. Kazimi, plays a key role in several operational and strategic decisions such that any loss of his services due to death or disability would adversely impact our day-to-day operations. We have a life insurance policy covering the life of Mr. Kazimi. We have entered into agreements with each of our employees that </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contain restrictive covenants relating to non-competition and non-solicitation of our customers and suppliers for one year after termination of employment. Nevertheless, each of our officers and key employees may terminate his or her employment at any time without notice and without cause or good reason, and so as a practical matter these agreements do not guarantee the continued service of these employees. Our success depends on our ability to attract and retain highly qualified scientific, technical, sales and managerial personnel and research partners. Competition among pharmaceutical companies for qualified employees is intense, and we may not be able to retain existing personnel or attract and retain qualified staff in the future. If we experience difficulties in hiring and retaining personnel in key positions, we could suffer from delays in product development, loss of customers and sales and diversion of management resources, which could adversely affect operating results.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have recently observed an overall tightening and increasingly competitive labor market. Our business could be adversely affected by an inability to retain personnel or upward pressure on wages as a result of the competitive labor market.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The size of our organization and our potential growth may lead to difficulties in managing operations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had 91 employees. We may need to continue to expand our managerial, operational, financial and other resources in order to increase our marketing efforts with regard to our currently marketed products, continue our business development and product development activities and commercialize our product candidates. We have experienced, and may continue to experience, growth and increased expenses in the scope of our operations in connection with the continued marketing and development of our products. Our financial performance will depend, in part, on our ability to manage any such growth and expenses of the current organization effectively.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability for a product or product candidate and may have to limit its commercialization.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability lawsuits related to the testing of our product candidates and the commercial sale of our products. An individual may bring a liability claim against us if one of our product candidates or products causes, or appears to have caused, an injury. If we cannot successfully defend ourselves against the product liability claim, we may incur substantial liabilities. Liability claims may result in decreased demand for our products; injury to our reputation; withdrawal of clinical trial participants; significant litigation costs; substantial monetary awards to or costly settlement with patients; product recalls; loss of revenue; and the inability to commercialize our product candidates.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have product liability insurance that covers our clinical trials, the marketing and sale of our products up to a $10 million annual aggregate limit, subject to specified deductibles. Our current or future insurance coverage may prove insufficient to cover any liability claims brought against us.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the increasing costs of insurance coverage, we may not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory approval for any approved product is limited by the FDA to those specific indications and conditions for which clinical safety and efficacy have been demonstrated.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any regulatory approval is limited to those specific diseases and indications for which a product is deemed to be safe and effective by the FDA. In addition to the FDA approval required for new formulations, any new indication for an approved product also requires FDA approval. If we are not able to obtain FDA approval for any desired future indications for our products, our ability to effectively market and sell our products may be reduced and our business may be adversely affected.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to follow FDA rules and guidelines relating to promotion and advertising  may cause the FDA to suspend or withdraw an approved product from the market, require a recall or payment of fines, or could result in disgorgement of money, operating restrictions, injunctions or criminal prosecution, any of which could harm our business.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and operations would suffer in the event of system failures, security breaches, including any cybersecurity incidents, adverse events or other disruptions within our information technology infrastructure at our corporate headquarters; or in the event of intellectual property infringement.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business depends on effective, secure and operational information systems which include systems provided by external contractors and other service providers. Despite the implementation of security measures, our computer systems and information technology infrastructure, including those resources at our corporate headquarters, are vulnerable to damage from cyber-attacks, computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Our business is at risk from and may be impacted by information security incidents, including ransomware, malware, phishing, social engineering, and other security events. Such incidents can range from individual attempts to gain unauthorized access to information technology systems to more sophisticated security threats. These events can also result from internal compromises, such as human error or malicious acts. These events can occur on our systems or on the systems of our partners and subcontractors. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we store sensitive data, including intellectual property, our proprietary business information and that of our customers. We also maintain personally identifiable information of our employees in our data centers and on our networks. The secure processing and maintenance of this information is critical to our operations. Problems with, or the failure of, our technology and systems or any system upgrades or programming changes associated with such technology and systems would have a substantial and material negative effect on our operations. Furthermore, any system failure, accident or security breach that causes interruptions in our operations could result in a material disruption of our drug development programs. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we continue to invest in data protection and information technology, our information technology and infrastructure may be vulnerable to attacks by hackers or breached due to employee error, malfeasance or other disruptions. Any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, lost or stolen. If we are subject to cyber-attacks or security breaches, this could result in business interruptions and delays; the loss, misappropriation, corruption or unauthorized access of data; litigation and potential liability under privacy, security and consumer protection laws or other applicable laws; reputational damage and federal and state governmental inquiries. Any such problems or failures and the costs incurred in correcting any such problems or failures, could have a material adverse effect on our business and financial condition, results of operations and cash flows. To the extent that any disruption or security breach results in a loss or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we may incur liability and the further development of our products or product candidates may be delayed. A failure to restore our information systems after the occurrence of any of these events could have a material adverse effect on our business and financial condition, results of operations and cash flows. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our information systems and applications also require maintenance, upgrading and enhancement to meet our operational needs. We regularly upgrade and expand our information systems&#8217; capabilities. If we experience difficulties with the transition and integration of information systems or are unable to implement, maintain, or expand our systems properly, we could suffer from, among other things, operational disruptions, regulatory problems and increases in administrative expenses. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As cyber threats continue to evolve, we may be required to expend significant capital and other resources to protect against the threat of security breaches or to mitigate and alleviate problems caused by breaches, including unauthorized access to proprietary information and personally identifiable information stored in our information systems, and the introduction of computer viruses or other malicious software programs to our systems. Our security measures may be inadequate to prevent security breaches and our business operations could be materially adversely affected by federal and state fines and penalties, legal claims or proceedings, cancellation of contracts and loss of customers if security breaches are not prevented.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our subcontractors and vendors take precautionary measures to prevent problems that could affect our business operations as a result of failure or disruption to their information systems. However, there is no guarantee such efforts will be successful in preventing a disruption, and it is possible that we may be impacted by information system failures. The occurrence of any information system failures could result in interruptions, delays, loss or corruption of data and cessations or interruptions in the availability of these systems. All of these events or </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">circumstances, among others, could have an adverse effect on our business, results of operations, financial position and cash flows, and they could harm our business reputation.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we have all the necessary licenses from third parties to use technology and software that we do not own. A third party could, however, allege that we are infringing its rights, which may deter our ability to obtain licenses on commercially reasonable terms from the third party, if at all, or cause the third party to commence litigation against us. In addition, we may find it necessary to initiate litigation to protect our trade secrets, to enforce our intellectual property rights and to determine the scope and validity of any proprietary rights of others. Any such litigation, or the failure to obtain any necessary licenses or other rights, could materially and adversely affect our business.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We license our products globally; therefore, we may have exposure to foreign regulatory requirements and fluctuations in foreign currency exchange rates.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Continued foreign licensure inherently subjects us to a number of risks and uncertainties, including:</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">longer payment cycles and difficulties in enforcing agreements and collecting receivables through certain foreign legal systems;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">political and economic instability or sanctions in areas in which we operate;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potentially adverse tax consequences, tariffs, customs charges, bureaucratic requirements and other trade barriers;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulations related to customs and import/export matters (including sanctions);</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">tax issues, such as tax law changes and variations in tax laws;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">challenges in collecting accounts receivable from customers in the jurisdictions in which we operate;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">complying with laws, rules and regulations relating to the manufacturing, marketing, distribution and sale of pharmaceutical products in the jurisdictions in which we do or will operate;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operating under regulations in jurisdictions related to obtaining eligibility for government or private payor reimbursement for our products at the wholesale/retail level;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition from local, regional and international competitors;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties and costs of staffing and managing foreign operations, including cultural and language differences and additional employment regulations, union workforce negotiations and potential disputes in the jurisdictions in which we operate;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties associated with compliance with a variety of laws and regulations governing international trade, including the Foreign Corrupt Practices Act;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties protecting or procuring intellectual property rights; and</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in foreign currency exchange rates.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these factors may, individually or as a group, have a material adverse effect on our business and results of operations. These or other similar risks could adversely affect our revenue and profitability. As we continue to develop internationally, our exposure to these factors will increase.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may decide not to commercialize one of our drug candidates once it obtains regulatory approval if we determine that commercialization of that product would require more capital and time than we are willing to invest.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if any of our drug candidates receives regulatory approval, it could be subject to matters such as post-regulatory surveillance, additional clinical trials or testing, reformulation,  changes in labeling, warnings to the public, recall, competition from similar or superior products, and lack of sufficient payor reimbursement by </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">insurance companies or Medicare. As a result, we may not commercialize or continue to commercialize a product that has obtained regulatory approval. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any approved drug product that we bring to the market may not gain market acceptance by physicians, patients, healthcare payors and others in the medical community.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are successful in gaining regulatory approval of any of our drug candidates or acquire rights to approved drug products, we may not generate significant product revenues and we may not become profitable if these drug products do not achieve an adequate level of acceptance. Physicians may not recommend our drug products until longer-term clinical data or other factors demonstrate the safety and efficacy of our drug products as compared to other alternative treatments. Even if the clinical safety and efficacy of our drug products is established, physicians may elect not to prescribe these drug products for a variety of reasons, including the reimbursement policies of government and other third-party payors and the effectiveness of our competitors in marketing their products.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market acceptance of our drug products, if approved for commercial sale, will depend on a number of factors, including:</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness and ability of patients and the healthcare community to use our drug products;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to manufacture our drug products in sufficient quantities with acceptable quality and to offer our drug products for sale at competitive prices;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perception of patients and the healthcare community, including third-party payors, regarding the safety, efficacy and benefits of our drug products compared to those of competing products or therapies;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the label and promotional claims allowed by the FDA; and</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pricing and reimbursement of our drug products relative to existing treatments.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may acquire businesses or assets, form joint ventures or make investments in other companies that may be unsuccessful, divert our management&#8217;s attention and harm our operating results and prospects.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our business strategy, we may pursue additional acquisitions of what we believe to be complementary businesses or assets or seek to enter into joint ventures. We also may pursue strategic alliances in an effort to leverage our existing infrastructure and industry experience to expand our product offerings or distribution, or make investments in other companies. The success of our acquisitions, joint ventures, strategic alliances and investments will depend on our ability to identify, negotiate, complete and, in the case of acquisitions, integrate those transactions and, if necessary, obtain satisfactory debt or equity financing to fund those transactions. We may not realize the anticipated benefits of any acquisition, joint venture, strategic alliance or investment. We may not be able to integrate acquisitions successfully into our existing business, maintain the key business relationships of businesses we acquire, or retain key personnel of an acquired business, and we could assume unknown or contingent liabilities or incur unanticipated expenses. Integration of acquired companies or businesses also may require management resources that otherwise would be available for ongoing development of our existing business. Any acquisitions or investments made by us also could result in significant write-offs or the incurrence of debt and contingent liabilities, any of which could harm our operating results. In addition, if we choose to issue shares of our stock as consideration for any acquisition, dilution to our shareholders could result.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be required to modify our business practices, pay fines and significant expenses or experience other losses due to governmental investigations or other enforcement activities.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may become subject to litigation or governmental investigations in the United States and foreign jurisdictions that may arise from the conduct of our business. Like many companies in our industry, we have from time to time received inquiries and other types of information requests from government authorities.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the ultimate outcomes of investigations and legal proceedings are difficult to predict, adverse resolutions or settlements of those matters could result in, among other things:</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant damage awards, fines, penalties or other payments, and administrative remedies, such as exclusion and/or debarment from government programs, or other rulings that preclude us from operating our business in a certain manner;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes and additional costs to our business operations to avoid risks associated with such litigation or investigations;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recalls;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reputational damage and decreased demand for our products; and</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenditure of significant time and resources that would otherwise be available for operating our business.</span></div><div id="i3928a3425fef4184806511a3516ffab1_1297"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">RISKS RELATING TO GOVERNMENT REGULATION</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Virtually all aspects of our business activities are regulated by government agencies. The manufacturing, processing, formulation, packaging, labeling, distribution, promotion and sampling, advertising of our products, and disposal of waste products arising from such activities are subject to governmental regulation. These activities are regulated by one or more of the FDA, the Federal Trade Commission, ("FTC"), the Consumer Product Safety Commission, the U.S. Department of Agriculture and the U.S. Environmental Protection Agency, ("EPA"), as well as by comparable agencies in foreign countries. These activities are also regulated by various agencies of the states and localities in which our products are sold. For more information, see &#8220; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business&#8212;Government Regulation"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part I, Item 1 of this Form 10-K.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Like all pharmaceutical manufacturers, we are subject to regulation by the FDA under the Federal Food, Drug and Cosmetic Act ("FDCA"). All new drugs must be the subject of an FDA-approved new drug application, ("NDA"), before they may be marketed in the United States. The FDA has the authority to withdraw existing NDA approvals and to review the regulatory status of products marketed under the enforcement policy. The FDA may require an approved NDA for any drug product marketed under the enforcement policy if new information reveals questions about the drug&#8217;s safety and effectiveness. All drugs must be manufactured in conformity with GMP, and drug products subject to an approved NDA must be manufactured, processed, packaged, held and labeled in accordance with information contained in the NDA. Since we rely on third parties to manufacture our products, GMP requirements directly affect our third party manufacturers and indirectly affect us. The manufacturing facilities of our third-party manufacturers are continually subject to inspection by such governmental agencies, and manufacturing operations could be interrupted or halted in any such facilities if such inspections prove unsatisfactory. Our third-party manufacturers are subject to periodic inspection by the FDA to assure such compliance.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even after regulatory approval, certain developments may decrease demand for our products, including the following:</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the re-review of products that are already marketed;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new scientific information and evolution of scientific theories;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the recall or loss of marketing approval of products that are already marketed;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changing government standards or public expectations regarding safety, efficacy or labeling changes; and</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">greater scrutiny in advertising and promotion.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain regulatory changes or decisions could make it more difficult for us to sell our products and could have a material adverse effect on our business, results of operations, financial condition and cash flows. Manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with GMP and other applicable regulations. If we or a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">frequency, or problems with a facility where the product is manufactured, a regulatory agency may impose restrictions on that product or the manufacturer, including withdrawal of the product from the market or suspension of manufacturing. If we, our partners or the manufacturing facilities for our products fail to comply with applicable regulatory requirements or violate healthcare laws, a regulatory agency may take the following actions, among others:</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issue warning letters or untitled letters;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose civil or criminal penalties</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend or withdraw regulatory approval;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend any ongoing clinical trials;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refuse to approve pending applications or supplements to applications submitted by us;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose restrictions on operations, including costly new manufacturing requirements; or</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seize or detain products or require us to initiate a product recall.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any change in the FDA&#8217;s enforcement policy could have a material adverse effect on our business, financial condition and results of operations. We cannot determine what effect changes in regulations or statutes or legal interpretation, when and if promulgated or enacted, may have on our business in the future. Such changes, or new legislation, could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proposed legislation may permit re-importation of drugs from other countries into the U.S., including foreign countries where the drugs are sold at lower prices than in the U.S., which could materially and adversely affect our operating results and our overall financial condition.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In previous years, legislation has been introduced in Congress that, if enacted, would permit more widespread re-importation of drugs from foreign countries into the U.S., which may include re-importation from foreign countries where the drugs are sold at lower prices than in the U.S. Such legislation, or similar regulatory changes, if enacted, could decrease the price we receive for any approved products which, in turn, could materially and adversely affect our operating results and our overall financial condition.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We must comply with the CREATES Act.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been a number of recent regulatory and legislative initiatives designed to encourage generic competition for pharmaceutical products, including expedited review procedures for generic manufacturers and incentives designed to spur generic competition of branded drugs. In particular, FDA and FTC have been focused on brand companies&#8217; denial of drug supply to potential generic competitors for testing. In December 2019, the Creating and Restoring Equal Access to Equivalent Samples Act, or the CREATES Act, was enacted, which provides a legislatively defined private right of action under which eligible product developers can bring suit against companies who refuse to sell sufficient quantities of their branded products on commercially reasonable, market-based terms to support such eligible product developers&#8217; marketing applications. We cannot currently predict the specific outcome or impact on our business of such regulatory and legislative initiatives. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We must comply with the Foreign Corrupt Practices Act.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to comply with the United States Foreign Corrupt Practices Act, which prohibits U.S. companies from engaging in bribery or other prohibited payments to foreign officials for the purpose of obtaining or retaining business. Foreign companies, including some of our competitors, are not subject to these prohibitions. If our competitors engage in these practices, they may receive preferential treatment from officials or agencies in some countries, giving our competitors an advantage in securing business from government officials who might give them priority in obtaining new licenses, which would put us at a disadvantage. We have established formal policies or procedures for prohibiting or monitoring this conduct, but we cannot assure you that our employees or other agents will not engage in such conduct for which we might be held responsible. If our employees or other agents are found to have engaged in such practices, we could suffer severe penalties.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We must comply with the Physician Payment Sunshine Act.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to comply with the United States Physician Payment Sunshine Act, which requires manufacturers of drugs, medical devices and biologicals that participate in U.S. federal healthcare programs to report certain payments and items of value given to physicians and teaching hospitals. Manufacturers are required to report this information annually to The Centers for Medicare &amp; Medicaid Services ("CMS"). In addition, some states require reporting information concerning payments to health care providers or other transfers of value by drug manufacturers beyond the requirements of the Federal Sunshine Act. Cumberland has implemented a series of policies and procedures for every employee involved in the data collection process, and has systems in place to capture the data, which is verified by an outside firm that specializes in reporting the payments. Cumberland has also established a system to ensure that data was reported completely, in the correct format, and on time. Despite these policies, procedures and systems, we cannot assure you that we will collect and report all data accurately. If we fail to accurately report this information, we could suffer severe penalties.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate program or other governmental pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We participate in the Medicaid Drug Rebate program, the 340B program, and other governmental pricing programs and have obligations to report the average sales price for certain of our drugs to CMS. These programs and rebate calculations vary across products and programs, are complex, and are often subject to interpretation by us, governmental or regulatory agencies and the courts, which can change over time.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the case of our Medicaid pricing data, if we become aware that our reporting for a prior quarter was incorrect or has changed as a result of recalculation of the pricing data, we are obligated to resubmit the corrected data for up to three years after those data originally were due. Such restatements and recalculations increase our costs for complying with the laws and regulations governing the Medicaid Drug Rebate program and could result in an overage or underage in our rebate liability for past quarters. Price recalculations also may affect the ceiling price at which we are required to offer our products under the 340B program.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Civil monetary penalties can be applied if we are found to have knowingly submitted any false price or product information to the government, if we are found to have made a misrepresentation in the reporting of our average sales price, if we fail to submit the required price data on a timely basis, or if we are found to have charged 340B covered entities more than the statutorily mandated ceiling price. CMS, could also decide to terminate our Medicaid drug rebate agreement, in which case federal payments may not be available under Medicaid or Medicare Part B for our covered outpatient drugs. We cannot assure you that our submissions will not be found by CMS to be incomplete or incorrect. Our failure to comply with our reporting and payment obligations under the Medicaid Drug Rebate program and other governmental programs could negatively impact our financial results.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to foreign, federal, and state data privacy and security laws, and failure to protect our information systems against security breaches, service interruptions, or misappropriation of data could disrupt operations, compromise sensitive data, and expose us to liability, possibly causing our business and reputation to suffer.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, numerous federal and state laws and regulations govern the collection, use, disclosure and protection of health-related and other personal information and could apply to our operations or the operations of our collaborators and third-party providers. Certain of these laws grant individual rights with respect to their information, and we may be required to expend significant resources to comply with these laws. For example, the California Consumer Privacy Act, or CCPA, was enacted in 2020. These laws and regulations are evolving and subject to interpretation and may impose limitations on our activities or otherwise adversely affect our business. Similarly, there are a number of legislative proposals in the European Union, the United States, at both the federal and state level, as well as other jurisdictions that could impose new obligations or limitations in areas affecting our business. These changes may lead to additional costs and increase our overall risk exposure.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">48</span></div></div></div><div id="i3928a3425fef4184806511a3516ffab1_1315"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATING TO INTELLECTUAL PROPERTY</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our strategy to secure and extend marketing exclusivity or patent rights may provide only limited or no protection from competition.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to secure and extend marketing exclusivity for our products through a variety of means, including FDA exclusivity and patent rights. Additional barriers for competitors seeking to enter the market include the time and cost associated with the development, regulatory approval and manufacturing of a similar product formulation.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Part I, Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business - Patents, Trademarks, and Other Intellectual Proprietary Rights,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this report on Form 10-K, we have several patents for formulations of Acetadote, and have previously engaged in litigation to enforce our patent rights. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to continue to vigorously defend and protect our Acetadote product and related intellectual property rights. If we are unsuccessful in protecting our Acetadote intellectual property rights, our competitors may be able to introduce products into the marketplace that reduce the sales and market share of our Acetadote product which may require us to take measures such as reducing prices or increasing our marketing expense, any of which may result in a material adverse effect to our financial condition and results of operations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we consider patent protection when evaluating product acquisition opportunities, any products we acquire in the future may not have significant patent protection. Neither the USPTO nor the courts have a consistent policy regarding the breadth of claims allowed or the degree of protection afforded under many pharmaceutical patents. Patent applications in the U.S. and many foreign jurisdictions are typically not published until 18 months following the filing date of the first related application, and in some cases not at all. In addition, publication of discoveries in scientific literature often lags significantly behind actual discoveries. Therefore, neither we nor our licensors can be certain that we or they were the first to make the inventions claimed in our issued patents or pending patent applications, or that we or they were the first to file for protection of the inventions set forth in these patent applications. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. In addition, changes in either patent laws or in interpretations of patent laws in the U.S. and other countries may increase the uncertainties and costs, diminish the value of our intellectual property, or narrow the scope of our patent protection. Furthermore, our competitors may independently develop similar technologies or duplicate technology developed by us in a manner that does not infringe our patents or other intellectual property. As a result of these factors, our patent rights may not provide any commercially valuable protection from competing products.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patents, we rely upon trade secrets, unpatented proprietary know-how and continuing technological innovation where we do not believe patent protection is appropriate or attainable. For example, the manufacturing process for Kristalose involves substantial trade secrets and proprietary know-how. We have entered into confidentiality agreements with certain key employees and consultants pursuant to which such employees and consultants must assign to us any inventions relating to our business if made by them while they are our employees, as well as certain confidentiality agreements relating to the acquisition of rights to products. Confidentiality agreements can be breached, though, and we might not have adequate remedies for any breach. Also, others could acquire or independently develop similar technology.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may depend on certain licensors for the maintenance and enforcement of intellectual property rights and have limited, if any, control over the amount or timing of resources that our licensors devote on our behalf.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we license products, we often depend on our licensors to protect the proprietary rights covering those products. We have limited, if any, control over the amount or timing of resources that our licensors devote on our behalf or the priority they place on maintaining patent or other rights and prosecuting patent applications to our advantage. While any such licensor is expected to be contractually obligated to diligently pursue its patent applications and allow us the opportunity to consult, review and comment on patent office communications, we cannot be sure that it will perform as required. If a licensor does not perform and if we do not assume the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">maintenance of the licensed patents in sufficient time to make required payments or filings with the appropriate governmental agencies, we risk losing the benefit of all or some of those patent rights.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the use of our technology conflicts with the intellectual property rights of third parties, we may incur substantial liabilities, and we may be unable to commercialize products based on this technology in a profitable manner or at all.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our products conflict with the intellectual property rights of others, they could bring legal action against us or our licensors, licensees, manufacturers, customers or collaborators. If we were found to be infringing a patent or other intellectual property rights held by a third party, we could be forced to seek a license to use the patented or otherwise protected technology. We might not be able to obtain such a license on terms acceptable to us or at all. If legal action involving an alleged infringement or misappropriation were to be brought against us or our licensors, we would incur substantial costs in defending the action. If such a dispute were to be resolved against us, we could be subject to significant damages, and the manufacturing or sale of one or more of our products could be enjoined.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be involved in lawsuits to protect or enforce our patents or the patents of our collaborators or licensors, which could be costly and time consuming.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been involved in lawsuits for infringement of the Acetadote Patents as previously described. Because of their nature, these lawsuits can be costly and time-consuming, and we only experience limited benefits and patent protection. A significant adverse ruling in any such lawsuit could put our patents at risk of being invalidated or interpreted narrowly and could compromise the issuance of our existing patent applications.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe on our patents or the patents of our collaborators or licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interference proceedings brought by the USPTO may be necessary to determine the priority of inventions with respect to our patent applications or those of our collaborators or licensors. Litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distraction of our management. We may not be able, alone or with our collaborators and licensors, to prevent misappropriation of our proprietary rights, particularly in countries where the laws may not protect such rights as fully as in the United States.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, some of our confidential information could be disclosed during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be involved in lawsuits to protect or enforce our trademarks or for allegedly infringing the trademark rights of others, which could be costly and time consuming.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own certain trademark registrations for each of our branded pharmaceutical products as well as for our corporate name and logo. We have applied for trademark registration for other various names and logos. We also may have common law trademark rights in unregistered names, phrases, and logos under which we market or offer certain products and services. Over time, we intend to obtain and maintain registrations on trademarks that remain valuable to our business.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may oppose registration of our federal trademark applications. Further, we could be involved in lawsuits for allegedly infringing the rights of others with respect to their prior-existing trademarks. These lawsuits or opposition proceedings can be costly and time-consuming. A significant adverse ruling in any such lawsuit could put our trademarks at risk of being invalidated and could compromise the issuance of our existing trademark applications.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe on our trademarks or the trademarks of our collaborators or licensors. To counter infringement or unauthorized use, we may be required to file trademark infringement claims, which can be expensive and time-consuming. In addition, in a trademark infringement proceeding, a court may decide that a trademark registration of ours is not valid or is unenforceable, or may refuse to stop the other party from using the mark or a mark that is similar to our registered mark at issue on the grounds that the competitor&#8217;s use of the mark is not confusingly similar to our registered trademark. An adverse result in any litigation or defense proceeding could put one or more of our trademark registrations at risk of being invalidated or interpreted narrowly and could put our trademark applications at risk of not registering.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, some of our confidential information could be disclosed during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we breach any of the agreements under which we license rights to our products and product candidates from others, we could lose the ability to continue commercialization of our products and development and commercialization of our product candidates.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have exclusive licenses for the marketing and sale of certain products and may acquire additional licenses. Such licenses may terminate prior to expiration if we breach our obligations under the license agreement related to these pharmaceutical products. For example, the licenses may terminate if we fail to meet specified quality control standards, including GMP with respect to the products, or commit a material breach of other terms and conditions of the licenses. Such early termination could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is common in the biotechnology and pharmaceutical industry, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that we or these employees have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. We are subject to stringent government regulation. All of our products face regulatory challenges.</span></div><div id="i3928a3425fef4184806511a3516ffab1_1334"></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO OUR FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results are likely to fluctuate from period to period.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a company actively seeking to deliver significant growth. As we execute our business strategy of adding new products, increasing market share in our existing growth products and striving to maintain market share in our other products, we anticipate that there may be fluctuations in our future operating results. We may not be able to maintain or improve our current levels of revenue or income. Potential causes of future fluctuations in our operating results may include:</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">New product launches, which could increase revenues but also increase sales and marketing expenses;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Acquisition activity and other charges;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increases in research and development expenses resulting from the acquisition of a product candidate that requires significant additional studies and development;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ability to utilize unrecognized federal and state net operating loss carryforwards as a result of the exercise of nonqualified options</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in the competitive, regulatory or reimbursement environment, which could drive down revenues or drive up sales and marketing or compliance costs; and</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unexpected product liability or intellectual property claims and lawsuits.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See also &#8220;Management&#8217;s discussion and analysis of financial condition and results of operations&#8212;Liquidity and capital resources.&#8221; Fluctuation in operating results, particularly if not anticipated by investors and other members of the financial community, could add to volatility in our stock price. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our focus on acquisitions as a growth strategy has created intangible assets whose amortization could negatively affect our results of operations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total assets include intangible assets related to our acquisitions. As of December&#160;31, 2023, intangible assets relating to products, which are being amortized, represented approximately 28 percent of our total assets. We may never realize the value of these assets. U.S. Generally Accepted Accounting Principles ("GAAP") require that we evaluate on a regular basis whether events and circumstances have occurred that indicate that all or a portion of the carrying amount of the asset may no longer be recoverable, in which case we would write down the value of the asset and take a corresponding charge to earnings. Any determination requiring the write-off of a significant portion of unamortized intangible assets would adversely affect our results of operations.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need additional funding and may be unable to raise capital when needed, which could force us to delay, reduce or eliminate our product development or commercialization and marketing efforts.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may need to raise additional funds in order to meet the capital requirements of running our business and acquiring and developing new pharmaceutical products. If we require additional funding, we may seek to sell common stock or other equity or equity-linked securities, which could result in dilution to our shareholders. We may also seek to raise capital through a debt financing, which would result in ongoing debt-service payments and increased interest expense. Furthermore, the terms of any additional debt securities we may issue in the future may impose restrictions on our operations, which may include limiting our ability to incur additional indebtedness, pay dividends on or repurchase our common shares, or make certain acquisitions or investments. In addition, we may be subject to covenants requiring us to satisfy certain financial tests and ratios, and our ability to satisfy such covenants may be affected by events outside of our control. Any financings would also likely involve operational and financial restrictions being imposed on us. If we are unable to obtain any needed additional funding, we may be required to reduce the scope of, delay, or eliminate some or all of, our planned research, development and commercialization activities or to license to third parties the rights to develop and/or commercialize products or technologies that we would otherwise seek to develop and/or commercialize ourselves or on terms that are less attractive than they might otherwise be, any of which could materially harm our business.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We might also seek to sell assets or rights in one or more commercial products or product development programs. Additional capital might not be available to us when we need it. We are unable to predict the impact of global credit market trends, and if economic conditions deteriorate, our business, results of operations and ability to raise needed capital could be materially and adversely affected. If we are unable to raise additional capital when needed due to the reasons listed above and lack of creditworthiness, bank failures, or price decline in market investments, we could be forced to scale back our operations to conserve cash.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may incur losses in the future and we may not achieve or maintain profitability.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to continue to spend significant amounts on our efforts to discover and develop drugs. As a result, we may incur losses in future periods.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our drug discovery and development efforts and related expenditures will increase as we focus on the studies, including clinical trials prior to seeking regulatory approval, that are required before we can sell a drug product.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of drug products will require us to spend significant funds on research, development, testing, obtaining regulatory approvals, manufacturing and marketing.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain whether or when we will achieve profitability because of the significant uncertainties relating to our ability to generate commercially successful drug products. Even if we are successful in obtaining regulatory approvals for manufacturing and commercializing additional drug products, we may incur losses if our drug products do not generate significant revenues. If we achieve profitability, we may not be able to sustain or increase profitability.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our officers, directors, and principal shareholders, acting as a group, could significantly influence corporate actions.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, our officers and directors control approximately 43.3 percent of our common stock. Acting together, these shareholders could significantly influence any matter requiring approval by our shareholders, including the election of directors and the approval of mergers or other business combinations. The interests of this group may not always coincide with our interests or the interests of other shareholders and may prevent or delay a change in control. This significant concentration of share ownership may adversely affect the trading price of our common stock because many investors perceive disadvantages to owning stock in companies with controlling shareholders.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research analysts may not continue to provide or initiate coverage of our common stock or may issue negative reports.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market for our common stock may be affected by the reports financial analysts publish about us. If one of the analysts covering us downgrades our stock, its price could decline rapidly and significantly. Securities analysts covering our common stock may discontinue coverage. A lack of research coverage may adversely affect our stock&#8217;s market price.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div id="i3928a3425fef4184806511a3516ffab1_1352"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO OWNING OUR STOCK</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our common stock may fluctuate substantially.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The price for the shares of our common stock sold in our initial public offering was determined by negotiation between the representatives of the underwriters and us. This price may not have reflected the market price of our common stock following our initial public offering. Moreover, the market price of our common stock might decline below current levels. In addition, the market price of our common stock is likely to be highly volatile and may fluctuate substantially. Sales of a substantial number of shares of our common stock in the public market or the perception that these sales may occur could cause the market price of our common stock to decline.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The realization of any of the risks described in these &#8220;Risk Factors&#8221; could have a dramatic and material adverse impact on the market price of our common stock. In addition, securities class action litigation has often been instituted against companies whose securities have experienced periods of volatility in market price. Any such securities litigation brought against us could result in substantial costs and a diversion of management&#8217;s attention and resources, which could negatively impact our business, operating results and financial condition. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unstable market conditions may have serious adverse consequences on our business.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our general business strategy may be adversely affected by unpredictable and unstable market conditions. While we believe we have adequate capital resources to meet current working capital and capital expenditure requirements, a radical economic downturn or increase in our expenses could require additional financing on less than attractive rates or on terms that are dilutive to existing shareholders. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical developments plans. There is a risk that one or more of our current service providers, manufacturers and other partners may encounter difficult economic circumstances, which would directly affect our ability to attain our operating goals on schedule and on budget. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The equity and lending markets have been and will most likely continue to be negatively impacted for an unknown period of time due to global events such as the COVID-19 pandemic, increased inflation and the U.S. government&#8217;s response thereto.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to maintain our listing on the NASDAQ Global Select Market (&#8220;NASDAQ&#8221;), which could have a material adverse effect on us and our stockholders.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The standards for continued listing on NASDAQ include, among other things, that the minimum bid price for the listed securities not fall below $1.00 for a period in excess of thirty consecutive business days. If the closing bid price of our common stock were to fail to meet NASDAQ&#8217;s minimum closing bid price requirement, or if we otherwise fail to meet any other applicable requirements of NASDAQ and we are unable to regain compliance, NASDAQ may make a determination to delist our common stock. The delisting of our common stock from NASDAQ could negatively impact us by (i) reducing the liquidity and market price of our common stock; (ii) reducing the number of investors willing to hold or acquire our common stock, which could negatively impact our ability to raise equity financing; (iii) impacting our ability to use a registration statement to offer and sell freely tradable securities, thereby preventing or limiting us from accessing the public capital markets; and (iv) impairing our ability to provide equity incentives to our employees.</span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some provisions of our third amended and restated charter, bylaws and Tennessee law may inhibit potential acquisition bids that you may consider favorable.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate documents contain provisions that may enable our board of directors to resist a change in control of our company even if a change in control were to be considered favorable by you and other shareholders. These provisions include:</span></div><div style="margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The authorization of undesignated preferred stock, the terms of which may be established and shares of which may be issued without shareholder approval;</span></div><div style="margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Advance notice procedures required for shareholders to nominate candidates for election as directors or to bring matters before an annual meeting of shareholders;</span></div><div style="margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Limitations on persons authorized to call a special meeting of shareholders;</span></div><div style="margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A staggered board of directors;</span></div><div style="margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A restriction prohibiting shareholders from removing directors without cause;</span></div><div style="margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A requirement that vacancies in directorships are to be filled by a majority of the directors then in office and the number of directors is to be fixed by the board of directors; and</span></div><div style="margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">No cumulative voting.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other provisions contained in our third amended and restated charter and bylaws could delay or discourage transactions involving an actual or potential change in control of us or our management, including transactions in which our shareholders might otherwise receive a premium for their shares over then current prices, and may limit the ability of shareholders to remove our current management or approve transactions that our shareholders may deem to be in their best interests and, therefore, could adversely affect the price of our common stock.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are subject to control share acquisitions provisions and affiliated transaction provisions of the Tennessee Business Corporation Act, the applications of which may have the effect of delaying or preventing a merger, takeover or other change in control of us and therefore could discourage attempts to acquire our company.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never paid cash dividends on our capital stock.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never paid cash dividends on our capital stock. The availability of funds for distributions to shareholders will depend on our financial performance and assets. Any future decision to declare or pay dividends will be at the sole discretion of our Board of Directors.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DEBT-RELATED RISKS</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Revolving Credit Agreement impose restrictive and financial covenants on us. Our failure to comply with these covenants could trigger events that would have a material adverse effect on our business.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Revolving Credit Agreement contains covenants that restrict the way we conduct business and require us to satisfy certain financial tests in order to incur debt or take other actions. Additionally, our Revolving Credit Agreement contains financial covenants that, for example, require us to maintain certain financial ratios which are measured at the end of each fiscal quarter.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Revolving Credit Agreement contains specified quarterly financial maintenance covenants. As of December&#160;31, 2023, we were in compliance with the Maximum Funded Debt Ratio financial covenant of the Revolving Credit Agreement. However, we can make no assurance that we will be able to comply with the restrictive and financial covenants contained in the Revolving Credit Agreement in the future.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to comply with the covenants in our debt instruments could lead to a default or an event of default under the terms thereof, for which we may need to seek relief from our lender in order to waive the associated default or event of default and avoid a potential acceleration of the related indebtedness or cross-default or cross-</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acceleration to other debt. There can be no assurance that we would be able to obtain such relief on commercially reasonable terms or otherwise and we may be required to incur significant additional costs. In addition, the lender under our Revolving Credit Agreement may impose additional operating and financial restrictions on us as a condition to granting any such waiver. If an event of default is not cured or is not otherwise waived, the lender under our Revolving Credit Agreement may accelerate the maturity of the related debt, foreclose upon any collateral securing the debt and terminate any commitments to lend, any of which would have a material adverse effect on our business, financial condition, cash flows and results of operations and would cause the market value of our securities to decline.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have risks related to interest rates.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revolving credit facility bears interest based on variable interest. Thus, a change in the short-term interest rate environment (especially a material change) could have a material adverse effect on our business, financial condition, cash flows and results of operations. As of December&#160;31, 2023, we did not have any outstanding interest rate swap contracts.</span></div><div id="i3928a3425fef4184806511a3516ffab1_94"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;1B. Unresolved Staff Comments.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i3928a3425fef4184806511a3516ffab1_1247"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item 1C. Cybersecurity</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk Management and Strategy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on information technology and data to operate our business and develop, market, and deliver our products to our customers. We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our communication systems, and our critical data which includes confidential, personal, proprietary, and other sensitive information (collectively &#8220;Information Assets&#8221;). </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, we maintain certain risk assessment processes intended to identify cybersecurity threats, determine their likelihood of occurring, and assess potential material impact to our business. Based on our assessment, we implement and maintain risk management processes designed to protect the confidentiality, integrity, and availability of our Information Assets and mitigate harm to our business.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our company&#8217;s general risk management program is designed to manage potential material risks, which includes material cybersecurity risks to our Information Assets. We engage in processes designed to identify such threats by, among other things, monitoring the threat environment using manual and automated tools, subscribing to services that identify cybersecurity threats, analyzing reports of threats and actors, conducting scans of the threat environment, evaluating threats reported to us, coordinating with law enforcement concerning threats, and conducting threats and vulnerability assessments. We rely on a multidisciplinary team to assess cybersecurity threats and a potential impact to our business. These assessments leverage industry tools and metrics designed to assist in the assessment of risks from such cybersecurity threats.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also implement and maintain various technical, physical and organizational measures designed to manage and mitigate material risks from cybersecurity threats to our Information Assets. The cybersecurity risk management and mitigation measures we implement include policies and procedures designed to address cybersecurity threats, including an incident response plan and a disaster recovery/business continuity plan. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To address the company&#8217;s cybersecurity risk, we utilize incident detection and response tools, internal and third-party assessments of our exposure to cybersecurity threats and compliance with risk mitigation procedures, and testing of our relevant controls including data segregation, insurance and assignment of cybersecurity responsibilities.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also work with third parties from time to time to assist us in identification, assessment and management of cybersecurity risks.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional informant and a description of the risks from cybersecurity threats that may materially affect us and how they may do so, refer to Part I, Item 1A. Risk Factors. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governance.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity risk assessment and management processes are implemented and maintained by certain company employees. Management is responsible for hiring appropriate personnel, integrating cybersecurity considerations into our company&#8217;s overall risk management strategy, and for communicating key priorities to employees, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports. Our cybersecurity incident response and vulnerability assessments processes involve management, who participates in our disclosure controls and procedures.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity processes are designed to escalate certain incidents and vulnerabilities to members of management depending on the circumstances, including cooperation with  our company&#8217;s incident response team to help mitigate and remediate cybersecurity incidents. In addition, these processes include reporting to the board of directors for certain cybersecurity incidents.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management including information technology, legal and accounting executives are involved with our company&#8217;s efforts to prevent, detect, and mitigate cybersecurity incidents by overseeing preparation of cybersecurity policies and procedures, testing of incident response plans, and engaging vendors with appropriate expertise. They participates in cybersecurity incident response efforts and directs the company&#8217;s response to cybersecurity incidents.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors addresses the company&#8217;s cybersecurity risk management as part of its general oversight function. The Board of Directors has access to various reports, summaries or presentations related to cybersecurity threats, risk, and mitigation.</span></div><div id="i3928a3425fef4184806511a3516ffab1_97"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;2. Properties.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we leased approximately 16,903 rentable square feet of space at the new Broadwest development in Nashville, Tennessee for our corporate headquarters. The lease commencement date occurred in October 2022 with a term of 157 months leased through November 2035. We believe these facilities are adequate to meet our current needs for office space. Manufacturing, packaging or warehousing services are provided to us through contracts with third-party organizations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laboratory space at CET, under an agreement amended in July 2012, is now leased through April 2028. During 2023, Cumberland exercised the 2nd Extension option to extend the lease for five more years though April 2028.  CET leases approximately 14,200 square feet of office and wet laboratory space in Nashville, Tennessee to operate the CET Life Sciences Center. Cumberland&#8217;s product formulation and testing laboratories are located at this facility, along with CET&#8217;s offices. The CET Life Sciences Center also provides laboratory and office space, equipment and infrastructure to early-stage life sciences companies and university spin-outs.</span></div><div id="i3928a3425fef4184806511a3516ffab1_100"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;3. Legal Proceedings.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see discussion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Melinta Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Note 19 Commitments and Contingencies contained in the Notes to Consolidated Financial Statements, which is incorporated herein by reference.</span></div><div id="i3928a3425fef4184806511a3516ffab1_103"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;4. Mine Safety Disclosures.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i3928a3425fef4184806511a3516ffab1_106"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i3928a3425fef4184806511a3516ffab1_109"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock, no par value, has been traded on the Nasdaq Global Select Market since August&#160;11, 2009 under the symbol &#8220;CPIX.&#8221; As of March&#160;8, 2024, we had 97 shareholders of record of our common stock. This excludes shareholders whose shares are held by brokers and other institutions on behalf of shareholders. The closing price of our common stock on the Nasdaq Global Select Market on March&#160;8, 2024 was $2.03 per share.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not declared or paid any cash dividends on our common stock. Any future decision to declare or pay dividends will be at the sole discretion of our Board of Directors.</span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock performance graph below illustrates a comparison of the total cumulative stockholder return on our common stock since December 31, 2018 to the Nasdaq Composite and a composite of ten Nasdaq Pharmaceutical and Specialty Pharmaceutical Stocks which most closely compare to our Company - Avadel Pharmaceuticals plc, Harrow Health, Inc., Eagle Pharmaceuticals, Inc., Assertio Holdings, Inc., HLS Therapeutics Inc., EyePoint Pharmaceuticals, Inc., Eton Pharmaceuticals, Inc., Theratechnologies Inc., Acorda Therapeutics Inc. and Talphera, Inc. The graph assumes an initial investment of $100 on December 31, 2018, and that all dividends were reinvested.</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><img src="cpix-20231231_g1.jpg" alt="1462" style="height:374px;margin-bottom:5pt;vertical-align:text-bottom;width:643px"/></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has a share repurchase program to repurchase up to $10.0 million of our common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934, as amended. In January 2019, the Company&#8217;s Board of Directors established the current $10.0 million repurchase program to replace the prior authorizations. We repurchased 402,143 shares and 367,793 shares of common stock for approximately $0.7 and $1.0 million during the years ended December&#160;31, 2023 and 2022, respectively. The following table summarizes the activity, by month, during the fourth quarter of 2023:</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"/><td style="width:23.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of Shares (or</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchased</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price&#160;Paid</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">per Share</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(or Unit)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares (or Units)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchased as</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Part of Publicly</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Announced Plans or</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Programs</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum&#160;Number&#160;(or</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate Dollar</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value) of Shares (or</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units)&#160;that&#160;May&#160;Yet&#160;Be</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchased Under the</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Plans or Programs</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.04</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,114</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3,135,727</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,220&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.81</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,220</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3,044,578</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.83</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,359</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3,005,385</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,693&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Of this amount, 25,000 shares were repurchased directly in private purchases at the then-current fair market value of common stock.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Of this amount, 971 shares were repurchased directly in private purchases at the then-current fair market value of common stock.</span></div><div id="i3928a3425fef4184806511a3516ffab1_112"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;6. Reserved.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i3928a3425fef4184806511a3516ffab1_115"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial position and results of operations should be read together with our audited consolidated financial statements and related notes appearing elsewhere in this Form 10-K. This discussion and analysis may contain forward-looking statements that involve risks and uncertainties &#8211; please refer to the section entitled, &#8220;Special Note Regarding Forward-Looking Statements,&#8221; contained in Part I, Item&#160;1A, &#8220;Risk Factors,&#8221; of this Form 10-K. You should review the &#8220;Risk Factors&#8221; section of this Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements described in the following discussion and analysis.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i3928a3425fef4184806511a3516ffab1_118"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXECUTIVE SUMMARY</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. We are dedicated to our mission of working together to provide unique products that improve the quality of patient care.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial portfolio includes seven branded products approved for marketing by the FDA. In addition to these commercial brands, we have Phase II clinical programs underway evaluating our ifetroban product candidate for patients with 1) cardiomyopathy associated with Duchenne Muscular Dystrophy, a fatal, genetic neuromuscular disease and 2) Systemic Sclerosis or scleroderma, a debilitating autoimmune disorder characterized by fibrosis of the skin and internal organs. We are also developing an oral capsule to treat Idiopathic Pulmonary Fibrosis, the most common form of progressive fibrosing interstitial lung disease. Following FDA clearance of our Investigational New Drug application in May 2023, we are in the process of initiating our Phase II study in patients in centers of excellence across the U.S.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary target markets are hospital acute care, gastroenterology and oncology. These medical specialties are characterized by relatively concentrated prescriber bases that we believe can be served effectively by small, targeted sales forces. We promote our approved products through our hospital, field and oncology sales divisions in the United States and are building a network of international partners to register and provide our medicines to patients in their countries.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established the capabilities needed to acquire, develop and commercialize branded pharmaceuticals in the U.S. We believe we can leverage this existing infrastructure to support new products and our expected growth.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management team consists of pharmaceutical industry veterans with significant experience in their areas of responsibility. Our business development team identifies, evaluates and negotiates product acquisition, licensing and co-promotion agreements. Our product development team creates proprietary formulations, manages our clinical studies, prepares our FDA submissions and staffs our medical call center. Our quality and manufacturing professionals oversee the manufacturing, release and shipment of our products. Our marketing and sales organization is responsible for our commercial activities, and we work closely with our distribution partners to ensure the availability of our brands.</span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023 Highlights</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a list of our Company&#8217;s highlights from 2023. For more information, please see Part I, Item I, Business of this Form 10-K.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Announced our newly refined mission statement: Working together to provide unique products that improve the quality of patient care.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Obtained FDA approval for our Caldolor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product, to include its use in infants. The non-narcotic agent may now be administered for the treatment of pain and fever in patients 3 to 6 months of age. With this newly approved labeling, Caldolor is the only non-opioid product approved to treat pain in infants that is delivered through injection.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Shared the publication of positive results from a clinical study investigating the safety and pharmacokinetics of Caldolor in newborns. Published in the journal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pediatric Drugs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the results of the study support the growing body of evidence that demonstrates Caldolor is a safe therapeutic option available to practitioners for the treatment of fever and pain in infants, children and adults.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Announced a new publication in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antimicrobial Agents and Chemotherapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> detailing the results of the first clinical study investigating the safety and pharmacokinetics of our Vibativ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product in children 2 to 17 years of age. The results of the study suggest that a single dose of Vibativ is safe in children.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Completed the Sancuso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> transition from Kyowa Kirin to Cumberland, including the NDA transfer, and initiation of the product&#8217;s manufacture at a new facility. We also expanded our oncology sales division to further support the brand.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Helped advance the submissions for the approval of Vibativ in China, South Korea and Saudi Arabia.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Completed the transition of our former RediTrex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product to Nordic Pharma.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Obtained FDA clearance of the Investigational New Drug application for a new ifetroban Phase II program in patients with Idiopathic Pulmonary Fibrosis, the most common form of progressive fibrosing interstitial lung disease.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Shared our fourth annual Sustainability Metrics, which detail the Company&#8217;s activities pertaining to our environmental, social and governance matters.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Entered into a new revolving credit loan agreement with Pinnacle Bank for a $20 million facility, expandable to $25 million over a three-year term.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued our corporate share repurchase initiative, with a group of our board members also purchasing shares through Rule 10b5-1 trading plans in order to add to their holdings in the Company.</span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">61</span></div></div></div><div id="i3928a3425fef4184806511a3516ffab1_121"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT JUDGMENTS AND ESTIMATES</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Estimates and Judgments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. We base our estimates on past experience and on other factors we deem reasonable given the circumstances. Past results help form the basis of our judgments about the carrying value of assets and liabilities that cannot be determined from other sources. Actual results could differ from these estimates. The Company&#8217;s most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory, (3) valuation of contingent consideration liabilities associated with business combinations and (4) valuation of continuing utility of intangible assets. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue in accordance with the Accounting Standards Codification (ASC) Topic 606. Effective January 1, 2018, we adopted the Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) amended guidance in the form of Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09, "Revenue from Contracts with Customers," (ASC 606). </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is derived primarily from the product sales of our FDA approved pharmaceutical brands. Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which occurs upon either shipment of the product or arrival at its destination, depending upon the shipping terms of the transaction. Payment terms typically range from 30 to 60 days from date of shipment. Our net product revenue reflects the reduction from gross product revenue for estimated allowances for chargebacks, and discounts and reflects sales related accruals for rebates, coupons, product returns, and certain administrative and service fees. Significant judgments must be made in determining the transaction price for our sales of products related to these adjustments. Other revenue, which is a component of net revenues, includes non-refundable upfront payments and milestone payments under licensing agreements along with grant and rental income. Other revenue was approximately 5.2% percent of net revenues in 2023 and 3.2% in 2022.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial statements reflect accounts receivable allowances of $0.6 million at December&#160;31, 2023 and 2022,  for chargebacks and early pay discounts for products. </span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects our sales-related accrual activity for the periods indicated below:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:63.586%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.595%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,347,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,680,677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provision</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,184,661&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,426,431&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual product returns and credits issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,952,092)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,759,894)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,579,783&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,347,214&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowances for chargebacks and discounts and sales related accruals for rebates, fee for service and product returns are determined on a product-by-product basis. We establish them using our best estimate at the time of sale based on: </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Each product&#8217;s historical experience adjusted to reflect known changes in the factors that impact such allowances; </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The contractual terms with direct and indirect customers;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Analyses of historical levels of chargebacks, discounts and returns of product; </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Communications with customers;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Purchased information about the rate of prescriptions being written and the level of inventory remaining in the distribution channel, if known; and</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expectations about the market for each product, including any anticipated introduction of competitive products.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from us based on either negotiated contracts to carry our products or reimbursements for filled prescriptions. These entities are considered our indirect customers. When recognizing a sale to a wholesaler, sales revenues are reduced and accrued liabilities are increased by our estimate of the rebate that may be claimed. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowances for chargebacks and accruals for rebates and product returns are the most significant estimates used in the recognition of our revenue from product sales. Of the accounts receivable allowances and our sales related accruals, our accrual for product returns and rebates represents the majority of the balance. Sales related accrued liabilities for rebates, product returns, service fees, and administrative fees totaled $7.6 million and $8.3 million as of December&#160;31, 2023 and 2022 , respectively. Of these amounts, our estimated liability for fee for services represented $1.4 million and $1.5 million, respectively, while our accrual for product returns totaled $2.6 million and $2.7 million, respectively. If the actual amount of cash discounts, chargebacks, rebates, and product returns differs from the amounts estimated by management, material differences may result from the amount of our revenue recognized from product sales. A change in our rebate estimate of one percentage point would have impacted net sales by approximately $0.6 million for the years ended December&#160;31, 2023 and 2022. A change in our product return estimate of one percentage point would have impacted net sales by $0.4 million for the years ended December&#160;31, 2023 and 2022. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record amounts for estimated obsolescence or unmarketable inventory in an amount equal to the difference between the cost of inventory and the net realizable value based upon assumptions about remaining shelf life, future demand and market conditions. The estimated inventory obsolescence amounts are calculated based upon specific review of the inventory expiration dates and the quantity on-hand at December&#160;31, 2023, in comparison to our expected inventory usage. The amount of actual inventory obsolescence and unmarketable inventory could differ (either higher or lower) in the near term from the estimated amounts. Changes in our estimates would be recorded in our statement of operations in the period of the change.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current inventories consist of active pharmaceutical ingredients which typically has an extended life and selected finished good products with extended life longer than one year.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for deferred taxes using the asset and liability approach. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to operating loss and tax credit carry-forwards and differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Our principal differences are related to the timing of deductibility of certain items such as depreciation, amortization and expense for options issued to nonemployees. Deferred tax assets and liabilities are measured using management&#8217;s estimate of tax rates expected to apply to taxable income in the years in which management believes those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in our results of operations in the period that includes the enactment date.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounting policy with respect to interest and penalties arising from income tax settlements is to recognize them as part of the provision for income taxes.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-Based Payments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize compensation expense for all share-based payments based on the fair value of the award on the date of grant. In addition, incremental compensation expense is recognized upon the modification of equity awards. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issue restricted stock and incentive stock option awards to employees, directors and consultants. Compensation expense for restricted equity awards granted to employees and directors is generally equal to the fair market value of the underlying common stock on the date of grant. If a sufficient disincentive for nonperformance does not exist at the date of grant, the compensation cost is remeasured at each reporting date at the then-current fair market value of the underlying common stock until the award vests.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for and expense research and development costs based on estimates of work performed, patient enrollment or fixed-fee-for-services. As work is performed and/or invoices are received, we adjust our estimates and accruals. To date, our accruals have not differed materially from our estimates. Total research and development costs are a function of studies being conducted and will increase or decrease based on the level of activity in any particular year.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets include product rights, license agreements, other identifiable intangible assets and goodwill associated with the Vibativ acquisition. We assess the impairment of goodwill at least annually. We assess the impairment of identifiable intangible assets subject to amortization whenever events or changes in circumstances indicate the carrying value may not be recoverable. In determining the recoverability of our intangible assets, we make assumptions regarding estimated future cash flows and other factors. If the estimated undiscounted future cash flows do not exceed the carrying value of the intangible assets, we must determine the fair value of the intangible assets. If the fair value of the intangible assets is less than the carrying value, an impairment loss will be recognized in an amount equal to the difference. Fair value is determined through various valuation techniques including quoted market prices, third-party independent appraisals and discounted cash flow models, as considered necessary.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">64</span></div></div></div><div id="i3928a3425fef4184806511a3516ffab1_124"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December&#160;31, 2023 compared to year ended December&#160;31, 2022</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the statements of operations for the years ended December&#160;31, 2023 and 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:38.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.353%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.353%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.356%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,552,507&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,010,949&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,458,442)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,066,611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,118,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,051,910)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,451,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,660,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,790,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,834,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,688,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(854,695)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,651,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,180,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization and impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,102,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,067,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,035,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,107,168&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,715,878&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,391,290&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,554,661)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,704,929)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,849,732)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,828,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,828,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income - settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income - insurance proceeds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(264,530)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(667,861)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(585,995)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81,866)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,284,997)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,581,189)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(703,808)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,769)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,850)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,330,766)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,650,039)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(680,727)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes net revenues for the years presented:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:38.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.353%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.353%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,981,850&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,205,155&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">776,695&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,812,692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,487,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325,230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,096,788&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,205,603&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,108,815)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,333,923&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,827,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(493,277)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458,759&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501,040&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,281)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,030&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,115)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,336&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(447,697)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599,033&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(341,886)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126,726)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(215,160)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,039,015&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,329,767&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">709,248&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,552,507&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,010,949&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,458,442)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Net revenues for the year ended December&#160;31, 2023, were approximately $39.6 million compared to $42.0 million for the year ended December&#160;31, 2022. As detailed in the table above, net revenue increased during 2023 for two of our marketed products: Kristalose and Vibativ. These increases were mainly offset by decreased net product sales of Sancuso and Caldolor.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kristalose revenue increased by $0.8 million, or 5.1%, compared to December&#160;31, 2022, primarily as a result of increased shipments of the product.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vibativ revenue increased to $8.8 million for the year ended December&#160;31, 2023, compared to $7.5 million in the same prior year period. The increase of  $1.3 million, or 17.7%, reflected fewer product returns in the current year.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sancuso revenue was $8.1 million compared to $13.2 million in the prior year. This decrease in net revenue was primarily a result of an inordinate amount of product returns and higher commercial rebates. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caldolor revenue was $4.3 million during the year ended December 31, 2023, compared to $4.8 million in the same period last year. This decrease in Caldolor revenue for the year ended December 31, 2023, w</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as the result of the timing of international shipments. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no Vaprisol revenue for the year ended December 31, 2023, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as Cumberland is currently out of commercial inventory of the product. Net revenue was positively impacted by various sales deduction adjustments. </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acetadote revenue included net sales of our branded product and our share of net sales from our Authorized Generic. For the year ended December 31, 2023, the Acetadote net revenue was $0.5 million, similar to the prior year period.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Omeclamox-Pak had no sales for the year ended December 31, 2023, as Cumberland is currently out of commercial inventory of this product. The packager for our Omeclamox-Pak product encountered financial difficulties and currently is under new management and is reorganizing.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reditrex revenue decreased $0.2 million in 2023 compared to 2022.  We discontinued sale of the product in 2023.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Revenue.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue increased due to the litigation settlement based on two $500,000 milestone payments due to us for the license associated with our Vibativ product.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Cost of products sold for the year ended December&#160;31, 2023, were $6.1 million compared to $9.1 million in the prior year, a decrease of $3.1 million. These cost savings were due to the availability of lower cost inventory and fewer inventory write downs.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling and marketing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Selling and marketing expense for the year ended December&#160;31, 2023, were $18.5&#160;million compared to $16.7 million in the prior year, which was an increase of $1.8 million. This increase was primarily a result of an increase in marketing expenses associated with the Sancuso acquisition including royalty costs, promotional spending and the cost associated with our expanded Oncology division. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Research and development costs for the year ended December&#160;31, 2023, were $5.8&#160;million, compared to $6.7 million last year, representing a decrease of $0.9 million due to reduced FDA fees. A portion of our research and development costs is variable based on the number of trials, study sites, number of patients and the cost per patient in each of our clinical programs. We continue to fund our ongoing clinical initiatives associated with our pipeline products. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. General and administrative expenses for the year ended December&#160;31, 2023, were $10.7 million compared to $10.2 million in the prior year. The change resulted from an increase in hiring costs and deferred compensation expenses.</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the statements of operations discussed above reflect the following impacts from Vibativ:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.049%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Impact of Vibativ</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,812,692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,637,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,423,399&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,535,851&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty and operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,379,939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ contribution</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,009,354&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,018,466&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> 2023 net revenue includes a $1,000,000 payment to Cumberland related to a settlement agreement of milestone payments.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Vibativ inventory included in the costs of product sold during the period was acquired and paid for by Cumberland as part of the acquisition of the brand during 2018.</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the statements of operations discussed above reflect the following impacts from Sancuso:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.049%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Impact of Sancuso</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,096,788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,555,603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,214,826&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,543,600&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty and operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,375,823&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,202,026&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso contribution</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,506,139&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,809,977&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Sancuso inventory included in the costs of product sold during the period was acquired and paid for by Cumberland as part of the acquisition of the brand during 2022.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization and impairment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Amortization and impairment expenses represent the ratable use of our capitalized intangible assets including product and license rights, patents, trademarks and patent defense costs. Amortization and impairment for 2023 totaled approximately $8.1&#160;million which is an increase of $3.0 million due to a $3.3 million write down of our Omeclamox intangible assets.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Income taxes totaled $45,769 for the year ended December&#160;31, 2023, and $68,850 for the year ended December&#160;31, 2022. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we recognized a $2.8 million refund of FDA fees for the periods of 2023 and 2022 to be used to further our product research efforts.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in 2023 we recognized a gain of $0.5 million to settle a manufacturing dispute and a gain of $0.3 million for a payout earned on a company owned insurance policy.</span></div><div id="i3928a3425fef4184806511a3516ffab1_127"></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of liquidity are cash flows provided by our operations, the amounts borrowed and available under our line of credit and the cash proceeds from our initial public offering of common stock that was completed in August 2009. We believe that our internally generated cash flows, existing working capital and our line of credit will be adequate to finance internal growth, finance business development initiatives, and fund capital expenditures for the foreseeable future.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023 and December&#160;31, 2022, all our investments had original maturities of less than ninety days and as a result were classified as cash equivalents. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our liquidity and working capital as of the years ended December 31:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:63.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.395%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.398%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:7pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,321,624&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,757,970&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,321,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,757,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital (current assets less current liabilities)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,732,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,290,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current ratio (multiple of current assets to current liabilities)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving line of credit availability</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,215,856&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,800,000&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our net changes in cash and cash equivalents for the years ended December&#160;31:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.002%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.370%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by (used in):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,093,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,453,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105,695)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,674,456)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,424,472)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,061,786)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash and </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">cash equivalents </span></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,436,346)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,282,846)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net $1.4 million decrease in cash and cash equivalents for the year ended December&#160;31, 2023, was attributable to cash provided by operating activities offset by cash used in investing and financing activities. Cash provided by operating activities of $6.1 million is primarily due to an increase in accounts payable and other accrued liabilities of $3.7 million, and a $3.4 million decrease in accounts receivable, partially offset by a decrease in non-cash contingent consideration of $1.3 million. Cash used in investing activities of $0.1 million was the result of additions of intangibles and property and equipment offset by life insurance proceeds received. Our financing activities included payments of $3.3 million of contingent consideration for Vibativ and Sancuso, a pay down on our line of credit of $3.4 and $0.7 million in cash used to repurchase shares of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, we continue to repurchase shares of our common stock, as discussed in Part II, Item&#160;5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities",</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Form 10-K.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net $7.3 million decrease in cash and cash equivalents for the year ended December 31, 2022, was attributable to cash provided by operating activities offset by cash used in investing and financing activities.  Cash provided by operating activities of $8.5 million includes a decrease of inventory of $0.9 million, most of which was Vibativ and Sancuso related, an increase in accounts payable and other accrued liabilities of $14.5 million, partially offset by a $6.1 million increase in accounts receivable and a decrease in non-cash contingent consideration of $2.1 million.  Cash used in investing activities of $13.7 million was the result of the acquisition of Sancuso of $13.5 </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million, additions to intangibles of $2.0 million, additions to property and equipment of $0.1 million and the proceeds of officer life insurance proceeds of $0.9 million.  Our financing activities included payments of $2.2 million of contingent consideration for Vibativ and Sancuso and $1.1 million in cash used to repurchase shares of our common stock.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shelf Registration</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Company filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100 million in corporate securities which also was declared effective in December 2023.  The Company intends to enter into an At the Market Sales Agreement in March 2024, in order to allow the Company to sell shares at market prices.  The Company did not issue any shares under its ATM program during the year ended December&#160;31, 2023.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Agreement</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 5, 2023, the Company entered into a new Revolving Credit Loan Agreement with Pinnacle Bank. This facility provides for an aggregate principal funding amount of up to $25&#160;million. The initial revolving line of credit is up to $20&#160;million, with the ability for Cumberland to increase the amount to $25&#160;million, under certain conditions. It has a three year term expiring on October 1, 2026. The interest rate is based on Benchmark (Term SOFR) plus a spread of 2.75%. Cumberland is subject to one financial covenant, the maintenance of a Funded Debt Ratio, determined on a quarterly basis. Borrowings under the line of credit are collateralized by substantially all of our assets.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Minimum Product Purchase Requirements</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing and supply agreements do not require minimum annual purchase obligations. </span></div><div style="margin-top:8pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual cash obligations</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contractual cash obligations as of December&#160;31, 2023:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.449%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Payments Due by Year</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contractual obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026 and thereafter</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Line of credit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,784,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,784,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated interest on debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,856,458&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038,712&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038,712&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779,034&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ contingent consideration liability payments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,033,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514,476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,271,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso contingent consideration liability payments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,306,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,565&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387,316&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,174&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,064&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084,881&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,131,702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863,320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934,180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,588,191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,111,577&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,271,958&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,776,604&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,347,260&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,770,940&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,944,815&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt">The sum of the individual amounts may not agree due to rounding.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt">The line of credit payments represent the estimated unused line of credit payments and the amount due at maturity. The estimated interest on debt represents the interest on the principal outstanding on the line of credit. These amounts are based on the $12.8 million line of credit assuming the current $12.8 million balance outstanding on December&#160;31, 2023 is consistently outstanding through maturity of October 2026. Interest and unused line of credit payments are due and payable quarterly in arrears. </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt">The contingent consideration liability represents the fair value of the royalty payments of up to 20% of future net sales as part of the Vibativ acquisition.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt">The contingent consideration liability represents the fair value of the royalty payments of up to 10% of future net sales as part of the Sancuso acquisition.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt">The Broadwest contractual cash obligation began upon commencement in October 2022 and CET began May 2023.</span></div><div id="i3928a3425fef4184806511a3516ffab1_130"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OFF-BALANCE SHEET ARRANGEMENTS</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023 and 2022 we did not engage in any off-balance sheet arrangements.</span></div><div style="text-indent:18pt"><span><br/></span></div><div id="i3928a3425fef4184806511a3516ffab1_133"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECENT ACCOUNTING PRONOUNCEMENTS</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#8217;s provisions as a cumulative-effect adjustment, if any, to accumulated deficit as of the beginning of the first reporting period in which the guidance is adopted.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably electing the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. We</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> adopted both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 did not have a material impact on the Company&#8217;s consolidated financial statements.</span></div><div style="text-indent:18pt"><span><br/></span></div><div id="i3928a3425fef4184806511a3516ffab1_136"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;7A. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk related to changes in interest rates on our cash on deposit in highly-liquid money market accounts and revolving credit facility. We do not utilize derivative financial instruments or other market risk-sensitive instruments to manage exposure to interest rate changes. The main objective of our cash investment activities is to preserve principal while maximizing interest income through low-risk investments. Our investment policy focuses on principal preservation and liquidity.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our interest rate risk related to our cash and cash equivalents is not material. The risk related to interest rates for these accounts would produce less income than expected if market interest rates fall. Based on current interest rates, we do not believe we are exposed to significant downside risk related to a change in interest on our money market accounts. The Company did not have any investments in marketable securities at December&#160;31, 2023.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate risk related to borrowings under our line of credit is based on a benchmark (Term SOFR) plus a spread of 2.75%.  As of December&#160;31, 2023, we had $12.8 million in borrowings outstanding under our revolving line of credit. </span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exchange Rate Risk</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we operate primarily in the U.S., we are exposed to foreign currency risk. A portion of our research and development is performed abroad. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, we do not utilize financial instruments to hedge exposure to foreign currency fluctuations. We believe our exposure to foreign currency fluctuation is minimal as our purchases in foreign currency have a maximum exposure of 90 days based on invoice terms with a portion of the exposure being limited to 30 days based on the due date of the invoice. Foreign currency exchange losses were immaterial for 2023 and 2022. Neither a five percent increase nor decrease from current exchange rates would have had a material effect on our operating results or financial condition.</span></div><div id="i3928a3425fef4184806511a3516ffab1_139"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;8. Financial Statements and Supplementary Data.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See consolidated financial statements, including the reports of the independent registered public accounting firm, starting on page F-1, which is incorporated herein by reference.</span></div><div id="i3928a3425fef4184806511a3516ffab1_142"></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i3928a3425fef4184806511a3516ffab1_145"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;9A. Controls and Procedures.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Chief Executive Officer and Chief Financial Officer, with the participation of other members of management, have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act") as of  December&#160;31, 2023. Based on such evaluations, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective (at the reasonable assurance level) to ensure that the information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized, and reported, within the time periods specified in the SEC&#8217;s rules and forms and to ensure that such information is accumulated and communicated to the Company&#8217;s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management&#8217;s report on internal control over financial reporting is included on page F-1 of this annual report on Form 10-K, and incorporated herein by reference. During our fourth quarter of 2023, there were no changes in our internal control over financial reporting (as defined in Rule&#160;13a-15(f) or 15d-15(f)) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i3928a3425fef4184806511a3516ffab1_148"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;9B. Other Information.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a) Recent Developments</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Form 8-K, Item 5.02(e).    Compensatory Arrangements of Certain Officers</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 7, 2024, the Company entered into new employment agreements with each of A.J. Kazimi, our Chief Executive Officer (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Kazimi Employment Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), Jim Herman, our Executive Vice President National Accounts and Chief Compliance Officer (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Herman Employment Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), Todd Anthony, our Vice President Organizational Development (the &#8220;Anthony Employment Agreement&#8221;), Chris T. Bitterman, Vice President Sales and Marketing (the &#8220;Bitterman Employment Agreement&#8221;) and John M. Hamm, our Vice President, Chief Financial Officer (the &#8220;Hamm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> Employment Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and together with the Kazimi Employment Agreement, the Herman Employment Agreement, the Anthony Employment Agreement, the Bitterman Employment Agreement and the Hamm Employment Agreement, (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Employment Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The Employment Agreements were effective as of January 1, 2024.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employment Agreements</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Employment Agreement provides for a salary for services performed, a potential annual bonus and a grant of restricted incentive stock options pursuant to a restricted stock agreement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the terms of each Employment Agreement, employment is at-will and may be terminated by the Company at any time, with or without notice and with or without cause. Similarly, each of Mr. Kazimi, Mr. Herman, Mr. Anthony, Mr. Bitterman, and Mr. Hamm may terminate his respective employment with us at any time, with or without notice. The Employment Agreements do not provide for any severance payments in the event employment is terminated for cause nor any severance benefits in the event employment is terminated as a result of death or permanent disability. The Employment Agreements include non-competition, non-solicitation and non-disclosure covenants on the part of employees. The Employment Agreements impose obligations regarding confidential information and state that any discoveries or improvements conceived, developed or otherwise made by the employees, or with others, are deemed our sole property. The Employment Agreements do not contain any termination or change in control provisions.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kazimi Employment Agreement</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Kazimi Employment Agreement, Mr. Kazimi will serve as the Company&#8217;s Chief Executive Officer and will receive a base salary of $702,000.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing description of the Kazimi Employment Agreement is qualified in its entirety by reference to the Kazimi Employment Agreement, which is included as Exhibit 10.11 to this Annual Report on Form 10-K and is incorporated by reference into this Item. The foregoing description of the Kazimi Employment Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Herman Employment Agreement</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Herman Employment Agreement, Mr. Herman will serve as the Company&#8217;s Senior Vice President, National Accounts and Chief Compliance Officer and will receive a base salary of $310,000.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing description of the Herman Employment Agreement is qualified in its entirety by reference to the Herman Employment Agreement, which is included as Exhibit 10.12 to this Annual Report on Form 10-K and is incorporated by reference into this Item. The foregoing description of the Herman Employment Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit.</span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anthony Employment Agreement</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Anthony Employment Agreement, Mr. Anthony will serve as the Company&#8217;s Vice President Organizational Development and will receive a base salary of $286,125.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing description of the Anthony Employment Agreement is qualified in its entirety by reference to the Anthony Employment Agreement, which is included as Exhibit 10.13 to this Annual Report on Form 10-K and is incorporated by reference into this Item. The foregoing description of the Anthony Employment Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bitterman Employment Agreement</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Bitterman Employment Agreement, Mr. Bitterman will serve as the Company&#8217;s Vice President Sales and Marketing and will receive a base salary of $268,840.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing description of the Bitterman Employment Agreement is qualified in its entirety by reference to the Bitterman Employment Agreement, which is included as Exhibit 10.14 to this Annual Report on Form 10-K and is incorporated by reference into this Item. The foregoing description of the Bitterman Employment Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hamm Employment Agreement</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Hamm Employment Agreement, Mr. Hamm will serve as the Company&#8217;s Vice President, Chief Financial Officer and will receive a base salary of $246,240.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing description of the Hamm Employment Agreement is qualified in its entirety by reference to the Hamm Employment Agreement, which is included as Exhibit 10.15 to this Annual Report on Form 10-K and is incorporated by reference into this Item. The foregoing description of the Hamm Employment Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)  Insider Trading Arrangements and Policies</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December 31, 2023, no &#8220;director&#8221; or &#8220;officer&#8221; (as defined in Rule 16a-1(f) under the Exchange Act) of the Company <ix:nonNumeric contextRef="c-4" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-38"><ix:nonNumeric contextRef="c-4" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-39">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-4" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-40"><ix:nonNumeric contextRef="c-4" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-41">terminated</ix:nonNumeric></ix:nonNumeric> a &#8220;Rule 10b5-1 trading arrangement&#8221; or a &#8220;non-Rule 10b5-1 trading arrangement,&#8221;as each term is defined in Item 408(a) of Regulation S-K.</span></div><div id="i3928a3425fef4184806511a3516ffab1_151"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item 9C:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i3928a3425fef4184806511a3516ffab1_154"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by Part III of Form 10-K (Item 10 &#8211; Directors, Executive Officers and Corporate Governance, Item&#160;11 &#8211; Executive Compensation, Item&#160;12 &#8211; Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters, Item&#160;13 &#8211; Certain Relationships and Related Transactions, and Director Independence, Item&#160;14 &#8211; Principal Accountant Fees and Services), is incorporated by reference from our proxy statement related to our 2024 annual meeting of shareholders, which is expected to be filed with the SEC on or around March 13, 2024.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">73</span></div></div></div><div id="i3928a3425fef4184806511a3516ffab1_157"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div id="i3928a3425fef4184806511a3516ffab1_160"></div><div style="-sec-extract:summary;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;15. Exhibits, Financial Statement Schedules.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt">Documents filed as part of this report:</span></div><div style="margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)  Financial Statements</span></div><div style="margin-top:8pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.307%"><tr><td style="width:1.0%"/><td style="width:74.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.686%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Page&#160;Number</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_169">Management&#8217;s Report on Internal Control over Financial Reporting</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-1</span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Report of Independent Registered Public Accounting Firm - Consolidated Financial Statements - Carr, Riggs &amp; Ingram; Nashville, TN; PCAOB ID: <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-42">213</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_172">Report of Independent Registered Public Accounting Firm &#8211; Consolidated Financial Statements - FORVIS, LLP (formerly BKD, LLP); Nashville, TN  PCAOB ID:</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> <ix:nonNumeric contextRef="c-5" name="dei:AuditorFirmId" id="f-43">686</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-2</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_175">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_175">8</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_178">Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_178">9</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_181">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_181">10</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_184">Consolidated Statements of Equity</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_184">12</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_187">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_187">13</a></span></div></td></tr></table></div><div style="margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Financial Statement Schedule</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.307%"><tr><td style="width:1.0%"/><td style="width:74.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.686%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_253">Valuation and Qualifying Accounts</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3928a3425fef4184806511a3516ffab1_253">39</a></span></div></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">b. Exhibits</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1087294/000162828022000440/finalforexecutionkkuscipde.htm">Asset Purchase Agreement, dated December 31, 2021, by and between Cumberland Pharmaceuticals Inc. and Kyowa Kirin, Inc., incorporated herein by reference to the corresponding exhibit 2.1 of the Registrant&#8217;s Form 8-K  (File No. 001- 001-33637) as filed with the SEC on January 6, 2022</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000095012309023228/c0628619exv3w1.htm">Third Amended and Restated Charter of Cumberland Pharmaceuticals Inc., incorporated herein by reference to the corresponding exhibit to Amendment No. 19 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-142535) as filed with the SEC on July 17, 2009</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000095012309023228/c0628619exv3w2.htm">Second Amended and Restated Bylaws of Cumberland Pharmaceuticals Inc., incorporated herein by reference to the corresponding exhibit to Amendment No. 19 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-142535) as filed with the SEC on July 17, 2009</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000095014407007248/g06286a5exv4w1.htm">Specimen Common Stock Certificate of Cumberland Pharmaceuticals Inc., incorporated herein by reference to the corresponding exhibit to Amendment No. 5 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-142535) as filed with the SEC on August 6, 2007</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000119312517372414/d489256dex42.htm">Preferred Stock Terms, Rights, and Provisions, incorporated herein by reference to the corresponding exhibit to Registrant's Registration Statement Form S-3 (File No. 333-221402) as filed with the SEC on December 19, 2017</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000119312517335943/d489256dex42.htm">Form of Senior Indenture, incorporated herein by reference to the corresponding exhibit to Registrant's Registration Statement Form S-3 (File No. 333-221402) as filed with the SEC on November 7, 2017</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000119312517335943/d489256dex43.htm">Form of Subordinated Indenture, incorporated herein by reference to the corresponding exhibit to Registrant's Registration Statement Form S-3 (File No. 333-221402) as filed with the SEC on November 7, 2017</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000095014407004069/g06286exv4w5.htm">Form of Option Agreement under 1999 Stock Option Plan of Cumberland Pharmaceuticals Inc., incorporated herein by reference to the corresponding exhibit to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-142535) as filed with the SEC on May 1, 2007</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6.1#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000144530513000573/cpixexhibit461.htm">Form of Incentive Stock Option Agreement under the Amended and Restated 2007 Long-Term Incentive Compensation Plan of Cumberland Pharmaceuticals Inc. incorporated herein by reference to the corresponding exhibit to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-33637) as filed with the SEC on March 12, 2013</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6.2#</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000144530513000573/cpixexhibit462.htm">Form of Non-Statutory Stock Option Agreement under the Amended and Restated 2007 Long-Term Incentive Compensation Plan of Cumberland Pharmaceuticals Inc. incorporated herein by reference to the corresponding exhibit to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-33637) as filed with the SEC on March 12, 2013</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7#</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000144530513000573/cpixexhibit47.htm">Form of Non-Statutory Stock Option Agreement under the Amended and Restated 2007 Directors&#8217; Compensation Plan of Cumberland Pharmaceuticals Inc. incorporated herein by reference to the corresponding exhibit to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-33637) as filed with the SEC on March 12, 2013</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000095012310026333/g22569exv4w8.htm">Warrant to Purchase Common Stock of Cumberland Pharmaceuticals Inc., issued to Bank of America, N.A. on July 22, 2009, incorporated herein by reference to the corresponding exhibit to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-33637) as filed with the SEC on March 19, 2010</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000119312517335943/d489256dex42.htm">Form of Senior Indenture, incorporated herein by reference to the corresponding exhibit to Registrant's Registration Statement Form S-3 (File No. 333-184091) as filed with the SEC on September 25, 2012.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000119312517335943/d489256dex43.htm">Form of Subordinated Indenture, incorporated herein by reference to the corresponding exhibit to Registrant's Registration Statement Form S-3 (File No. 333-184091) as filed with the SEC on September 25, 2012</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.11</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023q4exhibit411.htm">Description of Cumberland Pharmaceutical's Common Stock</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000129993310003084/exhibit1.htm">Exclusive Distribution Agreement, effective as of July 1, 2010, by and between Cardinal Health 105, Inc. and Cumberland Pharmaceuticals Inc., incorporated herein by reference to the corresponding exhibit of the Registrant&#8217;s Current Report on Form 8-K (File No. 001-33637) as filed with the SEC on August 13, 2010</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000108729413000004/exhibit1071amendmenttoexcl.htm">First Amendment to Exclusive Distribution Agreement, dated March 31, 2013, by and between Cardinal Health 105, Inc. and Cumberland Pharmaceuticals Inc., incorporated herein by reference to the corresponding exhibit of the Registrant's Current Report on Form 8-K (File No. 001-33637) as filed with the SEC on June 3, 2013</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000095014407006504/g06286a3exv10w10.htm">License Agreement, dated May 28, 1999, by and between Vanderbilt University and Cumberland Pharmaceuticals Inc., incorporated herein by reference to the corresponding exhibit to Amendment No. 3 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-142535) as filed with the SEC on July 11, 2007</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registrant's Quarterly Report on Form 10-Q (File No. 001-33637) as filed with the SEC on May13, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex-1011ajkazimix202310k.htm">Employment Agreement dated March 8, 2024, effective as of January 1, 2024, by and between A.J. Kazimi and Cumberland Pharmaceuticals Inc.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex-1012jimhermanx202310k.htm">Employment Agreement dated March 8, 2024, effective as of January 1, 2024, by and between Jim Herman and Cumberland Pharmaceuticals Inc.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex-1013toddanthonyx202310k.htm">Employment Agreement dated March 8, 2024, effective as of January 1, 2024, by and between Todd Anthony and Cumberland Pharmaceuticals Inc.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex-1014chrisbittermanx2023.htm">Employment Agreement dated March 7, 2024, effective as of January 1, 2024, by and between Chris Bitterman and Cumberland Pharmaceuticals Inc.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex-1015johnhammx202310k.htm">Employment Agreement dated March 7, 2024, effective as of January 1, 2024, by and between John M. Hamm and Cumberland Pharmaceuticals Inc.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000095014407004069/g06286exv10w17.htm">1999 Stock Option Plan of Cumberland Pharmaceuticals Inc., incorporated herein by reference to the corresponding exhibit to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-142535) as filed with the SEC on May 1, 2007</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000119312512107956/d293470ddef14a.htm">Amended and Restated 2007 Long-Term Incentive Compensation Plan of Cumberland Pharmaceuticals Inc., incorporated herein by reference to Appendix A of the Registrant&#8217;s Schedule 14A as filed with the SEC on March 12, 2012 and approved by the Registrant's shareholders on April 17, 2012 </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000119312512107956/d293470ddef14a.htm">Amended and Restated 2007 Directors&#8217; Incentive Plan of Cumberland Pharmaceuticals Inc., incorporated herein by reference to Appendix B of the Registrant's Schedule 14A as filed with the SEC on March 12, 2012 and approved by the Registrant's shareholders on April 17, 2012</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000095014407004069/g06286exv10w20.htm">Form of Indemnification Agreement between Cumberland Pharmaceuticals Inc. and all members of its Board of Directors, incorporated herein by reference to the corresponding exhibit to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-142535) as filed with the SEC on May 1, 2007</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000095014407004069/g06286exv10w23.htm">Amended and Restated Lease Agreement, dated November 11, 2004, by and between The Gateway to Nashville LLC and Cumberland Emerging Technologies, Inc., incorporated herein by reference to the corresponding exhibit to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-142535) as filed with the SEC on May 1, 2007</a></span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000095014407004069/g06286exv10w24.htm">First Amendment to Amended and Restated Lease Agreement, dated August 23, 2005, by and between The Gateway to Nashville LLC and Cumberland Emerging Technologies, Inc., incorporated herein by reference to the corresponding exhibit to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-142535) as filed with the SEC on May 1, 2007</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000095014408004306/g06286b1exv10w24w1.htm">Second Amendment to Amended and Restated Lease Agreement, dated January 9, 2006, by and between The Gateway to Nashville LLC and Cumberland Emerging Technologies, Inc., incorporated herein by reference to the corresponding exhibit to Amendment No. 10 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-142535) as filed with the SEC on May 21, 2008</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24.2&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000119312512347942/d334181dex10241.htm">Third Amendment to Amended and Restated Lease Agreement, dated July 3, 2012, by and between The Gateway to Nashville LLC and Cumberland Emerging Technologies, Inc., incorporated herein by reference to the corresponding exhibit to the Registrant's Quarterly Report on Form 10-Q (File No. 001-33637) as filed with the SEC on August 9, 2012</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000162828016012682/a2015-10kxexhibit1025gelli.htm">License and Supply Agreement, dated November 16, 2015, by and between Cumberland Pharmaceuticals Inc. and Gastro-Entero Logic, LLC incorporated herein by reference to the corresponding exhibit of the Registrant's Annual Report on Form 10-K (File No. 001-33637) as filed with the SEC on March 14, 2016</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000129993311003397/exhibit1.htm">Asset Purchase and Royalty Agreement for Kristalose dated November 15, 2011 by and between Mylan Inc. and Cumberland Pharmaceuticals Inc., incorporated herein by reference to the corresponding exhibit of the Registrant&#8217;s Current Report on Form 8-K (File No. 001-33637) as filed with the SEC on November 22, 2011</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000119312512247355/d358671dex1030.htm">Supplemental Executive Retirement and Savings Plan, incorporated herein by reference to the corresponding exhibit to the Registrant's Current Report on Form 8-K (File No. 001-33637) as filed with the SEC on May 24, 2012</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000144530513000573/cpixexhibit1031-perrigoxpa.htm">Settlement Agreement, dated November 9, 2012, by and between Cumberland Pharmaceuticals Inc., Paddock Laboratories, LLC and Perrigo Company incorporated herein by reference to the corresponding exhibit to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-33637) as filed with the SEC on March 12, 2013</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000144530513000573/cpixexhibit1032-perrigoxpa.htm">License and Supply Agreement, dated November 9, 2012, by and between Cumberland Pharmaceuticals Inc., Paddock Laboratories, LLC and Perrigo Company incorporated herein by reference to the corresponding exhibit to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-33637) as filed with the SEC on March 12, 2013</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.38#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1087294/000162828020012738/exhibit101-amendment2l.htm">Amendment Number 2 to the Amended and Restated 2007 Long-Term Incentive Plan, incorporated herein by reference to Exhibit 10.1 of the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-33637) as filed with the SEC on August 14, 2020</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1087294/000162828020012738/exhibit102-amendment2d.htm">Amendment Number 2 to the Amended and Restated 2007 Directors&#8217; Incentive Compensation Plan, incorporated herein by reference to Exhibit 10.2 of the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-33637) as filed with the SEC on August 14, 2020</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.44</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1087294/000162828022005942/a1600westendavepartnersl.htm">Lease Agreement, dated November 15, 2021, by and between Cumberland Pharmaceuticals Inc. and  1600 West End Avenue Partners, LLC., incorporated herein by reference to the corresponding exhibit of the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-33637) as filed with the SEC on March 11, 2022</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1087294/000162828023019604/a00exhibit161fromforvis.htm">Letter to the SEC from FORVIS, LLP, incorporated herein by reference to Exhibit 16.1 of the Company&#8217;s Current Report on Form 8-K (File No. 001-33637) as filed with the SEC on May 24, 2023</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000095014407004069/g06286exv21.htm">Subsidiaries of Cumberland Pharmaceuticals Inc., incorporated herein by reference to the corresponding exhibit to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-142535) as filed with the SEC on May&#160;1, 2007</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023-10kxex231consentofcri.htm">Consent of Carr, Riggs &amp; Ingram, LLC</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023-xex232consentofforvi.htm">Consent of FORVIS, LLP</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023-10kxexhibit311.htm">Certification of Chief Executive Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023-10kxexhibit312.htm">Certification of Chief Financial Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023-xex971compensationre.htm">Policy for the Recovery of Previously Awarded Incentive Compensation</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023-10kxexhibit321.htm">Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL INSTANCE DOCUMENT - THE INSTANCE DOCUMENT DOES NOT APPEAR IN THE INTERACTIVE DATA FILE BECAUSE ITS XBRL TAGS ARE EMBEDDED WITHIN THE INLINE XBRL DOCUMENT.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"/><td style="width:15.055%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicates a management contract or compensatory plan.</span></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Confidential treatment has been granted for portions of this exhibit. These portions have been omitted from the Registration Statement and submitted separately to the Securities and Exchange Commission.</span></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Confidential treatment has been requested for portions of this exhibit. These portions have been omitted from the Registration Statement and submitted separately to the Securities and Exchange Commission.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule will be furnished supplementally to the U.S. Securities and Exchange Commission upon request, provided, however, that the parties may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended for any document so furnished.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith. </span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div id="i3928a3425fef4184806511a3516ffab1_163"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item 16. Form 10-K Summary</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrants may voluntarily include a summary of information required by Form 10-K under this Item 16. The Company has elected not to include such summary information.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">78</span></div></div></div><div id="i3928a3425fef4184806511a3516ffab1_166"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on March&#160;12, 2024.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"/><td style="width:49.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.362%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumberland Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ A. J. Kazimi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A. J. Kazimi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr></table></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="margin-top:8pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"/><td style="width:42.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.287%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.458%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ A. J. Kazimi</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman and CEO</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 12, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A. J. Kazimi</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer and Director)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ John M. Hamm</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President, Chief Financial Officer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 12, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John M. Hamm</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accounting Officer</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Gordon R. Bernard</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 12, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gordon R. Bernard</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ James R. Jones</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 12, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James R. Jones</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Caroline R. Young</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 12, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caroline R. Young </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Kenneth J. Krogulski</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 12, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kenneth J. Krogulski</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Joseph C. Galante</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 12, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph C. Galante</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Martin S. Brown, Jr.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 12, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Martin S. Brown, Jr.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:8pt"><span><br/></span></div><div id="i3928a3425fef4184806511a3516ffab1_169"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The management of Cumberland Pharmaceuticals Inc. and its subsidiaries (the&#160;"Company") is responsible for establishing and maintaining adequate internal control over financial reporting.&#160;The Company&#8217;s internal control system was designed to provide reasonable assurance to the Company&#8217;s management and board of directors regarding the preparation and fair presentation of published financial statements.&#160;All internal control systems, no matter how well designed, have inherent limitations.&#160;Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of December&#160;31, 2023.&#160;In making this assessment, it used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8211; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on its assessment, management has concluded that, as of December&#160;31, 2023, the Company&#8217;s internal control over financial reporting was effective based on those criteria.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.628%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ A. J. Kazimi</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A. J. Kazimi</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 12, 2024</span></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.628%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ John M. Hamm</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John M. Hamm</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 12, 2024</span></td></tr></table></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="i3928a3425fef4184806511a3516ffab1_172"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders, Board of Directors and Audit Committee of</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Opinion on the Consolidated Financial Statements</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheet of Cumberland Pharmaceuticals Inc. and subsidiaries (the "Company") as of December&#160;31, 2023, the related consolidated statements of operations, equity, and cash flows for the year then ended, and the related notes and schedule (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2023, and the results of its operations and its cash flows for the year then ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audit.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Audit Matter </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Customer Allowances for Chargebacks, Discounts and Damaged Goods, and Accruals for Rebates, Coupons, Product Returns, and Certain Fees </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 2 to the consolidated financial statements, the allowances against accounts receivable and accrued liabilities for chargebacks, discounts, service fees and expired product returns are determined on a product-by-product basis and established by management as the Company&#8217;s best estimate at the time of sale based on each product&#8217;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and returns of expired product.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, allowances in accounts receivable for chargebacks, cash discounts, and damaged goods were $0.6 million and the estimated liability for rebates, coupons, product returns, and certain fees were $7.6 million. These provisions are recognized concurrently with the sales of products. Provisions for chargebacks involve estimates of usage by retailers and other indirect buyers with varying contract prices for multiple wholesalers. The provision for chargebacks varies in relation to changes in sales volume, product mix, pricing, and the level of inventory at the wholesalers. Provisions are calculated using historical chargeback experience, and/or expected chargeback levels for new products and anticipated pricing changes. Provisions for rebates are recognized based on contractual obligations in place at the time of sales with consideration given to relevant factors that may affect the payment, as well as historical experience for estimated market activity. Provisions for product returns are calculated based on the expiration dates of products sold, the window where customers are permitted to return products, and the history of returns for individual products in relation to the sales volume for each product.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified the customer allowances for chargebacks, discounts, and damaged goods and accruals for rebates, coupons, product returns, and certain fees as a critical audit matter. The principal consideration for our determination was the significant measurement uncertainty involved in developing the reserves.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management exercises judgment in computing the amount of sales subject to the allowances and tracks the amount of allowances taken over time. All of this in turn led to a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating management&#8217;s significant assumptions, which includes the assumption that historical activity is a good predictor of future allowance activity and modifications made to calculations based on more recent history.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary procedures we performed to address this critical audit matter included: </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Tested management&#8217;s process for calculating certain allowances and developed an independent expectation of the reserve balance for the remaining allowances. </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Performed a look back analysis of prior year reserves compared to actual experience in the current year.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Tested the completeness and accuracy of underlying data used to estimate the accrual by evaluating a service organization from which data was obtained, agreeing sales data used in the calculations to reports that were reconciled to the consolidated financial statements, reconciling various allowance percentages to signed customer contracts, and tracing allowance amounts used by various customers during the year to supporting documentation.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Evaluated the reasonableness of significant assumptions used by management in the computation of selected allowances, including comparison to historical results and considering recent changes in factors that could influence claims, such as changes in the shelf life of the products.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Tested the clerical accuracy of individual customer allowances computed by management and agreeing the total of all estimated allowances to the respective accounts on the consolidated financial statements.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Compared actual activity for chargebacks, discounts, and damaged goods and rebates, coupons, product returns, and certain fees reported after December 31, 2023, to estimated reserves and accruals on the December 31, 2023, consolidated balance sheet. </span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-44">Carr, Riggs &amp; Ingram, LLC</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2023.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-45">Nashville, Tennessee</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;12, 2024</span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders, Board of Directors and Audit Committee</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nashville, Tennessee</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Opinion on the Consolidated Financial Statements</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheet of Cumberland Pharmaceuticals Inc. (&#8220;Company&#8221;) as of December 31, 2022, the related consolidated statements of operations, equity, and cash flows for the year ended December 31, 2022, and the related notes and schedule (collectively referred to as the financial statements).  In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2022, and the results of its operations and its cash flows for the year ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management.  Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audit.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a public accounting firm registered with the Public Company Accounting Oversight Board (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission (SEC) and the PCAOB.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB.  Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.  The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.  As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting.  Accordingly, we express no such opinion.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks.  Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.  Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.  We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Audit Matters </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that:  (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments.  The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Customer Allowances for Chargebacks, Discounts, and Damaged Goods and Accruals for Rebates, Coupons, Product Returns, and Certain Fees </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 2 to the consolidated financial statements, the allowances against accounts receivable and accrued liabilities for chargebacks, discounts, service fees and expired product returns are determined on a product-by-product basis and established by management as the Company&#8217;s best estimate at the time of sale based on each product&#8217;s historical experience adjusted to reflect known changes in the factors that impact such allowances.  These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and returns of expired product.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, allowances in accounts receivable for chargebacks, cash discounts, and damaged goods were $0.6 million and the estimated liability for rebates, coupons, product returns, and certain fees were $8.3 million.  These provisions are recognized concurrently with the sales of products.  Provisions for chargebacks involve estimates of usage by retailers and other indirect buyers with varying contract prices for multiple wholesalers.  The provision for chargebacks varies in relation to changes in sales volume, product mix, pricing, and the level of inventory at the wholesalers.  Provisions are calculated using historical chargeback experience, and/or expected chargeback levels for new products and anticipated pricing changes.  Provisions for rebates are recognized based on contractual obligations in place at the time of sales with consideration given to relevant factors that may affect the payment, as well as historical experience for estimated market activity.  Provisions for product returns are calculated based on the expiration dates of products sold, the window where customers are permitted to return products, and the history of returns for individual products in relation to the sales volume for each product.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified the customer allowances for chargebacks, discounts, and damaged goods and accruals for rebates, coupons, product returns, and certain fees as a critical audit matter.  The principal consideration for our determination was the significant measurement uncertainty involved in developing the reserves.  Management exercises judgment in computing the amount of sales subject to the allowances and tracks the amount of allowances taken over time.  All of this in turn led to a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating management&#8217;s significant assumptions, which includes the assumption that historical activity is a good predictor of future allowance activity and modifications made to calculations based on more recent history.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary procedures we performed to address this critical audit matter included: </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Tested management&#8217;s process for calculating the allowances, including a look back analysis of prior year reserves compared to actual experience in the current year.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Tested the completeness and accuracy of underlying data used to estimate the accrual by agreeing sales data used in the calculations to reports that were reconciled to the consolidated financial statements, reconciling various allowance percentages to signed customer contracts, and tracing allowance amounts used by various customers during the year to supporting documentation.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Evaluated the reasonableness of significant assumptions used by management in the computation of allowances, including comparison to historical results and considering recent changes in factors that could influence the future allowances to be claimed, such as changes in the shelf life of the products.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Tested the clerical accuracy of individual customer allowances computed by management and agreeing the total of all estimated allowances to the respective accounts on the consolidated financial statements.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Developed an independent expectation of the reserve balance for certain allowances and comparing that to the balance recorded on the December 31, 2022, consolidated balance sheet.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Compared actual activity for chargebacks, discounts, and damaged goods and rebates, coupons, product returns, and certain fees reported after December 31, 2022, to estimated reserves and accruals on the December 31, 2022, consolidated balance sheet.  </span></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Valuation of Contingent Consideration, Acquired Intangible Assets, and Inventory Associated with Business Combinations</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 3 to the consolidated financial statements, the Company acquired the U.S. rights to the FDA approved oncology-supportive care medicine Sancuso from Kyowa Kirin, Inc., the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd. during the year ended December 31, 2022, resulting in the expansion of the Company&#8217;s product offerings.  This acquisition resulted in additional goodwill of $0.03 million, additional intangible assets of $14.1 million, and contingent liabilities of $5.1 million being recognized on the Company&#8217;s consolidated balance sheet.  As part of this acquisition, management assessed that the acquisition qualified as a business combination and all identifiable assets and liabilities acquired were recorded at fair value as part of the purchase price allocation as of the asset date.  The identification and valuation of such acquired assets and assumed liabilities requires management to exercise significant judgment and consider the use of outside vendors to estimate the fair value allocations.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified the consummated acquisition and the valuation of acquired assets and assumed liabilities as a critical audit matter.  Our principal consideration for this determination included high degree of audit effort, including utilizing individuals with specialized skills, in evaluating management&#8217;s significant assumptions including its forecasts of future performance of the component, discount rates and other inputs into the model used in computing the fair value of the intangible asset, acquired inventory, and contingent consideration liability.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary procedures we performed to address this critical audit matter included:</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">We obtained an understanding of management&#8217;s process for determining the fair value measurements of the contingent consideration, acquired intangible assets and inventory, including reviewing the executed Asset Purchase Agreement documents to gain an understanding of the underlying terms of the consummated acquisition.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Evaluated forward-looking assumptions, such as forecasted revenue and earnings used by management by performing procedures that included, but not limited to, comparisons to industry and historical performance data, and sensitivity analysis to assess their reasonableness.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Utilizing a valuation specialist, we evaluated the significant assumptions and methods utilized in developing the fair value of the contingent consideration, acquired intangible assets, and inventory including:</span></div><div style="margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-23.27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Evaluated the reasonableness of the Company&#8217;s third-party valuation models and methodologies, expected cash flow calculations, and reviewed significant assumptions.</span></div><div style="margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-26.04pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Developed an independent calculation of the discount rates used and compared our rates to those used by management.</span></div><div style="margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-28.81pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Prepared an independent calculation of the fair value of the contingent consideration and the intangible assets to test the accuracy of management&#8217;s valuation models.</span></div><div style="margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-23.27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Reviewing and evaluating the adequacy of the disclosures made in the Company&#8217;s SEC filings.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="c-5" name="dei:AuditorName" id="f-46">FORVIS, LLP</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We served as the Company&#8217;s auditor from 2020 to 2023.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-5" name="dei:AuditorLocation" id="f-47">Nashville, Tennessee</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 13, 2023</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><div id="i3928a3425fef4184806511a3516ffab1_175"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Balance Sheets</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023 and 2022 </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"/><td style="width:64.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="f-48">18,321,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="f-49">19,757,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="0" id="f-50">9,758,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="0" id="f-51">13,163,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="0" id="f-52">4,609,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="0" id="f-53">9,863,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-54">3,025,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-55">3,084,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-56">35,714,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-57">45,870,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-58">12,804,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-59">7,527,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-60">367,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-61">284,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="f-62">22,607,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="f-63">30,590,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="f-64">914,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="f-65">914,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="f-66">6,674,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="f-67">5,218,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-68">2,692,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-69">2,520,661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="f-70">81,776,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="f-71">92,925,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="f-72">14,037,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="f-73">10,819,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="f-74">348,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="f-75">172,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-76">13,596,528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-77">17,587,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-78">27,982,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-79">28,579,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving line of credit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:LongTermLineOfCredit" format="ixt:num-dot-decimal" scale="0" id="f-80">12,784,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:LongTermLineOfCredit" format="ixt:num-dot-decimal" scale="0" id="f-81">16,200,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-82">5,296,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-83">4,586,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-84">6,453,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-85">7,585,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="f-86">52,516,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="f-87">56,951,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-6" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-88"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-7" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-89"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock &#8211; <ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="0" name="us-gaap:CommonStockNoParValue" format="ixt:fixed-zero" scale="0" id="f-90"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="0" name="us-gaap:CommonStockNoParValue" format="ixt:fixed-zero" scale="0" id="f-91">no</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-92"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-93">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-94"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-95">14,121,833</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-96"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-97">14,366,316</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2023 and 2022, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:CommonStockValueOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-98">47,091,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:CommonStockValueOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-99">47,474,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="f-100">17,488,161</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="f-101">11,208,841</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-102">29,603,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-103">36,266,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" sign="-" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="0" id="f-104">343,572</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" sign="-" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="0" id="f-105">292,126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-106">29,259,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-107">35,974,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-108">81,776,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-109">92,925,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><div id="i3928a3425fef4184806511a3516ffab1_178"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Operations</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Years ended December&#160;31, 2023 and 2022 </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"/><td style="width:61.862%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.766%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.452%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.766%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.454%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-110">37,513,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-111">40,681,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-112">2,039,015</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-113">1,329,767</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-114">39,552,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-115">42,010,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="0" id="f-116">6,066,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="0" id="f-117">9,118,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and marketing</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="0" id="f-118">18,451,765</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="0" id="f-119">16,660,945</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-120">5,834,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-121">6,688,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="f-122">10,651,915</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="f-123">10,180,120</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization and impairment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="f-124">8,102,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="f-125">5,067,368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="0" id="f-126">49,107,168</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="0" id="f-127">47,715,878</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-128">9,554,661</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-129">5,704,929</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="0" id="f-130">286,854</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="0" id="f-131">98,405</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="0" id="f-132">2,828,871</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:OtherIncome" format="ixt:fixed-zero" scale="0" id="f-133">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income - settlement</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="0" id="f-134">475,000</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:fixed-zero" scale="0" id="f-135">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income - gain on insurance proceeds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:InsuredEventGainLoss" format="ixt:num-dot-decimal" scale="0" id="f-136">346,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:InsuredEventGainLoss" format="ixt:num-dot-decimal" scale="0" id="f-137">611,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="f-138">667,861</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="f-139">585,995</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-140">6,284,997</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-141">5,581,189</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="f-142">45,769</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="f-143">68,850</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="f-144">6,330,766</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="f-145">5,650,039</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss at subsidiary attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-146">51,446</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-147">79,798</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-148">6,279,320</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-149">5,570,241</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share attributable to common shareholders:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-150">0.44</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-151">0.38</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-152">0.44</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-153">0.38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-154">14,298,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-155">14,563,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-156">14,298,774</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-157">14,563,592</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><div id="i3928a3425fef4184806511a3516ffab1_181"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Cash Flows </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Years ended December&#160;31, 2023 and 2022 </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.871%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.871%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.226%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="f-158">6,330,766</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="f-159">5,650,039</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash flows provided by operating activities:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="0" id="f-160">4,935,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="0" id="f-161">5,328,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment loss on intangible assets</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="0" id="f-162">3,343,842</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="f-163">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of operating lease right-of-use asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="0" id="f-164">834,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:fixed-zero" scale="0" id="f-165">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposal of assets</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="0" id="f-166">20,256</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:fixed-zero" scale="0" id="f-167">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-168">365,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-169">447,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in non-cash contingent consideration</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="0" id="f-170">1,253,840</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="0" id="f-171">2,088,296</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease (increase) in cash surrender value of life insurance policies over premiums paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" format="ixt:num-dot-decimal" scale="0" id="f-172">124,736</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" format="ixt:num-dot-decimal" scale="0" id="f-173">613,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncash interest expense</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="0" id="f-174">15,523</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="0" id="f-175">11,237</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncash gain on RediTrex transaction</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="cpix:NoncashOrPartNoncashGainOnTransaction" format="ixt:fixed-zero" scale="0" id="f-176">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="cpix:NoncashOrPartNoncashGainOnTransaction" format="ixt:num-dot-decimal" scale="0" id="f-177">37,882</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on receipt of life insurance policies</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OtherNonoperatingGainsLosses" format="ixt:num-dot-decimal" scale="0" id="f-178">346,800</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:OtherNonoperatingGainsLosses" format="ixt:num-dot-decimal" scale="0" id="f-179">611,330</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net changes in assets and liabilities affecting operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="0" id="f-180">3,404,949</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="0" id="f-181">6,115,640</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="0" id="f-182">23,143</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="0" id="f-183">911,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets and other assets</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="0" id="f-184">65,684</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="0" id="f-185">689,260</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="f-186">1,405,363</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:fixed-zero" scale="0" id="f-187">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other current liabilities</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-188">3,724,174</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-189">14,536,076</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-190">1,131,453</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-191">419,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="f-192">6,093,821</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="f-193">8,453,396</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to property and equipment</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-194">281,268</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-195">102,148</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="f-196">171,783</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="f-197">1,971,662</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return of RediTrex</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="cpix:ProceedsFromCollaborativeArrangement" format="ixt:fixed-zero" scale="0" id="f-198">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="cpix:ProceedsFromCollaborativeArrangement" format="ixt:num-dot-decimal" scale="0" id="f-199">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life insurance policy proceeds received</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ProceedsFromLifeInsurancePolicies" format="ixt:num-dot-decimal" scale="0" id="f-200">347,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:ProceedsFromLifeInsurancePolicies" format="ixt:num-dot-decimal" scale="0" id="f-201">877,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement of patent litigation</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="cpix:ProceedsFromSettlementOfPatentLitigation" format="ixt:fixed-zero" scale="0" id="f-202">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="cpix:ProceedsFromSettlementOfPatentLitigation" format="ixt:num-dot-decimal" scale="0" id="f-203">21,757</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for acquisition</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:fixed-zero" scale="0" id="f-204">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="0" id="f-205">13,500,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="f-206">105,695</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="f-207">13,674,456</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:4pt;text-align:center"><span><br/></span></div><div style="margin-top:4pt;text-align:center"><span><br/></span></div><div style="margin-top:4pt;text-align:center"><span><br/></span></div><div style="margin-top:4pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Cash Flows </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Years ended December&#160;31, 2023 and 2022 </span></div><div style="margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.579%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.441%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrowings on line of credit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" format="ixt:num-dot-decimal" scale="0" id="f-208">31,475,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" format="ixt:num-dot-decimal" scale="0" id="f-209">52,900,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments on line of credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="0" id="f-210">34,890,856</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="0" id="f-211">51,700,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments made in connection with repurchase of common shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="f-212">740,533</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="f-213">1,053,042</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash settlement of contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="f-214">3,268,083</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="f-215">2,208,744</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 49pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="f-216">7,424,472</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="f-217">2,061,786</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="f-218">1,436,346</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="f-219">7,282,846</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-220">19,757,970</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-221">27,040,816</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-222">18,321,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-223">19,757,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid during the year for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="0" id="f-224">647,137</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="0" id="f-225">523,161</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="0" id="f-226">108,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="0" id="f-227">3,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash paid included in measurement of lease liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="cpix:CashPaymentIncludedInMeasurementOfLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="f-228">804,818</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="cpix:CashPaymentIncludedInMeasurementOfLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="f-229">1,011,313</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncash investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in unpaid invoices for intangible asset additions</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="cpix:PurchasesOfIntangibleAssetsIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="0" id="f-230">51,895</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="cpix:PurchasesOfIntangibleAssetsIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="0" id="f-231">1,803,403</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in unpaid invoices for offering costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="cpix:ChangeInUnpaidInvoicesForOfferingCosts" format="ixt:num-dot-decimal" scale="0" id="f-232">69,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="cpix:ChangeInUnpaidInvoicesForOfferingCosts" format="ixt:num-dot-decimal" scale="0" id="f-233">94,689</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability obtained from right-of-use assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="f-234">1,158,367</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="f-235">4,590,978</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex forgiveness of milestone payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="cpix:CreditIssuedForMilestonePayable" format="ixt:fixed-zero" scale="0" id="f-236">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="cpix:CreditIssuedForMilestonePayable" format="ixt:num-dot-decimal" scale="0" id="f-237">1,000,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return of shares related to RediTrex</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" format="ixt:fixed-zero" scale="0" id="f-238">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="f-239">399,600</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements</span></div><div style="margin-top:4pt;text-align:center"><span><br/></span></div><div style="margin-top:4pt;text-align:center"><span><br/></span></div><div style="margin-top:4pt;text-align:center"><span><br/></span></div><div style="margin-top:4pt;text-align:center"><span><br/></span></div><div style="margin-top:4pt;text-align:center"><span><br/></span></div><div style="margin-top:4pt;text-align:center"><span><br/></span></div><div style="margin-top:4pt;text-align:center"><span><br/></span></div><div style="margin-top:4pt;text-align:center"><span><br/></span></div><div style="margin-top:4pt;text-align:center"><span><br/></span></div><div style="margin-top:4pt;text-align:center"><span><br/></span></div><div style="margin-top:4pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><div id="i3928a3425fef4184806511a3516ffab1_184"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Equity</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Years ended December&#160;31, 2023 and 2022 </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:29.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.767%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.767%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.767%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.767%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.767%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumberland Pharmaceuticals Inc. Shareholders</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-controlling interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total equity</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-240">14,742,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-241">48,452,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-242">5,638,600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-243">212,328</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-244">42,601,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="f-245">5,570,241</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="f-246">79,798</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="f-247">5,650,039</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return of common stock - Methotrexate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:StockRedeemedOrCalledDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="f-248">180,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="f-249">399,600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="f-250">399,600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-251">171,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-252">447,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-253">447,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="f-254">367,793</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="f-255">1,025,836</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="f-256">1,025,836</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-257">14,366,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-258">47,474,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-259">11,208,841</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-260">292,126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-261">35,974,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="f-262">6,279,320</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="f-263">51,446</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="f-264">6,330,766</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-265">157,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-266">365,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-267">365,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="f-268">402,143</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="f-269">748,411</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="f-270">748,411</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-271">14,121,833</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-272">47,091,602</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-273">17,488,161</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-274">343,572</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-275">29,259,869</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><div id="i3928a3425fef4184806511a3516ffab1_187"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  </span></div></div><div style="margin-top:4pt;text-align:center"><span><br/></span></div><div id="i3928a3425fef4184806511a3516ffab1_190"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1)   <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-276" continuedAt="f-276-1" escape="true">Organization</ix:nonNumeric></span></div><ix:continuation id="f-276-1"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company&#8217;s primary target markets are hospital acute care, gastroenterology  and oncology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs. The Company promotes its approved products through its hospital, field and oncology sales forces in the United States and is establishing a network of international partners to bring its medicines to patients in their countries.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#8217;s products are manufactured by third parties, which are overseen by Cumberland&#8217;s quality and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to build a pipeline of early-stage product candidates, the Company formed a subsidiary, Cumberland Emerging Technologies, Inc. ("CET"), which teams with universities and other research organizations to help advance scientific discoveries from the laboratory to the marketplace. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April, 2019, CET entered into an agreement with HongKong WinHealth Pharma Group Co. Limited ("WinHealth") whereby WinHealth made a $<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="cpix:SubsidiaryInvestmentPurchaseOfShares" format="ixt:num-dot-decimal" scale="6" id="f-277">1.0</ix:nonFraction>&#160;million investment through the purchase of shares of CET stock. As part of the agreement, WinHealth obtained a board position at CET and the first opportunity to license CET products for the Chinese market. In connection with WinHealth's investment in CET, Cumberland also made an additional $<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="cpix:SubsidiaryInvestmentPurchaseOfShares" format="ixt:num-dot-decimal" scale="6" id="f-278">1.0</ix:nonFraction> million investment in CET. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ownership in CET is now <ix:nonFraction unitRef="number" contextRef="c-29" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="f-279">85</ix:nonFraction>% while the remaining interest is owned by WinHealth, Vanderbilt University and the Tennessee Technology Development Corporation. The operating results of CET allocated to noncontrolling interests in the consolidated statements of operations were  $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-280">51,446</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-281">79,798</ix:nonFraction> for the years ended December&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January&#160;1, 2007, the Company formed a wholly-owned subsidiary, Cumberland Pharma Sales Corp. ("CPSC"). CPSC is the subsidiary that employs the Company's hospital and field sales force personnel.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Company formed the Cumberland Pharma Foundation (the "Foundation") to serve as a vehicle to facilitate the ongoing philanthropic endeavors of Cumberland Pharmaceuticals Inc. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Foundation was formed as a nonprofit corporation designed to qualify as a tax-exempt organization pursuant to Section 501(a) of the Internal Revenue Code. The Foundation&#8217;s Board of Directors is comprised of Cumberland Pharmaceuticals executives who are responsible for overseeing the Foundation&#8217;s ongoing activities including charitable contributions. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, Cumberland provided a grant of <ix:nonFraction unitRef="shares" contextRef="c-30" decimals="INF" name="cpix:SharebasedCompensationCharitableContributionofSharesShares" format="ixt:num-dot-decimal" scale="0" id="f-282">50,000</ix:nonFraction> shares of the Company&#8217;s common stock to the Foundation. The shares will address the ongoing financial needs of the Foundation. The organization also plans to hold a portion of the shares for long-term appreciation. The Foundation maintains separate financial statements and its ongoing operations do not impact the financial statements of Cumberland Pharmaceuticals. Initial annual grants by the Foundation have been and are expected to remain consistent with the historic level of contributions made by Cumberland Pharmaceuticals.  Since 2019, Cumberland has made annual cash contributions to the Foundation. During the years 2023 and 2022,  the Company made cash contributions of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="cpix:ShareBasedCompensationCharitableContributionOfSharesCashContributions" format="ixt:num-dot-decimal" scale="0" id="f-283">40,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="cpix:ShareBasedCompensationCharitableContributionOfSharesCashContributions" format="ixt:num-dot-decimal" scale="0" id="f-284">25,000</ix:nonFraction>, respectively.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><div id="i3928a3425fef4184806511a3516ffab1_193"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2)   <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-285" continuedAt="f-285-1" escape="true">Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-285-1" continuedAt="f-285-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-286" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements of the Company are stated in U.S. dollars and are prepared using U.S. generally accepted accounting principles. These financial statements include the accounts of the Company and its wholly and majority-owned subsidiaries. All significant intercompany transactions and accounts have been eliminated in consolidation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-287" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates under different assumptions and conditions. The Company&#8217;s most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory, (3) valuation of contingent consideration liability associated with business combinations and (4) evaluation of continuing utility of intangible assets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-288" continuedAt="f-288-1" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-288-1">The Company has <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-289">one</ix:nonFraction> operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, evaluated that our specialty pharmaceutical products compete in similar economic markets and similar circumstances. Substantially all of the Company&#8217;s assets are located in the United States. Total revenues are primarily attributable to U.S.&#160;customers.</ix:continuation> Net revenues from customers outside the United States were approximately $<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-290">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-291">1.5</ix:nonFraction> million for the years ended December&#160;31, 2023 and 2022, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-292" continuedAt="f-292-1" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of financial assets and liabilities is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date. The Company&#8217;s fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements. It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 -   Quoted prices for identical instruments in active markets.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 -  Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 -    Significant inputs to the valuation model are unobservable.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain policies and procedures to value instruments using the best and most relevant data available. The following section describes the valuation methodologies we use to measure different financial instruments at fair value on a recurring basis.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="f-285-2" continuedAt="f-285-3"><ix:continuation id="f-292-1" continuedAt="f-292-2"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, contingent consideration liability and a revolving line of credit. The carrying values for cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to their short-term nature. The revolving line of credit has a variable interest rate, which approximates the current market rate.</span></div></ix:continuation><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-292-2">The Company&#8217;s contingent consideration liability is a Level 3 fair value measurement that is updated on a recurring basis at each reporting period using a valuation model. Consistent with Level 3 fair value measurements, there are significant inputs to the valuation model that are unobservable.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-293" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include highly liquid investments with original maturities of three months or less. As of December&#160;31, 2023 and 2022, cash equivalents consist primarily of money market funds.  The Company monitors concentration of credit risk with the financial institutions in which it conducts business.  The Company has cash deposits which fluctuate in excess of federally insured limits throughout the year.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="f-294" escape="true"><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable are recorded at the invoiced amount. The Company records allowances for amounts that could become uncollectible in the future based on historical experience, as well as amounts related to chargebacks and cash discounts. The Company reviews each customer balance to assess collection status.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s products are distributed through independent pharmaceutical wholesalers. The allowances against accounts receivable for chargebacks and discounts are determined on a product-by-product basis, and established by management as the Company&#8217;s best estimate at the time of sale based on each product&#8217;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks and discounts. The allowances in accounts receivable for chargebacks and cash discounts were $<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-295">0.6</ix:nonFraction> million at December&#160;31, 2023 and 2022. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#8217;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, revenues are reduced and accrued liabilities are increased by the Company&#8217;s estimate of the rebate that may be claimed. Cash discounts are reductions to invoiced amounts offered to customers for payment within a specified period of time from the date of the invoice.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryPolicyTextBlock" id="f-296" continuedAt="f-296-1" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company works closely with third parties to manufacture and package finished goods for sale. Based on the customer relationship with the manufacturer or packager, the Company will either take title to finished goods at the time of shipment or at the time of arrival from the manufacturer. The Company then warehouses such goods until distribution and sale at third party facilities located in the U.S. and international locations. Periodic inventory counts are made by the warehouse teams and by the Company on a regular basis. In addition, the Company re-tests API inventory prior to use to confirm product expiration. Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually evaluates inventories for potential losses due to expired, short-dated or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates the carrying value of a product may not be recoverable, a charge is recorded to reduce the inventory to its current net realizable value.</span></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-296-1">Non-current inventories consist of active pharmaceutical ingredients which typically has an extended life and selected finished good products with extended life longer than one year.</ix:continuation> </span></div></ix:continuation><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="f-285-3" continuedAt="f-285-4"><ix:nonNumeric contextRef="c-1" name="cpix:PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock" id="f-297" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid and Other Current Assets</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid and other current assets consist of deferred offering costs, prepaid insurance premiums, prepaid consulting services, deposits and annual fees paid to the U.S. Food and Drug Administration ("FDA"). The Company expenses all prepaid and other current asset amounts as used or over the period of benefit primarily on a straight-line basis, as applicable.</span></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, the Company filed its Shelf Registration on Form S-3 with the SEC associated with the sale of up to $<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-6" name="cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" format="ixt:num-dot-decimal" scale="6" id="f-298">100</ix:nonFraction>&#160;million in corporate securities. The Shelf Registration was declared effective in January 2018. It also included an At the Market ("ATM") feature that allows the Company to sell common shares at market prices.  The Company filed an updated Form S-3 with the SEC in December 2020 (the &#8220;Prior Registration Statement&#8221;), which was declared effective in January 2021. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 27, 2021, the Company filed a related prospectus supplement in connection with the sale and issuance of shares having an aggregate gross sales price of up to $<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-6" name="cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" format="ixt:num-dot-decimal" scale="6" id="f-299">19</ix:nonFraction>&#160;million. The Company amended the ATM Sales Agreement on December 27, 2021, in order to allow the Company to continue using its ATM feature to sell shares at market prices.  This ATM program was under the Prior Registration Statement and is no longer active.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company filed an updated Form S-3 with the SEC on December 14, 2023, which was declared effective on December 26, 2023 (the &#8220;Current Registration Statement&#8221;).  The Company intends to enter into an agreement with H.C. Wainwright &amp; Co., LLC to establish a new ATM program under the Current Registration Statement.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recorded deferred offering costs for payments directly related to the current Shelf Registration on Form S-3 that was completed during December 2021 and December 2023. These costs consist of legal and accounting fees that the Company has capitalized. Deferred costs associated with the Shelf Registration will be reclassified to additional paid in capital on a pro-rata basis as the Company completes sales of shares under the Shelf Registration. The Company did not issue any shares under this ATM during the year ended December&#160;31, 2023. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-300" escape="true"><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, including leasehold improvements, are stated at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the initial lease term plus renewal options, if reasonably assured, or the remaining useful life of the asset. Upon retirement or disposal of assets, any gain or loss is reflected as a component of operating loss in the consolidated statement of operations. Improvements that extend an asset&#8217;s useful life are capitalized. Repairs and maintenance costs are expensed as incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="f-301" continuedAt="f-301-1" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible assets and goodwill consist of capitalized costs related to product and license rights, patents, trademarks and goodwill obtained in the Vibativ and Sancuso acquisitions. Goodwill is not amortized for financial reporting purposes, but is subject to impairment analysis at least annually.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of acquiring product and license rights are capitalized at fair value at the date of acquisition for products that are approved by the FDA for commercial use. These costs are amortized ratably over the estimated economic life of the product. The economic life is estimated based upon several factors. This includes the term of the license agreement, the patent life or market exclusivity of the product and as well as  management&#8217;s expectations of continued involvement with the product and the assessment of future sales, the future periods under which the product will be sold and the profitability of the product. This estimate is evaluated on a regular basis during the amortization period and adjusted if appropriate. If there are any changes made to the useful life of the product and license rights, the costs associated with such a change, if any, will be capitalized and amortized over the revised useful life.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Given the delay in identifying a packager for Omeclamox-Pak, the Company has taken a non-cash write down of the related intangible asset of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="f-302">3.3</ix:nonFraction> million. The financial statements reflect this adjustment as efforts to identify a packager continue.   </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="f-285-4" continuedAt="f-285-5"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-301-1">Capitalized patent costs consist of outside legal costs associated with obtaining and protecting patents on products that have been approved for marketing by the FDA. If it becomes probable that a patent will not be issued or a patent has been declared invalid, related costs associated with the patent application are expensed at the time such determination is made. All costs associated with obtaining patents for products that have not been approved for marketing by the FDA are expensed as incurred.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="f-303" continuedAt="f-303-1" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense is recognized ratably over the following periods:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.141%"><tr><td style="width:1.0%"/><td style="width:46.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated economic life</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License rights</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term of license agreement</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life of patent</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ReceivablesPolicyTextBlock" id="f-304" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade and Note Receivables</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current Expected Credit Losses (&#8220;CECL&#8221;) is applicable to all financial assets measured at amortized cost. All financial instruments are evaluated, which principally relates to trade receivables and two notes receivable. CECL requires the measurement of expected credit losses on a collective (pool) basis when similar risk characteristics exist. This may include, either individually or in combination, some of the following characteristics of Accounting Standards Codification ("ASC") 326-20-55-5:</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Internal or external credit score/rating</span></div><div style="margin-top:2pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Risk ratings or classification</span></div><div style="margin-top:2pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Financial asset type</span></div><div style="margin-top:2pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Size</span></div><div style="margin-top:2pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Effective interest rate</span></div><div style="margin-top:2pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Term</span></div><div style="margin-top:2pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Geographical location</span></div><div style="margin-top:2pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Historical or expected credit loss patterns</span></div><div style="margin-top:2pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Reasonable and supportable forecast periods</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The standard requires entities to pool financial assets but allows them to choose which risk characteristics to use. Under the requirements of the guidance, the Company reassesses at the end of each reporting period whether the pool of assets continue to display similar risk characteristics.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With twenty years of experience, Cumberland has experienced virtually no write downs of receivables as most of our receivables are due from large successful pharmaceutical, healthcare or government customers, consistently making payments on account. Although the payment behaviors of all of our customers are consistently reliable, for the sake of transparency, we have separated our customer base into seven separate pools. The Company performs a monthly analysis of aged accounts receivable to determine how much, if any, of the accounts receivable balance should be reserved as potential bad debt. The Company reviews all balances over 90 days past due for a possible reserve and considers any specific factors or information for balances aged under 90 days if there are indicators that the balance should be reserved, such as other aged balances with the customer or bankruptcy as well as any economic issues with a customer, industry or region. The adoption of ASC 326 did not result in a material impact to the Company.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="f-305" continuedAt="f-305-1" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-305-1">Long-lived assets, such as property and equipment, operating lease right-of-use assets and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If events or circumstances arise that require a long-lived asset to be tested for potential impairment, the Company first compares undiscounted cash flows expected to be generated by the asset to its carrying value. If the carrying amount of the long-lived asset is not recoverable on an undiscounted cash flow basis, an impairment charge is recognized to the extent that the carrying value exceeds the fair value. Fair value is determined through various valuation techniques including quoted market prices, third-party independent appraisals and discounted cash flow models.</ix:continuation>   </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="f-285-5" continuedAt="f-285-6"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and other indefinite lived intangible assets that are not subject to amortization are tested at least annually for impairment. The impairment analysis for goodwill requires a comparison of fair value to the carrying value of the reporting unit. The Company&#8217;s goodwill was acquired in November 2018 with the Vibativ acquisition and in January 2022 with the Sancuso acquisition. As a result, the Vibativ and Sancuso components of the Company are the reporting units evaluated for goodwill impairment. Cumberland determined the fair value of the reporting units through current and future estimated revenue and profitability of the product. The Company recorded <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="f-306"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="f-307">no</ix:nonFraction></ix:nonFraction> impairment charges during 2022.  In 2023, given the delay in identifying a packager for Omeclamox-Pak the Company has taken a non-cash write down of the related intangible assets of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="f-308">3.3</ix:nonFraction> million, which is included in amortization expense in the statement operations.  These intangible assets consisted of product and license rights and trademarks.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Joint Venture Agreement</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, Cumberland entered into an agreement with WinHealth Investment (Singapore) Ltd creating WHC Biopharmaceuticals, Pte. Ltd. The joint venture, as a limited liability company, focuses on acquiring, developing, registering, and commercializing development stage and commercial stage biopharmaceuticals for China, Hong Kong and other Asian markets. The agreement provided for initial investment from WinHealth in the form of a $<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="6" id="f-309">0.2</ix:nonFraction>&#160;million equity contribution and an initial investment from Cumberland in the form of $<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="6" id="f-310">0.2</ix:nonFraction>&#160;million convertible note. The joint venture will seek additional future capital from additional investors and has entered into exclusive option agreements to license intellectual property from both Cumberland Pharmaceuticals Inc. and Cumberland Emerging Technologies.  </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-311" continuedAt="f-311-1" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recognized in the amount that reflects the consideration that we expect to receive for these goods. Depending upon the shipping terms of the transaction, the revenue is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation. This occurs upon either shipment of the product or arrival at its ship to destination. Payment terms typically range from 30 to 60 days from date of shipment. The Company&#8217;s net product revenue reflects the reduction from gross product revenue for estimated allowances for chargebacks, discounts and damaged goods, and reflects sales related accruals for rebates, coupons, product returns, and certain administrative and service fees. Significant judgments must be made in determining the transaction price for our sales of products related to these adjustments. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company revised its estimate for rebates related to Sancuso revenues based on additional information related to actual product activities.  As a result, the Company recognized additional revenue allowances of $0.6 million for rebates as a change of estimate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Rebates and Discounts</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowances against accounts receivable and accrued liabilities for chargebacks, discounts, service fees and expired product returns are determined on a product-by-product basis, and established by management as the Company&#8217;s best estimate at the time of sale based on each product&#8217;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and returns of expired product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#8217;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, sales revenues are reduced and accrued liabilities are increased by the Company&#8217;s estimate of the rebate that may be claimed.</span></div><div style="margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Returns</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, the Company maintains a return policy that allows customers to return product within a specified period prior to and subsequent to the expiration date. The Company&#8217;s estimate of the provision for returns is based upon historical experience, expiration date by product as well as any other factor </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="f-285-6" continuedAt="f-285-7"><ix:continuation id="f-311-1"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expected to impact future returns. Any changes in the assumptions used to estimate the provision for returns are recognized in the period those assumptions are changed.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Revenues</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues primarily consist of income from grant funding programs, licensing agreements, leases and contract services. Revenue related to grants is recognized when all conditions related to such grants have been met. All other revenue is recognized when earned.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:CostOfSalesPolicyTextBlock" id="f-312" continuedAt="f-312-1" escape="true"><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Products Sold</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold consists principally of the cost to acquire each unit of product sold, including in-bound freight expense as well as any adjustment in the net realizable value of inventory acquired in acquisitions. Cost of products sold also includes expenses associated with the reduction in the net realizable value of slow-moving or expired product.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling and Marketing Expense</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling and marketing expense consists primarily of expenses relating to the advertising, promotion, distribution and sale of products, including royalty expense, salaries and related costs.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distribution Costs</span></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-312-1">Distribution costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations.</ix:continuation> <ix:nonNumeric contextRef="c-1" name="cpix:ScheduleOfDistributionCostsTableTextBlock" id="f-313" continuedAt="f-313-1" escape="true">Distribution costs were as follows for the years ended December 31:</ix:nonNumeric></span></div><ix:continuation id="f-313-1"><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:65.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.790%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.792%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ProductionAndDistributionCosts" format="ixt:num-dot-decimal" scale="0" id="f-314">881,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:ProductionAndDistributionCosts" format="ixt:num-dot-decimal" scale="0" id="f-315">857,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="f-316" continuedAt="f-316-1" escape="true"><div style="margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Costs</span></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-316-1">Advertising costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations.</ix:continuation> <ix:nonNumeric contextRef="c-1" name="cpix:ScheduleOfAdvertisingCostsTableTextBlock" id="f-317" continuedAt="f-317-1" escape="true">Advertising costs were as follows for the years ended December 31:</ix:nonNumeric></span></div><ix:continuation id="f-317-1"><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:65.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.790%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.792%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advertising costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="0" id="f-318">2,903,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="0" id="f-319">2,927,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-320" escape="true"><div style="margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed in the period incurred. Research and development costs are comprised mainly of clinical trial expenses, salaries, wages and other related costs such as materials and supplies. Research and development expense includes activities performed by third-party providers participating in the Company&#8217;s clinical studies. The Company accounts for these costs based on estimates of work performed, patients enrolled or fixed fees for services over the period of time the clinical trials are performed.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-321" continuedAt="f-321-1" escape="true"><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for deferred taxes using the asset and liability approach. Under this method, deferred tax assets and liabilities are recognized for future tax consequences attributable to operating loss and tax credit carryforwards, as well as differences between the carrying amounts of existing assets and liabilities and their respective tax bases. The Company&#8217;s principal differences are related to the timing of deductibility of certain items, such as inventory, depreciation, amortization and share-based compensation. Deferred tax assets and liabilities are measured using enacted statutory tax rates that are expected to apply to taxable income in the years such temporary differences are anticipated to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. The Company only recognizes income tax benefits </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="f-285-7" continuedAt="f-285-8"><ix:continuation id="f-321-1"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">associated with an income tax position in which it is &#8220;more likely than not&#8221; that the position would be sustained upon examination by the taxing authorities.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, management considers whether some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of existing temporary differences, projected future taxable income and tax planning strategies in making this assessment. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounting policy with respect to interest and penalties arising from income tax settlements is to recognize them as part of the provision for income taxes.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-322" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss per Share</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share is calculated by dividing net loss attributable to common shareholders by the weighted-average number of shares outstanding. Except where the result would be antidilutive, diluted loss per share is calculated by assuming the vesting of unvested restricted stock and the exercise of stock options and warrants and unrecognized compensation costs.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-323" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Payments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation cost for all share-based payments issued, modified, repurchased or canceled. Depending on the nature of the vesting provisions, restricted stock awards are measured using either the fair value on the grant date or the fair value of common stock on the date the vesting provisions lapse. Prior to the lapse for those equity grants not valued on the grant date, the fair value is measured on the last day of the reporting period.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="f-324" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Agreements</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment discussed in Note 3, related to the Vibativ and Sancuso contingent consideration payments, do not meet the criteria for accounting under ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The agreements do not specifically designate each party&#8217;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party. Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the consolidated statements of operations.</span></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Related Party Transactions</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, Cumberland named Martin S. Brown Jr. to our Board of Directors. Mr. Brown is an attorney with over 30 years of corporate law experience who brings significant legal, public company, health care and civic experience to our board. The Company relies on several law firms for legal advice, including the firm with which Mr. Brown is affiliated.  In 2023 and 2022, the Company paid Mr. Brown&#8217;s law firm $<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-4" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-325">0.05</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-4" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-326">0.04</ix:nonFraction> million, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-327" continuedAt="f-327-1" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Adopted</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies are required to use a new forward-looking &#8220;expected loss&#8221; model that generally results in an earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies measure credit losses in a manner similar with previous guidance, except that the losses are recognized as </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="f-327-1" continuedAt="f-327-2"><ix:continuation id="f-285-8" continuedAt="f-285-9"><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allowances rather than as reductions in the amortized cost of the securities. Companies have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies apply the ASU&#8217;s provisions as a cumulative-effect adjustment, if any, to the accumulated deficit as of the beginning of the first reporting period in which the guidance is adopted.</span></div></ix:continuation></ix:continuation><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><ix:continuation id="f-327-2" continuedAt="f-327-3"><ix:continuation id="f-285-9" continuedAt="f-285-10"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. </span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-327-3"><ix:continuation id="f-285-10">The Company adopted both ASU 2016-13 and ASU 2019-05 on January 1, 2023</ix:continuation></ix:continuation>, and the adoption did not have a material impact on the Company&#8217;s consolidated financial statements.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standards Not Yet Adpoted</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued final guidance intended to improve transparency of segment disclosures, primarily through expanded disclosures for significant segment expenses.  The guidance is effective for annual periods beginning in 2024 and interim periods beginning in 2025.  Early adoption is permitted.  This new guidance will result in incremental disclosures in the notes to the Company&#8217;s segment reporting disclosures.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued final guidance to improve transparency of income tax disclosures. The final guidance requires enhanced disclosures primarily related to existing rate reconciliation and income taxes paid information.  The guidance is effective for 2025 annual reporting.  Early adoption is permitted.  This new guidance will result in incremental disclosures in the notes to the Company&#8217;s income tax disclosures.</span></div><div id="i3928a3425fef4184806511a3516ffab1_196"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="f-328" continuedAt="f-328-1" escape="true">Vibativ</ix:nonNumeric></span><ix:continuation id="f-328-1" continuedAt="f-328-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Sancuso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">and RediTrex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Products</span></ix:continuation></div><ix:continuation id="f-328-2" continuedAt="f-328-3"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vibativ</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2018, the Company executed an agreement with Theravance Biopharma ("Theravance") to acquire the assets and global rights to Vibativ including responsibility for the marketing, distribution, manufacturing and regulatory activities associated with the brand. Vibativ is a patented, FDA approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="f-329">20</ix:nonFraction>&#160;million at the closing of the transaction and a $<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-5" name="cpix:PaymentsToAcquireBusinessMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="f-330">5</ix:nonFraction>&#160;million milestone payment in early April 2019. In addition, Cumberland has agreed to pay royalties of up to <ix:nonFraction unitRef="number" contextRef="c-41" decimals="2" name="cpix:PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage" scale="-2" id="f-331">20</ix:nonFraction>% of on-going net sales of the product in the U.S. after a $<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-5" name="cpix:PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold" format="ixt:num-dot-decimal" scale="6" id="f-332">2.5</ix:nonFraction>&#160;million threshold is met. The future royalty payments were recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland prepared the valuations of the contingent consideration liability utilizing significant unobservable inputs. As a result, the valuation is classified as Level 3 fair value measurement.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" id="f-333" continuedAt="f-333-1" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis. The contingent consideration earned and accrued in operating expenses is paid to Theravance annually.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="f-328-3" continuedAt="f-328-4"><ix:continuation id="f-333-1" continuedAt="f-333-2"><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.265%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent Consideration Liability</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="0" id="f-334">6,515,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="0" name="us-gaap:PaymentsForRoyalties" format="ixt:num-dot-decimal" scale="0" id="f-335">1,133,113</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="0" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="0" id="f-336">2,104,690</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="0" name="cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="f-337">876,999</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="0" id="f-338">4,154,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="0" name="us-gaap:PaymentsForRoyalties" format="ixt:num-dot-decimal" scale="0" id="f-339">1,018,451</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="0" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="0" id="f-340">270,485</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="0" name="cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="f-341">1,167,486</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="0" id="f-342">4,033,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current portion of the contingent consideration liability is $<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-343">1.7</ix:nonFraction>&#160;million and the non-current portion is $<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-344">2.3</ix:nonFraction>&#160;million, as of December&#160;31, 2023. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sancuso</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 3, 2022, Cumberland acquired the U.S. rights to the FDA-approved oncology-supportive care medicine Sancuso from Kyowa Kirin, Inc. ("Kyowa Kirin"), the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sancuso is the first and only FDA-approved prescription patch for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment. The active drug in Sancuso, granisetron, slowly dissolves in the thin layer of adhesive that sticks to the patient&#8217;s skin and is released into their bloodstream over several days, working continuously to prevent chemotherapy-induced nausea and vomiting (&#8220;CINV&#8221;). It is applied 24 to 48 hours before receiving chemotherapy and can prevent CINV for up to five consecutive days. Alternative oral treatments must be taken several times (day and night) to deliver the same therapeutic doses.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland acquired U.S. rights to Sancuso and assumed full commercial responsibility for the product in the U.S. &#8211; including its marketing, promotion, distribution, manufacturing and medical support activities. The product&#8217;s FDA registration was subsequently transferred from Kyowa Kirin to Cumberland in August 2023. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="f-345">13.5</ix:nonFraction>&#160;million at the closing of the transaction. The Agreement calls for milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-5" name="cpix:PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold" format="ixt:num-dot-decimal" scale="6" id="f-346">3.5</ix:nonFraction>&#160;million based on the attainment of various approvals and sales performance. In January 2023, Cumberland made a $<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-5" name="cpix:PaymentsToAcquireBusinessMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="f-347">1.0</ix:nonFraction>&#160;million milestone payment to Kwoya Kirin based on the FDA approval of a manufacturing site for the product. In October 2023, Cumberland made a $<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-5" name="cpix:PaymentsToAcquireBusinessMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="f-348">0.5</ix:nonFraction>&#160;million milestone payment based on the successful transfer of the product&#8217;s FDA registration from Kyowa Kirin to Cumberland.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining $<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-5" name="cpix:PaymentsToAcquireBusinessMilestonePaymentRemaining" format="ixt:num-dot-decimal" scale="6" id="f-349">2</ix:nonFraction>&#160;million in milestone payments are tied to achievement of certain annual sales levels for the product.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Cumberland has agreed to pay a royalty of up to <ix:nonFraction unitRef="number" contextRef="c-51" decimals="2" name="cpix:PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage" scale="-2" id="f-350">10</ix:nonFraction>% of on-going net sales of the product. The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland has prepared a valuation of the contingent consideration liability utilizing significant unobservable inputs. As a result, the valuation is classified as Level 3 fair value measurement. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition was funded by cash and the Company's revolving credit facility. The fair value for the assets and liabilities assumed using Level 3 fair value inputs were as follows: prepaid expenses of  $<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="0" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="6" id="f-351">1.8</ix:nonFraction>&#160;million, inventory $<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="0" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" format="ixt:num-dot-decimal" scale="6" id="f-352">2.6</ix:nonFraction>&#160;million, goodwill $<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="0" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-353">0.03</ix:nonFraction>&#160;million, intangible assets $<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="0" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-354">14.1</ix:nonFraction>&#160;million, milestone payable $<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-5" name="cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMilestonePayable" format="ixt:num-dot-decimal" scale="6" id="f-355">1.7</ix:nonFraction>&#160;million and contingent liability $<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" format="ixt:num-dot-decimal" scale="6" id="f-356">3.4</ix:nonFraction>&#160;million.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><ix:continuation id="f-328-4" continuedAt="f-328-5"><ix:continuation id="f-333-2"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.271%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.215%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent Consideration Liability</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent Consideration Liability Including Milestone</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Balance at January 3, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="0" id="f-357">3,384,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3,946,716&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash payment of royalty during the period</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="0" name="us-gaap:PaymentsForRoyalties" format="ixt:num-dot-decimal" scale="0" id="f-358">1,075,631</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1,075,631)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Change in fair value</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="0" id="f-359">16,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,210,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Contingent consideration earned and accrued</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="0" name="cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="f-360">675,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">675,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Balance at December 31, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="0" id="f-361">3,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4,757,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash payment of royalty during the period</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="0" name="us-gaap:PaymentsForRoyalties" format="ixt:num-dot-decimal" scale="0" id="f-362">790,632</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(2,249,632)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Change in fair value</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="0" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="0" id="f-363">685,355</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(983,355)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Contingent consideration earned and accrued</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="0" name="cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="f-364">781,987</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">781,987&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Balance at December 31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="0" id="f-365">2,306,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,306,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div></ix:continuation><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current portion of the contingent consideration liability is $<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-366">1.3</ix:nonFraction> million and the non-current portion is $<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-367">1.0</ix:nonFraction> million, as of December&#160;31, 2023. </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RediTrex</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the Company announced an agreement with the Nordic Group B.V. ("Nordic") to acquire the exclusive U.S. rights to Nordic&#8217;s injectable methotrexate product line designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the license Cumberland paid a deposit of $<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="cpix:CollaborativeArrangementRightsAndObligationsDepositPayment" format="ixt:num-dot-decimal" scale="6" id="f-368">0.1</ix:nonFraction> million at closing. The Company provided $<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="cpix:CollaborativeArrangementRightsAndObligationsStockConsiderationValue" format="ixt:num-dot-decimal" scale="6" id="f-369">0.9</ix:nonFraction> million in consideration through a grant of <ix:nonFraction unitRef="shares" contextRef="c-58" decimals="INF" name="cpix:CollaborativeArrangementRightsAndObligationsStockConsiderationShares" format="ixt:num-dot-decimal" scale="0" id="f-370">180,000</ix:nonFraction> restricted shares of Cumberland common stock to be vested upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments tied to the products&#8217; FDA approval, launch and achievement of certain sales milestones. Under the terms of the agreement, Cumberland is responsible for the product registration and commercialization in the U.S. Nordic is responsible for product manufacturing and supply. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2019, Cumberland received FDA approval for the first Nordic injectable product and authorization to market them under the RediTrex brand name. The <ix:nonFraction unitRef="shares" contextRef="c-58" decimals="INF" name="cpix:CollaborativeArrangementRightsAndObligationsStockConsiderationShares" format="ixt:num-dot-decimal" scale="0" id="f-371">180,000</ix:nonFraction> shares of restricted Cumberland common stock previously provided to Nordic vested upon approval and were valued at $<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-5" name="cpix:CollaborativeArrangementRightsAndObligationsStockConsiderationVestedValue" format="ixt:num-dot-decimal" scale="6" id="f-372">0.9</ix:nonFraction> million on the vesting date. The FDA approval also resulted in a $<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-5" name="cpix:CollaborativeArrangementRightsAndObligationsMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="f-373">1.0</ix:nonFraction>&#160;million milestone payment due to Nordic. This milestone payment was paid in July 2020. During December 2020, Cumberland began distributing RediTrex which also resulted in a $<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-5" name="cpix:CollaborativeArrangementRightsAndObligationsMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="f-374">1.0</ix:nonFraction>&#160;million milestone payment due to Nordic. The full launch of RediTrex occurred in October 2021.</span></div></ix:continuation><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-328-5">Effective July 12, 2022, the Company entered into an amendment to our agreement with Nordic whereby they may assume responsibility for RediTrex marketing authorization in the U.S. and the opportunity to commercialize the product in the U.S. after June 30, 2023.  In accordance with the terms of the amendment, Nordic a) returned the <ix:nonFraction unitRef="shares" contextRef="c-62" decimals="0" name="cpix:CollaborativeArrangementRightsAndObligationsStockConsiderationCancelledAndRefunded" format="ixt:num-dot-decimal" scale="0" id="f-375">180,000</ix:nonFraction> restricted Cumberland shares we previously issued to Nordic which were cancelled; b) refunded to Cumberland the milestone payment of $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="cpix:CollaborativeArrangementRightsAndObligationsMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="f-376">1.0</ix:nonFraction>&#160;million we made associated with the brand&#8217;s U.S. approval; and c) issued a credit note in favor of the Company in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="cpix:CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue" format="ixt:num-dot-decimal" scale="6" id="f-377">1.0</ix:nonFraction>&#160;million for the unpaid milestone payment due from us for launch of the product line all in 2023.  Cumberland will receive a long-term royalty on any Nordic sales of the product.</ix:continuation> </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i3928a3425fef4184806511a3516ffab1_199"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(4)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-378" continuedAt="f-378-1" escape="true">Revenues</ix:nonNumeric></span></div><ix:continuation id="f-378-1"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenue</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="f-379" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net product revenues consisted of the following for the years ended December&#160;31:</span></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.085%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.088%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-380">15,981,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-381">15,205,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-382">8,812,692</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-383">7,487,462</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-384">8,096,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-385">13,205,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-386">4,333,923</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-387">4,827,200</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-388">458,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-389">501,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-390">20,030</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-391">29,145</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-392">151,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="0" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-393">447,697</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="0" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-394">341,886</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="0" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-395">126,726</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-396">37,513,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-397">40,681,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with international partners for commercialization of the Company&#8217;s products with associated payments included in other revenues. Those agreements provide that each of the partners is responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner&#8217;s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies. The contractual payments associated with the partner&#8217;s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2023, the Company received $<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-5" name="us-gaap:ProceedsFromLegalSettlements" format="ixt:num-dot-decimal" scale="6" id="f-398">1</ix:nonFraction> million relating to a litigation settlement based on <ix:nonFraction unitRef="payment" contextRef="c-81" decimals="INF" name="cpix:ProceedsFromLegalSettlementsMilestonePaymentsReceivableNumberOfPayments" format="ixt-sec:numwordsen" scale="0" id="f-399">two</ix:nonFraction> $<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="INF" name="cpix:ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentTwo" format="ixt:num-dot-decimal" scale="0" id="f-400"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="INF" name="cpix:ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentOne" format="ixt:num-dot-decimal" scale="0" id="f-401">500,000</ix:nonFraction></ix:nonFraction> milestone payments due to us for the license associated with our Vibativ product that is included in other revenue for the year ended  December&#160;31, 2023.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues includes funding from federal grant programs including those secured from the FDA and from those secured by CET through the Small Business Administration. Grant revenue from these federal grant programs totaled approximately $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-402">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-403">0.2</ix:nonFraction> million for the year ended December&#160;31, 2023 and 2022,respectively.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues also includes lease income generated by CET&#8217;s Life Sciences Center. It is a research facility that provides scientists with access to flexible lab space and other resources to develop biomedical products. This lease income, as noted in Footnote 15 - Leases, was approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="f-404">0.5</ix:nonFraction>&#160;million for the years ended December&#160;31, 2023 and 2022.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><div id="i3928a3425fef4184806511a3516ffab1_202"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryDisclosureTextBlock" id="f-405" continuedAt="f-405-1" escape="true">Inventories, Net</ix:nonNumeric></span></div><ix:continuation id="f-405-1" continuedAt="f-405-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-406" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's net inventories consisted of the following as of December 31:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.265%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.178%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="0" id="f-407">12,619,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="0" id="f-408">12,899,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" format="ixt:num-dot-decimal" scale="0" id="f-409">149,701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" format="ixt:num-dot-decimal" scale="0" id="f-410">168,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods, net of reserve</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="0" id="f-411">4,645,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="0" id="f-412">4,322,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="0" id="f-413">17,413,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="0" id="f-414">17,390,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-415">12,804,529</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-416">7,527,167</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="0" id="f-417">4,609,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="0" id="f-418">9,863,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock" id="f-419" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's non-current inventories consisted of the following as of December 31:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.105%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.178%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ - raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-420">6,611,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-421">7,138,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ - finished goods</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-422">810,454</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:fixed-zero" scale="0" id="f-423">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose - raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-424">3,263,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:fixed-zero" scale="0" id="f-425">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol - raw materials</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-426">1,170,641</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:fixed-zero" scale="0" id="f-427">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor - finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-428">67,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:fixed-zero" scale="0" id="f-429">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso - raw materials</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-430">574,502</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:fixed-zero" scale="0" id="f-431">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Study drug - raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-432">203,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-433">256,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Study drug - finished goods</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:fixed-zero" scale="0" id="f-434">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-435">131,757</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-436">103,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:fixed-zero" scale="0" id="f-437">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current inventory</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-438">12,804,529</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-439">7,527,167</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company purchases the active pharmaceutical ingredient (&#8220;API&#8221;) for Kristalose and maintains the inventory of that raw material.  API for the Company's Vaprisol and Vibativ brands were included in the assets associated with the acquisition of those brands and are also included in the raw materials inventory.  As part of the Vibativ acquisition, the Company acquired API and work in process inventories of $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-440">15.6</ix:nonFraction> million that were all initially classified as non-current inventories at the date of acquisition.  Consigned inventory represents Authorized Generic inventory stored with Padagis until shipment.  </span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-405-2">At December&#160;31, 2023, there were <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="INF" name="us-gaap:InventoryValuationReserves" format="ixt:fixed-zero" scale="0" id="f-441">no</ix:nonFraction> cumulative obsolescence or discontinuance losses necessary to recognize.  At December 31, 2022, the Company had recognized and maintained cumulative net realizable value charges for potential obsolescence and discontinuance losses of approximately $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="6" id="f-442">0.5</ix:nonFraction> million.</ix:continuation> </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><div id="i3928a3425fef4184806511a3516ffab1_205"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(6)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-443" continuedAt="f-443-1" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="f-443-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-444" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following at December&#160;31:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.699%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">useful lives</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-103" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-445">3</ix:nonNumeric>&#160;&#8211;&#160;<ix:nonNumeric contextRef="c-104" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-446">5</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-447">499,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-448">465,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-107" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-449">3</ix:nonNumeric>&#160;&#8211;&#160;<ix:nonNumeric contextRef="c-108" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-450">15</ix:nonNumeric> years&#160;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-451">771,667</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-452">746,602</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-111" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-453">5</ix:nonNumeric>&#160;&#8211;&#160;<ix:nonNumeric contextRef="c-112" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-454">15</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-455">533,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-456">369,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-115" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-457">3</ix:nonNumeric>&#160;&#8211;&#160;<ix:nonNumeric contextRef="c-116" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-458">15</ix:nonNumeric> years,&#160;or remaining&#160;lease&#160;term</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-459">800,974</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-460">787,749</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">equipment, gross</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-461">2,605,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-462">2,369,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and amortization</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-463">2,238,073</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-464">2,085,185</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">equipment, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-465">367,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-466">284,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense, including amortization expense related to leasehold improvements, is included in general and administrative expense in the consolidated statements of operations. <ix:nonNumeric contextRef="c-1" name="cpix:ScheduleofDepreciationExpenseTableTextBlock" id="f-467" continuedAt="f-467-1" escape="true">Depreciation expense was as follows for the years ended December 31:</ix:nonNumeric></span></div><ix:continuation id="f-467-1"><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.819%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" format="ixt:num-dot-decimal" scale="0" id="f-468">177,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" format="ixt:num-dot-decimal" scale="0" id="f-469">260,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:continuation><div id="i3928a3425fef4184806511a3516ffab1_208"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(7)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="f-470" continuedAt="f-470-1" escape="true">Intangible Assets and Goodwill</ix:nonNumeric></span></div><ix:continuation id="f-470-1" continuedAt="f-470-2"><ix:continuation id="f-303-1"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets and Goodwill consisted of the following at December&#160;31, 2023 and 2022. </span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:51.387%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.692%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product and license rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="f-471">43,250,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="f-472">49,668,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="f-473">22,755,543</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="f-474">21,891,974</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product and license rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="f-475">20,494,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="f-476">27,776,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="f-477">10,712,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="f-478">10,610,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="f-479">8,819,287</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="f-480">8,051,018</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="f-481">1,893,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="f-482">2,559,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="f-483">413,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="f-484">397,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="f-485">193,773</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="f-486">142,673</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="f-487">220,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="f-488">255,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="f-489">22,607,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="f-490">30,590,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="f-491">914,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="f-492">914,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product and license rights include assets associated with the Company&#8217;s acquired products, including those discussed in Note 3, Vibativ and Sancuso. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="f-470-2"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023 and 2022, the Company recorded an additional $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-493">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-494">0.2</ix:nonFraction> million, respectively, in intangible assets for patents, trademarks and capitalized patent costs, including amounts incurred in the protection of the Company's intellectual property. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="f-495" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to product and license rights, trademarks and patents were as follows for the years ended December 31:</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:51.387%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.692%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.695%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization and impairment expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="f-496">8,102,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="f-497">5,067,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected amortization expense for the Company's current balance of intangible assets are as follows:</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:73.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="0" id="f-498">4,304,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="0" id="f-499">4,245,825</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="0" id="f-500">3,859,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="0" id="f-501">3,452,780</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="cpix:FiniteLivedIntangibleAssetsAmortizationExpenseYearFourAndAfter" format="ixt:num-dot-decimal" scale="0" id="f-502">6,745,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="f-503">22,607,918</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i3928a3425fef4184806511a3516ffab1_211"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(8)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:OtherLiabilitiesDisclosureTextBlock" id="f-504" continuedAt="f-504-1" escape="true">Other Current and Other Long-term Liabilities</ix:nonNumeric></span></div><ix:continuation id="f-504-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-505" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities consisted of the following at December&#160;31:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.867%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates, product returns, administrative fees </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and service fees</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="cpix:ProductSalesRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-506">7,579,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="cpix:ProductSalesRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-507">8,347,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee wages and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-508">1,197,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-509">1,440,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso related liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="cpix:AccruedLiabilitiesStockPayable" format="ixt:num-dot-decimal" scale="0" id="f-510">827,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="cpix:AccruedLiabilitiesStockPayable" format="ixt:num-dot-decimal" scale="0" id="f-511">2,226,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of accrued contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="cpix:BusinessCombinationContingentConsiderationLiabilityAccruedCurrent" format="ixt:num-dot-decimal" scale="0" id="f-512">2,424,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="cpix:BusinessCombinationContingentConsiderationLiabilityAccruedCurrent" format="ixt:num-dot-decimal" scale="0" id="f-513">3,006,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Studies accrual</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="cpix:AccruedLiabilitiesStudies" format="ixt:num-dot-decimal" scale="0" id="f-514">385,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="cpix:AccruedLiabilitiesStudies" format="ixt:num-dot-decimal" scale="0" id="f-515">400,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued inventory purchases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="cpix:AccruedLiabilitiesInventoryPurchases" format="ixt:fixed-zero" scale="0" id="f-516">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="cpix:AccruedLiabilitiesInventoryPurchases" format="ixt:num-dot-decimal" scale="0" id="f-517">609,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current deferred charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="f-518">220,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="f-519">614,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-520">961,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-521">941,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-522">13,596,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-523">17,587,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:OtherNoncurrentLiabilitiesTableTextBlock" id="f-524" escape="true"><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities consisted of the following at December 31:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.867%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of accrued contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-525">3,284,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-526">4,931,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-527">2,894,894</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-528">2,522,506</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-529">274,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-530">131,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-531">6,453,566</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-532">7,585,019</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i3928a3425fef4184806511a3516ffab1_214"></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(9)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-533" continuedAt="f-533-1" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="f-533-1"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 5, 2023, the Company entered into a new Revolving Credit Loan Agreement with Pinnacle Bank. This facility provides for an aggregate principal funding amount of up to $<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-534">25</ix:nonFraction>&#160;million. The initial revolving line of credit is up to $<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-535">20</ix:nonFraction>&#160;million, with the ability for Cumberland to increase the amount to $<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-5" name="cpix:LineOfCreditFacilityAdditionalBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-536">25</ix:nonFraction>&#160;million, under certain conditions. It has a <ix:nonNumeric contextRef="c-129" name="us-gaap:LineOfCreditFacilityExpirationPeriod" format="ixt-sec:durwordsen" id="f-537">three year</ix:nonNumeric> term expiring on October 1, 2026. The interest rate is based on a benchmark (Term SOFR) plus a spread of <ix:nonFraction unitRef="number" contextRef="c-130" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-538">2.75</ix:nonFraction>%. Cumberland is subject to one financial covenant, the maintenance of a Funded Debt Ratio, determined on a quarterly basis. Borrowings under the line of credit are collateralized by substantially all of our assets.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 and December&#160;31, 2022, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="us-gaap:LongTermLineOfCredit" format="ixt:num-dot-decimal" scale="6" id="f-539">12.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:LongTermLineOfCredit" format="ixt:num-dot-decimal" scale="6" id="f-540">16.2</ix:nonFraction> million, respectively, in borrowings outstanding under its revolving credit facility. The applicable interest rate under the Pinnacle Agreement was <ix:nonFraction unitRef="number" contextRef="c-131" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-541">8.125</ix:nonFraction>% at December&#160;31, 2023.  In 2022, under a previous agreement with Pinnacle Bank, the applicable interest rate was based on LIBOR plus an interest rate spread and was <ix:nonFraction unitRef="number" contextRef="c-132" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" format="ixt:num-dot-decimal" id="f-542">6.75</ix:nonFraction>% at December 31, 2022.</span></div></ix:continuation><div id="i3928a3425fef4184806511a3516ffab1_217"></div><div style="margin-top:8pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(10)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-543" continuedAt="f-543-1" escape="true">Shareholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="f-543-1"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Initial Public Offering</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-133" name="us-gaap:SaleOfStockTransactionDate" format="ixt:date-monthname-day-year-en" id="f-544">August&#160;10, 2009</ix:nonNumeric>, the Company completed its initial public offering of <ix:nonFraction unitRef="shares" contextRef="c-133" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-545">5,000,000</ix:nonFraction> shares of common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-133" decimals="INF" name="cpix:StockIssuedDuringPeriodPricePerShareNewIssues" scale="0" id="f-546">17.00</ix:nonFraction> per share, raising gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="cpix:StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering" format="ixt:num-dot-decimal" scale="6" id="f-547">85.0</ix:nonFraction> million. After deducting underwriting discounts of approximately $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="cpix:StockIssuedDuringPeriodNewSharesUnderwritingDiscounts" format="ixt:num-dot-decimal" scale="6" id="f-548">6.0</ix:nonFraction> million and offering costs incurred of approximately $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-549">4.2</ix:nonFraction> million, the net proceeds to the Company were approximately $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="6" id="f-550">74.8</ix:nonFraction> million. </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Preferred Stock</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-551">20,000,000</ix:nonFraction>&#160;shares of preferred stock. The Board of Directors is authorized to divide these shares into classes or series, and to fix and determine the relative rights, preferences, qualifications and limitations of the shares of any class or series so established. At December&#160;31, 2023 and 2022, there was <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-552"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-553">no</ix:nonFraction></ix:nonFraction> preferred stock outstanding.</span></div><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Common Stock</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023 and 2022, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-554">157,360</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-555">171,655</ix:nonFraction>  shares of common stock, respectively, as a result of restricted shares vesting as well as other common share issuances. There were no option exercise transactions during 2023 and  2022.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Share Repurchases</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has a share repurchase program available to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="f-556">10</ix:nonFraction>&#160;million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934.  The Company repurchased <ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="f-557">402,143</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="f-558">367,793</ix:nonFraction> shares of common stock for approximately $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="f-559">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="f-560">1.0</ix:nonFraction> million during the years ended December&#160;31, 2023 and 2022, respectively.  There remains approximately $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="6" id="f-561">3</ix:nonFraction> million  available under the current repurchase program available for share repurchases at December&#160;31, 2023.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><div id="i3928a3425fef4184806511a3516ffab1_220"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(11)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-562" continuedAt="f-562-1" escape="true">Loss Per Share </ix:nonNumeric></span></div><ix:continuation id="f-562-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-563" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the computation of the numerator and the denominator used to calculate diluted loss per share for the years ended December 31:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.791%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.412%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.415%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="f-564">6,330,766</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="f-565">5,650,039</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss at subsidiary attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-566">51,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-567">79,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-568">6,279,320</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-569">5,570,241</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-570">14,298,774</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-571">14,563,592</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-572">14,298,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-573">14,563,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-574" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's anti-dilutive restricted shares and stock options outstanding were as follows for the years ended December 31:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.791%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.412%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.415%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive shares and options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-575">452,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-576">227,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div><div id="i3928a3425fef4184806511a3516ffab1_223"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(12)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-577" continuedAt="f-577-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="f-577-1" continuedAt="f-577-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-578" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company's net deferred tax assets at December&#160;31 are as follows:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.573%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.575%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss and tax credits</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="cpix:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="0" id="f-579">15,427,801</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="cpix:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="0" id="f-580">16,164,754</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment and intangibles</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="cpix:DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" format="ixt:num-dot-decimal" scale="0" id="f-581">71,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="cpix:DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" format="ixt:num-dot-decimal" scale="0" id="f-582">264,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="cpix:DeferredTaxAssetOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-583">1,307,178</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="cpix:DeferredTaxAssetOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-584">1,121,800</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="f-585">2,337,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="f-586">866,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="0" id="f-587">2,208,093</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="0" id="f-588">1,481,455</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="0" id="f-589">147,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="0" id="f-590">145,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for expired product</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="cpix:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" format="ixt:num-dot-decimal" scale="0" id="f-591">616,979</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="cpix:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" format="ixt:num-dot-decimal" scale="0" id="f-592">654,148</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:DeferredTaxAssetsInventory" format="ixt:num-dot-decimal" scale="0" id="f-593">185,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:DeferredTaxAssetsInventory" format="ixt:num-dot-decimal" scale="0" id="f-594">217,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="cpix:DeferredTaxAssetsDeferredCharges" format="ixt:num-dot-decimal" scale="0" id="f-595">937,935</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="cpix:DeferredTaxAssetsDeferredCharges" format="ixt:num-dot-decimal" scale="0" id="f-596">1,156,150</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative compensation costs incurred on deductible equity awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="0" id="f-597">176,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="0" id="f-598">635,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="0" id="f-599">23,417,101</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="0" id="f-600">22,708,719</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="cpix:DeferredTaxLiabilityOperatingLeaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="0" id="f-601">1,547,773</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="cpix:DeferredTaxLiabilityOperatingLeaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="0" id="f-602">1,150,935</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:fixed-zero" scale="0" id="f-603">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:fixed-zero" scale="0" id="f-604">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets, before valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="cpix:NetDeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="0" id="f-605">21,869,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="cpix:NetDeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="0" id="f-606">21,557,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: deferred tax asset valuation allowance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="f-607">21,869,328</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="f-608">21,557,784</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="0" id="f-609">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="0" id="f-610">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock" id="f-611" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amount and year of expiration of the Company's federal and state net operating loss carryforwards as of December&#160;31, 2023:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:55.561%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.606%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years of expiration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Federal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">State</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="0" name="us-gaap:OperatingLossCarryforwards" format="ixt:fixed-zero" scale="0" id="f-612">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="0" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="f-613">30,756,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025-2042</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="0" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="f-614">45,709,390</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="0" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="f-615">28,333,628</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="0" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="f-616">6,405,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="0" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="f-617">473,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total federal and state net operating loss carryforwards</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="0" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="f-618">52,115,225</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="0" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="f-619">59,563,210</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:8pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="f-577-2" continuedAt="f-577-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-620" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense includes the following components for the years ended December 31:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.201%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.207%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.370%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-621">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-622">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="f-623">45,769</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="f-624">68,850</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="f-625">45,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="f-626">68,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-627">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-628">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-629">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-630">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:DeferredOtherTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-631">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:DeferredOtherTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-632">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="f-633">45,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="f-634">68,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-635" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective income tax rate for 2023 and 2022 reconciles with the federal statutory tax rate as follows: </span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:62.302%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.235%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.237%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal tax expense at statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-636">21.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-637">21.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax expense (net of federal income tax benefit)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-638">0.58</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-639">2.11</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences associated with general business credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-640">0.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" format="ixt:fixed-zero" scale="-2" id="f-641">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-642">4.96</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-5" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-643">21.76</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="f-644">6.51</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-5" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="f-645">2.58</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiring tax credits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-646">3.32</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" format="ixt:fixed-zero" scale="-2" id="f-647">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred True-ups</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" sign="-" name="cpix:EffectiveIncomeTaxRateReconciliationDeferredTrueUpsPercent" scale="-2" id="f-648">7.16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="4" name="cpix:EffectiveIncomeTaxRateReconciliationDeferredTrueUpsPercent" format="ixt:fixed-zero" scale="-2" id="f-649">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss tax expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-650">0.73</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-5" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-651">1.23</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that it is not more likely than not that its net deferred tax assets will be realized.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As such, the net deferred tax assets are fully offset with a valuation allowance as of the periods ended December&#160;31, 2023 and  2022.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company has general business credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-652">1.3</ix:nonFraction>&#160;million. These credit carryforwards will expire in years 2024 through 2044. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><ix:nonNumeric contextRef="c-1" name="us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock" id="f-653" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:64.334%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.925%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.341%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years of expiration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Federal</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="0" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="0" id="f-654">18,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025-2044</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="0" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="0" id="f-655">1,322,531</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total federal and state credit carryforwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="0" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="0" id="f-656">1,340,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:nonNumeric></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects it will continue to pay minimal taxes in future periods through the continued utilization of net operating loss carryforwards, as it is able to achieve taxable income through its operations.</span></div></ix:continuation><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-577-3">The Company is no longer subject to U.S. federal tax examinations for tax years before 2020, and with few exceptions, the Company is not subject to examination by state tax authorities for tax years which ended before 2020. Loss carryforwards and credit carryforwards generated or utilized in years earlier than 2020 remain subject to examination and adjustment. The Company has no unrecognized tax benefits in 2023 and 2022.</ix:continuation>             </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-31</span></div></div></div><div id="i3928a3425fef4184806511a3516ffab1_226"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(13)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-657" continuedAt="f-657-1" escape="true">Stock-Based Compensation Plans</ix:nonNumeric></span></div><ix:continuation id="f-657-1" continuedAt="f-657-2"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has grants outstanding under <ix:nonFraction unitRef="plan" contextRef="c-1" decimals="INF" name="cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants" format="ixt-sec:numwordsen" scale="0" id="f-658">two</ix:nonFraction> equity compensation plans. The 2007 Long-Term Incentive Compensation Plan (the "2007 Plan") and the 2007 Directors&#8217; Incentive Plan (the "Directors&#8217; Plan"), which were approved by shareholders, superseded the 1999 Stock Option Plan. Both plans are available for future grants of equity compensation awards to employees, consultants and directors. The 2007 Plan and the Directors&#8217; Plan provide for the issuance of stock options, stock appreciation rights and restricted stock. Vesting is determined on a grant-by-grant basis in accordance with the terms of the plans and the related grant agreements. The Company has reserved <ix:nonFraction unitRef="shares" contextRef="c-146" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-659">3.2</ix:nonFraction> million shares of common stock for issuance under the 2007 Plan and <ix:nonFraction unitRef="shares" contextRef="c-147" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-660">250,000</ix:nonFraction> shares for issuance under the Directors&#8217; Plan.  As of December&#160;31, 2023, the Company had <ix:nonFraction unitRef="shares" contextRef="c-146" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-661">933,517</ix:nonFraction> shares available for future grants under the 2007 Plan and <ix:nonFraction unitRef="shares" contextRef="c-147" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-662">130,507</ix:nonFraction> shares available under the Directors&#8217; Plan.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price of stock options is generally <ix:nonFraction unitRef="number" contextRef="c-148" decimals="INF" name="cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue" scale="-2" id="f-663">100</ix:nonFraction>% of the fair market value of the underlying common stock on the grant date, except for incentive stock options granted to <ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent" scale="-2" id="f-664">10</ix:nonFraction>% shareholders, which the exercise price is no less than <ix:nonFraction unitRef="number" contextRef="c-149" decimals="INF" name="cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue" scale="-2" id="f-665">110</ix:nonFraction>% of the fair market value.  The maximum contractual term of stock options is <ix:nonNumeric contextRef="c-150" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-666">ten years</ix:nonNumeric> from the grant date, except for incentive stock options granted to <ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent" scale="-2" id="f-667">10</ix:nonFraction>% shareholders, which is no more than <ix:nonNumeric contextRef="c-151" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-668">five years</ix:nonNumeric>.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2011, the Company began issuing shares of restricted stock with no exercise price to employees and directors. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the grant date. Restricted stock issued to directors vests on the <ix:nonNumeric contextRef="c-152" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-669">one year</ix:nonNumeric> anniversary of the grant date.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock compensation expense is presented as a component of general and administrative expense in the consolidated statements of operations. Stock compensation expense was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-670"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-671">0.4</ix:nonFraction></ix:nonFraction>&#160;million for the years ended December&#160;31, 2023 and 2022.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023, there was approximately $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="f-672">0.5</ix:nonFraction> million of unrecognized compensation cost related to share-based payments, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="c-154" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-673">1.85</ix:nonNumeric> years. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-674" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options activity was as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:35.176%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.286%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">of option shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">exercise price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-average remaining contractual term</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-675">170,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-676">3.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-677">178,950</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-678">2.68</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="f-679">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-680">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/canceled</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-681">29,900</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-682">2.98</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-683">319,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-684">3.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-685">6.15</ix:nonNumeric></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-686">192,750</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-687">2.06</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="f-688">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-689">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/canceled</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-690">25,150</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-691">2.55</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-692">487,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-693">2.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-694">5.59</ix:nonNumeric></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The weighted-average grant-date fair value of options granted during  the years 2023 and 2022 was <ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-695">1.16</ix:nonFraction> and  <ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-696">1.29</ix:nonFraction>, respectively.  <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:fixed-zero" scale="0" id="f-697"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" format="ixt:fixed-zero" scale="0" id="f-698">No</ix:nonFraction></ix:nonFraction> options were vested and exercisable at December&#160;31, 2023.  The aggregate intrinsic value of options outstanding was minimal.</span></div></ix:continuation><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="f-657-2"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options is calculated using the Black-Scholes (&#8220;Black-Scholes-Merton&#8221;, or &#8220;BSM&#8221;) option-pricing model on the grant date. Since 2012, the Company had been issuing Restricted Share Awards where the grant date Fair Value (&#8220;FV&#8221;) equaled the closing share price. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-699" continuedAt="f-699-1" escape="true">The assumptions used in the Black-Scholes valuation to determine the FV of stock options were as follows at December 31: </ix:nonNumeric></span></div><ix:continuation id="f-699-1"><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.470%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.311%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-155" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-700">5.71</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-156" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-701">5.88</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-155" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="f-702">65.87</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-156" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="f-703">54.38</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-155" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-704">3.45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-156" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-705">2.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" format="ixt:fixed-zero" scale="0" id="f-706">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" format="ixt:fixed-zero" scale="0" id="f-707">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Term - The Company has estimated the expected life of its stock options using the simplified method, whereby the expected life equals the average of the vesting term and the original contractual term of the option. </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company&#8217;s historical stock price volatility.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk Free rate - The Company bases the risk-free interest rate assumption for equity awards on the rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expected dividend yield - The Company&#8217;s expected dividend yield assumption is <ix:nonFraction unitRef="usd" contextRef="c-155" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" format="ixt:fixed-zero" scale="0" id="f-708">zero</ix:nonFraction> as it has never paid dividends and has no present intention to do so in the future.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Awards</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="f-709" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock activity was as follows:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-average grant-date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">fair value</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-157" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-710">568,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-157" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-711">5.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-158" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-712">65,225</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-158" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-713">2.59</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested/released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-158" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-714">171,655</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-158" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-715">6.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/canceled</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-158" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-716">66,000</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-158" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-717">4.67</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-159" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-718">395,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-159" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-719">4.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-160" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-720">34,250</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-160" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-721">1.93</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested/released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-160" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-722">157,360</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-160" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-723">5.73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/canceled</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-160" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-724">12,075</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-160" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-725">3.63</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-161" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-726">260,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-161" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-727">3.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of restricted stock granted was based on the closing market price of the Company&#8217;s common stock on the grant date. The fair value of restricted stock awards that vested during the years 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="f-728">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="f-729">0.5</ix:nonFraction> million, respectively.  At December&#160;31, 2023, there was approximately $<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="f-730">0.2</ix:nonFraction>&#160;million of unrecognized compensation costs related to restricted stock awards, which is expected to be recognized over a weighted-average period of less than a year.  The restricted stock grants are included in the diluted weighted shares outstanding computation until they cliff-vest. Once vested they are included in the basic weighted shares outstanding computation.</span></div></ix:continuation><div id="i3928a3425fef4184806511a3516ffab1_229"></div><div style="margin-top:8pt;text-align:justify;text-indent:-4.5pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(14)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="f-731" continuedAt="f-731-1" escape="true">Employee Benefit Plans</ix:nonNumeric></span></div><ix:continuation id="f-731-1"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors an employee benefit plan that was established on January&#160;1, 2006, the Cumberland Pharmaceuticals 401(k) Plan (the&#160;"Plan"), under Section&#160;401(k) of the Internal Revenue Code of 1986, as amended, for the benefit of all employees over the age of <ix:nonNumeric contextRef="c-1" name="cpix:DefinedContributionPlanEligibilityMinimumEmployeeAge" format="ixt-sec:duryear" id="f-732">21</ix:nonNumeric>, having been employed by the Company for at least <ix:nonNumeric contextRef="c-1" name="cpix:DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility" format="ixt-sec:durwordsen" id="f-733">six months</ix:nonNumeric>. The Plan provides that participants may contribute up to the maximum amount of their compensation as set forth by the Internal Revenue Service each year. Employee contributions are invested in various investment funds based upon elections made by the employees. During 2023 and 2022, the Company contributed approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-4" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="f-734">0.08</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-4" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="f-735">0.06</ix:nonFraction> million, respectively, in each year to the Plan as an employer match of participant contributions.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012 and 2013, the Company established non-qualified unfunded deferred compensation plans that allow participants to defer receipt of a portion of their compensation. The liability under the plans, reflected in other long term liabilities in the consolidated balance sheets, was $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-736">2.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-737">2.5</ix:nonFraction> million as of December&#160;31, 2023 and 2022, respectively. The Company had assets consisting of company-owned life insurance contracts generally designated to pay benefits of the deferred compensation plans reflected in other assets in the consolidated balance sheet of $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:DeferredCompensationPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-738">2.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:DeferredCompensationPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-739">2.3</ix:nonFraction> million as of December&#160;31, 2023 and 2022, respectively.</span></div></ix:continuation><div id="i3928a3425fef4184806511a3516ffab1_232"></div><div style="margin-top:8pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(15)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-740" continuedAt="f-740-1" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="f-740-1" continuedAt="f-740-2"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 15, 2021, Cumberland entered into a lease, pursuant to which the Company leases approximately <ix:nonFraction unitRef="sqft" contextRef="c-162" decimals="0" name="cpix:LesseeOperatingLeaseLeasedArea" format="ixt:num-dot-decimal" scale="0" id="f-741">16,903</ix:nonFraction> rentable square feet of space at the new development Broadwest located in Nashville, Tennessee with 1600 West End Avenue Partners, LLC. The leased premise serves as the Company's new corporate headquarters. The initial term of the lease is one hundred fifty-seven (<ix:nonNumeric contextRef="c-162" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth" id="f-742">157</ix:nonNumeric>) months, with <ix:nonFraction unitRef="renewalterm" contextRef="c-163" decimals="INF" name="cpix:LesseeOperatingLeaseNumberOfRenewalTerms" format="ixt-sec:numwordsen" scale="0" id="f-743">two</ix:nonFraction> consecutive options to renew for a period of <ix:nonNumeric contextRef="c-163" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-744">five years</ix:nonNumeric> each, with the commencement date of October 25, 2022. This lease currently expires in November 2035.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for paying rent to the Landlord under the lease beginning three months after the commencement date. The Company pays a base rent of $<ix:nonFraction unitRef="usdPerSqft" contextRef="c-162" decimals="2" name="cpix:LesseeOperatingLeaseBaseRent" scale="0" id="f-745">33.06</ix:nonFraction> per square foot of rentable space with a gradual rental rate increase of <ix:nonFraction unitRef="number" contextRef="c-164" decimals="3" name="cpix:LesseeOperatingLeaseRentIncrease" scale="-2" id="f-746">2.5</ix:nonFraction>% for each year period thereafter of the prior year's base rental. In addition to the monthly base rent, the Company is responsible for its percentage share of the operating expenses of the building. The lease also provides for a tenant improvement allowance for the space. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 24, 2022, the CET lease with The Gateway to Nashville, LLC provided the notice of exercise to extend the lease for <ix:nonNumeric contextRef="c-165" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:durwordsen" id="f-747">five years</ix:nonNumeric>.  The lease is for approximately <ix:nonFraction unitRef="sqft" contextRef="c-166" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="f-748">14,200</ix:nonFraction> square feet of wet laboratory and office space in Nashville, Tennessee where CET operates the CET Life Sciences Center.The wet laboratory and office space is leased through April 2028. The Company also subleases a portion of the space under this lease.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also included within the right-of-use assets are start up expenditures related to a new supply agreement with Nephron Pharmaceuticals Corporation (&#8220;Nephron&#8221;).   These expenditures are classified as an embedded lease resulting in a right-of-use asset to be amortized over the life of the Nephron contract.  As of December&#160;31, 2023, the value of this asset was $<ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-749">1.0</ix:nonFraction> million.</span></div><ix:nonNumeric contextRef="c-1" name="cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" id="f-750" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense is recognized over the expected term of the lease on a straight-line basis as a component of general and administrative expense. Rent expense and sublease income  as follows for the years ended December 31:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.207%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.210%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="0" id="f-751">1,304,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="0" id="f-752">1,159,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="0" id="f-753">544,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="0" id="f-754">529,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the FASB issued ASU 2016-02. ASU 2016-02&#8217;s core principle is to increase transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information. The primary effect of adopting ASU 2016-02 to the Company was to record right-of-use assets and obligations for the leases currently classified as operating leases. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="f-740-2"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities were recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As the Company&#8217;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at October 25, 2022 and May 1, 2023. Incremental borrowing rates reflect the Company&#8217;s estimated interest rates for collateralized borrowings over similar lease terms. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average remaining lease term for the Broadwest and Gateway leases is <ix:nonNumeric contextRef="c-168" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-755">10.42</ix:nonNumeric> years and <ix:nonNumeric contextRef="c-169" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-756">12.69</ix:nonNumeric> years for the years ended December 31, 2023 and 2022, respectively.. The weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments of both leases is <ix:nonFraction unitRef="number" contextRef="c-168" decimals="INF" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-757">9.40</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-169" decimals="INF" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-758">9.24</ix:nonFraction>% for the years ended December 31, 2023 and 2023, respectively.</span></div><div style="margin-top:8pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    Lease Position</span></div><ix:nonNumeric contextRef="c-1" name="cpix:AssetsAndLiabilitiesLesseeTableTextBlock" id="f-759" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023 and 2022, the Company recorded the following on the Consolidated Balance Sheet: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.271%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.130%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.133%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-Use Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="f-760">6,674,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="f-761">5,218,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.271%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.130%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.133%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="f-762">348,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="f-763">172,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-764">5,296,247</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-765">4,586,301</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="f-766">5,644,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="f-767">4,759,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="6" id="f-768">0.3</ix:nonFraction> million and will be paid through the leases ending in April 2024. Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-769" escape="true"><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.585%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.132%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of Leases Liabilities at December&#160;31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="0" id="f-770">863,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="0" id="f-771">836,100</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="0" id="f-772">909,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="0" id="f-773">934,180</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="0" id="f-774">740,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2028</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="0" id="f-775">4,847,400</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="0" id="f-776">9,131,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="0" id="f-777">3,487,363</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="f-778">5,644,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i3928a3425fef4184806511a3516ffab1_235"></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(16)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskDisclosureTextBlock" id="f-779" continuedAt="f-779-1" escape="true">Market Concentrations</ix:nonNumeric></span></div><ix:continuation id="f-779-1"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s principal financial instruments subject to potential concentration of credit risk are accounts receivable, which are unsecured, and cash equivalents. The Company&#8217;s cash equivalents consist primarily of money market funds. Certain bank deposits may be in excess of the insurance limits provided by the Federal Deposit Insurance Corporation.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s primary customers are wholesale pharmaceutical distributors in the U.S. &#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="f-780" continuedAt="f-780-1" escape="true">Total revenues by customer for each customer representing 10% or more of consolidated revenues are summarized below for the years ended December 31: </ix:nonNumeric></span></div><ix:continuation id="f-780-1"><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.592%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.592%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.594%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-170" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-781">29</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-171" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-782">22</ix:nonFraction>%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-172" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-783">26</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-173" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-784">29</ix:nonFraction>%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-174" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-785">24</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-175" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-786">24</ix:nonFraction>%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts receivable, net of allowances, due from the customers representing 10% or more of consolidated revenue was <ix:nonFraction unitRef="number" contextRef="c-176" decimals="4" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-787">62.3</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-177" decimals="4" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-788">51.8</ix:nonFraction>% at December&#160;31, 2023 and 2022, respectively.</span></div></ix:continuation><div id="i3928a3425fef4184806511a3516ffab1_238"></div><div style="margin-top:8pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(17)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="cpix:ManufacturingAndSupplyAgreementsTextBlock" id="f-789" continuedAt="f-789-1" escape="true">Manufacturing and Supply Agreements</ix:nonNumeric></span></div><ix:continuation id="f-789-1"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes <ix:nonFraction unitRef="supplier" contextRef="c-178" decimals="INF" name="cpix:ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" format="ixt-sec:numwordsen" scale="0" id="f-790">one</ix:nonFraction> or <ix:nonFraction unitRef="supplier" contextRef="c-179" decimals="INF" name="cpix:ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" format="ixt-sec:numwordsen" scale="0" id="f-791">two</ix:nonFraction> primary suppliers to manufacture each of its products and product candidates. Although there are a limited number of manufacturers of pharmaceutical products, the Company believes it could utilize other suppliers to manufacture its prescription products on comparable terms. A change in suppliers, problems with its third-party manufacturing operations or related production capacity, or contract disputes with suppliers could cause a delay in manufacturing or shipment of finished goods and possible loss of sales, which could adversely affect operating results.</span></div></ix:continuation><div id="i3928a3425fef4184806511a3516ffab1_241"></div><div style="margin-top:8pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(18)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="cpix:EmploymentAgreementsTextBlock" id="f-792" continuedAt="f-792-1" escape="true">Employment Agreements</ix:nonNumeric></span></div><ix:continuation id="f-792-1"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment agreements with all its full-time employees. Each employment agreement provides for a salary for services performed, a potential annual bonus and, if applicable, a grant of restricted common shares pursuant to a restricted stock and incentive stock option agreement.</span></div></ix:continuation><div id="i3928a3425fef4184806511a3516ffab1_247"></div><div style="margin-top:8pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(19)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-793" continuedAt="f-793-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-793-1" continuedAt="f-793-2"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its licensing agreements for Caldolor,  the Company is required to pay royalties based on net sales over the life of the product. Royalty expense is recognized as a component of selling and marketing expense in the period that revenue is recognized. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Vibativ, the Company is required to pay royalties based on net sales of the product. At the purchase date, Cumberland recorded the fair value of this liability and will continue to evaluate the liability each period and the royalty expense is recognized as a component of selling and marketing expense in the period that the change in fair value is recognized. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Sancuso, the Company is required to pay up to $<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-5" name="cpix:PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold" format="ixt:num-dot-decimal" scale="6" id="f-794">3.5</ix:nonFraction>&#160;million in milestones and tiered royalties ranging from <ix:nonFraction unitRef="number" contextRef="c-51" decimals="2" name="cpix:PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage" scale="-2" id="f-795">10</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-180" decimals="2" name="cpix:PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage" scale="-2" id="f-796">5</ix:nonFraction>% on U.S. net product sales for <ix:nonNumeric contextRef="c-47" name="cpix:PaymentsToAcquireBusinessTieredRoyaltyPaymentsTerm" format="ixt-sec:durwordsen" id="f-797">ten years</ix:nonNumeric>.   </span></div></ix:continuation><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="f-793-2"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has a number of patents issued through the United States Patent and Trademark Office (the &#8220;USPTO&#8221;) including U.S. Patent number 8,148,356 (the &#8220;356 Acetadote Patent&#8221;) which is assigned to the Company. The claims of the 356 Acetadote Patent encompass the new Acetadote formulation and include composition of matter claims. Following its issuance, the 356 Acetadote Patent was listed in the FDA Orange Book. The 356 Acetadote Patent is scheduled to expire in May 2026, which time period includes a 270-day patent term adjustment granted by the USPTO.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2012, Cumberland has continued to vigorously defend and protect its Acetadote product and related intellectual property rights including the use of all its legal options. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Melinta Litigation</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2022, the Company filed an action for breach of contract against Melinta Therapeutics, LLC and Targanta Therapeutics Corporation (collectively, the &#8220;Defendants&#8221;) in the United States District Court for the Southern District of New York (Case No. 1:22-cv-00915-VM). The Company and the Defendants are parties to an agreement (the &#8220;Agreement&#8221;), pursuant to which the Defendants have a license to develop and commercialize products under certain Company patents, in exchange for the Defendants paying the Company certain milestone payments and royalties on net sales of the licensed products. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, the Agreement requires the Defendants to, among other things, make a $<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-3" name="cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable" format="ixt:num-dot-decimal" scale="0" id="f-798">500,000</ix:nonFraction> payment to the Company within 30 days following the first filing of an sNDA in relation to the Product (as defined by the Agreement) and a $<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-3" name="cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable" format="ixt:num-dot-decimal" scale="0" id="f-799">500,000</ix:nonFraction> payment to the Company following the approval of the first sNDA in relation to the Product. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After Defendants disclosed the domiciles of its limited partners to the Company, as required by the Court, on October 24, 2022, the action for breach of contract was refiled in the Supreme Court of the State of New York, County of New York (Index No. 654234/2022) on November 7, 2022.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The complaint alleges that, despite the Defendants filing an NDA and sNDA for the Product and receiving FDA approval for both applications, the Defendants failed to make the required total of $<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-6" name="cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable" format="ixt:num-dot-decimal" scale="6" id="f-800">1</ix:nonFraction>&#160;million in milestone payments to the Company. The Company was seeking damages in the amount of no less than $<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-6" name="us-gaap:ProceedsFromLegalSettlements" format="ixt:num-dot-decimal" scale="6" id="f-801">1</ix:nonFraction>&#160;million, pre- and post-judgment interest under N.Y. C.P.L.R. &#167; 5001, costs, and such further relief as the court deems just and proper.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     On April 18, 2023 the state court ruled in favor of the Company.  On June 16, 2023, the Company received consideration related to the breach of contract action with the Defendants that finalized a settlement agreement that was entered into by the Company and the Defendants to close the case.</span></div></ix:continuation><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-37</span></div></div></div><div id="i3928a3425fef4184806511a3516ffab1_250"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(20)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="f-802" continuedAt="f-802-1" escape="true">Quarterly Financial Information (Unaudited)</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="f-803" escape="true"><ix:continuation id="f-802-1"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the unaudited operating results for each fiscal quarter of 2023 and 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">First</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Second</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Third</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fourth</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-804">9,224,638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-805">10,888,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-806">10,085,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-807">9,353,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-808">39,552,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-184" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-809">1,531,678</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="0" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-810">22,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-811">1,866,603</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-812">6,179,239</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-813">9,554,661</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="0" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="f-814">172,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="0" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="f-815">862,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="f-816">1,063,219</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="f-817">6,301,987</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="f-818">6,330,766</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="0" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-819">192,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="0" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-820">872,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-821">1,049,298</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-822">6,294,406</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-823">6,279,320</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share attributable to common shareholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-184" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-824">0.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-80" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-825">0.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-185" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-826">0.07</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-827">0.44</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-828">0.44</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-184" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-829">0.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-80" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-830">0.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-185" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-831">0.07</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-832">0.44</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-833">0.44</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-834">11,175,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-835">10,299,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-836">11,413,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-837">9,123,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-838">42,010,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-839">1,291,999</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-840">1,846,538</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-188" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-841">288,588</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-189" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-842">2,277,804</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-843">5,704,929</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="f-844">1,402,433</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="f-845">1,364,666</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-188" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="f-846">423,226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-189" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="f-847">2,459,714</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="f-848">5,650,039</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-849">1,385,253</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-850">1,335,620</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-188" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-851">408,639</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-189" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-852">2,440,729</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-853">5,570,241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share attributable to common shareholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-186" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-854">0.09</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-187" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-855">0.09</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-188" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-856">0.03</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-189" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-857">0.17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-858">0.38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-186" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-859">0.09</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-187" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-860">0.09</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-188" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-861">0.03</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-189" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-862">0.17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-863">0.38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Due to the nature of interim earnings per share calculations, the sum of the quarterly earnings (loss) per share amounts may not equal the reported earnings (loss) per share for the full year.</span></div></ix:continuation></ix:nonNumeric><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-38</span></div></div></div><div id="i3928a3425fef4184806511a3516ffab1_253"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" id="f-864" escape="true"><div style="margin-top:8pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Schedule II</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation and Qualifying Accounts</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Years ended December&#160;31, 2023 and 2022.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.470%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.079%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.957%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.585%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.406%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">beginning&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">period</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Charged to</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">costs and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">expenses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Charged&#160;to</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">accounts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">end&#160;of&#160;period</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for uncollectible amounts, cash discounts, chargebacks, and credits issued for damaged products:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the years ended </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="0" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="0" id="f-865">340,964</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="0" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="0" id="f-866">6,673,104</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="0" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:fixed-zero" scale="0" id="f-867">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-191" decimals="0" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="0" id="f-868">6,417,977</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;text-align:center"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="0" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="0" id="f-869">596,091</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="0" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="0" id="f-870">596,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="0" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="0" id="f-871">5,953,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="0" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:fixed-zero" scale="0" id="f-872">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-193" decimals="0" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="0" id="f-873">5,969,671</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="0" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="0" id="f-874">579,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the years ended </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="0" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="0" id="f-875">19,761,922</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="0" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="0" id="f-876">1,795,862</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="0" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:fixed-zero" scale="0" id="f-877">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="0" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:fixed-zero" scale="0" id="f-878">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="0" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="0" id="f-879">21,557,784</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="0" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="0" id="f-880">21,557,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="0" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="0" id="f-881">311,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="0" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:fixed-zero" scale="0" id="f-882">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="0" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:fixed-zero" scale="0" id="f-883">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="0" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="0" id="f-884">21,869,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Composed of actual returns and credits for chargebacks and cash discounts.</span></div></ix:nonNumeric><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-39</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.11
<SEQUENCE>2
<FILENAME>a2023q4exhibit411.htm
<DESCRIPTION>EX-4.11
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i845267e8740647cd8d3fe9b9114066ec_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Exhibit 4.11</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">DESCRIPTION OF THE REGISTRANT&#8217;S COMMON STOCK </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">REGISTERED PURSUANT TO SECTION 12 OF THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECURITIES EXCHANGE ACT OF 1934</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The common stock of Cumberland Pharmaceuticals, Inc. ( &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; or the &#8220;Company&#8221;) is registered under Section 12 of the Securities Exchange Act of 1934, as amended.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The following description of our common stock is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to the actual terms and provisions contained in our Third Amended and Restated Charter, as amended (the &#8220;Charter&#8221;), and our Second Amended and Restated Bylaws (the &#8220;Bylaws&#8221;), copies of are filed as an exhibit to this Annual Report on Form 10-K and are incorporated herein, and to the applicable provisions of Tennessee law. We encourage you to read our Charter and Bylaws and the applicable provisions of Tennessee law for additional information.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Authorized Capital </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">We are authorized to issue up to 120,000,000 shares of capital stock, of which 100,000,000 may be shares of common stock, par value $0.00 per share, and 20,000,000 may be shares of preferred stock, par value $0.00 per share. The Company currently has no preferred stock issued and outstanding. All of the Company&#8217;s outstanding shares of common stock are fully paid and nonassessable. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Voting Rights</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Holders of common stock are entitled to one vote for each share registered in his or her name on our books on all matters voted on by our shareholders.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Holders of our common stock do not have cumulative voting rights. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Dividends </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subject to any preferences or other rights of any of our preferred stock that may be issued from time to time, each share of our common stock is entitled to share equally with each other share of common stock in dividends from sources legally available therefore, when, as, and if declared by the Board of Directors of the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Absence of Other Rights </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Holders of our common stock do not have any preemptive rights to subscribe for or purchase any of our securities of any class or kind. Holders of our common stock do not have any subscription, redemption or conversion privileges. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Liquidation Rights</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Upon our liquidation or dissolution, whether voluntary or involuntary, each share of our common stock is entitled to share equally in the assets that are available for distribution to our shareholders, after payment of all debts and liabilities and subject to the prior rights of nay holders of preferred stock then outstanding. </font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Listing </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#8220;CPIX.&#8221;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Transfer Agent and Registrar </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Continental Stock Transfer &#38; Trust Company is the transfer agent and registrar of our common stock.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Anti-Takeover Effects of our Charter and Bylaws</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Our Charter and Bylaws contain certain provisions that could have the effect of delaying, deferring or discouraging another party from acquiring control of the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">These provisions, which are summarized below, could discourage takeovers, coercive or otherwise.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">These provisions are also designed, in part, to encourage persons seeking to acquire control of us to negotiate first with our Board of Directors.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Staggered Board</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Our Charter divides our Board of Directors into three separate classes, and directors are assigned to each class in accordance by resolution of the Board of Directors.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Each class of directors serves for a full term of three years, and the terms of the respective classes expire in succession so that only one class of directors is required to stand for re-election at each annual meeting.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">This provision prevents our shareholders or a potential acquirer from replacing all of our incumbent directors at a single annual meeting.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Removal of Directors</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Under Tennessee law, a director can be removed by the shareholders with or without cause, unless a corporation&#8217;s charter provides that the director can only be removed for cause.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Our Charter includes this restriction, which could make it more difficult for shareholders to remove incumbent directors.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Advance Notice Provisions</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Our Bylaws contain advance notice provisions applicable to shareholder proposals and the nomination of candidates for election as directors by shareholders.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">These advance notice provisions may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed and may also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempt to obtain control of the Company. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Vacancies</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Our Charter provides that the Board of Directors, by a majority vote of the remaining directors in office, shall fill any vacant directorships caused by the death, resignation, disqualification, removal of a director.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Our Charter also gives the Board of Directors the power to fill any vacancies resulting from the increase in the number of directors serving on the Board.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">These provisions could make it more difficult for an acquiror to gain control of our Board of Directors.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Calling of Special Meetings</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Under Tennessee law, a special meeting of a Tennessee corporation&#8217;s shareholders can be called by its board of directors or, unless the charter provides otherwise, the holders of at least 10% of the outstanding voting stock of the corporation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Our Charter provides that a special meeting can be called by our Chairman of the Board or the Chief Executive Officer only when shareholders owning at least two-thirds of the votes entitled to be cast on any issue proposed to be considered at the meeting deliver to the Company a written demand stating the purposes of the special meeting and a certified check in the amount of $50,000.00.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">This provision may make it harder for our shareholders to call special meetings without the consent of the Board of Directors of the Company. </font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Undesignated Preferred Stock</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Our Board of Directors has the ability to designate and issue preferred stock without shareholder approval, and such preferred stock could have voting or other rights or preferences that could deter hostile takeovers or delay changes in control.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">No Cumulative Voting</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Our Charter and Bylaws do not allow shareholders to cumulate votes for the election of directors, which may have the effect of deterring our shareholder&#8217;s ability to replace incumbent directors serving on the Board of Directors.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Tennessee Anti-Takeover Statutes</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">In addition to the Charter and Bylaws provisions discussed above, Tennessee has adopted a series of statutes which can have an anti-takeover effect and may delay or prevent a tender offer or takeover attempt that a shareholder might consider in its best interest, including those attempts that might result in a premium over the market price for our capital stock.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Tennessee Business Combination Act </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Tennessee Business Combination Act (the &#8220;TBCA&#8221;) governs all Tennessee corporations. It imposes a five-year standstill on transactions such as mergers, share exchanges, sales of assets, liquidations and other interested party transactions between Tennessee corporations and &#8220;interested shareholders&#8221; and their associates or affiliates, unless the business combination is approved by the board of directors before the interested shareholder goes above the 10% ownership threshold. Thereafter, the transaction either requires a two-thirds vote of the shareholders other than the interested shareholder or satisfaction of certain fair price standards.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The TBCA also provides for additional exculpatory protection for the board of directors in resisting mergers, exchanges and tender offers if a Tennessee corporation&#8217;s charter specifically opts-in to such provisions. In particular, a Tennessee corporation&#8217;s charter may specifically authorize the members of a board of directors, in the exercise of their judgment, to give due consideration to factors other than price and to consider whether a merger, exchange, tender offer or significant disposition of assets would adversely affect the corporation&#8217;s employees, customers, suppliers, the communities in which the corporation operates, or any other relevant factor in the exercise of their fiduciary duty to the shareholders.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our Charter currently does not opt-in to the additional exculpation provisions available under the TBCA. In the future, if we amend our Charter to opt-in to such provisions, it could have the effect of protecting our management and Board of Directors from hostile takeover bids.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Tennessee Control Share Acquisition Act</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Tennessee Control Share Acquisition Act (the &#8220;TCSA&#8221;) limits the voting rights of shares owned by a person above certain percentage thresholds, unless the non-interested shareholders of the corporation approve the acquisition above the designated threshold. However, the TCSA only applies to corporations whose charter or bylaws contain an express declaration that control share acquisitions are to be governed by the TCSA. In addition, the charter or bylaws must specifically provide for the redemption of control shares or appraisal rights for dissenting shareholders in a control share transaction. Neither our Charter nor our Bylaws make the express declarations necessary to opt into the TCSA. In the future, if we amend our Bylaws or our Charter to opt into the TCSA, it will have the general effect of discouraging, or rendering more difficult, acquisition attempts.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Tennessee Investor Protection Act</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The Tennessee Investor Protection Act (&#8220;TIPA&#8221;) generally requires the registration, or an exemption from registration, before a person can make a tender offer for shares of a Tennessee corporation which, if successful, will result in the offeror beneficially owning more than 10% of any class of shares. Registration requires the filing with the Tennessee Commissioner of Commerce and Insurance of a registration statement, a copy of which must be sent to the target company, and the public disclosure of the material terms of the proposed offer. Additional requirements are imposed under that act if the offeror beneficially owns 5% or more of any class of equity securities of the target company, any of which was purchased within one year prior to the proposed takeover offer. TIPA also prohibits fraudulent and deceptive practices in connection with takeover offers, and provides remedies for violations.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">TIPA does not apply to an offer involving a vote by holders of equity securities of the offeree company, pursuant to its charter, on a share exchange, consolidation or sale of corporate assets in consideration of the issuance of securities of another corporation, or on a sale of its securities in exchange for cash or securities of another corporation. Also exempt from TIPA are tender offers which are open on substantially equal terms to all shareholders, are recommended by the board of directors of the target company, and include full disclosure of all terms.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Tennessee Greenmail Act</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The Tennessee Greenmail Act (&#8220;TGA&#8221;) prohibits us from purchasing or agreeing to purchase any of our securities, at a price higher than fair market value, from a holder of 3% or more of any class of its securities who has beneficially owned the securities for less than two years. We can, however, make this purchase if the majority of the outstanding shares of each class of voting stock issued by us approves the purchase or if we make an offer of at least equal value per share to all holders of shares of the same class of securities as those held by the prospective seller.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>3
<FILENAME>ex-1011ajkazimix202310k.htm
<DESCRIPTION>EX-10.11
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="id80db5b5908c411a81f0d889d6ab9d46_40"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 10.11</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Effective January 1, 2024</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.J. Kazimi</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1600 West End Avenue, Suite 1300</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nashville, TN 37203</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Re&#58;&#160;&#160;&#160;&#160;Employment of  A.J. Kazimi, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Dear A.J., </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Effective January 1, 2024, this agreement (the &#8220;Agreement&#8221;) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;). In consideration of your appointment as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Company, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation&#47;Benefits.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  The Company agrees to compensate you as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;The Company will pay you an annual salary for services performed of seven hundred two thousand dollars ($702,000.00), in accordance with the Company&#8217;s payroll practices.  Currently, employees are paid in equal monthly installments payable in arrears on the 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> day of each calendar month.  For each year hereof any adjustments to your annual salary will be determined by the Company in its sole discretion&#59; provided, however, that any obligation to make payments under this Section 1(a) will cease effective upon termination of your employment for any reason.  Notwithstanding the foregoing, nothing in this Section 1(a) alters or is intended to alter the at-will nature of your employment as described in Section 3 of this Agreement.  All payments to you under this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;You will be eligible to participate in any Company-wide employee benefits, including vacation and holiday time, as approved by the Board of Directors.  The terms of your eligibility and participation will be governed by the provisions of the employee benefit plans and arrangements as such plans or arrangements may be amended from time to time in the discretion of the Company's Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;You will be eligible to participate in a Company bonus program(s). Bonuses are based upon a combination of your performance in meeting your assigned responsibilities and objectives and the Company&#8217;s overall performance in meeting its annual objectives, as determined and approved by the Board of Directors of the Company.  Any such bonus will be discretionary and will be subject to the terms of the applicable bonus program, the terms of which program may be modified from year to year in the sole discretion of the Company&#8217;s Board of Directors.  Bonuses are paid only to those employed by the Company on the day bonuses are provided.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;You  will also receive a grant of Cumberland Pharmaceuticals common stock, pursuant to a stock option agreement (&#8220;SOA&#8221;).  Such shares will be subject to the SOA and the terms set forth in the incentive compensation plan under which they are awarded.  You may, at the Company&#8217;s sole discretion, receive additional awards of Company equity, which will be subject to their designated agreements and the incentive compensation plans under which they are awarded.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Place of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  You will perform your duties under this Agreement principally from one of the following (check as applicable)&#58;  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">   X   Company headquarters in Nashville, Tennessee or</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">____ Remotely from your home address shown above</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You understand that remote work requires reliable internet access, use of approved Company equipment, the performance of services and availability during business hours, a quiet place to work, and adherence to all of the Company&#8217;s policies and practices when working remotely.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Duties and Conflicts of Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  You will have such duties and responsibilities typically associated with your position and as may be assigned from time to time by your supervisor.  You are hired with the understanding that the Company is your sole employer and you will provide a full-time work effort. You will diligently devote your entire professional and business-related time and best efforts to the services required of you by the express and implicit terms of this Agreement, to the reasonable satisfaction of the Company in its sole and complete discretion. You agree to comply with the Company&#8217;s policies and practices applicable to employees that are in effect from time to time. Engaging in activities outside of work that create a conflict of interest, or detract from your ability to perform your assigned duties and responsibilities or meet your assigned goals and objectives with the Company, is a problem and may lead to disciplinary action up to and including termination of your employment.  If you believe that you are potentially involved in a situation that could create a conflict of interest and affect your ability to adequately perform your job with&#160;the Company, you should immediately inform your direct supervisor and the Company&#8217;s Human Resources Department.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. During the term of this Agreement, you willl be entitled to receive prompt reimbursement for all reasonable and documented expenses approved in advance by the Company and incurred in the performance of your employment in accordance with the expense reimbursement policy of the Company.  Such reimbursement policy requires adequate and satisfactory documentation from you of all expenses and submission within a reasonable period after the close of the applicable calendar month.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Employment at Will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement is not intended to and shall not be understood in any manner as affecting or modifying the at-will status of your employment with the Company. You are an at-will employee.  Either you or the Company may terminate your employment relationship at any time with or without cause or notice.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> 6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All knowledge and information, not already available to the public, which you acquire, have acquired, or will acquire in the course of your employment with the Company with respect to the Company&#8217;s business, including but not limited to, financial information, customers, vendors, licensees, work methods, data, all papers, resumes, and records (including computer records) and&#47;or regulatory matters, or other Company matters that are treated by the Company as confidential or as trade secrets, shall be referred to as (&#8220;Confidential Information&#8221;) and shall be treated by you as strictly confidential.  Such Confidential Information shall not either directly or indirectly be used, disclosed, or made accessible to anyone by you for any purpose, except in the ordinary course of the Company&#8217;s business under circumstances in which you are authorized to use or disclose such information. You agree to not use or disclose Confidential Information outside of those you are authorized to make in the regular and ordinary course of your duties unless and until you receive prior written permission of the Board of Directors of the Company to make such disclosure.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Discoveries and Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  During the time that you are employed by the Company, all Confidential Information, trade secrets, or proprietary information and all other discoveries, inventions, software programs, processes, methods and improvements that are conceived, developed, or otherwise made by you, alone or with others, that relate in any way to the Company&#8217;s present or planned business or products (collectively the &#8220;Developments&#8221;), whether or not patentable or subject to copyright protection and whether or not reduced to tangible form or reduced to practice, shall be the sole property of the Company. You agree to disclose all Developments promptly, fully and in writing to the Company.  You agree to keep and maintain adequate and current dated and witnessed written records of all such Developments, in the form of notes, sketches, drawings, or reports, which records shall be promptly submitted to the Company and shall be and remain the property of the Company at all times.  You agree to assign, and hereby do assign, to, the Company all your right, title and interest throughout the world in and to all Developments.  You agree that all Developments shall constitute &#8220;Works for Hire&#8221; (as such are defined under the U.S. Copyright Laws) and you hereby assign to the Company, and will execute assignment documents of all copyrights, patents and other proprietary rights you may have in any Developments without any obligation on the part of the Company to pay royalties or any other consideration to you for such Developments.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All documents and other writings produced by you during the term of your employment, which relate to work you are doing or have done for the Company or to the business of the Company or its Affiliates (as defined below) shall belong to the Company. You will not publish outside of the Company any such writing without the prior written consent of the Board of Directors. You will, without further compensation, execute at any time (whether or not you are still employed by the Company) all documents requested of you relating to the protection of such rights, including the assignment of such rights to the Company.  The term &#8220;Affiliate&#8221; shall mean the Company and any entity controlling, controlled by, or under common control with the Company. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Litigation and Regulatory Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  You shall give Notice to the Company within three (3) business days pursuant to Section 15 of this Agreement if you are no longer employed and immediately if you are still employed by the Company if you are contacted by any person relating to any claim or litigation against the Company.  During and after your employment, you shall cooperate fully with the Company in the defense or prosecution of any claims or actions now in existence or that may be brought in the future against or on behalf of the Company that relate to events or occurrences that transpired while you were employed by the Company. Your full cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times.  During and after you employment, you shall also cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority to the extent any any such investigation or review relates to events or occurrences that transpired while you were employed by the Company. The Company shall reimburse you for any reasonable out-of-pocket expenses incurred in connection with your performance of obligations pursuant to this Section&#160;9.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.   </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;For so long as you are employed by the Company or any Affiliate and for a period of one (1) year after you cease to be employed by the Company or any Affiliate, you shall not, within the Territory (as defined below), directly or indirectly, engage in any work or other activity--whether as owner, stockholder, partner, officer, consultant, or otherwise--involving a trademark, product, or process that, in the opinion of the Company&#8217;s Board of Directors, is  similar to a trademark, product or process on which you worked for the Company (or any Affiliate) or obtained knowledge about while working for the Company at any time during the period of employment, if such work or other activity is then, or reasonably expected to become, competitive with that of the Company or any Affiliate </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;In recognition of the broad geographic scope of the Company and of the ease of competing with the Company from any location throughout the United States, the restrictions in this Section 10 are intended to cover the following geographic areas (collectively, the &#8220;Territory&#8221;)&#58; (a) the United States&#59; and, (b) each state in the United States where the Company conducted the Business during the term of my employment. If a court determines that the Territory described above in clause (a) is too restrictive, then the parties agree that the Territory shall be the area specified in clause (b). If the court determines that all of the areas mentioned above are too restrictive, then the parties agree the court may reduce or limit the area to enable the intent of this Section 10 to be enforced in the largest acceptable area.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;The restrictions in this Section 10 shall not apply if you have disclosed to the Company in writing all the known facts relating to such work or activity and have received a release in writing from the Board of Directors allowing you to engage in such work or activity. The Company&#8217;s Board of Directors shall have sole discretion to determine whether your work or activity for another employer involves trademarks, products, or processes that are similar to trademarks, products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or less of the outstanding shares of stock of any company either (i) listed on a national securities exchange, or (ii) having at least one hundred (100) stockholders shall not make you a &#8220;stockholder&#8221; within the meaning of that term as used in this paragraph.  For one year after you cease to work for the Company, you will not engage in any work or activity that will cause you to inevitably disclose to anyone not employed by the Company or an Affiliate any trade secret or confidential information that belongs to the Company or one of its Affiliates.   Nothing in this paragraph shall limit the rights or remedies of the Company arising, directly or indirectly, from such competitive employment, including, without limitation, claims based upon breach of fiduciary duty, misappropriation, or theft of confidential information. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;By executing this Agreement, you acknowledge that you understand that the restrictions set forth in this Section 10 and in Section 11 of this Agreement are intended to protect the Company&#8217;s interest in its Confidential Information, including its trade secrets, and established employee, customer, and supplier relationships and goodwill, and you agree that such restrictions are reasonable and appropriate for this purpose.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  For a period of one year after you cease to be employed by the Company (or a Company Affiliate) you agree (a) not to solicit, directly or indirectly, business related to the development or sales of pharmaceutical products from any entity, organization, or person which is contracted with the Company, has been doing business with the Company, or from which the Company was soliciting at the time of your termination, or a firm which you knew or had reason to know that the Company was going to solicit business at the time you ceased to be employed by the Company. The restriction set forth in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such solicitation and have received a release in writing from the Board of Directors of the Company to engage in such solicitation and (b) not to solicit, recruit, hire, or assist in the hiring of any employee of the Company to work for you or another person, firm, corporation, or business in competition with, or reasonably likely to become in competition with, the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Conflicting Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  You represent and warrant that you are not now under any obligation resulting from any contract or arrangement, to any person, firm, or corporation, which is inconsistent or in conflict with this Agreement or which would prevent, limit, or impair in any way the performance by you of your obligations to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Return of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All documents, records, data, apparatus, equipment and other physical property, whether or not pertaining to Confidential Information, that are furnished to you by the Company or are produced by you in connection with your employment with the Company will be and remain the sole property of the Company. You shall return to the Company all such materials and property immediately upon termination of employment or upon request by the Company for any reason.  You shall not retain with you any such material or property or any copies after termination of your employment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  You acknowledge that in the event of breach of this Agreement by you, actual damages to the Company will be difficult to calculate, the Company will suffer irreparable harm, and that in any event money damages would be an inadequate remedy for any such breach.  Therefore, you agree that any of the covenants contained in this Agreement may be specifically enforced through injunctive relief, but such right to injunctive relief shall not preclude the Company from other remedies which may be available to it. You further agree that should you fail to keep any of the promises made by you in this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all monies the Company is required to spend, including attorneys&#8217; fees, to enforce the provisions of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Debarment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  You represent and warrant that you have not been debarred, suspended or proposed for debarment or excluded from participation in any state or federal program or under the Food, Drug and Cosmetic Act and will notify the Company immediately of possible suspension or disbarment.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any notice required or permitted to be given under this Agreement shall be sent in writing by registered or certified mail to your residence or to the Company at the address on this letterhead, Attention&#58; Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver&#47;Entire Agreement&#47;Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The waiver by either party of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach. This Agreement contains the entire agreement of the parties. This Agreement may be amended or modified only by a written agreement signed by you and by a duly authorized representative of the Company.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Governance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement shall be governed by the laws of the State of Tennessee.  Any dispute arising out of this Agreement shall be resolved, at the Company&#8217;s sole option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In the event that any provision of this Agreement shall be held by a court to be unenforceable, such provision will be enforced to the maximum extent permissible, and the remaining portions of this Agreement shall remain in full force and effect.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Notwithstanding any termination of your employment, this Agreement shall survive and remain in effect in accordance with its terms. The obligations of Sections 6, 7, 8,  9, 10, 11 and 12 shall survive the termination of our employment relationship or of this Agreement. This Agreement may be signed in one or more counterparts, each of which shall be an original and all of which will constitute one and the same instrument.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">                                                             Sincerely yours,</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">                                                             CUMBERLAND PHARMACEUTICALS INC.</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:202.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;_</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Todd Anthony</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">_</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">_____________________&#160;&#160;&#160;&#160;Todd Anthony, VP, Organizational Development</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accepted as to all terms and conditions</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as of the 8th of March 2024&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Sign here&#58;____</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; A. J. Kazimi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">______________</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Print name&#58; __</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">A.J. Kazimi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">_________________</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>4
<FILENAME>ex-1012jimhermanx202310k.htm
<DESCRIPTION>EX-10.12
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i384e200db32942bb97accba6a7431458_62"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 10.12</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Effective January 1, 2024</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">James &#8220;Jim&#8221; Herman</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">430 Brentwood Oaks Drive</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nashville, TN 37211</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Re&#58;&#160;&#160;&#160;&#160;Employment of James Herman,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%"> Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Vice President National Accounts, Chief Compliance Officer</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Dear Jim, </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Effective January 1, 2024, this agreement (the &#8220;Agreement&#8221;) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;). In consideration of your appointment as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Executive Vice President National Accounts, Chief Compliance Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Company, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation&#47;Benefits.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  The Company agrees to compensate you as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;The Company will pay you an annual salary for services performed of three hundred ten thousand dollars ($310,000.00), in accordance with the Company&#8217;s payroll practices.  Currently, employees are paid in equal monthly installments payable in arrears on the 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> day of each calendar month.  For each year hereof any adjustments to your annual salary will be determined by the Company in its sole discretion&#59; provided, however, that any obligation to make payments under this Section 1(a) will cease effective upon termination of your employment for any reason.  Notwithstanding the foregoing, nothing in this Section 1(a) alters or is intended to alter the at-will nature of your employment as described in Section 3 of this Agreement.  All payments to you under this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;You will be eligible to participate in any Company-wide employee benefits, including vacation and holiday time, as approved by the Board of Directors.  The terms of your eligibility and participation will be governed by the provisions of the employee benefit plans and arrangements as such plans or arrangements may be amended from time to time in the discretion of the Company's Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;You will be eligible to participate in a Company bonus program(s). Bonuses are based upon a combination of your performance in meeting your assigned responsibilities and objectives and the Company&#8217;s overall performance in meeting its annual objectives, as determined and approved by the Board of Directors of the Company.  Any such bonus will be discretionary and will be subject to the terms of the applicable bonus program, the terms of which program may be modified from year to year in the sole discretion of the Company&#8217;s Board of Directors.  Bonuses are paid only to those employed by the Company on the day bonuses are provided.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;You  will also receive a grant of Cumberland Pharmaceuticals common stock, pursuant to a stock option agreement (&#8220;SOA&#8221;).  Such shares will be subject to the SOA and the terms set forth in the incentive compensation plan under which they are awarded.  You may, at the Company&#8217;s sole discretion, receive additional awards of Company equity, which will be subject to their designated agreements and the incentive compensation plans under which they are awarded.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Place of Employment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  You will perform your duties under this Agreement principally from one of the following (check as applicable)&#58;  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> X</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">   Company headquarters in Nashville, Tennessee or</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">____ Remotely from your home address shown above</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You understand that remote work requires reliable internet access, use of approved Company equipment, the performance of services and availability during business hours, a quiet place to work, and adherence to all of the Company&#8217;s policies and practices when working remotely.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Duties and Conflicts of Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  You will have such duties and responsibilities typically associated with your position and as may be assigned from time to time by your supervisor.  You are hired with the understanding that the Company is your sole employer and you will provide a full-time work effort. You will diligently devote your entire professional and business-related time and best efforts to the services required of you by the express and implicit terms of this Agreement, to the reasonable satisfaction of the Company in its sole and complete discretion. You agree to comply with the Company&#8217;s policies and practices applicable to employees that are in effect from time to time. Engaging in activities outside of work that create a conflict of interest, or detract from your ability to perform your assigned duties and responsibilities or meet your assigned goals and objectives with the Company, is a problem and may lead to disciplinary action up to and including termination of your employment.  If you believe that you are potentially involved in a situation that could create a conflict of interest and affect your ability to adequately perform your job with&#160;the Company, you should immediately inform your direct supervisor and the Company&#8217;s Human Resources Department.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. During the term of this Agreement, you willl be entitled to receive prompt reimbursement for all reasonable and documented expenses approved in advance by the Company and incurred in the performance of your employment in accordance with the expense reimbursement policy of the Company.  Such reimbursement policy requires adequate and satisfactory documentation from you of all expenses and submission within a reasonable period after the close of the applicable calendar month.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Employment at Will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement is not intended to and shall not be understood in any manner as affecting or modifying the at-will status of your employment with the Company. You are an at-will employee.  Either you or the Company may terminate your employment relationship at any time with or without cause or notice.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> 6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All knowledge and information, not already available to the public, which you acquire, have acquired, or will acquire in the course of your employment with the Company with respect to the Company&#8217;s business, including but not limited to, financial information, customers, vendors, licensees, work methods, data, all papers, resumes, and records (including computer records) and&#47;or regulatory matters, or other Company matters that are treated by the Company as confidential or as trade secrets, shall be referred to as (&#8220;Confidential Information&#8221;) and shall be treated by you as strictly confidential.  Such Confidential Information shall not either directly or indirectly be used, disclosed, or made accessible to anyone by you for any purpose, except in the ordinary course of the Company&#8217;s business under circumstances in which you are authorized to use or disclose such information. You agree to not use or disclose Confidential Information outside of those you are authorized to make in the regular and ordinary course of your duties unless and until you receive prior written permission of the Chief Executive Officer of the Company to make such disclosure.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Discoveries and Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  During the time that you are employed by the Company, all Confidential Information, trade secrets, or proprietary information and all other discoveries, inventions, software programs, processes, methods and improvements that are conceived, developed, or otherwise made by you, alone or with others, that relate in any way to the Company&#8217;s present or planned business or products (collectively the &#8220;Developments&#8221;), whether or not patentable or subject to copyright protection and whether or not reduced to tangible form or reduced to practice, shall be the sole property of the Company. You agree to disclose all Developments promptly, fully and in writing to the Company.  You agree to keep and maintain adequate and current dated and witnessed written records of all such Developments, in the form of notes, sketches, drawings, or reports, which records shall be promptly submitted to the Company and shall be and remain the property of the Company at all times.  You agree to assign, and hereby do assign, to, the Company all your right, title and interest throughout the world in and to all Developments.  You agree that all Developments shall constitute &#8220;Works for Hire&#8221; (as such are defined under the U.S. Copyright Laws) and you hereby assign to the Company, and will execute assignment documents of all copyrights, patents and other proprietary rights you may have in any Developments without any obligation on the part of the Company to pay royalties or any other consideration to you for such Developments.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All documents and other writings produced by you during the term of your employment, which relate to work you are doing or have done for the Company or to the business of the Company or its Affiliates (as defined below) shall belong to the Company. You will not publish outside of the Company any such writing without the prior written consent of the Chief Commercial Officer. You will, without further compensation, execute at any time (whether or not you are still employed by the Company) all documents requested of you relating to the protection of such rights, including the assignment of such rights to the Company.  The term &#8220;Affiliate&#8221; shall mean the Company and any entity controlling, controlled by, or under common control with the Company. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Litigation and Regulatory Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  You shall give Notice to the Company within three (3) business days pursuant to Section 15 of this Agreement if you are no longer employed and immediately if you are still employed by the Company if you are contacted by any person relating to any claim or litigation against the Company.  During and after your employment, you shall cooperate fully with the Company in the defense or prosecution of any claims or actions now in existence or that may be brought in the future against or on behalf of the Company that relate to events or occurrences that transpired while you were employed by the Company. Your full cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times.  During and after you employment, you shall also cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority to the extent any any such investigation or review relates to events or occurrences that transpired while you were employed by the Company. The Company shall reimburse you for any reasonable out-of-pocket expenses incurred in connection with your performance of obligations pursuant to this Section&#160;9.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.   </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;For so long as you are employed by the Company or any Affiliate and for a period of one (1) year after you cease to be employed by the Company or any Affiliate, you shall not, within the Territory (as defined below), directly or indirectly, engage in any work or other activity--whether as owner, stockholder, partner, officer, consultant, or otherwise--involving a trademark, product, or process that, in the opinion of the Company&#8217;s Chief Executive Officer, is  similar to a trademark, product or process on which you worked for the Company (or any Affiliate) or obtained knowledge about while working for the Company at any time during the period of employment, if such work or other activity is then, or reasonably expected to become, competitive with that of the Company or any Affiliate </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;In recognition of the broad geographic scope of the Company and of the ease of competing with the Company from any location throughout the United States, the restrictions in this Section 10 are intended to cover the following geographic areas (collectively, the &#8220;Territory&#8221;)&#58; (a) the United States&#59; and, (b) each state in the United States where the Company conducted the Business during the term of my employment. If a court determines that the Territory described above in clause (a) is too restrictive, then the parties agree that the Territory shall be the area specified in clause (b). If the court determines that all of the areas mentioned above are too restrictive, then the parties agree the court may reduce or limit the area to enable the intent of this Section 10 to be enforced in the largest acceptable area.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;The restrictions in this Section 10 shall not apply if you have disclosed to the Company in writing all the known facts relating to such work or activity and have received a release in writing from the Chief Commercial Officer allowing you to engage in such work or activity. The Company&#8217;s Chief Executive Officer shall have sole discretion to determine whether your work or activity for another employer involves trademarks, products, or processes that are similar to trademarks, products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or less of the outstanding shares of stock of any company either (i) listed on a national securities exchange, or (ii) having at least one hundred (100) stockholders shall not make you a &#8220;stockholder&#8221; within the meaning of that term as used in this paragraph.  For one year after you cease to work for the Company, you will not engage in any work or activity that will cause you to inevitably disclose to anyone not employed by the Company or an Affiliate any trade secret or confidential information that belongs to the Company or one of its Affiliates.   Nothing in this paragraph shall limit the rights or remedies of the Company arising, directly or indirectly, from such competitive employment, including, without limitation, claims based upon breach of fiduciary duty, misappropriation, or theft of confidential information. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;By executing this Agreement, you acknowledge that you understand that the restrictions set forth in this Section 10 and in Section 11 of this Agreement are intended to protect the Company&#8217;s interest in its Confidential Information, including its trade secrets, and established employee, customer, and supplier relationships and goodwill, and you agree that such restrictions are reasonable and appropriate for this purpose.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  For a period of one year after you cease to be employed by the Company (or a Company Affiliate) you agree (a) not to solicit, directly or indirectly, business related to the development or sales of pharmaceutical products from any entity, organization, or person which is contracted with the Company, has been doing business with the Company, or from which the Company was soliciting at the time of your termination, or a firm which you knew or had reason to know that the Company was going to solicit business at the time you ceased to be employed by the Company. The restriction set forth in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such solicitation and have received a release in writing from the Chief Executive Officer of the Company to engage in such solicitation and (b) not to solicit, recruit, hire, or assist in the hiring of any employee of the Company to work for you or another person, firm, corporation, or business in competition with, or reasonably likely to become in competition with, the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Conflicting Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  You represent and warrant that you are not now under any obligation resulting from any contract or arrangement, to any person, firm, or corporation, which is inconsistent or in conflict with this Agreement or which would prevent, limit, or impair in any way the performance by you of your obligations to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Return of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All documents, records, data, apparatus, equipment and other physical property, whether or not pertaining to Confidential Information, that are furnished to you by the Company or are produced by you in connection with your employment with the Company will be and remain the sole property of the Company. You shall return to the Company all such materials and property immediately upon termination of employment or upon request by the Company for any reason.  You shall not retain with you any such material or property or any copies after termination of your employment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  You acknowledge that in the event of breach of this Agreement by you, actual damages to the Company will be difficult to calculate, the Company will suffer irreparable harm, and that in any event money damages would be an inadequate remedy for any such breach.  Therefore, you agree that any of the covenants contained in this Agreement may be specifically enforced through injunctive relief, but such right to injunctive relief shall not preclude the Company from other remedies which may be available to it. You further agree that should you fail to keep any of the promises made by you in this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all monies the Company is required to spend, including attorneys&#8217; fees, to enforce the provisions of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Debarment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  You represent and warrant that you have not been debarred, suspended or proposed for debarment or excluded from participation in any state or federal program or under the Food, Drug and Cosmetic Act and will notify the Company immediately of possible suspension or disbarment.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any notice required or permitted to be given under this Agreement shall be sent in writing by registered or certified mail to your residence or to the Company at the address on this letterhead, Attention&#58; Chief Executive Officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver&#47;Entire Agreement&#47;Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The waiver by either party of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach. This Agreement contains the entire agreement of the parties. This Agreement may be amended or modified only by a written agreement signed by you and by a duly authorized representative of the Company.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Governance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement shall be governed by the laws of the State of Tennessee.  Any dispute arising out of this Agreement shall be resolved, at the Company&#8217;s sole option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In the event that any provision of this Agreement shall be held by a court to be unenforceable, such provision will be enforced to the maximum extent permissible, and the remaining portions of this Agreement shall remain in full force and effect.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Notwithstanding any termination of your employment, this Agreement shall survive and remain in effect in accordance with its terms. The obligations of Sections 6, 7, 8,  9, 10, 11 and 12 shall survive the termination of our employment relationship or of this Agreement. This Agreement may be signed in one or more counterparts, each of which shall be an original and all of which will constitute one and the same instrument.</font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Sincerely yours,</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> CUMBERLAND PHARMACEUTICALS INC.</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;__</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47;A.J. Kazimi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">______________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;A.J. Kazimi, Chief Executive Officer</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accepted as to all terms and conditions</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as of the 8th of March 2024&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Sign here&#58;__</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47;Jim Herman</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">_______________________</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Print name&#58; __</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Jim Herman</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">_______________________</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>5
<FILENAME>ex-1013toddanthonyx202310k.htm
<DESCRIPTION>EX-10.13
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i2b0b156f5cd0497a977eca93d0a18f9a_40"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 10.13</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Effective January 1, 2024</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Todd Anthony</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">702 Meeting Street</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Franklin, TN 37064</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Re&#58;&#160;&#160;&#160;&#160;Employment of Todd Anthony, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Vice President Organizational Development</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Dear Todd, </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Effective January 1, 2024, this agreement (the &#8220;Agreement&#8221;) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;). In consideration of your appointment as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Vice President Organizational Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Company, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation&#47;Benefits.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  The Company agrees to compensate you as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;The Company will pay you an annual salary for services performed of two hundred eighty-six thousand one hundred twenty-five dollars ($286,125.00), in accordance with the Company&#8217;s payroll practices.  Currently, employees are paid in equal monthly installments payable in arrears on the 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> day of each calendar month.  For each year hereof any adjustments to your annual salary will be determined by the Company in its sole discretion&#59; provided, however, that any obligation to make payments under this Section 1(a) will cease effective upon termination of your employment for any reason.  Notwithstanding the foregoing, nothing in this Section 1(a) alters or is intended to alter the at-will nature of your employment as described in Section 3 of this Agreement.  All payments to you under this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;You will be eligible to participate in any Company-wide employee benefits, including vacation and holiday time, as approved by the Board of Directors.  The terms of your eligibility and participation will be governed by the provisions of the employee benefit plans and arrangements as such plans or arrangements may be amended from time to time in the discretion of the Company's Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;You will be eligible to participate in a Company bonus program(s). Bonuses are based upon a combination of your performance in meeting your assigned responsibilities and objectives and the Company&#8217;s overall performance in meeting its annual objectives, as determined and approved by the Board of Directors of the Company.  Any such bonus will be discretionary and will be subject to the terms of the applicable bonus program, the terms of which program may be modified from year to year in the sole discretion of the Company&#8217;s Board of Directors.  Bonuses are paid only to those employed by the Company on the day bonuses are provided.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;You  will also receive a grant of Cumberland Pharmaceuticals common stock, pursuant to a stock option agreement (&#8220;SOA&#8221;).  Such shares will be subject to the SOA and the terms set forth in the incentive compensation plan under which they are awarded.  You may, at the Company&#8217;s sole discretion, receive additional awards of Company equity, which will be subject to their designated agreements and the incentive compensation plans under which they are awarded.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Place of Employment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  You will perform your duties under this Agreement principally from one of the following (check as applicable)&#58;  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">   X   Company headquarters in Nashville, Tennessee or</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">____ Remotely from your home address shown above</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You understand that remote work requires reliable internet access, use of approved Company equipment, the performance of services and availability during business hours, a quiet place to work, and adherence to all of the Company&#8217;s policies and practices when working remotely.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Duties and Conflicts of Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  You will have such duties and responsibilities typically associated with your position and as may be assigned from time to time by your supervisor.  You are hired with the understanding that the Company is your sole employer and you will provide a full-time work effort. You will diligently devote your entire professional and business-related time and best efforts to the services required of you by the express and implicit terms of this Agreement, to the reasonable satisfaction of the Company in its sole and complete discretion. You agree to comply with the Company&#8217;s policies and practices applicable to employees that are in effect from time to time. Engaging in activities outside of work that create a conflict of interest, or detract from your ability to perform your assigned duties and responsibilities or meet your assigned goals and objectives with the Company, is a problem and may lead to disciplinary action up to and including termination of your employment.  If you believe that you are potentially involved in a situation that could create a conflict of interest and affect your ability to adequately perform your job with&#160;the Company, you should immediately inform your direct supervisor and the Company&#8217;s Human Resources Department.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. During the term of this Agreement, you willl be entitled to receive prompt reimbursement for all reasonable and documented expenses approved in advance by the Company and incurred in the performance of your employment in accordance with the expense reimbursement policy of the Company.  Such reimbursement policy requires adequate and satisfactory documentation from you of all expenses and submission within a reasonable period after the close of the applicable calendar month.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Employment at Will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement is not intended to and shall not be understood in any manner as affecting or modifying the at-will status of your employment with the Company. You are an at-will employee.  Either you or the Company may terminate your employment relationship at any time with or without cause or notice.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> 6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All knowledge and information, not already available to the public, which you acquire, have acquired, or will acquire in the course of your employment with the Company with respect to the Company&#8217;s business, including but not limited to, financial information, customers, vendors, licensees, work methods, data, all papers, resumes, and records (including computer records) and&#47;or regulatory matters, or other Company matters that are treated by the Company as confidential or as trade secrets, shall be referred to as (&#8220;Confidential Information&#8221;) and shall be treated by you as strictly confidential.  Such Confidential Information shall not either directly or indirectly be used, disclosed, or made accessible to anyone by you for any purpose, except in the ordinary course of the Company&#8217;s business under circumstances in which you are authorized to use or disclose such information. You agree to not use or disclose Confidential Information outside of those you are authorized to make in the regular and ordinary course of your duties unless and until you receive prior written permission of the Chief Executive Officer of the Company to make such disclosure.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Discoveries and Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  During the time that you are employed by the Company, all Confidential Information, trade secrets, or proprietary information and all other discoveries, inventions, software programs, processes, methods and improvements that are conceived, developed, or otherwise made by you, alone or with others, that relate in any way to the Company&#8217;s present or planned business or products (collectively the &#8220;Developments&#8221;), whether or not patentable or subject to copyright protection and whether or not reduced to tangible form or reduced to practice, shall be the sole property of the Company. You agree to disclose all Developments promptly, fully and in writing to the Company.  You agree to keep and maintain adequate and current dated and witnessed written records of all such Developments, in the form of notes, sketches, drawings, or reports, which records shall be promptly submitted to the Company and shall be and remain the property of the Company at all times.  You agree to assign, and hereby do assign, to, the Company all your right, title and interest throughout the world in and to all Developments.  You agree that all Developments shall constitute &#8220;Works for Hire&#8221; (as such are defined under the U.S. Copyright Laws) and you hereby assign to the Company, and will execute assignment documents of all copyrights, patents and other proprietary rights you may have in any Developments without any obligation on the part of the Company to pay royalties or any other consideration to you for such Developments.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All documents and other writings produced by you during the term of your employment, which relate to work you are doing or have done for the Company or to the business of the Company or its Affiliates (as defined below) shall belong to the Company. You will not publish outside of the Company any such writing without the prior written consent of the Chief Commercial Officer. You will, without further compensation, execute at any time (whether or not you are still employed by the Company) all documents requested of you relating to the protection of such rights, including the assignment of such rights to the Company.  The term &#8220;Affiliate&#8221; shall mean the Company and any entity controlling, controlled by, or under common control with the Company. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Litigation and Regulatory Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  You shall give Notice to the Company within three (3) business days pursuant to Section 15 of this Agreement if you are no longer employed and immediately if you are still employed by the Company if you are contacted by any person relating to any claim or litigation against the Company.  During and after your employment, you shall cooperate fully with the Company in the defense or prosecution of any claims or actions now in existence or that may be brought in the future against or on behalf of the Company that relate to events or occurrences that transpired while you were employed by the Company. Your full cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times.  During and after you employment, you shall also cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority to the extent any any such investigation or review relates to events or occurrences that transpired while you were employed by the Company. The Company shall reimburse you for any reasonable out-of-pocket expenses incurred in connection with your performance of obligations pursuant to this Section&#160;9.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.   </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;For so long as you are employed by the Company or any Affiliate and for a period of one (1) year after you cease to be employed by the Company or any Affiliate, you shall not, within the Territory (as defined below), directly or indirectly, engage in any work or other activity--whether as owner, stockholder, partner, officer, consultant, or otherwise--involving a trademark, product, or process that, in the opinion of the Company&#8217;s Chief Executive Officer, is  similar to a trademark, product or process on which you worked for the Company (or any Affiliate) or obtained knowledge about while working for the Company at any time during the period of employment, if such work or other activity is then, or reasonably expected to become, competitive with that of the Company or any Affiliate </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;In recognition of the broad geographic scope of the Company and of the ease of competing with the Company from any location throughout the United States, the restrictions in this Section 10 are intended to cover the following geographic areas (collectively, the &#8220;Territory&#8221;)&#58; (a) the United States&#59; and, (b) each state in the United States where the Company conducted the Business during the term of my employment. If a court determines that the Territory described above in clause (a) is too restrictive, then the parties agree that the Territory shall be the area specified in clause (b). If the court determines that all of the areas mentioned above are too restrictive, then the parties agree the court may reduce or limit the area to enable the intent of this Section 10 to be enforced in the largest acceptable area.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;The restrictions in this Section 10 shall not apply if you have disclosed to the Company in writing all the known facts relating to such work or activity and have received a release in writing from the Chief Commercial Officer allowing you to engage in such work or activity. The Company&#8217;s Chief Executive Officer shall have sole discretion to determine whether your work or activity for another employer involves trademarks, products, or processes that are similar to trademarks, products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or less of the outstanding shares of stock of any company either (i) listed on a national securities exchange, or (ii) having at least one hundred (100) stockholders shall not make you a &#8220;stockholder&#8221; within the meaning of that term as used in this paragraph.  For one year after you cease to work for the Company, you will not engage in any work or activity that will cause you to inevitably disclose to anyone not employed by the Company or an Affiliate any trade secret or confidential information that belongs to the Company or one of its Affiliates.   Nothing in this paragraph shall limit the rights or remedies of the Company arising, directly or indirectly, from such competitive employment, including, without limitation, claims based upon breach of fiduciary duty, misappropriation, or theft of confidential information. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;By executing this Agreement, you acknowledge that you understand that the restrictions set forth in this Section 10 and in Section 11 of this Agreement are intended to protect the Company&#8217;s interest in its Confidential Information, including its trade secrets, and established employee, customer, and supplier relationships and goodwill, and you agree that such restrictions are reasonable and appropriate for this purpose.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  For a period of one year after you cease to be employed by the Company (or a Company Affiliate) you agree (a) not to solicit, directly or indirectly, business related to the development or sales of pharmaceutical products from any entity, organization, or person which is contracted with the Company, has been doing business with the Company, or from which the Company was soliciting at the time of your termination, or a firm which you knew or had reason to know that the Company was going to solicit business at the time you ceased to be employed by the Company. The restriction set forth in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such solicitation and have received a release in writing from the Chief Executive Officer of the Company to engage in such solicitation and (b) not to solicit, recruit, hire, or assist in the hiring of any employee of the Company to work for you or another person, firm, corporation, or business in competition with, or reasonably likely to become in competition with, the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Conflicting Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  You represent and warrant that you are not now under any obligation resulting from any contract or arrangement, to any person, firm, or corporation, which is inconsistent or in conflict with this Agreement or which would prevent, limit, or impair in any way the performance by you of your obligations to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Return of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All documents, records, data, apparatus, equipment and other physical property, whether or not pertaining to Confidential Information, that are furnished to you by the Company or are produced by you in connection with your employment with the Company will be and remain the sole property of the Company. You shall return to the Company all such materials and property immediately upon termination of employment or upon request by the Company for any reason.  You shall not retain with you any such material or property or any copies after termination of your employment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  You acknowledge that in the event of breach of this Agreement by you, actual damages to the Company will be difficult to calculate, the Company will suffer irreparable harm, and that in any event money damages would be an inadequate remedy for any such breach.  Therefore, you agree that any of the covenants contained in this Agreement may be specifically enforced through injunctive relief, but such right to injunctive relief shall not preclude the Company from other remedies which may be available to it. You further agree that should you fail to keep any of the promises made by you in this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all monies the Company is required to spend, including attorneys&#8217; fees, to enforce the provisions of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Debarment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  You represent and warrant that you have not been debarred, suspended or proposed for debarment or excluded from participation in any state or federal program or under the Food, Drug and Cosmetic Act and will notify the Company immediately of possible suspension or disbarment.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any notice required or permitted to be given under this Agreement shall be sent in writing by registered or certified mail to your residence or to the Company at the address on this letterhead, Attention&#58; Chief Executive Officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver&#47;Entire Agreement&#47;Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The waiver by either party of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach. This Agreement contains the entire agreement of the parties. This Agreement may be amended or modified only by a written agreement signed by you and by a duly authorized representative of the Company.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Governance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement shall be governed by the laws of the State of Tennessee.  Any dispute arising out of this Agreement shall be resolved, at the Company&#8217;s sole option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In the event that any provision of this Agreement shall be held by a court to be unenforceable, such provision will be enforced to the maximum extent permissible, and the remaining portions of this Agreement shall remain in full force and effect.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Notwithstanding any termination of your employment, this Agreement shall survive and remain in effect in accordance with its terms. The obligations of Sections 6, 7, 8,  9, 10, 11 and 12 shall survive the termination of our employment relationship or of this Agreement. This Agreement may be signed in one or more counterparts, each of which shall be an original and all of which will constitute one and the same instrument.</font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Sincerely yours,</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> CUMBERLAND PHARMACEUTICALS INC.</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;__</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; A.J. Kazimi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">_____________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;A.J. Kazimi, Chief Executive Officer</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accepted as to all terms and conditions</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as of the 8th of March 2024&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Sign here&#58;__</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Todd Anthony</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">_________________________</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Print name&#58; __</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Todd Anthony</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">_________________________</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>6
<FILENAME>ex-1014chrisbittermanx2023.htm
<DESCRIPTION>EX-10.14
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i0a9fd558712f4419b0721ff5d618873a_40"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 10.14</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Effective January 1, 2024</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chris Bitterman</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">605 Press Place, Apt. 107</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nashville, TN 37208</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Re&#58;&#160;&#160;&#160;&#160;Employment of Chris Bitterman, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Vice President Sales &#38; Marketing</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Dear Chris, </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Effective January 1, 2024, this agreement (the &#8220;Agreement&#8221;) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;). In consideration of your appointment as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Vice President Sales &#38; Marketing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Company, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation&#47;Benefits.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  The Company agrees to compensate you as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;The Company will pay you an annual salary for services performed of two hundred sixty-eight thousand eight hundred forty dollars ($268,840.00), in accordance with the Company&#8217;s payroll practices.  Currently, employees are paid in equal monthly installments payable in arrears on the 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> day of each calendar month.  For each year hereof any adjustments to your annual salary will be determined by the Company in its sole discretion&#59; provided, however, that any obligation to make payments under this Section 1(a) will cease effective upon termination of your employment for any reason.  Notwithstanding the foregoing, nothing in this Section 1(a) alters or is intended to alter the at-will nature of your employment as described in Section 3 of this Agreement.  All payments to you under this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;You will be eligible to participate in any Company-wide employee benefits, including vacation and holiday time, as approved by the Board of Directors.  The terms of your eligibility and participation will be governed by the provisions of the employee benefit plans and arrangements as such plans or arrangements may be amended from time to time in the discretion of the Company's Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;You will be eligible to participate in a Company bonus program(s). Bonuses are based upon a combination of your performance in meeting your assigned responsibilities and objectives and the Company&#8217;s overall performance in meeting its annual objectives, as determined and approved by the Board of Directors of the Company.  Any such bonus will be discretionary and will be subject to the terms of the applicable bonus program, the terms of which program may be modified from year to year in the sole discretion of the Company&#8217;s Board of Directors.  Bonuses are paid only to those employed by the Company on the day bonuses are provided.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;You  will also receive a grant of Cumberland Pharmaceuticals common stock, pursuant to a stock option agreement (&#8220;SOA&#8221;).  Such shares will be subject to the SOA and the terms set forth in the incentive compensation plan under which they are awarded.  You may, at the Company&#8217;s sole discretion, receive additional awards of Company equity, which will be subject to their designated agreements and the incentive compensation plans under which they are awarded.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Place of Employment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  You will perform your duties under this Agreement principally from one of the following (check as applicable)&#58;  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">   X</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Company headquarters in Nashville, Tennessee or</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">___ Remotely from your home address shown above</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You understand that remote work requires reliable internet access, use of approved Company equipment, the performance of services and availability during business hours, a quiet place to work, and adherence to all of the Company&#8217;s policies and practices when working remotely.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Duties and Conflicts of Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  You will have such duties and responsibilities typically associated with your position and as may be assigned from time to time by your supervisor.  You are hired with the understanding that the Company is your sole employer and you will provide a full-time work effort. You will diligently devote your entire professional and business-related time and best efforts to the services required of you by the express and implicit terms of this Agreement, to the reasonable satisfaction of the Company in its sole and complete discretion. You agree to comply with the Company&#8217;s policies and practices applicable to employees that are in effect from time to time. Engaging in activities outside of work that create a conflict of interest, or detract from your ability to perform your assigned duties and responsibilities or meet your assigned goals and objectives with the Company, is a problem and may lead to disciplinary action up to and including termination of your employment.  If you believe that you are potentially involved in a situation that could create a conflict of interest and affect your ability to adequately perform your job with&#160;the Company, you should immediately inform your direct supervisor and the Company&#8217;s Human Resources Department.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. During the term of this Agreement, you willl be entitled to receive prompt reimbursement for all reasonable and documented expenses approved in advance by the Company and incurred in the performance of your employment in accordance with the expense reimbursement policy of the Company.  Such reimbursement policy requires adequate and satisfactory documentation from you of all expenses and submission within a reasonable period after the close of the applicable calendar month.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Employment at Will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement is not intended to and shall not be understood in any manner as affecting or modifying the at-will status of your employment with the Company. You are an at-will employee.  Either you or the Company may terminate your employment relationship at any time with or without cause or notice.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> 6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All knowledge and information, not already available to the public, which you acquire, have acquired, or will acquire in the course of your employment with the Company with respect to the Company&#8217;s business, including but not limited to, financial information, customers, vendors, licensees, work methods, data, all papers, resumes, and records (including computer records) and&#47;or regulatory matters, or other Company matters that are treated by the Company as confidential or as trade secrets, shall be referred to as (&#8220;Confidential Information&#8221;) and shall be treated by you as strictly confidential.  Such Confidential Information shall not either directly or indirectly be used, disclosed, or made accessible to anyone by you for any purpose, except in the ordinary course of the Company&#8217;s business under circumstances in which you are authorized to use or disclose such information. You agree to not use or disclose Confidential Information outside of those you are authorized to make in the regular and ordinary course of your duties unless and until you receive prior written permission of the Chief Executive Officer of the Company to make such disclosure.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Discoveries and Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  During the time that you are employed by the Company, all Confidential Information, trade secrets, or proprietary information and all other discoveries, inventions, software programs, processes, methods and improvements that are conceived, developed, or otherwise made by you, alone or with others, that relate in any way to the Company&#8217;s present or planned business or products (collectively the &#8220;Developments&#8221;), whether or not patentable or subject to copyright protection and whether or not reduced to tangible form or reduced to practice, shall be the sole property of the Company. You agree to disclose all Developments promptly, fully and in writing to the Company.  You agree to keep and maintain adequate and current dated and witnessed written records of all such Developments, in the form of notes, sketches, drawings, or reports, which records shall be promptly submitted to the Company and shall be and remain the property of the Company at all times.  You agree to assign, and hereby do assign, to, the Company all your right, title and interest throughout the world in and to all Developments.  You agree that all Developments shall constitute &#8220;Works for Hire&#8221; (as such are defined under the U.S. Copyright Laws) and you hereby assign to the Company, and will execute assignment documents of all copyrights, patents and other proprietary rights you may have in any Developments without any obligation on the part of the Company to pay royalties or any other consideration to you for such Developments.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All documents and other writings produced by you during the term of your employment, which relate to work you are doing or have done for the Company or to the business of the Company or its Affiliates (as defined below) shall belong to the Company. You will not publish outside of the Company any such writing without the prior written consent of the Chief Commercial Officer. You will, without further compensation, execute at any time (whether or not you are still employed by the Company) all documents requested of you relating to the protection of such rights, including the assignment of such rights to the Company.  The term &#8220;Affiliate&#8221; shall mean the Company and any entity controlling, controlled by, or under common control with the Company. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Litigation and Regulatory Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  You shall give Notice to the Company within three (3) business days pursuant to Section 15 of this Agreement if you are no longer employed and immediately if you are still employed by the Company if you are contacted by any person relating to any claim or litigation against the Company.  During and after your employment, you shall cooperate fully with the Company in the defense or prosecution of any claims or actions now in existence or that may be brought in the future against or on behalf of the Company that relate to events or occurrences that transpired while you were employed by the Company. Your full cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times.  During and after you employment, you shall also cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority to the extent any any such investigation or review relates to events or occurrences that transpired while you were employed by the Company. The Company shall reimburse you for any reasonable out-of-pocket expenses incurred in connection with your performance of obligations pursuant to this Section&#160;9.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.   </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;For so long as you are employed by the Company or any Affiliate and for a period of one (1) year after you cease to be employed by the Company or any Affiliate, you shall not, within the Territory (as defined below), directly or indirectly, engage in any work or other activity--whether as owner, stockholder, partner, officer, consultant, or otherwise--involving a trademark, product, or process that, in the opinion of the Company&#8217;s Chief Executive Officer, is  similar to a trademark, product or process on which you worked for the Company (or any Affiliate) or obtained knowledge about while working for the Company at any time during the period of employment, if such work or other activity is then, or reasonably expected to become, competitive with that of the Company or any Affiliate </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;In recognition of the broad geographic scope of the Company and of the ease of competing with the Company from any location throughout the United States, the restrictions in this Section 10 are intended to cover the following geographic areas (collectively, the &#8220;Territory&#8221;)&#58; (a) the United States&#59; and, (b) each state in the United States where the Company conducted the Business during the term of my employment. If a court determines that the Territory described above in clause (a) is too restrictive, then the parties agree that the Territory shall be the area specified in clause (b). If the court determines that all of the areas mentioned above are too restrictive, then the parties agree the court may reduce or limit the area to enable the intent of this Section 10 to be enforced in the largest acceptable area.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;The restrictions in this Section 10 shall not apply if you have disclosed to the Company in writing all the known facts relating to such work or activity and have received a release in writing from the Chief Commercial Officer allowing you to engage in such work or activity. The Company&#8217;s Chief Executive Officer shall have sole discretion to determine whether your work or activity for another employer involves trademarks, products, or processes that are similar to trademarks, products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or less of the outstanding shares of stock of any company either (i) listed on a national securities exchange, or (ii) having at least one hundred (100) stockholders shall not make you a &#8220;stockholder&#8221; within the meaning of that term as used in this paragraph.  For one year after you cease to work for the Company, you will not engage in any work or activity that will cause you to inevitably disclose to anyone not employed by the Company or an Affiliate any trade secret or confidential information that belongs to the Company or one of its Affiliates.   Nothing in this paragraph shall limit the rights or remedies of the Company arising, directly or indirectly, from such competitive employment, including, without limitation, claims based upon breach of fiduciary duty, misappropriation, or theft of confidential information. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;By executing this Agreement, you acknowledge that you understand that the restrictions set forth in this Section 10 and in Section 11 of this Agreement are intended to protect the Company&#8217;s interest in its Confidential Information, including its trade secrets, and established employee, customer, and supplier relationships and goodwill, and you agree that such restrictions are reasonable and appropriate for this purpose.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  For a period of one year after you cease to be employed by the Company (or a Company Affiliate) you agree (a) not to solicit, directly or indirectly, business related to the development or sales of pharmaceutical products from any entity, organization, or person which is contracted with the Company, has been doing business with the Company, or from which the Company was soliciting at the time of your termination, or a firm which you knew or had reason to know that the Company was going to solicit business at the time you ceased to be employed by the Company. The restriction set forth in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such solicitation and have received a release in writing from the Chief Executive Officer of the Company to engage in such solicitation and (b) not to solicit, recruit, hire, or assist in the hiring of any employee of the Company to work for you or another person, firm, corporation, or business in competition with, or reasonably likely to become in competition with, the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Conflicting Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  You represent and warrant that you are not now under any obligation resulting from any contract or arrangement, to any person, firm, or corporation, which is inconsistent or in conflict with this Agreement or which would prevent, limit, or impair in any way the performance by you of your obligations to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Return of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All documents, records, data, apparatus, equipment and other physical property, whether or not pertaining to Confidential Information, that are furnished to you by the Company or are produced by you in connection with your employment with the Company will be and remain the sole property of the Company. You shall return to the Company all such materials and property immediately upon termination of employment or upon request by the Company for any reason.  You shall not retain with you any such material or property or any copies after termination of your employment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  You acknowledge that in the event of breach of this Agreement by you, actual damages to the Company will be difficult to calculate, the Company will suffer irreparable harm, and that in any event money damages would be an inadequate remedy for any such breach.  Therefore, you agree that any of the covenants contained in this Agreement may be specifically enforced through injunctive relief, but such right to injunctive relief shall not preclude the Company from other remedies which may be available to it. You further agree that should you fail to keep any of the promises made by you in this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all monies the Company is required to spend, including attorneys&#8217; fees, to enforce the provisions of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Debarment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  You represent and warrant that you have not been debarred, suspended or proposed for debarment or excluded from participation in any state or federal program or under the Food, Drug and Cosmetic Act and will notify the Company immediately of possible suspension or disbarment.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any notice required or permitted to be given under this Agreement shall be sent in writing by registered or certified mail to your residence or to the Company at the address on this letterhead, Attention&#58; Chief Executive Officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver&#47;Entire Agreement&#47;Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The waiver by either party of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach. This Agreement contains the entire agreement of the parties. This Agreement may be amended or modified only by a written agreement signed by you and by a duly authorized representative of the Company.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Governance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement shall be governed by the laws of the State of Tennessee.  Any dispute arising out of this Agreement shall be resolved, at the Company&#8217;s sole option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In the event that any provision of this Agreement shall be held by a court to be unenforceable, such provision will be enforced to the maximum extent permissible, and the remaining portions of this Agreement shall remain in full force and effect.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Notwithstanding any termination of your employment, this Agreement shall survive and remain in effect in accordance with its terms. The obligations of Sections 6, 7, 8,  9, 10, 11 and 12 shall survive the termination of our employment relationship or of this Agreement. This Agreement may be signed in one or more counterparts, each of which shall be an original and all of which will constitute one and the same instrument.</font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Sincerely yours,</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> CUMBERLAND PHARMACEUTICALS INC.</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;__</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; A.J. Kazimi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">______________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;A.J. Kazimi, Chief Executive Officer</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accepted as to all terms and conditions</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as of the 7th of March 2024&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Sign here&#58;__</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Chris Bitterman</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">_______________________</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Print name&#58; ___</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Chris Bitterman</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">_______________________</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>7
<FILENAME>ex-1015johnhammx202310k.htm
<DESCRIPTION>EX-10.15
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i59968055bfe34bd3877d328c33c1b5d1_40"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 10.15</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Effective January 1, 2024</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">John Hamm</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1659 Kirkwood Place</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Brentwood, TN 37207</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Re&#58;&#160;&#160;&#160;&#160;Employment of John Hamm,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%"> Vice President, Chief Financial Officer</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Dear John, </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Effective January 1, 2024, this agreement (the &#8220;Agreement&#8221;) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;). In consideration of your appointment as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Vice President, Chief Financial Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Company, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation&#47;Benefits.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  The Company agrees to compensate you as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;The Company will pay you an annual salary for services performed of two hundred forty-six thousand two hundred forty dollars ($246,240.00), in accordance with the Company&#8217;s payroll practices.  Currently, employees are paid in equal monthly installments payable in arrears on the 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> day of each calendar month.  For each year hereof any adjustments to your annual salary will be determined by the Company in its sole discretion&#59; provided, however, that any obligation to make payments under this Section 1(a) will cease effective upon termination of your employment for any reason.  Notwithstanding the foregoing, nothing in this Section 1(a) alters or is intended to alter the at-will nature of your employment as described in Section 3 of this Agreement.  All payments to you under this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;You will be eligible to participate in any Company-wide employee benefits, including vacation and holiday time, as approved by the Board of Directors.  The terms of your eligibility and participation will be governed by the provisions of the employee benefit plans and arrangements as such plans or arrangements may be amended from time to time in the discretion of the Company's Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;You will be eligible to participate in a Company bonus program(s). Bonuses are based upon a combination of your performance in meeting your assigned responsibilities and objectives and the Company&#8217;s overall performance in meeting its annual objectives, as determined and approved by the Board of Directors of the Company.  Any such bonus will be discretionary and will be subject to the terms of the applicable bonus program, the terms of which program may be modified from year to year in the sole discretion of the Company&#8217;s Board of Directors.  Bonuses are paid only to those employed by the Company on the day bonuses are provided.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;You  will also receive a grant of Cumberland Pharmaceuticals common stock, pursuant to a stock option agreement (&#8220;SOA&#8221;).  Such shares will be subject to the SOA and the terms set forth in the incentive compensation plan under which they are awarded.  You may, at the Company&#8217;s sole discretion, receive additional awards of Company equity, which will be subject to their designated agreements and the incentive compensation plans under which they are awarded.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Place of Employment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  You will perform your duties under this Agreement principally from one of the following (check as applicable)&#58;  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">   X   Company headquarters in Nashville, Tennessee or</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">____ Remotely from your home address shown above</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You understand that remote work requires reliable internet access, use of approved Company equipment, the performance of services and availability during business hours, a quiet place to work, and adherence to all of the Company&#8217;s policies and practices when working remotely.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Duties and Conflicts of Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  You will have such duties and responsibilities typically associated with your position and as may be assigned from time to time by your supervisor.  You are hired with the understanding that the Company is your sole employer and you will provide a full-time work effort. You will diligently devote your entire professional and business-related time and best efforts to the services required of you by the express and implicit terms of this Agreement, to the reasonable satisfaction of the Company in its sole and complete discretion. You agree to comply with the Company&#8217;s policies and practices applicable to employees that are in effect from time to time. Engaging in activities outside of work that create a conflict of interest, or detract from your ability to perform your assigned duties and responsibilities or meet your assigned goals and objectives with the Company, is a problem and may lead to disciplinary action up to and including termination of your employment.  If you believe that you are potentially involved in a situation that could create a conflict of interest and affect your ability to adequately perform your job with&#160;the Company, you should immediately inform your direct supervisor and the Company&#8217;s Human Resources Department.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. During the term of this Agreement, you willl be entitled to receive prompt reimbursement for all reasonable and documented expenses approved in advance by the Company and incurred in the performance of your employment in accordance with the expense reimbursement policy of the Company.  Such reimbursement policy requires adequate and satisfactory documentation from you of all expenses and submission within a reasonable period after the close of the applicable calendar month.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Employment at Will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement is not intended to and shall not be understood in any manner as affecting or modifying the at-will status of your employment with the Company. You are an at-will employee.  Either you or the Company may terminate your employment relationship at any time with or without cause or notice.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> 6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All knowledge and information, not already available to the public, which you acquire, have acquired, or will acquire in the course of your employment with the Company with respect to the Company&#8217;s business, including but not limited to, financial information, customers, vendors, licensees, work methods, data, all papers, resumes, and records (including computer records) and&#47;or regulatory matters, or other Company matters that are treated by the Company as confidential or as trade secrets, shall be referred to as (&#8220;Confidential Information&#8221;) and shall be treated by you as strictly confidential.  Such Confidential Information shall not either directly or indirectly be used, disclosed, or made accessible to anyone by you for any purpose, except in the ordinary course of the Company&#8217;s business under circumstances in which you are authorized to use or disclose such information. You agree to not use or disclose Confidential Information outside of those you are authorized to make in the regular and ordinary course of your duties unless and until you receive prior written permission of the Chief Executive Officer of the Company to make such disclosure.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Discoveries and Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  During the time that you are employed by the Company, all Confidential Information, trade secrets, or proprietary information and all other discoveries, inventions, software programs, processes, methods and improvements that are conceived, developed, or otherwise made by you, alone or with others, that relate in any way to the Company&#8217;s present or planned business or products (collectively the &#8220;Developments&#8221;), whether or not patentable or subject to copyright protection and whether or not reduced to tangible form or reduced to practice, shall be the sole property of the Company. You agree to disclose all Developments promptly, fully and in writing to the Company.  You agree to keep and maintain adequate and current dated and witnessed written records of all such Developments, in the form of notes, sketches, drawings, or reports, which records shall be promptly submitted to the Company and shall be and remain the property of the Company at all times.  You agree to assign, and hereby do assign, to, the Company all your right, title and interest throughout the world in and to all Developments.  You agree that all Developments shall constitute &#8220;Works for Hire&#8221; (as such are defined under the U.S. Copyright Laws) and you hereby assign to the Company, and will execute assignment documents of all copyrights, patents and other proprietary rights you may have in any Developments without any obligation on the part of the Company to pay royalties or any other consideration to you for such Developments.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All documents and other writings produced by you during the term of your employment, which relate to work you are doing or have done for the Company or to the business of the Company or its Affiliates (as defined below) shall belong to the Company. You will not publish outside of the Company any such writing without the prior written consent of the Chief Commercial Officer. You will, without further compensation, execute at any time (whether or not you are still employed by the Company) all documents requested of you relating to the protection of such rights, including the assignment of such rights to the Company.  The term &#8220;Affiliate&#8221; shall mean the Company and any entity controlling, controlled by, or under common control with the Company. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Litigation and Regulatory Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  You shall give Notice to the Company within three (3) business days pursuant to Section 15 of this Agreement if you are no longer employed and immediately if you are still employed by the Company if you are contacted by any person relating to any claim or litigation against the Company.  During and after your employment, you shall cooperate fully with the Company in the defense or prosecution of any claims or actions now in existence or that may be brought in the future against or on behalf of the Company that relate to events or occurrences that transpired while you were employed by the Company. Your full cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times.  During and after you employment, you shall also cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority to the extent any any such investigation or review relates to events or occurrences that transpired while you were employed by the Company. The Company shall reimburse you for any reasonable out-of-pocket expenses incurred in connection with your performance of obligations pursuant to this Section&#160;9.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.   </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;For so long as you are employed by the Company or any Affiliate and for a period of one (1) year after you cease to be employed by the Company or any Affiliate, you shall not, within the Territory (as defined below), directly or indirectly, engage in any work or other activity--whether as owner, stockholder, partner, officer, consultant, or otherwise--involving a trademark, product, or process that, in the opinion of the Company&#8217;s Chief Executive Officer, is  similar to a trademark, product or process on which you worked for the Company (or any Affiliate) or obtained knowledge about while working for the Company at any time during the period of employment, if such work or other activity is then, or reasonably expected to become, competitive with that of the Company or any Affiliate </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;In recognition of the broad geographic scope of the Company and of the ease of competing with the Company from any location throughout the United States, the restrictions in this Section 10 are intended to cover the following geographic areas (collectively, the &#8220;Territory&#8221;)&#58; (a) the United States&#59; and, (b) each state in the United States where the Company conducted the Business during the term of my employment. If a court determines that the Territory described above in clause (a) is too restrictive, then the parties agree that the Territory shall be the area specified in clause (b). If the court determines that all of the areas mentioned above are too restrictive, then the parties agree the court may reduce or limit the area to enable the intent of this Section 10 to be enforced in the largest acceptable area.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;The restrictions in this Section 10 shall not apply if you have disclosed to the Company in writing all the known facts relating to such work or activity and have received a release in writing from the Chief Commercial Officer allowing you to engage in such work or activity. The Company&#8217;s Chief Executive Officer shall have sole discretion to determine whether your work or activity for another employer involves trademarks, products, or processes that are similar to trademarks, products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or less of the outstanding shares of stock of any company either (i) listed on a national securities exchange, or (ii) having at least one hundred (100) stockholders shall not make you a &#8220;stockholder&#8221; within the meaning of that term as used in this paragraph.  For one year after you cease to work for the Company, you will not engage in any work or activity that will cause you to inevitably disclose to anyone not employed by the Company or an Affiliate any trade secret or confidential information that belongs to the Company or one of its Affiliates.   Nothing in this paragraph shall limit the rights or remedies of the Company arising, directly or indirectly, from such competitive employment, including, without limitation, claims based upon breach of fiduciary duty, misappropriation, or theft of confidential information. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;By executing this Agreement, you acknowledge that you understand that the restrictions set forth in this Section 10 and in Section 11 of this Agreement are intended to protect the Company&#8217;s interest in its Confidential Information, including its trade secrets, and established employee, customer, and supplier relationships and goodwill, and you agree that such restrictions are reasonable and appropriate for this purpose.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  For a period of one year after you cease to be employed by the Company (or a Company Affiliate) you agree (a) not to solicit, directly or indirectly, business related to the development or sales of pharmaceutical products from any entity, organization, or person which is contracted with the Company, has been doing business with the Company, or from which the Company was soliciting at the time of your termination, or a firm which you knew or had reason to know that the Company was going to solicit business at the time you ceased to be employed by the Company. The restriction set forth in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such solicitation and have received a release in writing from the Chief Executive Officer of the Company to engage in such solicitation and (b) not to solicit, recruit, hire, or assist in the hiring of any employee of the Company to work for you or another person, firm, corporation, or business in competition with, or reasonably likely to become in competition with, the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Conflicting Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  You represent and warrant that you are not now under any obligation resulting from any contract or arrangement, to any person, firm, or corporation, which is inconsistent or in conflict with this Agreement or which would prevent, limit, or impair in any way the performance by you of your obligations to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Return of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All documents, records, data, apparatus, equipment and other physical property, whether or not pertaining to Confidential Information, that are furnished to you by the Company or are produced by you in connection with your employment with the Company will be and remain the sole property of the Company. You shall return to the Company all such materials and property immediately upon termination of employment or upon request by the Company for any reason.  You shall not retain with you any such material or property or any copies after termination of your employment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  You acknowledge that in the event of breach of this Agreement by you, actual damages to the Company will be difficult to calculate, the Company will suffer irreparable harm, and that in any event money damages would be an inadequate remedy for any such breach.  Therefore, you agree that any of the covenants contained in this Agreement may be specifically enforced through injunctive relief, but such right to injunctive relief shall not preclude the Company from other remedies which may be available to it. You further agree that should you fail to keep any of the promises made by you in this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all monies the Company is required to spend, including attorneys&#8217; fees, to enforce the provisions of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Debarment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  You represent and warrant that you have not been debarred, suspended or proposed for debarment or excluded from participation in any state or federal program or under the Food, Drug and Cosmetic Act and will notify the Company immediately of possible suspension or disbarment.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any notice required or permitted to be given under this Agreement shall be sent in writing by registered or certified mail to your residence or to the Company at the address on this letterhead, Attention&#58; Chief Executive Officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver&#47;Entire Agreement&#47;Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The waiver by either party of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach. This Agreement contains the entire agreement of the parties. This Agreement may be amended or modified only by a written agreement signed by you and by a duly authorized representative of the Company.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Governance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement shall be governed by the laws of the State of Tennessee.  Any dispute arising out of this Agreement shall be resolved, at the Company&#8217;s sole option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In the event that any provision of this Agreement shall be held by a court to be unenforceable, such provision will be enforced to the maximum extent permissible, and the remaining portions of this Agreement shall remain in full force and effect.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Notwithstanding any termination of your employment, this Agreement shall survive and remain in effect in accordance with its terms. The obligations of Sections 6, 7, 8,  9, 10, 11 and 12 shall survive the termination of our employment relationship or of this Agreement. This Agreement may be signed in one or more counterparts, each of which shall be an original and all of which will constitute one and the same instrument.</font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Sincerely yours,</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> CUMBERLAND PHARMACEUTICALS INC.</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;__</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47;A.J. Kazimi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">______________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;A.J. Kazimi, Chief Executive Officer</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accepted as to all terms and conditions</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as of the 7th of March 2024&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Sign here&#58;__</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; John Hamm</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">__________________________</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Print name&#58; ___</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">John Hamm</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">__________________________</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>8
<FILENAME>a2023-10kxex231consentofcri.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i5e3b6741ceda44efbc93147bff7d2f25_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 23.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the registration statement of Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;) on Form S-3 (No. 333-276052) and Form S-8 (Nos. 333-164376 and 333-271978) of our report dated March 12, 2024, on our audit of the consolidated financial statements of the Company as of December 31, 2023, and for the year then ended, which report is included in this Annual Report on Form 10-K.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Carr, Riggs &#38; Ingram, LLC</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nashville, Tennessee</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 12, 2024</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>9
<FILENAME>a2023-xex232consentofforvi.htm
<DESCRIPTION>EX-23.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ie0541c7d9b144297ab4bb2a4673598b1_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 23.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We consent to the incorporation by reference in the registration statement of Cumberland Pharmaceuticals Inc. (Company) on Form S-3 (No. 333-276052) and Form S-8 (No. 333-164376 and 333-271978) of our report dated March&#160;13, 2023, on our audits of the consolidated financial statements of the Company as of December&#160;31, 2022, and for the year ended December&#160;31, 2022, which report is included in this Annual Report on Form 10-K.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; FORVIS, LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nashville, Tennessee</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 12, 2024</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>10
<FILENAME>a2023-10kxexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ibcf4511b532643bcaa7a9d03694c8ea1_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, A.J. Kazimi, certify that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:30.48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Form 10-K of Cumberland Pharmaceuticals Inc.&#59;</font></div><div style="padding-left:30.48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:30.48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:30.48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="padding-left:30.48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:30.48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:30.48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:30.48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; </font></div><div style="padding-left:30.48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:30.48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:30.48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:40.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.017%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.226%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 12, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; A.J. Kazimi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.J. Kazimi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>11
<FILENAME>a2023-10kxexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i1679497634144a548b887054d0ae84e2_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, John M. Hamm, certify that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:8pt;padding-left:30.48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Form 10-K of Cumberland Pharmaceuticals Inc.&#59;&#160;</font></div><div style="margin-top:8pt;padding-left:30.48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:8pt;padding-left:30.48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#59;</font></div><div style="margin-top:8pt;padding-left:30.48pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:34.59pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:8pt;padding-left:30.48pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:34.02pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:8pt;padding-left:30.48pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:34.59pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59;</font></div><div style="margin-top:8pt;padding-left:30.48pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:34.02pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59;</font></div><div style="margin-top:8pt;padding-left:30.48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#59;</font></div><div style="margin-top:8pt;padding-left:30.48pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:34.59pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:8pt;padding-left:30.48pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:34.02pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:41.020%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.170%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.289%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 12, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John M. Hamm</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John M. Hamm</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President and Chief Financial Officer</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>12
<FILENAME>a2023-10kxexhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i626ae5a1d2284b4485f7d3f24264e72f_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION&#160;906</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;) on Form&#160;10-K for the fiscal year ended December&#160;31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, A.J. Kazimi, Chief Executive Officer, and John M. Hamm, Vice President and Chief Financial Officer, of the Company, certify, pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. section 1350), that, based on my knowledge&#58;</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:35.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.804%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; A.J. Kazimi</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.J. Kazimi</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 12, 2024</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:35.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.804%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; John M. Hamm</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John M. Hamm</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President and Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 12, 2024</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>13
<FILENAME>a2023-xex971compensationre.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i06bc828c8fb94c5b8587c5f258f9a9a6_40"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">POLICY FOR THE</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RECOVERY OF PREVIOUSLY AWARDED INCENTIVE COMPENSATION</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">____________________________________</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">A.&#160;&#160;&#160;&#160;OVERVIEW</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In accordance with the applicable rules of the Nasdaq Stock Market (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Nasdaq Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), Section 10D and Rule 10D-1 of the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Rule 10D-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), the Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) of Cumberland Pharmaceuticals Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) has adopted this Policy (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to provide for the recovery of certain previously awarded Incentive-based Compensation from Executive Officers. All capitalized terms used and not otherwise defined herein shall have the meanings set forth in Section H, below.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">B.&#160;&#160;&#160;&#160;RECOVERY OF PREVIOUSLY AWARDED COMPENSATION</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;In the event of an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accounting Restatement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the Company will reasonably promptly recover the Previously Awarded Compensation Received for the relevant period in accordance with Nasdaq Rules and Rule 10D-1 as follows&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;After an Accounting Restatement, the Compensation Committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) shall determine the amount of any Previously Awarded Compensation Received by each Executive Officer and shall promptly notify each Executive Officer with a written notice containing the amount of any such Compensation and a request for repayment or return of such compensation, as applicable.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;For Incentive-based Compensation based on (or derived from) the Company&#8217;s stock price or total shareholder return, where the amount of Previously Awarded Compensation is not subject to mathematical recalculation directly from the information in the applicable Accounting Restatement&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">i.&#160;&#160;&#160;&#160;The amount to be repaid or returned shall be determined by the Committee based on a reasonable estimate of the effect of the Accounting Restatement on the Company&#8217;s stock price or total shareholder return upon which the Incentive-based Compensation was Received&#59; and</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ii.&#160;&#160;&#160;&#160;The Company shall maintain documentation of the determination of such reasonable estimate and provide the relevant documentation as required to Nasdaq.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;The Committee shall have discretion to determine the appropriate means of recovering such Previously Awarded Compensation based on the particular facts and circumstances. </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;To the extent that the Executive Officer has already reimbursed the Company for any such Previously Awarded Compensation Received under any duplicative recovery obligations established by the Company or applicable law, it shall be appropriate for any such reimbursed amount to be credited to the amount of Previously Awarded Compensation that is subject to recovery under this Policy.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;To the extent that an Executive Officer fails to repay all </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">such Previously</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Awarded Compensation to the Company when due, the Company shall take all actions reasonable and appropriate to recover </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">it</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> from the applicable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> individual</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Notwithstanding anything herein to the contrary, the Company shall not be required to take the actions contemplated by Section B(1) above if the Committee determines that recovery would be impracticable and any of the following three conditions are met&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;The Committee has determined that the direct expenses paid to a third party to assist in enforcing the Policy will exceed the amount to be recovered. Before making this determination, the Company must make a reasonable attempt to recover the Previously Awarded Compensation, documented such attempt(s) and provided such documentation to Nasdaq&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Recovery would violate home country law where that law was adopted prior to November 28, 2022, provided that, before determining that it would be impracticable to recover any amount of Previously Awarded Compensation based on violation of home country law, the Company has obtained an opinion of home country counsel, acceptable to Nasdaq, that recovery would result in such a violation and a copy of the opinion is provided to Nasdaq&#59; or</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Section 401(a)(13) or Section 411(a) of the Internal Revenue Code of 1986, as amended, and regulations thereunder.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">C.&#160;&#160;&#160;&#160;DISCLOSURE REQUIREMENTS</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company shall file all disclosures with respect to this Policy as required by applicable U.S. Securities and Exchange Commission (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) filings and rules.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">D.&#160;&#160;&#160;&#160;PROHIBITION OF INDEMNIFICATION</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company shall not be permitted to insure or indemnify any Executive Officer against (i) the loss of any such Previously Awarded Compensation that is repaid, returned or recovered pursuant to the terms of this Policy, or (ii) any claims relating to the Company&#8217;s enforcement of its rights under this Policy. Further, the Company shall not enter into any agreement that exempts any Incentive-based Compensation that is granted, paid or awarded to an Executive Officer from the application of this Policy or that waives the Company&#8217;s right to recovery of any such Previously Awarded Compensation, and this Policy shall supersede any such agreement (whether entered into before, on or after the Effective Date of this Policy).</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">E.&#160;&#160;&#160;&#160;ADMINISTRATION AND INTERPRETATION</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Policy shall be administered by the Committee, and any determinations made by the Committee shall be final and binding on all affected individuals.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Committee is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this Policy and for the Company&#8217;s compliance with Nasdaq Rules, Section 10D, Rule 10D-1 and any other applicable law, regulation, rule or interpretation of the SEC or Nasdaq promulgated or issued in connection therewith.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">F.&#160;&#160;&#160;&#160;AMENDMENT&#59; TERMINATION</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Committee may amend this Policy from time to time in its discretion and shall amend this Policy as it deems necessary. Notwithstanding anything in this Section F to the contrary, no amendment or termination of this Policy shall be effective if such amendment or termination would (after taking into account any actions taken by the Company contemporaneously with such amendment or termination) cause the Company to violate any federal securities laws, SEC rule or Nasdaq rule.</font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">G.&#160;&#160;&#160;&#160;OTHER RECOVERY RIGHTS</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any employment agreement, equity award agreement, compensatory plan or any other agreement or arrangement with an Executive Officer shall be deemed to include, as a condition to the grant of any benefit thereunder, an agreement by the Executive Officer to abide by the terms of this Policy. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any right of recovery under this Policy is in addition to, and not in lieu of, any other remedies or rights of recovery that may be available to the Company under applicable law, regulation or rule or pursuant to the terms of any policy of the Company or any provision in any employment agreement, equity award agreement, compensatory plan, agreement or other arrangement.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">H.&#160;&#160;&#160;&#160;DEFINITIONS</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For purposes of this Policy, the following capitalized terms shall have the meanings set forth below.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accounting Restatement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Big R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; restatement), or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">little r</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; restatement).</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Retrieval Eligible Incentive Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means all Incentive-based Compensation Received by an Executive Officer (i) on or after the effective date of the applicable Nasdaq rules, (ii) after beginning service as an Executive Officer, (iii) who served as an Executive Officer at any time during the applicable performance period relating to any Incentive-based Compensation (whether or not such Executive Officer is serving at the time the Previously Awarded Compensation is required to be repaid to the Company), (iv) while the Company has a class of securities listed on a national securities exchange or a national securities association, and (v) during the applicable Retrieval Period (as defined below).</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Retrieval Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Accounting Restatement, the three completed fiscal years of the Company immediately preceding the Restatement Date (as defined below), and if the Company changes its fiscal year, any transition period of less than nine months within or immediately following those three completed fiscal years.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Previously Awarded Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to each Executive Officer in connection with an Accounting Restatement, the amount of Retrieval Eligible Incentive Compensation that exceeds the amount of Incentive-based Compensation that otherwise would have been Received had it been determined based on the restated amounts, computed without regard to any taxes paid.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means each individual who is currently or was previously designated as an &#8220;officer&#8221; of the Company as defined in Rule 16a-1(f) under the Exchange Act. For the avoidance of doubt, the identification of an executive officer for purposes of this Policy shall include each executive officer who is or was identified pursuant to Item 401(b) of Regulation S-K, as well as the principal financial officer and principal accounting officer (or, if there is no principal accounting officer, the controller).</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(6)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Financial Reporting Measures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements, and all other measures that are derived wholly or in part from such measures. Stock price and total shareholder return (and any measures that are derived wholly or in part from stock price or total shareholder return) shall, for purposes of this Policy, be considered Financial Reporting Measures. For the avoidance of doubt, a Financial Reporting Measure need not be presented in the Company&#8217;s financial statements or included in a filing with the SEC.</font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(7)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Incentive-based Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(8)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Nasdaq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means The Nasdaq Stock Market.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(9)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Received</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Incentive-based Compensation, actual or deemed receipt, and Incentive-based Compensation shall be deemed received in the Company&#8217;s fiscal period during which the Financial Reporting Measure specified in the Incentive-based Compensation award is attained, even if the payment or grant of the Incentive-based Compensation to the Executive Officer occurs after the end of that period.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(10)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Restatement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the earlier to occur of (i) the date the Board, a committee of the Board or the officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement, or (ii) the date a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Effective as of December 1, 2023.</font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="i06bc828c8fb94c5b8587c5f258f9a9a6_43"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ATTESTATION AND ACKNOWLEDGEMENT OF POLICY FOR THE RECOVERY OF PREVIOUSLY AWARDED COMPENSATION</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By my signature below, I acknowledge and agree that&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;I have received and read the attached Policy for the Recovery of Previously Awarded Compensation (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;I hereby agree to abide by all of the terms of this Policy both during and after my employment with the Company, including, without limitation, by promptly repaying or returning any Previously Awarded Compensation to the Company in accordance with this Policy.</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Signature&#58;&#160;&#160;&#160;&#160;________________________________</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Printed Name&#58;&#160;&#160;&#160;&#160;________________________________</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Date&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;________________________________</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>14
<FILENAME>cpix-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:6edb08b2-28be-4fe2-96a1-5228f16440ba,g:0b7981d4-3364-432a-a869-7a65f1514fac-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cpix="http://www.cumberlandpharma.com/20231231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:srt-types="http://fasb.org/srt-types/2023" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cumberlandpharma.com/20231231">
  <xs:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd"/>
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.cumberlandpharma.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.cumberlandpharma.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations">
        <link:definition>0000005 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEquity" roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity">
        <link:definition>0000007 - Statement - Consolidated Statements of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ValuationandQualifyingAccounts" roleURI="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccounts">
        <link:definition>0000008 - Statement - Valuation and Qualifying Accounts</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://www.cumberlandpharma.com/role/Organization">
        <link:definition>0000009 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPolicies" roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPolicies">
        <link:definition>0000010 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VibativSancusoandRediTrexProducts" roleURI="http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProducts">
        <link:definition>0000011 - Disclosure - Vibativ&#174;, Sancuso&#174; and RediTrex&#174; Products</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.cumberlandpharma.com/role/Revenues">
        <link:definition>0000012 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesNet" roleURI="http://www.cumberlandpharma.com/role/InventoriesNet">
        <link:definition>0000013 - Disclosure - Inventories, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipment">
        <link:definition>0000014 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwill" roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwill">
        <link:definition>0000015 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCurrentandOtherLongtermLiabilities" roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities">
        <link:definition>0000016 - Disclosure - Other Current and Other Long-term Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.cumberlandpharma.com/role/Debt">
        <link:definition>0000017 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquity" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquity">
        <link:definition>0000018 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerShare" roleURI="http://www.cumberlandpharma.com/role/LossPerShare">
        <link:definition>0000019 - Disclosure - Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes">
        <link:definition>0000020 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlans" roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlans">
        <link:definition>0000021 - Disclosure - Stock-Based Compensation Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlans" roleURI="http://www.cumberlandpharma.com/role/EmployeeBenefitPlans">
        <link:definition>0000022 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.cumberlandpharma.com/role/Leases">
        <link:definition>0000023 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketConcentrations" roleURI="http://www.cumberlandpharma.com/role/MarketConcentrations">
        <link:definition>0000024 - Disclosure - Market Concentrations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ManufacturingandSupplyAgreements" roleURI="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreements">
        <link:definition>0000025 - Disclosure - Manufacturing and Supply Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmploymentAgreements" roleURI="http://www.cumberlandpharma.com/role/EmploymentAgreements">
        <link:definition>0000026 - Disclosure - Employment Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.cumberlandpharma.com/role/CommitmentsandContingencies">
        <link:definition>0000027 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialInformationUnaudited" roleURI="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited">
        <link:definition>0000028 - Disclosure - Quarterly Financial Information (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesPolicies" roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesTables" roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables">
        <link:definition>9954472 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VibativSancusoandRediTrexProductsTables" roleURI="http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsTables">
        <link:definition>9954473 - Disclosure - Vibativ&#174;, Sancuso&#174; and RediTrex&#174; Products (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.cumberlandpharma.com/role/RevenuesTables">
        <link:definition>9954474 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesNetTables" roleURI="http://www.cumberlandpharma.com/role/InventoriesNetTables">
        <link:definition>9954475 - Disclosure - Inventories, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentTables">
        <link:definition>9954476 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillTables" roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillTables">
        <link:definition>9954477 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCurrentandOtherLongtermLiabilitiesTables" roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables">
        <link:definition>9954478 - Disclosure - Other Current and Other Long-term Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerShareTables" roleURI="http://www.cumberlandpharma.com/role/LossPerShareTables">
        <link:definition>9954479 - Disclosure - Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesTables">
        <link:definition>9954480 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansTables" roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables">
        <link:definition>9954481 - Disclosure - Stock-Based Compensation Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.cumberlandpharma.com/role/LeasesTables">
        <link:definition>9954482 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketConcentrationsTables" roleURI="http://www.cumberlandpharma.com/role/MarketConcentrationsTables">
        <link:definition>9954483 - Disclosure - Market Concentrations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialInformationUnauditedTables" roleURI="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables">
        <link:definition>9954484 - Disclosure - Quarterly Financial Information (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails">
        <link:definition>9954485 - Disclosure - Organization (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails">
        <link:definition>9954486 - Disclosure - Significant Accounting Policies (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesScheduleofDistributionCostsDetails" roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofDistributionCostsDetails">
        <link:definition>9954487 - Disclosure - Significant Accounting Policies (Schedule of Distribution Costs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesScheduleofAdvertisingCostsDetails" roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofAdvertisingCostsDetails">
        <link:definition>9954488 - Disclosure - Significant Accounting Policies (Schedule of Advertising Costs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VibativSancusoandRediTrexProductsNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails">
        <link:definition>9954489 - Disclosure - Vibativ&#174;, Sancuso&#174; and RediTrex&#174; Products - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VibativSancusoandRediTrexProductsChangesInFairValueOfContingentConsiderationLiabilityDetails" roleURI="http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsChangesInFairValueOfContingentConsiderationLiabilityDetails">
        <link:definition>9954490 - Disclosure - Vibativ&#174;, Sancuso&#174; and RediTrex&#174; Products - Changes In Fair Value Of Contingent Consideration Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesScheduleofNetProductRevenuesbyProductDetails" roleURI="http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails">
        <link:definition>9954491 - Disclosure - Revenues (Schedule of Net Product Revenues by Product) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails">
        <link:definition>9954492 - Disclosure - Revenues (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesNetScheduleofInventoriesDetails" roleURI="http://www.cumberlandpharma.com/role/InventoriesNetScheduleofInventoriesDetails">
        <link:definition>9954493 - Disclosure - Inventories, Net - Schedule of Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesNetScheduleofNonCurrentInventoriesDetails" roleURI="http://www.cumberlandpharma.com/role/InventoriesNetScheduleofNonCurrentInventoriesDetails">
        <link:definition>9954494 - Disclosure - Inventories, Net - Schedule of Non-Current Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesNetNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/InventoriesNetNarrativeDetails">
        <link:definition>9954495 - Disclosure - Inventories, Net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentScheduleofPropertyandEquipmentDetails" roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails">
        <link:definition>9954496 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentDepreciationExpenseDetails" roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentDepreciationExpenseDetails">
        <link:definition>9954497 - Disclosure - Property and Equipment (Depreciation Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails" roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails">
        <link:definition>9954498 - Disclosure - Intangible Assets and Goodwill - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillNarrativeDetails">
        <link:definition>9954499 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillAmortizationExpenseDetails" roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillAmortizationExpenseDetails">
        <link:definition>9954500 - Disclosure - Intangible Assets and Goodwill - Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails" roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails">
        <link:definition>9954501 - Disclosure - Intangible Assets and Goodwill - Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails" roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails">
        <link:definition>9954502 - Disclosure - Other Current and Other Long-term Liabilities (Schedule of Other Current Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCurrentandOtherLongtermLiabilitiesScheduleofNoncurrentLiabilitiesDetails" roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofNoncurrentLiabilitiesDetails">
        <link:definition>9954503 - Disclosure - Other Current and Other Long-term Liabilities (Schedule of Noncurrent Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtDetails" roleURI="http://www.cumberlandpharma.com/role/DebtDetails">
        <link:definition>9954504 - Disclosure - Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityDetails" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityDetails">
        <link:definition>9954505 - Disclosure - Shareholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails" roleURI="http://www.cumberlandpharma.com/role/LossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails">
        <link:definition>9954506 - Disclosure - Loss Per Share - Schedule of Computation of Numerator and Denominator in Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails" roleURI="http://www.cumberlandpharma.com/role/LossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails">
        <link:definition>9954507 - Disclosure - Loss Per Share - Schedule of Anti-dilutive Securities Excluded From Computation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails">
        <link:definition>9954508 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails">
        <link:definition>9954509 - Disclosure - Income Taxes - Schedule of Net Operating Loss Carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails">
        <link:definition>9954510 - Disclosure - Income Taxes - Schedule of the Components of Income Tax Benefit (Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>9954511 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleOfTaxCreditCarryforwardsDetails" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleOfTaxCreditCarryforwardsDetails">
        <link:definition>9954512 - Disclosure - Income Taxes - Schedule Of Tax Credit Carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails">
        <link:definition>9954513 - Disclosure - Stock-Based Compensation Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansStockOptionsActivityDetails" roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansStockOptionsActivityDetails">
        <link:definition>9954514 - Disclosure - Stock-Based Compensation Plans - Stock Options Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansValuationAssumptionsDetails" roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansValuationAssumptionsDetails">
        <link:definition>9954515 - Disclosure - Stock-Based Compensation Plans - Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansRestrictedStockActivityDetails" roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansRestrictedStockActivityDetails">
        <link:definition>9954516 - Disclosure - Stock-Based Compensation Plans - Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansDetails" roleURI="http://www.cumberlandpharma.com/role/EmployeeBenefitPlansDetails">
        <link:definition>9954517 - Disclosure - Employee Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails">
        <link:definition>9954518 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofRentExpenseandSubleaseIncomeDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails">
        <link:definition>9954519 - Disclosure - Leases - Schedule of Rent Expense and Sublease Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeasePositionDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails">
        <link:definition>9954520 - Disclosure - Leases - Lease Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails">
        <link:definition>9954521 - Disclosure - Leases - Schedule of Lease Liability Maturities and Future Minimum Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1" roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1">
        <link:definition>9954521 - Disclosure - Leases - Schedule of Lease Liability Maturities and Future Minimum Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails">
        <link:definition>9954522 - Disclosure - Market Concentrations (Schedule of Revenues Concentration from Major Customers and Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails">
        <link:definition>9954523 - Disclosure - Manufacturing and Supply Agreements Manufacturing and Supply Agreements (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails">
        <link:definition>9954524 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails" roleURI="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails">
        <link:definition>9954525 - Disclosure - Quarterly Financial Information (Schedule of Quarterly Financial Information (Unaudited)) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ValuationandQualifyingAccountsDetails" roleURI="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails">
        <link:definition>9954526 - Disclosure - Valuation and Qualifying Accounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cpix_ExpirationTimePeriodAxis" abstract="true" name="ExpirationTimePeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" abstract="false" name="StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_FollowingApprovalOfFirstSNDAMember" abstract="true" name="FollowingApprovalOfFirstSNDAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cpix_EmploymentAgreementsTextBlock" abstract="false" name="EmploymentAgreementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="cpix_FinishedGoodsMember" abstract="true" name="FinishedGoodsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_LesseeOperatingLeaseNumberOfRenewalTerms" abstract="false" name="LesseeOperatingLeaseNumberOfRenewalTerms" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember" abstract="true" name="MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cpix_ProductKristaloseMember" abstract="true" name="ProductKristaloseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_InventoryNoncurrentLineItems" abstract="true" name="InventoryNoncurrentLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationCancelledAndRefunded" abstract="false" name="CollaborativeArrangementRightsAndObligationsStockConsiderationCancelledAndRefunded" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cpix_OtherProductsMember" abstract="true" name="OtherProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_A1600WestEndAvenuePartnersLLCMember" abstract="true" name="A1600WestEndAvenuePartnersLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cpix_EffectiveIncomeTaxRateReconciliationDeferredTrueUpsPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationDeferredTrueUpsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" abstract="false" name="DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_Within30DaysOfFirstSNDAFilingMember" abstract="true" name="Within30DaysOfFirstSNDAFilingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cpix_CustomerTwoMember" abstract="true" name="CustomerTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cpix_DeferredTaxAssetOperatingLeaseLiabilities" abstract="false" name="DeferredTaxAssetOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_AccruedLiabilitiesStockPayable" abstract="false" name="AccruedLiabilitiesStockPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ProductAndLicenseRightsMember" abstract="true" name="ProductAndLicenseRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFourAndAfter" abstract="false" name="FiniteLivedIntangibleAssetsAmortizationExpenseYearFourAndAfter" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_AccruedLiabilitiesInventoryPurchases" abstract="false" name="AccruedLiabilitiesInventoryPurchases" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" abstract="false" name="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ManufacturingAndSupplyAgreementsTextBlock" abstract="false" name="ManufacturingAndSupplyAgreementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="cpix_ProductCaldolorMember" abstract="true" name="ProductCaldolorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" abstract="false" name="DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ExpirationTermOneMember" abstract="true" name="ExpirationTermOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" abstract="false" name="IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions" abstract="false" name="ShareBasedCompensationCharitableContributionOfSharesCashContributions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_CollaborativeArrangementMilestonePaymentThresholdDomain" abstract="true" name="CollaborativeArrangementMilestonePaymentThresholdDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cpix_CollaborativeArrangementRightsAndObligationsMilestonePayment" abstract="false" name="CollaborativeArrangementRightsAndObligationsMilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" abstract="false" name="DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ChangeInUnpaidInvoicesForOfferingCosts" abstract="false" name="ChangeInUnpaidInvoicesForOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_MartinS.BrownJr.sLawFirmMember" abstract="true" name="MartinS.BrownJr.sLawFirmMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_CustomerOneMember" abstract="true" name="CustomerOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cpix_ScheduleofDepreciationExpenseTableTextBlock" abstract="false" name="ScheduleofDepreciationExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="cpix_CashPaidDuringYearAbstract" abstract="true" name="CashPaidDuringYearAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_SubsidiaryInvestmentPurchaseOfShares" abstract="false" name="SubsidiaryInvestmentPurchaseOfShares" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ProductSancusoMember" abstract="true" name="ProductSancusoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage" abstract="false" name="PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsTerm" abstract="false" name="PaymentsToAcquireBusinessTieredRoyaltyPaymentsTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cpix_FederalGrantProgramsMember" abstract="true" name="FederalGrantProgramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cpix_ScheduleOfAdvertisingCostsTableTextBlock" abstract="false" name="ScheduleOfAdvertisingCostsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationValue" abstract="false" name="CollaborativeArrangementRightsAndObligationsStockConsiderationValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_CaldolorMember" abstract="true" name="CaldolorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable" abstract="false" name="CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts" abstract="false" name="StockIssuedDuringPeriodNewSharesUnderwritingDiscounts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ProductOmeclamoxPakMember" abstract="true" name="ProductOmeclamoxPakMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_ScheduleOfDistributionCostsTableTextBlock" abstract="false" name="ScheduleOfDistributionCostsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="cpix_CreditIssuedForMilestonePayable" abstract="false" name="CreditIssuedForMilestonePayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_StockIssuedDuringPeriodPricePerShareNewIssues" abstract="false" name="StockIssuedDuringPeriodPricePerShareNewIssues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="cpix_ManufacturingandSupplyAgreementLineItems" abstract="true" name="ManufacturingandSupplyAgreementLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent" abstract="false" name="BusinessCombinationContingentConsiderationLiabilityAccruedCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_NephronPharmaceuticalsCorporationNephronMember" abstract="true" name="NephronPharmaceuticalsCorporationNephronMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_VibativMember" abstract="true" name="VibativMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cpix_NonprincipalOwnerMember" abstract="true" name="NonprincipalOwnerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility" abstract="false" name="DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cpix_SancusoMember" abstract="true" name="SancusoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cpix_LongTermIncentiveCompensationPlan2007Member" abstract="true" name="LongTermIncentiveCompensationPlan2007Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationShares" abstract="false" name="CollaborativeArrangementRightsAndObligationsStockConsiderationShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cpix_PaymentsToAcquireBusinessMilestonePaymentRemaining" abstract="false" name="PaymentsToAcquireBusinessMilestonePaymentRemaining" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_NordicGroupBVMember" abstract="true" name="NordicGroupBVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cpix_ExpirationTimePeriodDomain" abstract="true" name="ExpirationTimePeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cpix_HongKongWinHealthPharmaGroupCoLimitedMember" abstract="true" name="HongKongWinHealthPharmaGroupCoLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cpix_ProceedsFromCollaborativeArrangement" abstract="false" name="ProceedsFromCollaborativeArrangement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentOne" abstract="false" name="ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentOne" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_NetDeferredTaxAssetsGross" abstract="false" name="NetDeferredTaxAssetsGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_CollaborativeArrangementRightsAndObligationsDepositPayment" abstract="false" name="CollaborativeArrangementRightsAndObligationsDepositPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets" abstract="false" name="DeferredTaxLiabilityOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivableNumberOfPayments" abstract="false" name="ProceedsFromLegalSettlementsMilestonePaymentsReceivableNumberOfPayments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cpix_NoncashOrPartNoncashGainOnTransaction" abstract="false" name="NoncashOrPartNoncashGainOnTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ExpirationTermTwoMember" abstract="true" name="ExpirationTermTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationVestedValue" abstract="false" name="CollaborativeArrangementRightsAndObligationsStockConsiderationVestedValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ProductAssetsAndGlobalRightsVibativMember" abstract="true" name="ProductAssetsAndGlobalRightsVibativMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_LesseeOperatingLeaseLeasedArea" abstract="false" name="LesseeOperatingLeaseLeasedArea" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:areaItemType"/>
  <xs:element id="cpix_ActivePharmaceuticalIngredientAPIAndWorkInProgressMember" abstract="true" name="ActivePharmaceuticalIngredientAPIAndWorkInProgressMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_WinHealthInvestmentSingaporeLtdMember" abstract="true" name="WinHealthInvestmentSingaporeLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cpix_KristaloseMember" abstract="true" name="KristaloseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cpix_CollaborativeArrangementMilestonePaymentThresholdAxis" abstract="true" name="CollaborativeArrangementMilestonePaymentThresholdAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cpix_InventoryNoncurrentTable" abstract="true" name="InventoryNoncurrentTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="cpix_IndefiniteMember" abstract="true" name="IndefiniteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cpix_BroadwestLeaseFiveYearRenewalOptionMember" abstract="true" name="BroadwestLeaseFiveYearRenewalOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cpix_ManufacturingAndSupplyAgreementsAbstract" abstract="true" name="ManufacturingAndSupplyAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_ProductVaprisolMember" abstract="true" name="ProductVaprisolMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_DeferredTaxAssetsDeferredCharges" abstract="false" name="DeferredTaxAssetsDeferredCharges" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_PinnacleBankMember" abstract="true" name="PinnacleBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cpix_ProductRediTrexMember" abstract="true" name="ProductRediTrexMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_ChargebacksCashDiscountsAndDamagedGoodsMember" abstract="true" name="ChargebacksCashDiscountsAndDamagedGoodsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cpix_LesseeOperatingLeaseBaseRent" abstract="false" name="LesseeOperatingLeaseBaseRent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="srt-types:perUnitItemType"/>
  <xs:element id="cpix_StudyDrugMember" abstract="true" name="StudyDrugMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_AccountsReceivableAllowancesByComponentAxis" abstract="true" name="AccountsReceivableAllowancesByComponentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMilestonePayable" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMilestonePayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue" abstract="false" name="CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold" abstract="false" name="PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_AccountsReceivableAllowancesByComponentDomain" abstract="true" name="AccountsReceivableAllowancesByComponentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cpix_VaprisolMember" abstract="true" name="VaprisolMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cpix_FederalAndStateMember" abstract="true" name="FederalAndStateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" abstract="false" name="ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cpix_PaymentsToAcquireBusinessMilestonePayment" abstract="false" name="PaymentsToAcquireBusinessMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_DirectorsIncentivePlan2007Member" abstract="true" name="DirectorsIncentivePlan2007Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" abstract="false" name="ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="cpix_MethotrexateMember" abstract="true" name="MethotrexateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentTwo" abstract="false" name="ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="cpix_CashPaymentIncludedInMeasurementOfLeaseLiability" abstract="false" name="CashPaymentIncludedInMeasurementOfLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_SalesRevenueGoodsGrossMember" abstract="true" name="SalesRevenueGoodsGrossMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" abstract="false" name="LineOfCreditFacilityAdditionalBorrowingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_BusinessCombinationContingentConsiderationLiabilityRollForward" abstract="true" name="BusinessCombinationContingentConsiderationLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_CustomerThreeMember" abstract="true" name="CustomerThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cpix_Customer12And3Member" abstract="true" name="Customer12And3Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge" abstract="false" name="DefinedContributionPlanEligibilityMinimumEmployeeAge" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cpix_ManufacturingandSupplyAgreementTable" abstract="true" name="ManufacturingandSupplyAgreementTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="cpix_ProductAcetadoteMember" abstract="true" name="ProductAcetadoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_AuditorInformationAbstract" abstract="true" name="AuditorInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_ProceedsFromSettlementOfPatentLitigation" abstract="false" name="ProceedsFromSettlementOfPatentLitigation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" abstract="false" name="BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ProductSalesRelatedLiabilitiesCurrent" abstract="false" name="ProductSalesRelatedLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_U.S.ProductAssetRightsSancusoMember" abstract="true" name="U.S.ProductAssetRightsSancusoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering" abstract="false" name="StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock" abstract="false" name="PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="cpix_SharebasedCompensationCharitableContributionofSharesShares" abstract="false" name="SharebasedCompensationCharitableContributionofSharesShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cpix_ProductVibativMember" abstract="true" name="ProductVibativMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cpix_EmploymentAgreementsAbstract" abstract="true" name="EmploymentAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid" abstract="false" name="PurchasesOfIntangibleAssetsIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_LesseeOperatingLeaseRentIncrease" abstract="false" name="LesseeOperatingLeaseRentIncrease" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="cpix_AccruedLiabilitiesStudies" abstract="false" name="AccruedLiabilitiesStudies" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_CumberlandEmergingTechnologiesIncMember" abstract="true" name="CumberlandEmergingTechnologiesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>15
<FILENAME>cpix-20231231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:6edb08b2-28be-4fe2-96a1-5228f16440ba,g:0b7981d4-3364-432a-a869-7a65f1514fac-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20231231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0ada4f2c-50f4-4af4-aed1-4332514437e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_37388d6d-88bb-4c3d-b9f1-d26747c51c05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0ada4f2c-50f4-4af4-aed1-4332514437e6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_37388d6d-88bb-4c3d-b9f1-d26747c51c05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5f4ab3c1-76fe-4aa6-9b12-1fcf88e9c836" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0ada4f2c-50f4-4af4-aed1-4332514437e6" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5f4ab3c1-76fe-4aa6-9b12-1fcf88e9c836" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0cc9a3a8-7b89-4bbd-8a18-534fe8b49645" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0ada4f2c-50f4-4af4-aed1-4332514437e6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0cc9a3a8-7b89-4bbd-8a18-534fe8b49645" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6fa00eea-caab-4608-a53f-2a873b634124" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0ada4f2c-50f4-4af4-aed1-4332514437e6" xlink:to="loc_us-gaap_AssetsCurrent_6fa00eea-caab-4608-a53f-2a873b634124" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_831ccd9d-b2a8-4ae3-be96-ec3fcf33bfb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0ada4f2c-50f4-4af4-aed1-4332514437e6" xlink:to="loc_us-gaap_InventoryNoncurrent_831ccd9d-b2a8-4ae3-be96-ec3fcf33bfb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_77c7ee68-4ac3-4e3a-8ea0-8894e7fc8eee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0ada4f2c-50f4-4af4-aed1-4332514437e6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_77c7ee68-4ac3-4e3a-8ea0-8894e7fc8eee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4547bc82-249d-4409-8b19-b6c087338c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0ada4f2c-50f4-4af4-aed1-4332514437e6" xlink:to="loc_us-gaap_Goodwill_4547bc82-249d-4409-8b19-b6c087338c8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_51964fee-9ff5-43fb-a5f2-c6a20c256c06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_78592b4d-555e-4b51-a752-bc9f199429ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_51964fee-9ff5-43fb-a5f2-c6a20c256c06" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_78592b4d-555e-4b51-a752-bc9f199429ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_fd16f225-e921-4036-99fd-10f21a0bfa9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_51964fee-9ff5-43fb-a5f2-c6a20c256c06" xlink:to="loc_us-gaap_CommonStockValueOutstanding_fd16f225-e921-4036-99fd-10f21a0bfa9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9c0f2273-e7c7-4ef8-ac50-027c6238bc13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_ba72f86a-ccca-43da-8dc1-44136f127b28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9c0f2273-e7c7-4ef8-ac50-027c6238bc13" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_ba72f86a-ccca-43da-8dc1-44136f127b28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f8e080c4-e1e6-4acb-9035-d393009e03c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9c0f2273-e7c7-4ef8-ac50-027c6238bc13" xlink:to="loc_us-gaap_AccountsPayableCurrent_f8e080c4-e1e6-4acb-9035-d393009e03c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_12ab13da-1829-48c3-88d0-3f0619ac3121" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9c0f2273-e7c7-4ef8-ac50-027c6238bc13" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_12ab13da-1829-48c3-88d0-3f0619ac3121" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6b241dd6-dac9-444b-8763-835cd9ea73ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dfe26d77-f247-4e01-a352-bac344dfd336" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6b241dd6-dac9-444b-8763-835cd9ea73ad" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dfe26d77-f247-4e01-a352-bac344dfd336" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b1f88ab0-67d0-4ff7-bd04-3d15bcb1cf75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6b241dd6-dac9-444b-8763-835cd9ea73ad" xlink:to="loc_us-gaap_InventoryNet_b1f88ab0-67d0-4ff7-bd04-3d15bcb1cf75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_321e4d5c-0f41-4bca-b23d-d94ba2ca4cac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6b241dd6-dac9-444b-8763-835cd9ea73ad" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_321e4d5c-0f41-4bca-b23d-d94ba2ca4cac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_554e292d-d716-4aa6-a24e-b8937e91df15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6b241dd6-dac9-444b-8763-835cd9ea73ad" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_554e292d-d716-4aa6-a24e-b8937e91df15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_aad1a3a1-d1ef-46aa-8c6c-d7dd6b9bcd5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6f3b5ae9-5eab-42a2-8020-075e3e684e33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_aad1a3a1-d1ef-46aa-8c6c-d7dd6b9bcd5e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6f3b5ae9-5eab-42a2-8020-075e3e684e33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8b233d69-3426-4edd-9cc6-29c92fdee0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_aad1a3a1-d1ef-46aa-8c6c-d7dd6b9bcd5e" xlink:to="loc_us-gaap_Liabilities_8b233d69-3426-4edd-9cc6-29c92fdee0a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2e081baa-6428-4f78-a322-a50f856c5676" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_fcb1cea8-3ddc-4acc-9598-cf639e5ab946" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2e081baa-6428-4f78-a322-a50f856c5676" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_fcb1cea8-3ddc-4acc-9598-cf639e5ab946" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_c07cade1-035b-4fdc-a148-df02b6eeef39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2e081baa-6428-4f78-a322-a50f856c5676" xlink:to="loc_us-gaap_LongTermLineOfCredit_c07cade1-035b-4fdc-a148-df02b6eeef39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_155bf293-8537-4dda-bd6b-701fe38f12f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2e081baa-6428-4f78-a322-a50f856c5676" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_155bf293-8537-4dda-bd6b-701fe38f12f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6ec17a24-ee79-4b0d-b2fe-307ba029bfc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2e081baa-6428-4f78-a322-a50f856c5676" xlink:to="loc_us-gaap_LiabilitiesCurrent_6ec17a24-ee79-4b0d-b2fe-307ba029bfc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_13d533db-33af-49c8-bad6-534370cefade" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_051ec589-8a92-42c5-9e57-87d90fa960fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_13d533db-33af-49c8-bad6-534370cefade" xlink:to="loc_us-gaap_StockholdersEquity_051ec589-8a92-42c5-9e57-87d90fa960fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_e005879e-e499-4d76-bf72-b300a85496c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_13d533db-33af-49c8-bad6-534370cefade" xlink:to="loc_us-gaap_MinorityInterest_e005879e-e499-4d76-bf72-b300a85496c6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="cpix-20231231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ab026b07-e909-48f8-b408-ccc9002a3cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_923b6e24-ddf8-44fa-9e5e-d93ccce495e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ab026b07-e909-48f8-b408-ccc9002a3cd3" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_923b6e24-ddf8-44fa-9e5e-d93ccce495e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_164735e1-d965-4f64-8c28-8d84d639121a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ab026b07-e909-48f8-b408-ccc9002a3cd3" xlink:to="loc_us-gaap_SellingAndMarketingExpense_164735e1-d965-4f64-8c28-8d84d639121a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_bc7cb2df-4a7d-4ecd-af74-d26e21bdb9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ab026b07-e909-48f8-b408-ccc9002a3cd3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_bc7cb2df-4a7d-4ecd-af74-d26e21bdb9b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_fee86fcc-61d5-45bb-9de6-71184a977035" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ab026b07-e909-48f8-b408-ccc9002a3cd3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_fee86fcc-61d5-45bb-9de6-71184a977035" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_48e37242-8bf1-42b3-b550-93664355c19c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ab026b07-e909-48f8-b408-ccc9002a3cd3" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_48e37242-8bf1-42b3-b550-93664355c19c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_cbe0be20-8e49-46da-a6f1-06824b9d208d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6554173e-0db8-40f5-aaa0-0f45ab9341a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_cbe0be20-8e49-46da-a6f1-06824b9d208d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6554173e-0db8-40f5-aaa0-0f45ab9341a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_7c12df16-95bf-4e40-96be-ae5ded19213f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_cbe0be20-8e49-46da-a6f1-06824b9d208d" xlink:to="loc_us-gaap_CostsAndExpenses_7c12df16-95bf-4e40-96be-ae5ded19213f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_06da15ad-ace6-4497-bb24-c5353ef67959" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_96a7d817-b275-472f-8449-958e4a781b81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_06da15ad-ace6-4497-bb24-c5353ef67959" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_96a7d817-b275-472f-8449-958e4a781b81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_39931e09-1b3f-4fb2-9bd5-92d5567fafa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_06da15ad-ace6-4497-bb24-c5353ef67959" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_39931e09-1b3f-4fb2-9bd5-92d5567fafa0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_15bfc6b3-341b-4e46-9491-028df54db85b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a6b4051c-680e-4728-958a-625f9a59be28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_15bfc6b3-341b-4e46-9491-028df54db85b" xlink:to="loc_us-gaap_ProfitLoss_a6b4051c-680e-4728-958a-625f9a59be28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b5e76375-1b5f-413a-8ad3-684aca4858a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_15bfc6b3-341b-4e46-9491-028df54db85b" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b5e76375-1b5f-413a-8ad3-684aca4858a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a49077a4-bb61-4677-9966-5cbe88817e43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuredEventGainLoss_d4fbff1e-6444-4093-b377-452babaa466a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuredEventGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a49077a4-bb61-4677-9966-5cbe88817e43" xlink:to="loc_us-gaap_InsuredEventGainLoss_d4fbff1e-6444-4093-b377-452babaa466a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_799e13cd-082a-4d7d-8e04-705241e7a845" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a49077a4-bb61-4677-9966-5cbe88817e43" xlink:to="loc_us-gaap_InvestmentIncomeInterest_799e13cd-082a-4d7d-8e04-705241e7a845" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_efccf78d-cae0-48b5-932a-1007d05eb2d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a49077a4-bb61-4677-9966-5cbe88817e43" xlink:to="loc_us-gaap_InterestExpense_efccf78d-cae0-48b5-932a-1007d05eb2d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_97c7bdd1-28d1-4f63-966b-d74ffa761bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a49077a4-bb61-4677-9966-5cbe88817e43" xlink:to="loc_us-gaap_OtherIncome_97c7bdd1-28d1-4f63-966b-d74ffa761bc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_38d12e8d-210f-4309-be7f-eccdcfa3df7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a49077a4-bb61-4677-9966-5cbe88817e43" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_38d12e8d-210f-4309-be7f-eccdcfa3df7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f2f3f893-44e6-4459-96e3-97abdecf0d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a49077a4-bb61-4677-9966-5cbe88817e43" xlink:to="loc_us-gaap_OperatingIncomeLoss_f2f3f893-44e6-4459-96e3-97abdecf0d5c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20231231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1e1e848d-f223-4f5d-9b2d-e1d3a07426fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLifeInsurancePolicies_60f311ba-073e-44b6-b3ff-2d26fde673be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLifeInsurancePolicies"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1e1e848d-f223-4f5d-9b2d-e1d3a07426fb" xlink:to="loc_us-gaap_ProceedsFromLifeInsurancePolicies_60f311ba-073e-44b6-b3ff-2d26fde673be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_d2b9baf6-3cc7-4db5-b467-5ee92beba98a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1e1e848d-f223-4f5d-9b2d-e1d3a07426fb" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_d2b9baf6-3cc7-4db5-b467-5ee92beba98a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_10541cbb-138b-4f1b-860f-1fa7bc035a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1e1e848d-f223-4f5d-9b2d-e1d3a07426fb" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_10541cbb-138b-4f1b-860f-1fa7bc035a1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromSettlementOfPatentLitigation_00ff473c-64d1-4d5b-8686-c89319d5beca" xlink:href="cpix-20231231.xsd#cpix_ProceedsFromSettlementOfPatentLitigation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1e1e848d-f223-4f5d-9b2d-e1d3a07426fb" xlink:to="loc_cpix_ProceedsFromSettlementOfPatentLitigation_00ff473c-64d1-4d5b-8686-c89319d5beca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromCollaborativeArrangement_f1912ed6-6840-4837-9c93-579fc271bf44" xlink:href="cpix-20231231.xsd#cpix_ProceedsFromCollaborativeArrangement"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1e1e848d-f223-4f5d-9b2d-e1d3a07426fb" xlink:to="loc_cpix_ProceedsFromCollaborativeArrangement_f1912ed6-6840-4837-9c93-579fc271bf44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_c7c605f0-8b1f-4115-8c0c-1509c399241c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1e1e848d-f223-4f5d-9b2d-e1d3a07426fb" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_c7c605f0-8b1f-4115-8c0c-1509c399241c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_de2f199e-a783-4d0d-aa5a-48a5ee618bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e41e73fd-620c-40d4-aeb2-d4b4e345044b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_de2f199e-a783-4d0d-aa5a-48a5ee618bfc" xlink:to="loc_us-gaap_ShareBasedCompensation_e41e73fd-620c-40d4-aeb2-d4b4e345044b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingGainsLosses_4caf2e7e-0c02-416d-891d-081058202e20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingGainsLosses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_de2f199e-a783-4d0d-aa5a-48a5ee618bfc" xlink:to="loc_us-gaap_OtherNonoperatingGainsLosses_4caf2e7e-0c02-416d-891d-081058202e20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_641b427f-474e-4577-900f-a7f9ac9d5e25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_de2f199e-a783-4d0d-aa5a-48a5ee618bfc" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_641b427f-474e-4577-900f-a7f9ac9d5e25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_aa33b4e4-c3f0-4f7a-b9d3-6610a587cb94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_de2f199e-a783-4d0d-aa5a-48a5ee618bfc" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_aa33b4e4-c3f0-4f7a-b9d3-6610a587cb94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_98384827-91da-4026-baf1-619501897a58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_de2f199e-a783-4d0d-aa5a-48a5ee618bfc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_98384827-91da-4026-baf1-619501897a58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f0751445-07bc-4d8d-b04e-b24b52731316" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_de2f199e-a783-4d0d-aa5a-48a5ee618bfc" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f0751445-07bc-4d8d-b04e-b24b52731316" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NoncashOrPartNoncashGainOnTransaction_fb642dca-ba57-4e94-825c-2dd6a4493deb" xlink:href="cpix-20231231.xsd#cpix_NoncashOrPartNoncashGainOnTransaction"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_de2f199e-a783-4d0d-aa5a-48a5ee618bfc" xlink:to="loc_cpix_NoncashOrPartNoncashGainOnTransaction_fb642dca-ba57-4e94-825c-2dd6a4493deb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_0c922273-d643-4f4c-a749-3a96ca033e43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_de2f199e-a783-4d0d-aa5a-48a5ee618bfc" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_0c922273-d643-4f4c-a749-3a96ca033e43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_002b410d-a22d-4e36-aa3e-f665cc75356a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_de2f199e-a783-4d0d-aa5a-48a5ee618bfc" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_002b410d-a22d-4e36-aa3e-f665cc75356a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_914acb51-1e98-47bb-9080-f9c97347fa15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_de2f199e-a783-4d0d-aa5a-48a5ee618bfc" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_914acb51-1e98-47bb-9080-f9c97347fa15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_585539e1-39c0-4a90-89a4-72cebc0fe1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_de2f199e-a783-4d0d-aa5a-48a5ee618bfc" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_585539e1-39c0-4a90-89a4-72cebc0fe1c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a80b43d0-d3b8-412f-b506-50809f9cc5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_de2f199e-a783-4d0d-aa5a-48a5ee618bfc" xlink:to="loc_us-gaap_ProfitLoss_a80b43d0-d3b8-412f-b506-50809f9cc5b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_9dd73c5a-ff31-4295-9bed-9ca6edcb3280" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_de2f199e-a783-4d0d-aa5a-48a5ee618bfc" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_9dd73c5a-ff31-4295-9bed-9ca6edcb3280" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3c5f62b8-f2f9-4a4c-8935-926b24cdd570" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_de2f199e-a783-4d0d-aa5a-48a5ee618bfc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3c5f62b8-f2f9-4a4c-8935-926b24cdd570" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_145032e4-758b-4848-92a9-c6a51a4085ee" xlink:href="cpix-20231231.xsd#cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_de2f199e-a783-4d0d-aa5a-48a5ee618bfc" xlink:to="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_145032e4-758b-4848-92a9-c6a51a4085ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_6005e86a-49b6-4044-a258-45b219167375" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_de2f199e-a783-4d0d-aa5a-48a5ee618bfc" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_6005e86a-49b6-4044-a258-45b219167375" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_d55a51dc-ae8a-4aba-99c5-fe46648ab788" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_de2f199e-a783-4d0d-aa5a-48a5ee618bfc" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_d55a51dc-ae8a-4aba-99c5-fe46648ab788" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_247197a4-48a6-47de-8fb1-9b3e0cad838a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_20e2d14c-2ef8-435b-af5c-c659b243d52c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_247197a4-48a6-47de-8fb1-9b3e0cad838a" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_20e2d14c-2ef8-435b-af5c-c659b243d52c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_ab530f29-66be-4e02-9c8e-5cba88036875" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_247197a4-48a6-47de-8fb1-9b3e0cad838a" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_ab530f29-66be-4e02-9c8e-5cba88036875" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_8c6f8ee6-03ca-4093-b743-19fe311cfada" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_247197a4-48a6-47de-8fb1-9b3e0cad838a" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_8c6f8ee6-03ca-4093-b743-19fe311cfada" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4ed439c7-a695-46d9-90c5-41d9a1e2ee0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_247197a4-48a6-47de-8fb1-9b3e0cad838a" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4ed439c7-a695-46d9-90c5-41d9a1e2ee0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dba87514-2f2a-4f96-8180-801a3e1952d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb79c3cc-21a9-43c1-b4bf-1c20ecb99955" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dba87514-2f2a-4f96-8180-801a3e1952d1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb79c3cc-21a9-43c1-b4bf-1c20ecb99955" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_43bee162-3afd-423f-a233-4b8ffa12de90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dba87514-2f2a-4f96-8180-801a3e1952d1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_43bee162-3afd-423f-a233-4b8ffa12de90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_597d1ea2-f412-46fb-af7e-4f75d20e319c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dba87514-2f2a-4f96-8180-801a3e1952d1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_597d1ea2-f412-46fb-af7e-4f75d20e319c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNetScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#InventoriesNetScheduleofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNetScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_c09f1c5c-aef3-4f4f-9a13-71639b40a9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_e6807638-b2da-4df9-a7a4-b43c91b327c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_c09f1c5c-aef3-4f4f-9a13-71639b40a9f8" xlink:to="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_e6807638-b2da-4df9-a7a4-b43c91b327c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_f4409f17-accb-4217-b213-b1aef8da2d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_c09f1c5c-aef3-4f4f-9a13-71639b40a9f8" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_f4409f17-accb-4217-b213-b1aef8da2d3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_ab72c75d-3735-45dc-b495-3681e9cc4a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_c09f1c5c-aef3-4f4f-9a13-71639b40a9f8" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_ab72c75d-3735-45dc-b495-3681e9cc4a4e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f6751204-32bd-4f3a-b50b-6cea1b87cb66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_ff269c68-e4df-4d1c-b2fd-8afd22f8a98c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_f6751204-32bd-4f3a-b50b-6cea1b87cb66" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_ff269c68-e4df-4d1c-b2fd-8afd22f8a98c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_98e19bf1-9067-45aa-8d9c-4a80e1542f66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_f6751204-32bd-4f3a-b50b-6cea1b87cb66" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_98e19bf1-9067-45aa-8d9c-4a80e1542f66" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d914460e-0844-4397-9d07-29a8d6706055" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e4d067b0-1bc3-4eee-9bb8-4fce8a3d64f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d914460e-0844-4397-9d07-29a8d6706055" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e4d067b0-1bc3-4eee-9bb8-4fce8a3d64f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_07cad55c-993a-4d6f-85ff-a2ab395183b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d914460e-0844-4397-9d07-29a8d6706055" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_07cad55c-993a-4d6f-85ff-a2ab395183b5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5109fdcf-0bae-40eb-ad7a-b1221169a938" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_f8733db4-f4fd-4c5a-94b8-110bc279b95c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5109fdcf-0bae-40eb-ad7a-b1221169a938" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_f8733db4-f4fd-4c5a-94b8-110bc279b95c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ba5fd8fc-7c42-49bc-b981-f0a5abe8711d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5109fdcf-0bae-40eb-ad7a-b1221169a938" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ba5fd8fc-7c42-49bc-b981-f0a5abe8711d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_a97c6e19-0678-47ca-addf-d4f00b60cc73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5109fdcf-0bae-40eb-ad7a-b1221169a938" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_a97c6e19-0678-47ca-addf-d4f00b60cc73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFourAndAfter_0878cf96-e565-4a32-8ff2-fdcffa29dfc1" xlink:href="cpix-20231231.xsd#cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFourAndAfter"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5109fdcf-0bae-40eb-ad7a-b1221169a938" xlink:to="loc_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFourAndAfter_0878cf96-e565-4a32-8ff2-fdcffa29dfc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7ab50d1d-271e-43fc-9c22-b503e86a32b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5109fdcf-0bae-40eb-ad7a-b1221169a938" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7ab50d1d-271e-43fc-9c22-b503e86a32b0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_800a4e97-2bc1-46fa-b299-3734c949205d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccruedLiabilitiesInventoryPurchases_b2e5250c-1d80-4c6a-97e1-a94862afa116" xlink:href="cpix-20231231.xsd#cpix_AccruedLiabilitiesInventoryPurchases"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_800a4e97-2bc1-46fa-b299-3734c949205d" xlink:to="loc_cpix_AccruedLiabilitiesInventoryPurchases_b2e5250c-1d80-4c6a-97e1-a94862afa116" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccruedLiabilitiesStockPayable_df9c71d2-fee6-480f-914f-6d4cb4ae21ca" xlink:href="cpix-20231231.xsd#cpix_AccruedLiabilitiesStockPayable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_800a4e97-2bc1-46fa-b299-3734c949205d" xlink:to="loc_cpix_AccruedLiabilitiesStockPayable_df9c71d2-fee6-480f-914f-6d4cb4ae21ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent_991dd538-eb65-4fdf-af0b-90091396aa19" xlink:href="cpix-20231231.xsd#cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_800a4e97-2bc1-46fa-b299-3734c949205d" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent_991dd538-eb65-4fdf-af0b-90091396aa19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccruedLiabilitiesStudies_3c6e71e5-5a1d-4b19-86ce-30b0088c1ed7" xlink:href="cpix-20231231.xsd#cpix_AccruedLiabilitiesStudies"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_800a4e97-2bc1-46fa-b299-3734c949205d" xlink:to="loc_cpix_AccruedLiabilitiesStudies_3c6e71e5-5a1d-4b19-86ce-30b0088c1ed7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_633fd572-4153-4dc6-819c-8d528a5964c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_800a4e97-2bc1-46fa-b299-3734c949205d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_633fd572-4153-4dc6-819c-8d528a5964c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_bd64c2fc-ed48-450d-935d-909c0d788c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_800a4e97-2bc1-46fa-b299-3734c949205d" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_bd64c2fc-ed48-450d-935d-909c0d788c6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductSalesRelatedLiabilitiesCurrent_a610c59f-a1b5-420c-826d-7ea0f8cb209a" xlink:href="cpix-20231231.xsd#cpix_ProductSalesRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_800a4e97-2bc1-46fa-b299-3734c949205d" xlink:to="loc_cpix_ProductSalesRelatedLiabilitiesCurrent_a610c59f-a1b5-420c-826d-7ea0f8cb209a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e98ee3ee-1b90-44da-91a3-07b3a01904f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_800a4e97-2bc1-46fa-b299-3734c949205d" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e98ee3ee-1b90-44da-91a3-07b3a01904f8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofNoncurrentLiabilitiesDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#OtherCurrentandOtherLongtermLiabilitiesScheduleofNoncurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofNoncurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3dac187a-e1ab-4a6e-8696-b989de3e2c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_a8617a42-cd12-4d8b-b479-1159ccff9d28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_3dac187a-e1ab-4a6e-8696-b989de3e2c9f" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_a8617a42-cd12-4d8b-b479-1159ccff9d28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_b2ca09f7-1403-4b2e-8c89-be79fed91cda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_3dac187a-e1ab-4a6e-8696-b989de3e2c9f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_b2ca09f7-1403-4b2e-8c89-be79fed91cda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_3ee44a01-9642-49ea-bb9c-473384efe3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_3dac187a-e1ab-4a6e-8696-b989de3e2c9f" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_3ee44a01-9642-49ea-bb9c-473384efe3bc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_b55707f6-46f1-4d84-9a7b-301fb9b9cf70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_4d292434-eee9-4b4a-9017-f3d5c50d9002" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_b55707f6-46f1-4d84-9a7b-301fb9b9cf70" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_4d292434-eee9-4b4a-9017-f3d5c50d9002" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_93a7d00c-5a77-49c3-aa36-fbad52520671" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_b55707f6-46f1-4d84-9a7b-301fb9b9cf70" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_93a7d00c-5a77-49c3-aa36-fbad52520671" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_5d5a1911-3eac-472f-b668-d87ae02ce1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_b55707f6-46f1-4d84-9a7b-301fb9b9cf70" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_5d5a1911-3eac-472f-b668-d87ae02ce1b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_985d8cff-e715-48ea-8237-109506a80c89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_b55707f6-46f1-4d84-9a7b-301fb9b9cf70" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_985d8cff-e715-48ea-8237-109506a80c89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct_a185e4c7-4ce0-4950-8079-203c5e4c44a0" xlink:href="cpix-20231231.xsd#cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_b55707f6-46f1-4d84-9a7b-301fb9b9cf70" xlink:to="loc_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct_a185e4c7-4ce0-4950-8079-203c5e4c44a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsDeferredCharges_a3d4773f-89e4-4d62-a0a7-8bb08718cb84" xlink:href="cpix-20231231.xsd#cpix_DeferredTaxAssetsDeferredCharges"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_b55707f6-46f1-4d84-9a7b-301fb9b9cf70" xlink:to="loc_cpix_DeferredTaxAssetsDeferredCharges_a3d4773f-89e4-4d62-a0a7-8bb08718cb84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetOperatingLeaseLiabilities_fad3e324-4d1d-422b-bc48-37d582c99368" xlink:href="cpix-20231231.xsd#cpix_DeferredTaxAssetOperatingLeaseLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_b55707f6-46f1-4d84-9a7b-301fb9b9cf70" xlink:to="loc_cpix_DeferredTaxAssetOperatingLeaseLiabilities_fad3e324-4d1d-422b-bc48-37d582c99368" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_303f87d2-5fba-4391-a5ad-15bd2518abc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_b55707f6-46f1-4d84-9a7b-301fb9b9cf70" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_303f87d2-5fba-4391-a5ad-15bd2518abc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_8bb48300-815f-400f-bf44-8962cfec3672" xlink:href="cpix-20231231.xsd#cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_b55707f6-46f1-4d84-9a7b-301fb9b9cf70" xlink:to="loc_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_8bb48300-815f-400f-bf44-8962cfec3672" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles_e3157ebb-3e37-4262-ae21-4703ee6378b1" xlink:href="cpix-20231231.xsd#cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_b55707f6-46f1-4d84-9a7b-301fb9b9cf70" xlink:to="loc_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles_e3157ebb-3e37-4262-ae21-4703ee6378b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_6a194b34-4182-4ce7-b8ff-101c1081a4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NetDeferredTaxAssetsGross_df29fae5-da23-44e4-9a8c-350e1d5b4d74" xlink:href="cpix-20231231.xsd#cpix_NetDeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_6a194b34-4182-4ce7-b8ff-101c1081a4f5" xlink:to="loc_cpix_NetDeferredTaxAssetsGross_df29fae5-da23-44e4-9a8c-350e1d5b4d74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_495fe2a9-809d-4249-9fc6-61d65273ad7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_6a194b34-4182-4ce7-b8ff-101c1081a4f5" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_495fe2a9-809d-4249-9fc6-61d65273ad7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NetDeferredTaxAssetsGross_c306f35c-8666-4c74-be15-943d2500ce5c" xlink:href="cpix-20231231.xsd#cpix_NetDeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets_b2b511ad-4fc6-424f-83a0-2d56863800e2" xlink:href="cpix-20231231.xsd#cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cpix_NetDeferredTaxAssetsGross_c306f35c-8666-4c74-be15-943d2500ce5c" xlink:to="loc_cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets_b2b511ad-4fc6-424f-83a0-2d56863800e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_57b9f59e-a243-47f5-9d6d-85d134de2845" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cpix_NetDeferredTaxAssetsGross_c306f35c-8666-4c74-be15-943d2500ce5c" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_57b9f59e-a243-47f5-9d6d-85d134de2845" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_12be78d5-e255-470b-b981-0b4f736aa4eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cpix_NetDeferredTaxAssetsGross_c306f35c-8666-4c74-be15-943d2500ce5c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_12be78d5-e255-470b-b981-0b4f736aa4eb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e6c574ab-e1e1-40e3-8d70-998a68f72ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_ab63d7a1-27f0-4a52-858b-95fc9e29febc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e6c574ab-e1e1-40e3-8d70-998a68f72ebf" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_ab63d7a1-27f0-4a52-858b-95fc9e29febc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_c133c6f0-34fa-4aa2-8ee1-300602d46dab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e6c574ab-e1e1-40e3-8d70-998a68f72ebf" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_c133c6f0-34fa-4aa2-8ee1-300602d46dab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_fc3e3110-8fdc-4168-bc64-de7a9ca74986" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_afae1fb0-3310-46a8-9748-139c6708702c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_fc3e3110-8fdc-4168-bc64-de7a9ca74986" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_afae1fb0-3310-46a8-9748-139c6708702c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOtherTaxExpenseBenefit_86876208-9206-4816-9195-afb0d87db8b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_fc3e3110-8fdc-4168-bc64-de7a9ca74986" xlink:to="loc_us-gaap_DeferredOtherTaxExpenseBenefit_86876208-9206-4816-9195-afb0d87db8b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOtherTaxExpenseBenefit_e1afc6af-e693-430b-9978-68ed68044c88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_f645e1e5-40cd-4b8f-8ffb-439a4a54154b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredOtherTaxExpenseBenefit_e1afc6af-e693-430b-9978-68ed68044c88" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_f645e1e5-40cd-4b8f-8ffb-439a4a54154b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_732f2f72-6db3-4e6d-b118-785674d99d59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredOtherTaxExpenseBenefit_e1afc6af-e693-430b-9978-68ed68044c88" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_732f2f72-6db3-4e6d-b118-785674d99d59" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0fd195f2-c6e0-49cb-9600-75cf6cedf38f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8ccc9acf-9bd6-4d1a-a5c5-31bad279154d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0fd195f2-c6e0-49cb-9600-75cf6cedf38f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8ccc9acf-9bd6-4d1a-a5c5-31bad279154d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_32e9d09d-190e-48e3-a568-3fdea3eb7c92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0fd195f2-c6e0-49cb-9600-75cf6cedf38f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_32e9d09d-190e-48e3-a568-3fdea3eb7c92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_172f5bc4-c726-4def-b70b-80bd85348c19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0fd195f2-c6e0-49cb-9600-75cf6cedf38f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_172f5bc4-c726-4def-b70b-80bd85348c19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_33c91aba-4f25-4a7e-9b73-69535f29b767" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0fd195f2-c6e0-49cb-9600-75cf6cedf38f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_33c91aba-4f25-4a7e-9b73-69535f29b767" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5ca91154-a824-46a8-87a8-284c97cc4a13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0fd195f2-c6e0-49cb-9600-75cf6cedf38f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5ca91154-a824-46a8-87a8-284c97cc4a13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EffectiveIncomeTaxRateReconciliationDeferredTrueUpsPercent_61e5a596-de6b-420d-8400-e3a970e41985" xlink:href="cpix-20231231.xsd#cpix_EffectiveIncomeTaxRateReconciliationDeferredTrueUpsPercent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0fd195f2-c6e0-49cb-9600-75cf6cedf38f" xlink:to="loc_cpix_EffectiveIncomeTaxRateReconciliationDeferredTrueUpsPercent_61e5a596-de6b-420d-8400-e3a970e41985" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_b9580b59-a0d9-4365-8991-353833082f18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0fd195f2-c6e0-49cb-9600-75cf6cedf38f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_b9580b59-a0d9-4365-8991-353833082f18" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#LeasesLeasePositionDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_7e378785-0d42-4e3e-b865-1e221e21ae15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_cc90f429-a7f2-4204-abb0-1b2ef5a920c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_7e378785-0d42-4e3e-b865-1e221e21ae15" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_cc90f429-a7f2-4204-abb0-1b2ef5a920c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_913ed44c-493a-4123-ac27-e054958e553c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_7e378785-0d42-4e3e-b865-1e221e21ae15" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_913ed44c-493a-4123-ac27-e054958e553c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c5df1166-c535-4fb7-8a4e-9d80e34720c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_85861ecf-84af-460f-9a97-822a32eaefe9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c5df1166-c535-4fb7-8a4e-9d80e34720c1" xlink:to="loc_us-gaap_OperatingLeaseLiability_85861ecf-84af-460f-9a97-822a32eaefe9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0d21fb0e-c5c3-4183-9818-cef957d5845c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c5df1166-c535-4fb7-8a4e-9d80e34720c1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0d21fb0e-c5c3-4183-9818-cef957d5845c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1" xlink:type="simple" xlink:href="cpix-20231231.xsd#LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_bd34b827-880e-4def-94a2-881cc34961f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_356c6341-4f18-4a60-bc52-52f9b0a5a25a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_bd34b827-880e-4def-94a2-881cc34961f3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_356c6341-4f18-4a60-bc52-52f9b0a5a25a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_dd144da0-2148-481a-bd12-795d8ec4be48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_bd34b827-880e-4def-94a2-881cc34961f3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_dd144da0-2148-481a-bd12-795d8ec4be48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0a56526a-1165-444d-b46a-a83b0e384aef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_bd34b827-880e-4def-94a2-881cc34961f3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0a56526a-1165-444d-b46a-a83b0e384aef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_01242d7d-2db4-4c4b-9965-15b6467c67de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_bd34b827-880e-4def-94a2-881cc34961f3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_01242d7d-2db4-4c4b-9965-15b6467c67de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a2e8c12d-c220-486a-9371-d42b9bea32f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_bd34b827-880e-4def-94a2-881cc34961f3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a2e8c12d-c220-486a-9371-d42b9bea32f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4ca43f0e-c09c-44b2-baa0-6955b40b2a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_bd34b827-880e-4def-94a2-881cc34961f3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4ca43f0e-c09c-44b2-baa0-6955b40b2a3c" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>16
<FILENAME>cpix-20231231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:6edb08b2-28be-4fe2-96a1-5228f16440ba,g:0b7981d4-3364-432a-a869-7a65f1514fac-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="cpix-20231231.xsd#ConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c91c6650-64bb-47f9-ba31-4ab7358debfe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_07b916b2-05e0-4226-b0db-eed2669c4d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c91c6650-64bb-47f9-ba31-4ab7358debfe" xlink:to="loc_us-gaap_StatementTable_07b916b2-05e0-4226-b0db-eed2669c4d0e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fd71491b-20f9-4b25-bef7-5163743d16ab" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_07b916b2-05e0-4226-b0db-eed2669c4d0e" xlink:to="loc_srt_ProductOrServiceAxis_fd71491b-20f9-4b25-bef7-5163743d16ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fd71491b-20f9-4b25-bef7-5163743d16ab_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_fd71491b-20f9-4b25-bef7-5163743d16ab" xlink:to="loc_srt_ProductsAndServicesDomain_fd71491b-20f9-4b25-bef7-5163743d16ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d91bfb9d-1984-4aa1-b795-4de0af3cad00" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_fd71491b-20f9-4b25-bef7-5163743d16ab" xlink:to="loc_srt_ProductsAndServicesDomain_d91bfb9d-1984-4aa1-b795-4de0af3cad00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_36967a74-c403-4b3e-aca3-6d5ba8455cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d91bfb9d-1984-4aa1-b795-4de0af3cad00" xlink:to="loc_us-gaap_ProductMember_36967a74-c403-4b3e-aca3-6d5ba8455cbf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturedProductOtherMember_0e49d894-3378-449b-bc70-28c971d84ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManufacturedProductOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d91bfb9d-1984-4aa1-b795-4de0af3cad00" xlink:to="loc_us-gaap_ManufacturedProductOtherMember_0e49d894-3378-449b-bc70-28c971d84ad2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_68b32b7f-9a84-4746-abeb-6ac094881691" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c91c6650-64bb-47f9-ba31-4ab7358debfe" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_68b32b7f-9a84-4746-abeb-6ac094881691" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_7a4d1a4f-9569-4e36-b9d0-c11418516f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c91c6650-64bb-47f9-ba31-4ab7358debfe" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_7a4d1a4f-9569-4e36-b9d0-c11418516f0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5b833643-7f69-4825-8cab-cd41fb215463" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7a4d1a4f-9569-4e36-b9d0-c11418516f0d" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5b833643-7f69-4825-8cab-cd41fb215463" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_dd77bdad-06cd-4d34-9fad-dc1755e9afc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7a4d1a4f-9569-4e36-b9d0-c11418516f0d" xlink:to="loc_us-gaap_SellingAndMarketingExpense_dd77bdad-06cd-4d34-9fad-dc1755e9afc1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0e5b77eb-551b-49aa-aee3-d30c35008e95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7a4d1a4f-9569-4e36-b9d0-c11418516f0d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0e5b77eb-551b-49aa-aee3-d30c35008e95" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_5d7b7ad8-2dc1-4c66-9676-4395ab3ddbbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7a4d1a4f-9569-4e36-b9d0-c11418516f0d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_5d7b7ad8-2dc1-4c66-9676-4395ab3ddbbe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_b926249e-81d5-4d80-91f7-8f1e8590c093" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7a4d1a4f-9569-4e36-b9d0-c11418516f0d" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_b926249e-81d5-4d80-91f7-8f1e8590c093" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b1946114-0cba-4f17-8f7f-4b91dc80abf5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7a4d1a4f-9569-4e36-b9d0-c11418516f0d" xlink:to="loc_us-gaap_CostsAndExpenses_b1946114-0cba-4f17-8f7f-4b91dc80abf5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bd765521-9cce-4da7-b275-e6ce3721092f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7a4d1a4f-9569-4e36-b9d0-c11418516f0d" xlink:to="loc_us-gaap_OperatingIncomeLoss_bd765521-9cce-4da7-b275-e6ce3721092f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_23ee84e6-8e0b-4da4-8b75-c075524a07a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c91c6650-64bb-47f9-ba31-4ab7358debfe" xlink:to="loc_us-gaap_InvestmentIncomeInterest_23ee84e6-8e0b-4da4-8b75-c075524a07a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_5bb71215-5da2-4dd1-b04d-4e3f31682fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c91c6650-64bb-47f9-ba31-4ab7358debfe" xlink:to="loc_us-gaap_OtherIncome_5bb71215-5da2-4dd1-b04d-4e3f31682fe8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_1c612fa3-0147-4ce0-b2eb-45531bf46db3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c91c6650-64bb-47f9-ba31-4ab7358debfe" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_1c612fa3-0147-4ce0-b2eb-45531bf46db3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuredEventGainLoss_6bf19adb-20e3-4f09-b796-954c7ac13a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuredEventGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c91c6650-64bb-47f9-ba31-4ab7358debfe" xlink:to="loc_us-gaap_InsuredEventGainLoss_6bf19adb-20e3-4f09-b796-954c7ac13a4b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f8e4ec3f-4644-4bf0-a5c6-5da9c4015837" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c91c6650-64bb-47f9-ba31-4ab7358debfe" xlink:to="loc_us-gaap_InterestExpense_f8e4ec3f-4644-4bf0-a5c6-5da9c4015837" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9ac941f0-03fd-4958-8b15-94b3ff4bc711" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c91c6650-64bb-47f9-ba31-4ab7358debfe" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9ac941f0-03fd-4958-8b15-94b3ff4bc711" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0857d8b6-3932-416d-ad8d-5fb3760075ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c91c6650-64bb-47f9-ba31-4ab7358debfe" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0857d8b6-3932-416d-ad8d-5fb3760075ca" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3a103792-f59f-46c3-bccc-de77769e2968" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c91c6650-64bb-47f9-ba31-4ab7358debfe" xlink:to="loc_us-gaap_ProfitLoss_3a103792-f59f-46c3-bccc-de77769e2968" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_486618b2-b17e-464b-885e-f2cebe914035" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c91c6650-64bb-47f9-ba31-4ab7358debfe" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_486618b2-b17e-464b-885e-f2cebe914035" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6f2547fc-d380-474a-a90e-2f4af8343e94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c91c6650-64bb-47f9-ba31-4ab7358debfe" xlink:to="loc_us-gaap_NetIncomeLoss_6f2547fc-d380-474a-a90e-2f4af8343e94" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_97318d54-cba7-4d34-9917-1e260c93844a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c91c6650-64bb-47f9-ba31-4ab7358debfe" xlink:to="loc_us-gaap_EarningsPerShareAbstract_97318d54-cba7-4d34-9917-1e260c93844a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_03c6bf04-3b6d-44b9-8c97-9052468bd0db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_97318d54-cba7-4d34-9917-1e260c93844a" xlink:to="loc_us-gaap_EarningsPerShareBasic_03c6bf04-3b6d-44b9-8c97-9052468bd0db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_8d6244b8-9d95-4a1c-ad71-285ca87426e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_97318d54-cba7-4d34-9917-1e260c93844a" xlink:to="loc_us-gaap_EarningsPerShareDiluted_8d6244b8-9d95-4a1c-ad71-285ca87426e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f03d2a1d-d0fb-4a7f-987b-39c319e2590a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c91c6650-64bb-47f9-ba31-4ab7358debfe" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f03d2a1d-d0fb-4a7f-987b-39c319e2590a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_20d8c464-a09f-4a62-9337-b25edea21efc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f03d2a1d-d0fb-4a7f-987b-39c319e2590a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_20d8c464-a09f-4a62-9337-b25edea21efc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_955e861d-8110-4690-b121-db60828e54ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f03d2a1d-d0fb-4a7f-987b-39c319e2590a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_955e861d-8110-4690-b121-db60828e54ed" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="cpix-20231231.xsd#ConsolidatedStatementsofEquity"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f34816a2-ea84-49ff-8e8b-889fc1c17fab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_eaea31e4-692d-4821-9c4e-30e5f4864c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f34816a2-ea84-49ff-8e8b-889fc1c17fab" xlink:to="loc_us-gaap_StatementTable_eaea31e4-692d-4821-9c4e-30e5f4864c2a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_37bcc066-676b-46fb-9b33-5bc5c1d723fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_eaea31e4-692d-4821-9c4e-30e5f4864c2a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_37bcc066-676b-46fb-9b33-5bc5c1d723fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_37bcc066-676b-46fb-9b33-5bc5c1d723fa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_37bcc066-676b-46fb-9b33-5bc5c1d723fa" xlink:to="loc_us-gaap_EquityComponentDomain_37bcc066-676b-46fb-9b33-5bc5c1d723fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8a08b8ac-8120-464a-b2b7-7225a6c9ada2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_37bcc066-676b-46fb-9b33-5bc5c1d723fa" xlink:to="loc_us-gaap_EquityComponentDomain_8a08b8ac-8120-464a-b2b7-7225a6c9ada2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a7f23e7b-ec3c-46d3-81f6-2426e2db5bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8a08b8ac-8120-464a-b2b7-7225a6c9ada2" xlink:to="loc_us-gaap_CommonStockMember_a7f23e7b-ec3c-46d3-81f6-2426e2db5bbf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ba4ede33-0696-4598-8884-8cc5e8e760b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8a08b8ac-8120-464a-b2b7-7225a6c9ada2" xlink:to="loc_us-gaap_RetainedEarningsMember_ba4ede33-0696-4598-8884-8cc5e8e760b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_0490ff12-8806-45b7-9054-9328b00b55fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8a08b8ac-8120-464a-b2b7-7225a6c9ada2" xlink:to="loc_us-gaap_NoncontrollingInterestMember_0490ff12-8806-45b7-9054-9328b00b55fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31e74e44-f185-4e7e-8162-49655371bab2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f34816a2-ea84-49ff-8e8b-889fc1c17fab" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31e74e44-f185-4e7e-8162-49655371bab2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_681335d2-ac3e-4c22-bf8a-68594e548a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31e74e44-f185-4e7e-8162-49655371bab2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_681335d2-ac3e-4c22-bf8a-68594e548a1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_43d4f0ce-cd59-4e85-971b-3fbf8a390684" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31e74e44-f185-4e7e-8162-49655371bab2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_43d4f0ce-cd59-4e85-971b-3fbf8a390684" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3798e89e-f2a1-4842-b0f4-9813e4f025a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31e74e44-f185-4e7e-8162-49655371bab2" xlink:to="loc_us-gaap_ProfitLoss_3798e89e-f2a1-4842-b0f4-9813e4f025a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRedeemedOrCalledDuringPeriodShares_106eaf0e-3776-461d-a39b-478e3781d217" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31e74e44-f185-4e7e-8162-49655371bab2" xlink:to="loc_us-gaap_StockRedeemedOrCalledDuringPeriodShares_106eaf0e-3776-461d-a39b-478e3781d217" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue_6ddc53b4-becf-4925-a662-21f6341e557b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31e74e44-f185-4e7e-8162-49655371bab2" xlink:to="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue_6ddc53b4-becf-4925-a662-21f6341e557b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_436d86e9-7d94-4542-859c-975cadd68aba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31e74e44-f185-4e7e-8162-49655371bab2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_436d86e9-7d94-4542-859c-975cadd68aba" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c039445a-e0b6-4dac-86f3-bec9f4d9a033" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31e74e44-f185-4e7e-8162-49655371bab2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c039445a-e0b6-4dac-86f3-bec9f4d9a033" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_6b5be975-ccc6-44b3-b66b-828beb70521f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31e74e44-f185-4e7e-8162-49655371bab2" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_6b5be975-ccc6-44b3-b66b-828beb70521f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_32cd3d8c-e139-4ff8-904e-4ca156ad9b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31e74e44-f185-4e7e-8162-49655371bab2" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_32cd3d8c-e139-4ff8-904e-4ca156ad9b0c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_75b28116-026c-420e-8918-2a987d4f10df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_32d71ffe-fcc7-47b7-b08f-cfcaccc29ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#OrganizationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_282d56a7-e802-4a70-9d44-3f512528da57" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_e843a44c-8eb1-4669-a0e4-1e8eb9e2542e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_282d56a7-e802-4a70-9d44-3f512528da57" xlink:to="loc_dei_EntitiesTable_e843a44c-8eb1-4669-a0e4-1e8eb9e2542e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_bf6ca88b-993a-4380-83dd-2849791f5629" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_e843a44c-8eb1-4669-a0e4-1e8eb9e2542e" xlink:to="loc_dei_LegalEntityAxis_bf6ca88b-993a-4380-83dd-2849791f5629" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_bf6ca88b-993a-4380-83dd-2849791f5629_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_bf6ca88b-993a-4380-83dd-2849791f5629" xlink:to="loc_dei_EntityDomain_bf6ca88b-993a-4380-83dd-2849791f5629_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_52610ad2-9ebf-45be-81f4-4ebd671d5111" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_bf6ca88b-993a-4380-83dd-2849791f5629" xlink:to="loc_dei_EntityDomain_52610ad2-9ebf-45be-81f4-4ebd671d5111" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CumberlandEmergingTechnologiesIncMember_031c75d2-d766-46eb-b0e5-40657cce4c79" xlink:href="cpix-20231231.xsd#cpix_CumberlandEmergingTechnologiesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_52610ad2-9ebf-45be-81f4-4ebd671d5111" xlink:to="loc_cpix_CumberlandEmergingTechnologiesIncMember_031c75d2-d766-46eb-b0e5-40657cce4c79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1afcc298-67c1-47b7-bf60-9de954f377db" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_e843a44c-8eb1-4669-a0e4-1e8eb9e2542e" xlink:to="loc_srt_CounterpartyNameAxis_1afcc298-67c1-47b7-bf60-9de954f377db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1afcc298-67c1-47b7-bf60-9de954f377db_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_1afcc298-67c1-47b7-bf60-9de954f377db" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1afcc298-67c1-47b7-bf60-9de954f377db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_beccb878-685a-42c0-878c-86e2d3f2a68a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_1afcc298-67c1-47b7-bf60-9de954f377db" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_beccb878-685a-42c0-878c-86e2d3f2a68a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_9199eab0-55a5-48cc-b67e-ffac91c07820" xlink:href="cpix-20231231.xsd#cpix_HongKongWinHealthPharmaGroupCoLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_beccb878-685a-42c0-878c-86e2d3f2a68a" xlink:to="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_9199eab0-55a5-48cc-b67e-ffac91c07820" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_b016a6a9-f95c-467c-8d95-c5b0b553390c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_e843a44c-8eb1-4669-a0e4-1e8eb9e2542e" xlink:to="loc_srt_OwnershipAxis_b016a6a9-f95c-467c-8d95-c5b0b553390c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_b016a6a9-f95c-467c-8d95-c5b0b553390c_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_b016a6a9-f95c-467c-8d95-c5b0b553390c" xlink:to="loc_srt_OwnershipDomain_b016a6a9-f95c-467c-8d95-c5b0b553390c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_49742183-96e0-4d8a-8f9b-0b1dd721069e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_b016a6a9-f95c-467c-8d95-c5b0b553390c" xlink:to="loc_srt_OwnershipDomain_49742183-96e0-4d8a-8f9b-0b1dd721069e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CumberlandEmergingTechnologiesIncMember_f68f1ea7-7a69-4f8f-820a-6a898853e199" xlink:href="cpix-20231231.xsd#cpix_CumberlandEmergingTechnologiesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_49742183-96e0-4d8a-8f9b-0b1dd721069e" xlink:to="loc_cpix_CumberlandEmergingTechnologiesIncMember_f68f1ea7-7a69-4f8f-820a-6a898853e199" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_48fe95cc-bae3-40b9-8490-2dd26cee8f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_282d56a7-e802-4a70-9d44-3f512528da57" xlink:to="loc_us-gaap_NoncontrollingInterestAbstract_48fe95cc-bae3-40b9-8490-2dd26cee8f7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_c7bec69e-2b7a-4d8b-9b82-8f49c35fcf49" xlink:href="cpix-20231231.xsd#cpix_SubsidiaryInvestmentPurchaseOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_48fe95cc-bae3-40b9-8490-2dd26cee8f7c" xlink:to="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_c7bec69e-2b7a-4d8b-9b82-8f49c35fcf49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_290b207d-cb77-44c4-ade8-af3ff288966a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_48fe95cc-bae3-40b9-8490-2dd26cee8f7c" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_290b207d-cb77-44c4-ade8-af3ff288966a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_236f1fdb-3fb8-4e17-b64c-3c41c5bd0fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_48fe95cc-bae3-40b9-8490-2dd26cee8f7c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_236f1fdb-3fb8-4e17-b64c-3c41c5bd0fc6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharebasedCompensationCharitableContributionofSharesShares_2c7647ff-3a7f-4b2c-bfdd-12340dce75af" xlink:href="cpix-20231231.xsd#cpix_SharebasedCompensationCharitableContributionofSharesShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_48fe95cc-bae3-40b9-8490-2dd26cee8f7c" xlink:to="loc_cpix_SharebasedCompensationCharitableContributionofSharesShares_2c7647ff-3a7f-4b2c-bfdd-12340dce75af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions_2d035f6d-09e0-4aa9-9e02-c1223132cbf0" xlink:href="cpix-20231231.xsd#cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_48fe95cc-bae3-40b9-8490-2dd26cee8f7c" xlink:to="loc_cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions_2d035f6d-09e0-4aa9-9e02-c1223132cbf0" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#SignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_a30007fb-b6a3-4d2e-a207-e0ccbf5d38ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_bc888736-f015-4c54-bb70-6474b99b3ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_a30007fb-b6a3-4d2e-a207-e0ccbf5d38ff" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_bc888736-f015-4c54-bb70-6474b99b3ebb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8b86baf9-5a50-493a-819e-a709fc8d40cd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_bc888736-f015-4c54-bb70-6474b99b3ebb" xlink:to="loc_srt_CounterpartyNameAxis_8b86baf9-5a50-493a-819e-a709fc8d40cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8b86baf9-5a50-493a-819e-a709fc8d40cd_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_8b86baf9-5a50-493a-819e-a709fc8d40cd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8b86baf9-5a50-493a-819e-a709fc8d40cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_67268de5-9ff4-40f0-9847-5e4fa0f848f1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_8b86baf9-5a50-493a-819e-a709fc8d40cd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_67268de5-9ff4-40f0-9847-5e4fa0f848f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WinHealthInvestmentSingaporeLtdMember_eed8d81b-67f6-46ea-b5a1-8095ed3b2b7d" xlink:href="cpix-20231231.xsd#cpix_WinHealthInvestmentSingaporeLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_67268de5-9ff4-40f0-9847-5e4fa0f848f1" xlink:to="loc_cpix_WinHealthInvestmentSingaporeLtdMember_eed8d81b-67f6-46ea-b5a1-8095ed3b2b7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MartinS.BrownJr.sLawFirmMember_2ad0a75f-a5a0-4e55-8946-250509f30434" xlink:href="cpix-20231231.xsd#cpix_MartinS.BrownJr.sLawFirmMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_67268de5-9ff4-40f0-9847-5e4fa0f848f1" xlink:to="loc_cpix_MartinS.BrownJr.sLawFirmMember_2ad0a75f-a5a0-4e55-8946-250509f30434" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_bdba99a7-95b1-477e-9f3d-ab4904a57ed5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_bc888736-f015-4c54-bb70-6474b99b3ebb" xlink:to="loc_srt_StatementGeographicalAxis_bdba99a7-95b1-477e-9f3d-ab4904a57ed5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_bdba99a7-95b1-477e-9f3d-ab4904a57ed5_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_bdba99a7-95b1-477e-9f3d-ab4904a57ed5" xlink:to="loc_srt_SegmentGeographicalDomain_bdba99a7-95b1-477e-9f3d-ab4904a57ed5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b6808417-6cdd-453c-ac32-e0e44ef40679" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_bdba99a7-95b1-477e-9f3d-ab4904a57ed5" xlink:to="loc_srt_SegmentGeographicalDomain_b6808417-6cdd-453c-ac32-e0e44ef40679" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_ce9b4e95-4179-4aa1-b1ba-df97b57b9376" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b6808417-6cdd-453c-ac32-e0e44ef40679" xlink:to="loc_us-gaap_NonUsMember_ce9b4e95-4179-4aa1-b1ba-df97b57b9376" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccountsReceivableAllowancesByComponentAxis_b1f9e666-d008-4184-8e4c-3f11e0318650" xlink:href="cpix-20231231.xsd#cpix_AccountsReceivableAllowancesByComponentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_bc888736-f015-4c54-bb70-6474b99b3ebb" xlink:to="loc_cpix_AccountsReceivableAllowancesByComponentAxis_b1f9e666-d008-4184-8e4c-3f11e0318650" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccountsReceivableAllowancesByComponentDomain_b1f9e666-d008-4184-8e4c-3f11e0318650_default" xlink:href="cpix-20231231.xsd#cpix_AccountsReceivableAllowancesByComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cpix_AccountsReceivableAllowancesByComponentAxis_b1f9e666-d008-4184-8e4c-3f11e0318650" xlink:to="loc_cpix_AccountsReceivableAllowancesByComponentDomain_b1f9e666-d008-4184-8e4c-3f11e0318650_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccountsReceivableAllowancesByComponentDomain_6e2f7d7b-86c6-41be-b0cf-965d3b2b6061" xlink:href="cpix-20231231.xsd#cpix_AccountsReceivableAllowancesByComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cpix_AccountsReceivableAllowancesByComponentAxis_b1f9e666-d008-4184-8e4c-3f11e0318650" xlink:to="loc_cpix_AccountsReceivableAllowancesByComponentDomain_6e2f7d7b-86c6-41be-b0cf-965d3b2b6061" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember_91c96e6a-dad1-4ca4-aa0f-d3c24becfea8" xlink:href="cpix-20231231.xsd#cpix_ChargebacksCashDiscountsAndDamagedGoodsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_AccountsReceivableAllowancesByComponentDomain_6e2f7d7b-86c6-41be-b0cf-965d3b2b6061" xlink:to="loc_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember_91c96e6a-dad1-4ca4-aa0f-d3c24becfea8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_267ec083-ad78-4d27-a203-21d753d9fd6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_bc888736-f015-4c54-bb70-6474b99b3ebb" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_267ec083-ad78-4d27-a203-21d753d9fd6d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_267ec083-ad78-4d27-a203-21d753d9fd6d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_267ec083-ad78-4d27-a203-21d753d9fd6d" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_267ec083-ad78-4d27-a203-21d753d9fd6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_28b0a147-4b0d-4ef6-b72b-22d536cbc56a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_267ec083-ad78-4d27-a203-21d753d9fd6d" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_28b0a147-4b0d-4ef6-b72b-22d536cbc56a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_a9bf4acb-9cdd-403b-b5a0-9a78e10dfeef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_28b0a147-4b0d-4ef6-b72b-22d536cbc56a" xlink:to="loc_us-gaap_RelatedPartyMember_a9bf4acb-9cdd-403b-b5a0-9a78e10dfeef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c410eaed-4191-40c9-8cf2-d13291442cea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_a30007fb-b6a3-4d2e-a207-e0ccbf5d38ff" xlink:to="loc_us-gaap_SegmentReportingAbstract_c410eaed-4191-40c9-8cf2-d13291442cea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_7293519c-5a91-4214-a418-b4ef55215da9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAbstract_c410eaed-4191-40c9-8cf2-d13291442cea" xlink:to="loc_us-gaap_NumberOfOperatingSegments_7293519c-5a91-4214-a418-b4ef55215da9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a45a2099-107d-4038-926c-a89e77e6d364" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAbstract_c410eaed-4191-40c9-8cf2-d13291442cea" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a45a2099-107d-4038-926c-a89e77e6d364" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_16c00f7f-661a-44c4-8ebe-4f08b195534b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAbstract_c410eaed-4191-40c9-8cf2-d13291442cea" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_16c00f7f-661a-44c4-8ebe-4f08b195534b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_f6a9a3f3-c9f4-48cd-a6a2-43831081bd8a" xlink:href="cpix-20231231.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAbstract_c410eaed-4191-40c9-8cf2-d13291442cea" xlink:to="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_f6a9a3f3-c9f4-48cd-a6a2-43831081bd8a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_9f26cd75-a93b-4ff7-93b4-2457b3234268" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAbstract_c410eaed-4191-40c9-8cf2-d13291442cea" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_9f26cd75-a93b-4ff7-93b4-2457b3234268" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_5662c924-565c-4992-8fcd-5aaf633f1359" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAbstract_c410eaed-4191-40c9-8cf2-d13291442cea" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_5662c924-565c-4992-8fcd-5aaf633f1359" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_4a50aa3c-fdea-4605-99e2-71e8adb206f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAbstract_c410eaed-4191-40c9-8cf2-d13291442cea" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_4a50aa3c-fdea-4605-99e2-71e8adb206f5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_959043c0-a728-4b4b-97ba-b09c9318547f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAbstract_c410eaed-4191-40c9-8cf2-d13291442cea" xlink:to="loc_us-gaap_CostsAndExpenses_959043c0-a728-4b4b-97ba-b09c9318547f" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#VibativSancusoandRediTrexProductsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_34003409-3447-4d8c-aa92-4cc67de5cef3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38d2875e-825b-42a6-b7f0-d0952a604ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34003409-3447-4d8c-aa92-4cc67de5cef3" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38d2875e-825b-42a6-b7f0-d0952a604ca9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0ab6c7f0-8f81-4f80-a4a0-b830c7fa5b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38d2875e-825b-42a6-b7f0-d0952a604ca9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0ab6c7f0-8f81-4f80-a4a0-b830c7fa5b5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0ab6c7f0-8f81-4f80-a4a0-b830c7fa5b5b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0ab6c7f0-8f81-4f80-a4a0-b830c7fa5b5b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0ab6c7f0-8f81-4f80-a4a0-b830c7fa5b5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_45f01dcd-495e-42c0-a994-906e2228915b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0ab6c7f0-8f81-4f80-a4a0-b830c7fa5b5b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_45f01dcd-495e-42c0-a994-906e2228915b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductAssetsAndGlobalRightsVibativMember_b056391e-e951-4ac1-a275-cabf1a96164d" xlink:href="cpix-20231231.xsd#cpix_ProductAssetsAndGlobalRightsVibativMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_45f01dcd-495e-42c0-a994-906e2228915b" xlink:to="loc_cpix_ProductAssetsAndGlobalRightsVibativMember_b056391e-e951-4ac1-a275-cabf1a96164d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_U.S.ProductAssetRightsSancusoMember_ad682603-f2f3-4093-aeae-b18315e67d46" xlink:href="cpix-20231231.xsd#cpix_U.S.ProductAssetRightsSancusoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_45f01dcd-495e-42c0-a994-906e2228915b" xlink:to="loc_cpix_U.S.ProductAssetRightsSancusoMember_ad682603-f2f3-4093-aeae-b18315e67d46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_741106c1-75cd-4711-8de8-406f63079c58" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38d2875e-825b-42a6-b7f0-d0952a604ca9" xlink:to="loc_srt_RangeAxis_741106c1-75cd-4711-8de8-406f63079c58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_741106c1-75cd-4711-8de8-406f63079c58_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_741106c1-75cd-4711-8de8-406f63079c58" xlink:to="loc_srt_RangeMember_741106c1-75cd-4711-8de8-406f63079c58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fc9cc1a2-2386-49c4-808d-3a3b066c4ea7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_741106c1-75cd-4711-8de8-406f63079c58" xlink:to="loc_srt_RangeMember_fc9cc1a2-2386-49c4-808d-3a3b066c4ea7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c6ffbf54-a172-4ad4-9e72-9cd3b0ad298e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fc9cc1a2-2386-49c4-808d-3a3b066c4ea7" xlink:to="loc_srt_MaximumMember_c6ffbf54-a172-4ad4-9e72-9cd3b0ad298e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_9b3df18c-1859-43fd-a2c2-a446306d533b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34003409-3447-4d8c-aa92-4cc67de5cef3" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_9b3df18c-1859-43fd-a2c2-a446306d533b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsToAcquireBusinessMilestonePayment_5b2611d7-cf5f-413c-badb-ed3098ebb018" xlink:href="cpix-20231231.xsd#cpix_PaymentsToAcquireBusinessMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34003409-3447-4d8c-aa92-4cc67de5cef3" xlink:to="loc_cpix_PaymentsToAcquireBusinessMilestonePayment_5b2611d7-cf5f-413c-badb-ed3098ebb018" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage_d263eb13-ad3d-465f-94b6-001819c6cad8" xlink:href="cpix-20231231.xsd#cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34003409-3447-4d8c-aa92-4cc67de5cef3" xlink:to="loc_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage_d263eb13-ad3d-465f-94b6-001819c6cad8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold_cb0883d9-06ad-4551-bc48-b4944d849405" xlink:href="cpix-20231231.xsd#cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34003409-3447-4d8c-aa92-4cc67de5cef3" xlink:to="loc_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold_cb0883d9-06ad-4551-bc48-b4944d849405" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_4fb0f0aa-3b7e-4743-80ed-bf3ea8fff291" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34003409-3447-4d8c-aa92-4cc67de5cef3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_4fb0f0aa-3b7e-4743-80ed-bf3ea8fff291" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_0538d905-e536-4585-a1fe-0ae501f20309" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34003409-3447-4d8c-aa92-4cc67de5cef3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_0538d905-e536-4585-a1fe-0ae501f20309" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsToAcquireBusinessMilestonePaymentRemaining_5b93ba17-0f9c-4ba4-8caf-0eaa8ba3eaef" xlink:href="cpix-20231231.xsd#cpix_PaymentsToAcquireBusinessMilestonePaymentRemaining"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34003409-3447-4d8c-aa92-4cc67de5cef3" xlink:to="loc_cpix_PaymentsToAcquireBusinessMilestonePaymentRemaining_5b93ba17-0f9c-4ba4-8caf-0eaa8ba3eaef" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_baae6b22-358a-4cb9-861b-9102d958cbd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34003409-3447-4d8c-aa92-4cc67de5cef3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_baae6b22-358a-4cb9-861b-9102d958cbd9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_8e6ecb17-97b6-4f16-bc1a-fe1982fe6c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34003409-3447-4d8c-aa92-4cc67de5cef3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_8e6ecb17-97b6-4f16-bc1a-fe1982fe6c4d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_86646bd2-2240-4d5f-952f-5d3968044932" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34003409-3447-4d8c-aa92-4cc67de5cef3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_86646bd2-2240-4d5f-952f-5d3968044932" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a8403eaa-0317-41a9-94ed-6b27551a9124" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34003409-3447-4d8c-aa92-4cc67de5cef3" xlink:to="loc_us-gaap_Goodwill_a8403eaa-0317-41a9-94ed-6b27551a9124" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_b1040a2d-5cf9-466c-ab65-cbd3643ff253" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34003409-3447-4d8c-aa92-4cc67de5cef3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_b1040a2d-5cf9-466c-ab65-cbd3643ff253" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMilestonePayable_f19dd984-d6c9-4131-bb24-baa317404f29" xlink:href="cpix-20231231.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMilestonePayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34003409-3447-4d8c-aa92-4cc67de5cef3" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMilestonePayable_f19dd984-d6c9-4131-bb24-baa317404f29" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25c8459b-8849-4a50-82fa-67560b7a4f00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_141985df-4a72-461a-9043-ae4024a2a87f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25c8459b-8849-4a50-82fa-67560b7a4f00" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_141985df-4a72-461a-9043-ae4024a2a87f" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b4f357e9-cffc-4cd2-ab60-7bc28477d5c0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_141985df-4a72-461a-9043-ae4024a2a87f" xlink:to="loc_srt_CounterpartyNameAxis_b4f357e9-cffc-4cd2-ab60-7bc28477d5c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b4f357e9-cffc-4cd2-ab60-7bc28477d5c0_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_b4f357e9-cffc-4cd2-ab60-7bc28477d5c0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b4f357e9-cffc-4cd2-ab60-7bc28477d5c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_59ad923f-6af4-4b68-9f11-5add72c91955" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_b4f357e9-cffc-4cd2-ab60-7bc28477d5c0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_59ad923f-6af4-4b68-9f11-5add72c91955" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NordicGroupBVMember_1a497356-1b7b-44be-8de0-98727b63b04b" xlink:href="cpix-20231231.xsd#cpix_NordicGroupBVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_59ad923f-6af4-4b68-9f11-5add72c91955" xlink:to="loc_cpix_NordicGroupBVMember_1a497356-1b7b-44be-8de0-98727b63b04b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9032ac38-5fae-4047-afff-2005392b2a4b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_141985df-4a72-461a-9043-ae4024a2a87f" xlink:to="loc_srt_ProductOrServiceAxis_9032ac38-5fae-4047-afff-2005392b2a4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9032ac38-5fae-4047-afff-2005392b2a4b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9032ac38-5fae-4047-afff-2005392b2a4b" xlink:to="loc_srt_ProductsAndServicesDomain_9032ac38-5fae-4047-afff-2005392b2a4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_29a527e9-5a50-4e5a-9ba9-e7f4e6ff1966" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9032ac38-5fae-4047-afff-2005392b2a4b" xlink:to="loc_srt_ProductsAndServicesDomain_29a527e9-5a50-4e5a-9ba9-e7f4e6ff1966" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember_09c7c8fc-389f-463a-9421-fa9b7eaaea31" xlink:href="cpix-20231231.xsd#cpix_MethotrexateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_29a527e9-5a50-4e5a-9ba9-e7f4e6ff1966" xlink:to="loc_cpix_MethotrexateMember_09c7c8fc-389f-463a-9421-fa9b7eaaea31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6d0409e6-f7f4-47de-9efe-3b5fcbc86ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_141985df-4a72-461a-9043-ae4024a2a87f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6d0409e6-f7f4-47de-9efe-3b5fcbc86ca7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d0409e6-f7f4-47de-9efe-3b5fcbc86ca7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6d0409e6-f7f4-47de-9efe-3b5fcbc86ca7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d0409e6-f7f4-47de-9efe-3b5fcbc86ca7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e96e9544-5c05-4575-9a67-bcc646371f14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6d0409e6-f7f4-47de-9efe-3b5fcbc86ca7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e96e9544-5c05-4575-9a67-bcc646371f14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_a54b40a6-dd71-474c-b52a-2952b2546a48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e96e9544-5c05-4575-9a67-bcc646371f14" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_a54b40a6-dd71-474c-b52a-2952b2546a48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cc3b1ebd-0471-4865-a425-677934d8e213" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_141985df-4a72-461a-9043-ae4024a2a87f" xlink:to="loc_us-gaap_AwardTypeAxis_cc3b1ebd-0471-4865-a425-677934d8e213" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc3b1ebd-0471-4865-a425-677934d8e213_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_cc3b1ebd-0471-4865-a425-677934d8e213" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc3b1ebd-0471-4865-a425-677934d8e213_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1b883030-41d8-4785-a9bc-27492fd05516" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_cc3b1ebd-0471-4865-a425-677934d8e213" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1b883030-41d8-4785-a9bc-27492fd05516" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_104a7051-01aa-4872-ac8d-c62fea5334d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1b883030-41d8-4785-a9bc-27492fd05516" xlink:to="loc_us-gaap_RestrictedStockMember_104a7051-01aa-4872-ac8d-c62fea5334d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsDepositPayment_5b21beab-6987-4d2e-bf30-803cbc25a01b" xlink:href="cpix-20231231.xsd#cpix_CollaborativeArrangementRightsAndObligationsDepositPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25c8459b-8849-4a50-82fa-67560b7a4f00" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsDepositPayment_5b21beab-6987-4d2e-bf30-803cbc25a01b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationValue_9722466a-9875-4ccc-aa19-63d8255d7df0" xlink:href="cpix-20231231.xsd#cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25c8459b-8849-4a50-82fa-67560b7a4f00" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationValue_9722466a-9875-4ccc-aa19-63d8255d7df0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationShares_8ddf4418-67a7-42bd-9008-572f17a6077e" xlink:href="cpix-20231231.xsd#cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25c8459b-8849-4a50-82fa-67560b7a4f00" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationShares_8ddf4418-67a7-42bd-9008-572f17a6077e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationVestedValue_30ac0a46-218d-45e9-9102-f87fa2ce288d" xlink:href="cpix-20231231.xsd#cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationVestedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25c8459b-8849-4a50-82fa-67560b7a4f00" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationVestedValue_30ac0a46-218d-45e9-9102-f87fa2ce288d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePayment_f0bbdf47-170a-432e-ac7e-7cf7a32be3c7" xlink:href="cpix-20231231.xsd#cpix_CollaborativeArrangementRightsAndObligationsMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25c8459b-8849-4a50-82fa-67560b7a4f00" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePayment_f0bbdf47-170a-432e-ac7e-7cf7a32be3c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationCancelledAndRefunded_f2635e2c-70fb-4124-bf70-f92e705d732b" xlink:href="cpix-20231231.xsd#cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationCancelledAndRefunded"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25c8459b-8849-4a50-82fa-67560b7a4f00" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationCancelledAndRefunded_f2635e2c-70fb-4124-bf70-f92e705d732b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue_7db24ef1-5d4c-468c-9d27-12dcb83d67f1" xlink:href="cpix-20231231.xsd#cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25c8459b-8849-4a50-82fa-67560b7a4f00" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue_7db24ef1-5d4c-468c-9d27-12dcb83d67f1" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsChangesInFairValueOfContingentConsiderationLiabilityDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#VibativSancusoandRediTrexProductsChangesInFairValueOfContingentConsiderationLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsChangesInFairValueOfContingentConsiderationLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_407d2519-a11f-4c5e-a604-9e3b5314187f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_f1b9201d-e238-4750-8f89-8a10b55551b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_407d2519-a11f-4c5e-a604-9e3b5314187f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_f1b9201d-e238-4750-8f89-8a10b55551b3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1f38dcd6-bcd4-4e10-a8bb-9a635dcbeef9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_f1b9201d-e238-4750-8f89-8a10b55551b3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1f38dcd6-bcd4-4e10-a8bb-9a635dcbeef9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1f38dcd6-bcd4-4e10-a8bb-9a635dcbeef9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1f38dcd6-bcd4-4e10-a8bb-9a635dcbeef9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1f38dcd6-bcd4-4e10-a8bb-9a635dcbeef9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7fa35802-31c7-4191-a0eb-2d7fc1985523" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1f38dcd6-bcd4-4e10-a8bb-9a635dcbeef9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7fa35802-31c7-4191-a0eb-2d7fc1985523" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductAssetsAndGlobalRightsVibativMember_5651fdb4-028c-470d-9cf8-4eccd84731e5" xlink:href="cpix-20231231.xsd#cpix_ProductAssetsAndGlobalRightsVibativMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7fa35802-31c7-4191-a0eb-2d7fc1985523" xlink:to="loc_cpix_ProductAssetsAndGlobalRightsVibativMember_5651fdb4-028c-470d-9cf8-4eccd84731e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_U.S.ProductAssetRightsSancusoMember_b5a1396c-505a-4363-a974-9bac3696db93" xlink:href="cpix-20231231.xsd#cpix_U.S.ProductAssetRightsSancusoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7fa35802-31c7-4191-a0eb-2d7fc1985523" xlink:to="loc_cpix_U.S.ProductAssetRightsSancusoMember_b5a1396c-505a-4363-a974-9bac3696db93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationLiabilityRollForward_ab99cf3b-d4ee-4f7a-b92f-dd0e6d31554a" xlink:href="cpix-20231231.xsd#cpix_BusinessCombinationContingentConsiderationLiabilityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_407d2519-a11f-4c5e-a604-9e3b5314187f" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationLiabilityRollForward_ab99cf3b-d4ee-4f7a-b92f-dd0e6d31554a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_39b2ef9c-63e4-4093-b83a-f50bb108dc1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_BusinessCombinationContingentConsiderationLiabilityRollForward_ab99cf3b-d4ee-4f7a-b92f-dd0e6d31554a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_39b2ef9c-63e4-4093-b83a-f50bb108dc1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_84916e31-4a5a-4ce6-916c-6dd62df6cf1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_BusinessCombinationContingentConsiderationLiabilityRollForward_ab99cf3b-d4ee-4f7a-b92f-dd0e6d31554a" xlink:to="loc_us-gaap_PaymentsForRoyalties_84916e31-4a5a-4ce6-916c-6dd62df6cf1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_772f70c3-b5dc-444c-a369-f3cb6b947749" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_BusinessCombinationContingentConsiderationLiabilityRollForward_ab99cf3b-d4ee-4f7a-b92f-dd0e6d31554a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_772f70c3-b5dc-444c-a369-f3cb6b947749" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_b0a30a11-5c41-4e37-8a3e-fc96dd241cb0" xlink:href="cpix-20231231.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_BusinessCombinationContingentConsiderationLiabilityRollForward_ab99cf3b-d4ee-4f7a-b92f-dd0e6d31554a" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_b0a30a11-5c41-4e37-8a3e-fc96dd241cb0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c1cee686-4169-4911-aac7-98af55f48362" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#RevenuesScheduleofNetProductRevenuesbyProductDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_16646c11-c8de-4b1a-b6db-2c14a56742e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_c0f581a6-641d-4a9e-82b0-d32cb5e9fa14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_16646c11-c8de-4b1a-b6db-2c14a56742e4" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_c0f581a6-641d-4a9e-82b0-d32cb5e9fa14" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5a7cfdfb-2f58-446e-b5b3-896d5025a03b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_c0f581a6-641d-4a9e-82b0-d32cb5e9fa14" xlink:to="loc_srt_ProductOrServiceAxis_5a7cfdfb-2f58-446e-b5b3-896d5025a03b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5a7cfdfb-2f58-446e-b5b3-896d5025a03b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5a7cfdfb-2f58-446e-b5b3-896d5025a03b" xlink:to="loc_srt_ProductsAndServicesDomain_5a7cfdfb-2f58-446e-b5b3-896d5025a03b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_eeeb478b-2e3a-4da2-b7d2-dfd073096ccd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5a7cfdfb-2f58-446e-b5b3-896d5025a03b" xlink:to="loc_srt_ProductsAndServicesDomain_eeeb478b-2e3a-4da2-b7d2-dfd073096ccd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_cec093e2-627b-4b8a-9db9-90751d1cb36c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_eeeb478b-2e3a-4da2-b7d2-dfd073096ccd" xlink:to="loc_us-gaap_ProductMember_cec093e2-627b-4b8a-9db9-90751d1cb36c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductKristaloseMember_f8b199c9-ccee-4380-8135-2997c8d8f76d" xlink:href="cpix-20231231.xsd#cpix_ProductKristaloseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_cec093e2-627b-4b8a-9db9-90751d1cb36c" xlink:to="loc_cpix_ProductKristaloseMember_f8b199c9-ccee-4380-8135-2997c8d8f76d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductVibativMember_86c2c2c6-dc50-4e9c-90cb-53fa81161e8e" xlink:href="cpix-20231231.xsd#cpix_ProductVibativMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_cec093e2-627b-4b8a-9db9-90751d1cb36c" xlink:to="loc_cpix_ProductVibativMember_86c2c2c6-dc50-4e9c-90cb-53fa81161e8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductSancusoMember_bb4699a4-4475-4f8c-af46-cbd2b16aae57" xlink:href="cpix-20231231.xsd#cpix_ProductSancusoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_cec093e2-627b-4b8a-9db9-90751d1cb36c" xlink:to="loc_cpix_ProductSancusoMember_bb4699a4-4475-4f8c-af46-cbd2b16aae57" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductCaldolorMember_d2c2f647-c9bc-4eb6-a350-f400dce4f889" xlink:href="cpix-20231231.xsd#cpix_ProductCaldolorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_cec093e2-627b-4b8a-9db9-90751d1cb36c" xlink:to="loc_cpix_ProductCaldolorMember_d2c2f647-c9bc-4eb6-a350-f400dce4f889" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductAcetadoteMember_0af63aa1-b28a-45eb-ae2b-d6727468bfad" xlink:href="cpix-20231231.xsd#cpix_ProductAcetadoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_cec093e2-627b-4b8a-9db9-90751d1cb36c" xlink:to="loc_cpix_ProductAcetadoteMember_0af63aa1-b28a-45eb-ae2b-d6727468bfad" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductOmeclamoxPakMember_bc94cd62-4989-4b09-b955-699c78aa04c3" xlink:href="cpix-20231231.xsd#cpix_ProductOmeclamoxPakMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_cec093e2-627b-4b8a-9db9-90751d1cb36c" xlink:to="loc_cpix_ProductOmeclamoxPakMember_bc94cd62-4989-4b09-b955-699c78aa04c3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductVaprisolMember_09acf473-fbe1-4960-9377-a69451b4a98f" xlink:href="cpix-20231231.xsd#cpix_ProductVaprisolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_cec093e2-627b-4b8a-9db9-90751d1cb36c" xlink:to="loc_cpix_ProductVaprisolMember_09acf473-fbe1-4960-9377-a69451b4a98f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductRediTrexMember_fa3ff71f-84a8-400e-b73b-c0ea0b767db3" xlink:href="cpix-20231231.xsd#cpix_ProductRediTrexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_cec093e2-627b-4b8a-9db9-90751d1cb36c" xlink:to="loc_cpix_ProductRediTrexMember_fa3ff71f-84a8-400e-b73b-c0ea0b767db3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5a70fde5-e0fa-463a-b2b7-864ff883352d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_16646c11-c8de-4b1a-b6db-2c14a56742e4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5a70fde5-e0fa-463a-b2b7-864ff883352d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#RevenuesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_ef17a2f3-5db4-42e2-a717-c4997f6bd2aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a73e9571-2596-4136-9411-1d0f0d1dda5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ef17a2f3-5db4-42e2-a717-c4997f6bd2aa" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a73e9571-2596-4136-9411-1d0f0d1dda5c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7a9c19b9-7917-4803-a918-a30f8a6f7eda" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a73e9571-2596-4136-9411-1d0f0d1dda5c" xlink:to="loc_srt_ProductOrServiceAxis_7a9c19b9-7917-4803-a918-a30f8a6f7eda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7a9c19b9-7917-4803-a918-a30f8a6f7eda_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7a9c19b9-7917-4803-a918-a30f8a6f7eda" xlink:to="loc_srt_ProductsAndServicesDomain_7a9c19b9-7917-4803-a918-a30f8a6f7eda_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_890ff90b-1a76-4419-8c9f-082e096a8685" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7a9c19b9-7917-4803-a918-a30f8a6f7eda" xlink:to="loc_srt_ProductsAndServicesDomain_890ff90b-1a76-4419-8c9f-082e096a8685" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VibativMember_0f6a3334-4bb8-4e91-aa24-33199904ae83" xlink:href="cpix-20231231.xsd#cpix_VibativMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_890ff90b-1a76-4419-8c9f-082e096a8685" xlink:to="loc_cpix_VibativMember_0f6a3334-4bb8-4e91-aa24-33199904ae83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_de588f96-4e7c-4f07-bcd6-f0dbb5a37e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_890ff90b-1a76-4419-8c9f-082e096a8685" xlink:to="loc_us-gaap_GrantMember_de588f96-4e7c-4f07-bcd6-f0dbb5a37e2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e38ac15b-b484-4643-ac62-83b5effcab1c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a73e9571-2596-4136-9411-1d0f0d1dda5c" xlink:to="loc_srt_CounterpartyNameAxis_e38ac15b-b484-4643-ac62-83b5effcab1c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e38ac15b-b484-4643-ac62-83b5effcab1c_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e38ac15b-b484-4643-ac62-83b5effcab1c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e38ac15b-b484-4643-ac62-83b5effcab1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9d258138-d5c1-452e-9103-ab45b0274ee6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e38ac15b-b484-4643-ac62-83b5effcab1c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9d258138-d5c1-452e-9103-ab45b0274ee6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FederalGrantProgramsMember_c9da1c43-9717-4c64-90bb-c0ff5fda2b96" xlink:href="cpix-20231231.xsd#cpix_FederalGrantProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9d258138-d5c1-452e-9103-ab45b0274ee6" xlink:to="loc_cpix_FederalGrantProgramsMember_c9da1c43-9717-4c64-90bb-c0ff5fda2b96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLegalSettlements_d51758d7-2af2-4707-95f3-b72cb4e916f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ef17a2f3-5db4-42e2-a717-c4997f6bd2aa" xlink:to="loc_us-gaap_ProceedsFromLegalSettlements_d51758d7-2af2-4707-95f3-b72cb4e916f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivableNumberOfPayments_48205fcd-4c62-4457-8803-c280e009d369" xlink:href="cpix-20231231.xsd#cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivableNumberOfPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ef17a2f3-5db4-42e2-a717-c4997f6bd2aa" xlink:to="loc_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivableNumberOfPayments_48205fcd-4c62-4457-8803-c280e009d369" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentOne_78ab20a2-4e04-4958-aee1-1b4fa4502171" xlink:href="cpix-20231231.xsd#cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ef17a2f3-5db4-42e2-a717-c4997f6bd2aa" xlink:to="loc_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentOne_78ab20a2-4e04-4958-aee1-1b4fa4502171" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentTwo_0b3f27b8-7b11-4f1c-a832-6e73a1f15ce3" xlink:href="cpix-20231231.xsd#cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ef17a2f3-5db4-42e2-a717-c4997f6bd2aa" xlink:to="loc_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentTwo_0b3f27b8-7b11-4f1c-a832-6e73a1f15ce3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6770b1d2-7caa-43d4-87fb-d5712b69533c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ef17a2f3-5db4-42e2-a717-c4997f6bd2aa" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6770b1d2-7caa-43d4-87fb-d5712b69533c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_237292da-e822-4469-aade-609a1fb53a01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ef17a2f3-5db4-42e2-a717-c4997f6bd2aa" xlink:to="loc_us-gaap_SubleaseIncome_237292da-e822-4469-aade-609a1fb53a01" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNetScheduleofNonCurrentInventoriesDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#InventoriesNetScheduleofNonCurrentInventoriesDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNetScheduleofNonCurrentInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_InventoryNoncurrentLineItems_97a0165c-f07e-4148-a92b-b575620cff7c" xlink:href="cpix-20231231.xsd#cpix_InventoryNoncurrentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_InventoryNoncurrentTable_e064ab12-01e9-4706-b25f-9ac1970df428" xlink:href="cpix-20231231.xsd#cpix_InventoryNoncurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cpix_InventoryNoncurrentLineItems_97a0165c-f07e-4148-a92b-b575620cff7c" xlink:to="loc_cpix_InventoryNoncurrentTable_e064ab12-01e9-4706-b25f-9ac1970df428" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_085888f7-4b93-4494-8ef6-0ae6d2d7d619" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cpix_InventoryNoncurrentTable_e064ab12-01e9-4706-b25f-9ac1970df428" xlink:to="loc_srt_ProductOrServiceAxis_085888f7-4b93-4494-8ef6-0ae6d2d7d619" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_085888f7-4b93-4494-8ef6-0ae6d2d7d619_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_085888f7-4b93-4494-8ef6-0ae6d2d7d619" xlink:to="loc_srt_ProductsAndServicesDomain_085888f7-4b93-4494-8ef6-0ae6d2d7d619_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b81d00e9-4474-4f8c-aaef-242fd24cfb8b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_085888f7-4b93-4494-8ef6-0ae6d2d7d619" xlink:to="loc_srt_ProductsAndServicesDomain_b81d00e9-4474-4f8c-aaef-242fd24cfb8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VibativMember_14f23feb-5f6d-4d87-8ee3-6b303cb260fc" xlink:href="cpix-20231231.xsd#cpix_VibativMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b81d00e9-4474-4f8c-aaef-242fd24cfb8b" xlink:to="loc_cpix_VibativMember_14f23feb-5f6d-4d87-8ee3-6b303cb260fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember_a1943006-2a2f-4f96-a4ea-83cef08d4699" xlink:href="cpix-20231231.xsd#cpix_KristaloseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b81d00e9-4474-4f8c-aaef-242fd24cfb8b" xlink:to="loc_cpix_KristaloseMember_a1943006-2a2f-4f96-a4ea-83cef08d4699" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember_f4f1b485-84b8-4d7d-8c25-6dba9f1b6e35" xlink:href="cpix-20231231.xsd#cpix_VaprisolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b81d00e9-4474-4f8c-aaef-242fd24cfb8b" xlink:to="loc_cpix_VaprisolMember_f4f1b485-84b8-4d7d-8c25-6dba9f1b6e35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember_61894e85-8993-4c16-a8b8-8d4ee7c5a5af" xlink:href="cpix-20231231.xsd#cpix_CaldolorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b81d00e9-4474-4f8c-aaef-242fd24cfb8b" xlink:to="loc_cpix_CaldolorMember_61894e85-8993-4c16-a8b8-8d4ee7c5a5af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SancusoMember_c065ccf4-9afe-4d73-88b7-dcbf3aab6f8b" xlink:href="cpix-20231231.xsd#cpix_SancusoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b81d00e9-4474-4f8c-aaef-242fd24cfb8b" xlink:to="loc_cpix_SancusoMember_c065ccf4-9afe-4d73-88b7-dcbf3aab6f8b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StudyDrugMember_c40cfb63-e28e-4ead-b92e-5e40fc4f5787" xlink:href="cpix-20231231.xsd#cpix_StudyDrugMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b81d00e9-4474-4f8c-aaef-242fd24cfb8b" xlink:to="loc_cpix_StudyDrugMember_c40cfb63-e28e-4ead-b92e-5e40fc4f5787" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_00d05ff2-4f2c-44dd-8df2-0fcd369c6256" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cpix_InventoryNoncurrentTable_e064ab12-01e9-4706-b25f-9ac1970df428" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_00d05ff2-4f2c-44dd-8df2-0fcd369c6256" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_00d05ff2-4f2c-44dd-8df2-0fcd369c6256_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_00d05ff2-4f2c-44dd-8df2-0fcd369c6256" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_00d05ff2-4f2c-44dd-8df2-0fcd369c6256_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_dbb45cf9-99a8-4b1d-b658-ba91a8ae43a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_00d05ff2-4f2c-44dd-8df2-0fcd369c6256" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_dbb45cf9-99a8-4b1d-b658-ba91a8ae43a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryRawMaterialsMember_add9a1aa-0df5-48c4-84ea-f8bc3ce64452" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryRawMaterialsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_dbb45cf9-99a8-4b1d-b658-ba91a8ae43a2" xlink:to="loc_us-gaap_PublicUtilitiesInventoryRawMaterialsMember_add9a1aa-0df5-48c4-84ea-f8bc3ce64452" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FinishedGoodsMember_037e41fb-cf5f-4bf7-9ed7-d2ba8aef841d" xlink:href="cpix-20231231.xsd#cpix_FinishedGoodsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_dbb45cf9-99a8-4b1d-b658-ba91a8ae43a2" xlink:to="loc_cpix_FinishedGoodsMember_037e41fb-cf5f-4bf7-9ed7-d2ba8aef841d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherProductsMember_a69674b1-1c4c-4d03-9a35-fc0f2b697876" xlink:href="cpix-20231231.xsd#cpix_OtherProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_dbb45cf9-99a8-4b1d-b658-ba91a8ae43a2" xlink:to="loc_cpix_OtherProductsMember_a69674b1-1c4c-4d03-9a35-fc0f2b697876" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_af58bacc-164a-4232-bba4-46c5ca65766f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_InventoryNoncurrentLineItems_97a0165c-f07e-4148-a92b-b575620cff7c" xlink:to="loc_us-gaap_InventoryNoncurrent_af58bacc-164a-4232-bba4-46c5ca65766f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNetNarrativeDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#InventoriesNetNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_6975fbc1-0e0f-4a83-bfe2-ecf05673d01f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_327ebcb8-c050-40d6-8a48-3e12da76d6b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_6975fbc1-0e0f-4a83-bfe2-ecf05673d01f" xlink:to="loc_us-gaap_InventoryCurrentTable_327ebcb8-c050-40d6-8a48-3e12da76d6b7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0fdb7d49-2c0d-4a7f-be75-a1e532c8e7d3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_327ebcb8-c050-40d6-8a48-3e12da76d6b7" xlink:to="loc_srt_ProductOrServiceAxis_0fdb7d49-2c0d-4a7f-be75-a1e532c8e7d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0fdb7d49-2c0d-4a7f-be75-a1e532c8e7d3_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0fdb7d49-2c0d-4a7f-be75-a1e532c8e7d3" xlink:to="loc_srt_ProductsAndServicesDomain_0fdb7d49-2c0d-4a7f-be75-a1e532c8e7d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9edd3696-f21e-44b3-b574-b39c0d1e2939" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0fdb7d49-2c0d-4a7f-be75-a1e532c8e7d3" xlink:to="loc_srt_ProductsAndServicesDomain_9edd3696-f21e-44b3-b574-b39c0d1e2939" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VibativMember_85c7e71e-46f1-4ddd-9322-038fc509d0c6" xlink:href="cpix-20231231.xsd#cpix_VibativMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9edd3696-f21e-44b3-b574-b39c0d1e2939" xlink:to="loc_cpix_VibativMember_85c7e71e-46f1-4ddd-9322-038fc509d0c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_4552a7b3-b9f3-425d-be51-09e324458577" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_327ebcb8-c050-40d6-8a48-3e12da76d6b7" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_4552a7b3-b9f3-425d-be51-09e324458577" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_4552a7b3-b9f3-425d-be51-09e324458577_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_4552a7b3-b9f3-425d-be51-09e324458577" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_4552a7b3-b9f3-425d-be51-09e324458577_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_23578f4b-d7e4-46a4-aede-775d8f34d660" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_4552a7b3-b9f3-425d-be51-09e324458577" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_23578f4b-d7e4-46a4-aede-775d8f34d660" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ActivePharmaceuticalIngredientAPIAndWorkInProgressMember_13dfdd1a-ea0e-4795-a575-215eb73c6604" xlink:href="cpix-20231231.xsd#cpix_ActivePharmaceuticalIngredientAPIAndWorkInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_23578f4b-d7e4-46a4-aede-775d8f34d660" xlink:to="loc_cpix_ActivePharmaceuticalIngredientAPIAndWorkInProgressMember_13dfdd1a-ea0e-4795-a575-215eb73c6604" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_67d17ed1-ddf7-4ce7-b959-034c497ec7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_6975fbc1-0e0f-4a83-bfe2-ecf05673d01f" xlink:to="loc_us-gaap_InventoryNoncurrent_67d17ed1-ddf7-4ce7-b959-034c497ec7a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_4fef41a3-1fe1-4407-b91e-503a7c59519d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_6975fbc1-0e0f-4a83-bfe2-ecf05673d01f" xlink:to="loc_us-gaap_InventoryValuationReserves_4fef41a3-1fe1-4407-b91e-503a7c59519d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_243df088-cd11-4d42-9306-d82d269e0cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d198aa0e-c1be-4385-bfd4-25af7875e620" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_243df088-cd11-4d42-9306-d82d269e0cc2" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d198aa0e-c1be-4385-bfd4-25af7875e620" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0a430da3-ac38-428d-bd20-2574231f3d62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d198aa0e-c1be-4385-bfd4-25af7875e620" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0a430da3-ac38-428d-bd20-2574231f3d62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0a430da3-ac38-428d-bd20-2574231f3d62_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0a430da3-ac38-428d-bd20-2574231f3d62" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0a430da3-ac38-428d-bd20-2574231f3d62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4cae1cdc-31c3-4f27-8c6b-6e2f65ff936e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0a430da3-ac38-428d-bd20-2574231f3d62" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4cae1cdc-31c3-4f27-8c6b-6e2f65ff936e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_3edcba75-fd63-44ad-8cf6-7413ec50bee8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4cae1cdc-31c3-4f27-8c6b-6e2f65ff936e" xlink:to="loc_us-gaap_ComputerEquipmentMember_3edcba75-fd63-44ad-8cf6-7413ec50bee8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_5d6a7cee-ee01-4cbe-a532-fdb56ecc178d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4cae1cdc-31c3-4f27-8c6b-6e2f65ff936e" xlink:to="loc_us-gaap_OfficeEquipmentMember_5d6a7cee-ee01-4cbe-a532-fdb56ecc178d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_b278793f-2571-43ce-81db-7387cb148438" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4cae1cdc-31c3-4f27-8c6b-6e2f65ff936e" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_b278793f-2571-43ce-81db-7387cb148438" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_3160fd8c-5897-484d-95fd-f92cd0367315" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4cae1cdc-31c3-4f27-8c6b-6e2f65ff936e" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_3160fd8c-5897-484d-95fd-f92cd0367315" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ddb4e70d-a120-4bdb-955c-4f660378c1f1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d198aa0e-c1be-4385-bfd4-25af7875e620" xlink:to="loc_srt_RangeAxis_ddb4e70d-a120-4bdb-955c-4f660378c1f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ddb4e70d-a120-4bdb-955c-4f660378c1f1_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ddb4e70d-a120-4bdb-955c-4f660378c1f1" xlink:to="loc_srt_RangeMember_ddb4e70d-a120-4bdb-955c-4f660378c1f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e3745dcf-e878-4951-9bfa-bf5173dc6448" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ddb4e70d-a120-4bdb-955c-4f660378c1f1" xlink:to="loc_srt_RangeMember_e3745dcf-e878-4951-9bfa-bf5173dc6448" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f3a311c0-cbf3-4933-b271-b2c2b416276a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e3745dcf-e878-4951-9bfa-bf5173dc6448" xlink:to="loc_srt_MinimumMember_f3a311c0-cbf3-4933-b271-b2c2b416276a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e6386b33-0177-4668-89f6-09060b3b1094" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e3745dcf-e878-4951-9bfa-bf5173dc6448" xlink:to="loc_srt_MaximumMember_e6386b33-0177-4668-89f6-09060b3b1094" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_be666f68-170f-42b4-88a0-d26dfdc6bbf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_243df088-cd11-4d42-9306-d82d269e0cc2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_be666f68-170f-42b4-88a0-d26dfdc6bbf4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c6a4432f-39ab-49ea-a040-c76231b04c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_243df088-cd11-4d42-9306-d82d269e0cc2" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c6a4432f-39ab-49ea-a040-c76231b04c1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_95366a51-acfb-487c-80d5-1b430ebf3c35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_243df088-cd11-4d42-9306-d82d269e0cc2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_95366a51-acfb-487c-80d5-1b430ebf3c35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_7b6c268c-f8e8-43a0-878a-95dee201a3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_243df088-cd11-4d42-9306-d82d269e0cc2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_7b6c268c-f8e8-43a0-878a-95dee201a3b0" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cffed7f3-44f4-44e2-9225-9e426007b213" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6d69f634-8857-4ecb-9729-ea2b69df2d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cffed7f3-44f4-44e2-9225-9e426007b213" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6d69f634-8857-4ecb-9729-ea2b69df2d6f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_964162c9-fccd-48a8-ab49-b154446ea7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6d69f634-8857-4ecb-9729-ea2b69df2d6f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_964162c9-fccd-48a8-ab49-b154446ea7f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_964162c9-fccd-48a8-ab49-b154446ea7f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_964162c9-fccd-48a8-ab49-b154446ea7f2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_964162c9-fccd-48a8-ab49-b154446ea7f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_908bea33-3623-4ad6-8387-f5a2201cfe31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_964162c9-fccd-48a8-ab49-b154446ea7f2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_908bea33-3623-4ad6-8387-f5a2201cfe31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductAndLicenseRightsMember_1361a826-055e-462a-9f1c-c3a22b708c77" xlink:href="cpix-20231231.xsd#cpix_ProductAndLicenseRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_908bea33-3623-4ad6-8387-f5a2201cfe31" xlink:to="loc_cpix_ProductAndLicenseRightsMember_1361a826-055e-462a-9f1c-c3a22b708c77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_5a8d7031-883c-4710-af85-ccfe50ac3f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_908bea33-3623-4ad6-8387-f5a2201cfe31" xlink:to="loc_us-gaap_PatentsMember_5a8d7031-883c-4710-af85-ccfe50ac3f0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_e47717d8-1c37-4362-b102-a0a4747023fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_908bea33-3623-4ad6-8387-f5a2201cfe31" xlink:to="loc_us-gaap_TrademarksMember_e47717d8-1c37-4362-b102-a0a4747023fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5ed00638-f98c-4da6-97f1-dfe7443b0ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cffed7f3-44f4-44e2-9225-9e426007b213" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5ed00638-f98c-4da6-97f1-dfe7443b0ecc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e5361ddb-b6e8-4328-b1d6-4995b7f86eea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cffed7f3-44f4-44e2-9225-9e426007b213" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e5361ddb-b6e8-4328-b1d6-4995b7f86eea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f868e6b3-ef55-4c47-8e0c-eb1066624ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cffed7f3-44f4-44e2-9225-9e426007b213" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f868e6b3-ef55-4c47-8e0c-eb1066624ac3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ecd86ea9-da67-4ea3-92bd-4a94bfcc5fce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cffed7f3-44f4-44e2-9225-9e426007b213" xlink:to="loc_us-gaap_Goodwill_ecd86ea9-da67-4ea3-92bd-4a94bfcc5fce" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#IntangibleAssetsandGoodwillNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9ed88d9c-3756-46af-9b4a-418a25b325d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_24cda440-9c7c-4155-b615-63eafd5cea4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9ed88d9c-3756-46af-9b4a-418a25b325d5" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_24cda440-9c7c-4155-b615-63eafd5cea4b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_171d3b88-05bc-4728-983c-c343997e51d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_24cda440-9c7c-4155-b615-63eafd5cea4b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_171d3b88-05bc-4728-983c-c343997e51d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_171d3b88-05bc-4728-983c-c343997e51d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_171d3b88-05bc-4728-983c-c343997e51d0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_171d3b88-05bc-4728-983c-c343997e51d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_71cce40d-5425-47bd-acac-f07374ebf8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_171d3b88-05bc-4728-983c-c343997e51d0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_71cce40d-5425-47bd-acac-f07374ebf8e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_1e04cb14-05e7-4612-9a14-b834db1810ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_71cce40d-5425-47bd-acac-f07374ebf8e5" xlink:to="loc_us-gaap_PatentsMember_1e04cb14-05e7-4612-9a14-b834db1810ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_dd812d5b-278b-4218-9272-605231191c36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9ed88d9c-3756-46af-9b4a-418a25b325d5" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_dd812d5b-278b-4218-9272-605231191c36" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DebtDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#DebtDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/DebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_4eb69cfb-bafb-4870-83f3-7b4e7cd498a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_1de68344-e696-4e00-afcc-035d7486e576" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4eb69cfb-bafb-4870-83f3-7b4e7cd498a8" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_1de68344-e696-4e00-afcc-035d7486e576" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_7c5e1a66-3357-4829-aa2f-2cb1d76cf195" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1de68344-e696-4e00-afcc-035d7486e576" xlink:to="loc_us-gaap_CreditFacilityAxis_7c5e1a66-3357-4829-aa2f-2cb1d76cf195" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_7c5e1a66-3357-4829-aa2f-2cb1d76cf195_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_7c5e1a66-3357-4829-aa2f-2cb1d76cf195" xlink:to="loc_us-gaap_CreditFacilityDomain_7c5e1a66-3357-4829-aa2f-2cb1d76cf195_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_0a7028e4-819b-4847-b11b-106d044b1e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_7c5e1a66-3357-4829-aa2f-2cb1d76cf195" xlink:to="loc_us-gaap_CreditFacilityDomain_0a7028e4-819b-4847-b11b-106d044b1e3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_032045f9-d069-4cf5-8a09-9a81ff4f77e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_0a7028e4-819b-4847-b11b-106d044b1e3f" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_032045f9-d069-4cf5-8a09-9a81ff4f77e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b1bf2cf0-092a-4b17-b41f-1fb7d75ac5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1de68344-e696-4e00-afcc-035d7486e576" xlink:to="loc_us-gaap_DebtInstrumentAxis_b1bf2cf0-092a-4b17-b41f-1fb7d75ac5e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b1bf2cf0-092a-4b17-b41f-1fb7d75ac5e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b1bf2cf0-092a-4b17-b41f-1fb7d75ac5e5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b1bf2cf0-092a-4b17-b41f-1fb7d75ac5e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_cd9151b2-9da0-45f7-816f-9a36e9726636" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b1bf2cf0-092a-4b17-b41f-1fb7d75ac5e5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_cd9151b2-9da0-45f7-816f-9a36e9726636" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_59a3bbe3-d924-4d56-89b4-3146308c6d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cd9151b2-9da0-45f7-816f-9a36e9726636" xlink:to="loc_us-gaap_LineOfCreditMember_59a3bbe3-d924-4d56-89b4-3146308c6d2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_7df9ddc4-7d96-4f11-9192-570b6fe2d01d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1de68344-e696-4e00-afcc-035d7486e576" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_7df9ddc4-7d96-4f11-9192-570b6fe2d01d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_7df9ddc4-7d96-4f11-9192-570b6fe2d01d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_7df9ddc4-7d96-4f11-9192-570b6fe2d01d" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_7df9ddc4-7d96-4f11-9192-570b6fe2d01d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_ed49afd9-3580-4fcf-94e7-b1a3bce483d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_7df9ddc4-7d96-4f11-9192-570b6fe2d01d" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_ed49afd9-3580-4fcf-94e7-b1a3bce483d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_d1f0a75c-b5be-422d-a715-cf3cf64fda76" xlink:href="cpix-20231231.xsd#cpix_PinnacleBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_ed49afd9-3580-4fcf-94e7-b1a3bce483d1" xlink:to="loc_cpix_PinnacleBankMember_d1f0a75c-b5be-422d-a715-cf3cf64fda76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2d7fa6f3-4727-4364-8659-3edd1e67ae44" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1de68344-e696-4e00-afcc-035d7486e576" xlink:to="loc_srt_RangeAxis_2d7fa6f3-4727-4364-8659-3edd1e67ae44" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2d7fa6f3-4727-4364-8659-3edd1e67ae44_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2d7fa6f3-4727-4364-8659-3edd1e67ae44" xlink:to="loc_srt_RangeMember_2d7fa6f3-4727-4364-8659-3edd1e67ae44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_65b87a4e-0a23-44a5-a99e-675b04dbf9d8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2d7fa6f3-4727-4364-8659-3edd1e67ae44" xlink:to="loc_srt_RangeMember_65b87a4e-0a23-44a5-a99e-675b04dbf9d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c48a2079-7fe0-46ec-b63f-5cb004c7763f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_65b87a4e-0a23-44a5-a99e-675b04dbf9d8" xlink:to="loc_srt_MaximumMember_c48a2079-7fe0-46ec-b63f-5cb004c7763f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_55194cb0-d52f-4514-986f-8bfd86223ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1de68344-e696-4e00-afcc-035d7486e576" xlink:to="loc_us-gaap_VariableRateAxis_55194cb0-d52f-4514-986f-8bfd86223ba8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_55194cb0-d52f-4514-986f-8bfd86223ba8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_55194cb0-d52f-4514-986f-8bfd86223ba8" xlink:to="loc_us-gaap_VariableRateDomain_55194cb0-d52f-4514-986f-8bfd86223ba8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_703a7cd1-70df-4b74-9d0b-87bfce24a76a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_55194cb0-d52f-4514-986f-8bfd86223ba8" xlink:to="loc_us-gaap_VariableRateDomain_703a7cd1-70df-4b74-9d0b-87bfce24a76a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_710d7dc2-6499-4bc2-8257-79f4f98411ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_703a7cd1-70df-4b74-9d0b-87bfce24a76a" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_710d7dc2-6499-4bc2-8257-79f4f98411ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7a8369d5-4237-49a8-805f-314b710a92bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4eb69cfb-bafb-4870-83f3-7b4e7cd498a8" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7a8369d5-4237-49a8-805f-314b710a92bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_04d4e97b-bca0-467c-8bfe-61f527646b15" xlink:href="cpix-20231231.xsd#cpix_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4eb69cfb-bafb-4870-83f3-7b4e7cd498a8" xlink:to="loc_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_04d4e97b-bca0-467c-8bfe-61f527646b15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_4bc41295-b3ac-4f5a-b842-3aff6ed1f870" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4eb69cfb-bafb-4870-83f3-7b4e7cd498a8" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_4bc41295-b3ac-4f5a-b842-3aff6ed1f870" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a2cef141-b411-4685-87a5-ca14aa51e286" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4eb69cfb-bafb-4870-83f3-7b4e7cd498a8" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a2cef141-b411-4685-87a5-ca14aa51e286" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_006ef66b-9d58-4c17-96df-f7b66486c85b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4eb69cfb-bafb-4870-83f3-7b4e7cd498a8" xlink:to="loc_us-gaap_LongTermLineOfCredit_006ef66b-9d58-4c17-96df-f7b66486c85b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_96aa9683-6c94-4f82-9b1e-c0890dd2a497" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4eb69cfb-bafb-4870-83f3-7b4e7cd498a8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_96aa9683-6c94-4f82-9b1e-c0890dd2a497" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#ShareholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_14ad4998-0e9c-4287-a220-1fa7c30e2eac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_9719192b-f9c7-440a-94c6-ff4e98ff7d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_14ad4998-0e9c-4287-a220-1fa7c30e2eac" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_9719192b-f9c7-440a-94c6-ff4e98ff7d6b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e764330d-1b82-405c-8cbd-2bb21b972c83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9719192b-f9c7-440a-94c6-ff4e98ff7d6b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e764330d-1b82-405c-8cbd-2bb21b972c83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e764330d-1b82-405c-8cbd-2bb21b972c83_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e764330d-1b82-405c-8cbd-2bb21b972c83" xlink:to="loc_us-gaap_ClassOfStockDomain_e764330d-1b82-405c-8cbd-2bb21b972c83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_da914f78-dc43-4b6f-b0f3-ecca2954c413" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e764330d-1b82-405c-8cbd-2bb21b972c83" xlink:to="loc_us-gaap_ClassOfStockDomain_da914f78-dc43-4b6f-b0f3-ecca2954c413" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9177634d-ae0f-46bd-9ea0-4129766757f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_da914f78-dc43-4b6f-b0f3-ecca2954c413" xlink:to="loc_us-gaap_CommonStockMember_9177634d-ae0f-46bd-9ea0-4129766757f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_74401797-0e4f-4493-aa1f-602a74c20126" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9719192b-f9c7-440a-94c6-ff4e98ff7d6b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_74401797-0e4f-4493-aa1f-602a74c20126" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_74401797-0e4f-4493-aa1f-602a74c20126_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_74401797-0e4f-4493-aa1f-602a74c20126" xlink:to="loc_us-gaap_EquityComponentDomain_74401797-0e4f-4493-aa1f-602a74c20126_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9ea832a8-1842-4731-9099-82f945559c98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_74401797-0e4f-4493-aa1f-602a74c20126" xlink:to="loc_us-gaap_EquityComponentDomain_9ea832a8-1842-4731-9099-82f945559c98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_00841bab-78f7-4650-a6b7-8481730024ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9ea832a8-1842-4731-9099-82f945559c98" xlink:to="loc_us-gaap_CommonStockMember_00841bab-78f7-4650-a6b7-8481730024ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockTransactionDate_45b0dfd8-d053-49b4-b307-b60d54301600" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockTransactionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_14ad4998-0e9c-4287-a220-1fa7c30e2eac" xlink:to="loc_us-gaap_SaleOfStockTransactionDate_45b0dfd8-d053-49b4-b307-b60d54301600" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a23f3925-3bb7-49c2-8487-268f64cf32ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_14ad4998-0e9c-4287-a220-1fa7c30e2eac" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a23f3925-3bb7-49c2-8487-268f64cf32ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodPricePerShareNewIssues_c00b78ba-fa3c-4d15-93aa-9a3e04d0c861" xlink:href="cpix-20231231.xsd#cpix_StockIssuedDuringPeriodPricePerShareNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_14ad4998-0e9c-4287-a220-1fa7c30e2eac" xlink:to="loc_cpix_StockIssuedDuringPeriodPricePerShareNewIssues_c00b78ba-fa3c-4d15-93aa-9a3e04d0c861" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering_7c57f8ac-a821-4c6b-8bb4-9073a2f667ce" xlink:href="cpix-20231231.xsd#cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_14ad4998-0e9c-4287-a220-1fa7c30e2eac" xlink:to="loc_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering_7c57f8ac-a821-4c6b-8bb4-9073a2f667ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts_a5cd235d-9c5c-479d-8730-0f094fb591f7" xlink:href="cpix-20231231.xsd#cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_14ad4998-0e9c-4287-a220-1fa7c30e2eac" xlink:to="loc_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts_a5cd235d-9c5c-479d-8730-0f094fb591f7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_39985b50-36be-41ae-bab4-28217dc5492c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_14ad4998-0e9c-4287-a220-1fa7c30e2eac" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_39985b50-36be-41ae-bab4-28217dc5492c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_f0bc3d75-4e33-4b26-95a0-bde04ffab3bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_14ad4998-0e9c-4287-a220-1fa7c30e2eac" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_f0bc3d75-4e33-4b26-95a0-bde04ffab3bf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_ee656809-ca76-4ce2-89b7-e8088292e309" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_14ad4998-0e9c-4287-a220-1fa7c30e2eac" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_ee656809-ca76-4ce2-89b7-e8088292e309" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_7e530bd2-b32a-425e-9be2-83525d75d37b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_14ad4998-0e9c-4287-a220-1fa7c30e2eac" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_7e530bd2-b32a-425e-9be2-83525d75d37b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_39e7d8cd-9450-40a5-b465-fbab667a6570" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_14ad4998-0e9c-4287-a220-1fa7c30e2eac" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_39e7d8cd-9450-40a5-b465-fbab667a6570" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_bf7e530d-eabc-4a8d-948f-7005b29f8ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_14ad4998-0e9c-4287-a220-1fa7c30e2eac" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_bf7e530d-eabc-4a8d-948f-7005b29f8ed4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_5001fb0c-c4e2-4d6b-811e-20dc5da3d56a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_14ad4998-0e9c-4287-a220-1fa7c30e2eac" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_5001fb0c-c4e2-4d6b-811e-20dc5da3d56a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_41b2fcd8-0305-47af-be92-a56ddf86d540" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_14ad4998-0e9c-4287-a220-1fa7c30e2eac" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_41b2fcd8-0305-47af-be92-a56ddf86d540" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_b0fe270e-cb99-4831-8b39-2f21223b1ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_14ad4998-0e9c-4287-a220-1fa7c30e2eac" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_b0fe270e-cb99-4831-8b39-2f21223b1ff7" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_4bc0f6a2-4878-4708-80fa-c519e32d2e24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_cc9a9969-1bf9-4c20-9a87-6c91266b4134" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4bc0f6a2-4878-4708-80fa-c519e32d2e24" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_cc9a9969-1bf9-4c20-9a87-6c91266b4134" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodAxis_ea8db3f5-63b7-49c4-b4b0-9579f26ffef3" xlink:href="cpix-20231231.xsd#cpix_ExpirationTimePeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_cc9a9969-1bf9-4c20-9a87-6c91266b4134" xlink:to="loc_cpix_ExpirationTimePeriodAxis_ea8db3f5-63b7-49c4-b4b0-9579f26ffef3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodDomain_ea8db3f5-63b7-49c4-b4b0-9579f26ffef3_default" xlink:href="cpix-20231231.xsd#cpix_ExpirationTimePeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cpix_ExpirationTimePeriodAxis_ea8db3f5-63b7-49c4-b4b0-9579f26ffef3" xlink:to="loc_cpix_ExpirationTimePeriodDomain_ea8db3f5-63b7-49c4-b4b0-9579f26ffef3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodDomain_45784715-3a54-42cf-bc97-27da1698f0dc" xlink:href="cpix-20231231.xsd#cpix_ExpirationTimePeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cpix_ExpirationTimePeriodAxis_ea8db3f5-63b7-49c4-b4b0-9579f26ffef3" xlink:to="loc_cpix_ExpirationTimePeriodDomain_45784715-3a54-42cf-bc97-27da1698f0dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermOneMember_59c9a518-72c2-414c-baa9-ce48633ff12b" xlink:href="cpix-20231231.xsd#cpix_ExpirationTermOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ExpirationTimePeriodDomain_45784715-3a54-42cf-bc97-27da1698f0dc" xlink:to="loc_cpix_ExpirationTermOneMember_59c9a518-72c2-414c-baa9-ce48633ff12b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermTwoMember_a1931c70-490a-41fe-9f6a-d17f9d539ef8" xlink:href="cpix-20231231.xsd#cpix_ExpirationTermTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ExpirationTimePeriodDomain_45784715-3a54-42cf-bc97-27da1698f0dc" xlink:to="loc_cpix_ExpirationTermTwoMember_a1931c70-490a-41fe-9f6a-d17f9d539ef8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IndefiniteMember_319b71b9-e97c-42bb-a2fb-0afdc9aca126" xlink:href="cpix-20231231.xsd#cpix_IndefiniteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ExpirationTimePeriodDomain_45784715-3a54-42cf-bc97-27da1698f0dc" xlink:to="loc_cpix_IndefiniteMember_319b71b9-e97c-42bb-a2fb-0afdc9aca126" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_237d6d29-9bb7-47a2-85e9-7d8e16d58643" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_cc9a9969-1bf9-4c20-9a87-6c91266b4134" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_237d6d29-9bb7-47a2-85e9-7d8e16d58643" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_237d6d29-9bb7-47a2-85e9-7d8e16d58643_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_237d6d29-9bb7-47a2-85e9-7d8e16d58643" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_237d6d29-9bb7-47a2-85e9-7d8e16d58643_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_34f18908-8df6-42e5-bbae-1b1c82338a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_237d6d29-9bb7-47a2-85e9-7d8e16d58643" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_34f18908-8df6-42e5-bbae-1b1c82338a9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_88129cd5-6524-4a6f-8efa-52b95f9390b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_34f18908-8df6-42e5-bbae-1b1c82338a9c" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_88129cd5-6524-4a6f-8efa-52b95f9390b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_486ddc27-a4df-4bfc-89b6-8c60a6fcf2e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_34f18908-8df6-42e5-bbae-1b1c82338a9c" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_486ddc27-a4df-4bfc-89b6-8c60a6fcf2e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_061eab7e-f44b-4f55-ac1d-2297b298c739" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4bc0f6a2-4878-4708-80fa-c519e32d2e24" xlink:to="loc_us-gaap_OperatingLossCarryforwards_061eab7e-f44b-4f55-ac1d-2297b298c739" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleOfTaxCreditCarryforwardsDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#IncomeTaxesScheduleOfTaxCreditCarryforwardsDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleOfTaxCreditCarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_f3f02b9f-91c1-41a6-8b91-12c37e91564b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_619533b6-8838-48b2-9c2b-0f23cb3f49da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_f3f02b9f-91c1-41a6-8b91-12c37e91564b" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_619533b6-8838-48b2-9c2b-0f23cb3f49da" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodAxis_46cbccde-7bc3-4eef-bdc9-25db163ee0cd" xlink:href="cpix-20231231.xsd#cpix_ExpirationTimePeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_619533b6-8838-48b2-9c2b-0f23cb3f49da" xlink:to="loc_cpix_ExpirationTimePeriodAxis_46cbccde-7bc3-4eef-bdc9-25db163ee0cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodDomain_46cbccde-7bc3-4eef-bdc9-25db163ee0cd_default" xlink:href="cpix-20231231.xsd#cpix_ExpirationTimePeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cpix_ExpirationTimePeriodAxis_46cbccde-7bc3-4eef-bdc9-25db163ee0cd" xlink:to="loc_cpix_ExpirationTimePeriodDomain_46cbccde-7bc3-4eef-bdc9-25db163ee0cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodDomain_10bbd2dc-b2fa-4f0d-88ff-2f6809af3cd4" xlink:href="cpix-20231231.xsd#cpix_ExpirationTimePeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cpix_ExpirationTimePeriodAxis_46cbccde-7bc3-4eef-bdc9-25db163ee0cd" xlink:to="loc_cpix_ExpirationTimePeriodDomain_10bbd2dc-b2fa-4f0d-88ff-2f6809af3cd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermOneMember_b6b2a491-241a-4971-abe4-d3aa10681802" xlink:href="cpix-20231231.xsd#cpix_ExpirationTermOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ExpirationTimePeriodDomain_10bbd2dc-b2fa-4f0d-88ff-2f6809af3cd4" xlink:to="loc_cpix_ExpirationTermOneMember_b6b2a491-241a-4971-abe4-d3aa10681802" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermTwoMember_b93d4faf-2747-4c61-8bca-47a28b6359a6" xlink:href="cpix-20231231.xsd#cpix_ExpirationTermTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ExpirationTimePeriodDomain_10bbd2dc-b2fa-4f0d-88ff-2f6809af3cd4" xlink:to="loc_cpix_ExpirationTermTwoMember_b93d4faf-2747-4c61-8bca-47a28b6359a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_6c48e3cd-ba22-4eb3-b749-93938cf4bde6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_619533b6-8838-48b2-9c2b-0f23cb3f49da" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_6c48e3cd-ba22-4eb3-b749-93938cf4bde6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_6c48e3cd-ba22-4eb3-b749-93938cf4bde6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6c48e3cd-ba22-4eb3-b749-93938cf4bde6" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_6c48e3cd-ba22-4eb3-b749-93938cf4bde6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_6cf9642b-f330-49ca-be38-5699a7ad03cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6c48e3cd-ba22-4eb3-b749-93938cf4bde6" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_6cf9642b-f330-49ca-be38-5699a7ad03cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FederalAndStateMember_ba667943-a5d4-43a7-9b70-d2b670766217" xlink:href="cpix-20231231.xsd#cpix_FederalAndStateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_6cf9642b-f330-49ca-be38-5699a7ad03cc" xlink:to="loc_cpix_FederalAndStateMember_ba667943-a5d4-43a7-9b70-d2b670766217" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_094d9475-47b8-42cc-a0ed-28a1db4619d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_f3f02b9f-91c1-41a6-8b91-12c37e91564b" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_094d9475-47b8-42cc-a0ed-28a1db4619d3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#StockBasedCompensationPlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b882f42-843d-434f-ace0-fc17c99a22df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_93b8e394-7cb9-4f0f-a92d-ab179744f0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b882f42-843d-434f-ace0-fc17c99a22df" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_93b8e394-7cb9-4f0f-a92d-ab179744f0bb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_936d7580-e922-4e8f-bf66-0967b46a0916" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_93b8e394-7cb9-4f0f-a92d-ab179744f0bb" xlink:to="loc_us-gaap_PlanNameAxis_936d7580-e922-4e8f-bf66-0967b46a0916" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_936d7580-e922-4e8f-bf66-0967b46a0916_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_936d7580-e922-4e8f-bf66-0967b46a0916" xlink:to="loc_us-gaap_PlanNameDomain_936d7580-e922-4e8f-bf66-0967b46a0916_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ac4a2255-9f65-47be-96a3-2ffcc0900dee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_936d7580-e922-4e8f-bf66-0967b46a0916" xlink:to="loc_us-gaap_PlanNameDomain_ac4a2255-9f65-47be-96a3-2ffcc0900dee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LongTermIncentiveCompensationPlan2007Member_2bfa43e2-dab6-44b4-af42-ece081086d83" xlink:href="cpix-20231231.xsd#cpix_LongTermIncentiveCompensationPlan2007Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ac4a2255-9f65-47be-96a3-2ffcc0900dee" xlink:to="loc_cpix_LongTermIncentiveCompensationPlan2007Member_2bfa43e2-dab6-44b4-af42-ece081086d83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DirectorsIncentivePlan2007Member_b90b6e63-3f72-4430-bdcb-3f153dfc12e0" xlink:href="cpix-20231231.xsd#cpix_DirectorsIncentivePlan2007Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ac4a2255-9f65-47be-96a3-2ffcc0900dee" xlink:to="loc_cpix_DirectorsIncentivePlan2007Member_b90b6e63-3f72-4430-bdcb-3f153dfc12e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_db0b81a5-ad9e-475a-8121-0df676aedb2b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_93b8e394-7cb9-4f0f-a92d-ab179744f0bb" xlink:to="loc_srt_TitleOfIndividualAxis_db0b81a5-ad9e-475a-8121-0df676aedb2b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_db0b81a5-ad9e-475a-8121-0df676aedb2b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_db0b81a5-ad9e-475a-8121-0df676aedb2b" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_db0b81a5-ad9e-475a-8121-0df676aedb2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f5a2b2db-9d0d-4076-b6bd-52bfd0f5019b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_db0b81a5-ad9e-475a-8121-0df676aedb2b" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f5a2b2db-9d0d-4076-b6bd-52bfd0f5019b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NonprincipalOwnerMember_90f5ae73-57c6-4b55-84b9-dc571a4408aa" xlink:href="cpix-20231231.xsd#cpix_NonprincipalOwnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f5a2b2db-9d0d-4076-b6bd-52bfd0f5019b" xlink:to="loc_cpix_NonprincipalOwnerMember_90f5ae73-57c6-4b55-84b9-dc571a4408aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrincipalOwnerMember_6c2e8a7c-c2ec-4b25-93f4-be80cd125240" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrincipalOwnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f5a2b2db-9d0d-4076-b6bd-52bfd0f5019b" xlink:to="loc_us-gaap_PrincipalOwnerMember_6c2e8a7c-c2ec-4b25-93f4-be80cd125240" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_99895dc3-476a-4db9-b059-e1e5602de254" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f5a2b2db-9d0d-4076-b6bd-52bfd0f5019b" xlink:to="loc_srt_DirectorMember_99895dc3-476a-4db9-b059-e1e5602de254" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e3134829-e3a0-4e00-9cec-42b04ad3d3f6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_93b8e394-7cb9-4f0f-a92d-ab179744f0bb" xlink:to="loc_srt_RangeAxis_e3134829-e3a0-4e00-9cec-42b04ad3d3f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e3134829-e3a0-4e00-9cec-42b04ad3d3f6_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e3134829-e3a0-4e00-9cec-42b04ad3d3f6" xlink:to="loc_srt_RangeMember_e3134829-e3a0-4e00-9cec-42b04ad3d3f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f70f29ca-6029-4d8d-8f65-059eac249350" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e3134829-e3a0-4e00-9cec-42b04ad3d3f6" xlink:to="loc_srt_RangeMember_f70f29ca-6029-4d8d-8f65-059eac249350" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c1e4dd4e-c5f8-4706-91f8-b9121a792ed9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f70f29ca-6029-4d8d-8f65-059eac249350" xlink:to="loc_srt_MaximumMember_c1e4dd4e-c5f8-4706-91f8-b9121a792ed9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0608811f-178b-4037-8407-d2d0424bb5d8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f70f29ca-6029-4d8d-8f65-059eac249350" xlink:to="loc_srt_MinimumMember_0608811f-178b-4037-8407-d2d0424bb5d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ad7d73eb-352e-4368-9745-c7359e9b5179" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_93b8e394-7cb9-4f0f-a92d-ab179744f0bb" xlink:to="loc_us-gaap_AwardTypeAxis_ad7d73eb-352e-4368-9745-c7359e9b5179" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ad7d73eb-352e-4368-9745-c7359e9b5179_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ad7d73eb-352e-4368-9745-c7359e9b5179" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ad7d73eb-352e-4368-9745-c7359e9b5179_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_79dff463-f21b-4cf8-928d-6729fa5db2fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ad7d73eb-352e-4368-9745-c7359e9b5179" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_79dff463-f21b-4cf8-928d-6729fa5db2fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a8a8bf41-a58d-4a3e-809b-61f51b15df37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_79dff463-f21b-4cf8-928d-6729fa5db2fb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a8a8bf41-a58d-4a3e-809b-61f51b15df37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_02b69354-f460-4dc7-b072-8ecb3d364d18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_79dff463-f21b-4cf8-928d-6729fa5db2fb" xlink:to="loc_us-gaap_RestrictedStockMember_02b69354-f460-4dc7-b072-8ecb3d364d18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants_84400b2b-6bdd-4885-8b9d-9f6485c7a42a" xlink:href="cpix-20231231.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b882f42-843d-434f-ace0-fc17c99a22df" xlink:to="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants_84400b2b-6bdd-4885-8b9d-9f6485c7a42a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_740442dd-84d3-4312-8efa-4b3dc1512223" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b882f42-843d-434f-ace0-fc17c99a22df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_740442dd-84d3-4312-8efa-4b3dc1512223" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_fceb6d89-a883-4c61-b83f-b825a49abfcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b882f42-843d-434f-ace0-fc17c99a22df" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_fceb6d89-a883-4c61-b83f-b825a49abfcd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue_dae171dd-dcfe-4f2a-9f6e-973b6248c962" xlink:href="cpix-20231231.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b882f42-843d-434f-ace0-fc17c99a22df" xlink:to="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue_dae171dd-dcfe-4f2a-9f6e-973b6248c962" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent_cf3246f4-9601-4937-b58a-06a47724d50d" xlink:href="cpix-20231231.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b882f42-843d-434f-ace0-fc17c99a22df" xlink:to="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent_cf3246f4-9601-4937-b58a-06a47724d50d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_7375359c-ac18-4eba-bc45-cb3ba6cc18bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b882f42-843d-434f-ace0-fc17c99a22df" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_7375359c-ac18-4eba-bc45-cb3ba6cc18bb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e14ec98c-7da6-4245-9ebd-c4f6c5b84189" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b882f42-843d-434f-ace0-fc17c99a22df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e14ec98c-7da6-4245-9ebd-c4f6c5b84189" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_79ae1659-d100-41fc-afea-00f695cbb0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b882f42-843d-434f-ace0-fc17c99a22df" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_79ae1659-d100-41fc-afea-00f695cbb0c0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_80446f48-d664-48f1-8f72-d09b73351945" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b882f42-843d-434f-ace0-fc17c99a22df" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_80446f48-d664-48f1-8f72-d09b73351945" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_670ed5a1-2ab9-41a5-aa30-0082d65e18ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b882f42-843d-434f-ace0-fc17c99a22df" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_670ed5a1-2ab9-41a5-aa30-0082d65e18ce" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_73d719b1-82eb-4492-bf5a-e2d413c11609" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b882f42-843d-434f-ace0-fc17c99a22df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_73d719b1-82eb-4492-bf5a-e2d413c11609" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_b088c026-8f6f-4cbd-989f-065014dd9a66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b882f42-843d-434f-ace0-fc17c99a22df" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_b088c026-8f6f-4cbd-989f-065014dd9a66" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_55e65324-ce0c-4d92-b0a3-c28eda7037a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b882f42-843d-434f-ace0-fc17c99a22df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_55e65324-ce0c-4d92-b0a3-c28eda7037a6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b8a31c9e-cc46-412c-b5ea-4f759551cee7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b882f42-843d-434f-ace0-fc17c99a22df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b8a31c9e-cc46-412c-b5ea-4f759551cee7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_9f932a1c-f217-44ff-bf91-87898fc6ca8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b882f42-843d-434f-ace0-fc17c99a22df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_9f932a1c-f217-44ff-bf91-87898fc6ca8f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_3a2372d6-a014-4642-9d1a-8babe5a2e459" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b882f42-843d-434f-ace0-fc17c99a22df" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_3a2372d6-a014-4642-9d1a-8babe5a2e459" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansValuationAssumptionsDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#StockBasedCompensationPlansValuationAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49cc5629-c582-4269-8864-e43fb2e94b22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a079d2d-616c-4814-9ce5-61b84571cfd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49cc5629-c582-4269-8864-e43fb2e94b22" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a079d2d-616c-4814-9ce5-61b84571cfd2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9f2126d7-4f6a-4015-ad0a-67f997f11777" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a079d2d-616c-4814-9ce5-61b84571cfd2" xlink:to="loc_us-gaap_AwardTypeAxis_9f2126d7-4f6a-4015-ad0a-67f997f11777" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f2126d7-4f6a-4015-ad0a-67f997f11777_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9f2126d7-4f6a-4015-ad0a-67f997f11777" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f2126d7-4f6a-4015-ad0a-67f997f11777_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c4f054c6-cd4c-44bb-9b44-d94815ef88ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9f2126d7-4f6a-4015-ad0a-67f997f11777" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c4f054c6-cd4c-44bb-9b44-d94815ef88ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_950716c0-4837-4ca6-9c56-4cbc8789d008" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c4f054c6-cd4c-44bb-9b44-d94815ef88ba" xlink:to="loc_us-gaap_EmployeeStockOptionMember_950716c0-4837-4ca6-9c56-4cbc8789d008" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_55ccf454-b07e-4c89-b974-581811df9307" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49cc5629-c582-4269-8864-e43fb2e94b22" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_55ccf454-b07e-4c89-b974-581811df9307" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_85831f30-568f-4e60-8823-50a8e1baf2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49cc5629-c582-4269-8864-e43fb2e94b22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_85831f30-568f-4e60-8823-50a8e1baf2e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e63eb401-c43d-4661-968c-fe620b4da01b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49cc5629-c582-4269-8864-e43fb2e94b22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e63eb401-c43d-4661-968c-fe620b4da01b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_dd8c0501-31ed-440c-b9e6-064b8194f0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49cc5629-c582-4269-8864-e43fb2e94b22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_dd8c0501-31ed-440c-b9e6-064b8194f0a5" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansRestrictedStockActivityDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#StockBasedCompensationPlansRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7bc0c164-8c1c-422b-b5c4-5a1903ee5060" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2ff4e30-2018-42f2-9881-69039b29755e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7bc0c164-8c1c-422b-b5c4-5a1903ee5060" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2ff4e30-2018-42f2-9881-69039b29755e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6a794dbd-5ec4-480d-a18d-410f77012a87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2ff4e30-2018-42f2-9881-69039b29755e" xlink:to="loc_us-gaap_AwardTypeAxis_6a794dbd-5ec4-480d-a18d-410f77012a87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a794dbd-5ec4-480d-a18d-410f77012a87_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6a794dbd-5ec4-480d-a18d-410f77012a87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a794dbd-5ec4-480d-a18d-410f77012a87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99eb772f-d724-41b9-a781-91c01275c096" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6a794dbd-5ec4-480d-a18d-410f77012a87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99eb772f-d724-41b9-a781-91c01275c096" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_75041e58-f747-4913-bf35-e414fedf9180" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99eb772f-d724-41b9-a781-91c01275c096" xlink:to="loc_us-gaap_RestrictedStockMember_75041e58-f747-4913-bf35-e414fedf9180" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_76a6e497-92f0-45fc-9a24-1be1189f821f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7bc0c164-8c1c-422b-b5c4-5a1903ee5060" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_76a6e497-92f0-45fc-9a24-1be1189f821f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f1d8c976-7397-4dee-a272-f725e2e2d848" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_76a6e497-92f0-45fc-9a24-1be1189f821f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f1d8c976-7397-4dee-a272-f725e2e2d848" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_670418b2-81b1-4846-a76b-7dd212f0bd17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_76a6e497-92f0-45fc-9a24-1be1189f821f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_670418b2-81b1-4846-a76b-7dd212f0bd17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_14b9f658-6e39-4dc6-961f-5c1f4a4bbdf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_76a6e497-92f0-45fc-9a24-1be1189f821f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_14b9f658-6e39-4dc6-961f-5c1f4a4bbdf7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_29c97060-e357-4519-967f-c7f8037c2c50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_76a6e497-92f0-45fc-9a24-1be1189f821f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_29c97060-e357-4519-967f-c7f8037c2c50" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_05fe627d-31d4-4d0b-9c56-cfeb488d85b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7c3ff650-a3ca-481e-82b0-2088a6a6e04a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7bc0c164-8c1c-422b-b5c4-5a1903ee5060" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7c3ff650-a3ca-481e-82b0-2088a6a6e04a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1d2fa527-49be-4c7e-911e-60d248e12f00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7c3ff650-a3ca-481e-82b0-2088a6a6e04a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1d2fa527-49be-4c7e-911e-60d248e12f00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ddae03da-f73c-4630-bba7-bf02f45eabd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7c3ff650-a3ca-481e-82b0-2088a6a6e04a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ddae03da-f73c-4630-bba7-bf02f45eabd3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_fcf6d04e-f78b-4d22-a2cc-d930b48f0538" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7c3ff650-a3ca-481e-82b0-2088a6a6e04a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_fcf6d04e-f78b-4d22-a2cc-d930b48f0538" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e3af2d19-6889-4ab0-8622-b31ccf2bec03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7c3ff650-a3ca-481e-82b0-2088a6a6e04a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e3af2d19-6889-4ab0-8622-b31ccf2bec03" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_befd23dc-d027-424a-b1c7-a59293504247" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_db08a750-0b63-4914-a501-59c2ce9f9448" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_a3b56b6b-6e75-4ba0-9ce6-81cc83c24378" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_db08a750-0b63-4914-a501-59c2ce9f9448" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_a3b56b6b-6e75-4ba0-9ce6-81cc83c24378" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b3a7b8f7-8276-4227-8a38-2dc2abd014ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a3b56b6b-6e75-4ba0-9ce6-81cc83c24378" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b3a7b8f7-8276-4227-8a38-2dc2abd014ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b3a7b8f7-8276-4227-8a38-2dc2abd014ea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b3a7b8f7-8276-4227-8a38-2dc2abd014ea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b3a7b8f7-8276-4227-8a38-2dc2abd014ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f0248e6-6de7-4c0d-a32e-9f98ad5c546c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b3a7b8f7-8276-4227-8a38-2dc2abd014ea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f0248e6-6de7-4c0d-a32e-9f98ad5c546c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficeBuildingMember_3cfff126-5bf5-4155-89f2-a6d5f02e085d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OfficeBuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f0248e6-6de7-4c0d-a32e-9f98ad5c546c" xlink:to="loc_srt_OfficeBuildingMember_3cfff126-5bf5-4155-89f2-a6d5f02e085d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_0f45376c-8eae-439b-9fda-6791e54b33ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a3b56b6b-6e75-4ba0-9ce6-81cc83c24378" xlink:to="loc_us-gaap_LeaseContractualTermAxis_0f45376c-8eae-439b-9fda-6791e54b33ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_0f45376c-8eae-439b-9fda-6791e54b33ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_0f45376c-8eae-439b-9fda-6791e54b33ee" xlink:to="loc_us-gaap_LeaseContractualTermDomain_0f45376c-8eae-439b-9fda-6791e54b33ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_54f8045d-d125-41a4-92cb-435de203dd65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_0f45376c-8eae-439b-9fda-6791e54b33ee" xlink:to="loc_us-gaap_LeaseContractualTermDomain_54f8045d-d125-41a4-92cb-435de203dd65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BroadwestLeaseFiveYearRenewalOptionMember_404c10e9-0744-45ae-9b80-389050db96e4" xlink:href="cpix-20231231.xsd#cpix_BroadwestLeaseFiveYearRenewalOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_54f8045d-d125-41a4-92cb-435de203dd65" xlink:to="loc_cpix_BroadwestLeaseFiveYearRenewalOptionMember_404c10e9-0744-45ae-9b80-389050db96e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_522dcdf0-6af0-41c7-87b6-bbef13e9da24" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a3b56b6b-6e75-4ba0-9ce6-81cc83c24378" xlink:to="loc_srt_CounterpartyNameAxis_522dcdf0-6af0-41c7-87b6-bbef13e9da24" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_522dcdf0-6af0-41c7-87b6-bbef13e9da24_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_522dcdf0-6af0-41c7-87b6-bbef13e9da24" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_522dcdf0-6af0-41c7-87b6-bbef13e9da24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e3ef61fd-a65b-45fe-b1a3-43b9579f508d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_522dcdf0-6af0-41c7-87b6-bbef13e9da24" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e3ef61fd-a65b-45fe-b1a3-43b9579f508d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_A1600WestEndAvenuePartnersLLCMember_100d0739-1962-4540-a1a7-894858cc1014" xlink:href="cpix-20231231.xsd#cpix_A1600WestEndAvenuePartnersLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e3ef61fd-a65b-45fe-b1a3-43b9579f508d" xlink:to="loc_cpix_A1600WestEndAvenuePartnersLLCMember_100d0739-1962-4540-a1a7-894858cc1014" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NephronPharmaceuticalsCorporationNephronMember_b686f5a7-6708-4a77-9a7e-e83b1ceaeec1" xlink:href="cpix-20231231.xsd#cpix_NephronPharmaceuticalsCorporationNephronMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e3ef61fd-a65b-45fe-b1a3-43b9579f508d" xlink:to="loc_cpix_NephronPharmaceuticalsCorporationNephronMember_b686f5a7-6708-4a77-9a7e-e83b1ceaeec1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseLeasedArea_a3e761f3-c64c-4c12-a90b-52eb101e3534" xlink:href="cpix-20231231.xsd#cpix_LesseeOperatingLeaseLeasedArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_db08a750-0b63-4914-a501-59c2ce9f9448" xlink:to="loc_cpix_LesseeOperatingLeaseLeasedArea_a3e761f3-c64c-4c12-a90b-52eb101e3534" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_7fe8d1c6-eedb-4b81-a931-5843228fb761" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_db08a750-0b63-4914-a501-59c2ce9f9448" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_7fe8d1c6-eedb-4b81-a931-5843228fb761" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseNumberOfRenewalTerms_1bdb3c85-68f4-41d4-a3a9-2f225b57cc2c" xlink:href="cpix-20231231.xsd#cpix_LesseeOperatingLeaseNumberOfRenewalTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_db08a750-0b63-4914-a501-59c2ce9f9448" xlink:to="loc_cpix_LesseeOperatingLeaseNumberOfRenewalTerms_1bdb3c85-68f4-41d4-a3a9-2f225b57cc2c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_532f14ce-5296-4721-bd76-0fde9e67d2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_db08a750-0b63-4914-a501-59c2ce9f9448" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_532f14ce-5296-4721-bd76-0fde9e67d2a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseBaseRent_e649a8de-800a-464b-887f-fb5780d82f2f" xlink:href="cpix-20231231.xsd#cpix_LesseeOperatingLeaseBaseRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_db08a750-0b63-4914-a501-59c2ce9f9448" xlink:to="loc_cpix_LesseeOperatingLeaseBaseRent_e649a8de-800a-464b-887f-fb5780d82f2f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseRentIncrease_aaf02735-9b23-45ae-9043-f4efe37ff31d" xlink:href="cpix-20231231.xsd#cpix_LesseeOperatingLeaseRentIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_db08a750-0b63-4914-a501-59c2ce9f9448" xlink:to="loc_cpix_LesseeOperatingLeaseRentIncrease_aaf02735-9b23-45ae-9043-f4efe37ff31d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_c9945358-3872-448d-9b0a-f728683bac5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_db08a750-0b63-4914-a501-59c2ce9f9448" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_c9945358-3872-448d-9b0a-f728683bac5f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_ab96c40e-2359-47f3-8b06-2b81a9c8b78a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_db08a750-0b63-4914-a501-59c2ce9f9448" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_ab96c40e-2359-47f3-8b06-2b81a9c8b78a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e961dbab-ce12-4b51-8340-7e95abde12ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_db08a750-0b63-4914-a501-59c2ce9f9448" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e961dbab-ce12-4b51-8340-7e95abde12ad" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2c959adc-9909-4c4f-9578-759432b7a863" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_db08a750-0b63-4914-a501-59c2ce9f9448" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2c959adc-9909-4c4f-9578-759432b7a863" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f0d35eb9-2146-4715-9db8-d6b2a0d70854" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_db08a750-0b63-4914-a501-59c2ce9f9448" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f0d35eb9-2146-4715-9db8-d6b2a0d70854" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_7213511b-b5fe-48ce-9e04-0645ec0d5ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_db08a750-0b63-4914-a501-59c2ce9f9448" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_7213511b-b5fe-48ce-9e04-0645ec0d5ed8" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_850651cb-8cdf-41f7-8175-5dba3a493ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_0e8f9144-7432-45e7-adc5-a490e8a83066" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_850651cb-8cdf-41f7-8175-5dba3a493ea1" xlink:to="loc_us-gaap_ConcentrationRiskTable_0e8f9144-7432-45e7-adc5-a490e8a83066" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_bebc1183-5681-4cae-b67d-ed605d00f691" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_0e8f9144-7432-45e7-adc5-a490e8a83066" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_bebc1183-5681-4cae-b67d-ed605d00f691" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_bebc1183-5681-4cae-b67d-ed605d00f691_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_bebc1183-5681-4cae-b67d-ed605d00f691" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_bebc1183-5681-4cae-b67d-ed605d00f691_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_61516898-9deb-4f73-90d1-e018ca777e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_bebc1183-5681-4cae-b67d-ed605d00f691" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_61516898-9deb-4f73-90d1-e018ca777e8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_397c6a0f-d2b3-4725-939e-635d793ee746" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_61516898-9deb-4f73-90d1-e018ca777e8e" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_397c6a0f-d2b3-4725-939e-635d793ee746" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7d981cdc-1d17-4787-817e-dc3837d0cc59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_0e8f9144-7432-45e7-adc5-a490e8a83066" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7d981cdc-1d17-4787-817e-dc3837d0cc59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7d981cdc-1d17-4787-817e-dc3837d0cc59_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7d981cdc-1d17-4787-817e-dc3837d0cc59" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7d981cdc-1d17-4787-817e-dc3837d0cc59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e8920037-9a2f-4d5c-8bcc-f1bf0d523c77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7d981cdc-1d17-4787-817e-dc3837d0cc59" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e8920037-9a2f-4d5c-8bcc-f1bf0d523c77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SalesRevenueGoodsGrossMember_e432cff3-3bcd-4f3f-9f13-0e49cdb8eff1" xlink:href="cpix-20231231.xsd#cpix_SalesRevenueGoodsGrossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e8920037-9a2f-4d5c-8bcc-f1bf0d523c77" xlink:to="loc_cpix_SalesRevenueGoodsGrossMember_e432cff3-3bcd-4f3f-9f13-0e49cdb8eff1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_3ff18beb-f54d-4af6-90e5-085585dda25d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e8920037-9a2f-4d5c-8bcc-f1bf0d523c77" xlink:to="loc_us-gaap_AccountsReceivableMember_3ff18beb-f54d-4af6-90e5-085585dda25d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_3444af84-ca75-4e63-984b-31c0573458b6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_0e8f9144-7432-45e7-adc5-a490e8a83066" xlink:to="loc_srt_MajorCustomersAxis_3444af84-ca75-4e63-984b-31c0573458b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_3444af84-ca75-4e63-984b-31c0573458b6_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_3444af84-ca75-4e63-984b-31c0573458b6" xlink:to="loc_srt_NameOfMajorCustomerDomain_3444af84-ca75-4e63-984b-31c0573458b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_fc6e2722-6c0c-4945-ac21-c0f574d11ba0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_3444af84-ca75-4e63-984b-31c0573458b6" xlink:to="loc_srt_NameOfMajorCustomerDomain_fc6e2722-6c0c-4945-ac21-c0f574d11ba0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CustomerOneMember_f36c7dd5-aa74-4378-b9f8-5f2ac929d45d" xlink:href="cpix-20231231.xsd#cpix_CustomerOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_fc6e2722-6c0c-4945-ac21-c0f574d11ba0" xlink:to="loc_cpix_CustomerOneMember_f36c7dd5-aa74-4378-b9f8-5f2ac929d45d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CustomerTwoMember_782d68ba-8027-4629-ae64-ec74af5600de" xlink:href="cpix-20231231.xsd#cpix_CustomerTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_fc6e2722-6c0c-4945-ac21-c0f574d11ba0" xlink:to="loc_cpix_CustomerTwoMember_782d68ba-8027-4629-ae64-ec74af5600de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CustomerThreeMember_7014e488-2137-4171-8283-402473b378fa" xlink:href="cpix-20231231.xsd#cpix_CustomerThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_fc6e2722-6c0c-4945-ac21-c0f574d11ba0" xlink:to="loc_cpix_CustomerThreeMember_7014e488-2137-4171-8283-402473b378fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_Customer12And3Member_9bcc6a41-7851-4b18-b724-63ee05ed615f" xlink:href="cpix-20231231.xsd#cpix_Customer12And3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_fc6e2722-6c0c-4945-ac21-c0f574d11ba0" xlink:to="loc_cpix_Customer12And3Member_9bcc6a41-7851-4b18-b724-63ee05ed615f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_09a81088-15ab-4d6b-9e15-f3a529e00d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_850651cb-8cdf-41f7-8175-5dba3a493ea1" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_09a81088-15ab-4d6b-9e15-f3a529e00d5f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingandSupplyAgreementLineItems_29d9a674-de9a-4c7a-99f8-3c5f76e84442" xlink:href="cpix-20231231.xsd#cpix_ManufacturingandSupplyAgreementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingandSupplyAgreementTable_1419c6be-c66f-47c7-8840-9aa563df94d2" xlink:href="cpix-20231231.xsd#cpix_ManufacturingandSupplyAgreementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cpix_ManufacturingandSupplyAgreementLineItems_29d9a674-de9a-4c7a-99f8-3c5f76e84442" xlink:to="loc_cpix_ManufacturingandSupplyAgreementTable_1419c6be-c66f-47c7-8840-9aa563df94d2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3f9587e4-9bd6-4cde-9129-2f0d9e3ab049" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cpix_ManufacturingandSupplyAgreementTable_1419c6be-c66f-47c7-8840-9aa563df94d2" xlink:to="loc_srt_RangeAxis_3f9587e4-9bd6-4cde-9129-2f0d9e3ab049" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3f9587e4-9bd6-4cde-9129-2f0d9e3ab049_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3f9587e4-9bd6-4cde-9129-2f0d9e3ab049" xlink:to="loc_srt_RangeMember_3f9587e4-9bd6-4cde-9129-2f0d9e3ab049_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_22078f62-d143-4547-8be5-fbb9ea52fbe9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3f9587e4-9bd6-4cde-9129-2f0d9e3ab049" xlink:to="loc_srt_RangeMember_22078f62-d143-4547-8be5-fbb9ea52fbe9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2712859b-75d9-4cd7-bd87-5f69e76f4dd4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_22078f62-d143-4547-8be5-fbb9ea52fbe9" xlink:to="loc_srt_MinimumMember_2712859b-75d9-4cd7-bd87-5f69e76f4dd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ef2c340d-3d29-4fca-b115-9a87010427ea" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_22078f62-d143-4547-8be5-fbb9ea52fbe9" xlink:to="loc_srt_MaximumMember_ef2c340d-3d29-4fca-b115-9a87010427ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct_d279d894-9997-450b-bd0e-e94dc586800d" xlink:href="cpix-20231231.xsd#cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ManufacturingandSupplyAgreementLineItems_29d9a674-de9a-4c7a-99f8-3c5f76e84442" xlink:to="loc_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct_d279d894-9997-450b-bd0e-e94dc586800d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_e085b3f4-2fb1-415a-bf62-0c78ead30d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_64d83f98-59f9-4079-9454-40b467f4f385" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e085b3f4-2fb1-415a-bf62-0c78ead30d0d" xlink:to="loc_us-gaap_OtherCommitmentsTable_64d83f98-59f9-4079-9454-40b467f4f385" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_de0eafbb-f148-447a-9541-7755c8165f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_64d83f98-59f9-4079-9454-40b467f4f385" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_de0eafbb-f148-447a-9541-7755c8165f8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_de0eafbb-f148-447a-9541-7755c8165f8a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_de0eafbb-f148-447a-9541-7755c8165f8a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_de0eafbb-f148-447a-9541-7755c8165f8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_faee813f-aaf9-4958-809e-28327df67a03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_de0eafbb-f148-447a-9541-7755c8165f8a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_faee813f-aaf9-4958-809e-28327df67a03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_U.S.ProductAssetRightsSancusoMember_436e4cd6-edeb-4f77-9a51-4c5bb862392f" xlink:href="cpix-20231231.xsd#cpix_U.S.ProductAssetRightsSancusoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_faee813f-aaf9-4958-809e-28327df67a03" xlink:to="loc_cpix_U.S.ProductAssetRightsSancusoMember_436e4cd6-edeb-4f77-9a51-4c5bb862392f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e875fceb-199f-4453-aeaa-6e13284761e5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_64d83f98-59f9-4079-9454-40b467f4f385" xlink:to="loc_srt_RangeAxis_e875fceb-199f-4453-aeaa-6e13284761e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e875fceb-199f-4453-aeaa-6e13284761e5_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e875fceb-199f-4453-aeaa-6e13284761e5" xlink:to="loc_srt_RangeMember_e875fceb-199f-4453-aeaa-6e13284761e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_242062a5-ac7a-4f53-b23f-b00c6a9e3a7c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e875fceb-199f-4453-aeaa-6e13284761e5" xlink:to="loc_srt_RangeMember_242062a5-ac7a-4f53-b23f-b00c6a9e3a7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1c28be22-dd8c-47d9-9a36-aa41bea18c62" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_242062a5-ac7a-4f53-b23f-b00c6a9e3a7c" xlink:to="loc_srt_MaximumMember_1c28be22-dd8c-47d9-9a36-aa41bea18c62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_688e90eb-ccfa-41a8-b0ac-a6010bb46904" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_242062a5-ac7a-4f53-b23f-b00c6a9e3a7c" xlink:to="loc_srt_MinimumMember_688e90eb-ccfa-41a8-b0ac-a6010bb46904" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c43c2c13-be74-46bd-9d64-982e7a072e23" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_64d83f98-59f9-4079-9454-40b467f4f385" xlink:to="loc_srt_CounterpartyNameAxis_c43c2c13-be74-46bd-9d64-982e7a072e23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c43c2c13-be74-46bd-9d64-982e7a072e23_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c43c2c13-be74-46bd-9d64-982e7a072e23" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c43c2c13-be74-46bd-9d64-982e7a072e23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_31fd0ae4-cd78-440a-bfe1-c7186c921f34" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c43c2c13-be74-46bd-9d64-982e7a072e23" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_31fd0ae4-cd78-440a-bfe1-c7186c921f34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember_c58bc552-16e9-43b5-af20-2db27bbd7f86" xlink:href="cpix-20231231.xsd#cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_31fd0ae4-cd78-440a-bfe1-c7186c921f34" xlink:to="loc_cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember_c58bc552-16e9-43b5-af20-2db27bbd7f86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d0c51263-ce9f-49bb-b33b-2a998b8506ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_64d83f98-59f9-4079-9454-40b467f4f385" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d0c51263-ce9f-49bb-b33b-2a998b8506ac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d0c51263-ce9f-49bb-b33b-2a998b8506ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d0c51263-ce9f-49bb-b33b-2a998b8506ac" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d0c51263-ce9f-49bb-b33b-2a998b8506ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8f5325dc-93f3-4483-b602-83f2cbd36cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d0c51263-ce9f-49bb-b33b-2a998b8506ac" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8f5325dc-93f3-4483-b602-83f2cbd36cd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_97a52349-6750-413c-99d7-89655405efe2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8f5325dc-93f3-4483-b602-83f2cbd36cd0" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_97a52349-6750-413c-99d7-89655405efe2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdAxis_a14c6131-0c78-4043-adfa-87e0206ec233" xlink:href="cpix-20231231.xsd#cpix_CollaborativeArrangementMilestonePaymentThresholdAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_64d83f98-59f9-4079-9454-40b467f4f385" xlink:to="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdAxis_a14c6131-0c78-4043-adfa-87e0206ec233" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdDomain_a14c6131-0c78-4043-adfa-87e0206ec233_default" xlink:href="cpix-20231231.xsd#cpix_CollaborativeArrangementMilestonePaymentThresholdDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdAxis_a14c6131-0c78-4043-adfa-87e0206ec233" xlink:to="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdDomain_a14c6131-0c78-4043-adfa-87e0206ec233_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdDomain_535d0dfa-97c0-4686-8909-3a8e0d86cc7d" xlink:href="cpix-20231231.xsd#cpix_CollaborativeArrangementMilestonePaymentThresholdDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdAxis_a14c6131-0c78-4043-adfa-87e0206ec233" xlink:to="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdDomain_535d0dfa-97c0-4686-8909-3a8e0d86cc7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_Within30DaysOfFirstSNDAFilingMember_8fdbd967-9bf5-436c-ae43-5a500056b474" xlink:href="cpix-20231231.xsd#cpix_Within30DaysOfFirstSNDAFilingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdDomain_535d0dfa-97c0-4686-8909-3a8e0d86cc7d" xlink:to="loc_cpix_Within30DaysOfFirstSNDAFilingMember_8fdbd967-9bf5-436c-ae43-5a500056b474" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FollowingApprovalOfFirstSNDAMember_1163b580-ceda-4d68-b34e-e3d1f7753ab4" xlink:href="cpix-20231231.xsd#cpix_FollowingApprovalOfFirstSNDAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdDomain_535d0dfa-97c0-4686-8909-3a8e0d86cc7d" xlink:to="loc_cpix_FollowingApprovalOfFirstSNDAMember_1163b580-ceda-4d68-b34e-e3d1f7753ab4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold_828bd3c1-8654-4a5a-9cce-7f61c47e5a23" xlink:href="cpix-20231231.xsd#cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e085b3f4-2fb1-415a-bf62-0c78ead30d0d" xlink:to="loc_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold_828bd3c1-8654-4a5a-9cce-7f61c47e5a23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage_95c59d9a-5cda-42e8-af32-34af80a5c49f" xlink:href="cpix-20231231.xsd#cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e085b3f4-2fb1-415a-bf62-0c78ead30d0d" xlink:to="loc_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage_95c59d9a-5cda-42e8-af32-34af80a5c49f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsTerm_70b37043-e284-446a-a6d0-d05162d507b4" xlink:href="cpix-20231231.xsd#cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e085b3f4-2fb1-415a-bf62-0c78ead30d0d" xlink:to="loc_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsTerm_70b37043-e284-446a-a6d0-d05162d507b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable_d9af79fe-4544-4299-a829-436dce116abe" xlink:href="cpix-20231231.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e085b3f4-2fb1-415a-bf62-0c78ead30d0d" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable_d9af79fe-4544-4299-a829-436dce116abe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLegalSettlements_fccaadc2-687a-4361-95f5-5d41fc979726" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e085b3f4-2fb1-415a-bf62-0c78ead30d0d" xlink:to="loc_us-gaap_ProceedsFromLegalSettlements_fccaadc2-687a-4361-95f5-5d41fc979726" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#ValuationandQualifyingAccountsDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_9d243d55-04ff-4f15-852f-9683d8639595" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_cf5949e3-d938-491a-ae40-d363d8573c97" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_9d243d55-04ff-4f15-852f-9683d8639595" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_cf5949e3-d938-491a-ae40-d363d8573c97" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_79747ed1-c213-4e93-a0e5-0898249bba8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_cf5949e3-d938-491a-ae40-d363d8573c97" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_79747ed1-c213-4e93-a0e5-0898249bba8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_79747ed1-c213-4e93-a0e5-0898249bba8d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_79747ed1-c213-4e93-a0e5-0898249bba8d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_79747ed1-c213-4e93-a0e5-0898249bba8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_884c3ab0-3aab-4195-b384-8a03ad1b5006" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_79747ed1-c213-4e93-a0e5-0898249bba8d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_884c3ab0-3aab-4195-b384-8a03ad1b5006" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossMember_4330f16e-e423-4527-83ee-02cece21b98d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForCreditLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_884c3ab0-3aab-4195-b384-8a03ad1b5006" xlink:to="loc_us-gaap_AllowanceForCreditLossMember_4330f16e-e423-4527-83ee-02cece21b98d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_9ccc99af-a992-485b-b2b8-7ebbafad57f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_884c3ab0-3aab-4195-b384-8a03ad1b5006" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_9ccc99af-a992-485b-b2b8-7ebbafad57f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_07e33499-6918-4cdd-a88d-27b2d7c63d08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_9d243d55-04ff-4f15-852f-9683d8639595" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_07e33499-6918-4cdd-a88d-27b2d7c63d08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_4642aac6-be60-4dd5-a578-a695cad9bf81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_07e33499-6918-4cdd-a88d-27b2d7c63d08" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_4642aac6-be60-4dd5-a578-a695cad9bf81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_c93d0aab-1d30-41f3-a6de-0df7e1a61c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_07e33499-6918-4cdd-a88d-27b2d7c63d08" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_c93d0aab-1d30-41f3-a6de-0df7e1a61c4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_b65dd8da-00a5-454d-9dc2-790d41d70b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_07e33499-6918-4cdd-a88d-27b2d7c63d08" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_b65dd8da-00a5-454d-9dc2-790d41d70b6f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_b4b49b0d-4bcf-43ac-b0b5-819e4f39cd2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_07e33499-6918-4cdd-a88d-27b2d7c63d08" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_b4b49b0d-4bcf-43ac-b0b5-819e4f39cd2b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_000ef178-7f9d-4862-8234-7dfb3540535f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockMember" xlink:type="arc" order="4"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>17
<FILENAME>cpix-20231231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:6edb08b2-28be-4fe2-96a1-5228f16440ba,g:0b7981d4-3364-432a-a869-7a65f1514fac-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_05ea726e-fb23-410c-998f-b340f67a333c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_0ea3fcab-e550-457a-90f3-56cee96ffba9_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0168f7a8-37e1-410e-95fa-b96b00a373b5_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net loss at subsidiary attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_62406c18-6891-4067-bec1-b54e1ccfd76f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net loss at subsidiary attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_b79a7047-d504-4417-821f-925a886f7f74_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_c8b1cb90-bae5-41ec-85b3-8980077dce0b_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_a9fd5150-58e3-4d77-a6c9-9b835d81ae66_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of accrued liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_f0072045-561d-4822-9327-846882389d3e_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_3069f145-90c2-44ce-8c53-4ad9e236369e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory reserves, obsolescence and discontinuance</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_0e5a412c-d472-4bf0-b9ef-e599caa2e012_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of credit, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_a5e51be4-bfe0-4507-ada7-dc33626dd126_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dee63ec1-b42a-4c49-b33d-662980b079db_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net changes in assets and liabilities affecting operating activities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c5a3fd69-e8ac-46e2-b67b-ade4c624b6ea_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options, expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ChangeInUnpaidInvoicesForOfferingCosts_ac28d426-3ea1-48d2-913a-22a95cf44221_terseLabel_en-US" xlink:label="lab_cpix_ChangeInUnpaidInvoicesForOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in unpaid invoices for offering costs</link:label>
    <link:label id="lab_cpix_ChangeInUnpaidInvoicesForOfferingCosts_label_en-US" xlink:label="lab_cpix_ChangeInUnpaidInvoicesForOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Unpaid Invoices For Offering Costs</link:label>
    <link:label id="lab_cpix_ChangeInUnpaidInvoicesForOfferingCosts_documentation_en-US" xlink:label="lab_cpix_ChangeInUnpaidInvoicesForOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Unpaid Invoices For Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ChangeInUnpaidInvoicesForOfferingCosts" xlink:href="cpix-20231231.xsd#cpix_ChangeInUnpaidInvoicesForOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ChangeInUnpaidInvoicesForOfferingCosts" xlink:to="lab_cpix_ChangeInUnpaidInvoicesForOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_7ba173b8-cc26-4496-9a0b-70c96cd11623_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of net product revenues by product</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ed7714e5-57d9-40e5-a5c5-b6e4fd7882b9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_d7c75ebe-5ad9-4f66-b8f4-174a063be24d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_546d182a-84f7-4be6-8e8c-d9630c2512db_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Nonvested, beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_01554be5-87e6-4b6a-a872-51449ffbc2b0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Nonvested, end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CumberlandEmergingTechnologiesIncMember_d579e6ec-48ea-44c5-86a0-ba1eba6c8ce0_terseLabel_en-US" xlink:label="lab_cpix_CumberlandEmergingTechnologiesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumberland Emerging Technologies, Inc (CET)</link:label>
    <link:label id="lab_cpix_CumberlandEmergingTechnologiesIncMember_label_en-US" xlink:label="lab_cpix_CumberlandEmergingTechnologiesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumberland Emerging Technologies, Inc [Member]</link:label>
    <link:label id="lab_cpix_CumberlandEmergingTechnologiesIncMember_documentation_en-US" xlink:label="lab_cpix_CumberlandEmergingTechnologiesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cumberland Emerging Technologies, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CumberlandEmergingTechnologiesIncMember" xlink:href="cpix-20231231.xsd#cpix_CumberlandEmergingTechnologiesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CumberlandEmergingTechnologiesIncMember" xlink:to="lab_cpix_CumberlandEmergingTechnologiesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_9f360e92-353f-4907-b828-a0725bbda5b7_negatedTerseLabel_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decrease (increase) in cash surrender value of life insurance policies over premiums paid</link:label>
    <link:label id="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_label_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy</link:label>
    <link:label id="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_documentation_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:href="cpix-20231231.xsd#cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:to="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_Customer12And3Member_b30a9051-bdce-4e0c-8ba8-1b75c0a53de2_terseLabel_en-US" xlink:label="lab_cpix_Customer12And3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer 1, 2, and 3</link:label>
    <link:label id="lab_cpix_Customer12And3Member_label_en-US" xlink:label="lab_cpix_Customer12And3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer 1, 2, and 3 [Member]</link:label>
    <link:label id="lab_cpix_Customer12And3Member_documentation_en-US" xlink:label="lab_cpix_Customer12And3Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer 1, 2, and 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_Customer12And3Member" xlink:href="cpix-20231231.xsd#cpix_Customer12And3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_Customer12And3Member" xlink:to="lab_cpix_Customer12And3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_ea064825-bebf-44b9-93e7-605160bdc300_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_ca149443-acda-492b-b54d-c52255309530_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_8651feb5-4258-49c2-80cf-949848c3e687_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_4f2794f0-cc60-4746-b60a-2bd9a85e1ab7_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment to acquire business upon closing</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_da64ea65-3c3a-4330-a615-e26d8dd06f63_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_a64942a9-6d4e-4bb8-8eea-305afdea0331_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined contribution plan, employer discretionary contribution amount</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_2696ffa7-3f4f-4807-a24c-8d2e3f1005f9_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_c2caef95-c019-4bf3-98a4-53ae1abb4839_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment loss on intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Finite-Lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_75a17508-bfe9-427a-9f8c-98bc32a9ef54_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_be721681-caed-4949-98be-ec5b479730a4_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_a1dfac6d-f03e-426f-be13-8bdb2bb72696_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_22b445f3-4b9b-4365-894c-c050c1a9c0c8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_73aff2f7-d28e-467c-9518-b1c9f91344c8_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal tax expense at statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_20371a89-70ba-4429-b9b8-57f6ccb16e0b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_44757506-7695-41ca-9439-4029ac3e228c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease Liabilities, Payments Due [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_80627fa3-d871-4c75-aa77-8e026a4587d0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent_fe947052-1ad3-44c1-be9e-ad226d7419a9_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of accrued contingent consideration</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent_label_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Accrued, Current</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Accrued, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent" xlink:href="cpix-20231231.xsd#cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent" xlink:to="lab_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts_25b1ce7a-806f-4d76-9ead-09d586896ee8_terseLabel_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial public offering, underwriting discounts</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts_label_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, New Shares, Underwriting Discounts</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts_documentation_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, New Shares, Underwriting Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts" xlink:href="cpix-20231231.xsd#cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts" xlink:to="lab_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_913e15b3-b80b-49c8-afba-4ed8baddd914_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_cd554e8e-69c2-4813-83ff-34eec2c19a74_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct_1a8166bc-380b-461d-84c0-b7d2be650c7d_terseLabel_en-US" xlink:label="lab_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing agreements, number of primary suppliers for each product</link:label>
    <link:label id="lab_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct_label_en-US" xlink:label="lab_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacturing agreements, number of primary suppliers for each product</link:label>
    <link:label id="lab_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct_documentation_en-US" xlink:label="lab_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Manufacturing agreements, number of primary suppliers for each product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" xlink:href="cpix-20231231.xsd#cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" xlink:to="lab_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements_f6780ac9-dfc2-48b5-9a1d-ecfd4af07c15_terseLabel_en-US" xlink:label="lab_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, including amortization related to leasehold improvements</link:label>
    <link:label id="lab_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements_label_en-US" xlink:label="lab_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Including Amortization Related to Leasehold Improvements</link:label>
    <link:label id="lab_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements_documentation_en-US" xlink:label="lab_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Depreciation, Including Amortization Related to Leasehold Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" xlink:href="cpix-20231231.xsd#cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" xlink:to="lab_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_c1a65bec-315d-4427-9718-ae3e0d3b3e2a_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_ebd9a3a7-69d0-4fff-ad1d-de1504d2861b_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_61680b91-2258-439a-8315-4d741d995a59_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_f897ad4a-09a1-49e4-bbe5-e14cfb5aa0c6_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_2189d11f-3439-446f-9353-5a6664a04396_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_EmploymentAgreementsAbstract_label_en-US" xlink:label="lab_cpix_EmploymentAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employment Agreements [Abstract]</link:label>
    <link:label id="lab_cpix_EmploymentAgreementsAbstract_documentation_en-US" xlink:label="lab_cpix_EmploymentAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employment Agreements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmploymentAgreementsAbstract" xlink:href="cpix-20231231.xsd#cpix_EmploymentAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_EmploymentAgreementsAbstract" xlink:to="lab_cpix_EmploymentAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_1a19c7d4-b9c5-4a0a-a22f-6a0a22d96393_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_8f4be898-0f5c-404f-b0df-8985c22e3182_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_e768a923-a0a8-44ef-b8dc-322a7964979a_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_bbb52053-2155-4ed0-9425-19910143012b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings on line of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Repayments of) Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LesseeOperatingLeaseBaseRent_758319bb-de16-44da-93b2-8d3c749180e8_terseLabel_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseBaseRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Base Rent</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseBaseRent_label_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseBaseRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Base Rent</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseBaseRent_documentation_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseBaseRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Base Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseBaseRent" xlink:href="cpix-20231231.xsd#cpix_LesseeOperatingLeaseBaseRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LesseeOperatingLeaseBaseRent" xlink:to="lab_cpix_LesseeOperatingLeaseBaseRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLifeInsurancePolicies_71875d0b-a132-478b-a331-52b56c561db0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLifeInsurancePolicies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Life insurance policy proceeds received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLifeInsurancePolicies_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLifeInsurancePolicies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Life Insurance Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLifeInsurancePolicies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLifeInsurancePolicies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLifeInsurancePolicies" xlink:to="lab_us-gaap_ProceedsFromLifeInsurancePolicies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_7a568c88-8904-43d4-9629-be7cdd27fa9a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_70091b04-7449-4358-8579-f215de9ef1ed_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_e26d9418-6bbf-4b76-a979-d8dcbab5fbeb_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract" xlink:to="lab_us-gaap_NoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_0623ef68-184a-497e-8122-1b68b83786fe_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Customers [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_ddb51680-0f26-4ca5-8b52-805ed13f8c3c_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_9406ceb5-9aea-463f-9c72-910228937ade_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_77b2487f-e5b7-43cf-a9b4-ab0b03c5ec65_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b807a5dd-e7bd-4fff-b094-3e88cbdebcca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average grant-date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_3777fcf4-cf0c-478a-b90d-953d7517505e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cash settlement of contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_ac9bedd0-a632-42b9-b15f-fd213fc88bdd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited/cancelled (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_44be6027-b0b7-4855-b673-713f08242d5a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b7342445-9d9f-41cb-a6e6-c7c251ecd491_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_3d672d0d-79a6-434a-bd44-55cbd2433a6c_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_002a324d-c561-4d24-85ed-f63c01cc35bd_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_905a97d3-73c6-40d7-8a15-17e209b374ee_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5f1ea5cb-fe1b-4132-a89f-ce3597469049_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ExpirationTermTwoMember_f751ed10-1600-4fe4-9f59-723db8280325_terseLabel_en-US" xlink:label="lab_cpix_ExpirationTermTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025-2042</link:label>
    <link:label id="lab_cpix_ExpirationTermTwoMember_label_en-US" xlink:label="lab_cpix_ExpirationTermTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expiration, Term Two [Member]</link:label>
    <link:label id="lab_cpix_ExpirationTermTwoMember_documentation_en-US" xlink:label="lab_cpix_ExpirationTermTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expiration, Term Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermTwoMember" xlink:href="cpix-20231231.xsd#cpix_ExpirationTermTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ExpirationTermTwoMember" xlink:to="lab_cpix_ExpirationTermTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_37e47a73-c0f6-4a43-aa2e-26cdaed4c86b_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_666bb6e7-c32e-4029-99ce-b14cd4d577d0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_63aea49d-be04-4233-ae7d-8435b13decf8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b6670105-b1cd-4a0b-85f9-13296b34a827_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_8675550c-25fc-43a2-9aa7-fb98f2407991_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_5252534d-4ea6-4494-b895-941751e62337_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_d99811cb-5fcd-430a-a0c3-5ab3fbc7e074_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_95b906e7-4f31-4f2e-9cac-7eb472b4b443_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_e55c6fb0-b732-4cb2-933e-751d94cb0264_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate</link:label>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_label_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:to="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid_04009011-66f1-4507-9c36-e2e859f5c3ad_terseLabel_en-US" xlink:label="lab_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in unpaid invoices for intangible asset additions</link:label>
    <link:label id="lab_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid_label_en-US" xlink:label="lab_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchases of Intangible Assets Incurred But Not Yet Paid</link:label>
    <link:label id="lab_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchases of Intangible Assets Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid" xlink:href="cpix-20231231.xsd#cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid" xlink:to="lab_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_51fe8eed-f324-4aa0-bcda-5ff777dd382f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ExpirationTimePeriodDomain_ecdf58da-dc34-425e-8742-fa9bfdc71fd5_terseLabel_en-US" xlink:label="lab_cpix_ExpirationTimePeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Time Period [Domain]</link:label>
    <link:label id="lab_cpix_ExpirationTimePeriodDomain_label_en-US" xlink:label="lab_cpix_ExpirationTimePeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expiration Time Period [Domain]</link:label>
    <link:label id="lab_cpix_ExpirationTimePeriodDomain_documentation_en-US" xlink:label="lab_cpix_ExpirationTimePeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Expiration Time Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodDomain" xlink:href="cpix-20231231.xsd#cpix_ExpirationTimePeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ExpirationTimePeriodDomain" xlink:to="lab_cpix_ExpirationTimePeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d3a2d239-a1c1-4564-9547-9f4e6b8759f7_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_5e013dc8-cd66-43c9-995c-a069af72a3ae_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future minimum sublease income under noncancelable operating subleases</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_a2101c0f-2c49-4e6e-864c-fb137aca7584_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_a5ec1494-a6b8-4031-a3b0-8ce6bc7bda49_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_0af3c428-5050-4900-adbd-68ce3282fcfe_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_d8ee0705-30ec-4e88-8483-e12544055706_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProductSalesRelatedLiabilitiesCurrent_f3e98d9c-5cde-4569-8cd5-80cce7834629_terseLabel_en-US" xlink:label="lab_cpix_ProductSalesRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rebates, product returns, administrative fees and service fees</link:label>
    <link:label id="lab_cpix_ProductSalesRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_cpix_ProductSalesRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Sales-Related Liabilities, Current</link:label>
    <link:label id="lab_cpix_ProductSalesRelatedLiabilitiesCurrent_documentation_en-US" xlink:label="lab_cpix_ProductSalesRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product Sales-Related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductSalesRelatedLiabilitiesCurrent" xlink:href="cpix-20231231.xsd#cpix_ProductSalesRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductSalesRelatedLiabilitiesCurrent" xlink:to="lab_cpix_ProductSalesRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c6632c00-362d-4069-947d-a7810a7830b2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsTerm_b7a372f6-c784-4286-b4bd-636d54650dac_terseLabel_en-US" xlink:label="lab_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tiered royalty payments term (in years)</link:label>
    <link:label id="lab_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsTerm_label_en-US" xlink:label="lab_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments To Acquire Business, Tiered Royalty Payments, Term</link:label>
    <link:label id="lab_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsTerm_documentation_en-US" xlink:label="lab_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments To Acquire Business, Tiered Royalty Payments, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsTerm" xlink:href="cpix-20231231.xsd#cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsTerm" xlink:to="lab_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BroadwestLeaseFiveYearRenewalOptionMember_7a2466f1-9ef0-4a1a-a636-f1f0d1346aff_terseLabel_en-US" xlink:label="lab_cpix_BroadwestLeaseFiveYearRenewalOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Broadwest Lease, Five Year Renewal Option</link:label>
    <link:label id="lab_cpix_BroadwestLeaseFiveYearRenewalOptionMember_label_en-US" xlink:label="lab_cpix_BroadwestLeaseFiveYearRenewalOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Broadwest Lease, Five Year Renewal Option [Member]</link:label>
    <link:label id="lab_cpix_BroadwestLeaseFiveYearRenewalOptionMember_documentation_en-US" xlink:label="lab_cpix_BroadwestLeaseFiveYearRenewalOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Broadwest Lease, Five Year Renewal Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BroadwestLeaseFiveYearRenewalOptionMember" xlink:href="cpix-20231231.xsd#cpix_BroadwestLeaseFiveYearRenewalOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BroadwestLeaseFiveYearRenewalOptionMember" xlink:to="lab_cpix_BroadwestLeaseFiveYearRenewalOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_f5f876a3-93dd-433f-9160-799ffe381359_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1286baff-9d09-456d-9104-fe833cf0f163_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of calculation of numerator and denominator in earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_cab7940f-5637-46c8-b39d-3a7caf37d414_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade and Note Receivables</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_ab7275ed-6c17-4641-b58c-19dcd5384e3d_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrincipalOwnerMember_d919832d-ad50-485e-983a-7bd01cc69d89_terseLabel_en-US" xlink:label="lab_us-gaap_PrincipalOwnerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal Owner</link:label>
    <link:label id="lab_us-gaap_PrincipalOwnerMember_label_en-US" xlink:label="lab_us-gaap_PrincipalOwnerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Principal Owner [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrincipalOwnerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrincipalOwnerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrincipalOwnerMember" xlink:to="lab_us-gaap_PrincipalOwnerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_5506572a-f55f-4fbd-a9cb-06e14fff119c_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold_ce1021d9-c0da-4044-b04e-3694a830c320_terseLabel_en-US" xlink:label="lab_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tiered royalty payments, threshold</link:label>
    <link:label id="lab_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold_label_en-US" xlink:label="lab_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments To Acquire Business, Tiered Royalty Payments, Threshold</link:label>
    <link:label id="lab_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold_documentation_en-US" xlink:label="lab_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments To Acquire Business, Tiered Royalty Payments, Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold" xlink:href="cpix-20231231.xsd#cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold" xlink:to="lab_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7738e5f6-7630-41ef-bb30-95c9a6554195_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_b67708f1-e77d-445b-8732-3b9ed7c98ecd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Noncurrent</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Noncurrent [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CashPaymentIncludedInMeasurementOfLeaseLiability_0f7a684c-f53b-4b84-971a-a067a7c241a9_terseLabel_en-US" xlink:label="lab_cpix_CashPaymentIncludedInMeasurementOfLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total cash paid included in measurement of lease liability</link:label>
    <link:label id="lab_cpix_CashPaymentIncludedInMeasurementOfLeaseLiability_label_en-US" xlink:label="lab_cpix_CashPaymentIncludedInMeasurementOfLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Payment Included In Measurement Of Lease Liability</link:label>
    <link:label id="lab_cpix_CashPaymentIncludedInMeasurementOfLeaseLiability_documentation_en-US" xlink:label="lab_cpix_CashPaymentIncludedInMeasurementOfLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Payment Included In Measurement Of Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CashPaymentIncludedInMeasurementOfLeaseLiability" xlink:href="cpix-20231231.xsd#cpix_CashPaymentIncludedInMeasurementOfLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CashPaymentIncludedInMeasurementOfLeaseLiability" xlink:to="lab_cpix_CashPaymentIncludedInMeasurementOfLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SalesRevenueGoodsGrossMember_656e4efa-691c-4d39-8566-ea59fa96e100_terseLabel_en-US" xlink:label="lab_cpix_SalesRevenueGoodsGrossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales Revenue, Goods, Gross</link:label>
    <link:label id="lab_cpix_SalesRevenueGoodsGrossMember_label_en-US" xlink:label="lab_cpix_SalesRevenueGoodsGrossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Goods, Gross [Member]</link:label>
    <link:label id="lab_cpix_SalesRevenueGoodsGrossMember_documentation_en-US" xlink:label="lab_cpix_SalesRevenueGoodsGrossMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales Revenue, Goods, Gross [Member] [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SalesRevenueGoodsGrossMember" xlink:href="cpix-20231231.xsd#cpix_SalesRevenueGoodsGrossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SalesRevenueGoodsGrossMember" xlink:to="lab_cpix_SalesRevenueGoodsGrossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ff377b13-a078-4f38-aafb-1d2442c92cae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_VaprisolMember_7e29395f-13e4-4565-8b84-0f8b78fc57d5_terseLabel_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vaprisol</link:label>
    <link:label id="lab_cpix_VaprisolMember_label_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vaprisol [Member]</link:label>
    <link:label id="lab_cpix_VaprisolMember_documentation_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vaprisol [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember" xlink:href="cpix-20231231.xsd#cpix_VaprisolMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_VaprisolMember" xlink:to="lab_cpix_VaprisolMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PaymentsToAcquireBusinessMilestonePaymentRemaining_86a007bb-787c-4119-b981-b6ab943d696e_terseLabel_en-US" xlink:label="lab_cpix_PaymentsToAcquireBusinessMilestonePaymentRemaining" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment remaining</link:label>
    <link:label id="lab_cpix_PaymentsToAcquireBusinessMilestonePaymentRemaining_label_en-US" xlink:label="lab_cpix_PaymentsToAcquireBusinessMilestonePaymentRemaining" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments To Acquire Business, Milestone Payment Remaining</link:label>
    <link:label id="lab_cpix_PaymentsToAcquireBusinessMilestonePaymentRemaining_documentation_en-US" xlink:label="lab_cpix_PaymentsToAcquireBusinessMilestonePaymentRemaining" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments To Acquire Business, Milestone Payment Remaining</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsToAcquireBusinessMilestonePaymentRemaining" xlink:href="cpix-20231231.xsd#cpix_PaymentsToAcquireBusinessMilestonePaymentRemaining"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PaymentsToAcquireBusinessMilestonePaymentRemaining" xlink:to="lab_cpix_PaymentsToAcquireBusinessMilestonePaymentRemaining" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_7860c77b-fcf0-4760-96c1-6e07f6a81132_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_67f08ca3-75fe-438b-80b0-2bc77e444399_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember_bf2285cf-3c1c-4f52-822c-e8f3bef25cb3_terseLabel_en-US" xlink:label="lab_cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Melinta Therapeutics, LLC and Targanta Therapeutics Corporation</link:label>
    <link:label id="lab_cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember_label_en-US" xlink:label="lab_cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Melinta Therapeutics, LLC and Targanta Therapeutics Corporation [Member]</link:label>
    <link:label id="lab_cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember_documentation_en-US" xlink:label="lab_cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Melinta Therapeutics, LLC and Targanta Therapeutics Corporation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember" xlink:href="cpix-20231231.xsd#cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember" xlink:to="lab_cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c652631f-0a8e-4333-b67a-3ea0e9e292a7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMilestonePayable_4c00335e-cba9-441c-bc03-fb64ebe1301f_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMilestonePayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payable</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMilestonePayable_label_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMilestonePayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Milestone Payable</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMilestonePayable_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMilestonePayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Milestone Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMilestonePayable" xlink:href="cpix-20231231.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMilestonePayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMilestonePayable" xlink:to="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMilestonePayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentsMember_169955db-f794-41b0-b385-df01c1b5a6ec_terseLabel_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patents</link:label>
    <link:label id="lab_us-gaap_PatentsMember_label_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_1df9d904-8ad0-4bd8-a3b6-306488ad5838_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_aba1ded3-9819-47fa-bf33-c6d8cea4ed0f_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_eb58a1eb-1704-4ebd-97fd-f46f6c6022a7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_d077c7e1-f39f-4891-ab0c-25fd7968c2eb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_919ac813-9e0a-4c32-b988-819c3a3c0b2e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_834e327b-caa9-4641-8543-662d108158e5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_ab75730c-30aa-46f5-9d3b-ae54aeeea8e3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expense and other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_6d2abf9f-cc43-4292-afc3-1619ef9c6d09_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_8ae534fd-5a9f-4301-a3cd-bdfa148d7abd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility_d4973bf8-7c1b-4081-b1df-55750155e81a_terseLabel_en-US" xlink:label="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined contribution plan, eligibility, minimum employee service time for participation eligibility</link:label>
    <link:label id="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility_label_en-US" xlink:label="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Eligibility, Minimum Employee Service Time for Participation Eligibility</link:label>
    <link:label id="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility_documentation_en-US" xlink:label="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Eligibility, Minimum Employee Service Time for Participation Eligibility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility" xlink:href="cpix-20231231.xsd#cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility" xlink:to="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_6997b7e1-7377-4454-b72f-1e119c6351d4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_a498556d-9470-4765-9b96-bda37b3ba891_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_007d1aa7-c523-4204-8036-f159426c8ac5_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_be84dc73-4c0e-4257-aa87-0d5cacbb0f1e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_123db6ad-808a-42a8-b784-ccc2c2406424_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NephronPharmaceuticalsCorporationNephronMember_5c7e21b2-7b49-4510-b22f-5feab1b920d1_terseLabel_en-US" xlink:label="lab_cpix_NephronPharmaceuticalsCorporationNephronMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nephron Pharmaceuticals Corporation (&#8220;Nephron&#8221;)</link:label>
    <link:label id="lab_cpix_NephronPharmaceuticalsCorporationNephronMember_label_en-US" xlink:label="lab_cpix_NephronPharmaceuticalsCorporationNephronMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nephron Pharmaceuticals Corporation (&#8220;Nephron&#8221;) [Member]</link:label>
    <link:label id="lab_cpix_NephronPharmaceuticalsCorporationNephronMember_documentation_en-US" xlink:label="lab_cpix_NephronPharmaceuticalsCorporationNephronMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nephron Pharmaceuticals Corporation (&#8220;Nephron&#8221;)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NephronPharmaceuticalsCorporationNephronMember" xlink:href="cpix-20231231.xsd#cpix_NephronPharmaceuticalsCorporationNephronMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NephronPharmaceuticalsCorporationNephronMember" xlink:to="lab_cpix_NephronPharmaceuticalsCorporationNephronMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNoParValue_129a8b62-316d-47fc-8874-c56dbb69aa28_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockNoParValue_label_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, No Par Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNoParValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockNoParValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNoParValue" xlink:to="lab_us-gaap_CommonStockNoParValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_FollowingApprovalOfFirstSNDAMember_2b55ba8c-1ab7-4e42-84c3-8ed84967bea1_terseLabel_en-US" xlink:label="lab_cpix_FollowingApprovalOfFirstSNDAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Following Approval Of First sNDA</link:label>
    <link:label id="lab_cpix_FollowingApprovalOfFirstSNDAMember_label_en-US" xlink:label="lab_cpix_FollowingApprovalOfFirstSNDAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Following Approval Of First sNDA [Member]</link:label>
    <link:label id="lab_cpix_FollowingApprovalOfFirstSNDAMember_documentation_en-US" xlink:label="lab_cpix_FollowingApprovalOfFirstSNDAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Following Approval Of First sNDA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FollowingApprovalOfFirstSNDAMember" xlink:href="cpix-20231231.xsd#cpix_FollowingApprovalOfFirstSNDAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_FollowingApprovalOfFirstSNDAMember" xlink:to="lab_cpix_FollowingApprovalOfFirstSNDAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_b079c8f4-92fa-461c-bcb3-cffae06226d5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_6880c23c-8b1a-46f5-b6d4-47a8f56154ca_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_f220ad9e-7341-43be-bbae-9f8dff6748d4_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_ce2c7c5f-81de-4249-a1ce-9640c2af8c5e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_dde30f65-f515-47be-ba7b-36a68f0a0b9b_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial public offering, issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_d35c7505-67ac-4e63-b101-5cdc71fa5123_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksMember_3bff3dac-934c-4e4c-a5da-0d581230cd01_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trademarks</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_a2b5c18c-40ca-48c9-8f12-647046ffdac1_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_c18efcca-a7c0-4df3-97d4-734e018c2638_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Permanent differences associated with general business credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3a53ab2b-4be7-4a08-875f-429386f5ab6d_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NetDeferredTaxAssetsGross_4b7e16b8-b77d-4c72-9208-80355a58bab5_totalLabel_en-US" xlink:label="lab_cpix_NetDeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets, before valuation allowance</link:label>
    <link:label id="lab_cpix_NetDeferredTaxAssetsGross_label_en-US" xlink:label="lab_cpix_NetDeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Deferred Tax Assets, Gross</link:label>
    <link:label id="lab_cpix_NetDeferredTaxAssetsGross_documentation_en-US" xlink:label="lab_cpix_NetDeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NetDeferredTaxAssetsGross" xlink:href="cpix-20231231.xsd#cpix_NetDeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NetDeferredTaxAssetsGross" xlink:to="lab_cpix_NetDeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_48914dd2-ded1-46a9-afc5-2468330fc648_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of operating lease liability maturities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CustomerTwoMember_befb9c23-8e8f-4d8a-9250-facb66b0e6ca_terseLabel_en-US" xlink:label="lab_cpix_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer 2</link:label>
    <link:label id="lab_cpix_CustomerTwoMember_label_en-US" xlink:label="lab_cpix_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Two [Member]</link:label>
    <link:label id="lab_cpix_CustomerTwoMember_documentation_en-US" xlink:label="lab_cpix_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CustomerTwoMember" xlink:href="cpix-20231231.xsd#cpix_CustomerTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CustomerTwoMember" xlink:to="lab_cpix_CustomerTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ac14cf4e-5e94-4fb5-a593-4377f94d61b4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_2a8478f5-c99d-4d2a-af3f-5762134dd3ca_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of Products Sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_4fd60aff-bd1c-4607-adfc-9a838a23801e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of anti-dilutive securities excluded from computation of earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_457ac015-9c79-4d60-b83f-2a608c8fcc7d_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_0505b559-6927-4a55-8e50-43d7968e28c4_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LesseeOperatingLeaseNumberOfRenewalTerms_edc99a86-0d0a-4c00-b103-949790218c4c_terseLabel_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of renewal terms</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseNumberOfRenewalTerms_label_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Terms</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseNumberOfRenewalTerms_documentation_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:href="cpix-20231231.xsd#cpix_LesseeOperatingLeaseNumberOfRenewalTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:to="lab_cpix_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProductCaldolorMember_e77cdba6-835f-41da-aba4-e94c6b9cbbc6_terseLabel_en-US" xlink:label="lab_cpix_ProductCaldolorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Caldolor</link:label>
    <link:label id="lab_cpix_ProductCaldolorMember_label_en-US" xlink:label="lab_cpix_ProductCaldolorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product - Caldolor [Member]</link:label>
    <link:label id="lab_cpix_ProductCaldolorMember_documentation_en-US" xlink:label="lab_cpix_ProductCaldolorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product - Caldolor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductCaldolorMember" xlink:href="cpix-20231231.xsd#cpix_ProductCaldolorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductCaldolorMember" xlink:to="lab_cpix_ProductCaldolorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f82096e4-adb0-4e89-b5d8-f2a7bba82bce_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7392fb3d-0f37-4d8c-8340-ceb6d34a7c0d_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Anti-dilutive shares and options (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_eb3ffeda-4212-4703-bc30-cf6d03733288_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_dbf0b9bc-7e8f-4cfc-a2ac-b9ce52964efb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_011b7557-e25c-4c0e-a3e2-1c6ed7049bd8_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_StockIssuedDuringPeriodPricePerShareNewIssues_5e4ee33f-1cee-4942-a2f8-23da08497df7_terseLabel_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodPricePerShareNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial public offering, price per share</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodPricePerShareNewIssues_label_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodPricePerShareNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Price Per Share, New Issues</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodPricePerShareNewIssues_documentation_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodPricePerShareNewIssues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Price Per Share, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodPricePerShareNewIssues" xlink:href="cpix-20231231.xsd#cpix_StockIssuedDuringPeriodPricePerShareNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_StockIssuedDuringPeriodPricePerShareNewIssues" xlink:to="lab_cpix_StockIssuedDuringPeriodPricePerShareNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LongTermIncentiveCompensationPlan2007Member_9e4b7d9c-c26e-46f5-a8f1-526c81a446b3_terseLabel_en-US" xlink:label="lab_cpix_LongTermIncentiveCompensationPlan2007Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Incentive Compensation Plan 2007</link:label>
    <link:label id="lab_cpix_LongTermIncentiveCompensationPlan2007Member_label_en-US" xlink:label="lab_cpix_LongTermIncentiveCompensationPlan2007Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Incentive Compensation Plan 2007 [Member]</link:label>
    <link:label id="lab_cpix_LongTermIncentiveCompensationPlan2007Member_documentation_en-US" xlink:label="lab_cpix_LongTermIncentiveCompensationPlan2007Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-Term Incentive Compensation Plan 2007 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LongTermIncentiveCompensationPlan2007Member" xlink:href="cpix-20231231.xsd#cpix_LongTermIncentiveCompensationPlan2007Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LongTermIncentiveCompensationPlan2007Member" xlink:to="lab_cpix_LongTermIncentiveCompensationPlan2007Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_3e6dfb1b-1efa-4038-9773-680b416d4ca1_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_2bdff3bd-389c-4516-aff7-b28dfd75fe07_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_292ed659-b962-425d-bfa7-a0af313fa520_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares reserved for issuance under equity compensation plans</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_cba5fb52-60a8-4c79-8969-83967874d163_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_814b19d7-3e9a-40ac-b946-41f64deece5b_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information (Unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a106beba-4f3f-4bd0-a023-af2fa4cb4836_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_bd908397-8341-467f-9dab-e37e22cfaed3_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liability obtained from right-of-use assets</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_6c234e5e-82bd-4f85-8a9a-ce0d144a45ab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash payment of royalty during the period</link:label>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_label_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRoyalties" xlink:to="lab_us-gaap_PaymentsForRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_a687beb2-b73c-41b7-be98-dbb9c893bf33_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d1b8423c-1d11-43b3-8d71-4615cc2092cb_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions_2df0076f-9bc3-4b36-b878-7bfc96981c53_terseLabel_en-US" xlink:label="lab_cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash contributions</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions_label_en-US" xlink:label="lab_cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Charitable Contribution of Shares, Cash Contributions</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions_documentation_en-US" xlink:label="lab_cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Charitable Contribution of Shares, Cash Contributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions" xlink:href="cpix-20231231.xsd#cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions" xlink:to="lab_cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_1d7ea368-4149-4186-ba93-49177762097a_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_3a004ab9-ebcc-4e7a-8b9f-840c8232a8e7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of the components of income tax benefit (expense)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryRawMaterialsMember_87d29d40-af26-45a0-970d-8b1d7682ce94_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryRawMaterialsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw Materials</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryRawMaterialsMember_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryRawMaterialsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Raw Materials [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryRawMaterialsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryRawMaterialsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryRawMaterialsMember" xlink:to="lab_us-gaap_PublicUtilitiesInventoryRawMaterialsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_ad83acf5-3f61-4c53-8ce8-372efc37a7d6_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_32fa45d2-0fb9-40e9-b326-410f32fda5cc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_f9fe6526-fe1e-4c58-84d4-1682c7b7840a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">After 2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PinnacleBankMember_a30dce1e-6caa-4a7f-9dbb-725cba770230_terseLabel_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pinnacle Bank</link:label>
    <link:label id="lab_cpix_PinnacleBankMember_label_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pinnacle Bank [Member]</link:label>
    <link:label id="lab_cpix_PinnacleBankMember_documentation_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pinnacle Bank [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember" xlink:href="cpix-20231231.xsd#cpix_PinnacleBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PinnacleBankMember" xlink:to="lab_cpix_PinnacleBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_0e2120c8-28f4-4281-8eed-00873fa65997_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_0487765e-8f56-42ab-8ce0-0bf9ce38c906_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_EffectiveIncomeTaxRateReconciliationDeferredTrueUpsPercent_e13b70f7-ac3e-489b-9b54-c0aaf851bf25_terseLabel_en-US" xlink:label="lab_cpix_EffectiveIncomeTaxRateReconciliationDeferredTrueUpsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred True-ups</link:label>
    <link:label id="lab_cpix_EffectiveIncomeTaxRateReconciliationDeferredTrueUpsPercent_label_en-US" xlink:label="lab_cpix_EffectiveIncomeTaxRateReconciliationDeferredTrueUpsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deferred True-Ups, Percent</link:label>
    <link:label id="lab_cpix_EffectiveIncomeTaxRateReconciliationDeferredTrueUpsPercent_documentation_en-US" xlink:label="lab_cpix_EffectiveIncomeTaxRateReconciliationDeferredTrueUpsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deferred True-Ups, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EffectiveIncomeTaxRateReconciliationDeferredTrueUpsPercent" xlink:href="cpix-20231231.xsd#cpix_EffectiveIncomeTaxRateReconciliationDeferredTrueUpsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_EffectiveIncomeTaxRateReconciliationDeferredTrueUpsPercent" xlink:to="lab_cpix_EffectiveIncomeTaxRateReconciliationDeferredTrueUpsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_c5913f4a-cddd-4d88-be95-66081263ed3f_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_4adc9842-48d4-437d-ae3c-2e8ba3ba2813_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization and impairment</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_9ac31243-44f6-4b9b-be4f-cbcd98dc4288_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization and impairment expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_849c73fb-c296-4fa3-92a2-da8dfc3aca1c_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_fdcea946-8185-4696-97ec-0facedca0274_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_24843b8f-98e8-49da-8141-268e515b4b0a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_f274131e-91b7-4ca3-bab3-6c8ba0c7ee8b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b4f1be86-9fca-488b-9b34-fd5954d1a903_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Guidance</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_239380d5-3473-46ce-b12b-b94c35a26b83_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_7b1e516d-66ee-4a62-a6cc-0b7499795be9_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_078e74b3-6ed9-4dea-b1e8-0ecade1fb67a_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance for deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:to="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentOne_ec6a85ab-7bc2-4770-bcf2-630912098b66_terseLabel_en-US" xlink:label="lab_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payments receivable, payment one</link:label>
    <link:label id="lab_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentOne_label_en-US" xlink:label="lab_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Legal Settlements, Milestone Payments Receivable, Payment One</link:label>
    <link:label id="lab_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentOne_documentation_en-US" xlink:label="lab_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Legal Settlements, Milestone Payments Receivable, Payment One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentOne" xlink:href="cpix-20231231.xsd#cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentOne" xlink:to="lab_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentOne" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_27adec48-505a-4f95-89c6-1c777480a0f0_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3869b7cf-99f3-4564-acd7-3cc1b9b0157b_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f5412fae-fc42-4a79-bd44-11174c4fb363_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b3e8cb11-686f-44c3-9a8d-c0c21e3cccf2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0446fa9c-26fa-451e-ae2a-06b8384167bb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_784bf189-274d-4d12-9733-298545270008_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_490655a9-2986-43d6-8a24-f31fc5e22609_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_bde7eff3-9b46-4183-bfc1-8cd3fee15a46_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_96f073ea-a181-497f-990e-da54d010891c_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_50a059aa-10f7-4a8b-b43b-c86139cd6f84_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_3d95eecf-3b08-4ad8-9908-77d774d08469_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current deferred charges</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_97bcf40d-b9ad-4038-bfcb-417094b0ea3b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_072fd2af-8424-40bc-84b6-94e588d6c860_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRedeemedOrCalledDuringPeriodValue_d43c1303-2435-480e-bf5e-4d3f1b0404be_verboseLabel_en-US" xlink:label="lab_us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Return of shares related to RediTrex</link:label>
    <link:label id="lab_us-gaap_StockRedeemedOrCalledDuringPeriodValue_8308490c-4797-4667-9122-0886e1fcca8d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Return of common stock - Methotrexate</link:label>
    <link:label id="lab_us-gaap_StockRedeemedOrCalledDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Redeemed or Called During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:to="lab_us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_f4ba1db3-5061-4975-b5c2-444d03a97a9b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payments</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_A1600WestEndAvenuePartnersLLCMember_84ff86de-d399-4864-b937-d5d97ba90e58_terseLabel_en-US" xlink:label="lab_cpix_A1600WestEndAvenuePartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1600 West End Avenue Partners, LLC</link:label>
    <link:label id="lab_cpix_A1600WestEndAvenuePartnersLLCMember_label_en-US" xlink:label="lab_cpix_A1600WestEndAvenuePartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1600 West End Avenue Partners, LLC [Member]</link:label>
    <link:label id="lab_cpix_A1600WestEndAvenuePartnersLLCMember_documentation_en-US" xlink:label="lab_cpix_A1600WestEndAvenuePartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">1600 West End Avenue Partners, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_A1600WestEndAvenuePartnersLLCMember" xlink:href="cpix-20231231.xsd#cpix_A1600WestEndAvenuePartnersLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_A1600WestEndAvenuePartnersLLCMember" xlink:to="lab_cpix_A1600WestEndAvenuePartnersLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_97130361-9a0b-4178-87bc-72908c82240b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivableNumberOfPayments_db31db5a-278f-430d-8f03-234c78eedc69_terseLabel_en-US" xlink:label="lab_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivableNumberOfPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payments receivable, number of payments</link:label>
    <link:label id="lab_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivableNumberOfPayments_label_en-US" xlink:label="lab_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivableNumberOfPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Legal Settlements, Milestone Payments Receivable, Number of Payments</link:label>
    <link:label id="lab_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivableNumberOfPayments_documentation_en-US" xlink:label="lab_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivableNumberOfPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Legal Settlements, Milestone Payments Receivable, Number of Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivableNumberOfPayments" xlink:href="cpix-20231231.xsd#cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivableNumberOfPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivableNumberOfPayments" xlink:to="lab_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivableNumberOfPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_eaee9825-695d-4b96-9ae9-11153c808402_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_ba10b8c6-a19f-4784-a4dd-42805920221a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_00a56f5e-03a1-490c-90a4-57951b0d8c34_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost related to share-based payments, period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_5670478e-49ea-4048-a5e7-e326ab697441_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_7001ead7-155f-43da-9812-3af9feb66509_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_bd4b7f31-18fb-4d3a-bc1d-8868000a6bd3_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_650abbc3-1ba6-40e6-86e1-9f38dfe8da08_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost related to share-based payments</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_WinHealthInvestmentSingaporeLtdMember_bc02d918-0386-4597-be95-fb764b93252a_terseLabel_en-US" xlink:label="lab_cpix_WinHealthInvestmentSingaporeLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">WinHealth Investment (Singapore) Ltd</link:label>
    <link:label id="lab_cpix_WinHealthInvestmentSingaporeLtdMember_label_en-US" xlink:label="lab_cpix_WinHealthInvestmentSingaporeLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">WinHealth Investment (Singapore) Ltd [Member]</link:label>
    <link:label id="lab_cpix_WinHealthInvestmentSingaporeLtdMember_documentation_en-US" xlink:label="lab_cpix_WinHealthInvestmentSingaporeLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">WinHealth Investment (Singapore) Ltd</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WinHealthInvestmentSingaporeLtdMember" xlink:href="cpix-20231231.xsd#cpix_WinHealthInvestmentSingaporeLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_WinHealthInvestmentSingaporeLtdMember" xlink:to="lab_cpix_WinHealthInvestmentSingaporeLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_08f140d7-6f7f-4e7e-a78c-0ce56f31f535_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProductVibativMember_25775d27-dc59-4af0-a7b3-a48dff95bbd7_terseLabel_en-US" xlink:label="lab_cpix_ProductVibativMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vibativ</link:label>
    <link:label id="lab_cpix_ProductVibativMember_label_en-US" xlink:label="lab_cpix_ProductVibativMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product - Vibativ [Member]</link:label>
    <link:label id="lab_cpix_ProductVibativMember_documentation_en-US" xlink:label="lab_cpix_ProductVibativMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product - Vibativ</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductVibativMember" xlink:href="cpix-20231231.xsd#cpix_ProductVibativMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductVibativMember" xlink:to="lab_cpix_ProductVibativMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_15e0cab8-bc90-418a-94ad-2b5f903e0fb9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_02c63586-9b8f-42d5-9913-3720b4703944_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_6ff287c1-867f-45ff-99fb-0a17f12d3f50_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_c3196402-2774-406f-8c12-828a36b98ba5_terseLabel_en-US" xlink:label="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of rent expense and sublease income</link:label>
    <link:label id="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_label_en-US" xlink:label="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Rent Expense and Sublease Income [Table Text Block]</link:label>
    <link:label id="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_documentation_en-US" xlink:label="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Rent Expense and Sublease Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:href="cpix-20231231.xsd#cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:to="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent_68077690-8259-4a98-80e1-2734a6c389f3_terseLabel_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholder, percent</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent_label_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shareholder, Percent</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent_documentation_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shareholder, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent" xlink:href="cpix-20231231.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent" xlink:to="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ManufacturingandSupplyAgreementTable_cf41e4a1-259a-470e-a6e8-746c378516b2_terseLabel_en-US" xlink:label="lab_cpix_ManufacturingandSupplyAgreementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing and Supply Agreement [Table]</link:label>
    <link:label id="lab_cpix_ManufacturingandSupplyAgreementTable_label_en-US" xlink:label="lab_cpix_ManufacturingandSupplyAgreementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacturing and Supply Agreement [Table]</link:label>
    <link:label id="lab_cpix_ManufacturingandSupplyAgreementTable_documentation_en-US" xlink:label="lab_cpix_ManufacturingandSupplyAgreementTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Manufacturing and Supply Agreement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingandSupplyAgreementTable" xlink:href="cpix-20231231.xsd#cpix_ManufacturingandSupplyAgreementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ManufacturingandSupplyAgreementTable" xlink:to="lab_cpix_ManufacturingandSupplyAgreementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5fa9a924-addc-41b1-a479-97b8d8ddd820_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_85591a34-0d54-4348-b4d2-fb2fff04a6d9_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_89772704-e63f-4fc7-a225-c69244b4d4ff_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, ownership percentage by parent</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Ownership Percentage, Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d9bb5fba-0ad7-4faa-bbd2-0aa98f00eab6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LesseeOperatingLeaseLeasedArea_9675d27d-965f-48f3-ae6b-c561169d4cc3_terseLabel_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseLeasedArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leased area</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseLeasedArea_label_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseLeasedArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Leased Area</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseLeasedArea_documentation_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseLeasedArea" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Leased Area</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseLeasedArea" xlink:href="cpix-20231231.xsd#cpix_LesseeOperatingLeaseLeasedArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LesseeOperatingLeaseLeasedArea" xlink:to="lab_cpix_LesseeOperatingLeaseLeasedArea" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_0df90670-2003-4e08-9542-3f7edccb1558_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_3da935dd-1129-42da-810c-89579e510570_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, allowances, current</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_35dc6661-71c8-4c25-a423-e784bc927abd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_87cbca55-cc7e-41ea-8018-7f93bb3f8fdd_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_9c7832a9-f0e4-460f-8779-6b9e63c8d342_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_680218d1-b993-4ea3-b3bf-f6cd8f6cbee3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_caaa6976-3f72-4111-bd7a-6693b02d9496_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_2baa9eaf-2d8a-4f97-82d6-569f6e9f6497_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_40f68756-0d97-4295-953b-d7865ed92566_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_43edb1fd-1b1f-4c2a-a544-259ec95659f5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_cf829e6c-df67-4839-8242-d4e738bbea4a_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c7c1de5a-29a2-4a79-aa1a-d81f927da790_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial public offering, shares issued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AccountsReceivableAllowancesByComponentDomain_f5faf5b4-c437-4fe1-b4fd-de9e4d61fbdc_terseLabel_en-US" xlink:label="lab_cpix_AccountsReceivableAllowancesByComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowances by Component [Domain]</link:label>
    <link:label id="lab_cpix_AccountsReceivableAllowancesByComponentDomain_label_en-US" xlink:label="lab_cpix_AccountsReceivableAllowancesByComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowances by Component [Domain]</link:label>
    <link:label id="lab_cpix_AccountsReceivableAllowancesByComponentDomain_documentation_en-US" xlink:label="lab_cpix_AccountsReceivableAllowancesByComponentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Accounts Receivable, Allowances by Component [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccountsReceivableAllowancesByComponentDomain" xlink:href="cpix-20231231.xsd#cpix_AccountsReceivableAllowancesByComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AccountsReceivableAllowancesByComponentDomain" xlink:to="lab_cpix_AccountsReceivableAllowancesByComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_82fd7511-dfbc-41bf-a2bd-be8aa4a69d1e_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_e478b025-3d34-4d41-986d-9e8d01acf5b2_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LesseeOperatingLeaseRentIncrease_af418789-c8fc-4c96-89b9-90fc4dfd8755_terseLabel_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseRentIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rent increase</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseRentIncrease_label_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseRentIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Rent Increase</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseRentIncrease_documentation_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseRentIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Rent Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseRentIncrease" xlink:href="cpix-20231231.xsd#cpix_LesseeOperatingLeaseRentIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LesseeOperatingLeaseRentIncrease" xlink:to="lab_cpix_LesseeOperatingLeaseRentIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_7e993229-deb4-48d4-8729-20b49e3fe101_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sublease Income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_43135e9c-3adf-4cc8-82f2-0db538dfafca_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vibativ&#174;, Sancuso&#174; and RediTrex&#174; Products</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockTransactionDate_db20ee1b-1121-46f1-bd1b-60a05ea48c2e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockTransactionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial public offering, effective date</link:label>
    <link:label id="lab_us-gaap_SaleOfStockTransactionDate_label_en-US" xlink:label="lab_us-gaap_SaleOfStockTransactionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Transaction Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockTransactionDate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockTransactionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockTransactionDate" xlink:to="lab_us-gaap_SaleOfStockTransactionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0ebefef8-45a2-45a9-871f-33acea876d80_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Nonvested, beginning of period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f5b306bb-b0c3-4546-9bf9-18a9bfc3d50c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Nonvested, end of period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_59ef9cbd-ae61-45dc-b31c-4a6cd402f259_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_542b6c6c-2ccc-4216-8075-e6196e44fafc_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationValue_c33bf8e2-662c-4c6b-9356-229f541f5dce_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share consideration, value</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationValue_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Stock Consideration, Value</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationValue_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Stock Consideration, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationValue" xlink:href="cpix-20231231.xsd#cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationValue" xlink:to="lab_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_7b19aec2-82cd-4e06-a1aa-f39a51ba52ad_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuredEventGainLoss_5e8a2e36-1804-46ee-a278-0b0c5b990289_terseLabel_en-US" xlink:label="lab_us-gaap_InsuredEventGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income - gain on insurance proceeds</link:label>
    <link:label id="lab_us-gaap_InsuredEventGainLoss_label_en-US" xlink:label="lab_us-gaap_InsuredEventGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insured Event, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuredEventGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuredEventGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuredEventGainLoss" xlink:to="lab_us-gaap_InsuredEventGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_14b8ea34-0395-4760-b01c-c376f8fb5ae2_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_ad32248b-3acb-40ec-b6b6-6467c8e5d874_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_32d0fb0e-8818-4466-8a9a-710940a1a8af_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_546530c1-972c-445d-8f72-1b380e1d71b6_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revolving line of credit</link:label>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_09198bb6-9380-4c21-bc7f-86fd81b1dae7_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings outstanding under revolving credit facility</link:label>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_label_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Line of Credit, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermLineOfCredit" xlink:to="lab_us-gaap_LongTermLineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_3f610c71-8807-4905-811a-bcaefff6bad0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ActivePharmaceuticalIngredientAPIAndWorkInProgressMember_f94925ed-46ed-4b0e-b263-030b179f2b21_terseLabel_en-US" xlink:label="lab_cpix_ActivePharmaceuticalIngredientAPIAndWorkInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Active Pharmaceutical Ingredient ("API") And Work In Progress</link:label>
    <link:label id="lab_cpix_ActivePharmaceuticalIngredientAPIAndWorkInProgressMember_label_en-US" xlink:label="lab_cpix_ActivePharmaceuticalIngredientAPIAndWorkInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Active Pharmaceutical Ingredient ("API") And Work In Progress [Member]</link:label>
    <link:label id="lab_cpix_ActivePharmaceuticalIngredientAPIAndWorkInProgressMember_documentation_en-US" xlink:label="lab_cpix_ActivePharmaceuticalIngredientAPIAndWorkInProgressMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Active Pharmaceutical Ingredient ("API") And Work In Progress</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ActivePharmaceuticalIngredientAPIAndWorkInProgressMember" xlink:href="cpix-20231231.xsd#cpix_ActivePharmaceuticalIngredientAPIAndWorkInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ActivePharmaceuticalIngredientAPIAndWorkInProgressMember" xlink:to="lab_cpix_ActivePharmaceuticalIngredientAPIAndWorkInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_2931c5e0-37ef-4259-aed0-3897df1a77a5_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_6298d318-1492-444b-97cc-9875765c438f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_bd2725cd-d38c-4417-b0f1-bb66f1b322e6_negatedLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">less non-current inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue_6bc91430-e755-4177-8ba7-2dca0a557e30_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment credit due</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Milestone Payment, Credit Due</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Milestone Payment, Credit Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue" xlink:href="cpix-20231231.xsd#cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue" xlink:to="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_EmploymentAgreementsTextBlock_def52e68-41ba-4cc8-b229-c6418220b01f_terseLabel_en-US" xlink:label="lab_cpix_EmploymentAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employment Agreements</link:label>
    <link:label id="lab_cpix_EmploymentAgreementsTextBlock_label_en-US" xlink:label="lab_cpix_EmploymentAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employment Agreements [Text Block]</link:label>
    <link:label id="lab_cpix_EmploymentAgreementsTextBlock_documentation_en-US" xlink:label="lab_cpix_EmploymentAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employment Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmploymentAgreementsTextBlock" xlink:href="cpix-20231231.xsd#cpix_EmploymentAgreementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_EmploymentAgreementsTextBlock" xlink:to="lab_cpix_EmploymentAgreementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_f8c25755-9a5a-4dc0-99b8-04e452938790_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_24c92f5d-3334-48e0-8a70-227057470c3c_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_b85f3fd4-954b-4848-8f5d-5cbf4d839c71_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising Costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DeferredTaxAssetsDeferredCharges_fcd34935-1e95-4814-967b-a8b16e2464fc_terseLabel_en-US" xlink:label="lab_cpix_DeferredTaxAssetsDeferredCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred charges</link:label>
    <link:label id="lab_cpix_DeferredTaxAssetsDeferredCharges_label_en-US" xlink:label="lab_cpix_DeferredTaxAssetsDeferredCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Charges</link:label>
    <link:label id="lab_cpix_DeferredTaxAssetsDeferredCharges_documentation_en-US" xlink:label="lab_cpix_DeferredTaxAssetsDeferredCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsDeferredCharges" xlink:href="cpix-20231231.xsd#cpix_DeferredTaxAssetsDeferredCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DeferredTaxAssetsDeferredCharges" xlink:to="lab_cpix_DeferredTaxAssetsDeferredCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_c2eaecc8-6990-4207-af6d-e2bc3d249e30_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments made in connection with repurchase of common shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_09104e33-cd08-415b-9eb9-97d09ce3bbe1_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_564a84a3-ccfb-48e9-b52e-88b4a71d6f9a_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_79a80d19-319e-425d-8170-a2abbd9fde4d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_d623d113-1e7d-4e7b-a452-fd25d7e7096b_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_MethotrexateMember_6985bd05-5025-4ab9-8459-57194a0a4ebc_terseLabel_en-US" xlink:label="lab_cpix_MethotrexateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Methotrexate</link:label>
    <link:label id="lab_cpix_MethotrexateMember_label_en-US" xlink:label="lab_cpix_MethotrexateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Methotrexate [Member]</link:label>
    <link:label id="lab_cpix_MethotrexateMember_documentation_en-US" xlink:label="lab_cpix_MethotrexateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Methotrexate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember" xlink:href="cpix-20231231.xsd#cpix_MethotrexateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_MethotrexateMember" xlink:to="lab_cpix_MethotrexateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ExpirationTimePeriodAxis_316abb57-46fa-4d7e-bd0c-4affec9d5d01_terseLabel_en-US" xlink:label="lab_cpix_ExpirationTimePeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Time Period [Axis]</link:label>
    <link:label id="lab_cpix_ExpirationTimePeriodAxis_label_en-US" xlink:label="lab_cpix_ExpirationTimePeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expiration Time Period [Axis]</link:label>
    <link:label id="lab_cpix_ExpirationTimePeriodAxis_documentation_en-US" xlink:label="lab_cpix_ExpirationTimePeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expiration Time Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodAxis" xlink:href="cpix-20231231.xsd#cpix_ExpirationTimePeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ExpirationTimePeriodAxis" xlink:to="lab_cpix_ExpirationTimePeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7dc8bb30-6ff0-4057-bedb-2020d7aeb758_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationPlanAssets_b926ac52-180c-4cf4-a564-b2eed6c6cb1f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred compensation assets</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationPlanAssets_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Compensation Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationPlanAssets" xlink:to="lab_us-gaap_DeferredCompensationPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_70e212c1-1f39-43a7-8302-061334642778_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1d7461f8-9894-422a-985d-39a0d4810069_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_cb837e38-9cf9-4cb6-907c-5e8923325a19_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income - settlement</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_f6b24808-3568-4a38-b6c5-6c5fabbb05c6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering_c92b61dc-764f-4b4e-a933-24fa600b7331_terseLabel_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial public offering, gross proceeds</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering_label_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Gross Proceeds from Initial Public Offering</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering_documentation_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Gross Proceeds from Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering" xlink:href="cpix-20231231.xsd#cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering" xlink:to="lab_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_2ef1d7b7-2877-4711-a0c7-b87991077b67_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_FederalAndStateMember_57a5e738-e697-44b6-acba-b164eb7e995e_terseLabel_en-US" xlink:label="lab_cpix_FederalAndStateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal And State</link:label>
    <link:label id="lab_cpix_FederalAndStateMember_label_en-US" xlink:label="lab_cpix_FederalAndStateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Federal And State [Member]</link:label>
    <link:label id="lab_cpix_FederalAndStateMember_documentation_en-US" xlink:label="lab_cpix_FederalAndStateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Federal And State</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FederalAndStateMember" xlink:href="cpix-20231231.xsd#cpix_FederalAndStateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_FederalAndStateMember" xlink:to="lab_cpix_FederalAndStateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_7c1378e1-0bea-4e1b-9abe-8fcec247132e_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_117d9297-d9be-403f-9ff8-bcae7939b2cc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_cfdc9eb0-05f2-48d9-8194-24b754c8b69f_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1b960c4f-b4ac-4326-a12c-ac7b255f1ba9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_fbd1ad2c-c94d-41bf-8015-b7858f32ef24_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of deferred tax assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_66086e2b-8346-49f5-9af8-d23b279eaefb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_1e2ee435-45e1-4461-ab6d-881d26baa2b7_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1b90c3d7-370a-460f-898c-e22759c3bcc2_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_70236278-0a85-4157-bcc8-56b2ba312b44_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Continuing operations - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_27283993-7721-49b0-bbbf-2bddeacde8a9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_e3262642-d4f9-41f6-908f-d08ff83eb00a_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_31ce90a8-b876-45ff-a4b3-9325249d9e28_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_77a2935e-4467-4046-afee-0c0148db064b_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_U.S.ProductAssetRightsSancusoMember_54ffc368-b29b-4d8a-b98e-8c10aff0c3fc_terseLabel_en-US" xlink:label="lab_cpix_U.S.ProductAssetRightsSancusoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Product Asset Rights - Sancuso</link:label>
    <link:label id="lab_cpix_U.S.ProductAssetRightsSancusoMember_label_en-US" xlink:label="lab_cpix_U.S.ProductAssetRightsSancusoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">U.S. Product Asset Rights - Sancuso [Member]</link:label>
    <link:label id="lab_cpix_U.S.ProductAssetRightsSancusoMember_documentation_en-US" xlink:label="lab_cpix_U.S.ProductAssetRightsSancusoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">U.S. Product Asset Rights - Sancuso</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_U.S.ProductAssetRightsSancusoMember" xlink:href="cpix-20231231.xsd#cpix_U.S.ProductAssetRightsSancusoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_U.S.ProductAssetRightsSancusoMember" xlink:to="lab_cpix_U.S.ProductAssetRightsSancusoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationCancelledAndRefunded_1e72c5fc-0b21-455f-9378-d183c9574159_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationCancelledAndRefunded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares cancelled and refunded</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationCancelledAndRefunded_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationCancelledAndRefunded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Stock Consideration, Cancelled And Refunded</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationCancelledAndRefunded_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationCancelledAndRefunded" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Stock Consideration, Cancelled And Refunded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationCancelledAndRefunded" xlink:href="cpix-20231231.xsd#cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationCancelledAndRefunded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationCancelledAndRefunded" xlink:to="lab_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationCancelledAndRefunded" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_e1041e26-3bc0-4805-8e8e-bd987b06ceae_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_ee72127e-5fd7-41ac-af9b-3e14cf458baf_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePayment_c1ed14c7-c505-478a-8a81-327cc921e78d_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePayment_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Milestone Payment</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePayment_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:href="cpix-20231231.xsd#cpix_CollaborativeArrangementRightsAndObligationsMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:to="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DeferredTaxAssetOperatingLeaseLiabilities_6db1f2ef-7184-4beb-bb85-1fc7dc1b1583_terseLabel_en-US" xlink:label="lab_cpix_DeferredTaxAssetOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_cpix_DeferredTaxAssetOperatingLeaseLiabilities_label_en-US" xlink:label="lab_cpix_DeferredTaxAssetOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, Operating Lease Liabilities</link:label>
    <link:label id="lab_cpix_DeferredTaxAssetOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_cpix_DeferredTaxAssetOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetOperatingLeaseLiabilities" xlink:href="cpix-20231231.xsd#cpix_DeferredTaxAssetOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DeferredTaxAssetOperatingLeaseLiabilities" xlink:to="lab_cpix_DeferredTaxAssetOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue_b8e8c012-dadc-41bb-afa1-3e28bc203867_terseLabel_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options, exercise price as percent of weighted-average grant date fair value</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price as Percent of Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price as Percent of Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue" xlink:href="cpix-20231231.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue" xlink:to="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AuditorInformationAbstract_label_en-US" xlink:label="lab_cpix_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:label id="lab_cpix_AuditorInformationAbstract_documentation_en-US" xlink:label="lab_cpix_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Auditor Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AuditorInformationAbstract" xlink:href="cpix-20231231.xsd#cpix_AuditorInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AuditorInformationAbstract" xlink:to="lab_cpix_AuditorInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_c23158ec-b999-4252-804a-84f6cbbf27c9_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_5496da6d-d0a0-49c5-91e7-b14320926fc6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_f40bfb50-452e-47a3-8a31-8f6311196176_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of Major Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_cbb5d781-c1b3-4fae-8bc0-6008ae8bd2f9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_525dea4a-8544-41e7-84e1-e21d135afac9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of option shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_89880059-1ede-4c1d-8f23-f089206d8e19_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a8b501ec-9401-47b3-b162-22455d56d068_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss tax expense</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_68d8666e-79fd-458d-8758-6f60b4678de0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of quarterly financial information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_c46eabe5-3dd2-449c-a1e8-04f4e075213e_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_1d65a7df-b887-4a8b-adbf-5958489577ef_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_2f746a84-14ce-4564-8469-86220f179d1c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_c1632437-7fad-47c8-b511-9ad0458a8669_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_8681eea2-19e7-4a3b-ae5b-f857fcd8c522_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_f00a524c-6693-4b00-833e-b81a4dc2032c_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current income tax expense</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ManufacturingAndSupplyAgreementsTextBlock_8d673597-93cf-4da7-b51c-68be9b5699cc_terseLabel_en-US" xlink:label="lab_cpix_ManufacturingAndSupplyAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing and Supply Agreements</link:label>
    <link:label id="lab_cpix_ManufacturingAndSupplyAgreementsTextBlock_label_en-US" xlink:label="lab_cpix_ManufacturingAndSupplyAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacturing and Supply Agreements [Text Block]</link:label>
    <link:label id="lab_cpix_ManufacturingAndSupplyAgreementsTextBlock_documentation_en-US" xlink:label="lab_cpix_ManufacturingAndSupplyAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Manufacturing and Supply Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingAndSupplyAgreementsTextBlock" xlink:href="cpix-20231231.xsd#cpix_ManufacturingAndSupplyAgreementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ManufacturingAndSupplyAgreementsTextBlock" xlink:to="lab_cpix_ManufacturingAndSupplyAgreementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1daa30a6-7371-4acf-aba7-357d4ec88a42_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_9c17a1d6-814d-433d-b03a-b502ab3707d9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_95c6964d-2f86-4d28-9b64-0a06ef357481_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charged to costs and expenses</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ScheduleOfDistributionCostsTableTextBlock_fdaa9cc7-8d08-401e-8c09-54a209ad90f5_terseLabel_en-US" xlink:label="lab_cpix_ScheduleOfDistributionCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Distribution Costs</link:label>
    <link:label id="lab_cpix_ScheduleOfDistributionCostsTableTextBlock_label_en-US" xlink:label="lab_cpix_ScheduleOfDistributionCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Distribution Costs [Table Text Block]</link:label>
    <link:label id="lab_cpix_ScheduleOfDistributionCostsTableTextBlock_documentation_en-US" xlink:label="lab_cpix_ScheduleOfDistributionCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Distribution Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleOfDistributionCostsTableTextBlock" xlink:href="cpix-20231231.xsd#cpix_ScheduleOfDistributionCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ScheduleOfDistributionCostsTableTextBlock" xlink:to="lab_cpix_ScheduleOfDistributionCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_161020f2-b89a-4b27-9f26-498553276a85_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for future grants (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_e807e85b-3390-460f-be8c-11ed54b9da02_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CaldolorMember_820e8881-1364-462f-b48f-b0d250989ae6_terseLabel_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Caldolor</link:label>
    <link:label id="lab_cpix_CaldolorMember_label_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Caldolor [Member]</link:label>
    <link:label id="lab_cpix_CaldolorMember_documentation_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Caldolor.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember" xlink:href="cpix-20231231.xsd#cpix_CaldolorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CaldolorMember" xlink:to="lab_cpix_CaldolorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_81442c72-addc-49c1-968d-0d2e1c7ac8dd_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_c8af2e78-d328-4f2f-ba84-31dfbc7fbc78_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_ae2ca90b-e704-4b57-b491-3466f0183a9e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized research cost</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_6e42b6d5-829d-4a81-8855-cc2ff8b52907_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_57e86b58-b069-4fa9-9165-615713b35bc8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_308521bc-65a8-4484-ae28-50d9ab55bc2e_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Loss per share attributable to common shareholders:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_43ad75e9-2b59-4bce-84b0-0d6abc5a4723_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per share attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_5ad31669-ee73-4dde-b4e7-d8134f002496_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProductVaprisolMember_bc9f238d-b466-4ccc-bc94-e643ce470880_terseLabel_en-US" xlink:label="lab_cpix_ProductVaprisolMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vaprisol</link:label>
    <link:label id="lab_cpix_ProductVaprisolMember_label_en-US" xlink:label="lab_cpix_ProductVaprisolMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product - Vaprisol [Member]</link:label>
    <link:label id="lab_cpix_ProductVaprisolMember_documentation_en-US" xlink:label="lab_cpix_ProductVaprisolMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product - Vaprisol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductVaprisolMember" xlink:href="cpix-20231231.xsd#cpix_ProductVaprisolMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductVaprisolMember" xlink:to="lab_cpix_ProductVaprisolMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PaymentsToAcquireBusinessMilestonePayment_cdffe5f2-9a61-4cdb-bf4f-a72959a2905c_terseLabel_en-US" xlink:label="lab_cpix_PaymentsToAcquireBusinessMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MIlestone payment</link:label>
    <link:label id="lab_cpix_PaymentsToAcquireBusinessMilestonePayment_label_en-US" xlink:label="lab_cpix_PaymentsToAcquireBusinessMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments To Acquire Business, Milestone Payment</link:label>
    <link:label id="lab_cpix_PaymentsToAcquireBusinessMilestonePayment_documentation_en-US" xlink:label="lab_cpix_PaymentsToAcquireBusinessMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments To Acquire Business, Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsToAcquireBusinessMilestonePayment" xlink:href="cpix-20231231.xsd#cpix_PaymentsToAcquireBusinessMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PaymentsToAcquireBusinessMilestonePayment" xlink:to="lab_cpix_PaymentsToAcquireBusinessMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_c3ff1c57-3f05-405c-8f5c-340b38529171_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_5e6a7f81-7779-42c5-acd0-f56c51b538a0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of operating lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_a88abada-3222-4a14-aad8-8736335e9527_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and other</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_67e1c492-def8-492f-b7a7-504e0b945c76_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_15ef7706-5234-44f0-a9c4-e20d1cf1c154_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_feb30487-da66-45fb-8524-7566945a2aa8_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial investment amount</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_15eda6f9-8cc1-4f58-9abf-26121de7da3e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SharebasedCompensationCharitableContributionofSharesShares_fdcbc911-e26d-43cf-8333-0b10842b37ac_terseLabel_en-US" xlink:label="lab_cpix_SharebasedCompensationCharitableContributionofSharesShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charitable contribution of shares (in shares)</link:label>
    <link:label id="lab_cpix_SharebasedCompensationCharitableContributionofSharesShares_label_en-US" xlink:label="lab_cpix_SharebasedCompensationCharitableContributionofSharesShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Charitable Contribution of Shares, Shares</link:label>
    <link:label id="lab_cpix_SharebasedCompensationCharitableContributionofSharesShares_documentation_en-US" xlink:label="lab_cpix_SharebasedCompensationCharitableContributionofSharesShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Charitable Contribution of Shares, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharebasedCompensationCharitableContributionofSharesShares" xlink:href="cpix-20231231.xsd#cpix_SharebasedCompensationCharitableContributionofSharesShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SharebasedCompensationCharitableContributionofSharesShares" xlink:to="lab_cpix_SharebasedCompensationCharitableContributionofSharesShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_7779794b-cd99-4aa5-9461-94ccddf064b4_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_fea6e864-ebef-43ec-aeb1-8cc6f338cef5_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_00663ae0-aebd-496d-8ff7-00af16121eea_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of revenues concentration from major customers</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_d436906f-f780-44b1-976f-286320940091_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProductOmeclamoxPakMember_a820e2f7-7ab3-427e-b39e-cf19d03c3daa_terseLabel_en-US" xlink:label="lab_cpix_ProductOmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Omeclamox-Pak</link:label>
    <link:label id="lab_cpix_ProductOmeclamoxPakMember_label_en-US" xlink:label="lab_cpix_ProductOmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product - Omeclamox-Pak [Member]</link:label>
    <link:label id="lab_cpix_ProductOmeclamoxPakMember_documentation_en-US" xlink:label="lab_cpix_ProductOmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product - Omeclamox-Pak</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductOmeclamoxPakMember" xlink:href="cpix-20231231.xsd#cpix_ProductOmeclamoxPakMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductOmeclamoxPakMember" xlink:to="lab_cpix_ProductOmeclamoxPakMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_26ccab03-eb92-4f8e-9c67-341880cc430b_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_53c3360a-d2af-4b6d-b20c-42ee5ef555cb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_c53662a2-ebe0-43e9-82f5-d9679c2da264_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current portion of accrued contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_49a39aea-c0f1-4b9c-945c-eee0198f1d22_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_bbe39efb-e629-4ce4-aafe-55037dd2739e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_03d3326c-6ad0-4f3e-9ca1-68eecd220566_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share repurchase program, number of shares authorized to be repurchased</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_c7a06d6b-9322-4921-93aa-d06ec049c1a4_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_5b892f0b-8b72-4edf-ab47-5397f8b22e7c_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_6a98f9eb-052f-4066-8a51-97bcdb49cc54_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember_cf6d557a-581c-496a-a414-6caf838fa61e_terseLabel_en-US" xlink:label="lab_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Sales Related Allowances - Chargebacks, Cash Discounts and Damaged Goods</link:label>
    <link:label id="lab_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember_label_en-US" xlink:label="lab_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chargebacks, Cash Discounts and Damaged Goods [Member]</link:label>
    <link:label id="lab_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember_documentation_en-US" xlink:label="lab_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Chargebacks, Cash Discounts and Damaged Goods [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember" xlink:href="cpix-20231231.xsd#cpix_ChargebacksCashDiscountsAndDamagedGoodsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember" xlink:to="lab_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_03f08756-f792-46db-b4b7-a993132cc49c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of effective tax rate reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_2d16617d-99a5-4129-ab80-15a14dbfd55f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_06216cb3-0d0d-4bbb-82d0-1fe154244f1c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ManufacturingAndSupplyAgreementsAbstract_label_en-US" xlink:label="lab_cpix_ManufacturingAndSupplyAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacturing and Supply Agreements [Abstract]</link:label>
    <link:label id="lab_cpix_ManufacturingAndSupplyAgreementsAbstract_documentation_en-US" xlink:label="lab_cpix_ManufacturingAndSupplyAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Manufacturing and Supply Agreements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingAndSupplyAgreementsAbstract" xlink:href="cpix-20231231.xsd#cpix_ManufacturingAndSupplyAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ManufacturingAndSupplyAgreementsAbstract" xlink:to="lab_cpix_ManufacturingAndSupplyAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_d5e509a2-7a12-48c2-a6bd-7c636036d4db_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_282423b5-d83b-4345-b434-fe43349d95a4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_dda79310-5031-4792-9424-170e64466780_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Tax Credit Carryforwards [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" xlink:to="lab_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_a824d2e6-3bc3-4f7e-8258-bf42cfd33d10_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State income tax expense (net of federal income tax benefit)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NordicGroupBVMember_2749d522-385d-49cd-99bd-797eb24ec2c4_terseLabel_en-US" xlink:label="lab_cpix_NordicGroupBVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nordic Group B.V.</link:label>
    <link:label id="lab_cpix_NordicGroupBVMember_label_en-US" xlink:label="lab_cpix_NordicGroupBVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nordic Group B.V. [Member]</link:label>
    <link:label id="lab_cpix_NordicGroupBVMember_documentation_en-US" xlink:label="lab_cpix_NordicGroupBVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nordic Group B.V.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NordicGroupBVMember" xlink:href="cpix-20231231.xsd#cpix_NordicGroupBVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NordicGroupBVMember" xlink:to="lab_cpix_NordicGroupBVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1b4a593f-f0da-4a15-b200-c0cddaa7a140_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_6653fa2a-0480-44a9-a7ca-9a37557b29f5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_5defeccd-38d3-47f5-a10a-c4a94360d991_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_a0cdbdc7-8950-42c7-b299-3d23f151c668_terseLabel_en-US" xlink:label="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum increase to line of credit</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_label_en-US" xlink:label="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line Of Credit Facility, Additional Borrowing Capacity</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_documentation_en-US" xlink:label="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line Of Credit Facility, Additional Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:href="cpix-20231231.xsd#cpix_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:to="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_5fae663c-54bc-49e5-962e-e15eac636880_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative compensation costs incurred on deductible equity awards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e2dd2d1-b070-416e-b688-a59d5712123d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_91cefe61-b8e2-41e9-a557-49de153930ba_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_66a0fdb6-4c8a-46f0-a994-bb81d5cb550a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of expected amortization expense of intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_c8520a5d-783c-48fc-bf3e-90dc7d22b6c2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_5e1699f9-6962-4cdc-8db9-ae115b55b33f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of accrued contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_e394380e-19b2-4383-9004-18ff1bf8c687_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage_084bc116-c74d-4f52-b355-79469ac75644_terseLabel_en-US" xlink:label="lab_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tiered royalty payments (percentage)</link:label>
    <link:label id="lab_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage_label_en-US" xlink:label="lab_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments To Acquire Business, Tiered Royalty Payments, Percentage</link:label>
    <link:label id="lab_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage_documentation_en-US" xlink:label="lab_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments To Acquire Business, Tiered Royalty Payments, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage" xlink:href="cpix-20231231.xsd#cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage" xlink:to="lab_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ExpirationTermOneMember_a48db19c-2258-4619-a2c0-cc9a054772ca_terseLabel_en-US" xlink:label="lab_cpix_ExpirationTermOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_cpix_ExpirationTermOneMember_label_en-US" xlink:label="lab_cpix_ExpirationTermOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expiration, Term One [Member]</link:label>
    <link:label id="lab_cpix_ExpirationTermOneMember_documentation_en-US" xlink:label="lab_cpix_ExpirationTermOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expiration, Term One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermOneMember" xlink:href="cpix-20231231.xsd#cpix_ExpirationTermOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ExpirationTermOneMember" xlink:to="lab_cpix_ExpirationTermOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_989b3d40-a4f0-4764-866c-434dd04dfacb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncome_3ed3a9a1-1a3f-4738-a920-6c06c4cc3539_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherIncome_label_en-US" xlink:label="lab_us-gaap_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncome" xlink:to="lab_us-gaap_OtherIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_4856598a-d344-4422-ad7d-d317450f48bc_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_934244b4-1a4a-4f17-b033-a944cf8b3c88_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_20cefc2e-4bcb-4746-b280-b3cd5504b894_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_0d0dcdd5-6710-48e9-bf32-0915b6e7a8b2_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_b6b1bcbb-4065-4754-8f8f-7cfc2bc0add5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_a97f5af4-6032-4077-8f2a-e1c3e47c9d11_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_ac2067f9-7f33-49a8-b56d-c225509f1f08_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForCreditLossMember_cfeb0806-8f8a-45cf-9972-ea4164ef4559_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForCreditLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for uncollectible amounts, cash discounts, chargebacks, and credits issued for damaged products:</link:label>
    <link:label id="lab_us-gaap_AllowanceForCreditLossMember_label_en-US" xlink:label="lab_us-gaap_AllowanceForCreditLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Allowance, Credit Loss [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForCreditLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForCreditLossMember" xlink:to="lab_us-gaap_AllowanceForCreditLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PostemploymentBenefitsAbstract_label_en-US" xlink:label="lab_us-gaap_PostemploymentBenefitsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Postemployment Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PostemploymentBenefitsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract" xlink:to="lab_us-gaap_PostemploymentBenefitsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_f8bd3cc6-8815-4c3b-8421-d564f2cab947_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_18409288-fc31-44d6-8cc3-f0f18853b716_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_5b9cb22c-7d04-49db-9245-12c8138827f4_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill, impairment loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_26814f74-e939-41ec-9a75-ecf159c87772_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: deferred tax asset valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_ba1feddc-6983-4296-93b2-277dd1ea8129_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4d544bbc-1ecb-45aa-95ce-da45af351966_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_6209236b-6cd8-4fc8-b9c5-d391895f3530_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1dc12616-1df4-4c2a-a0ba-315246f470e3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_1b5374cd-3ec2-4030-9b9f-df4aa892a9b5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_25f15033-8678-44f5-a028-719915b92984_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9f3c4e6c-b31f-4687-84d9-8f9d1797502a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d93ff2b6-c376-4376-889d-ced806f79877_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_98c51015-bcbe-407e-8b78-f61c58eb3f3b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Additions to intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_ff7127a0-28f1-4174-bf32-c6492253511e_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions to intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CustomerOneMember_7a078e63-2d64-42a8-9a91-1723f9e06cfe_terseLabel_en-US" xlink:label="lab_cpix_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer 1</link:label>
    <link:label id="lab_cpix_CustomerOneMember_label_en-US" xlink:label="lab_cpix_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer One [Member]</link:label>
    <link:label id="lab_cpix_CustomerOneMember_documentation_en-US" xlink:label="lab_cpix_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CustomerOneMember" xlink:href="cpix-20231231.xsd#cpix_CustomerOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CustomerOneMember" xlink:to="lab_cpix_CustomerOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b224685e-348c-4d61-8986-66ac1944f301_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_5afe3238-61e8-41de-91e4-43bb82e316fb_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProductAcetadoteMember_ebb396eb-5a0f-41b8-8493-cc3abe62c3e2_terseLabel_en-US" xlink:label="lab_cpix_ProductAcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acetadote</link:label>
    <link:label id="lab_cpix_ProductAcetadoteMember_label_en-US" xlink:label="lab_cpix_ProductAcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product - Acetadote [Member]</link:label>
    <link:label id="lab_cpix_ProductAcetadoteMember_documentation_en-US" xlink:label="lab_cpix_ProductAcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product - Acetadote</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductAcetadoteMember" xlink:href="cpix-20231231.xsd#cpix_ProductAcetadoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductAcetadoteMember" xlink:to="lab_cpix_ProductAcetadoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProductKristaloseMember_8e45c1cf-c3e3-414f-b81f-65018357c0bd_terseLabel_en-US" xlink:label="lab_cpix_ProductKristaloseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kristalose</link:label>
    <link:label id="lab_cpix_ProductKristaloseMember_label_en-US" xlink:label="lab_cpix_ProductKristaloseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product - Kristalose [Member]</link:label>
    <link:label id="lab_cpix_ProductKristaloseMember_documentation_en-US" xlink:label="lab_cpix_ProductKristaloseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product - Kristalose</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductKristaloseMember" xlink:href="cpix-20231231.xsd#cpix_ProductKristaloseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductKristaloseMember" xlink:to="lab_cpix_ProductKristaloseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_14f91127-ed15-450f-8995-1bfb847e382c_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProductSancusoMember_ab5d1532-7f8b-441b-9a28-921b70af05a6_terseLabel_en-US" xlink:label="lab_cpix_ProductSancusoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sancuso</link:label>
    <link:label id="lab_cpix_ProductSancusoMember_label_en-US" xlink:label="lab_cpix_ProductSancusoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product - Sancuso [Member]</link:label>
    <link:label id="lab_cpix_ProductSancusoMember_documentation_en-US" xlink:label="lab_cpix_ProductSancusoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product - Sancuso</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductSancusoMember" xlink:href="cpix-20231231.xsd#cpix_ProductSancusoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductSancusoMember" xlink:to="lab_cpix_ProductSancusoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_024bb649-11ac-4651-86f1-80a0eb0dfb72_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_85aa02c1-d621-4ec6-b2ae-6bd1d093e124_terseLabel_en-US" xlink:label="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">HongKong WinHealth Pharma Group Co. Limited</link:label>
    <link:label id="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_label_en-US" xlink:label="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">HongKong WinHealth Pharma Group Co. Limited [Member]</link:label>
    <link:label id="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_documentation_en-US" xlink:label="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">HongKong WinHealth Pharma Group Co. Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:href="cpix-20231231.xsd#cpix_HongKongWinHealthPharmaGroupCoLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:to="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_c731b9ea-0b90-4b79-b238-5ee6ee026108_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charged to other accounts</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_StudyDrugMember_a11104d6-3d4d-4daa-b28a-fb522dcd72bd_terseLabel_en-US" xlink:label="lab_cpix_StudyDrugMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Study Drug</link:label>
    <link:label id="lab_cpix_StudyDrugMember_label_en-US" xlink:label="lab_cpix_StudyDrugMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Study Drug [Member]</link:label>
    <link:label id="lab_cpix_StudyDrugMember_documentation_en-US" xlink:label="lab_cpix_StudyDrugMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Study Drug</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StudyDrugMember" xlink:href="cpix-20231231.xsd#cpix_StudyDrugMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_StudyDrugMember" xlink:to="lab_cpix_StudyDrugMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e5e46b68-125a-4623-af08-f448f6cff91b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Shareholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct_3350dd48-6202-4287-afe7-a4d662e612ca_terseLabel_en-US" xlink:label="lab_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reserve for expired product</link:label>
    <link:label id="lab_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct_label_en-US" xlink:label="lab_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves for Expired Product</link:label>
    <link:label id="lab_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct_documentation_en-US" xlink:label="lab_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves for Expired Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" xlink:href="cpix-20231231.xsd#cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" xlink:to="lab_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SubsidiaryInvestmentPurchaseOfShares_cc7cbafc-3391-43d8-9f79-35dac415dc1c_terseLabel_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in CET</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentPurchaseOfShares_label_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary Investment, Purchase Of Shares</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentPurchaseOfShares_documentation_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Subsidiary Investment, Purchase Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:href="cpix-20231231.xsd#cpix_SubsidiaryInvestmentPurchaseOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:to="lab_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_c58e3ad2-ba55-480c-81db-b43e8ec85a91_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7af55d28-59aa-4dfe-809a-7f9af199499c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OtherProductsMember_7ce953e6-c42a-46a0-b31a-f2b0a275e70a_terseLabel_en-US" xlink:label="lab_cpix_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Products</link:label>
    <link:label id="lab_cpix_OtherProductsMember_label_en-US" xlink:label="lab_cpix_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Products [Member]</link:label>
    <link:label id="lab_cpix_OtherProductsMember_documentation_en-US" xlink:label="lab_cpix_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherProductsMember" xlink:href="cpix-20231231.xsd#cpix_OtherProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OtherProductsMember" xlink:to="lab_cpix_OtherProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_35c6b7fe-69d3-4704-b7ba-1d7de4462ad2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_5244928c-ee26-4a87-b1e9-2692fdc71597_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8bbf08b3-6915-41a6-b1d2-ddabd104ab0a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning of period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_67aa5cdf-c66f-43be-bdce-94641b29248d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, end of period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_adf23202-7b89-4e9a-aa7f-0d3deefbf8e5_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_a2d2ee3c-6731-4d75-9527-13bb74be315c_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_8b92ae35-bf7f-488e-9c7e-f15893181471_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_06c220c3-8164-4916-8757-624537983d63_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_a90619ba-ca14-41df-b40d-8c827893480d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_87f43bcf-f090-474e-ae02-4a712a93af64_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredOtherTaxExpenseBenefit_53ab1384-d3ef-4b52-8579-a3d00bb8c8fc_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred income tax expense</link:label>
    <link:label id="lab_us-gaap_DeferredOtherTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Other Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_9fc042b2-1a52-4933-8583-cbd73f43f322_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_340721bd-e1b5-485b-a0ed-6eb725024b1c_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_cd5f66ce-1020-4928-9b39-2e88a30ff362_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants_e60523c1-ed04-48fe-b312-8a6d69dd56b8_terseLabel_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of equity compensation plans available for future grants</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants_label_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans Available for Future Grants</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants_documentation_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans Available for Future Grants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants" xlink:href="cpix-20231231.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants" xlink:to="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_4ddffd08-1a59-4120-bac3-b93aeb482c6c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_ccf451a3-e31e-46a4-b594-4040a6ef09c2_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5c9a2ee8-1714-491c-bc09-e700ef6d618f_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fc3565bc-7014-473b-b70b-8425f17d5c03_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2fa334ed-eebd-44b2-b924-3d54db395ca2_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_b4e9e644-932a-4e5b-9703-45f39f28bfe6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_101bfdb2-59f3-491b-ba69-7f53794f4e9e_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_aabab85e-43ab-40aa-a343-78976f7192b6_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLegalSettlements_927129c6-a3d1-4c0f-96e0-c651f82c858c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from litigation settlement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLegalSettlements_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLegalSettlements" xlink:to="lab_us-gaap_ProceedsFromLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3458df8e-8382-4dce-89ae-d8a09df25b07_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_8f9c66fd-be28-413d-8426-93dc510b5f2b_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_e37d31cf-d21a-4d76-a1b3-c9c7a93bf9a1_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_432eb36c-5469-4edc-b1a7-176536f83a7a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_63526b57-7afc-4f92-9ec2-d55c3112a0e3_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of real estate property</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e2339252-8734-47dd-8f13-09087aeb01d4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ManufacturedProductOtherMember_304c9774-ba64-464d-94e8-852f74f65636_terseLabel_en-US" xlink:label="lab_us-gaap_ManufacturedProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ManufacturedProductOtherMember_label_en-US" xlink:label="lab_us-gaap_ManufacturedProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufactured Product, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturedProductOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManufacturedProductOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManufacturedProductOtherMember" xlink:to="lab_us-gaap_ManufacturedProductOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_63cfde20-4ed4-4147-9f2b-a96c200d9198_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_fc28d9d9-040d-416c-adae-5fd2128db690_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge_0d375280-d1be-46f9-bc66-7dac3109cf6f_terseLabel_en-US" xlink:label="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined contribution plan, eligibiilty, minimum employee age</link:label>
    <link:label id="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge_label_en-US" xlink:label="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Eligibility, Minimum Employee Age</link:label>
    <link:label id="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge_documentation_en-US" xlink:label="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Eligibility, Minimum Employee Age</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge" xlink:href="cpix-20231231.xsd#cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge" xlink:to="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_3c5ffc41-4aee-4e08-b1bc-4bc260750ea6_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts</link:label>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_label_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:to="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_73ba0724-7c21-47b5-9864-4f086e32e0d8_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_28dc3f44-7c31-4c78-ac40-573578f7a65a_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_4f245c4b-e26a-4556-b03a-5ab0fe5827e1_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_fd8a8f1b-db6b-41c8-a6ae-576b5d69369d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_699cf0ca-5d9c-4e50-8015-6eb4fb23bec2_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementMilestonePaymentThresholdAxis_e90f237f-b531-433e-8cf0-5400218f551f_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementMilestonePaymentThresholdAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Milestone Payment, Threshold [Axis]</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementMilestonePaymentThresholdAxis_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementMilestonePaymentThresholdAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Milestone Payment, Threshold [Axis]</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementMilestonePaymentThresholdAxis_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementMilestonePaymentThresholdAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Milestone Payment, Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdAxis" xlink:href="cpix-20231231.xsd#cpix_CollaborativeArrangementMilestonePaymentThresholdAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdAxis" xlink:to="lab_cpix_CollaborativeArrangementMilestonePaymentThresholdAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_0fae4a8b-ba1f-4f08-bc87-4bcc575dd0d5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Continuing operations - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_70154111-cdab-42cf-8cc0-a8948f3241fa_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_87c48f03-80f0-49b1-82fd-9eac16e05858_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_d0bca9c5-0af6-41d2-8146-0b5f101cad18_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_0ef31d73-8afa-43be-821e-6890ab9f8e4f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CreditIssuedForMilestonePayable_932425e7-ca33-4ed3-addd-f0f260d3bb2b_terseLabel_en-US" xlink:label="lab_cpix_CreditIssuedForMilestonePayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RediTrex forgiveness of milestone payable</link:label>
    <link:label id="lab_cpix_CreditIssuedForMilestonePayable_label_en-US" xlink:label="lab_cpix_CreditIssuedForMilestonePayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Issued for Milestone Payable</link:label>
    <link:label id="lab_cpix_CreditIssuedForMilestonePayable_documentation_en-US" xlink:label="lab_cpix_CreditIssuedForMilestonePayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Credit Issued for Milestone Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CreditIssuedForMilestonePayable" xlink:href="cpix-20231231.xsd#cpix_CreditIssuedForMilestonePayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CreditIssuedForMilestonePayable" xlink:to="lab_cpix_CreditIssuedForMilestonePayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_f582b129-4988-44d6-919e-81c8835c980a_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_MartinS.BrownJr.sLawFirmMember_ef495592-b708-4c4d-bab3-ab6f0d0dcf2b_terseLabel_en-US" xlink:label="lab_cpix_MartinS.BrownJr.sLawFirmMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Martin S. Brown Jr.'s Law Firm</link:label>
    <link:label id="lab_cpix_MartinS.BrownJr.sLawFirmMember_label_en-US" xlink:label="lab_cpix_MartinS.BrownJr.sLawFirmMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Martin S. Brown Jr.'s Law Firm [Member]</link:label>
    <link:label id="lab_cpix_MartinS.BrownJr.sLawFirmMember_documentation_en-US" xlink:label="lab_cpix_MartinS.BrownJr.sLawFirmMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Martin S. Brown Jr.'s Law Firm</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MartinS.BrownJr.sLawFirmMember" xlink:href="cpix-20231231.xsd#cpix_MartinS.BrownJr.sLawFirmMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_MartinS.BrownJr.sLawFirmMember" xlink:to="lab_cpix_MartinS.BrownJr.sLawFirmMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_59ebf984-72b0-4fde-a559-97087c66ad0d_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a1f84160-1988-4b2d-9b25-0413f731fb5a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ScheduleofDepreciationExpenseTableTextBlock_6aef303d-5523-4ff5-8664-bf69501d6b38_terseLabel_en-US" xlink:label="lab_cpix_ScheduleofDepreciationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of depreciation expense</link:label>
    <link:label id="lab_cpix_ScheduleofDepreciationExpenseTableTextBlock_label_en-US" xlink:label="lab_cpix_ScheduleofDepreciationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Depreciation Expense [Table Text Block]</link:label>
    <link:label id="lab_cpix_ScheduleofDepreciationExpenseTableTextBlock_documentation_en-US" xlink:label="lab_cpix_ScheduleofDepreciationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Depreciation Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleofDepreciationExpenseTableTextBlock" xlink:href="cpix-20231231.xsd#cpix_ScheduleofDepreciationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ScheduleofDepreciationExpenseTableTextBlock" xlink:to="lab_cpix_ScheduleofDepreciationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_9f83c236-e048-4079-8b42-cb1126ba6f7b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_c4be3aea-ff85-4369-a159-1ca4183f88fd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_4f9644c5-3f15-41d3-bbd6-8997364a68c5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Disposal of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CustomerThreeMember_009b0f65-0640-40d7-bb4f-8ff99c19c983_terseLabel_en-US" xlink:label="lab_cpix_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer 3</link:label>
    <link:label id="lab_cpix_CustomerThreeMember_label_en-US" xlink:label="lab_cpix_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Three [Member]</link:label>
    <link:label id="lab_cpix_CustomerThreeMember_documentation_en-US" xlink:label="lab_cpix_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CustomerThreeMember" xlink:href="cpix-20231231.xsd#cpix_CustomerThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CustomerThreeMember" xlink:to="lab_cpix_CustomerThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_75914cd4-3e3d-422d-a138-a1d1efd79204_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable_b634c9a5-f63b-498b-82f5-c483cf7c5567_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales milestone payments, receivable</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Receivable</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable" xlink:href="cpix-20231231.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable" xlink:to="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_4bba1927-2eee-457f-a943-37211f0396e0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_8d48a600-158e-484d-806c-35ab344d90ac_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_64dcb85d-03ca-4c33-a23b-1db28b38a7e4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_42f116fa-6297-4d64-a963-dacda4b97dd6_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductionAndDistributionCosts_6145832f-9b1c-459d-bc79-9c9839766184_terseLabel_en-US" xlink:label="lab_us-gaap_ProductionAndDistributionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distribution costs</link:label>
    <link:label id="lab_us-gaap_ProductionAndDistributionCosts_label_en-US" xlink:label="lab_us-gaap_ProductionAndDistributionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Production and Distribution Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductionAndDistributionCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductionAndDistributionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductionAndDistributionCosts" xlink:to="lab_us-gaap_ProductionAndDistributionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_3299adc8-4a57-4ae2-8d1c-d0f2dd6202d0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_b9c994bd-d039-454b-9ae8-ffb613cbbdba_terseLabel_en-US" xlink:label="lab_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss and tax credits</link:label>
    <link:label id="lab_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_label_en-US" xlink:label="lab_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards and Tax Credit Carryforwards</link:label>
    <link:label id="lab_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_documentation_en-US" xlink:label="lab_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards and Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" xlink:href="cpix-20231231.xsd#cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" xlink:to="lab_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_46863536-1f32-4769-94ce-2bae28edcc95_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets_7f046103-97fb-4bd5-b7be-4686d3d2540c_negatedTerseLabel_en-US" xlink:label="lab_cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets_label_en-US" xlink:label="lab_cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liability, Operating Lease Right-of-Use Assets</link:label>
    <link:label id="lab_cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liability, Operating Lease Right-of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets" xlink:href="cpix-20231231.xsd#cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets" xlink:to="lab_cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_79cf5a2b-667f-43a9-998f-ea62b781fadc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consigned inventory</link:label>
    <link:label id="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_label_en-US" xlink:label="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:to="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0e6471ce-2b69-4dc6-a6e6-06db33b0e0a7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_51f4dd47-3184-4c2c-ba12-75c493fb2c39_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_f80e36c5-0bdc-483f-9dd7-fb3fb316d652_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount available under current repurchase program</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_FederalGrantProgramsMember_9df26a9a-fbaf-464a-8a37-4081c497e49a_terseLabel_en-US" xlink:label="lab_cpix_FederalGrantProgramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal Grant Programs</link:label>
    <link:label id="lab_cpix_FederalGrantProgramsMember_label_en-US" xlink:label="lab_cpix_FederalGrantProgramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Federal Grant Programs [Member]</link:label>
    <link:label id="lab_cpix_FederalGrantProgramsMember_documentation_en-US" xlink:label="lab_cpix_FederalGrantProgramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Federal Small Business Grant Programs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FederalGrantProgramsMember" xlink:href="cpix-20231231.xsd#cpix_FederalGrantProgramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_FederalGrantProgramsMember" xlink:to="lab_cpix_FederalGrantProgramsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_7038d1d5-c05b-4eee-9e51-4b053aa43a9f_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentTwo_4c4b7b97-2702-4a85-b3d8-3893c643d7d6_terseLabel_en-US" xlink:label="lab_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payments receivable, payment two</link:label>
    <link:label id="lab_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentTwo_label_en-US" xlink:label="lab_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Legal Settlements, Milestone Payments Receivable, Payment Two</link:label>
    <link:label id="lab_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentTwo_documentation_en-US" xlink:label="lab_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Legal Settlements, Milestone Payments Receivable, Payment Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentTwo" xlink:href="cpix-20231231.xsd#cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentTwo" xlink:to="lab_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AccountsReceivableAllowancesByComponentAxis_a0b9939d-44f2-4e47-a057-42535728163d_terseLabel_en-US" xlink:label="lab_cpix_AccountsReceivableAllowancesByComponentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowances by Component [Axis]</link:label>
    <link:label id="lab_cpix_AccountsReceivableAllowancesByComponentAxis_label_en-US" xlink:label="lab_cpix_AccountsReceivableAllowancesByComponentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowances by Component [Axis]</link:label>
    <link:label id="lab_cpix_AccountsReceivableAllowancesByComponentAxis_documentation_en-US" xlink:label="lab_cpix_AccountsReceivableAllowancesByComponentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowances by Component [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccountsReceivableAllowancesByComponentAxis" xlink:href="cpix-20231231.xsd#cpix_AccountsReceivableAllowancesByComponentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AccountsReceivableAllowancesByComponentAxis" xlink:to="lab_cpix_AccountsReceivableAllowancesByComponentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NoncashOrPartNoncashGainOnTransaction_cb8fd741-1358-4396-b5ae-b13cfbc8849b_negatedTerseLabel_en-US" xlink:label="lab_cpix_NoncashOrPartNoncashGainOnTransaction" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Noncash gain on RediTrex transaction</link:label>
    <link:label id="lab_cpix_NoncashOrPartNoncashGainOnTransaction_label_en-US" xlink:label="lab_cpix_NoncashOrPartNoncashGainOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash, Gain on Transaction</link:label>
    <link:label id="lab_cpix_NoncashOrPartNoncashGainOnTransaction_documentation_en-US" xlink:label="lab_cpix_NoncashOrPartNoncashGainOnTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash, Gain on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NoncashOrPartNoncashGainOnTransaction" xlink:href="cpix-20231231.xsd#cpix_NoncashOrPartNoncashGainOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NoncashOrPartNoncashGainOnTransaction" xlink:to="lab_cpix_NoncashOrPartNoncashGainOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_31c1a68c-2b77-4790-b2f4-300e53418fcd_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_c68be78f-4ae8-4e38-8deb-d8a4654e6c28_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c413aa4d-1f26-43b9-8fd9-ab53fe9deb3b_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash flows provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_KristaloseMember_e4bc6fa6-80fd-4ee2-ba55-c7cf3f12470a_terseLabel_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kristalose</link:label>
    <link:label id="lab_cpix_KristaloseMember_label_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kristalose [Member]</link:label>
    <link:label id="lab_cpix_KristaloseMember_documentation_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kristalose.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember" xlink:href="cpix-20231231.xsd#cpix_KristaloseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_KristaloseMember" xlink:to="lab_cpix_KristaloseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_21e54175-1ae6-4316-8695-197ea89ac83b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock &#8211; no par value; 100,000,000 shares authorized; 14,121,833 and 14,366,316 shares issued and outstanding as of December&#160;31, 2023 and 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_0fd51f17-6633-49eb-a60e-08b1042d49f4_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual with Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_FinishedGoodsMember_4149e946-4d62-4025-b132-ba067f47599c_terseLabel_en-US" xlink:label="lab_cpix_FinishedGoodsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished Goods</link:label>
    <link:label id="lab_cpix_FinishedGoodsMember_label_en-US" xlink:label="lab_cpix_FinishedGoodsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finished Goods [Member]</link:label>
    <link:label id="lab_cpix_FinishedGoodsMember_documentation_en-US" xlink:label="lab_cpix_FinishedGoodsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finished Goods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FinishedGoodsMember" xlink:href="cpix-20231231.xsd#cpix_FinishedGoodsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_FinishedGoodsMember" xlink:to="lab_cpix_FinishedGoodsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_0f3a4d1f-3c96-4336-bb87-2afc5494ac35_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of vested awards</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_5683d91c-26b9-46b9-8069-350816d8c3d7_terseLabel_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of balance sheet classification</link:label>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets and Liabilities, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="cpix-20231231.xsd#cpix_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_6ed293fe-fe74-4702-892e-79f998d45bfc_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:to="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4f06c36b-ae93-4fb3-b631-553e361b3a97_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_b033f2b1-ad4c-44a6-a143-5b25490732a8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_044b5e4e-ccfa-4880-bcea-56781fe9f9aa_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DirectorsIncentivePlan2007Member_a1c77dc9-e8fe-4367-a576-90f82faf55c0_terseLabel_en-US" xlink:label="lab_cpix_DirectorsIncentivePlan2007Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Directors&#8217; Incentive Plan 2007</link:label>
    <link:label id="lab_cpix_DirectorsIncentivePlan2007Member_label_en-US" xlink:label="lab_cpix_DirectorsIncentivePlan2007Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Directors&#8217; Incentive Plan 2007 [Member]</link:label>
    <link:label id="lab_cpix_DirectorsIncentivePlan2007Member_documentation_en-US" xlink:label="lab_cpix_DirectorsIncentivePlan2007Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Directors&#8217; Incentive Plan 2007 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DirectorsIncentivePlan2007Member" xlink:href="cpix-20231231.xsd#cpix_DirectorsIncentivePlan2007Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DirectorsIncentivePlan2007Member" xlink:to="lab_cpix_DirectorsIncentivePlan2007Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_adf72fca-4a71-4f95-8080-6a1e7eb68c73_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0fce115d-fec6-481a-9e5b-068c7eaa2c2e_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_3f6d01b3-ed0c-4e3f-8d82-fec837fe9287_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1eec0db0-aee5-4f1f-957b-ef2da347f455_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8b8a61a5-2885-4f9d-bb0a-5379941fd64c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ManufacturingandSupplyAgreementLineItems_638aad1f-f59f-41ec-b65b-db58ee30df30_terseLabel_en-US" xlink:label="lab_cpix_ManufacturingandSupplyAgreementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing and Supply Agreement [Line Items]</link:label>
    <link:label id="lab_cpix_ManufacturingandSupplyAgreementLineItems_label_en-US" xlink:label="lab_cpix_ManufacturingandSupplyAgreementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacturing and Supply Agreement [Line Items]</link:label>
    <link:label id="lab_cpix_ManufacturingandSupplyAgreementLineItems_documentation_en-US" xlink:label="lab_cpix_ManufacturingandSupplyAgreementLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Manufacturing and Supply Agreement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingandSupplyAgreementLineItems" xlink:href="cpix-20231231.xsd#cpix_ManufacturingandSupplyAgreementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ManufacturingandSupplyAgreementLineItems" xlink:to="lab_cpix_ManufacturingandSupplyAgreementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NonprincipalOwnerMember_667b1a4b-988f-4926-bd78-9aa358054efc_terseLabel_en-US" xlink:label="lab_cpix_NonprincipalOwnerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NonPrincipal Owner</link:label>
    <link:label id="lab_cpix_NonprincipalOwnerMember_label_en-US" xlink:label="lab_cpix_NonprincipalOwnerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NonPrincipal Owner [Member]</link:label>
    <link:label id="lab_cpix_NonprincipalOwnerMember_documentation_en-US" xlink:label="lab_cpix_NonprincipalOwnerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">NonPrincipal Owner [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NonprincipalOwnerMember" xlink:href="cpix-20231231.xsd#cpix_NonprincipalOwnerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NonprincipalOwnerMember" xlink:to="lab_cpix_NonprincipalOwnerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_30147260-efe5-4143-89f5-fe5658d7c72b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProductAndLicenseRightsMember_e36de528-aae4-4df3-827d-4d52cd2c709b_terseLabel_en-US" xlink:label="lab_cpix_ProductAndLicenseRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and License Rights</link:label>
    <link:label id="lab_cpix_ProductAndLicenseRightsMember_label_en-US" xlink:label="lab_cpix_ProductAndLicenseRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and License Rights [Member]</link:label>
    <link:label id="lab_cpix_ProductAndLicenseRightsMember_documentation_en-US" xlink:label="lab_cpix_ProductAndLicenseRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product and License Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductAndLicenseRightsMember" xlink:href="cpix-20231231.xsd#cpix_ProductAndLicenseRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductAndLicenseRightsMember" xlink:to="lab_cpix_ProductAndLicenseRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationVestedValue_9d598a05-9f75-4e8d-925d-7cf0d0d85d78_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationVestedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share consideration vested, value</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationVestedValue_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationVestedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Stock Consideration Vested, Value</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationVestedValue_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationVestedValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Stock Consideration Vested, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationVestedValue" xlink:href="cpix-20231231.xsd#cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationVestedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationVestedValue" xlink:to="lab_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationVestedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_440b84d4-9018-4bab-90ab-5942a26256f2_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_47c7e3fa-13c3-417a-bc8c-bbbcf62e5a8e_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration period (in years)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:to="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_853902a9-b52a-4f40-9ba1-64efe93dea4e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other current assets and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5e96c664-665c-40ae-b230-aa1f1729ca56_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_df702c96-6abf-46d5-96f1-20bb1134f0b2_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Decrease in non-cash contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_593637d6-4654-4e05-a92b-5d31a4837425_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_84404a6b-9412-471c-a9a2-9103b913074a_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_f324b9d6-1e83-47eb-9d9a-b860a4d1ec93_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_665be742-0102-408e-8252-e5e9881ec57c_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_713efe03-7c3a-4a2f-89fb-762a9babd491_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiring tax credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_68175f0d-1eb5-49eb-928f-11b45a6fecd7_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_fa892dfc-819d-4919-ab9f-7eb4da6b350f_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2e135d5e-4570-4216-ad26-24938a8722b9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AccruedLiabilitiesStockPayable_a8f1cd4b-583e-4461-aa35-a32f15f968e2_terseLabel_en-US" xlink:label="lab_cpix_AccruedLiabilitiesStockPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sancuso related liabilities</link:label>
    <link:label id="lab_cpix_AccruedLiabilitiesStockPayable_label_en-US" xlink:label="lab_cpix_AccruedLiabilitiesStockPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Stock Payable</link:label>
    <link:label id="lab_cpix_AccruedLiabilitiesStockPayable_documentation_en-US" xlink:label="lab_cpix_AccruedLiabilitiesStockPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Stock Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccruedLiabilitiesStockPayable" xlink:href="cpix-20231231.xsd#cpix_AccruedLiabilitiesStockPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AccruedLiabilitiesStockPayable" xlink:to="lab_cpix_AccruedLiabilitiesStockPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_87b31ba3-90ed-4cb8-be38-53601101a409_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProceedsFromCollaborativeArrangement_dcabd802-1aa9-410f-9478-7caade7369e1_terseLabel_en-US" xlink:label="lab_cpix_ProceedsFromCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Return of RediTrex</link:label>
    <link:label id="lab_cpix_ProceedsFromCollaborativeArrangement_label_en-US" xlink:label="lab_cpix_ProceedsFromCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Collaborative Arrangement</link:label>
    <link:label id="lab_cpix_ProceedsFromCollaborativeArrangement_documentation_en-US" xlink:label="lab_cpix_ProceedsFromCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Collaborative Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromCollaborativeArrangement" xlink:href="cpix-20231231.xsd#cpix_ProceedsFromCollaborativeArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProceedsFromCollaborativeArrangement" xlink:to="lab_cpix_ProceedsFromCollaborativeArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_a5e4bd87-0a31-4b0a-8345-2b9a8e74e1ee_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market Concentrations</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_db0fa7e1-b413-44c6-98be-98449821d986_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_f0d16027-7eeb-4172-aec6-29f11a8b648f_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_dc8d46e7-9db1-4a24-a796-eeb608db8e24_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_2980591b-cb5b-406c-9df3-43fc578a3ee6_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_0ae0bc27-424e-4b5c-a5f5-6d2b12c7c96b_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_bf235338-18f8-4de9-86a5-d96b5acb4414_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred compensation liability</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Compensation Liability, Current and Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_1860323b-7183-4708-9298-0d498914664f_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finished goods, net of reserve</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_d71d22b3-af70-4ef4-adcf-37b3d58ed76b_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-US</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_fe23380b-df48-4b09-94af-7eae3d995f69_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred compensation</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Compensation Liability, Classified, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_27481956-2455-4fa2-aa51-0ab4bb4d71e3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_42f54ae9-f92a-4c8d-9692-4af81b34e2b6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee wages and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SancusoMember_e7cd2ba3-ab56-425d-af36-a0cee6ce5573_terseLabel_en-US" xlink:label="lab_cpix_SancusoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sancuso</link:label>
    <link:label id="lab_cpix_SancusoMember_label_en-US" xlink:label="lab_cpix_SancusoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sancuso [Member]</link:label>
    <link:label id="lab_cpix_SancusoMember_documentation_en-US" xlink:label="lab_cpix_SancusoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sancuso</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SancusoMember" xlink:href="cpix-20231231.xsd#cpix_SancusoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SancusoMember" xlink:to="lab_cpix_SancusoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_b5e7dad3-b894-48b2-b422-567013a64359_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of federal and state net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Operating Loss Carryforwards [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_60d825cc-e3ac-4806-a49b-657b23932ac7_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_26ace1d6-b418-477d-8194-10777b196833_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_f71bea5f-9476-4b60-85e8-1b0b74f8be88_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories, Net</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_bf3c8c8a-3027-4cdd-8265-c958b086d83d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RisksAndUncertaintiesAbstract_label_en-US" xlink:label="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract" xlink:to="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_22d8ecd2-ea87-441a-9742-c404948b94b9_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2c85145d-6921-4932-990a-09fe5a313816_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_bbb082f6-2f11-4a33-b84b-e942e0a48a0f_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_InventoryNoncurrentTable_7e1512a7-9eb3-4617-b3f8-fec6d824e8ea_terseLabel_en-US" xlink:label="lab_cpix_InventoryNoncurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Noncurrent [Table]</link:label>
    <link:label id="lab_cpix_InventoryNoncurrentTable_label_en-US" xlink:label="lab_cpix_InventoryNoncurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Noncurrent [Table]</link:label>
    <link:label id="lab_cpix_InventoryNoncurrentTable_documentation_en-US" xlink:label="lab_cpix_InventoryNoncurrentTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_InventoryNoncurrentTable" xlink:href="cpix-20231231.xsd#cpix_InventoryNoncurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_InventoryNoncurrentTable" xlink:to="lab_cpix_InventoryNoncurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_a3319466-eae5-41ee-9913-67d0b13b8246_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_946782d5-a9f6-4823-b432-f70591bca9ec_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_99ccc298-ab98-4124-bd41-16513d1e40d0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsDepositPayment_0bd480ea-ce77-42fa-8c36-e286001e9176_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsDepositPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deposit payment</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsDepositPayment_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsDepositPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Deposit Payment</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsDepositPayment_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsDepositPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Deposit Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsDepositPayment" xlink:href="cpix-20231231.xsd#cpix_CollaborativeArrangementRightsAndObligationsDepositPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementRightsAndObligationsDepositPayment" xlink:to="lab_cpix_CollaborativeArrangementRightsAndObligationsDepositPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_838216ec-2b5d-4ffa-88d0-d47bf0d2e519_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total federal and state credit carryforwards</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_c3029ad3-f2af-4ea2-acf3-f7fdef108111_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_8381b987-dd2a-46d5-bee8-59292571b474_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments on line of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_17c64844-1750-4c05-92a6-9816801bfac2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average incremental borrowing rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AccruedLiabilitiesInventoryPurchases_0918d3dc-21aa-4452-9224-5f18408a47a4_terseLabel_en-US" xlink:label="lab_cpix_AccruedLiabilitiesInventoryPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued inventory purchases</link:label>
    <link:label id="lab_cpix_AccruedLiabilitiesInventoryPurchases_label_en-US" xlink:label="lab_cpix_AccruedLiabilitiesInventoryPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Inventory Purchases</link:label>
    <link:label id="lab_cpix_AccruedLiabilitiesInventoryPurchases_documentation_en-US" xlink:label="lab_cpix_AccruedLiabilitiesInventoryPurchases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Inventory Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccruedLiabilitiesInventoryPurchases" xlink:href="cpix-20231231.xsd#cpix_AccruedLiabilitiesInventoryPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AccruedLiabilitiesInventoryPurchases" xlink:to="lab_cpix_AccruedLiabilitiesInventoryPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_4911760a-19aa-42cd-8331-2fa5e9866d48_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_f03a9b29-b4bd-4da3-b500-780a8e75974d_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_742d7644-94bc-4126-8f1e-f717dcf821bb_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other permanent differences</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_4c17d80a-c945-4b3e-9c5c-d12c78366eb8_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_23118693-e391-42c4-a76f-bd9e4d2d8011_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis spread on variable rate (in percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_db39919d-d4e8-466e-9371-002c2f59e6b3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_84883438-4ec8-491b-8f64-50c2d02946fb_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_3860c5b2-cea5-4649-8448-94d15b8cfefe_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold Improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_7a36e68c-f368-4a8d-875d-e5f08248c0fa_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration earned and accrued</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_label_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:href="cpix-20231231.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:to="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ba0c6f12-d257-4148-8208-beacc7844bea_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3cb4c316-df91-4b25-8c72-cd88f7191cec_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares outstanding &#8211; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_80236837-259a-4bcd-bc81-341cbd726ab8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, other than goodwill</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_72f37ec2-3c0e-427b-a063-173069fc79fc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProceedsFromSettlementOfPatentLitigation_805ea2b5-bfe8-44df-9629-70acd26c1451_terseLabel_en-US" xlink:label="lab_cpix_ProceedsFromSettlementOfPatentLitigation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlement of patent litigation</link:label>
    <link:label id="lab_cpix_ProceedsFromSettlementOfPatentLitigation_label_en-US" xlink:label="lab_cpix_ProceedsFromSettlementOfPatentLitigation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Settlement of Patent Litigation</link:label>
    <link:label id="lab_cpix_ProceedsFromSettlementOfPatentLitigation_documentation_en-US" xlink:label="lab_cpix_ProceedsFromSettlementOfPatentLitigation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Settlement of Patent Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromSettlementOfPatentLitigation" xlink:href="cpix-20231231.xsd#cpix_ProceedsFromSettlementOfPatentLitigation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProceedsFromSettlementOfPatentLitigation" xlink:to="lab_cpix_ProceedsFromSettlementOfPatentLitigation" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CashPaidDuringYearAbstract_abd1257a-e006-4640-81cd-223c89ff185f_terseLabel_en-US" xlink:label="lab_cpix_CashPaidDuringYearAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash paid during the year for:</link:label>
    <link:label id="lab_cpix_CashPaidDuringYearAbstract_label_en-US" xlink:label="lab_cpix_CashPaidDuringYearAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Paid During Year [Abstract]</link:label>
    <link:label id="lab_cpix_CashPaidDuringYearAbstract_documentation_en-US" xlink:label="lab_cpix_CashPaidDuringYearAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Paid During Year For [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CashPaidDuringYearAbstract" xlink:href="cpix-20231231.xsd#cpix_CashPaidDuringYearAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CashPaidDuringYearAbstract" xlink:to="lab_cpix_CashPaidDuringYearAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_bccdeff9-5d1a-42bf-9a8c-6b3574036373_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3ff4908d-f556-45b9-9d49-d77da761bb23_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Additions to property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_5bab17ba-fe3e-4bfa-ac32-5757254cf5e9_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_c9225f8a-5e60-44d4-8969-c1f2a6a5f66f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for accounts receivable</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_f1908db0-dab4-4988-8eee-d0e392e20467_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_a0648cd5-3a17-4dc9-8507-09808da0554a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options vested (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationLiabilityRollForward_79fba068-3b76-4a1e-a418-69fd70c13fee_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability [Roll Forward]</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationLiabilityRollForward_label_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability [Roll Forward]</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationLiabilityRollForward_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationLiabilityRollForward" xlink:href="cpix-20231231.xsd#cpix_BusinessCombinationContingentConsiderationLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationContingentConsiderationLiabilityRollForward" xlink:to="lab_cpix_BusinessCombinationContingentConsiderationLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ScheduleOfAdvertisingCostsTableTextBlock_f882c6c9-31d2-4f03-adc6-22d827b8c1a1_terseLabel_en-US" xlink:label="lab_cpix_ScheduleOfAdvertisingCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Advertising Costs</link:label>
    <link:label id="lab_cpix_ScheduleOfAdvertisingCostsTableTextBlock_label_en-US" xlink:label="lab_cpix_ScheduleOfAdvertisingCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Advertising Costs [Table Text Block]</link:label>
    <link:label id="lab_cpix_ScheduleOfAdvertisingCostsTableTextBlock_documentation_en-US" xlink:label="lab_cpix_ScheduleOfAdvertisingCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Advertising Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleOfAdvertisingCostsTableTextBlock" xlink:href="cpix-20231231.xsd#cpix_ScheduleOfAdvertisingCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ScheduleOfAdvertisingCostsTableTextBlock" xlink:to="lab_cpix_ScheduleOfAdvertisingCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_50cabcaa-3061-48e1-a0ed-a1f745abdff5_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Noncash interest expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFourAndAfter_6d3280fb-d14c-44d9-a4ff-11487da662d8_terseLabel_en-US" xlink:label="lab_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFourAndAfter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028 and thereafter</link:label>
    <link:label id="lab_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFourAndAfter_label_en-US" xlink:label="lab_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFourAndAfter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four and After</link:label>
    <link:label id="lab_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFourAndAfter_documentation_en-US" xlink:label="lab_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFourAndAfter" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four and After</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFourAndAfter" xlink:href="cpix-20231231.xsd#cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFourAndAfter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFourAndAfter" xlink:to="lab_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFourAndAfter" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_InventoryNoncurrentLineItems_10b0a0c5-7e8d-414e-8b0e-08a10ddf045d_terseLabel_en-US" xlink:label="lab_cpix_InventoryNoncurrentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Noncurrent [Line Items]</link:label>
    <link:label id="lab_cpix_InventoryNoncurrentLineItems_label_en-US" xlink:label="lab_cpix_InventoryNoncurrentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Noncurrent [Line Items]</link:label>
    <link:label id="lab_cpix_InventoryNoncurrentLineItems_documentation_en-US" xlink:label="lab_cpix_InventoryNoncurrentLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory, Noncurrent [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_InventoryNoncurrentLineItems" xlink:href="cpix-20231231.xsd#cpix_InventoryNoncurrentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_InventoryNoncurrentLineItems" xlink:to="lab_cpix_InventoryNoncurrentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_b0746739-67a9-4745-a204-cf5ef0e9d02f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Current and Other Long-term Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantMember_2e5d93e7-6ab6-4b93-b3ce-2cf5cd200076_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant</link:label>
    <link:label id="lab_us-gaap_GrantMember_label_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_6719a9f7-3387-44cf-9aba-5429df1673e0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_5b815a27-a79f-4be6-8e77-37f1c599a1fc_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_82ab58b0-3d1d-4405-9855-e9c42a079adc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_18411146-311e-403a-b2b0-8b4922c75c2f_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_f7630b26-3b40-411d-834e-66f10b3cd144_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited/cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationShares_622a1af8-fd5a-41ec-a3ad-f61b8f821283_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share consideration (in shares)</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationShares_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Stock Consideration, Shares</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationShares_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Stock Consideration, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationShares" xlink:href="cpix-20231231.xsd#cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationShares" xlink:to="lab_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingGainsLosses_f97a0176-5ae4-4490-803a-56ccf7311613_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain on receipt of life insurance policies</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingGainsLosses_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingGainsLosses" xlink:to="lab_us-gaap_OtherNonoperatingGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementMilestonePaymentThresholdDomain_8657bb52-6c5a-4d8d-84ff-29137afeddc8_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementMilestonePaymentThresholdDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Milestone Payment, Threshold [Domain]</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementMilestonePaymentThresholdDomain_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementMilestonePaymentThresholdDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Milestone Payment, Threshold [Domain]</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementMilestonePaymentThresholdDomain_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementMilestonePaymentThresholdDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Milestone Payment, Threshold [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdDomain" xlink:href="cpix-20231231.xsd#cpix_CollaborativeArrangementMilestonePaymentThresholdDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdDomain" xlink:to="lab_cpix_CollaborativeArrangementMilestonePaymentThresholdDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRedeemedOrCalledDuringPeriodShares_a2e864d9-0c1e-4497-8efa-df0d96fc07ed_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Return of common stock - Methotrexate (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRedeemedOrCalledDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Redeemed or Called During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:to="lab_us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6c9c113f-bae0-4991-8aff-ab032745a690_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d67a88c-269c-40f6-a5a8-094ac03be03d_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_1c6b167f-e50d-4c67-9a92-9b84afb51ced_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_7022db60-df2a-4bb3-ac9a-f3fb8b2d1a7f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_24048b26-ded0-4fd4-ae6c-900529dd95af_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IndefiniteMember_a585d910-9faa-4184-8c90-e0134024af86_terseLabel_en-US" xlink:label="lab_cpix_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite Period</link:label>
    <link:label id="lab_cpix_IndefiniteMember_label_en-US" xlink:label="lab_cpix_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite [Member]</link:label>
    <link:label id="lab_cpix_IndefiniteMember_documentation_en-US" xlink:label="lab_cpix_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Indefinite</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IndefiniteMember" xlink:href="cpix-20231231.xsd#cpix_IndefiniteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IndefiniteMember" xlink:to="lab_cpix_IndefiniteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock_7d2227e0-2566-416b-8243-08c2263a2166_terseLabel_en-US" xlink:label="lab_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid and Other Current Assets</link:label>
    <link:label id="lab_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaids and Other Current Assets, Policy [Policy Text Block]</link:label>
    <link:label id="lab_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaids and Other Current Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:href="cpix-20231231.xsd#cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:to="lab_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TextBlockAbstract_label_en-US" xlink:label="lab_us-gaap_TextBlockAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Text Block [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TextBlockAbstract" xlink:to="lab_us-gaap_TextBlockAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d02efa04-cbcb-47b0-8545-b9ee003e1d76_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5bba458d-454d-4081-a9b3-dd0f92e8d109_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares outstanding &#8211; basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_98a4a34a-8030-4d46-99ed-090de92a9a46_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_e4236bfc-2bdf-4389-98a0-987d8703ec31_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AccruedLiabilitiesStudies_b55b42be-b9ce-46ef-97c7-3b3531e70285_terseLabel_en-US" xlink:label="lab_cpix_AccruedLiabilitiesStudies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Studies accrual</link:label>
    <link:label id="lab_cpix_AccruedLiabilitiesStudies_label_en-US" xlink:label="lab_cpix_AccruedLiabilitiesStudies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Studies</link:label>
    <link:label id="lab_cpix_AccruedLiabilitiesStudies_documentation_en-US" xlink:label="lab_cpix_AccruedLiabilitiesStudies" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Studies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccruedLiabilitiesStudies" xlink:href="cpix-20231231.xsd#cpix_AccruedLiabilitiesStudies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AccruedLiabilitiesStudies" xlink:to="lab_cpix_AccruedLiabilitiesStudies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_806b8807-9656-4c50-9a6c-cea879dc363c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_b06b5501-dae3-4ce5-9f47-2ffc722a580a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles_889aa0fa-4841-4e51-80bc-b61f7093b19b_terseLabel_en-US" xlink:label="lab_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment and intangibles</link:label>
    <link:label id="lab_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles_label_en-US" xlink:label="lab_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Property and Equipment and Intangibles</link:label>
    <link:label id="lab_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles_documentation_en-US" xlink:label="lab_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Property and Equipment and Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" xlink:href="cpix-20231231.xsd#cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" xlink:to="lab_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_d7e814c5-a1d1-43f1-87dc-2b207478159c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProductAssetsAndGlobalRightsVibativMember_0a792645-bd8b-48d9-9efe-d9abd4d114a1_terseLabel_en-US" xlink:label="lab_cpix_ProductAssetsAndGlobalRightsVibativMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Assets And Global Rights - Vibativ</link:label>
    <link:label id="lab_cpix_ProductAssetsAndGlobalRightsVibativMember_label_en-US" xlink:label="lab_cpix_ProductAssetsAndGlobalRightsVibativMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Assets And Global Rights - Vibativ [Member]</link:label>
    <link:label id="lab_cpix_ProductAssetsAndGlobalRightsVibativMember_documentation_en-US" xlink:label="lab_cpix_ProductAssetsAndGlobalRightsVibativMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product Assets And Global Rights - Vibativ</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductAssetsAndGlobalRightsVibativMember" xlink:href="cpix-20231231.xsd#cpix_ProductAssetsAndGlobalRightsVibativMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductAssetsAndGlobalRightsVibativMember" xlink:to="lab_cpix_ProductAssetsAndGlobalRightsVibativMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_VibativMember_272eada3-1990-4f2a-b1ff-b29298cb8a65_terseLabel_en-US" xlink:label="lab_cpix_VibativMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vibativ</link:label>
    <link:label id="lab_cpix_VibativMember_label_en-US" xlink:label="lab_cpix_VibativMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vibativ [Member]</link:label>
    <link:label id="lab_cpix_VibativMember_documentation_en-US" xlink:label="lab_cpix_VibativMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vibativ</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VibativMember" xlink:href="cpix-20231231.xsd#cpix_VibativMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_VibativMember" xlink:to="lab_cpix_VibativMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_ed4f4b3e-ab37-489b-bc1b-39523ce34af5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial public offering, net proceeds</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_5fb4a1e5-9d76-4f29-befd-935ab1d7a5d8_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_5eecc48c-5185-481e-ae12-701fba153483_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_6fd75943-6b58-4f0c-9724-4b06ee189546_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83b4d406-5f44-4d4c-b042-a1f6aa069b27_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_c410c97b-be49-4d4c-91f8-4f97db955b27_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_566c164b-e742-4509-9e52-a65ce8b70546_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_6089d7b0-ca41-4a6a-aeb0-342d9e57801d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_773dd63a-6d52-4866-a3b6-f4fcf3ff6afa_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OfficeBuildingMember_0fc5f63d-4d99-4bee-b250-2cd3c0398185_terseLabel_en-US" xlink:label="lab_srt_OfficeBuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office Building</link:label>
    <link:label id="lab_srt_OfficeBuildingMember_label_en-US" xlink:label="lab_srt_OfficeBuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficeBuildingMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OfficeBuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OfficeBuildingMember" xlink:to="lab_srt_OfficeBuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2c2b7e2d-389a-416e-91b2-d4ef26d9abee_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_Within30DaysOfFirstSNDAFilingMember_4dd60df6-4263-45fe-a5d3-08921051517e_terseLabel_en-US" xlink:label="lab_cpix_Within30DaysOfFirstSNDAFilingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Within 30 Days Of First sNDA Filing</link:label>
    <link:label id="lab_cpix_Within30DaysOfFirstSNDAFilingMember_label_en-US" xlink:label="lab_cpix_Within30DaysOfFirstSNDAFilingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Within 30 Days Of First sNDA Filing [Member]</link:label>
    <link:label id="lab_cpix_Within30DaysOfFirstSNDAFilingMember_documentation_en-US" xlink:label="lab_cpix_Within30DaysOfFirstSNDAFilingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Within 30 Days Of First sNDA Filing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_Within30DaysOfFirstSNDAFilingMember" xlink:href="cpix-20231231.xsd#cpix_Within30DaysOfFirstSNDAFilingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_Within30DaysOfFirstSNDAFilingMember" xlink:to="lab_cpix_Within30DaysOfFirstSNDAFilingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_d90ac148-fabc-4650-91cd-8f1f0c557d2b_terseLabel_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shelf Registration, sale of corporate securities (up to)</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_label_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shelf Registration, Proceeds From Sale of Corporate Securities</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_documentation_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shelf Registration, Proceeds From Sale of Corporate Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:href="cpix-20231231.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:to="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_78a7876a-23e7-44bb-80b5-0513be6b13bf_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProductRediTrexMember_a0cdc901-2f5b-4af2-bb82-3051514ef15b_terseLabel_en-US" xlink:label="lab_cpix_ProductRediTrexMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RediTrex</link:label>
    <link:label id="lab_cpix_ProductRediTrexMember_label_en-US" xlink:label="lab_cpix_ProductRediTrexMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product - RediTrex [Member]</link:label>
    <link:label id="lab_cpix_ProductRediTrexMember_documentation_en-US" xlink:label="lab_cpix_ProductRediTrexMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product - RediTrex</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductRediTrexMember" xlink:href="cpix-20231231.xsd#cpix_ProductRediTrexMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductRediTrexMember" xlink:to="lab_cpix_ProductRediTrexMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_b022516d-c298-4f64-b636-703b642dc5c1_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>18
<FILENAME>cpix-20231231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:6edb08b2-28be-4fe2-96a1-5228f16440ba,g:0b7981d4-3364-432a-a869-7a65f1514fac-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="simple" xlink:href="cpix-20231231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_083a1dc7-cec8-4880-b811-fe8ddcc5926b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_f7bf8e61-232a-43e4-9c26-4a98a79acaf5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_083a1dc7-cec8-4880-b811-fe8ddcc5926b" xlink:to="loc_dei_DocumentType_f7bf8e61-232a-43e4-9c26-4a98a79acaf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_e92a6f57-61f3-486e-9c67-7a4bee4f1452" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_083a1dc7-cec8-4880-b811-fe8ddcc5926b" xlink:to="loc_dei_DocumentAnnualReport_e92a6f57-61f3-486e-9c67-7a4bee4f1452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_1f76d591-c091-4c97-b8c5-4d283c31f0cd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_083a1dc7-cec8-4880-b811-fe8ddcc5926b" xlink:to="loc_dei_DocumentPeriodEndDate_1f76d591-c091-4c97-b8c5-4d283c31f0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_c770c716-9e62-46bd-8bb7-d4204d4e24a7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_083a1dc7-cec8-4880-b811-fe8ddcc5926b" xlink:to="loc_dei_DocumentTransitionReport_c770c716-9e62-46bd-8bb7-d4204d4e24a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_01770c1d-e1e9-4512-97f9-3ee2b5a540c2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_083a1dc7-cec8-4880-b811-fe8ddcc5926b" xlink:to="loc_dei_EntityRegistrantName_01770c1d-e1e9-4512-97f9-3ee2b5a540c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_51213915-b8c5-48bd-a238-f792ca2a4743" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_083a1dc7-cec8-4880-b811-fe8ddcc5926b" xlink:to="loc_dei_EntityIncorporationStateCountryCode_51213915-b8c5-48bd-a238-f792ca2a4743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_27fee4b3-e311-4c11-b57c-41aec44bbe07" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_083a1dc7-cec8-4880-b811-fe8ddcc5926b" xlink:to="loc_dei_EntityTaxIdentificationNumber_27fee4b3-e311-4c11-b57c-41aec44bbe07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_813bb2e6-c2f3-48da-a827-2790d848b700" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_083a1dc7-cec8-4880-b811-fe8ddcc5926b" xlink:to="loc_dei_EntityFileNumber_813bb2e6-c2f3-48da-a827-2790d848b700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_5484141f-4b99-4566-a947-075312dfe56d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_083a1dc7-cec8-4880-b811-fe8ddcc5926b" xlink:to="loc_dei_EntityCentralIndexKey_5484141f-4b99-4566-a947-075312dfe56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_cb53f4f4-76af-442f-ab5b-7eb1ddda5bf0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_083a1dc7-cec8-4880-b811-fe8ddcc5926b" xlink:to="loc_dei_CurrentFiscalYearEndDate_cb53f4f4-76af-442f-ab5b-7eb1ddda5bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_321a84ed-2764-4c7b-9d1c-e86fabcc5d99" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_083a1dc7-cec8-4880-b811-fe8ddcc5926b" xlink:to="loc_dei_DocumentFiscalYearFocus_321a84ed-2764-4c7b-9d1c-e86fabcc5d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_ee24d995-be6d-4edc-bd4a-159e98dc0a5f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_083a1dc7-cec8-4880-b811-fe8ddcc5926b" xlink:to="loc_dei_DocumentFiscalPeriodFocus_ee24d995-be6d-4edc-bd4a-159e98dc0a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_348a62ab-e98a-4c7f-ad6c-4718f2034755" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_083a1dc7-cec8-4880-b811-fe8ddcc5926b" xlink:to="loc_dei_AmendmentFlag_348a62ab-e98a-4c7f-ad6c-4718f2034755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ba8ceda0-833e-4613-8db9-122f60fdf2ec" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_083a1dc7-cec8-4880-b811-fe8ddcc5926b" xlink:to="loc_dei_EntityAddressAddressLine1_ba8ceda0-833e-4613-8db9-122f60fdf2ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_c39af47d-f3e3-4a87-bb02-1552f54c2edc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_083a1dc7-cec8-4880-b811-fe8ddcc5926b" xlink:to="loc_dei_EntityAddressAddressLine2_c39af47d-f3e3-4a87-bb02-1552f54c2edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_bc21108f-7bfc-46f4-a8d1-a479b8cb1dab" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_083a1dc7-cec8-4880-b811-fe8ddcc5926b" xlink:to="loc_dei_EntityAddressCityOrTown_bc21108f-7bfc-46f4-a8d1-a479b8cb1dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_d7af991e-cc6b-4ed7-a1c1-f8319e8a287b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_083a1dc7-cec8-4880-b811-fe8ddcc5926b" xlink:to="loc_dei_EntityAddressStateOrProvince_d7af991e-cc6b-4ed7-a1c1-f8319e8a287b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_0cc8696d-7a08-4665-af61-2a504201f4ff" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_083a1dc7-cec8-4880-b811-fe8ddcc5926b" xlink:to="loc_dei_EntityAddressPostalZipCode_0cc8696d-7a08-4665-af61-2a504201f4ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_2982bd54-c573-4d89-b27d-bd3758d2fd47" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_083a1dc7-cec8-4880-b811-fe8ddcc5926b" xlink:to="loc_dei_CityAreaCode_2982bd54-c573-4d89-b27d-bd3758d2fd47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_c51ab718-74c3-4300-9e9c-f5ee1d4bc0b4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_083a1dc7-cec8-4880-b811-fe8ddcc5926b" xlink:to="loc_dei_LocalPhoneNumber_c51ab718-74c3-4300-9e9c-f5ee1d4bc0b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_cbe30529-725c-43cf-a903-7efa19367e88" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_083a1dc7-cec8-4880-b811-fe8ddcc5926b" xlink:to="loc_dei_Security12bTitle_cbe30529-725c-43cf-a903-7efa19367e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f08e8ef7-062a-46c4-9c0a-0b8b59b9f965" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_083a1dc7-cec8-4880-b811-fe8ddcc5926b" xlink:to="loc_dei_TradingSymbol_f08e8ef7-062a-46c4-9c0a-0b8b59b9f965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_4b66a77e-8d05-4422-993e-cd153a613fad" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_083a1dc7-cec8-4880-b811-fe8ddcc5926b" xlink:to="loc_dei_SecurityExchangeName_4b66a77e-8d05-4422-993e-cd153a613fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_6775e4fa-b27c-4a17-bafe-0fc85c4770be" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_083a1dc7-cec8-4880-b811-fe8ddcc5926b" xlink:to="loc_dei_EntityFilerCategory_6775e4fa-b27c-4a17-bafe-0fc85c4770be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_63f56ce5-0dcc-4310-939f-83a23a778b0d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_083a1dc7-cec8-4880-b811-fe8ddcc5926b" xlink:to="loc_dei_EntityEmergingGrowthCompany_63f56ce5-0dcc-4310-939f-83a23a778b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_a058cc4a-2580-4625-8538-21f29b904c7b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_083a1dc7-cec8-4880-b811-fe8ddcc5926b" xlink:to="loc_dei_EntitySmallBusiness_a058cc4a-2580-4625-8538-21f29b904c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_ffb5667e-f053-4730-bd86-f12621681917" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_083a1dc7-cec8-4880-b811-fe8ddcc5926b" xlink:to="loc_dei_EntityShellCompany_ffb5667e-f053-4730-bd86-f12621681917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_b2409052-10aa-4431-ae76-6a223960e5a2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_083a1dc7-cec8-4880-b811-fe8ddcc5926b" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_b2409052-10aa-4431-ae76-6a223960e5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_b1e0d236-74cf-4a98-88d1-9b05010ff418" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_083a1dc7-cec8-4880-b811-fe8ddcc5926b" xlink:to="loc_dei_EntityVoluntaryFilers_b1e0d236-74cf-4a98-88d1-9b05010ff418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_234004c4-04ab-4bd8-b3ac-477f5fd67763" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_083a1dc7-cec8-4880-b811-fe8ddcc5926b" xlink:to="loc_dei_EntityCurrentReportingStatus_234004c4-04ab-4bd8-b3ac-477f5fd67763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_be4e18ef-0e6f-4228-b87b-3df998aabf2b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_083a1dc7-cec8-4880-b811-fe8ddcc5926b" xlink:to="loc_dei_EntityInteractiveDataCurrent_be4e18ef-0e6f-4228-b87b-3df998aabf2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_1b15a070-b2c7-4ead-92c2-ce29d759209c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_083a1dc7-cec8-4880-b811-fe8ddcc5926b" xlink:to="loc_dei_EntityPublicFloat_1b15a070-b2c7-4ead-92c2-ce29d759209c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_ee44f48c-d179-42cb-9b22-f88a2f3a8b63" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_083a1dc7-cec8-4880-b811-fe8ddcc5926b" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_ee44f48c-d179-42cb-9b22-f88a2f3a8b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_9c670b1b-d651-4098-be82-a7b03974c14a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_083a1dc7-cec8-4880-b811-fe8ddcc5926b" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_9c670b1b-d651-4098-be82-a7b03974c14a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_c5ef4e29-3fb2-436c-87ff-397aef85d80f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_083a1dc7-cec8-4880-b811-fe8ddcc5926b" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_c5ef4e29-3fb2-436c-87ff-397aef85d80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AuditInformation" xlink:type="simple" xlink:href="cpix-20231231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AuditorInformationAbstract_42acfa00-97ef-47c8-b355-07ab30eaf989" xlink:href="cpix-20231231.xsd#cpix_AuditorInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_ed98c00c-184b-46a5-845b-0c58951e2f63" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_AuditorInformationAbstract_42acfa00-97ef-47c8-b355-07ab30eaf989" xlink:to="loc_dei_AuditorName_ed98c00c-184b-46a5-845b-0c58951e2f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_6caaf14a-ab96-49e2-8db3-73648115ddc1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_AuditorInformationAbstract_42acfa00-97ef-47c8-b355-07ab30eaf989" xlink:to="loc_dei_AuditorLocation_6caaf14a-ab96-49e2-8db3-73648115ddc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_319415eb-4666-4e07-809b-dcaa1795a9c3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_AuditorInformationAbstract_42acfa00-97ef-47c8-b355-07ab30eaf989" xlink:to="loc_dei_AuditorFirmId_319415eb-4666-4e07-809b-dcaa1795a9c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20231231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_91674399-14f8-4726-8033-aa150d213ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_6d821d98-6b52-4c33-8988-9797f3f2d4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_91674399-14f8-4726-8033-aa150d213ff0" xlink:to="loc_us-gaap_AssetsAbstract_6d821d98-6b52-4c33-8988-9797f3f2d4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_0888f69e-7c76-42bf-aed3-3684703cc8de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6d821d98-6b52-4c33-8988-9797f3f2d4e3" xlink:to="loc_us-gaap_AssetsCurrentAbstract_0888f69e-7c76-42bf-aed3-3684703cc8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d05c58ea-bd92-4011-8bf4-27c9cefa615f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0888f69e-7c76-42bf-aed3-3684703cc8de" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d05c58ea-bd92-4011-8bf4-27c9cefa615f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a75f95bb-3e52-4def-8383-1eb58a7a5f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0888f69e-7c76-42bf-aed3-3684703cc8de" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a75f95bb-3e52-4def-8383-1eb58a7a5f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_8f8d8508-f070-4a11-9b7f-0cfc89e4068a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0888f69e-7c76-42bf-aed3-3684703cc8de" xlink:to="loc_us-gaap_InventoryNet_8f8d8508-f070-4a11-9b7f-0cfc89e4068a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_75b689e8-65e2-4397-aba2-2cacd9104c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0888f69e-7c76-42bf-aed3-3684703cc8de" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_75b689e8-65e2-4397-aba2-2cacd9104c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f37754b2-70da-4e25-9035-f9157abc6b07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0888f69e-7c76-42bf-aed3-3684703cc8de" xlink:to="loc_us-gaap_AssetsCurrent_f37754b2-70da-4e25-9035-f9157abc6b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_4d2b1e84-cfbf-4d8c-a8d6-366ab24d4b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6d821d98-6b52-4c33-8988-9797f3f2d4e3" xlink:to="loc_us-gaap_InventoryNoncurrent_4d2b1e84-cfbf-4d8c-a8d6-366ab24d4b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_27106bc3-e84c-4cc2-afee-851cd0bca394" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6d821d98-6b52-4c33-8988-9797f3f2d4e3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_27106bc3-e84c-4cc2-afee-851cd0bca394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0da405b5-e460-44c4-8c88-a2af8fd01bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6d821d98-6b52-4c33-8988-9797f3f2d4e3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0da405b5-e460-44c4-8c88-a2af8fd01bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0a6ce0f8-132f-4188-b8c8-fee162ad4067" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6d821d98-6b52-4c33-8988-9797f3f2d4e3" xlink:to="loc_us-gaap_Goodwill_0a6ce0f8-132f-4188-b8c8-fee162ad4067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_53c696cc-0c1e-4fbe-b1ee-31b9c38f8a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6d821d98-6b52-4c33-8988-9797f3f2d4e3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_53c696cc-0c1e-4fbe-b1ee-31b9c38f8a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ad5abd4e-bbe7-4036-acb7-1dea129b5bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6d821d98-6b52-4c33-8988-9797f3f2d4e3" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ad5abd4e-bbe7-4036-acb7-1dea129b5bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_14ec7053-2255-414d-b189-2c9479ab792d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6d821d98-6b52-4c33-8988-9797f3f2d4e3" xlink:to="loc_us-gaap_Assets_14ec7053-2255-414d-b189-2c9479ab792d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1f3ab24d-0269-4c73-a94d-287391c248da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_91674399-14f8-4726-8033-aa150d213ff0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1f3ab24d-0269-4c73-a94d-287391c248da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_4d4bdbc5-ee76-4bfa-909f-df65b0cc0278" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1f3ab24d-0269-4c73-a94d-287391c248da" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_4d4bdbc5-ee76-4bfa-909f-df65b0cc0278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_fe6f5582-367b-483b-b6f8-edb44431af3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4d4bdbc5-ee76-4bfa-909f-df65b0cc0278" xlink:to="loc_us-gaap_AccountsPayableCurrent_fe6f5582-367b-483b-b6f8-edb44431af3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_55502530-b7be-4a99-a137-13dfb495ce8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4d4bdbc5-ee76-4bfa-909f-df65b0cc0278" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_55502530-b7be-4a99-a137-13dfb495ce8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_4a2d043c-e89a-41f0-b57b-bb8cc1258663" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4d4bdbc5-ee76-4bfa-909f-df65b0cc0278" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_4a2d043c-e89a-41f0-b57b-bb8cc1258663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d8dc3bad-560b-4806-a226-501b72f62d72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4d4bdbc5-ee76-4bfa-909f-df65b0cc0278" xlink:to="loc_us-gaap_LiabilitiesCurrent_d8dc3bad-560b-4806-a226-501b72f62d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_66651794-15a2-4768-8819-861238a3e275" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1f3ab24d-0269-4c73-a94d-287391c248da" xlink:to="loc_us-gaap_LongTermLineOfCredit_66651794-15a2-4768-8819-861238a3e275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b13dd8b1-66dd-4b21-b1a0-f782c75142a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1f3ab24d-0269-4c73-a94d-287391c248da" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b13dd8b1-66dd-4b21-b1a0-f782c75142a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_e4c15885-44a5-48ec-969f-525f3afce079" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1f3ab24d-0269-4c73-a94d-287391c248da" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_e4c15885-44a5-48ec-969f-525f3afce079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6354856b-c7da-4f6b-839a-5b234c511ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1f3ab24d-0269-4c73-a94d-287391c248da" xlink:to="loc_us-gaap_Liabilities_6354856b-c7da-4f6b-839a-5b234c511ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_b99d985a-7055-4a3b-bcc1-34bbe11d1478" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1f3ab24d-0269-4c73-a94d-287391c248da" xlink:to="loc_us-gaap_CommitmentsAndContingencies_b99d985a-7055-4a3b-bcc1-34bbe11d1478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1425176c-631d-47da-86b9-d558fae829c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1f3ab24d-0269-4c73-a94d-287391c248da" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1425176c-631d-47da-86b9-d558fae829c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_250656df-a330-4632-a551-518930f40a17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1425176c-631d-47da-86b9-d558fae829c9" xlink:to="loc_us-gaap_StockholdersEquityAbstract_250656df-a330-4632-a551-518930f40a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_766cc688-7895-40f2-bd39-a71c112632dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_250656df-a330-4632-a551-518930f40a17" xlink:to="loc_us-gaap_CommonStockValueOutstanding_766cc688-7895-40f2-bd39-a71c112632dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_90d06589-f762-40b6-a15e-157758ea122a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_250656df-a330-4632-a551-518930f40a17" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_90d06589-f762-40b6-a15e-157758ea122a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_30d440d9-7d57-43a5-a845-95b03b611ade" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_250656df-a330-4632-a551-518930f40a17" xlink:to="loc_us-gaap_StockholdersEquity_30d440d9-7d57-43a5-a845-95b03b611ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_80dbdc92-8e9f-494d-bf2f-e183528858d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1425176c-631d-47da-86b9-d558fae829c9" xlink:to="loc_us-gaap_MinorityInterest_80dbdc92-8e9f-494d-bf2f-e183528858d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_46640e05-2d2a-4696-a50a-cfaddc2cb2e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1425176c-631d-47da-86b9-d558fae829c9" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_46640e05-2d2a-4696-a50a-cfaddc2cb2e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_fca8f388-9ab7-413b-b385-a473e66c4fab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1f3ab24d-0269-4c73-a94d-287391c248da" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_fca8f388-9ab7-413b-b385-a473e66c4fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cpix-20231231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_36fc21df-5475-49b3-9365-dc9d81174477" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNoParValue_25ea05b1-8164-4a16-9d85-d5f9b48f0d28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockNoParValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_36fc21df-5475-49b3-9365-dc9d81174477" xlink:to="loc_us-gaap_CommonStockNoParValue_25ea05b1-8164-4a16-9d85-d5f9b48f0d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_63af9751-5246-4503-b37b-643c5d110abb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_36fc21df-5475-49b3-9365-dc9d81174477" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_63af9751-5246-4503-b37b-643c5d110abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_904cbaf0-bbfe-4fc4-8a92-ed839c1b6daa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_36fc21df-5475-49b3-9365-dc9d81174477" xlink:to="loc_us-gaap_CommonStockSharesIssued_904cbaf0-bbfe-4fc4-8a92-ed839c1b6daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_78acd00d-16c6-44d0-ba12-4ef02b85f07e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_36fc21df-5475-49b3-9365-dc9d81174477" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_78acd00d-16c6-44d0-ba12-4ef02b85f07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="cpix-20231231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_3d8286aa-2f6e-4603-8f49-4eee65d4301b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_07b916b2-05e0-4226-b0db-eed2669c4d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3d8286aa-2f6e-4603-8f49-4eee65d4301b" xlink:to="loc_us-gaap_StatementTable_07b916b2-05e0-4226-b0db-eed2669c4d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fd71491b-20f9-4b25-bef7-5163743d16ab" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_07b916b2-05e0-4226-b0db-eed2669c4d0e" xlink:to="loc_srt_ProductOrServiceAxis_fd71491b-20f9-4b25-bef7-5163743d16ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d91bfb9d-1984-4aa1-b795-4de0af3cad00" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_fd71491b-20f9-4b25-bef7-5163743d16ab" xlink:to="loc_srt_ProductsAndServicesDomain_d91bfb9d-1984-4aa1-b795-4de0af3cad00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_36967a74-c403-4b3e-aca3-6d5ba8455cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d91bfb9d-1984-4aa1-b795-4de0af3cad00" xlink:to="loc_us-gaap_ProductMember_36967a74-c403-4b3e-aca3-6d5ba8455cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturedProductOtherMember_0e49d894-3378-449b-bc70-28c971d84ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManufacturedProductOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d91bfb9d-1984-4aa1-b795-4de0af3cad00" xlink:to="loc_us-gaap_ManufacturedProductOtherMember_0e49d894-3378-449b-bc70-28c971d84ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c91c6650-64bb-47f9-ba31-4ab7358debfe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_07b916b2-05e0-4226-b0db-eed2669c4d0e" xlink:to="loc_us-gaap_StatementLineItems_c91c6650-64bb-47f9-ba31-4ab7358debfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_68b32b7f-9a84-4746-abeb-6ac094881691" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c91c6650-64bb-47f9-ba31-4ab7358debfe" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_68b32b7f-9a84-4746-abeb-6ac094881691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_7a4d1a4f-9569-4e36-b9d0-c11418516f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c91c6650-64bb-47f9-ba31-4ab7358debfe" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_7a4d1a4f-9569-4e36-b9d0-c11418516f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5b833643-7f69-4825-8cab-cd41fb215463" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7a4d1a4f-9569-4e36-b9d0-c11418516f0d" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5b833643-7f69-4825-8cab-cd41fb215463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_dd77bdad-06cd-4d34-9fad-dc1755e9afc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7a4d1a4f-9569-4e36-b9d0-c11418516f0d" xlink:to="loc_us-gaap_SellingAndMarketingExpense_dd77bdad-06cd-4d34-9fad-dc1755e9afc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0e5b77eb-551b-49aa-aee3-d30c35008e95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7a4d1a4f-9569-4e36-b9d0-c11418516f0d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0e5b77eb-551b-49aa-aee3-d30c35008e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_5d7b7ad8-2dc1-4c66-9676-4395ab3ddbbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7a4d1a4f-9569-4e36-b9d0-c11418516f0d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_5d7b7ad8-2dc1-4c66-9676-4395ab3ddbbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_b926249e-81d5-4d80-91f7-8f1e8590c093" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7a4d1a4f-9569-4e36-b9d0-c11418516f0d" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_b926249e-81d5-4d80-91f7-8f1e8590c093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b1946114-0cba-4f17-8f7f-4b91dc80abf5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7a4d1a4f-9569-4e36-b9d0-c11418516f0d" xlink:to="loc_us-gaap_CostsAndExpenses_b1946114-0cba-4f17-8f7f-4b91dc80abf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bd765521-9cce-4da7-b275-e6ce3721092f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7a4d1a4f-9569-4e36-b9d0-c11418516f0d" xlink:to="loc_us-gaap_OperatingIncomeLoss_bd765521-9cce-4da7-b275-e6ce3721092f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_23ee84e6-8e0b-4da4-8b75-c075524a07a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c91c6650-64bb-47f9-ba31-4ab7358debfe" xlink:to="loc_us-gaap_InvestmentIncomeInterest_23ee84e6-8e0b-4da4-8b75-c075524a07a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_5bb71215-5da2-4dd1-b04d-4e3f31682fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c91c6650-64bb-47f9-ba31-4ab7358debfe" xlink:to="loc_us-gaap_OtherIncome_5bb71215-5da2-4dd1-b04d-4e3f31682fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_1c612fa3-0147-4ce0-b2eb-45531bf46db3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c91c6650-64bb-47f9-ba31-4ab7358debfe" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_1c612fa3-0147-4ce0-b2eb-45531bf46db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuredEventGainLoss_6bf19adb-20e3-4f09-b796-954c7ac13a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuredEventGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c91c6650-64bb-47f9-ba31-4ab7358debfe" xlink:to="loc_us-gaap_InsuredEventGainLoss_6bf19adb-20e3-4f09-b796-954c7ac13a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f8e4ec3f-4644-4bf0-a5c6-5da9c4015837" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c91c6650-64bb-47f9-ba31-4ab7358debfe" xlink:to="loc_us-gaap_InterestExpense_f8e4ec3f-4644-4bf0-a5c6-5da9c4015837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9ac941f0-03fd-4958-8b15-94b3ff4bc711" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c91c6650-64bb-47f9-ba31-4ab7358debfe" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9ac941f0-03fd-4958-8b15-94b3ff4bc711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0857d8b6-3932-416d-ad8d-5fb3760075ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c91c6650-64bb-47f9-ba31-4ab7358debfe" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0857d8b6-3932-416d-ad8d-5fb3760075ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3a103792-f59f-46c3-bccc-de77769e2968" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c91c6650-64bb-47f9-ba31-4ab7358debfe" xlink:to="loc_us-gaap_ProfitLoss_3a103792-f59f-46c3-bccc-de77769e2968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_486618b2-b17e-464b-885e-f2cebe914035" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c91c6650-64bb-47f9-ba31-4ab7358debfe" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_486618b2-b17e-464b-885e-f2cebe914035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6f2547fc-d380-474a-a90e-2f4af8343e94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c91c6650-64bb-47f9-ba31-4ab7358debfe" xlink:to="loc_us-gaap_NetIncomeLoss_6f2547fc-d380-474a-a90e-2f4af8343e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_97318d54-cba7-4d34-9917-1e260c93844a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c91c6650-64bb-47f9-ba31-4ab7358debfe" xlink:to="loc_us-gaap_EarningsPerShareAbstract_97318d54-cba7-4d34-9917-1e260c93844a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_03c6bf04-3b6d-44b9-8c97-9052468bd0db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_97318d54-cba7-4d34-9917-1e260c93844a" xlink:to="loc_us-gaap_EarningsPerShareBasic_03c6bf04-3b6d-44b9-8c97-9052468bd0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_8d6244b8-9d95-4a1c-ad71-285ca87426e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_97318d54-cba7-4d34-9917-1e260c93844a" xlink:to="loc_us-gaap_EarningsPerShareDiluted_8d6244b8-9d95-4a1c-ad71-285ca87426e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f03d2a1d-d0fb-4a7f-987b-39c319e2590a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c91c6650-64bb-47f9-ba31-4ab7358debfe" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f03d2a1d-d0fb-4a7f-987b-39c319e2590a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_20d8c464-a09f-4a62-9337-b25edea21efc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f03d2a1d-d0fb-4a7f-987b-39c319e2590a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_20d8c464-a09f-4a62-9337-b25edea21efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_955e861d-8110-4690-b121-db60828e54ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f03d2a1d-d0fb-4a7f-987b-39c319e2590a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_955e861d-8110-4690-b121-db60828e54ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20231231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0e9c3df6-c8a7-4eb4-b5ed-91fefdf90d63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7d84e909-579a-429a-9041-401cf05340af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0e9c3df6-c8a7-4eb4-b5ed-91fefdf90d63" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7d84e909-579a-429a-9041-401cf05340af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_62c2ed3e-c1e8-4085-99dc-12b338ffe668" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7d84e909-579a-429a-9041-401cf05340af" xlink:to="loc_us-gaap_ProfitLoss_62c2ed3e-c1e8-4085-99dc-12b338ffe668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1f7d09d3-24ba-4aaa-9c83-4e299611d9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7d84e909-579a-429a-9041-401cf05340af" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1f7d09d3-24ba-4aaa-9c83-4e299611d9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_bacd64fa-7083-4548-98e5-e28ae8041280" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1f7d09d3-24ba-4aaa-9c83-4e299611d9d5" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_bacd64fa-7083-4548-98e5-e28ae8041280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_f78abd41-7824-433a-88d3-a01a6eb64a24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1f7d09d3-24ba-4aaa-9c83-4e299611d9d5" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_f78abd41-7824-433a-88d3-a01a6eb64a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_e7a6dc0e-49d4-4d01-9066-22689ac2eafe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1f7d09d3-24ba-4aaa-9c83-4e299611d9d5" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_e7a6dc0e-49d4-4d01-9066-22689ac2eafe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_a436fd45-b615-4ce1-8853-5788e991900e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1f7d09d3-24ba-4aaa-9c83-4e299611d9d5" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_a436fd45-b615-4ce1-8853-5788e991900e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_53b09ed0-ce51-42fc-b526-17efc07a974d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1f7d09d3-24ba-4aaa-9c83-4e299611d9d5" xlink:to="loc_us-gaap_ShareBasedCompensation_53b09ed0-ce51-42fc-b526-17efc07a974d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_0f954903-f594-4143-b9f9-cf349d83118c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1f7d09d3-24ba-4aaa-9c83-4e299611d9d5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_0f954903-f594-4143-b9f9-cf349d83118c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_39bcb001-4649-4cf9-9fec-1a8dad99b772" xlink:href="cpix-20231231.xsd#cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1f7d09d3-24ba-4aaa-9c83-4e299611d9d5" xlink:to="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_39bcb001-4649-4cf9-9fec-1a8dad99b772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_19027e94-e45f-40a2-9a57-8f86b0f111cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1f7d09d3-24ba-4aaa-9c83-4e299611d9d5" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_19027e94-e45f-40a2-9a57-8f86b0f111cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NoncashOrPartNoncashGainOnTransaction_75d1773f-0503-4a26-ab06-467a45045e62" xlink:href="cpix-20231231.xsd#cpix_NoncashOrPartNoncashGainOnTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1f7d09d3-24ba-4aaa-9c83-4e299611d9d5" xlink:to="loc_cpix_NoncashOrPartNoncashGainOnTransaction_75d1773f-0503-4a26-ab06-467a45045e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingGainsLosses_95c2aca2-261c-470d-b94c-8f90c54ad898" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingGainsLosses"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1f7d09d3-24ba-4aaa-9c83-4e299611d9d5" xlink:to="loc_us-gaap_OtherNonoperatingGainsLosses_95c2aca2-261c-470d-b94c-8f90c54ad898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bac3c185-6be6-4678-947c-7ea49b1d6a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1f7d09d3-24ba-4aaa-9c83-4e299611d9d5" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bac3c185-6be6-4678-947c-7ea49b1d6a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ce10fd7e-9ba5-4f31-9a01-c7d638753d01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bac3c185-6be6-4678-947c-7ea49b1d6a2a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ce10fd7e-9ba5-4f31-9a01-c7d638753d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_68b18678-e6e5-4a87-8ce8-79ad7a46b2b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bac3c185-6be6-4678-947c-7ea49b1d6a2a" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_68b18678-e6e5-4a87-8ce8-79ad7a46b2b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_17de77e9-7739-492f-9d0f-78ec687cc2c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bac3c185-6be6-4678-947c-7ea49b1d6a2a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_17de77e9-7739-492f-9d0f-78ec687cc2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2dcebd9d-6053-48cf-a88c-3c2068a17045" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bac3c185-6be6-4678-947c-7ea49b1d6a2a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2dcebd9d-6053-48cf-a88c-3c2068a17045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_f7acf63f-c4d3-4456-b5a7-7ac2cc3fe14f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bac3c185-6be6-4678-947c-7ea49b1d6a2a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_f7acf63f-c4d3-4456-b5a7-7ac2cc3fe14f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_95c0e91d-c134-4fa1-8dec-9ab39f504d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bac3c185-6be6-4678-947c-7ea49b1d6a2a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_95c0e91d-c134-4fa1-8dec-9ab39f504d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e0bcf1d-498b-4480-a7c9-a533db09df31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7d84e909-579a-429a-9041-401cf05340af" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e0bcf1d-498b-4480-a7c9-a533db09df31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_aac79e9c-ec28-43e5-9d52-6ac2703ebf98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0e9c3df6-c8a7-4eb4-b5ed-91fefdf90d63" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_aac79e9c-ec28-43e5-9d52-6ac2703ebf98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9f04fae2-fc87-4363-970f-804aeba31362" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_aac79e9c-ec28-43e5-9d52-6ac2703ebf98" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9f04fae2-fc87-4363-970f-804aeba31362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_1b3dface-05e2-4783-b6a8-a9875e138120" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_aac79e9c-ec28-43e5-9d52-6ac2703ebf98" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_1b3dface-05e2-4783-b6a8-a9875e138120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromCollaborativeArrangement_38762586-daa7-411d-b379-794409111a6a" xlink:href="cpix-20231231.xsd#cpix_ProceedsFromCollaborativeArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_aac79e9c-ec28-43e5-9d52-6ac2703ebf98" xlink:to="loc_cpix_ProceedsFromCollaborativeArrangement_38762586-daa7-411d-b379-794409111a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLifeInsurancePolicies_274f325c-7240-4886-b987-0c8e53cc77c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLifeInsurancePolicies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_aac79e9c-ec28-43e5-9d52-6ac2703ebf98" xlink:to="loc_us-gaap_ProceedsFromLifeInsurancePolicies_274f325c-7240-4886-b987-0c8e53cc77c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromSettlementOfPatentLitigation_10e9cab0-1296-425d-8a5e-49572c246451" xlink:href="cpix-20231231.xsd#cpix_ProceedsFromSettlementOfPatentLitigation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_aac79e9c-ec28-43e5-9d52-6ac2703ebf98" xlink:to="loc_cpix_ProceedsFromSettlementOfPatentLitigation_10e9cab0-1296-425d-8a5e-49572c246451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_daee83fd-a395-4d63-941d-1d0ccf35524d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_aac79e9c-ec28-43e5-9d52-6ac2703ebf98" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_daee83fd-a395-4d63-941d-1d0ccf35524d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9262116b-0f8d-442c-9f57-c2bcf2ad2f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_aac79e9c-ec28-43e5-9d52-6ac2703ebf98" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9262116b-0f8d-442c-9f57-c2bcf2ad2f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dbc0db9c-f05f-4e11-b7a4-40dcf02abcac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0e9c3df6-c8a7-4eb4-b5ed-91fefdf90d63" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dbc0db9c-f05f-4e11-b7a4-40dcf02abcac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_f0d294a5-ded9-4707-a229-873d014d229e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dbc0db9c-f05f-4e11-b7a4-40dcf02abcac" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_f0d294a5-ded9-4707-a229-873d014d229e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_9f3dd58a-37a1-4499-9627-817e81a048ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dbc0db9c-f05f-4e11-b7a4-40dcf02abcac" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_9f3dd58a-37a1-4499-9627-817e81a048ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_77656aaa-1b90-44b9-9303-e7ac529fd110" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dbc0db9c-f05f-4e11-b7a4-40dcf02abcac" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_77656aaa-1b90-44b9-9303-e7ac529fd110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_28c4e517-dcca-4074-8c2a-13c7de7191e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dbc0db9c-f05f-4e11-b7a4-40dcf02abcac" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_28c4e517-dcca-4074-8c2a-13c7de7191e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_83b3e599-a2fe-4c98-a914-3c1c6c44e37c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dbc0db9c-f05f-4e11-b7a4-40dcf02abcac" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_83b3e599-a2fe-4c98-a914-3c1c6c44e37c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c7d05ec9-eebb-4e0e-b9b3-d7e0dacf6ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dbc0db9c-f05f-4e11-b7a4-40dcf02abcac" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c7d05ec9-eebb-4e0e-b9b3-d7e0dacf6ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b2d749e7-34a6-41ce-a14e-3d7e0ba6cabd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dbc0db9c-f05f-4e11-b7a4-40dcf02abcac" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b2d749e7-34a6-41ce-a14e-3d7e0ba6cabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b30e705c-ee17-4b2d-9158-11a720b4f061" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dbc0db9c-f05f-4e11-b7a4-40dcf02abcac" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b30e705c-ee17-4b2d-9158-11a720b4f061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_60b0f78d-1a0a-4166-8371-10db7141e2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0e9c3df6-c8a7-4eb4-b5ed-91fefdf90d63" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_60b0f78d-1a0a-4166-8371-10db7141e2e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CashPaidDuringYearAbstract_a3ba0bb8-b049-40be-aeca-a0b6ba6e6cf4" xlink:href="cpix-20231231.xsd#cpix_CashPaidDuringYearAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_60b0f78d-1a0a-4166-8371-10db7141e2e5" xlink:to="loc_cpix_CashPaidDuringYearAbstract_a3ba0bb8-b049-40be-aeca-a0b6ba6e6cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_77f4395e-1862-43e3-b0a1-58abb21384b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_CashPaidDuringYearAbstract_a3ba0bb8-b049-40be-aeca-a0b6ba6e6cf4" xlink:to="loc_us-gaap_InterestPaidNet_77f4395e-1862-43e3-b0a1-58abb21384b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_20b1592a-9b30-445f-90b3-133b426053de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_CashPaidDuringYearAbstract_a3ba0bb8-b049-40be-aeca-a0b6ba6e6cf4" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_20b1592a-9b30-445f-90b3-133b426053de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CashPaymentIncludedInMeasurementOfLeaseLiability_c5cd121e-dafe-4576-9764-4fc695127efb" xlink:href="cpix-20231231.xsd#cpix_CashPaymentIncludedInMeasurementOfLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_CashPaidDuringYearAbstract_a3ba0bb8-b049-40be-aeca-a0b6ba6e6cf4" xlink:to="loc_cpix_CashPaymentIncludedInMeasurementOfLeaseLiability_c5cd121e-dafe-4576-9764-4fc695127efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2e3797dc-bbf9-4545-83fe-8034d269c811" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0e9c3df6-c8a7-4eb4-b5ed-91fefdf90d63" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2e3797dc-bbf9-4545-83fe-8034d269c811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid_1e744ec4-d44c-4cb0-ba91-913686779a82" xlink:href="cpix-20231231.xsd#cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2e3797dc-bbf9-4545-83fe-8034d269c811" xlink:to="loc_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid_1e744ec4-d44c-4cb0-ba91-913686779a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ChangeInUnpaidInvoicesForOfferingCosts_d95ff461-6771-4df4-979f-0fe56bec77e0" xlink:href="cpix-20231231.xsd#cpix_ChangeInUnpaidInvoicesForOfferingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2e3797dc-bbf9-4545-83fe-8034d269c811" xlink:to="loc_cpix_ChangeInUnpaidInvoicesForOfferingCosts_d95ff461-6771-4df4-979f-0fe56bec77e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0f98cf4e-118d-405a-a03e-78a75a2429c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2e3797dc-bbf9-4545-83fe-8034d269c811" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0f98cf4e-118d-405a-a03e-78a75a2429c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CreditIssuedForMilestonePayable_e17b28e4-65b4-4e19-bb76-958f04949b83" xlink:href="cpix-20231231.xsd#cpix_CreditIssuedForMilestonePayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2e3797dc-bbf9-4545-83fe-8034d269c811" xlink:to="loc_cpix_CreditIssuedForMilestonePayable_e17b28e4-65b4-4e19-bb76-958f04949b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue_451557df-ba5d-401a-a652-2eb4912bc6f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2e3797dc-bbf9-4545-83fe-8034d269c811" xlink:to="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue_451557df-ba5d-401a-a652-2eb4912bc6f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="cpix-20231231.xsd#ConsolidatedStatementsofEquity"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_3f525164-7ac4-4b3f-bab1-08485833d79e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_eaea31e4-692d-4821-9c4e-30e5f4864c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_3f525164-7ac4-4b3f-bab1-08485833d79e" xlink:to="loc_us-gaap_StatementTable_eaea31e4-692d-4821-9c4e-30e5f4864c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_37bcc066-676b-46fb-9b33-5bc5c1d723fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_eaea31e4-692d-4821-9c4e-30e5f4864c2a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_37bcc066-676b-46fb-9b33-5bc5c1d723fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8a08b8ac-8120-464a-b2b7-7225a6c9ada2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_37bcc066-676b-46fb-9b33-5bc5c1d723fa" xlink:to="loc_us-gaap_EquityComponentDomain_8a08b8ac-8120-464a-b2b7-7225a6c9ada2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a7f23e7b-ec3c-46d3-81f6-2426e2db5bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8a08b8ac-8120-464a-b2b7-7225a6c9ada2" xlink:to="loc_us-gaap_CommonStockMember_a7f23e7b-ec3c-46d3-81f6-2426e2db5bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ba4ede33-0696-4598-8884-8cc5e8e760b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8a08b8ac-8120-464a-b2b7-7225a6c9ada2" xlink:to="loc_us-gaap_RetainedEarningsMember_ba4ede33-0696-4598-8884-8cc5e8e760b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_0490ff12-8806-45b7-9054-9328b00b55fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8a08b8ac-8120-464a-b2b7-7225a6c9ada2" xlink:to="loc_us-gaap_NoncontrollingInterestMember_0490ff12-8806-45b7-9054-9328b00b55fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f34816a2-ea84-49ff-8e8b-889fc1c17fab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_eaea31e4-692d-4821-9c4e-30e5f4864c2a" xlink:to="loc_us-gaap_StatementLineItems_f34816a2-ea84-49ff-8e8b-889fc1c17fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31e74e44-f185-4e7e-8162-49655371bab2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f34816a2-ea84-49ff-8e8b-889fc1c17fab" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31e74e44-f185-4e7e-8162-49655371bab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_681335d2-ac3e-4c22-bf8a-68594e548a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31e74e44-f185-4e7e-8162-49655371bab2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_681335d2-ac3e-4c22-bf8a-68594e548a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_43d4f0ce-cd59-4e85-971b-3fbf8a390684" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31e74e44-f185-4e7e-8162-49655371bab2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_43d4f0ce-cd59-4e85-971b-3fbf8a390684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3798e89e-f2a1-4842-b0f4-9813e4f025a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31e74e44-f185-4e7e-8162-49655371bab2" xlink:to="loc_us-gaap_ProfitLoss_3798e89e-f2a1-4842-b0f4-9813e4f025a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRedeemedOrCalledDuringPeriodShares_106eaf0e-3776-461d-a39b-478e3781d217" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31e74e44-f185-4e7e-8162-49655371bab2" xlink:to="loc_us-gaap_StockRedeemedOrCalledDuringPeriodShares_106eaf0e-3776-461d-a39b-478e3781d217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue_6ddc53b4-becf-4925-a662-21f6341e557b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31e74e44-f185-4e7e-8162-49655371bab2" xlink:to="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue_6ddc53b4-becf-4925-a662-21f6341e557b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_436d86e9-7d94-4542-859c-975cadd68aba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31e74e44-f185-4e7e-8162-49655371bab2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_436d86e9-7d94-4542-859c-975cadd68aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c039445a-e0b6-4dac-86f3-bec9f4d9a033" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31e74e44-f185-4e7e-8162-49655371bab2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c039445a-e0b6-4dac-86f3-bec9f4d9a033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_6b5be975-ccc6-44b3-b66b-828beb70521f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31e74e44-f185-4e7e-8162-49655371bab2" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_6b5be975-ccc6-44b3-b66b-828beb70521f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_32cd3d8c-e139-4ff8-904e-4ca156ad9b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31e74e44-f185-4e7e-8162-49655371bab2" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_32cd3d8c-e139-4ff8-904e-4ca156ad9b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_75b28116-026c-420e-8918-2a987d4f10df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31e74e44-f185-4e7e-8162-49655371bab2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_75b28116-026c-420e-8918-2a987d4f10df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_32d71ffe-fcc7-47b7-b08f-cfcaccc29ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31e74e44-f185-4e7e-8162-49655371bab2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_32d71ffe-fcc7-47b7-b08f-cfcaccc29ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccounts" xlink:type="simple" xlink:href="cpix-20231231.xsd#ValuationandQualifyingAccounts"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccounts" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_c9bf73c9-a2d0-436f-b01b-2a682cd164be" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_5e9585a1-141f-488a-b32d-f3b3a80d5b1c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_c9bf73c9-a2d0-436f-b01b-2a682cd164be" xlink:to="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_5e9585a1-141f-488a-b32d-f3b3a80d5b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Organization" xlink:type="simple" xlink:href="cpix-20231231.xsd#Organization"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Organization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5365427c-25ae-49a4-9ac9-37d5b5f4d841" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_ccf77228-170e-4ece-b314-26e7145fbf2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5365427c-25ae-49a4-9ac9-37d5b5f4d841" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_ccf77228-170e-4ece-b314-26e7145fbf2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="cpix-20231231.xsd#SignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_66af260d-f153-4727-bc0a-b65a9e16d31c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_c4b355e6-d06b-4988-a0c6-dc6f7f0eede2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_66af260d-f153-4727-bc0a-b65a9e16d31c" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_c4b355e6-d06b-4988-a0c6-dc6f7f0eede2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProducts" xlink:type="simple" xlink:href="cpix-20231231.xsd#VibativSancusoandRediTrexProducts"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProducts" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_e4c988e7-943c-43cb-bdf5-7c42eb5a66ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_8299bde8-40a5-4a35-87c1-673ca6c65248" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_e4c988e7-943c-43cb-bdf5-7c42eb5a66ce" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_8299bde8-40a5-4a35-87c1-673ca6c65248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Revenues" xlink:type="simple" xlink:href="cpix-20231231.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_0a0ead0e-046b-4e3b-aace-ed430396fc15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_1eeb65e5-1bea-45da-8ae0-d3c111679bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_0a0ead0e-046b-4e3b-aace-ed430396fc15" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_1eeb65e5-1bea-45da-8ae0-d3c111679bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNet" xlink:type="simple" xlink:href="cpix-20231231.xsd#InventoriesNet"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_2e2d9f7e-24d7-42a1-8620-cea5b95447a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_d2890ac8-f954-43da-a114-04ff839c5dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_2e2d9f7e-24d7-42a1-8620-cea5b95447a0" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_d2890ac8-f954-43da-a114-04ff839c5dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="cpix-20231231.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a3fd442e-c770-4fa2-9c48-b8775de75afd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_b9c1b78d-844d-4b97-ae69-ef3e1534dce7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a3fd442e-c770-4fa2-9c48-b8775de75afd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_b9c1b78d-844d-4b97-ae69-ef3e1534dce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwill" xlink:type="simple" xlink:href="cpix-20231231.xsd#IntangibleAssetsandGoodwill"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_45da0dac-b795-4ab1-a946-a4b56f96af83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_51cdc00b-8e90-42ef-a818-499cfe6ab445" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_45da0dac-b795-4ab1-a946-a4b56f96af83" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_51cdc00b-8e90-42ef-a818-499cfe6ab445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities" xlink:type="simple" xlink:href="cpix-20231231.xsd#OtherCurrentandOtherLongtermLiabilities"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrentAbstract_d6b6fb9c-b676-4fb0-9f28-0e826da6ab22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_26f83d78-67b2-494b-9ccf-c528e38ea2f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_d6b6fb9c-b676-4fb0-9f28-0e826da6ab22" xlink:to="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_26f83d78-67b2-494b-9ccf-c528e38ea2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Debt" xlink:type="simple" xlink:href="cpix-20231231.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7fe5b97b-4002-4451-920d-99a97e74d86f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_b6afef5b-e15e-479c-8c9f-d31b58e378b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7fe5b97b-4002-4451-920d-99a97e74d86f" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_b6afef5b-e15e-479c-8c9f-d31b58e378b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="cpix-20231231.xsd#ShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_ea04f77a-0873-4ed0-abfd-a5de20aae4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_81d4ed75-978f-47cd-9773-e7d2324b2447" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_ea04f77a-0873-4ed0-abfd-a5de20aae4a6" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_81d4ed75-978f-47cd-9773-e7d2324b2447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LossPerShare" xlink:type="simple" xlink:href="cpix-20231231.xsd#LossPerShare"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f32ee83c-4f1b-4974-8474-9de04ec9b75d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_4a233559-f4d9-4eb6-97a5-6787537a6ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f32ee83c-4f1b-4974-8474-9de04ec9b75d" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_4a233559-f4d9-4eb6-97a5-6787537a6ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cpix-20231231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_962b7524-310c-4956-8fc5-cb2feb529538" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_27b88d67-98f0-4b87-b8b7-21c3b9dedbcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_962b7524-310c-4956-8fc5-cb2feb529538" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_27b88d67-98f0-4b87-b8b7-21c3b9dedbcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlans" xlink:type="simple" xlink:href="cpix-20231231.xsd#StockBasedCompensationPlans"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e1c9649c-3ce1-402a-a14c-1ae435544ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9eb1504f-22c4-43ff-bb38-438999fce962" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e1c9649c-3ce1-402a-a14c-1ae435544ae3" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9eb1504f-22c4-43ff-bb38-438999fce962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="cpix-20231231.xsd#EmployeeBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsAbstract_46e6d7c1-0a42-4cfd-af77-021c71561f88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PostemploymentBenefitsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_7b66e719-66aa-4e57-bda7-d34ec0c90334" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_46e6d7c1-0a42-4cfd-af77-021c71561f88" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_7b66e719-66aa-4e57-bda7-d34ec0c90334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Leases" xlink:type="simple" xlink:href="cpix-20231231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_756bd84c-db03-4c4d-a784-78e0e3e9e14b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_2431b92d-f0c5-472d-a17b-ea2e9be0c5af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_756bd84c-db03-4c4d-a784-78e0e3e9e14b" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_2431b92d-f0c5-472d-a17b-ea2e9be0c5af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketConcentrations" xlink:type="simple" xlink:href="cpix-20231231.xsd#MarketConcentrations"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/MarketConcentrations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_cc46697a-0e23-4d76-a21d-688d164d9ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_224d66e5-5e0c-4380-8241-e5ffc097806d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_cc46697a-0e23-4d76-a21d-688d164d9ce0" xlink:to="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_224d66e5-5e0c-4380-8241-e5ffc097806d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreements" xlink:type="simple" xlink:href="cpix-20231231.xsd#ManufacturingandSupplyAgreements"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingAndSupplyAgreementsAbstract_a264492f-7121-490e-a98c-55be9bf5deeb" xlink:href="cpix-20231231.xsd#cpix_ManufacturingAndSupplyAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingAndSupplyAgreementsTextBlock_d66032d0-fdc2-4f6a-9720-1d9b4aaff990" xlink:href="cpix-20231231.xsd#cpix_ManufacturingAndSupplyAgreementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ManufacturingAndSupplyAgreementsAbstract_a264492f-7121-490e-a98c-55be9bf5deeb" xlink:to="loc_cpix_ManufacturingAndSupplyAgreementsTextBlock_d66032d0-fdc2-4f6a-9720-1d9b4aaff990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EmploymentAgreements" xlink:type="simple" xlink:href="cpix-20231231.xsd#EmploymentAgreements"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EmploymentAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmploymentAgreementsAbstract_d4951d7a-52f0-4f5d-b424-6123aae30ef9" xlink:href="cpix-20231231.xsd#cpix_EmploymentAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmploymentAgreementsTextBlock_2f13775b-9843-4082-be7f-b579d383098e" xlink:href="cpix-20231231.xsd#cpix_EmploymentAgreementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EmploymentAgreementsAbstract_d4951d7a-52f0-4f5d-b424-6123aae30ef9" xlink:to="loc_cpix_EmploymentAgreementsTextBlock_2f13775b-9843-4082-be7f-b579d383098e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="cpix-20231231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2f13f17c-fb26-4dc3-a754-b7ea138ea209" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_03a7d9d5-beac-426b-b856-eb7b64955699" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2f13f17c-fb26-4dc3-a754-b7ea138ea209" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_03a7d9d5-beac-426b-b856-eb7b64955699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="simple" xlink:href="cpix-20231231.xsd#QuarterlyFinancialInformationUnaudited"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_4b569995-e525-42bd-9d47-89997bc9d44b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_2388b400-f377-4df4-922f-24dcb54b298f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_4b569995-e525-42bd-9d47-89997bc9d44b" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_2388b400-f377-4df4-922f-24dcb54b298f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cpix-20231231.xsd#SignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bd5dda6f-bc2e-4bb3-b6d5-5f32a72125f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_4bf876f3-194b-442f-9aa6-a0d03c90552f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd5dda6f-bc2e-4bb3-b6d5-5f32a72125f6" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_4bf876f3-194b-442f-9aa6-a0d03c90552f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_56fe5e8a-b338-4e39-a821-74ca6b5ca8b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd5dda6f-bc2e-4bb3-b6d5-5f32a72125f6" xlink:to="loc_us-gaap_UseOfEstimates_56fe5e8a-b338-4e39-a821-74ca6b5ca8b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_1d882f3d-1203-4df1-aed0-101a9380f8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd5dda6f-bc2e-4bb3-b6d5-5f32a72125f6" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_1d882f3d-1203-4df1-aed0-101a9380f8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_dc36eda8-3e7e-4809-a06f-ca3d9e7cc542" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd5dda6f-bc2e-4bb3-b6d5-5f32a72125f6" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_dc36eda8-3e7e-4809-a06f-ca3d9e7cc542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_524e5844-07ed-4855-9e6b-bf25866ed009" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd5dda6f-bc2e-4bb3-b6d5-5f32a72125f6" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_524e5844-07ed-4855-9e6b-bf25866ed009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_40178eae-a3e7-49d0-b652-a4641e4a7bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd5dda6f-bc2e-4bb3-b6d5-5f32a72125f6" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_40178eae-a3e7-49d0-b652-a4641e4a7bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_5c384981-b39a-4ba9-94c4-7c6810f9e43f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd5dda6f-bc2e-4bb3-b6d5-5f32a72125f6" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_5c384981-b39a-4ba9-94c4-7c6810f9e43f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock_a2368f2f-695a-4efd-b290-fe45bdbc422a" xlink:href="cpix-20231231.xsd#cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd5dda6f-bc2e-4bb3-b6d5-5f32a72125f6" xlink:to="loc_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock_a2368f2f-695a-4efd-b290-fe45bdbc422a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_5ded80ae-4fa4-4017-9f68-4df6dd497b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd5dda6f-bc2e-4bb3-b6d5-5f32a72125f6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_5ded80ae-4fa4-4017-9f68-4df6dd497b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_6213f27f-5afa-412b-b1da-26b792739bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd5dda6f-bc2e-4bb3-b6d5-5f32a72125f6" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_6213f27f-5afa-412b-b1da-26b792739bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_f9f17c61-3eae-485e-81f6-476858b32332" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd5dda6f-bc2e-4bb3-b6d5-5f32a72125f6" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_f9f17c61-3eae-485e-81f6-476858b32332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_fdece403-8631-4deb-b591-caaf06e5c1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd5dda6f-bc2e-4bb3-b6d5-5f32a72125f6" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_fdece403-8631-4deb-b591-caaf06e5c1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_e304d71d-607c-476b-bd20-3d5b6b7d0cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd5dda6f-bc2e-4bb3-b6d5-5f32a72125f6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_e304d71d-607c-476b-bd20-3d5b6b7d0cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_5d3e4cad-fb89-4503-bc30-84b355cf5e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd5dda6f-bc2e-4bb3-b6d5-5f32a72125f6" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_5d3e4cad-fb89-4503-bc30-84b355cf5e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_28dcf72c-9669-4f65-b877-da2ec2313763" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd5dda6f-bc2e-4bb3-b6d5-5f32a72125f6" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_28dcf72c-9669-4f65-b877-da2ec2313763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_2e464ba6-50fb-4193-b2df-f17615419032" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd5dda6f-bc2e-4bb3-b6d5-5f32a72125f6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_2e464ba6-50fb-4193-b2df-f17615419032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_de759bfd-0dd0-4c47-8d0e-65ee27af40e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd5dda6f-bc2e-4bb3-b6d5-5f32a72125f6" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_de759bfd-0dd0-4c47-8d0e-65ee27af40e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_53af0a33-a341-4ed3-9581-2fcc139d3029" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd5dda6f-bc2e-4bb3-b6d5-5f32a72125f6" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_53af0a33-a341-4ed3-9581-2fcc139d3029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0445e695-5b73-4f26-86f9-b44452c05f88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd5dda6f-bc2e-4bb3-b6d5-5f32a72125f6" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0445e695-5b73-4f26-86f9-b44452c05f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_13b48897-cb0f-48a0-bea1-08a3496a6ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd5dda6f-bc2e-4bb3-b6d5-5f32a72125f6" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_13b48897-cb0f-48a0-bea1-08a3496a6ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5c74188b-3784-465f-b4bf-8660a7c7361a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd5dda6f-bc2e-4bb3-b6d5-5f32a72125f6" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5c74188b-3784-465f-b4bf-8660a7c7361a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="cpix-20231231.xsd#SignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5298ce72-aab9-4165-a43d-fc937076b8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_bb665cf1-138d-4d79-bf48-27eb77247e47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5298ce72-aab9-4165-a43d-fc937076b8f3" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_bb665cf1-138d-4d79-bf48-27eb77247e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleOfDistributionCostsTableTextBlock_3f5a8121-629b-40ed-b074-e2230663ce04" xlink:href="cpix-20231231.xsd#cpix_ScheduleOfDistributionCostsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5298ce72-aab9-4165-a43d-fc937076b8f3" xlink:to="loc_cpix_ScheduleOfDistributionCostsTableTextBlock_3f5a8121-629b-40ed-b074-e2230663ce04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleOfAdvertisingCostsTableTextBlock_d5a95c04-bc8c-46a8-8711-6bd8b9c0f911" xlink:href="cpix-20231231.xsd#cpix_ScheduleOfAdvertisingCostsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5298ce72-aab9-4165-a43d-fc937076b8f3" xlink:to="loc_cpix_ScheduleOfAdvertisingCostsTableTextBlock_d5a95c04-bc8c-46a8-8711-6bd8b9c0f911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsTables" xlink:type="simple" xlink:href="cpix-20231231.xsd#VibativSancusoandRediTrexProductsTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c5be9376-f2ac-44f4-a0f5-65e7fef2106e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_f9e799f5-437a-49eb-9a9d-9d0a648ffa79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c5be9376-f2ac-44f4-a0f5-65e7fef2106e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_f9e799f5-437a-49eb-9a9d-9d0a648ffa79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="simple" xlink:href="cpix-20231231.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_12ae5708-8e6d-426d-8ae2-bec9920075c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_c532efd4-2911-4c7e-a8c3-5a558c7d80c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_12ae5708-8e6d-426d-8ae2-bec9920075c6" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_c532efd4-2911-4c7e-a8c3-5a558c7d80c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNetTables" xlink:type="simple" xlink:href="cpix-20231231.xsd#InventoriesNetTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_a8f27add-3c55-417a-96fe-2ca00e6ad1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_a4952b57-e44d-401a-8fce-add6d0c760ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a8f27add-3c55-417a-96fe-2ca00e6ad1fc" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_a4952b57-e44d-401a-8fce-add6d0c760ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_fb1f415b-1517-4abb-abf8-e7ce0ac8445c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a8f27add-3c55-417a-96fe-2ca00e6ad1fc" xlink:to="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_fb1f415b-1517-4abb-abf8-e7ce0ac8445c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="cpix-20231231.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8aed0b86-5c61-487f-a662-ea0bad8440b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_24db5ec5-9470-47bd-b32f-9afd73f765b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8aed0b86-5c61-487f-a662-ea0bad8440b2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_24db5ec5-9470-47bd-b32f-9afd73f765b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleofDepreciationExpenseTableTextBlock_53773988-3079-468f-a1ac-9250171c19d0" xlink:href="cpix-20231231.xsd#cpix_ScheduleofDepreciationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8aed0b86-5c61-487f-a662-ea0bad8440b2" xlink:to="loc_cpix_ScheduleofDepreciationExpenseTableTextBlock_53773988-3079-468f-a1ac-9250171c19d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillTables" xlink:type="simple" xlink:href="cpix-20231231.xsd#IntangibleAssetsandGoodwillTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d63b69ae-7b35-49e5-a4c2-0e64abf1eb39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_ad838bb0-55da-4d54-a57d-65b09c5dd20e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d63b69ae-7b35-49e5-a4c2-0e64abf1eb39" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_ad838bb0-55da-4d54-a57d-65b09c5dd20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_b4abc770-f0a8-454a-a11f-826c60a5f4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d63b69ae-7b35-49e5-a4c2-0e64abf1eb39" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_b4abc770-f0a8-454a-a11f-826c60a5f4f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables" xlink:type="simple" xlink:href="cpix-20231231.xsd#OtherCurrentandOtherLongtermLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrentAbstract_31a74b91-b831-42b1-90a9-8b1e6ece49cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_aed8e5f5-0600-4562-8c44-721cff639f82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_31a74b91-b831-42b1-90a9-8b1e6ece49cd" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_aed8e5f5-0600-4562-8c44-721cff639f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_2affb1a6-5334-4be1-9a09-7fea4bb6340b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_31a74b91-b831-42b1-90a9-8b1e6ece49cd" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_2affb1a6-5334-4be1-9a09-7fea4bb6340b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LossPerShareTables" xlink:type="simple" xlink:href="cpix-20231231.xsd#LossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d4312455-3c53-4dd7-8b61-3b75a9228fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_368deef5-0d00-4b11-a5aa-1bfe691c3585" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d4312455-3c53-4dd7-8b61-3b75a9228fb1" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_368deef5-0d00-4b11-a5aa-1bfe691c3585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1ce300ea-dc3f-4440-ba51-7445421f0971" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d4312455-3c53-4dd7-8b61-3b75a9228fb1" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1ce300ea-dc3f-4440-ba51-7445421f0971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="cpix-20231231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6ef0cfa8-28fd-4651-af6a-01062ccbd2ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_5f1a12ab-4354-4ddb-8fba-6018f2e4e632" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6ef0cfa8-28fd-4651-af6a-01062ccbd2ff" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_5f1a12ab-4354-4ddb-8fba-6018f2e4e632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_236fc74e-e1bf-4874-bdab-d2ebd27510e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6ef0cfa8-28fd-4651-af6a-01062ccbd2ff" xlink:to="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_236fc74e-e1bf-4874-bdab-d2ebd27510e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_63288418-e6f0-4075-a44f-a62bdbc5eea0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6ef0cfa8-28fd-4651-af6a-01062ccbd2ff" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_63288418-e6f0-4075-a44f-a62bdbc5eea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_021d5515-7a18-42bf-b3a2-09c33cb32b38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6ef0cfa8-28fd-4651-af6a-01062ccbd2ff" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_021d5515-7a18-42bf-b3a2-09c33cb32b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_0f00f475-33d3-4915-82b3-32598d853b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6ef0cfa8-28fd-4651-af6a-01062ccbd2ff" xlink:to="loc_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_0f00f475-33d3-4915-82b3-32598d853b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables" xlink:type="simple" xlink:href="cpix-20231231.xsd#StockBasedCompensationPlansTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aa87be55-5ae1-4996-a264-e237a3df9b16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2c69a882-ec6a-49ed-b7cf-0a1b70db8d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aa87be55-5ae1-4996-a264-e237a3df9b16" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2c69a882-ec6a-49ed-b7cf-0a1b70db8d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1c65dabd-e3f2-4e23-be49-5556e0a325d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aa87be55-5ae1-4996-a264-e237a3df9b16" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1c65dabd-e3f2-4e23-be49-5556e0a325d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_1a3836a2-464a-4af7-9dc9-4b6502affe22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aa87be55-5ae1-4996-a264-e237a3df9b16" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_1a3836a2-464a-4af7-9dc9-4b6502affe22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="simple" xlink:href="cpix-20231231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d176b2d9-f047-4e4c-9fcd-74e2dae8ec83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_82c0e7bd-edb8-49db-a922-a278f18dfeb9" xlink:href="cpix-20231231.xsd#cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d176b2d9-f047-4e4c-9fcd-74e2dae8ec83" xlink:to="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_82c0e7bd-edb8-49db-a922-a278f18dfeb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_70d76a7f-ff11-4432-8f33-c085fd41a461" xlink:href="cpix-20231231.xsd#cpix_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d176b2d9-f047-4e4c-9fcd-74e2dae8ec83" xlink:to="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_70d76a7f-ff11-4432-8f33-c085fd41a461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_156f3aa5-aa16-4b58-932a-afa0ed824bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d176b2d9-f047-4e4c-9fcd-74e2dae8ec83" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_156f3aa5-aa16-4b58-932a-afa0ed824bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketConcentrationsTables" xlink:type="simple" xlink:href="cpix-20231231.xsd#MarketConcentrationsTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/MarketConcentrationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_650a3a45-c8f7-4625-a01e-f69a827a3d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_6a14e95d-6d11-4be0-b1b2-e9fed7c2e4a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_650a3a45-c8f7-4625-a01e-f69a827a3d2e" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_6a14e95d-6d11-4be0-b1b2-e9fed7c2e4a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="simple" xlink:href="cpix-20231231.xsd#QuarterlyFinancialInformationUnauditedTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_8d25f395-8f03-4524-9aaf-5012bfdd3bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_f7902a32-e921-4fd3-9e63-1642c246eca6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_8d25f395-8f03-4524-9aaf-5012bfdd3bd8" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_f7902a32-e921-4fd3-9e63-1642c246eca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#OrganizationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b814f958-9a3a-411c-8723-a257a3ed2ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_e843a44c-8eb1-4669-a0e4-1e8eb9e2542e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b814f958-9a3a-411c-8723-a257a3ed2ffb" xlink:to="loc_dei_EntitiesTable_e843a44c-8eb1-4669-a0e4-1e8eb9e2542e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_bf6ca88b-993a-4380-83dd-2849791f5629" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_e843a44c-8eb1-4669-a0e4-1e8eb9e2542e" xlink:to="loc_dei_LegalEntityAxis_bf6ca88b-993a-4380-83dd-2849791f5629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_52610ad2-9ebf-45be-81f4-4ebd671d5111" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_bf6ca88b-993a-4380-83dd-2849791f5629" xlink:to="loc_dei_EntityDomain_52610ad2-9ebf-45be-81f4-4ebd671d5111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CumberlandEmergingTechnologiesIncMember_031c75d2-d766-46eb-b0e5-40657cce4c79" xlink:href="cpix-20231231.xsd#cpix_CumberlandEmergingTechnologiesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_52610ad2-9ebf-45be-81f4-4ebd671d5111" xlink:to="loc_cpix_CumberlandEmergingTechnologiesIncMember_031c75d2-d766-46eb-b0e5-40657cce4c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1afcc298-67c1-47b7-bf60-9de954f377db" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_e843a44c-8eb1-4669-a0e4-1e8eb9e2542e" xlink:to="loc_srt_CounterpartyNameAxis_1afcc298-67c1-47b7-bf60-9de954f377db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_beccb878-685a-42c0-878c-86e2d3f2a68a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_1afcc298-67c1-47b7-bf60-9de954f377db" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_beccb878-685a-42c0-878c-86e2d3f2a68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_9199eab0-55a5-48cc-b67e-ffac91c07820" xlink:href="cpix-20231231.xsd#cpix_HongKongWinHealthPharmaGroupCoLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_beccb878-685a-42c0-878c-86e2d3f2a68a" xlink:to="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_9199eab0-55a5-48cc-b67e-ffac91c07820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_b016a6a9-f95c-467c-8d95-c5b0b553390c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_e843a44c-8eb1-4669-a0e4-1e8eb9e2542e" xlink:to="loc_srt_OwnershipAxis_b016a6a9-f95c-467c-8d95-c5b0b553390c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_49742183-96e0-4d8a-8f9b-0b1dd721069e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_b016a6a9-f95c-467c-8d95-c5b0b553390c" xlink:to="loc_srt_OwnershipDomain_49742183-96e0-4d8a-8f9b-0b1dd721069e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CumberlandEmergingTechnologiesIncMember_f68f1ea7-7a69-4f8f-820a-6a898853e199" xlink:href="cpix-20231231.xsd#cpix_CumberlandEmergingTechnologiesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_49742183-96e0-4d8a-8f9b-0b1dd721069e" xlink:to="loc_cpix_CumberlandEmergingTechnologiesIncMember_f68f1ea7-7a69-4f8f-820a-6a898853e199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_282d56a7-e802-4a70-9d44-3f512528da57" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_e843a44c-8eb1-4669-a0e4-1e8eb9e2542e" xlink:to="loc_dei_EntityInformationLineItems_282d56a7-e802-4a70-9d44-3f512528da57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_48fe95cc-bae3-40b9-8490-2dd26cee8f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_282d56a7-e802-4a70-9d44-3f512528da57" xlink:to="loc_us-gaap_NoncontrollingInterestAbstract_48fe95cc-bae3-40b9-8490-2dd26cee8f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_c7bec69e-2b7a-4d8b-9b82-8f49c35fcf49" xlink:href="cpix-20231231.xsd#cpix_SubsidiaryInvestmentPurchaseOfShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_48fe95cc-bae3-40b9-8490-2dd26cee8f7c" xlink:to="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_c7bec69e-2b7a-4d8b-9b82-8f49c35fcf49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_290b207d-cb77-44c4-ade8-af3ff288966a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_48fe95cc-bae3-40b9-8490-2dd26cee8f7c" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_290b207d-cb77-44c4-ade8-af3ff288966a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_236f1fdb-3fb8-4e17-b64c-3c41c5bd0fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_48fe95cc-bae3-40b9-8490-2dd26cee8f7c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_236f1fdb-3fb8-4e17-b64c-3c41c5bd0fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharebasedCompensationCharitableContributionofSharesShares_2c7647ff-3a7f-4b2c-bfdd-12340dce75af" xlink:href="cpix-20231231.xsd#cpix_SharebasedCompensationCharitableContributionofSharesShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_48fe95cc-bae3-40b9-8490-2dd26cee8f7c" xlink:to="loc_cpix_SharebasedCompensationCharitableContributionofSharesShares_2c7647ff-3a7f-4b2c-bfdd-12340dce75af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions_2d035f6d-09e0-4aa9-9e02-c1223132cbf0" xlink:href="cpix-20231231.xsd#cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_48fe95cc-bae3-40b9-8490-2dd26cee8f7c" xlink:to="loc_cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions_2d035f6d-09e0-4aa9-9e02-c1223132cbf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#SignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_72defe9e-4335-44da-b87c-e5d3ab6a74ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_bc888736-f015-4c54-bb70-6474b99b3ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_72defe9e-4335-44da-b87c-e5d3ab6a74ec" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_bc888736-f015-4c54-bb70-6474b99b3ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8b86baf9-5a50-493a-819e-a709fc8d40cd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_bc888736-f015-4c54-bb70-6474b99b3ebb" xlink:to="loc_srt_CounterpartyNameAxis_8b86baf9-5a50-493a-819e-a709fc8d40cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_67268de5-9ff4-40f0-9847-5e4fa0f848f1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_8b86baf9-5a50-493a-819e-a709fc8d40cd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_67268de5-9ff4-40f0-9847-5e4fa0f848f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WinHealthInvestmentSingaporeLtdMember_eed8d81b-67f6-46ea-b5a1-8095ed3b2b7d" xlink:href="cpix-20231231.xsd#cpix_WinHealthInvestmentSingaporeLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_67268de5-9ff4-40f0-9847-5e4fa0f848f1" xlink:to="loc_cpix_WinHealthInvestmentSingaporeLtdMember_eed8d81b-67f6-46ea-b5a1-8095ed3b2b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MartinS.BrownJr.sLawFirmMember_2ad0a75f-a5a0-4e55-8946-250509f30434" xlink:href="cpix-20231231.xsd#cpix_MartinS.BrownJr.sLawFirmMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_67268de5-9ff4-40f0-9847-5e4fa0f848f1" xlink:to="loc_cpix_MartinS.BrownJr.sLawFirmMember_2ad0a75f-a5a0-4e55-8946-250509f30434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_bdba99a7-95b1-477e-9f3d-ab4904a57ed5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_bc888736-f015-4c54-bb70-6474b99b3ebb" xlink:to="loc_srt_StatementGeographicalAxis_bdba99a7-95b1-477e-9f3d-ab4904a57ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b6808417-6cdd-453c-ac32-e0e44ef40679" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_bdba99a7-95b1-477e-9f3d-ab4904a57ed5" xlink:to="loc_srt_SegmentGeographicalDomain_b6808417-6cdd-453c-ac32-e0e44ef40679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_ce9b4e95-4179-4aa1-b1ba-df97b57b9376" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b6808417-6cdd-453c-ac32-e0e44ef40679" xlink:to="loc_us-gaap_NonUsMember_ce9b4e95-4179-4aa1-b1ba-df97b57b9376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccountsReceivableAllowancesByComponentAxis_b1f9e666-d008-4184-8e4c-3f11e0318650" xlink:href="cpix-20231231.xsd#cpix_AccountsReceivableAllowancesByComponentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_bc888736-f015-4c54-bb70-6474b99b3ebb" xlink:to="loc_cpix_AccountsReceivableAllowancesByComponentAxis_b1f9e666-d008-4184-8e4c-3f11e0318650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccountsReceivableAllowancesByComponentDomain_6e2f7d7b-86c6-41be-b0cf-965d3b2b6061" xlink:href="cpix-20231231.xsd#cpix_AccountsReceivableAllowancesByComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_AccountsReceivableAllowancesByComponentAxis_b1f9e666-d008-4184-8e4c-3f11e0318650" xlink:to="loc_cpix_AccountsReceivableAllowancesByComponentDomain_6e2f7d7b-86c6-41be-b0cf-965d3b2b6061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember_91c96e6a-dad1-4ca4-aa0f-d3c24becfea8" xlink:href="cpix-20231231.xsd#cpix_ChargebacksCashDiscountsAndDamagedGoodsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_AccountsReceivableAllowancesByComponentDomain_6e2f7d7b-86c6-41be-b0cf-965d3b2b6061" xlink:to="loc_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember_91c96e6a-dad1-4ca4-aa0f-d3c24becfea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_267ec083-ad78-4d27-a203-21d753d9fd6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_bc888736-f015-4c54-bb70-6474b99b3ebb" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_267ec083-ad78-4d27-a203-21d753d9fd6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_28b0a147-4b0d-4ef6-b72b-22d536cbc56a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_267ec083-ad78-4d27-a203-21d753d9fd6d" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_28b0a147-4b0d-4ef6-b72b-22d536cbc56a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_a9bf4acb-9cdd-403b-b5a0-9a78e10dfeef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_28b0a147-4b0d-4ef6-b72b-22d536cbc56a" xlink:to="loc_us-gaap_RelatedPartyMember_a9bf4acb-9cdd-403b-b5a0-9a78e10dfeef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_a30007fb-b6a3-4d2e-a207-e0ccbf5d38ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_bc888736-f015-4c54-bb70-6474b99b3ebb" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_a30007fb-b6a3-4d2e-a207-e0ccbf5d38ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c410eaed-4191-40c9-8cf2-d13291442cea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_a30007fb-b6a3-4d2e-a207-e0ccbf5d38ff" xlink:to="loc_us-gaap_SegmentReportingAbstract_c410eaed-4191-40c9-8cf2-d13291442cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_7293519c-5a91-4214-a418-b4ef55215da9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c410eaed-4191-40c9-8cf2-d13291442cea" xlink:to="loc_us-gaap_NumberOfOperatingSegments_7293519c-5a91-4214-a418-b4ef55215da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a45a2099-107d-4038-926c-a89e77e6d364" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c410eaed-4191-40c9-8cf2-d13291442cea" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a45a2099-107d-4038-926c-a89e77e6d364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_16c00f7f-661a-44c4-8ebe-4f08b195534b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c410eaed-4191-40c9-8cf2-d13291442cea" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_16c00f7f-661a-44c4-8ebe-4f08b195534b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_f6a9a3f3-c9f4-48cd-a6a2-43831081bd8a" xlink:href="cpix-20231231.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c410eaed-4191-40c9-8cf2-d13291442cea" xlink:to="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_f6a9a3f3-c9f4-48cd-a6a2-43831081bd8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_9f26cd75-a93b-4ff7-93b4-2457b3234268" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c410eaed-4191-40c9-8cf2-d13291442cea" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_9f26cd75-a93b-4ff7-93b4-2457b3234268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_5662c924-565c-4992-8fcd-5aaf633f1359" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c410eaed-4191-40c9-8cf2-d13291442cea" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_5662c924-565c-4992-8fcd-5aaf633f1359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_4a50aa3c-fdea-4605-99e2-71e8adb206f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c410eaed-4191-40c9-8cf2-d13291442cea" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_4a50aa3c-fdea-4605-99e2-71e8adb206f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_959043c0-a728-4b4b-97ba-b09c9318547f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c410eaed-4191-40c9-8cf2-d13291442cea" xlink:to="loc_us-gaap_CostsAndExpenses_959043c0-a728-4b4b-97ba-b09c9318547f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofDistributionCostsDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#SignificantAccountingPoliciesScheduleofDistributionCostsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofDistributionCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_86b66442-18d6-4a4a-bf77-13d9f5d35925" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductionAndDistributionCosts_fe100613-f6ce-4ae1-85bf-4ff6ae812d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductionAndDistributionCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_86b66442-18d6-4a4a-bf77-13d9f5d35925" xlink:to="loc_us-gaap_ProductionAndDistributionCosts_fe100613-f6ce-4ae1-85bf-4ff6ae812d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofAdvertisingCostsDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#SignificantAccountingPoliciesScheduleofAdvertisingCostsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofAdvertisingCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c4366abb-5b0a-450e-8b45-8c367f0b08c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_4949b9ad-93b6-4130-81cc-54ab16748b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c4366abb-5b0a-450e-8b45-8c367f0b08c1" xlink:to="loc_us-gaap_AdvertisingExpense_4949b9ad-93b6-4130-81cc-54ab16748b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#VibativSancusoandRediTrexProductsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1fbfe55a-1e43-43e4-b98b-f2ad3fd9a034" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38d2875e-825b-42a6-b7f0-d0952a604ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1fbfe55a-1e43-43e4-b98b-f2ad3fd9a034" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38d2875e-825b-42a6-b7f0-d0952a604ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0ab6c7f0-8f81-4f80-a4a0-b830c7fa5b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38d2875e-825b-42a6-b7f0-d0952a604ca9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0ab6c7f0-8f81-4f80-a4a0-b830c7fa5b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_45f01dcd-495e-42c0-a994-906e2228915b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0ab6c7f0-8f81-4f80-a4a0-b830c7fa5b5b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_45f01dcd-495e-42c0-a994-906e2228915b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductAssetsAndGlobalRightsVibativMember_b056391e-e951-4ac1-a275-cabf1a96164d" xlink:href="cpix-20231231.xsd#cpix_ProductAssetsAndGlobalRightsVibativMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_45f01dcd-495e-42c0-a994-906e2228915b" xlink:to="loc_cpix_ProductAssetsAndGlobalRightsVibativMember_b056391e-e951-4ac1-a275-cabf1a96164d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_U.S.ProductAssetRightsSancusoMember_ad682603-f2f3-4093-aeae-b18315e67d46" xlink:href="cpix-20231231.xsd#cpix_U.S.ProductAssetRightsSancusoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_45f01dcd-495e-42c0-a994-906e2228915b" xlink:to="loc_cpix_U.S.ProductAssetRightsSancusoMember_ad682603-f2f3-4093-aeae-b18315e67d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_741106c1-75cd-4711-8de8-406f63079c58" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38d2875e-825b-42a6-b7f0-d0952a604ca9" xlink:to="loc_srt_RangeAxis_741106c1-75cd-4711-8de8-406f63079c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fc9cc1a2-2386-49c4-808d-3a3b066c4ea7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_741106c1-75cd-4711-8de8-406f63079c58" xlink:to="loc_srt_RangeMember_fc9cc1a2-2386-49c4-808d-3a3b066c4ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c6ffbf54-a172-4ad4-9e72-9cd3b0ad298e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fc9cc1a2-2386-49c4-808d-3a3b066c4ea7" xlink:to="loc_srt_MaximumMember_c6ffbf54-a172-4ad4-9e72-9cd3b0ad298e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_34003409-3447-4d8c-aa92-4cc67de5cef3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38d2875e-825b-42a6-b7f0-d0952a604ca9" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_34003409-3447-4d8c-aa92-4cc67de5cef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_9b3df18c-1859-43fd-a2c2-a446306d533b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34003409-3447-4d8c-aa92-4cc67de5cef3" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_9b3df18c-1859-43fd-a2c2-a446306d533b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsToAcquireBusinessMilestonePayment_5b2611d7-cf5f-413c-badb-ed3098ebb018" xlink:href="cpix-20231231.xsd#cpix_PaymentsToAcquireBusinessMilestonePayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34003409-3447-4d8c-aa92-4cc67de5cef3" xlink:to="loc_cpix_PaymentsToAcquireBusinessMilestonePayment_5b2611d7-cf5f-413c-badb-ed3098ebb018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage_d263eb13-ad3d-465f-94b6-001819c6cad8" xlink:href="cpix-20231231.xsd#cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34003409-3447-4d8c-aa92-4cc67de5cef3" xlink:to="loc_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage_d263eb13-ad3d-465f-94b6-001819c6cad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold_cb0883d9-06ad-4551-bc48-b4944d849405" xlink:href="cpix-20231231.xsd#cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34003409-3447-4d8c-aa92-4cc67de5cef3" xlink:to="loc_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold_cb0883d9-06ad-4551-bc48-b4944d849405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_4fb0f0aa-3b7e-4743-80ed-bf3ea8fff291" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34003409-3447-4d8c-aa92-4cc67de5cef3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_4fb0f0aa-3b7e-4743-80ed-bf3ea8fff291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_0538d905-e536-4585-a1fe-0ae501f20309" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34003409-3447-4d8c-aa92-4cc67de5cef3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_0538d905-e536-4585-a1fe-0ae501f20309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsToAcquireBusinessMilestonePaymentRemaining_5b93ba17-0f9c-4ba4-8caf-0eaa8ba3eaef" xlink:href="cpix-20231231.xsd#cpix_PaymentsToAcquireBusinessMilestonePaymentRemaining"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34003409-3447-4d8c-aa92-4cc67de5cef3" xlink:to="loc_cpix_PaymentsToAcquireBusinessMilestonePaymentRemaining_5b93ba17-0f9c-4ba4-8caf-0eaa8ba3eaef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_baae6b22-358a-4cb9-861b-9102d958cbd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34003409-3447-4d8c-aa92-4cc67de5cef3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_baae6b22-358a-4cb9-861b-9102d958cbd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_8e6ecb17-97b6-4f16-bc1a-fe1982fe6c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34003409-3447-4d8c-aa92-4cc67de5cef3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_8e6ecb17-97b6-4f16-bc1a-fe1982fe6c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_86646bd2-2240-4d5f-952f-5d3968044932" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34003409-3447-4d8c-aa92-4cc67de5cef3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_86646bd2-2240-4d5f-952f-5d3968044932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a8403eaa-0317-41a9-94ed-6b27551a9124" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34003409-3447-4d8c-aa92-4cc67de5cef3" xlink:to="loc_us-gaap_Goodwill_a8403eaa-0317-41a9-94ed-6b27551a9124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_b1040a2d-5cf9-466c-ab65-cbd3643ff253" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34003409-3447-4d8c-aa92-4cc67de5cef3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_b1040a2d-5cf9-466c-ab65-cbd3643ff253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMilestonePayable_f19dd984-d6c9-4131-bb24-baa317404f29" xlink:href="cpix-20231231.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMilestonePayable"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34003409-3447-4d8c-aa92-4cc67de5cef3" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMilestonePayable_f19dd984-d6c9-4131-bb24-baa317404f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_141985df-4a72-461a-9043-ae4024a2a87f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1fbfe55a-1e43-43e4-b98b-f2ad3fd9a034" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_141985df-4a72-461a-9043-ae4024a2a87f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b4f357e9-cffc-4cd2-ab60-7bc28477d5c0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_141985df-4a72-461a-9043-ae4024a2a87f" xlink:to="loc_srt_CounterpartyNameAxis_b4f357e9-cffc-4cd2-ab60-7bc28477d5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_59ad923f-6af4-4b68-9f11-5add72c91955" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_b4f357e9-cffc-4cd2-ab60-7bc28477d5c0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_59ad923f-6af4-4b68-9f11-5add72c91955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NordicGroupBVMember_1a497356-1b7b-44be-8de0-98727b63b04b" xlink:href="cpix-20231231.xsd#cpix_NordicGroupBVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_59ad923f-6af4-4b68-9f11-5add72c91955" xlink:to="loc_cpix_NordicGroupBVMember_1a497356-1b7b-44be-8de0-98727b63b04b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9032ac38-5fae-4047-afff-2005392b2a4b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_141985df-4a72-461a-9043-ae4024a2a87f" xlink:to="loc_srt_ProductOrServiceAxis_9032ac38-5fae-4047-afff-2005392b2a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_29a527e9-5a50-4e5a-9ba9-e7f4e6ff1966" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9032ac38-5fae-4047-afff-2005392b2a4b" xlink:to="loc_srt_ProductsAndServicesDomain_29a527e9-5a50-4e5a-9ba9-e7f4e6ff1966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember_09c7c8fc-389f-463a-9421-fa9b7eaaea31" xlink:href="cpix-20231231.xsd#cpix_MethotrexateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_29a527e9-5a50-4e5a-9ba9-e7f4e6ff1966" xlink:to="loc_cpix_MethotrexateMember_09c7c8fc-389f-463a-9421-fa9b7eaaea31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6d0409e6-f7f4-47de-9efe-3b5fcbc86ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_141985df-4a72-461a-9043-ae4024a2a87f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6d0409e6-f7f4-47de-9efe-3b5fcbc86ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e96e9544-5c05-4575-9a67-bcc646371f14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6d0409e6-f7f4-47de-9efe-3b5fcbc86ca7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e96e9544-5c05-4575-9a67-bcc646371f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_a54b40a6-dd71-474c-b52a-2952b2546a48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e96e9544-5c05-4575-9a67-bcc646371f14" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_a54b40a6-dd71-474c-b52a-2952b2546a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cc3b1ebd-0471-4865-a425-677934d8e213" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_141985df-4a72-461a-9043-ae4024a2a87f" xlink:to="loc_us-gaap_AwardTypeAxis_cc3b1ebd-0471-4865-a425-677934d8e213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1b883030-41d8-4785-a9bc-27492fd05516" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_cc3b1ebd-0471-4865-a425-677934d8e213" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1b883030-41d8-4785-a9bc-27492fd05516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_104a7051-01aa-4872-ac8d-c62fea5334d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1b883030-41d8-4785-a9bc-27492fd05516" xlink:to="loc_us-gaap_RestrictedStockMember_104a7051-01aa-4872-ac8d-c62fea5334d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25c8459b-8849-4a50-82fa-67560b7a4f00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_141985df-4a72-461a-9043-ae4024a2a87f" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25c8459b-8849-4a50-82fa-67560b7a4f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsDepositPayment_5b21beab-6987-4d2e-bf30-803cbc25a01b" xlink:href="cpix-20231231.xsd#cpix_CollaborativeArrangementRightsAndObligationsDepositPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25c8459b-8849-4a50-82fa-67560b7a4f00" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsDepositPayment_5b21beab-6987-4d2e-bf30-803cbc25a01b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationValue_9722466a-9875-4ccc-aa19-63d8255d7df0" xlink:href="cpix-20231231.xsd#cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25c8459b-8849-4a50-82fa-67560b7a4f00" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationValue_9722466a-9875-4ccc-aa19-63d8255d7df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationShares_8ddf4418-67a7-42bd-9008-572f17a6077e" xlink:href="cpix-20231231.xsd#cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25c8459b-8849-4a50-82fa-67560b7a4f00" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationShares_8ddf4418-67a7-42bd-9008-572f17a6077e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationVestedValue_30ac0a46-218d-45e9-9102-f87fa2ce288d" xlink:href="cpix-20231231.xsd#cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationVestedValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25c8459b-8849-4a50-82fa-67560b7a4f00" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationVestedValue_30ac0a46-218d-45e9-9102-f87fa2ce288d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePayment_f0bbdf47-170a-432e-ac7e-7cf7a32be3c7" xlink:href="cpix-20231231.xsd#cpix_CollaborativeArrangementRightsAndObligationsMilestonePayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25c8459b-8849-4a50-82fa-67560b7a4f00" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePayment_f0bbdf47-170a-432e-ac7e-7cf7a32be3c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationCancelledAndRefunded_f2635e2c-70fb-4124-bf70-f92e705d732b" xlink:href="cpix-20231231.xsd#cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationCancelledAndRefunded"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25c8459b-8849-4a50-82fa-67560b7a4f00" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationCancelledAndRefunded_f2635e2c-70fb-4124-bf70-f92e705d732b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue_7db24ef1-5d4c-468c-9d27-12dcb83d67f1" xlink:href="cpix-20231231.xsd#cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25c8459b-8849-4a50-82fa-67560b7a4f00" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue_7db24ef1-5d4c-468c-9d27-12dcb83d67f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsChangesInFairValueOfContingentConsiderationLiabilityDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#VibativSancusoandRediTrexProductsChangesInFairValueOfContingentConsiderationLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsChangesInFairValueOfContingentConsiderationLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c24ade9c-8de5-4f9f-848e-db7952e22b79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_f1b9201d-e238-4750-8f89-8a10b55551b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c24ade9c-8de5-4f9f-848e-db7952e22b79" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_f1b9201d-e238-4750-8f89-8a10b55551b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1f38dcd6-bcd4-4e10-a8bb-9a635dcbeef9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_f1b9201d-e238-4750-8f89-8a10b55551b3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1f38dcd6-bcd4-4e10-a8bb-9a635dcbeef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7fa35802-31c7-4191-a0eb-2d7fc1985523" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1f38dcd6-bcd4-4e10-a8bb-9a635dcbeef9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7fa35802-31c7-4191-a0eb-2d7fc1985523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductAssetsAndGlobalRightsVibativMember_5651fdb4-028c-470d-9cf8-4eccd84731e5" xlink:href="cpix-20231231.xsd#cpix_ProductAssetsAndGlobalRightsVibativMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7fa35802-31c7-4191-a0eb-2d7fc1985523" xlink:to="loc_cpix_ProductAssetsAndGlobalRightsVibativMember_5651fdb4-028c-470d-9cf8-4eccd84731e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_U.S.ProductAssetRightsSancusoMember_b5a1396c-505a-4363-a974-9bac3696db93" xlink:href="cpix-20231231.xsd#cpix_U.S.ProductAssetRightsSancusoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7fa35802-31c7-4191-a0eb-2d7fc1985523" xlink:to="loc_cpix_U.S.ProductAssetRightsSancusoMember_b5a1396c-505a-4363-a974-9bac3696db93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_407d2519-a11f-4c5e-a604-9e3b5314187f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_f1b9201d-e238-4750-8f89-8a10b55551b3" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_407d2519-a11f-4c5e-a604-9e3b5314187f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationLiabilityRollForward_ab99cf3b-d4ee-4f7a-b92f-dd0e6d31554a" xlink:href="cpix-20231231.xsd#cpix_BusinessCombinationContingentConsiderationLiabilityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_407d2519-a11f-4c5e-a604-9e3b5314187f" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationLiabilityRollForward_ab99cf3b-d4ee-4f7a-b92f-dd0e6d31554a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_39b2ef9c-63e4-4093-b83a-f50bb108dc1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_BusinessCombinationContingentConsiderationLiabilityRollForward_ab99cf3b-d4ee-4f7a-b92f-dd0e6d31554a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_39b2ef9c-63e4-4093-b83a-f50bb108dc1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_84916e31-4a5a-4ce6-916c-6dd62df6cf1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_BusinessCombinationContingentConsiderationLiabilityRollForward_ab99cf3b-d4ee-4f7a-b92f-dd0e6d31554a" xlink:to="loc_us-gaap_PaymentsForRoyalties_84916e31-4a5a-4ce6-916c-6dd62df6cf1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_772f70c3-b5dc-444c-a369-f3cb6b947749" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_BusinessCombinationContingentConsiderationLiabilityRollForward_ab99cf3b-d4ee-4f7a-b92f-dd0e6d31554a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_772f70c3-b5dc-444c-a369-f3cb6b947749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_b0a30a11-5c41-4e37-8a3e-fc96dd241cb0" xlink:href="cpix-20231231.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_BusinessCombinationContingentConsiderationLiabilityRollForward_ab99cf3b-d4ee-4f7a-b92f-dd0e6d31554a" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_b0a30a11-5c41-4e37-8a3e-fc96dd241cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c1cee686-4169-4911-aac7-98af55f48362" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_BusinessCombinationContingentConsiderationLiabilityRollForward_ab99cf3b-d4ee-4f7a-b92f-dd0e6d31554a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c1cee686-4169-4911-aac7-98af55f48362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#RevenuesScheduleofNetProductRevenuesbyProductDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_5d22e789-4b61-46da-965b-639f80e2e75e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_c0f581a6-641d-4a9e-82b0-d32cb5e9fa14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_5d22e789-4b61-46da-965b-639f80e2e75e" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_c0f581a6-641d-4a9e-82b0-d32cb5e9fa14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5a7cfdfb-2f58-446e-b5b3-896d5025a03b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_c0f581a6-641d-4a9e-82b0-d32cb5e9fa14" xlink:to="loc_srt_ProductOrServiceAxis_5a7cfdfb-2f58-446e-b5b3-896d5025a03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_eeeb478b-2e3a-4da2-b7d2-dfd073096ccd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5a7cfdfb-2f58-446e-b5b3-896d5025a03b" xlink:to="loc_srt_ProductsAndServicesDomain_eeeb478b-2e3a-4da2-b7d2-dfd073096ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_cec093e2-627b-4b8a-9db9-90751d1cb36c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_eeeb478b-2e3a-4da2-b7d2-dfd073096ccd" xlink:to="loc_us-gaap_ProductMember_cec093e2-627b-4b8a-9db9-90751d1cb36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductKristaloseMember_f8b199c9-ccee-4380-8135-2997c8d8f76d" xlink:href="cpix-20231231.xsd#cpix_ProductKristaloseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_cec093e2-627b-4b8a-9db9-90751d1cb36c" xlink:to="loc_cpix_ProductKristaloseMember_f8b199c9-ccee-4380-8135-2997c8d8f76d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductVibativMember_86c2c2c6-dc50-4e9c-90cb-53fa81161e8e" xlink:href="cpix-20231231.xsd#cpix_ProductVibativMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_cec093e2-627b-4b8a-9db9-90751d1cb36c" xlink:to="loc_cpix_ProductVibativMember_86c2c2c6-dc50-4e9c-90cb-53fa81161e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductSancusoMember_bb4699a4-4475-4f8c-af46-cbd2b16aae57" xlink:href="cpix-20231231.xsd#cpix_ProductSancusoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_cec093e2-627b-4b8a-9db9-90751d1cb36c" xlink:to="loc_cpix_ProductSancusoMember_bb4699a4-4475-4f8c-af46-cbd2b16aae57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductCaldolorMember_d2c2f647-c9bc-4eb6-a350-f400dce4f889" xlink:href="cpix-20231231.xsd#cpix_ProductCaldolorMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_cec093e2-627b-4b8a-9db9-90751d1cb36c" xlink:to="loc_cpix_ProductCaldolorMember_d2c2f647-c9bc-4eb6-a350-f400dce4f889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductAcetadoteMember_0af63aa1-b28a-45eb-ae2b-d6727468bfad" xlink:href="cpix-20231231.xsd#cpix_ProductAcetadoteMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_cec093e2-627b-4b8a-9db9-90751d1cb36c" xlink:to="loc_cpix_ProductAcetadoteMember_0af63aa1-b28a-45eb-ae2b-d6727468bfad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductOmeclamoxPakMember_bc94cd62-4989-4b09-b955-699c78aa04c3" xlink:href="cpix-20231231.xsd#cpix_ProductOmeclamoxPakMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_cec093e2-627b-4b8a-9db9-90751d1cb36c" xlink:to="loc_cpix_ProductOmeclamoxPakMember_bc94cd62-4989-4b09-b955-699c78aa04c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductVaprisolMember_09acf473-fbe1-4960-9377-a69451b4a98f" xlink:href="cpix-20231231.xsd#cpix_ProductVaprisolMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_cec093e2-627b-4b8a-9db9-90751d1cb36c" xlink:to="loc_cpix_ProductVaprisolMember_09acf473-fbe1-4960-9377-a69451b4a98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductRediTrexMember_fa3ff71f-84a8-400e-b73b-c0ea0b767db3" xlink:href="cpix-20231231.xsd#cpix_ProductRediTrexMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_cec093e2-627b-4b8a-9db9-90751d1cb36c" xlink:to="loc_cpix_ProductRediTrexMember_fa3ff71f-84a8-400e-b73b-c0ea0b767db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_16646c11-c8de-4b1a-b6db-2c14a56742e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_c0f581a6-641d-4a9e-82b0-d32cb5e9fa14" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_16646c11-c8de-4b1a-b6db-2c14a56742e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5a70fde5-e0fa-463a-b2b7-864ff883352d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_16646c11-c8de-4b1a-b6db-2c14a56742e4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5a70fde5-e0fa-463a-b2b7-864ff883352d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#RevenuesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_e218bb4f-7f43-4084-9749-cee6033ec10b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a73e9571-2596-4136-9411-1d0f0d1dda5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_e218bb4f-7f43-4084-9749-cee6033ec10b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a73e9571-2596-4136-9411-1d0f0d1dda5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7a9c19b9-7917-4803-a918-a30f8a6f7eda" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a73e9571-2596-4136-9411-1d0f0d1dda5c" xlink:to="loc_srt_ProductOrServiceAxis_7a9c19b9-7917-4803-a918-a30f8a6f7eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_890ff90b-1a76-4419-8c9f-082e096a8685" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7a9c19b9-7917-4803-a918-a30f8a6f7eda" xlink:to="loc_srt_ProductsAndServicesDomain_890ff90b-1a76-4419-8c9f-082e096a8685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VibativMember_0f6a3334-4bb8-4e91-aa24-33199904ae83" xlink:href="cpix-20231231.xsd#cpix_VibativMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_890ff90b-1a76-4419-8c9f-082e096a8685" xlink:to="loc_cpix_VibativMember_0f6a3334-4bb8-4e91-aa24-33199904ae83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_de588f96-4e7c-4f07-bcd6-f0dbb5a37e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_890ff90b-1a76-4419-8c9f-082e096a8685" xlink:to="loc_us-gaap_GrantMember_de588f96-4e7c-4f07-bcd6-f0dbb5a37e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e38ac15b-b484-4643-ac62-83b5effcab1c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a73e9571-2596-4136-9411-1d0f0d1dda5c" xlink:to="loc_srt_CounterpartyNameAxis_e38ac15b-b484-4643-ac62-83b5effcab1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9d258138-d5c1-452e-9103-ab45b0274ee6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e38ac15b-b484-4643-ac62-83b5effcab1c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9d258138-d5c1-452e-9103-ab45b0274ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FederalGrantProgramsMember_c9da1c43-9717-4c64-90bb-c0ff5fda2b96" xlink:href="cpix-20231231.xsd#cpix_FederalGrantProgramsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9d258138-d5c1-452e-9103-ab45b0274ee6" xlink:to="loc_cpix_FederalGrantProgramsMember_c9da1c43-9717-4c64-90bb-c0ff5fda2b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_ef17a2f3-5db4-42e2-a717-c4997f6bd2aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a73e9571-2596-4136-9411-1d0f0d1dda5c" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_ef17a2f3-5db4-42e2-a717-c4997f6bd2aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLegalSettlements_d51758d7-2af2-4707-95f3-b72cb4e916f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLegalSettlements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ef17a2f3-5db4-42e2-a717-c4997f6bd2aa" xlink:to="loc_us-gaap_ProceedsFromLegalSettlements_d51758d7-2af2-4707-95f3-b72cb4e916f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivableNumberOfPayments_48205fcd-4c62-4457-8803-c280e009d369" xlink:href="cpix-20231231.xsd#cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivableNumberOfPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ef17a2f3-5db4-42e2-a717-c4997f6bd2aa" xlink:to="loc_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivableNumberOfPayments_48205fcd-4c62-4457-8803-c280e009d369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentOne_78ab20a2-4e04-4958-aee1-1b4fa4502171" xlink:href="cpix-20231231.xsd#cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentOne"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ef17a2f3-5db4-42e2-a717-c4997f6bd2aa" xlink:to="loc_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentOne_78ab20a2-4e04-4958-aee1-1b4fa4502171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentTwo_0b3f27b8-7b11-4f1c-a832-6e73a1f15ce3" xlink:href="cpix-20231231.xsd#cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentTwo"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ef17a2f3-5db4-42e2-a717-c4997f6bd2aa" xlink:to="loc_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentTwo_0b3f27b8-7b11-4f1c-a832-6e73a1f15ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6770b1d2-7caa-43d4-87fb-d5712b69533c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ef17a2f3-5db4-42e2-a717-c4997f6bd2aa" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6770b1d2-7caa-43d4-87fb-d5712b69533c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_237292da-e822-4469-aade-609a1fb53a01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ef17a2f3-5db4-42e2-a717-c4997f6bd2aa" xlink:to="loc_us-gaap_SubleaseIncome_237292da-e822-4469-aade-609a1fb53a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNetScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#InventoriesNetScheduleofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNetScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_6c260950-e602-4f5a-93e4-9244572def08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_1998e27a-9a55-40d6-b35b-15bbd031986b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6c260950-e602-4f5a-93e4-9244572def08" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_1998e27a-9a55-40d6-b35b-15bbd031986b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_7f8755f5-29e7-496a-9459-1e6fc31d1c54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6c260950-e602-4f5a-93e4-9244572def08" xlink:to="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_7f8755f5-29e7-496a-9459-1e6fc31d1c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_e13c7183-9fe4-4183-85b4-8ef1e3a512da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6c260950-e602-4f5a-93e4-9244572def08" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_e13c7183-9fe4-4183-85b4-8ef1e3a512da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_0fda4a94-e8d4-4155-b0a1-7e451cfd28e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6c260950-e602-4f5a-93e4-9244572def08" xlink:to="loc_us-gaap_InventoryGross_0fda4a94-e8d4-4155-b0a1-7e451cfd28e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_25dc6c3e-1326-4dc9-92e5-dc8e3fb00ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6c260950-e602-4f5a-93e4-9244572def08" xlink:to="loc_us-gaap_InventoryNoncurrent_25dc6c3e-1326-4dc9-92e5-dc8e3fb00ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_c0762dd5-bcd3-43c9-9c24-4328ce90bf61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6c260950-e602-4f5a-93e4-9244572def08" xlink:to="loc_us-gaap_InventoryNet_c0762dd5-bcd3-43c9-9c24-4328ce90bf61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNetScheduleofNonCurrentInventoriesDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#InventoriesNetScheduleofNonCurrentInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNetScheduleofNonCurrentInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_f7ac9d43-0bc3-42f8-b751-7afe145cbcdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_InventoryNoncurrentTable_e064ab12-01e9-4706-b25f-9ac1970df428" xlink:href="cpix-20231231.xsd#cpix_InventoryNoncurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_f7ac9d43-0bc3-42f8-b751-7afe145cbcdf" xlink:to="loc_cpix_InventoryNoncurrentTable_e064ab12-01e9-4706-b25f-9ac1970df428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_085888f7-4b93-4494-8ef6-0ae6d2d7d619" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_InventoryNoncurrentTable_e064ab12-01e9-4706-b25f-9ac1970df428" xlink:to="loc_srt_ProductOrServiceAxis_085888f7-4b93-4494-8ef6-0ae6d2d7d619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b81d00e9-4474-4f8c-aaef-242fd24cfb8b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_085888f7-4b93-4494-8ef6-0ae6d2d7d619" xlink:to="loc_srt_ProductsAndServicesDomain_b81d00e9-4474-4f8c-aaef-242fd24cfb8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VibativMember_14f23feb-5f6d-4d87-8ee3-6b303cb260fc" xlink:href="cpix-20231231.xsd#cpix_VibativMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b81d00e9-4474-4f8c-aaef-242fd24cfb8b" xlink:to="loc_cpix_VibativMember_14f23feb-5f6d-4d87-8ee3-6b303cb260fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember_a1943006-2a2f-4f96-a4ea-83cef08d4699" xlink:href="cpix-20231231.xsd#cpix_KristaloseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b81d00e9-4474-4f8c-aaef-242fd24cfb8b" xlink:to="loc_cpix_KristaloseMember_a1943006-2a2f-4f96-a4ea-83cef08d4699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember_f4f1b485-84b8-4d7d-8c25-6dba9f1b6e35" xlink:href="cpix-20231231.xsd#cpix_VaprisolMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b81d00e9-4474-4f8c-aaef-242fd24cfb8b" xlink:to="loc_cpix_VaprisolMember_f4f1b485-84b8-4d7d-8c25-6dba9f1b6e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember_61894e85-8993-4c16-a8b8-8d4ee7c5a5af" xlink:href="cpix-20231231.xsd#cpix_CaldolorMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b81d00e9-4474-4f8c-aaef-242fd24cfb8b" xlink:to="loc_cpix_CaldolorMember_61894e85-8993-4c16-a8b8-8d4ee7c5a5af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SancusoMember_c065ccf4-9afe-4d73-88b7-dcbf3aab6f8b" xlink:href="cpix-20231231.xsd#cpix_SancusoMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b81d00e9-4474-4f8c-aaef-242fd24cfb8b" xlink:to="loc_cpix_SancusoMember_c065ccf4-9afe-4d73-88b7-dcbf3aab6f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StudyDrugMember_c40cfb63-e28e-4ead-b92e-5e40fc4f5787" xlink:href="cpix-20231231.xsd#cpix_StudyDrugMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b81d00e9-4474-4f8c-aaef-242fd24cfb8b" xlink:to="loc_cpix_StudyDrugMember_c40cfb63-e28e-4ead-b92e-5e40fc4f5787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_00d05ff2-4f2c-44dd-8df2-0fcd369c6256" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_InventoryNoncurrentTable_e064ab12-01e9-4706-b25f-9ac1970df428" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_00d05ff2-4f2c-44dd-8df2-0fcd369c6256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_dbb45cf9-99a8-4b1d-b658-ba91a8ae43a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_00d05ff2-4f2c-44dd-8df2-0fcd369c6256" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_dbb45cf9-99a8-4b1d-b658-ba91a8ae43a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryRawMaterialsMember_add9a1aa-0df5-48c4-84ea-f8bc3ce64452" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryRawMaterialsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_dbb45cf9-99a8-4b1d-b658-ba91a8ae43a2" xlink:to="loc_us-gaap_PublicUtilitiesInventoryRawMaterialsMember_add9a1aa-0df5-48c4-84ea-f8bc3ce64452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FinishedGoodsMember_037e41fb-cf5f-4bf7-9ed7-d2ba8aef841d" xlink:href="cpix-20231231.xsd#cpix_FinishedGoodsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_dbb45cf9-99a8-4b1d-b658-ba91a8ae43a2" xlink:to="loc_cpix_FinishedGoodsMember_037e41fb-cf5f-4bf7-9ed7-d2ba8aef841d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherProductsMember_a69674b1-1c4c-4d03-9a35-fc0f2b697876" xlink:href="cpix-20231231.xsd#cpix_OtherProductsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_dbb45cf9-99a8-4b1d-b658-ba91a8ae43a2" xlink:to="loc_cpix_OtherProductsMember_a69674b1-1c4c-4d03-9a35-fc0f2b697876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_InventoryNoncurrentLineItems_97a0165c-f07e-4148-a92b-b575620cff7c" xlink:href="cpix-20231231.xsd#cpix_InventoryNoncurrentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_InventoryNoncurrentTable_e064ab12-01e9-4706-b25f-9ac1970df428" xlink:to="loc_cpix_InventoryNoncurrentLineItems_97a0165c-f07e-4148-a92b-b575620cff7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_af58bacc-164a-4232-bba4-46c5ca65766f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_InventoryNoncurrentLineItems_97a0165c-f07e-4148-a92b-b575620cff7c" xlink:to="loc_us-gaap_InventoryNoncurrent_af58bacc-164a-4232-bba4-46c5ca65766f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNetNarrativeDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#InventoriesNetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_3d7b55f5-6b95-4d1f-a7ed-9f7616e0164e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_327ebcb8-c050-40d6-8a48-3e12da76d6b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3d7b55f5-6b95-4d1f-a7ed-9f7616e0164e" xlink:to="loc_us-gaap_InventoryCurrentTable_327ebcb8-c050-40d6-8a48-3e12da76d6b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0fdb7d49-2c0d-4a7f-be75-a1e532c8e7d3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_327ebcb8-c050-40d6-8a48-3e12da76d6b7" xlink:to="loc_srt_ProductOrServiceAxis_0fdb7d49-2c0d-4a7f-be75-a1e532c8e7d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9edd3696-f21e-44b3-b574-b39c0d1e2939" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0fdb7d49-2c0d-4a7f-be75-a1e532c8e7d3" xlink:to="loc_srt_ProductsAndServicesDomain_9edd3696-f21e-44b3-b574-b39c0d1e2939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VibativMember_85c7e71e-46f1-4ddd-9322-038fc509d0c6" xlink:href="cpix-20231231.xsd#cpix_VibativMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9edd3696-f21e-44b3-b574-b39c0d1e2939" xlink:to="loc_cpix_VibativMember_85c7e71e-46f1-4ddd-9322-038fc509d0c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_4552a7b3-b9f3-425d-be51-09e324458577" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_327ebcb8-c050-40d6-8a48-3e12da76d6b7" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_4552a7b3-b9f3-425d-be51-09e324458577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_23578f4b-d7e4-46a4-aede-775d8f34d660" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_4552a7b3-b9f3-425d-be51-09e324458577" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_23578f4b-d7e4-46a4-aede-775d8f34d660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ActivePharmaceuticalIngredientAPIAndWorkInProgressMember_13dfdd1a-ea0e-4795-a575-215eb73c6604" xlink:href="cpix-20231231.xsd#cpix_ActivePharmaceuticalIngredientAPIAndWorkInProgressMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_23578f4b-d7e4-46a4-aede-775d8f34d660" xlink:to="loc_cpix_ActivePharmaceuticalIngredientAPIAndWorkInProgressMember_13dfdd1a-ea0e-4795-a575-215eb73c6604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_6975fbc1-0e0f-4a83-bfe2-ecf05673d01f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_327ebcb8-c050-40d6-8a48-3e12da76d6b7" xlink:to="loc_us-gaap_InventoryLineItems_6975fbc1-0e0f-4a83-bfe2-ecf05673d01f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_67d17ed1-ddf7-4ce7-b959-034c497ec7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_6975fbc1-0e0f-4a83-bfe2-ecf05673d01f" xlink:to="loc_us-gaap_InventoryNoncurrent_67d17ed1-ddf7-4ce7-b959-034c497ec7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_4fef41a3-1fe1-4407-b91e-503a7c59519d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_6975fbc1-0e0f-4a83-bfe2-ecf05673d01f" xlink:to="loc_us-gaap_InventoryValuationReserves_4fef41a3-1fe1-4407-b91e-503a7c59519d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_df6ade73-90bd-4592-a713-05ec20034ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d198aa0e-c1be-4385-bfd4-25af7875e620" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_df6ade73-90bd-4592-a713-05ec20034ab6" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d198aa0e-c1be-4385-bfd4-25af7875e620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0a430da3-ac38-428d-bd20-2574231f3d62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d198aa0e-c1be-4385-bfd4-25af7875e620" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0a430da3-ac38-428d-bd20-2574231f3d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4cae1cdc-31c3-4f27-8c6b-6e2f65ff936e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0a430da3-ac38-428d-bd20-2574231f3d62" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4cae1cdc-31c3-4f27-8c6b-6e2f65ff936e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_3edcba75-fd63-44ad-8cf6-7413ec50bee8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4cae1cdc-31c3-4f27-8c6b-6e2f65ff936e" xlink:to="loc_us-gaap_ComputerEquipmentMember_3edcba75-fd63-44ad-8cf6-7413ec50bee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_5d6a7cee-ee01-4cbe-a532-fdb56ecc178d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4cae1cdc-31c3-4f27-8c6b-6e2f65ff936e" xlink:to="loc_us-gaap_OfficeEquipmentMember_5d6a7cee-ee01-4cbe-a532-fdb56ecc178d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_b278793f-2571-43ce-81db-7387cb148438" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4cae1cdc-31c3-4f27-8c6b-6e2f65ff936e" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_b278793f-2571-43ce-81db-7387cb148438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_3160fd8c-5897-484d-95fd-f92cd0367315" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4cae1cdc-31c3-4f27-8c6b-6e2f65ff936e" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_3160fd8c-5897-484d-95fd-f92cd0367315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ddb4e70d-a120-4bdb-955c-4f660378c1f1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d198aa0e-c1be-4385-bfd4-25af7875e620" xlink:to="loc_srt_RangeAxis_ddb4e70d-a120-4bdb-955c-4f660378c1f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e3745dcf-e878-4951-9bfa-bf5173dc6448" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ddb4e70d-a120-4bdb-955c-4f660378c1f1" xlink:to="loc_srt_RangeMember_e3745dcf-e878-4951-9bfa-bf5173dc6448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f3a311c0-cbf3-4933-b271-b2c2b416276a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e3745dcf-e878-4951-9bfa-bf5173dc6448" xlink:to="loc_srt_MinimumMember_f3a311c0-cbf3-4933-b271-b2c2b416276a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e6386b33-0177-4668-89f6-09060b3b1094" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e3745dcf-e878-4951-9bfa-bf5173dc6448" xlink:to="loc_srt_MaximumMember_e6386b33-0177-4668-89f6-09060b3b1094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_243df088-cd11-4d42-9306-d82d269e0cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d198aa0e-c1be-4385-bfd4-25af7875e620" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_243df088-cd11-4d42-9306-d82d269e0cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_be666f68-170f-42b4-88a0-d26dfdc6bbf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_243df088-cd11-4d42-9306-d82d269e0cc2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_be666f68-170f-42b4-88a0-d26dfdc6bbf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c6a4432f-39ab-49ea-a040-c76231b04c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_243df088-cd11-4d42-9306-d82d269e0cc2" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c6a4432f-39ab-49ea-a040-c76231b04c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_95366a51-acfb-487c-80d5-1b430ebf3c35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_243df088-cd11-4d42-9306-d82d269e0cc2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_95366a51-acfb-487c-80d5-1b430ebf3c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_7b6c268c-f8e8-43a0-878a-95dee201a3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_243df088-cd11-4d42-9306-d82d269e0cc2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_7b6c268c-f8e8-43a0-878a-95dee201a3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentDepreciationExpenseDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#PropertyandEquipmentDepreciationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipmentDepreciationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_83cc9f9d-841a-4a94-8aeb-604bc33b0e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements_ecb484c1-0447-46c5-af64-29b255b1180d" xlink:href="cpix-20231231.xsd#cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_83cc9f9d-841a-4a94-8aeb-604bc33b0e6f" xlink:to="loc_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements_ecb484c1-0447-46c5-af64-29b255b1180d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b4f8a5a4-ca9b-4277-9d94-83a19d95beba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6d69f634-8857-4ecb-9729-ea2b69df2d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b4f8a5a4-ca9b-4277-9d94-83a19d95beba" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6d69f634-8857-4ecb-9729-ea2b69df2d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_964162c9-fccd-48a8-ab49-b154446ea7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6d69f634-8857-4ecb-9729-ea2b69df2d6f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_964162c9-fccd-48a8-ab49-b154446ea7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_908bea33-3623-4ad6-8387-f5a2201cfe31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_964162c9-fccd-48a8-ab49-b154446ea7f2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_908bea33-3623-4ad6-8387-f5a2201cfe31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductAndLicenseRightsMember_1361a826-055e-462a-9f1c-c3a22b708c77" xlink:href="cpix-20231231.xsd#cpix_ProductAndLicenseRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_908bea33-3623-4ad6-8387-f5a2201cfe31" xlink:to="loc_cpix_ProductAndLicenseRightsMember_1361a826-055e-462a-9f1c-c3a22b708c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_5a8d7031-883c-4710-af85-ccfe50ac3f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_908bea33-3623-4ad6-8387-f5a2201cfe31" xlink:to="loc_us-gaap_PatentsMember_5a8d7031-883c-4710-af85-ccfe50ac3f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_e47717d8-1c37-4362-b102-a0a4747023fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_908bea33-3623-4ad6-8387-f5a2201cfe31" xlink:to="loc_us-gaap_TrademarksMember_e47717d8-1c37-4362-b102-a0a4747023fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cffed7f3-44f4-44e2-9225-9e426007b213" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6d69f634-8857-4ecb-9729-ea2b69df2d6f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cffed7f3-44f4-44e2-9225-9e426007b213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5ed00638-f98c-4da6-97f1-dfe7443b0ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cffed7f3-44f4-44e2-9225-9e426007b213" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5ed00638-f98c-4da6-97f1-dfe7443b0ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e5361ddb-b6e8-4328-b1d6-4995b7f86eea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cffed7f3-44f4-44e2-9225-9e426007b213" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e5361ddb-b6e8-4328-b1d6-4995b7f86eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f868e6b3-ef55-4c47-8e0c-eb1066624ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cffed7f3-44f4-44e2-9225-9e426007b213" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f868e6b3-ef55-4c47-8e0c-eb1066624ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ecd86ea9-da67-4ea3-92bd-4a94bfcc5fce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cffed7f3-44f4-44e2-9225-9e426007b213" xlink:to="loc_us-gaap_Goodwill_ecd86ea9-da67-4ea3-92bd-4a94bfcc5fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#IntangibleAssetsandGoodwillNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cce18a78-dee4-40dc-81d6-e1596b5de5c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_24cda440-9c7c-4155-b615-63eafd5cea4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cce18a78-dee4-40dc-81d6-e1596b5de5c4" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_24cda440-9c7c-4155-b615-63eafd5cea4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_171d3b88-05bc-4728-983c-c343997e51d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_24cda440-9c7c-4155-b615-63eafd5cea4b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_171d3b88-05bc-4728-983c-c343997e51d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_71cce40d-5425-47bd-acac-f07374ebf8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_171d3b88-05bc-4728-983c-c343997e51d0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_71cce40d-5425-47bd-acac-f07374ebf8e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_1e04cb14-05e7-4612-9a14-b834db1810ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_71cce40d-5425-47bd-acac-f07374ebf8e5" xlink:to="loc_us-gaap_PatentsMember_1e04cb14-05e7-4612-9a14-b834db1810ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9ed88d9c-3756-46af-9b4a-418a25b325d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_24cda440-9c7c-4155-b615-63eafd5cea4b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9ed88d9c-3756-46af-9b4a-418a25b325d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_dd812d5b-278b-4218-9272-605231191c36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9ed88d9c-3756-46af-9b4a-418a25b325d5" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_dd812d5b-278b-4218-9272-605231191c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillAmortizationExpenseDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#IntangibleAssetsandGoodwillAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4d2ba2e3-44b0-4528-9d05-7b7900552dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_4de72330-a1d0-4edb-b584-90d3e6009bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4d2ba2e3-44b0-4528-9d05-7b7900552dc9" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_4de72330-a1d0-4edb-b584-90d3e6009bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cec1963b-e2e8-471c-b997-1262216bc2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_59af1732-95a0-42d1-8739-94b0b41d09e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cec1963b-e2e8-471c-b997-1262216bc2b3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_59af1732-95a0-42d1-8739-94b0b41d09e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1d0fdf00-b0a2-4057-9d4b-bf1f07d4a263" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cec1963b-e2e8-471c-b997-1262216bc2b3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1d0fdf00-b0a2-4057-9d4b-bf1f07d4a263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c893d2c3-ad80-4e3f-b30e-6665332fbbd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cec1963b-e2e8-471c-b997-1262216bc2b3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c893d2c3-ad80-4e3f-b30e-6665332fbbd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0415fc7b-82b3-468d-98c8-0004e7f869a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cec1963b-e2e8-471c-b997-1262216bc2b3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0415fc7b-82b3-468d-98c8-0004e7f869a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFourAndAfter_455aa745-2d2f-4a04-8f85-8b9ceaa03ce6" xlink:href="cpix-20231231.xsd#cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFourAndAfter"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cec1963b-e2e8-471c-b997-1262216bc2b3" xlink:to="loc_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFourAndAfter_455aa745-2d2f-4a04-8f85-8b9ceaa03ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8cd0457a-34e9-4b0f-a309-27aa7ec3e691" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cec1963b-e2e8-471c-b997-1262216bc2b3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8cd0457a-34e9-4b0f-a309-27aa7ec3e691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrentAbstract_be168977-2693-4a89-8294-bb2bcf2b7d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductSalesRelatedLiabilitiesCurrent_00872e78-426e-44d2-a4bb-fdcd8d6b0f13" xlink:href="cpix-20231231.xsd#cpix_ProductSalesRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_be168977-2693-4a89-8294-bb2bcf2b7d6a" xlink:to="loc_cpix_ProductSalesRelatedLiabilitiesCurrent_00872e78-426e-44d2-a4bb-fdcd8d6b0f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ccb0bff8-05f7-4ee7-b601-99c64d68b10b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_be168977-2693-4a89-8294-bb2bcf2b7d6a" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ccb0bff8-05f7-4ee7-b601-99c64d68b10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccruedLiabilitiesStockPayable_6705fb51-3026-49e0-a63d-3a482d68ec89" xlink:href="cpix-20231231.xsd#cpix_AccruedLiabilitiesStockPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_be168977-2693-4a89-8294-bb2bcf2b7d6a" xlink:to="loc_cpix_AccruedLiabilitiesStockPayable_6705fb51-3026-49e0-a63d-3a482d68ec89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent_0b92d25c-f591-4b0a-8918-34e786324467" xlink:href="cpix-20231231.xsd#cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_be168977-2693-4a89-8294-bb2bcf2b7d6a" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent_0b92d25c-f591-4b0a-8918-34e786324467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccruedLiabilitiesStudies_6974fed9-7d20-47ca-9013-9d0d197e3b18" xlink:href="cpix-20231231.xsd#cpix_AccruedLiabilitiesStudies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_be168977-2693-4a89-8294-bb2bcf2b7d6a" xlink:to="loc_cpix_AccruedLiabilitiesStudies_6974fed9-7d20-47ca-9013-9d0d197e3b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccruedLiabilitiesInventoryPurchases_deeabda6-91b1-4b75-bbb3-e5c14dc87f3e" xlink:href="cpix-20231231.xsd#cpix_AccruedLiabilitiesInventoryPurchases"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_be168977-2693-4a89-8294-bb2bcf2b7d6a" xlink:to="loc_cpix_AccruedLiabilitiesInventoryPurchases_deeabda6-91b1-4b75-bbb3-e5c14dc87f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e0dedd14-22a6-4488-b1a9-a52c262a92e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_be168977-2693-4a89-8294-bb2bcf2b7d6a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e0dedd14-22a6-4488-b1a9-a52c262a92e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_150dc42f-5123-4187-8b65-a6dd7d54bf0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_be168977-2693-4a89-8294-bb2bcf2b7d6a" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_150dc42f-5123-4187-8b65-a6dd7d54bf0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3a9526bf-a799-4ff7-ab07-ceb53ea2d5b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_be168977-2693-4a89-8294-bb2bcf2b7d6a" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3a9526bf-a799-4ff7-ab07-ceb53ea2d5b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofNoncurrentLiabilitiesDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#OtherCurrentandOtherLongtermLiabilitiesScheduleofNoncurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofNoncurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_f0d8005a-e59d-4a23-a8fa-bfbc59ffd096" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8205c7e5-ec7d-4bf0-a289-35c875c8ec82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_f0d8005a-e59d-4a23-a8fa-bfbc59ffd096" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8205c7e5-ec7d-4bf0-a289-35c875c8ec82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_cb903e4f-366a-4793-8b0d-e2ec5954d018" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_f0d8005a-e59d-4a23-a8fa-bfbc59ffd096" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_cb903e4f-366a-4793-8b0d-e2ec5954d018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_5ef34d6e-9fd2-41cc-9613-957eb024004c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_f0d8005a-e59d-4a23-a8fa-bfbc59ffd096" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_5ef34d6e-9fd2-41cc-9613-957eb024004c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_5fa2c29c-2320-4ca5-8a77-02e60f212aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_f0d8005a-e59d-4a23-a8fa-bfbc59ffd096" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_5fa2c29c-2320-4ca5-8a77-02e60f212aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DebtDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#DebtDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/DebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_445a93fb-d450-41af-95bd-7621b4d8afee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_1de68344-e696-4e00-afcc-035d7486e576" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_445a93fb-d450-41af-95bd-7621b4d8afee" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_1de68344-e696-4e00-afcc-035d7486e576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_7c5e1a66-3357-4829-aa2f-2cb1d76cf195" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1de68344-e696-4e00-afcc-035d7486e576" xlink:to="loc_us-gaap_CreditFacilityAxis_7c5e1a66-3357-4829-aa2f-2cb1d76cf195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_0a7028e4-819b-4847-b11b-106d044b1e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_7c5e1a66-3357-4829-aa2f-2cb1d76cf195" xlink:to="loc_us-gaap_CreditFacilityDomain_0a7028e4-819b-4847-b11b-106d044b1e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_032045f9-d069-4cf5-8a09-9a81ff4f77e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_0a7028e4-819b-4847-b11b-106d044b1e3f" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_032045f9-d069-4cf5-8a09-9a81ff4f77e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b1bf2cf0-092a-4b17-b41f-1fb7d75ac5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1de68344-e696-4e00-afcc-035d7486e576" xlink:to="loc_us-gaap_DebtInstrumentAxis_b1bf2cf0-092a-4b17-b41f-1fb7d75ac5e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_cd9151b2-9da0-45f7-816f-9a36e9726636" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b1bf2cf0-092a-4b17-b41f-1fb7d75ac5e5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_cd9151b2-9da0-45f7-816f-9a36e9726636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_59a3bbe3-d924-4d56-89b4-3146308c6d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cd9151b2-9da0-45f7-816f-9a36e9726636" xlink:to="loc_us-gaap_LineOfCreditMember_59a3bbe3-d924-4d56-89b4-3146308c6d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_7df9ddc4-7d96-4f11-9192-570b6fe2d01d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1de68344-e696-4e00-afcc-035d7486e576" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_7df9ddc4-7d96-4f11-9192-570b6fe2d01d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_ed49afd9-3580-4fcf-94e7-b1a3bce483d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_7df9ddc4-7d96-4f11-9192-570b6fe2d01d" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_ed49afd9-3580-4fcf-94e7-b1a3bce483d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_d1f0a75c-b5be-422d-a715-cf3cf64fda76" xlink:href="cpix-20231231.xsd#cpix_PinnacleBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_ed49afd9-3580-4fcf-94e7-b1a3bce483d1" xlink:to="loc_cpix_PinnacleBankMember_d1f0a75c-b5be-422d-a715-cf3cf64fda76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2d7fa6f3-4727-4364-8659-3edd1e67ae44" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1de68344-e696-4e00-afcc-035d7486e576" xlink:to="loc_srt_RangeAxis_2d7fa6f3-4727-4364-8659-3edd1e67ae44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_65b87a4e-0a23-44a5-a99e-675b04dbf9d8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2d7fa6f3-4727-4364-8659-3edd1e67ae44" xlink:to="loc_srt_RangeMember_65b87a4e-0a23-44a5-a99e-675b04dbf9d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c48a2079-7fe0-46ec-b63f-5cb004c7763f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_65b87a4e-0a23-44a5-a99e-675b04dbf9d8" xlink:to="loc_srt_MaximumMember_c48a2079-7fe0-46ec-b63f-5cb004c7763f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_55194cb0-d52f-4514-986f-8bfd86223ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1de68344-e696-4e00-afcc-035d7486e576" xlink:to="loc_us-gaap_VariableRateAxis_55194cb0-d52f-4514-986f-8bfd86223ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_703a7cd1-70df-4b74-9d0b-87bfce24a76a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_55194cb0-d52f-4514-986f-8bfd86223ba8" xlink:to="loc_us-gaap_VariableRateDomain_703a7cd1-70df-4b74-9d0b-87bfce24a76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_710d7dc2-6499-4bc2-8257-79f4f98411ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_703a7cd1-70df-4b74-9d0b-87bfce24a76a" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_710d7dc2-6499-4bc2-8257-79f4f98411ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_4eb69cfb-bafb-4870-83f3-7b4e7cd498a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1de68344-e696-4e00-afcc-035d7486e576" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_4eb69cfb-bafb-4870-83f3-7b4e7cd498a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7a8369d5-4237-49a8-805f-314b710a92bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4eb69cfb-bafb-4870-83f3-7b4e7cd498a8" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7a8369d5-4237-49a8-805f-314b710a92bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_04d4e97b-bca0-467c-8bfe-61f527646b15" xlink:href="cpix-20231231.xsd#cpix_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4eb69cfb-bafb-4870-83f3-7b4e7cd498a8" xlink:to="loc_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_04d4e97b-bca0-467c-8bfe-61f527646b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_4bc41295-b3ac-4f5a-b842-3aff6ed1f870" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4eb69cfb-bafb-4870-83f3-7b4e7cd498a8" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_4bc41295-b3ac-4f5a-b842-3aff6ed1f870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a2cef141-b411-4685-87a5-ca14aa51e286" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4eb69cfb-bafb-4870-83f3-7b4e7cd498a8" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a2cef141-b411-4685-87a5-ca14aa51e286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_006ef66b-9d58-4c17-96df-f7b66486c85b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4eb69cfb-bafb-4870-83f3-7b4e7cd498a8" xlink:to="loc_us-gaap_LongTermLineOfCredit_006ef66b-9d58-4c17-96df-f7b66486c85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_96aa9683-6c94-4f82-9b1e-c0890dd2a497" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4eb69cfb-bafb-4870-83f3-7b4e7cd498a8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_96aa9683-6c94-4f82-9b1e-c0890dd2a497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#ShareholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_3a68af20-f2e3-4011-a0df-149e51e3c990" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_9719192b-f9c7-440a-94c6-ff4e98ff7d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_3a68af20-f2e3-4011-a0df-149e51e3c990" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_9719192b-f9c7-440a-94c6-ff4e98ff7d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e764330d-1b82-405c-8cbd-2bb21b972c83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9719192b-f9c7-440a-94c6-ff4e98ff7d6b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e764330d-1b82-405c-8cbd-2bb21b972c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_da914f78-dc43-4b6f-b0f3-ecca2954c413" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e764330d-1b82-405c-8cbd-2bb21b972c83" xlink:to="loc_us-gaap_ClassOfStockDomain_da914f78-dc43-4b6f-b0f3-ecca2954c413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9177634d-ae0f-46bd-9ea0-4129766757f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_da914f78-dc43-4b6f-b0f3-ecca2954c413" xlink:to="loc_us-gaap_CommonStockMember_9177634d-ae0f-46bd-9ea0-4129766757f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_74401797-0e4f-4493-aa1f-602a74c20126" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9719192b-f9c7-440a-94c6-ff4e98ff7d6b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_74401797-0e4f-4493-aa1f-602a74c20126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9ea832a8-1842-4731-9099-82f945559c98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_74401797-0e4f-4493-aa1f-602a74c20126" xlink:to="loc_us-gaap_EquityComponentDomain_9ea832a8-1842-4731-9099-82f945559c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_00841bab-78f7-4650-a6b7-8481730024ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9ea832a8-1842-4731-9099-82f945559c98" xlink:to="loc_us-gaap_CommonStockMember_00841bab-78f7-4650-a6b7-8481730024ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_14ad4998-0e9c-4287-a220-1fa7c30e2eac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9719192b-f9c7-440a-94c6-ff4e98ff7d6b" xlink:to="loc_us-gaap_ClassOfStockLineItems_14ad4998-0e9c-4287-a220-1fa7c30e2eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockTransactionDate_45b0dfd8-d053-49b4-b307-b60d54301600" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockTransactionDate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_14ad4998-0e9c-4287-a220-1fa7c30e2eac" xlink:to="loc_us-gaap_SaleOfStockTransactionDate_45b0dfd8-d053-49b4-b307-b60d54301600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a23f3925-3bb7-49c2-8487-268f64cf32ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_14ad4998-0e9c-4287-a220-1fa7c30e2eac" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a23f3925-3bb7-49c2-8487-268f64cf32ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodPricePerShareNewIssues_c00b78ba-fa3c-4d15-93aa-9a3e04d0c861" xlink:href="cpix-20231231.xsd#cpix_StockIssuedDuringPeriodPricePerShareNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_14ad4998-0e9c-4287-a220-1fa7c30e2eac" xlink:to="loc_cpix_StockIssuedDuringPeriodPricePerShareNewIssues_c00b78ba-fa3c-4d15-93aa-9a3e04d0c861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering_7c57f8ac-a821-4c6b-8bb4-9073a2f667ce" xlink:href="cpix-20231231.xsd#cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_14ad4998-0e9c-4287-a220-1fa7c30e2eac" xlink:to="loc_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering_7c57f8ac-a821-4c6b-8bb4-9073a2f667ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts_a5cd235d-9c5c-479d-8730-0f094fb591f7" xlink:href="cpix-20231231.xsd#cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_14ad4998-0e9c-4287-a220-1fa7c30e2eac" xlink:to="loc_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts_a5cd235d-9c5c-479d-8730-0f094fb591f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_39985b50-36be-41ae-bab4-28217dc5492c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_14ad4998-0e9c-4287-a220-1fa7c30e2eac" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_39985b50-36be-41ae-bab4-28217dc5492c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_f0bc3d75-4e33-4b26-95a0-bde04ffab3bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_14ad4998-0e9c-4287-a220-1fa7c30e2eac" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_f0bc3d75-4e33-4b26-95a0-bde04ffab3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_ee656809-ca76-4ce2-89b7-e8088292e309" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_14ad4998-0e9c-4287-a220-1fa7c30e2eac" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_ee656809-ca76-4ce2-89b7-e8088292e309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_7e530bd2-b32a-425e-9be2-83525d75d37b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_14ad4998-0e9c-4287-a220-1fa7c30e2eac" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_7e530bd2-b32a-425e-9be2-83525d75d37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_39e7d8cd-9450-40a5-b465-fbab667a6570" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_14ad4998-0e9c-4287-a220-1fa7c30e2eac" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_39e7d8cd-9450-40a5-b465-fbab667a6570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_bf7e530d-eabc-4a8d-948f-7005b29f8ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_14ad4998-0e9c-4287-a220-1fa7c30e2eac" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_bf7e530d-eabc-4a8d-948f-7005b29f8ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_5001fb0c-c4e2-4d6b-811e-20dc5da3d56a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_14ad4998-0e9c-4287-a220-1fa7c30e2eac" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_5001fb0c-c4e2-4d6b-811e-20dc5da3d56a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_41b2fcd8-0305-47af-be92-a56ddf86d540" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_14ad4998-0e9c-4287-a220-1fa7c30e2eac" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_41b2fcd8-0305-47af-be92-a56ddf86d540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_b0fe270e-cb99-4831-8b39-2f21223b1ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_14ad4998-0e9c-4287-a220-1fa7c30e2eac" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_b0fe270e-cb99-4831-8b39-2f21223b1ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#LossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0f45fa9f-f8df-4dc2-8876-e3e3cacd0950" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_afde934f-3787-4246-b14b-4c1040868d00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0f45fa9f-f8df-4dc2-8876-e3e3cacd0950" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_afde934f-3787-4246-b14b-4c1040868d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6cc8d2af-b960-43c5-b3a5-efc6502243ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_afde934f-3787-4246-b14b-4c1040868d00" xlink:to="loc_us-gaap_ProfitLoss_6cc8d2af-b960-43c5-b3a5-efc6502243ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d0cf8a45-3a1e-4ae4-8f17-e942ec46c3c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_afde934f-3787-4246-b14b-4c1040868d00" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d0cf8a45-3a1e-4ae4-8f17-e942ec46c3c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_449873a8-f698-4c6a-8670-1ef469398fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_afde934f-3787-4246-b14b-4c1040868d00" xlink:to="loc_us-gaap_NetIncomeLoss_449873a8-f698-4c6a-8670-1ef469398fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_ecdf4170-87ec-4441-afe3-24403846f37c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0f45fa9f-f8df-4dc2-8876-e3e3cacd0950" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_ecdf4170-87ec-4441-afe3-24403846f37c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_aed22111-94dd-4184-8bd6-7b7cc744bb04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_ecdf4170-87ec-4441-afe3-24403846f37c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_aed22111-94dd-4184-8bd6-7b7cc744bb04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fab31841-9045-4400-a3ee-fc71b6e5c63e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_ecdf4170-87ec-4441-afe3-24403846f37c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fab31841-9045-4400-a3ee-fc71b6e5c63e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#LossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_eea90b96-e9ae-46bc-a833-ebd683cf0245" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2502960f-3b0c-40ec-bbdf-56655e8e4cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_eea90b96-e9ae-46bc-a833-ebd683cf0245" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2502960f-3b0c-40ec-bbdf-56655e8e4cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6dcbc571-9216-4ced-a0a7-486eedc9dc22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_e226dff1-9ddb-4dc6-9bb4-ff7dc7555cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6dcbc571-9216-4ced-a0a7-486eedc9dc22" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_e226dff1-9ddb-4dc6-9bb4-ff7dc7555cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_839455d2-1c95-4126-9800-442603969930" xlink:href="cpix-20231231.xsd#cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_e226dff1-9ddb-4dc6-9bb4-ff7dc7555cc4" xlink:to="loc_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_839455d2-1c95-4126-9800-442603969930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles_f6a31477-35a2-44cf-b9fb-0c8d5859ad17" xlink:href="cpix-20231231.xsd#cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_e226dff1-9ddb-4dc6-9bb4-ff7dc7555cc4" xlink:to="loc_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles_f6a31477-35a2-44cf-b9fb-0c8d5859ad17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetOperatingLeaseLiabilities_d4eca198-c90a-4a7b-a169-e9f70c83afd3" xlink:href="cpix-20231231.xsd#cpix_DeferredTaxAssetOperatingLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_e226dff1-9ddb-4dc6-9bb4-ff7dc7555cc4" xlink:to="loc_cpix_DeferredTaxAssetOperatingLeaseLiabilities_d4eca198-c90a-4a7b-a169-e9f70c83afd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_154dbd47-2a76-4104-92a1-0c9387d524f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_e226dff1-9ddb-4dc6-9bb4-ff7dc7555cc4" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_154dbd47-2a76-4104-92a1-0c9387d524f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_fffcf4e3-f141-4df2-b0d1-358ff979fff0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_e226dff1-9ddb-4dc6-9bb4-ff7dc7555cc4" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_fffcf4e3-f141-4df2-b0d1-358ff979fff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_a387d531-dfe6-489d-84a1-6858f1655d05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_e226dff1-9ddb-4dc6-9bb4-ff7dc7555cc4" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_a387d531-dfe6-489d-84a1-6858f1655d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct_f7786707-b7d2-4710-bcd0-c088997cfe80" xlink:href="cpix-20231231.xsd#cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_e226dff1-9ddb-4dc6-9bb4-ff7dc7555cc4" xlink:to="loc_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct_f7786707-b7d2-4710-bcd0-c088997cfe80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_1ca6baeb-3a7a-4418-9d27-e08e2dd85a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_e226dff1-9ddb-4dc6-9bb4-ff7dc7555cc4" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_1ca6baeb-3a7a-4418-9d27-e08e2dd85a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsDeferredCharges_e1acbfb9-c895-47d5-9a3c-40c8f28691a7" xlink:href="cpix-20231231.xsd#cpix_DeferredTaxAssetsDeferredCharges"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_e226dff1-9ddb-4dc6-9bb4-ff7dc7555cc4" xlink:to="loc_cpix_DeferredTaxAssetsDeferredCharges_e1acbfb9-c895-47d5-9a3c-40c8f28691a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_5bd5f44e-f450-45d9-99c2-58903d5dc34a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_e226dff1-9ddb-4dc6-9bb4-ff7dc7555cc4" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_5bd5f44e-f450-45d9-99c2-58903d5dc34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_ceb37667-9759-4961-ab68-3d4c86f8bff9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_e226dff1-9ddb-4dc6-9bb4-ff7dc7555cc4" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_ceb37667-9759-4961-ab68-3d4c86f8bff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_8d090178-80b9-4aa5-b395-90fccb1c9903" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6dcbc571-9216-4ced-a0a7-486eedc9dc22" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_8d090178-80b9-4aa5-b395-90fccb1c9903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets_740f0c86-3cd1-4a2b-9083-fcf49d4064af" xlink:href="cpix-20231231.xsd#cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_8d090178-80b9-4aa5-b395-90fccb1c9903" xlink:to="loc_cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets_740f0c86-3cd1-4a2b-9083-fcf49d4064af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_10a6041a-1ff4-4ac8-9758-b87180de0fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_8d090178-80b9-4aa5-b395-90fccb1c9903" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_10a6041a-1ff4-4ac8-9758-b87180de0fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NetDeferredTaxAssetsGross_4b6b3af1-90a7-4c98-8ffb-e3d17d2d3b9d" xlink:href="cpix-20231231.xsd#cpix_NetDeferredTaxAssetsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_8d090178-80b9-4aa5-b395-90fccb1c9903" xlink:to="loc_cpix_NetDeferredTaxAssetsGross_4b6b3af1-90a7-4c98-8ffb-e3d17d2d3b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b297497a-f66f-4aa0-9d38-d0d0525c6308" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_8d090178-80b9-4aa5-b395-90fccb1c9903" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b297497a-f66f-4aa0-9d38-d0d0525c6308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_fec85319-23b3-427d-854f-6c5e56655284" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_8d090178-80b9-4aa5-b395-90fccb1c9903" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_fec85319-23b3-427d-854f-6c5e56655284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ea01d599-6aab-4cc9-a026-a4dbef53647e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_cc9a9969-1bf9-4c20-9a87-6c91266b4134" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ea01d599-6aab-4cc9-a026-a4dbef53647e" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_cc9a9969-1bf9-4c20-9a87-6c91266b4134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodAxis_ea8db3f5-63b7-49c4-b4b0-9579f26ffef3" xlink:href="cpix-20231231.xsd#cpix_ExpirationTimePeriodAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_cc9a9969-1bf9-4c20-9a87-6c91266b4134" xlink:to="loc_cpix_ExpirationTimePeriodAxis_ea8db3f5-63b7-49c4-b4b0-9579f26ffef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodDomain_45784715-3a54-42cf-bc97-27da1698f0dc" xlink:href="cpix-20231231.xsd#cpix_ExpirationTimePeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ExpirationTimePeriodAxis_ea8db3f5-63b7-49c4-b4b0-9579f26ffef3" xlink:to="loc_cpix_ExpirationTimePeriodDomain_45784715-3a54-42cf-bc97-27da1698f0dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermOneMember_59c9a518-72c2-414c-baa9-ce48633ff12b" xlink:href="cpix-20231231.xsd#cpix_ExpirationTermOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ExpirationTimePeriodDomain_45784715-3a54-42cf-bc97-27da1698f0dc" xlink:to="loc_cpix_ExpirationTermOneMember_59c9a518-72c2-414c-baa9-ce48633ff12b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermTwoMember_a1931c70-490a-41fe-9f6a-d17f9d539ef8" xlink:href="cpix-20231231.xsd#cpix_ExpirationTermTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ExpirationTimePeriodDomain_45784715-3a54-42cf-bc97-27da1698f0dc" xlink:to="loc_cpix_ExpirationTermTwoMember_a1931c70-490a-41fe-9f6a-d17f9d539ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IndefiniteMember_319b71b9-e97c-42bb-a2fb-0afdc9aca126" xlink:href="cpix-20231231.xsd#cpix_IndefiniteMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ExpirationTimePeriodDomain_45784715-3a54-42cf-bc97-27da1698f0dc" xlink:to="loc_cpix_IndefiniteMember_319b71b9-e97c-42bb-a2fb-0afdc9aca126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_237d6d29-9bb7-47a2-85e9-7d8e16d58643" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_cc9a9969-1bf9-4c20-9a87-6c91266b4134" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_237d6d29-9bb7-47a2-85e9-7d8e16d58643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_34f18908-8df6-42e5-bbae-1b1c82338a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_237d6d29-9bb7-47a2-85e9-7d8e16d58643" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_34f18908-8df6-42e5-bbae-1b1c82338a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_88129cd5-6524-4a6f-8efa-52b95f9390b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_34f18908-8df6-42e5-bbae-1b1c82338a9c" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_88129cd5-6524-4a6f-8efa-52b95f9390b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_486ddc27-a4df-4bfc-89b6-8c60a6fcf2e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_34f18908-8df6-42e5-bbae-1b1c82338a9c" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_486ddc27-a4df-4bfc-89b6-8c60a6fcf2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_4bc0f6a2-4878-4708-80fa-c519e32d2e24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_cc9a9969-1bf9-4c20-9a87-6c91266b4134" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_4bc0f6a2-4878-4708-80fa-c519e32d2e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_061eab7e-f44b-4f55-ac1d-2297b298c739" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4bc0f6a2-4878-4708-80fa-c519e32d2e24" xlink:to="loc_us-gaap_OperatingLossCarryforwards_061eab7e-f44b-4f55-ac1d-2297b298c739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_27208f2b-dfeb-4e28-b5f4-5fcc241f0670" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_9f9f053d-c0e9-4956-b54e-f3f0187aabe2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_27208f2b-dfeb-4e28-b5f4-5fcc241f0670" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_9f9f053d-c0e9-4956-b54e-f3f0187aabe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_30f5b39b-34f8-452f-af8b-64b5afb11c50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_9f9f053d-c0e9-4956-b54e-f3f0187aabe2" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_30f5b39b-34f8-452f-af8b-64b5afb11c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_f4d0904f-9a37-4a68-8401-0f9e7d1bf9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_9f9f053d-c0e9-4956-b54e-f3f0187aabe2" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_f4d0904f-9a37-4a68-8401-0f9e7d1bf9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ac18dcd9-4136-4fc6-9da8-e2cb91c4cb41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_9f9f053d-c0e9-4956-b54e-f3f0187aabe2" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ac18dcd9-4136-4fc6-9da8-e2cb91c4cb41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_99328214-ac97-4609-ac49-0039740a3f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_27208f2b-dfeb-4e28-b5f4-5fcc241f0670" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_99328214-ac97-4609-ac49-0039740a3f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_59da1126-9a70-453c-93fb-7b354f7394b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_99328214-ac97-4609-ac49-0039740a3f4c" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_59da1126-9a70-453c-93fb-7b354f7394b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_e0477ae2-4b8f-48fc-a19b-3b213997dfe6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_99328214-ac97-4609-ac49-0039740a3f4c" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_e0477ae2-4b8f-48fc-a19b-3b213997dfe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOtherTaxExpenseBenefit_75f36ea2-3239-45b1-90e9-5af033c7b5c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_99328214-ac97-4609-ac49-0039740a3f4c" xlink:to="loc_us-gaap_DeferredOtherTaxExpenseBenefit_75f36ea2-3239-45b1-90e9-5af033c7b5c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ae9dcfb5-082f-4dad-af67-be81411dcb61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_27208f2b-dfeb-4e28-b5f4-5fcc241f0670" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ae9dcfb5-082f-4dad-af67-be81411dcb61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2141a462-a72d-4859-aa0d-f188d6de4f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_cded7654-51ce-4a5e-959d-a78abae13fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2141a462-a72d-4859-aa0d-f188d6de4f3e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_cded7654-51ce-4a5e-959d-a78abae13fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_d1fd6fc8-b287-42e1-8b7f-1c5e688199b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2141a462-a72d-4859-aa0d-f188d6de4f3e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_d1fd6fc8-b287-42e1-8b7f-1c5e688199b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_d7c741ae-9a1c-4b74-bc81-5b56996eb2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2141a462-a72d-4859-aa0d-f188d6de4f3e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_d7c741ae-9a1c-4b74-bc81-5b56996eb2c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2f22ebc8-0a56-4724-9d27-9a2e4633c0a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2141a462-a72d-4859-aa0d-f188d6de4f3e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2f22ebc8-0a56-4724-9d27-9a2e4633c0a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_e80d8545-7b67-4fee-8106-230321c598c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2141a462-a72d-4859-aa0d-f188d6de4f3e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_e80d8545-7b67-4fee-8106-230321c598c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_3016aa0a-dd60-4e0a-a220-17cdd4f74c74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2141a462-a72d-4859-aa0d-f188d6de4f3e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_3016aa0a-dd60-4e0a-a220-17cdd4f74c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EffectiveIncomeTaxRateReconciliationDeferredTrueUpsPercent_4b5a28d3-f3bb-4be9-a56b-45eacefc69e2" xlink:href="cpix-20231231.xsd#cpix_EffectiveIncomeTaxRateReconciliationDeferredTrueUpsPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2141a462-a72d-4859-aa0d-f188d6de4f3e" xlink:to="loc_cpix_EffectiveIncomeTaxRateReconciliationDeferredTrueUpsPercent_4b5a28d3-f3bb-4be9-a56b-45eacefc69e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a20865b1-082e-4fc8-b266-f0d4ff3301c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2141a462-a72d-4859-aa0d-f188d6de4f3e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a20865b1-082e-4fc8-b266-f0d4ff3301c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleOfTaxCreditCarryforwardsDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#IncomeTaxesScheduleOfTaxCreditCarryforwardsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleOfTaxCreditCarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract_db624419-06c5-4bb9-a901-41320ec964da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_619533b6-8838-48b2-9c2b-0f23cb3f49da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_db624419-06c5-4bb9-a901-41320ec964da" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_619533b6-8838-48b2-9c2b-0f23cb3f49da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodAxis_46cbccde-7bc3-4eef-bdc9-25db163ee0cd" xlink:href="cpix-20231231.xsd#cpix_ExpirationTimePeriodAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_619533b6-8838-48b2-9c2b-0f23cb3f49da" xlink:to="loc_cpix_ExpirationTimePeriodAxis_46cbccde-7bc3-4eef-bdc9-25db163ee0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodDomain_10bbd2dc-b2fa-4f0d-88ff-2f6809af3cd4" xlink:href="cpix-20231231.xsd#cpix_ExpirationTimePeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ExpirationTimePeriodAxis_46cbccde-7bc3-4eef-bdc9-25db163ee0cd" xlink:to="loc_cpix_ExpirationTimePeriodDomain_10bbd2dc-b2fa-4f0d-88ff-2f6809af3cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermOneMember_b6b2a491-241a-4971-abe4-d3aa10681802" xlink:href="cpix-20231231.xsd#cpix_ExpirationTermOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ExpirationTimePeriodDomain_10bbd2dc-b2fa-4f0d-88ff-2f6809af3cd4" xlink:to="loc_cpix_ExpirationTermOneMember_b6b2a491-241a-4971-abe4-d3aa10681802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermTwoMember_b93d4faf-2747-4c61-8bca-47a28b6359a6" xlink:href="cpix-20231231.xsd#cpix_ExpirationTermTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ExpirationTimePeriodDomain_10bbd2dc-b2fa-4f0d-88ff-2f6809af3cd4" xlink:to="loc_cpix_ExpirationTermTwoMember_b93d4faf-2747-4c61-8bca-47a28b6359a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_6c48e3cd-ba22-4eb3-b749-93938cf4bde6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_619533b6-8838-48b2-9c2b-0f23cb3f49da" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_6c48e3cd-ba22-4eb3-b749-93938cf4bde6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_6cf9642b-f330-49ca-be38-5699a7ad03cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6c48e3cd-ba22-4eb3-b749-93938cf4bde6" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_6cf9642b-f330-49ca-be38-5699a7ad03cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FederalAndStateMember_ba667943-a5d4-43a7-9b70-d2b670766217" xlink:href="cpix-20231231.xsd#cpix_FederalAndStateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_6cf9642b-f330-49ca-be38-5699a7ad03cc" xlink:to="loc_cpix_FederalAndStateMember_ba667943-a5d4-43a7-9b70-d2b670766217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_f3f02b9f-91c1-41a6-8b91-12c37e91564b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_619533b6-8838-48b2-9c2b-0f23cb3f49da" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_f3f02b9f-91c1-41a6-8b91-12c37e91564b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_094d9475-47b8-42cc-a0ed-28a1db4619d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_f3f02b9f-91c1-41a6-8b91-12c37e91564b" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_094d9475-47b8-42cc-a0ed-28a1db4619d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#StockBasedCompensationPlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd2efbc3-0588-4e17-bc4f-f19783d48a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_93b8e394-7cb9-4f0f-a92d-ab179744f0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd2efbc3-0588-4e17-bc4f-f19783d48a8d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_93b8e394-7cb9-4f0f-a92d-ab179744f0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_936d7580-e922-4e8f-bf66-0967b46a0916" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_93b8e394-7cb9-4f0f-a92d-ab179744f0bb" xlink:to="loc_us-gaap_PlanNameAxis_936d7580-e922-4e8f-bf66-0967b46a0916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ac4a2255-9f65-47be-96a3-2ffcc0900dee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_936d7580-e922-4e8f-bf66-0967b46a0916" xlink:to="loc_us-gaap_PlanNameDomain_ac4a2255-9f65-47be-96a3-2ffcc0900dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LongTermIncentiveCompensationPlan2007Member_2bfa43e2-dab6-44b4-af42-ece081086d83" xlink:href="cpix-20231231.xsd#cpix_LongTermIncentiveCompensationPlan2007Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ac4a2255-9f65-47be-96a3-2ffcc0900dee" xlink:to="loc_cpix_LongTermIncentiveCompensationPlan2007Member_2bfa43e2-dab6-44b4-af42-ece081086d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DirectorsIncentivePlan2007Member_b90b6e63-3f72-4430-bdcb-3f153dfc12e0" xlink:href="cpix-20231231.xsd#cpix_DirectorsIncentivePlan2007Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ac4a2255-9f65-47be-96a3-2ffcc0900dee" xlink:to="loc_cpix_DirectorsIncentivePlan2007Member_b90b6e63-3f72-4430-bdcb-3f153dfc12e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_db0b81a5-ad9e-475a-8121-0df676aedb2b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_93b8e394-7cb9-4f0f-a92d-ab179744f0bb" xlink:to="loc_srt_TitleOfIndividualAxis_db0b81a5-ad9e-475a-8121-0df676aedb2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f5a2b2db-9d0d-4076-b6bd-52bfd0f5019b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_db0b81a5-ad9e-475a-8121-0df676aedb2b" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f5a2b2db-9d0d-4076-b6bd-52bfd0f5019b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NonprincipalOwnerMember_90f5ae73-57c6-4b55-84b9-dc571a4408aa" xlink:href="cpix-20231231.xsd#cpix_NonprincipalOwnerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f5a2b2db-9d0d-4076-b6bd-52bfd0f5019b" xlink:to="loc_cpix_NonprincipalOwnerMember_90f5ae73-57c6-4b55-84b9-dc571a4408aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrincipalOwnerMember_6c2e8a7c-c2ec-4b25-93f4-be80cd125240" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrincipalOwnerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f5a2b2db-9d0d-4076-b6bd-52bfd0f5019b" xlink:to="loc_us-gaap_PrincipalOwnerMember_6c2e8a7c-c2ec-4b25-93f4-be80cd125240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_99895dc3-476a-4db9-b059-e1e5602de254" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f5a2b2db-9d0d-4076-b6bd-52bfd0f5019b" xlink:to="loc_srt_DirectorMember_99895dc3-476a-4db9-b059-e1e5602de254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e3134829-e3a0-4e00-9cec-42b04ad3d3f6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_93b8e394-7cb9-4f0f-a92d-ab179744f0bb" xlink:to="loc_srt_RangeAxis_e3134829-e3a0-4e00-9cec-42b04ad3d3f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f70f29ca-6029-4d8d-8f65-059eac249350" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e3134829-e3a0-4e00-9cec-42b04ad3d3f6" xlink:to="loc_srt_RangeMember_f70f29ca-6029-4d8d-8f65-059eac249350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c1e4dd4e-c5f8-4706-91f8-b9121a792ed9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f70f29ca-6029-4d8d-8f65-059eac249350" xlink:to="loc_srt_MaximumMember_c1e4dd4e-c5f8-4706-91f8-b9121a792ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0608811f-178b-4037-8407-d2d0424bb5d8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f70f29ca-6029-4d8d-8f65-059eac249350" xlink:to="loc_srt_MinimumMember_0608811f-178b-4037-8407-d2d0424bb5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ad7d73eb-352e-4368-9745-c7359e9b5179" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_93b8e394-7cb9-4f0f-a92d-ab179744f0bb" xlink:to="loc_us-gaap_AwardTypeAxis_ad7d73eb-352e-4368-9745-c7359e9b5179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_79dff463-f21b-4cf8-928d-6729fa5db2fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ad7d73eb-352e-4368-9745-c7359e9b5179" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_79dff463-f21b-4cf8-928d-6729fa5db2fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a8a8bf41-a58d-4a3e-809b-61f51b15df37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_79dff463-f21b-4cf8-928d-6729fa5db2fb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a8a8bf41-a58d-4a3e-809b-61f51b15df37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_02b69354-f460-4dc7-b072-8ecb3d364d18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_79dff463-f21b-4cf8-928d-6729fa5db2fb" xlink:to="loc_us-gaap_RestrictedStockMember_02b69354-f460-4dc7-b072-8ecb3d364d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b882f42-843d-434f-ace0-fc17c99a22df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_93b8e394-7cb9-4f0f-a92d-ab179744f0bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b882f42-843d-434f-ace0-fc17c99a22df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants_84400b2b-6bdd-4885-8b9d-9f6485c7a42a" xlink:href="cpix-20231231.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b882f42-843d-434f-ace0-fc17c99a22df" xlink:to="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants_84400b2b-6bdd-4885-8b9d-9f6485c7a42a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_740442dd-84d3-4312-8efa-4b3dc1512223" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b882f42-843d-434f-ace0-fc17c99a22df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_740442dd-84d3-4312-8efa-4b3dc1512223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_fceb6d89-a883-4c61-b83f-b825a49abfcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b882f42-843d-434f-ace0-fc17c99a22df" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_fceb6d89-a883-4c61-b83f-b825a49abfcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue_dae171dd-dcfe-4f2a-9f6e-973b6248c962" xlink:href="cpix-20231231.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b882f42-843d-434f-ace0-fc17c99a22df" xlink:to="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue_dae171dd-dcfe-4f2a-9f6e-973b6248c962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent_cf3246f4-9601-4937-b58a-06a47724d50d" xlink:href="cpix-20231231.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b882f42-843d-434f-ace0-fc17c99a22df" xlink:to="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent_cf3246f4-9601-4937-b58a-06a47724d50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_7375359c-ac18-4eba-bc45-cb3ba6cc18bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b882f42-843d-434f-ace0-fc17c99a22df" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_7375359c-ac18-4eba-bc45-cb3ba6cc18bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e14ec98c-7da6-4245-9ebd-c4f6c5b84189" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b882f42-843d-434f-ace0-fc17c99a22df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e14ec98c-7da6-4245-9ebd-c4f6c5b84189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_79ae1659-d100-41fc-afea-00f695cbb0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b882f42-843d-434f-ace0-fc17c99a22df" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_79ae1659-d100-41fc-afea-00f695cbb0c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_80446f48-d664-48f1-8f72-d09b73351945" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b882f42-843d-434f-ace0-fc17c99a22df" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_80446f48-d664-48f1-8f72-d09b73351945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_670ed5a1-2ab9-41a5-aa30-0082d65e18ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b882f42-843d-434f-ace0-fc17c99a22df" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_670ed5a1-2ab9-41a5-aa30-0082d65e18ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_73d719b1-82eb-4492-bf5a-e2d413c11609" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b882f42-843d-434f-ace0-fc17c99a22df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_73d719b1-82eb-4492-bf5a-e2d413c11609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_b088c026-8f6f-4cbd-989f-065014dd9a66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b882f42-843d-434f-ace0-fc17c99a22df" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_b088c026-8f6f-4cbd-989f-065014dd9a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_55e65324-ce0c-4d92-b0a3-c28eda7037a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b882f42-843d-434f-ace0-fc17c99a22df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_55e65324-ce0c-4d92-b0a3-c28eda7037a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b8a31c9e-cc46-412c-b5ea-4f759551cee7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b882f42-843d-434f-ace0-fc17c99a22df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b8a31c9e-cc46-412c-b5ea-4f759551cee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_9f932a1c-f217-44ff-bf91-87898fc6ca8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b882f42-843d-434f-ace0-fc17c99a22df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_9f932a1c-f217-44ff-bf91-87898fc6ca8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_3a2372d6-a014-4642-9d1a-8babe5a2e459" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b882f42-843d-434f-ace0-fc17c99a22df" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_3a2372d6-a014-4642-9d1a-8babe5a2e459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansStockOptionsActivityDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#StockBasedCompensationPlansStockOptionsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansStockOptionsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_869c52a4-a740-47fa-9d38-69cd24e378aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8fc7b483-73f7-464c-9710-cbfdb59ae6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_869c52a4-a740-47fa-9d38-69cd24e378aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8fc7b483-73f7-464c-9710-cbfdb59ae6f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3ed04d2f-bdb6-4d02-bce1-0fe43de29ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8fc7b483-73f7-464c-9710-cbfdb59ae6f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3ed04d2f-bdb6-4d02-bce1-0fe43de29ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ce9ae2f1-1de0-4648-a14b-ba1c0407451d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8fc7b483-73f7-464c-9710-cbfdb59ae6f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ce9ae2f1-1de0-4648-a14b-ba1c0407451d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f47585cf-e399-4b17-881c-0bbc2a74e3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8fc7b483-73f7-464c-9710-cbfdb59ae6f6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f47585cf-e399-4b17-881c-0bbc2a74e3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_0be4e7c8-ae67-4be9-b3ca-5dd2b16804a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8fc7b483-73f7-464c-9710-cbfdb59ae6f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_0be4e7c8-ae67-4be9-b3ca-5dd2b16804a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b596bcab-b007-4b4f-a83d-3c5f63f6a9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8fc7b483-73f7-464c-9710-cbfdb59ae6f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b596bcab-b007-4b4f-a83d-3c5f63f6a9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70ebdf76-3dbe-404a-9728-32e6d03124af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_869c52a4-a740-47fa-9d38-69cd24e378aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70ebdf76-3dbe-404a-9728-32e6d03124af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a17a6d5c-f218-4f6b-b278-b84dd85d8155" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70ebdf76-3dbe-404a-9728-32e6d03124af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a17a6d5c-f218-4f6b-b278-b84dd85d8155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_80ca4ebc-99c4-4f86-ad30-554feabeaaeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70ebdf76-3dbe-404a-9728-32e6d03124af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_80ca4ebc-99c4-4f86-ad30-554feabeaaeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_93531a1b-bb4a-4659-86f3-0cb2b1292bac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70ebdf76-3dbe-404a-9728-32e6d03124af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_93531a1b-bb4a-4659-86f3-0cb2b1292bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_75ac4e77-a9b3-4693-947a-597a4aa0830b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70ebdf76-3dbe-404a-9728-32e6d03124af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_75ac4e77-a9b3-4693-947a-597a4aa0830b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9e79d7a8-a9fe-4ff6-8273-4f747cb0439a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70ebdf76-3dbe-404a-9728-32e6d03124af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9e79d7a8-a9fe-4ff6-8273-4f747cb0439a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a1468053-e150-45d5-afee-445812875051" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_869c52a4-a740-47fa-9d38-69cd24e378aa" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a1468053-e150-45d5-afee-445812875051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansValuationAssumptionsDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#StockBasedCompensationPlansValuationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dd3502c0-1916-4fc3-944a-8ff78588015c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a079d2d-616c-4814-9ce5-61b84571cfd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dd3502c0-1916-4fc3-944a-8ff78588015c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a079d2d-616c-4814-9ce5-61b84571cfd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9f2126d7-4f6a-4015-ad0a-67f997f11777" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a079d2d-616c-4814-9ce5-61b84571cfd2" xlink:to="loc_us-gaap_AwardTypeAxis_9f2126d7-4f6a-4015-ad0a-67f997f11777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c4f054c6-cd4c-44bb-9b44-d94815ef88ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9f2126d7-4f6a-4015-ad0a-67f997f11777" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c4f054c6-cd4c-44bb-9b44-d94815ef88ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_950716c0-4837-4ca6-9c56-4cbc8789d008" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c4f054c6-cd4c-44bb-9b44-d94815ef88ba" xlink:to="loc_us-gaap_EmployeeStockOptionMember_950716c0-4837-4ca6-9c56-4cbc8789d008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49cc5629-c582-4269-8864-e43fb2e94b22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a079d2d-616c-4814-9ce5-61b84571cfd2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49cc5629-c582-4269-8864-e43fb2e94b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_55ccf454-b07e-4c89-b974-581811df9307" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49cc5629-c582-4269-8864-e43fb2e94b22" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_55ccf454-b07e-4c89-b974-581811df9307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_85831f30-568f-4e60-8823-50a8e1baf2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49cc5629-c582-4269-8864-e43fb2e94b22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_85831f30-568f-4e60-8823-50a8e1baf2e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e63eb401-c43d-4661-968c-fe620b4da01b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49cc5629-c582-4269-8864-e43fb2e94b22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e63eb401-c43d-4661-968c-fe620b4da01b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_dd8c0501-31ed-440c-b9e6-064b8194f0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49cc5629-c582-4269-8864-e43fb2e94b22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_dd8c0501-31ed-440c-b9e6-064b8194f0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansRestrictedStockActivityDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#StockBasedCompensationPlansRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a35eb472-b3bb-45b6-8258-aae29834d3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2ff4e30-2018-42f2-9881-69039b29755e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a35eb472-b3bb-45b6-8258-aae29834d3d4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2ff4e30-2018-42f2-9881-69039b29755e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6a794dbd-5ec4-480d-a18d-410f77012a87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2ff4e30-2018-42f2-9881-69039b29755e" xlink:to="loc_us-gaap_AwardTypeAxis_6a794dbd-5ec4-480d-a18d-410f77012a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99eb772f-d724-41b9-a781-91c01275c096" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6a794dbd-5ec4-480d-a18d-410f77012a87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99eb772f-d724-41b9-a781-91c01275c096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_75041e58-f747-4913-bf35-e414fedf9180" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99eb772f-d724-41b9-a781-91c01275c096" xlink:to="loc_us-gaap_RestrictedStockMember_75041e58-f747-4913-bf35-e414fedf9180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7bc0c164-8c1c-422b-b5c4-5a1903ee5060" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2ff4e30-2018-42f2-9881-69039b29755e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7bc0c164-8c1c-422b-b5c4-5a1903ee5060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_76a6e497-92f0-45fc-9a24-1be1189f821f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7bc0c164-8c1c-422b-b5c4-5a1903ee5060" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_76a6e497-92f0-45fc-9a24-1be1189f821f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f1d8c976-7397-4dee-a272-f725e2e2d848" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_76a6e497-92f0-45fc-9a24-1be1189f821f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f1d8c976-7397-4dee-a272-f725e2e2d848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_670418b2-81b1-4846-a76b-7dd212f0bd17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_76a6e497-92f0-45fc-9a24-1be1189f821f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_670418b2-81b1-4846-a76b-7dd212f0bd17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_14b9f658-6e39-4dc6-961f-5c1f4a4bbdf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_76a6e497-92f0-45fc-9a24-1be1189f821f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_14b9f658-6e39-4dc6-961f-5c1f4a4bbdf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_29c97060-e357-4519-967f-c7f8037c2c50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_76a6e497-92f0-45fc-9a24-1be1189f821f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_29c97060-e357-4519-967f-c7f8037c2c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_05fe627d-31d4-4d0b-9c56-cfeb488d85b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_76a6e497-92f0-45fc-9a24-1be1189f821f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_05fe627d-31d4-4d0b-9c56-cfeb488d85b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7c3ff650-a3ca-481e-82b0-2088a6a6e04a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7bc0c164-8c1c-422b-b5c4-5a1903ee5060" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7c3ff650-a3ca-481e-82b0-2088a6a6e04a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1d2fa527-49be-4c7e-911e-60d248e12f00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7c3ff650-a3ca-481e-82b0-2088a6a6e04a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1d2fa527-49be-4c7e-911e-60d248e12f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ddae03da-f73c-4630-bba7-bf02f45eabd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7c3ff650-a3ca-481e-82b0-2088a6a6e04a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ddae03da-f73c-4630-bba7-bf02f45eabd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_fcf6d04e-f78b-4d22-a2cc-d930b48f0538" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7c3ff650-a3ca-481e-82b0-2088a6a6e04a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_fcf6d04e-f78b-4d22-a2cc-d930b48f0538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e3af2d19-6889-4ab0-8622-b31ccf2bec03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7c3ff650-a3ca-481e-82b0-2088a6a6e04a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e3af2d19-6889-4ab0-8622-b31ccf2bec03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_befd23dc-d027-424a-b1c7-a59293504247" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7c3ff650-a3ca-481e-82b0-2088a6a6e04a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_befd23dc-d027-424a-b1c7-a59293504247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EmployeeBenefitPlansDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#EmployeeBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EmployeeBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsAbstract_c7e93929-978f-4083-baad-d3288d54f13e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PostemploymentBenefitsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge_53506f6b-1cd4-42c4-8f8a-e2595fa54175" xlink:href="cpix-20231231.xsd#cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_c7e93929-978f-4083-baad-d3288d54f13e" xlink:to="loc_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge_53506f6b-1cd4-42c4-8f8a-e2595fa54175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility_5223ae51-7f11-488a-9d0b-d1a79803ce89" xlink:href="cpix-20231231.xsd#cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_c7e93929-978f-4083-baad-d3288d54f13e" xlink:to="loc_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility_5223ae51-7f11-488a-9d0b-d1a79803ce89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_34db34df-6eaa-436d-ae05-51d244e48644" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_c7e93929-978f-4083-baad-d3288d54f13e" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_34db34df-6eaa-436d-ae05-51d244e48644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_85127b27-acb6-416f-ae9c-abfdc9b80143" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_c7e93929-978f-4083-baad-d3288d54f13e" xlink:to="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_85127b27-acb6-416f-ae9c-abfdc9b80143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationPlanAssets_3551cb03-c516-4619-975a-105bc42df110" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationPlanAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_c7e93929-978f-4083-baad-d3288d54f13e" xlink:to="loc_us-gaap_DeferredCompensationPlanAssets_3551cb03-c516-4619-975a-105bc42df110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3caba8e8-5f50-415d-84c0-29c2cc41a56a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_a3b56b6b-6e75-4ba0-9ce6-81cc83c24378" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3caba8e8-5f50-415d-84c0-29c2cc41a56a" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_a3b56b6b-6e75-4ba0-9ce6-81cc83c24378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b3a7b8f7-8276-4227-8a38-2dc2abd014ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a3b56b6b-6e75-4ba0-9ce6-81cc83c24378" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b3a7b8f7-8276-4227-8a38-2dc2abd014ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f0248e6-6de7-4c0d-a32e-9f98ad5c546c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b3a7b8f7-8276-4227-8a38-2dc2abd014ea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f0248e6-6de7-4c0d-a32e-9f98ad5c546c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficeBuildingMember_3cfff126-5bf5-4155-89f2-a6d5f02e085d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OfficeBuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f0248e6-6de7-4c0d-a32e-9f98ad5c546c" xlink:to="loc_srt_OfficeBuildingMember_3cfff126-5bf5-4155-89f2-a6d5f02e085d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_0f45376c-8eae-439b-9fda-6791e54b33ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a3b56b6b-6e75-4ba0-9ce6-81cc83c24378" xlink:to="loc_us-gaap_LeaseContractualTermAxis_0f45376c-8eae-439b-9fda-6791e54b33ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_54f8045d-d125-41a4-92cb-435de203dd65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_0f45376c-8eae-439b-9fda-6791e54b33ee" xlink:to="loc_us-gaap_LeaseContractualTermDomain_54f8045d-d125-41a4-92cb-435de203dd65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BroadwestLeaseFiveYearRenewalOptionMember_404c10e9-0744-45ae-9b80-389050db96e4" xlink:href="cpix-20231231.xsd#cpix_BroadwestLeaseFiveYearRenewalOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_54f8045d-d125-41a4-92cb-435de203dd65" xlink:to="loc_cpix_BroadwestLeaseFiveYearRenewalOptionMember_404c10e9-0744-45ae-9b80-389050db96e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_522dcdf0-6af0-41c7-87b6-bbef13e9da24" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a3b56b6b-6e75-4ba0-9ce6-81cc83c24378" xlink:to="loc_srt_CounterpartyNameAxis_522dcdf0-6af0-41c7-87b6-bbef13e9da24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e3ef61fd-a65b-45fe-b1a3-43b9579f508d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_522dcdf0-6af0-41c7-87b6-bbef13e9da24" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e3ef61fd-a65b-45fe-b1a3-43b9579f508d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_A1600WestEndAvenuePartnersLLCMember_100d0739-1962-4540-a1a7-894858cc1014" xlink:href="cpix-20231231.xsd#cpix_A1600WestEndAvenuePartnersLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e3ef61fd-a65b-45fe-b1a3-43b9579f508d" xlink:to="loc_cpix_A1600WestEndAvenuePartnersLLCMember_100d0739-1962-4540-a1a7-894858cc1014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NephronPharmaceuticalsCorporationNephronMember_b686f5a7-6708-4a77-9a7e-e83b1ceaeec1" xlink:href="cpix-20231231.xsd#cpix_NephronPharmaceuticalsCorporationNephronMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e3ef61fd-a65b-45fe-b1a3-43b9579f508d" xlink:to="loc_cpix_NephronPharmaceuticalsCorporationNephronMember_b686f5a7-6708-4a77-9a7e-e83b1ceaeec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_db08a750-0b63-4914-a501-59c2ce9f9448" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a3b56b6b-6e75-4ba0-9ce6-81cc83c24378" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_db08a750-0b63-4914-a501-59c2ce9f9448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseLeasedArea_a3e761f3-c64c-4c12-a90b-52eb101e3534" xlink:href="cpix-20231231.xsd#cpix_LesseeOperatingLeaseLeasedArea"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_db08a750-0b63-4914-a501-59c2ce9f9448" xlink:to="loc_cpix_LesseeOperatingLeaseLeasedArea_a3e761f3-c64c-4c12-a90b-52eb101e3534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_7fe8d1c6-eedb-4b81-a931-5843228fb761" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_db08a750-0b63-4914-a501-59c2ce9f9448" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_7fe8d1c6-eedb-4b81-a931-5843228fb761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseNumberOfRenewalTerms_1bdb3c85-68f4-41d4-a3a9-2f225b57cc2c" xlink:href="cpix-20231231.xsd#cpix_LesseeOperatingLeaseNumberOfRenewalTerms"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_db08a750-0b63-4914-a501-59c2ce9f9448" xlink:to="loc_cpix_LesseeOperatingLeaseNumberOfRenewalTerms_1bdb3c85-68f4-41d4-a3a9-2f225b57cc2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_532f14ce-5296-4721-bd76-0fde9e67d2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_db08a750-0b63-4914-a501-59c2ce9f9448" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_532f14ce-5296-4721-bd76-0fde9e67d2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseBaseRent_e649a8de-800a-464b-887f-fb5780d82f2f" xlink:href="cpix-20231231.xsd#cpix_LesseeOperatingLeaseBaseRent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_db08a750-0b63-4914-a501-59c2ce9f9448" xlink:to="loc_cpix_LesseeOperatingLeaseBaseRent_e649a8de-800a-464b-887f-fb5780d82f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseRentIncrease_aaf02735-9b23-45ae-9043-f4efe37ff31d" xlink:href="cpix-20231231.xsd#cpix_LesseeOperatingLeaseRentIncrease"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_db08a750-0b63-4914-a501-59c2ce9f9448" xlink:to="loc_cpix_LesseeOperatingLeaseRentIncrease_aaf02735-9b23-45ae-9043-f4efe37ff31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_c9945358-3872-448d-9b0a-f728683bac5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_db08a750-0b63-4914-a501-59c2ce9f9448" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_c9945358-3872-448d-9b0a-f728683bac5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_ab96c40e-2359-47f3-8b06-2b81a9c8b78a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_db08a750-0b63-4914-a501-59c2ce9f9448" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_ab96c40e-2359-47f3-8b06-2b81a9c8b78a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e961dbab-ce12-4b51-8340-7e95abde12ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_db08a750-0b63-4914-a501-59c2ce9f9448" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e961dbab-ce12-4b51-8340-7e95abde12ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2c959adc-9909-4c4f-9578-759432b7a863" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_db08a750-0b63-4914-a501-59c2ce9f9448" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2c959adc-9909-4c4f-9578-759432b7a863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f0d35eb9-2146-4715-9db8-d6b2a0d70854" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_db08a750-0b63-4914-a501-59c2ce9f9448" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f0d35eb9-2146-4715-9db8-d6b2a0d70854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_7213511b-b5fe-48ce-9e04-0645ec0d5ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_db08a750-0b63-4914-a501-59c2ce9f9448" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_7213511b-b5fe-48ce-9e04-0645ec0d5ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#LeasesScheduleofRentExpenseandSubleaseIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e06dce57-3bb9-4179-b75a-19d2714ebf8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_4de557a5-f1c2-4792-b36b-09b40ac24336" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e06dce57-3bb9-4179-b75a-19d2714ebf8e" xlink:to="loc_us-gaap_OperatingLeaseExpense_4de557a5-f1c2-4792-b36b-09b40ac24336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_c435d932-13eb-45c2-9e39-95ef6b72f50c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e06dce57-3bb9-4179-b75a-19d2714ebf8e" xlink:to="loc_us-gaap_SubleaseIncome_c435d932-13eb-45c2-9e39-95ef6b72f50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#LeasesLeasePositionDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract_f1b3bb29-966d-4a70-9ca1-401d608fd0c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_42757f88-af54-420c-8d99-ca3f17d1e73d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_f1b3bb29-966d-4a70-9ca1-401d608fd0c6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_42757f88-af54-420c-8d99-ca3f17d1e73d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_49d79568-08c0-4f0d-9c35-3fc80830ece0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_f1b3bb29-966d-4a70-9ca1-401d608fd0c6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_49d79568-08c0-4f0d-9c35-3fc80830ece0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c1987456-bb67-4a36-a37d-6571203f31c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_f1b3bb29-966d-4a70-9ca1-401d608fd0c6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c1987456-bb67-4a36-a37d-6571203f31c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3b5665e0-41d9-48e2-875f-f6693c758455" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_f1b3bb29-966d-4a70-9ca1-401d608fd0c6" xlink:to="loc_us-gaap_OperatingLeaseLiability_3b5665e0-41d9-48e2-875f-f6693c758455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3224bd35-46e8-4998-b531-e80a15398e9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2958b6ae-4a01-4b12-931f-f583c18a5bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3224bd35-46e8-4998-b531-e80a15398e9d" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2958b6ae-4a01-4b12-931f-f583c18a5bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d6563b83-0a50-40e1-9c19-7fec3ec970ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2958b6ae-4a01-4b12-931f-f583c18a5bd5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d6563b83-0a50-40e1-9c19-7fec3ec970ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_63b59f00-d415-453d-9546-3c559783a6db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2958b6ae-4a01-4b12-931f-f583c18a5bd5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_63b59f00-d415-453d-9546-3c559783a6db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5199cca4-3210-4db1-91c9-0d8d76bb85b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2958b6ae-4a01-4b12-931f-f583c18a5bd5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5199cca4-3210-4db1-91c9-0d8d76bb85b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_18a8f0c5-92af-4fff-98b9-5bea0b56d83e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2958b6ae-4a01-4b12-931f-f583c18a5bd5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_18a8f0c5-92af-4fff-98b9-5bea0b56d83e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1c9cfdbb-995d-498f-b6fe-da703e1f1a47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2958b6ae-4a01-4b12-931f-f583c18a5bd5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1c9cfdbb-995d-498f-b6fe-da703e1f1a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1759fb81-9984-4124-8cd4-cc90441cbdbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2958b6ae-4a01-4b12-931f-f583c18a5bd5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1759fb81-9984-4124-8cd4-cc90441cbdbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fba1ab99-a479-4ea4-8cb5-30758f59e6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2958b6ae-4a01-4b12-931f-f583c18a5bd5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fba1ab99-a479-4ea4-8cb5-30758f59e6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ecd6b9d7-8f56-497d-89ec-88652fd9c4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2958b6ae-4a01-4b12-931f-f583c18a5bd5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ecd6b9d7-8f56-497d-89ec-88652fd9c4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a94e09a5-3e6c-4438-b257-00e824d054a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2958b6ae-4a01-4b12-931f-f583c18a5bd5" xlink:to="loc_us-gaap_OperatingLeaseLiability_a94e09a5-3e6c-4438-b257-00e824d054a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1" xlink:type="simple" xlink:href="cpix-20231231.xsd#LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_426869b7-f726-42da-ba41-cfaddd60cc38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_0e8f9144-7432-45e7-adc5-a490e8a83066" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_426869b7-f726-42da-ba41-cfaddd60cc38" xlink:to="loc_us-gaap_ConcentrationRiskTable_0e8f9144-7432-45e7-adc5-a490e8a83066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_bebc1183-5681-4cae-b67d-ed605d00f691" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_0e8f9144-7432-45e7-adc5-a490e8a83066" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_bebc1183-5681-4cae-b67d-ed605d00f691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_61516898-9deb-4f73-90d1-e018ca777e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_bebc1183-5681-4cae-b67d-ed605d00f691" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_61516898-9deb-4f73-90d1-e018ca777e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_397c6a0f-d2b3-4725-939e-635d793ee746" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_61516898-9deb-4f73-90d1-e018ca777e8e" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_397c6a0f-d2b3-4725-939e-635d793ee746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7d981cdc-1d17-4787-817e-dc3837d0cc59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_0e8f9144-7432-45e7-adc5-a490e8a83066" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7d981cdc-1d17-4787-817e-dc3837d0cc59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e8920037-9a2f-4d5c-8bcc-f1bf0d523c77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7d981cdc-1d17-4787-817e-dc3837d0cc59" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e8920037-9a2f-4d5c-8bcc-f1bf0d523c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SalesRevenueGoodsGrossMember_e432cff3-3bcd-4f3f-9f13-0e49cdb8eff1" xlink:href="cpix-20231231.xsd#cpix_SalesRevenueGoodsGrossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e8920037-9a2f-4d5c-8bcc-f1bf0d523c77" xlink:to="loc_cpix_SalesRevenueGoodsGrossMember_e432cff3-3bcd-4f3f-9f13-0e49cdb8eff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_3ff18beb-f54d-4af6-90e5-085585dda25d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e8920037-9a2f-4d5c-8bcc-f1bf0d523c77" xlink:to="loc_us-gaap_AccountsReceivableMember_3ff18beb-f54d-4af6-90e5-085585dda25d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_3444af84-ca75-4e63-984b-31c0573458b6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_0e8f9144-7432-45e7-adc5-a490e8a83066" xlink:to="loc_srt_MajorCustomersAxis_3444af84-ca75-4e63-984b-31c0573458b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_fc6e2722-6c0c-4945-ac21-c0f574d11ba0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_3444af84-ca75-4e63-984b-31c0573458b6" xlink:to="loc_srt_NameOfMajorCustomerDomain_fc6e2722-6c0c-4945-ac21-c0f574d11ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CustomerOneMember_f36c7dd5-aa74-4378-b9f8-5f2ac929d45d" xlink:href="cpix-20231231.xsd#cpix_CustomerOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_fc6e2722-6c0c-4945-ac21-c0f574d11ba0" xlink:to="loc_cpix_CustomerOneMember_f36c7dd5-aa74-4378-b9f8-5f2ac929d45d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CustomerTwoMember_782d68ba-8027-4629-ae64-ec74af5600de" xlink:href="cpix-20231231.xsd#cpix_CustomerTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_fc6e2722-6c0c-4945-ac21-c0f574d11ba0" xlink:to="loc_cpix_CustomerTwoMember_782d68ba-8027-4629-ae64-ec74af5600de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CustomerThreeMember_7014e488-2137-4171-8283-402473b378fa" xlink:href="cpix-20231231.xsd#cpix_CustomerThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_fc6e2722-6c0c-4945-ac21-c0f574d11ba0" xlink:to="loc_cpix_CustomerThreeMember_7014e488-2137-4171-8283-402473b378fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_Customer12And3Member_9bcc6a41-7851-4b18-b724-63ee05ed615f" xlink:href="cpix-20231231.xsd#cpix_Customer12And3Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_fc6e2722-6c0c-4945-ac21-c0f574d11ba0" xlink:to="loc_cpix_Customer12And3Member_9bcc6a41-7851-4b18-b724-63ee05ed615f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_850651cb-8cdf-41f7-8175-5dba3a493ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_0e8f9144-7432-45e7-adc5-a490e8a83066" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_850651cb-8cdf-41f7-8175-5dba3a493ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_09a81088-15ab-4d6b-9e15-f3a529e00d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_850651cb-8cdf-41f7-8175-5dba3a493ea1" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_09a81088-15ab-4d6b-9e15-f3a529e00d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingAndSupplyAgreementsAbstract_feb6913f-074a-46d3-81f0-a06f4841af2b" xlink:href="cpix-20231231.xsd#cpix_ManufacturingAndSupplyAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingandSupplyAgreementTable_1419c6be-c66f-47c7-8840-9aa563df94d2" xlink:href="cpix-20231231.xsd#cpix_ManufacturingandSupplyAgreementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ManufacturingAndSupplyAgreementsAbstract_feb6913f-074a-46d3-81f0-a06f4841af2b" xlink:to="loc_cpix_ManufacturingandSupplyAgreementTable_1419c6be-c66f-47c7-8840-9aa563df94d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3f9587e4-9bd6-4cde-9129-2f0d9e3ab049" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ManufacturingandSupplyAgreementTable_1419c6be-c66f-47c7-8840-9aa563df94d2" xlink:to="loc_srt_RangeAxis_3f9587e4-9bd6-4cde-9129-2f0d9e3ab049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_22078f62-d143-4547-8be5-fbb9ea52fbe9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3f9587e4-9bd6-4cde-9129-2f0d9e3ab049" xlink:to="loc_srt_RangeMember_22078f62-d143-4547-8be5-fbb9ea52fbe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2712859b-75d9-4cd7-bd87-5f69e76f4dd4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_22078f62-d143-4547-8be5-fbb9ea52fbe9" xlink:to="loc_srt_MinimumMember_2712859b-75d9-4cd7-bd87-5f69e76f4dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ef2c340d-3d29-4fca-b115-9a87010427ea" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_22078f62-d143-4547-8be5-fbb9ea52fbe9" xlink:to="loc_srt_MaximumMember_ef2c340d-3d29-4fca-b115-9a87010427ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingandSupplyAgreementLineItems_29d9a674-de9a-4c7a-99f8-3c5f76e84442" xlink:href="cpix-20231231.xsd#cpix_ManufacturingandSupplyAgreementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ManufacturingandSupplyAgreementTable_1419c6be-c66f-47c7-8840-9aa563df94d2" xlink:to="loc_cpix_ManufacturingandSupplyAgreementLineItems_29d9a674-de9a-4c7a-99f8-3c5f76e84442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct_d279d894-9997-450b-bd0e-e94dc586800d" xlink:href="cpix-20231231.xsd#cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ManufacturingandSupplyAgreementLineItems_29d9a674-de9a-4c7a-99f8-3c5f76e84442" xlink:to="loc_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct_d279d894-9997-450b-bd0e-e94dc586800d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_535ac63a-cd64-4d32-a5a7-7927a8b2b7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_64d83f98-59f9-4079-9454-40b467f4f385" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_535ac63a-cd64-4d32-a5a7-7927a8b2b7c7" xlink:to="loc_us-gaap_OtherCommitmentsTable_64d83f98-59f9-4079-9454-40b467f4f385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_de0eafbb-f148-447a-9541-7755c8165f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_64d83f98-59f9-4079-9454-40b467f4f385" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_de0eafbb-f148-447a-9541-7755c8165f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_faee813f-aaf9-4958-809e-28327df67a03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_de0eafbb-f148-447a-9541-7755c8165f8a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_faee813f-aaf9-4958-809e-28327df67a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_U.S.ProductAssetRightsSancusoMember_436e4cd6-edeb-4f77-9a51-4c5bb862392f" xlink:href="cpix-20231231.xsd#cpix_U.S.ProductAssetRightsSancusoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_faee813f-aaf9-4958-809e-28327df67a03" xlink:to="loc_cpix_U.S.ProductAssetRightsSancusoMember_436e4cd6-edeb-4f77-9a51-4c5bb862392f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e875fceb-199f-4453-aeaa-6e13284761e5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_64d83f98-59f9-4079-9454-40b467f4f385" xlink:to="loc_srt_RangeAxis_e875fceb-199f-4453-aeaa-6e13284761e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_242062a5-ac7a-4f53-b23f-b00c6a9e3a7c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e875fceb-199f-4453-aeaa-6e13284761e5" xlink:to="loc_srt_RangeMember_242062a5-ac7a-4f53-b23f-b00c6a9e3a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1c28be22-dd8c-47d9-9a36-aa41bea18c62" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_242062a5-ac7a-4f53-b23f-b00c6a9e3a7c" xlink:to="loc_srt_MaximumMember_1c28be22-dd8c-47d9-9a36-aa41bea18c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_688e90eb-ccfa-41a8-b0ac-a6010bb46904" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_242062a5-ac7a-4f53-b23f-b00c6a9e3a7c" xlink:to="loc_srt_MinimumMember_688e90eb-ccfa-41a8-b0ac-a6010bb46904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c43c2c13-be74-46bd-9d64-982e7a072e23" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_64d83f98-59f9-4079-9454-40b467f4f385" xlink:to="loc_srt_CounterpartyNameAxis_c43c2c13-be74-46bd-9d64-982e7a072e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_31fd0ae4-cd78-440a-bfe1-c7186c921f34" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c43c2c13-be74-46bd-9d64-982e7a072e23" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_31fd0ae4-cd78-440a-bfe1-c7186c921f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember_c58bc552-16e9-43b5-af20-2db27bbd7f86" xlink:href="cpix-20231231.xsd#cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_31fd0ae4-cd78-440a-bfe1-c7186c921f34" xlink:to="loc_cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember_c58bc552-16e9-43b5-af20-2db27bbd7f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d0c51263-ce9f-49bb-b33b-2a998b8506ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_64d83f98-59f9-4079-9454-40b467f4f385" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d0c51263-ce9f-49bb-b33b-2a998b8506ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8f5325dc-93f3-4483-b602-83f2cbd36cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d0c51263-ce9f-49bb-b33b-2a998b8506ac" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8f5325dc-93f3-4483-b602-83f2cbd36cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_97a52349-6750-413c-99d7-89655405efe2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8f5325dc-93f3-4483-b602-83f2cbd36cd0" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_97a52349-6750-413c-99d7-89655405efe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdAxis_a14c6131-0c78-4043-adfa-87e0206ec233" xlink:href="cpix-20231231.xsd#cpix_CollaborativeArrangementMilestonePaymentThresholdAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_64d83f98-59f9-4079-9454-40b467f4f385" xlink:to="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdAxis_a14c6131-0c78-4043-adfa-87e0206ec233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdDomain_535d0dfa-97c0-4686-8909-3a8e0d86cc7d" xlink:href="cpix-20231231.xsd#cpix_CollaborativeArrangementMilestonePaymentThresholdDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdAxis_a14c6131-0c78-4043-adfa-87e0206ec233" xlink:to="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdDomain_535d0dfa-97c0-4686-8909-3a8e0d86cc7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_Within30DaysOfFirstSNDAFilingMember_8fdbd967-9bf5-436c-ae43-5a500056b474" xlink:href="cpix-20231231.xsd#cpix_Within30DaysOfFirstSNDAFilingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdDomain_535d0dfa-97c0-4686-8909-3a8e0d86cc7d" xlink:to="loc_cpix_Within30DaysOfFirstSNDAFilingMember_8fdbd967-9bf5-436c-ae43-5a500056b474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FollowingApprovalOfFirstSNDAMember_1163b580-ceda-4d68-b34e-e3d1f7753ab4" xlink:href="cpix-20231231.xsd#cpix_FollowingApprovalOfFirstSNDAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdDomain_535d0dfa-97c0-4686-8909-3a8e0d86cc7d" xlink:to="loc_cpix_FollowingApprovalOfFirstSNDAMember_1163b580-ceda-4d68-b34e-e3d1f7753ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_e085b3f4-2fb1-415a-bf62-0c78ead30d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_64d83f98-59f9-4079-9454-40b467f4f385" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_e085b3f4-2fb1-415a-bf62-0c78ead30d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold_828bd3c1-8654-4a5a-9cce-7f61c47e5a23" xlink:href="cpix-20231231.xsd#cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e085b3f4-2fb1-415a-bf62-0c78ead30d0d" xlink:to="loc_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold_828bd3c1-8654-4a5a-9cce-7f61c47e5a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage_95c59d9a-5cda-42e8-af32-34af80a5c49f" xlink:href="cpix-20231231.xsd#cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e085b3f4-2fb1-415a-bf62-0c78ead30d0d" xlink:to="loc_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage_95c59d9a-5cda-42e8-af32-34af80a5c49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsTerm_70b37043-e284-446a-a6d0-d05162d507b4" xlink:href="cpix-20231231.xsd#cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e085b3f4-2fb1-415a-bf62-0c78ead30d0d" xlink:to="loc_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsTerm_70b37043-e284-446a-a6d0-d05162d507b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable_d9af79fe-4544-4299-a829-436dce116abe" xlink:href="cpix-20231231.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e085b3f4-2fb1-415a-bf62-0c78ead30d0d" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable_d9af79fe-4544-4299-a829-436dce116abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLegalSettlements_fccaadc2-687a-4361-95f5-5d41fc979726" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLegalSettlements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e085b3f4-2fb1-415a-bf62-0c78ead30d0d" xlink:to="loc_us-gaap_ProceedsFromLegalSettlements_fccaadc2-687a-4361-95f5-5d41fc979726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_579f70f4-fc0d-436d-83ad-5b6485e95237" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_043477e7-80b7-4d56-a849-3d3bcbc919ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_579f70f4-fc0d-436d-83ad-5b6485e95237" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_043477e7-80b7-4d56-a849-3d3bcbc919ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_72a398d5-5ce6-4e59-8dbd-6440b7126a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_579f70f4-fc0d-436d-83ad-5b6485e95237" xlink:to="loc_us-gaap_OperatingIncomeLoss_72a398d5-5ce6-4e59-8dbd-6440b7126a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7f289ae0-9ec3-4dd8-bc3b-af67907fa726" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_579f70f4-fc0d-436d-83ad-5b6485e95237" xlink:to="loc_us-gaap_ProfitLoss_7f289ae0-9ec3-4dd8-bc3b-af67907fa726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_258bbe07-5921-4950-88dd-ba01d939eab4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_579f70f4-fc0d-436d-83ad-5b6485e95237" xlink:to="loc_us-gaap_NetIncomeLoss_258bbe07-5921-4950-88dd-ba01d939eab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_06cd518e-6377-4d87-b097-c98f9e04e3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_579f70f4-fc0d-436d-83ad-5b6485e95237" xlink:to="loc_us-gaap_EarningsPerShareAbstract_06cd518e-6377-4d87-b097-c98f9e04e3ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e25e338f-8421-4257-8c1e-a3a1ab02df80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_06cd518e-6377-4d87-b097-c98f9e04e3ff" xlink:to="loc_us-gaap_EarningsPerShareBasic_e25e338f-8421-4257-8c1e-a3a1ab02df80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_ebe778b6-c084-4fb9-ba53-3774b9ab8eba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_06cd518e-6377-4d87-b097-c98f9e04e3ff" xlink:to="loc_us-gaap_EarningsPerShareDiluted_ebe778b6-c084-4fb9-ba53-3774b9ab8eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_7f01ab87-ca58-473b-9036-ab2b8d457b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_06cd518e-6377-4d87-b097-c98f9e04e3ff" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_7f01ab87-ca58-473b-9036-ab2b8d457b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_0264fd10-3065-47e2-b4b6-a239fc1bdb04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_06cd518e-6377-4d87-b097-c98f9e04e3ff" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_0264fd10-3065-47e2-b4b6-a239fc1bdb04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails" xlink:type="simple" xlink:href="cpix-20231231.xsd#ValuationandQualifyingAccountsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_60dfc4a9-a99f-470c-8e46-4bac8aab238b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_cf5949e3-d938-491a-ae40-d363d8573c97" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_60dfc4a9-a99f-470c-8e46-4bac8aab238b" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_cf5949e3-d938-491a-ae40-d363d8573c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_79747ed1-c213-4e93-a0e5-0898249bba8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_cf5949e3-d938-491a-ae40-d363d8573c97" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_79747ed1-c213-4e93-a0e5-0898249bba8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_884c3ab0-3aab-4195-b384-8a03ad1b5006" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_79747ed1-c213-4e93-a0e5-0898249bba8d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_884c3ab0-3aab-4195-b384-8a03ad1b5006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossMember_4330f16e-e423-4527-83ee-02cece21b98d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForCreditLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_884c3ab0-3aab-4195-b384-8a03ad1b5006" xlink:to="loc_us-gaap_AllowanceForCreditLossMember_4330f16e-e423-4527-83ee-02cece21b98d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_9ccc99af-a992-485b-b2b8-7ebbafad57f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_884c3ab0-3aab-4195-b384-8a03ad1b5006" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_9ccc99af-a992-485b-b2b8-7ebbafad57f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_9d243d55-04ff-4f15-852f-9683d8639595" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_cf5949e3-d938-491a-ae40-d363d8573c97" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_9d243d55-04ff-4f15-852f-9683d8639595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_07e33499-6918-4cdd-a88d-27b2d7c63d08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_9d243d55-04ff-4f15-852f-9683d8639595" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_07e33499-6918-4cdd-a88d-27b2d7c63d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_4642aac6-be60-4dd5-a578-a695cad9bf81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_07e33499-6918-4cdd-a88d-27b2d7c63d08" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_4642aac6-be60-4dd5-a578-a695cad9bf81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_c93d0aab-1d30-41f3-a6de-0df7e1a61c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_07e33499-6918-4cdd-a88d-27b2d7c63d08" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_c93d0aab-1d30-41f3-a6de-0df7e1a61c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_b65dd8da-00a5-454d-9dc2-790d41d70b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_07e33499-6918-4cdd-a88d-27b2d7c63d08" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_b65dd8da-00a5-454d-9dc2-790d41d70b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_b4b49b0d-4bcf-43ac-b0b5-819e4f39cd2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_07e33499-6918-4cdd-a88d-27b2d7c63d08" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_b4b49b0d-4bcf-43ac-b0b5-819e4f39cd2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_000ef178-7f9d-4862-8234-7dfb3540535f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_07e33499-6918-4cdd-a88d-27b2d7c63d08" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_000ef178-7f9d-4862-8234-7dfb3540535f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>cpix-20231231_g1.jpg
<TEXT>
begin 644 cpix-20231231_g1.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@T5XUX$_X*%?L5?$WQEI_P /? ?[1WAS4M:U2Y%OI^G07#"2>4YPB[E W''
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M]H'11JVKW<5KIEA*LT<ES-*X2-%#H,EF90/J*]EH **Q_P#A/_!A\?'X6?\
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M?\%*/V%Y=8_X1V/]I+06U 2&,V*B8S;QU79Y>[(QTQ6]\-OVV/V5_C#XNG\
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M/ 6MZ]KNEQW2^)?*U+PWKUSIUW;2^:X21);=T8E2=VQLHQ #*PXJ/X5ZG?\
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MI3&?^!!UQ]10!^T4L44\30S1JZ.I5T89# ]01W%>(_\ !-6TMK+]@SX5V]I
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M"^$? _B2[2]UN7^P+_Q5?CG[;JMW,+B]FSW#3RR8ST7:.@K];?\ @I\B2?\
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MRR"$QD]@Y-?&7_!Q+96>F_L9^"M/TZTB@MX/B+:QP00QA4C0:=? *JC@  8
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M6SN+2XAG.P\$>8D;1-S]V0^@KTF]O;/3;.74=0NHX+>")I)YI7"I&BC+,Q/
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_#ND:H-0L[#2_#:R3O<"%HMTLTD^& #R8"HGW^=Q -?1]% 'C?[%?[+/B/\
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M9+?Q!IMFDDDMJP):VD1B-R;\.N3E#NQ]]L_2-% 'S]\,OV/_ (S?##]F*?\
M9;LOVH_[4TLZ3+I>G:UJ_A 2W]A921O&849;I4;8K 1ET;8!M^8!0ODW[*/_
M  1]\1?L7^,[_P <_ O]K_4[2[U33_L5_%?^#;6XBFBWJXRK2<$,H(((/4=#
M7VU10!\N^/\ _@GW\7OC1\3O!_CGXX_MK:_X@TKP=XGLM;M/"5OX7M+&PN)K
M:995$BPL"Y.TKN?<5#-MQDU],:W#K4^E3P^'-0M;2^9,6UQ>V;7$2-GJT:R1
MEQC/ =?K5JB@#X?T3_@C5=:%^U5_PV+:?M4W[^,#XFEUQQ+X1A-JT\K,7C,8
MG!\LAV3 8,%_BSS7VQI4>JPZ;#%KE[;W%XL8%Q/:6S0QN_<JC.Y0>Q9OJ:L4
M4 ?,/[>W_!+CX1?MRZKIOQ F\6:AX/\ &VD0+!9>)]*A$N^)7+HDT19-^QF8
MJRNC#)^8C %_PY^RE^V3K'AA/A[\;_V^[K6- :V%MJ!\->!+;2M4OX,89&O?
M.E,6X<,\:+(020ZDYKZ/HH P=+\#VO@7X=V?P]^$=OIN@VVDZ?%9Z)#+I[3V
MUI%& JKY2RQLX"C'WP<\DGG/R!X%_P"".%Y\/_VK?^&R-'_:HOIO&#>(KS69
MA=>$83:RSW7F^>AC6=2(V6:1<*P(!X((!K[=HH \)_;<_8-^'W[=WP?T[X??
M%/6/L.MZ1<)<Z;XHTFP >VF(43A(G=CY4H',9<X(0[B4!./^RQ^Q/\9/V1_@
MY<?!#X=_M6-J&D;Y7TB3Q!X.6XFTAI#E_LY6Z1=NXL^QU=0Q)Q@D'Z.HH \K
M_9*_9]\;_LR?"ZP^#^M?&'_A+M(TB%H]*N+W0A;7D2M(7VO*DS+(HW$#Y P[
ML<8I?VQ?V2OAK^VA\$-1^#7Q&@\HS#S]&U>.(--I=ZH(CN(\XSC)#+D;T9ER
M,Y'J=% %/P]I1T+0+'1#/YIL[.* R!<;]B!<X[9QTJY110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8_C#
MXA>!_A]_9?\ PF_BNPTK^V]8@TG2/M]RL?VR^FW>5;1Y^](^UMJCDX-;%?A+
MJTNJ_M\?&D^)_P!H#X[:Q;^*M8^/6B^%+'P?%>!3H^DW<ERDL]O"^<>2T<48
MVC"L29-S2J:_3G]DWX*?MS?LH?LE>+_A_P"._'>D_$KQ3IEK=2_#6.+49&<M
MY+"&TGFNQ$ @E"$;FPJLR[MJK@ ^H:*_**7_ ()F?M6>+/V<O''[7?[87[4'
MC3PS\2M%M-2U6PT^364E@MHK:)I%WR0RE4$A0A1"56-=N%/W1[7^PE^VO\6/
M&O\ P22\=?'7XO:]<7NN>!K'6K"PURZ<^?J'D64<MM([_P <GF3K%OZL8\L2
MQ)(!]Y45^)'[(WP+C_:-^&VC^*/B)_P6$E^'_B+6[R>&T\(ZCK$D]P%24Q(S
M,^I0[6D()5"H)!!&<BOKS_@I)\7_ (K_ /!.G_@G/X0^"W@GXOZAJOB_5;E=
M#;QLZ-#>-;(DDT]PFZ21HY2/+C#;V91(6#!@I !]]T5^//[0'P6_:%_X),:%
M\*OVM_ W[1WB77K_ ,07D4?CC1-5NW-I<W#0K.UN06/FQ,HF3+@NI174@D;?
MUY\-:_IWBSPYI_BG2)"UIJ5E%=6K$<F.1 ZG\B* +M%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\
MGYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ M
MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P#
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MVH_X0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV**
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M?_ MJ/\ A!](_P"?F]_\"VK8HH Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P#
MMJV** .6\-^&['5K![FZN;H,MQ(@V73 8!P.]:/_  @^D?\ /S>_^!;4>!_^
M01+_ -?LW_H5;% &/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M6Q10!C_P#"
M#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\
M/S>_^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\
MWO\ X%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\
M@6U;%% &/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M6Q10!C_P#"#Z1_S\WO
M_@6U'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;5
ML44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\WO\ X%M1
M_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U;%% '
MG'Q4\1^#?A9=:#'K>I7,<>L:JMH2UVWR*>LAYX5<C)[9%=?_ ,(/I'_/S>_^
M!;5\8?M7_%C_ (6E\5KG^S[G?I>D9L].VG*OM/[R0?[S9P>ZJM?37[*'Q8_X
M6E\*;;^T+G?JFD8L]1W'+/M'[N0_[RXR>[*U ':_\(/I'_/S>_\ @6U'_"#Z
M1_S\WO\ X%M6Q10!C_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M6Q10!C_ /"#
MZ1_S\WO_ (%M1_P@^D?\_-[_ .!;5L44 8__  @^D?\ /S>_^!;4?\(/I'_/
MS>_^!;5L44 8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@6U;%% &/_P (/I'_
M #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\
MX%M6Q10!C_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M6Q10!C_ /"#Z1_S\WO_
M (%M1_P@^D?\_-[_ .!;5L44 8__  @^D?\ /S>_^!;4?\(/I'_/S>_^!;5L
M44 8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@6U;%% &/_P (/I'_ #\WO_@6
MU'_"#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\ @6U9WAOPW8ZM8/<W5S=!EN)$
M&RZ8# .!WKJ:Q_ __((E_P"OV;_T*@ _X0?2/^?F]_\  MJ/^$'TC_GYO?\
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M!](_Y^;W_P "VH_X0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\
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M444 %%%% !1110 5C^!_^01+_P!?LW_H5;%8_@?_ )!$O_7[-_Z%0!L4444
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M .OT_P#H)K8K'\2_\A?1_P#K]/\ Z": -BBBB@ HHHH **** "BBB@ HHHH
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MV*Q_ _\ R")?^OV;_P!"H V**** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O!?\
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M#X/^N*_R%35#IW_(/@_ZXK_(5-0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %>"_P#!.K_DA^K_ /8]ZQ_Z
M/KWJO!?^"=7_ "0_5_\ L>]8_P#1] 'O5%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %8_B7_D+Z/\ ]?I_]!-;%8_B
M7_D+Z/\ ]?I_]!- &Q1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+J_\
MT*%[_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ $*%
M[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PDNK_]
M"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H
M7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+J_\
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M[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:
M-BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A
M)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$
MEU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%
M"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: #Q+_ ,A?1_\
MK]/_ *":V*Y37-<U&?4=-DD\-W,9CN2R(S+F0[>@K3_X275_^A0O?^^EH V*
M*Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH V**Q_P#A)=7_ .A0O?\ OI:/
M^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI: -BBL?\
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M^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\
MZ%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\
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MHK'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\
MA)=7_P"A0O?^^EH V*S?&/\ R+%[_P!<#4/_  DNK_\ 0H7O_?2U1\1Z[J5W
MH5U;S^&KJ!6A.99&7"_7% '0:=_R#X/^N*_R%35#IW_(/@_ZXK_(5-0 4444
M %%%% !1110 4444 %%%% !1110 4444 %1W=K;7UK+97D"RPS1LDL;C*NI&
M"".X(J2B@#\=OVB/V"/VP/V#/B%X7T/X#^-]'U?P%XB^.&B7O@*RU&8;[;Q
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M*BO(/@5^UUX-^*1B\.^*!'HNO-A1;ROB"Y;_ *9L>A)_@;GG +5Z_0 4444
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M ()U?\D/U?\ ['O6/_1]>]5X+_P3J_Y(?J__ &/>L?\ H^@#WJBBB@ HHHH
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q_$O\
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M2_\ (7T?_K]/_H)K8K'\2_\ (7T?_K]/_H)K8H **** "BBB@ HHHH ****
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MHHH **** "BBB@ HHHH **** "O!?^"=7_)#]7_['O6/_1]>]5X+_P $ZO\
MDA^K_P#8]ZQ_Z/H ]ZHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"$M*CT3PSHUM86D0^2WM80BCWP.I]2>35ZB@ HHHH **** "BBB@ HHHH
M**** ,?P/_R")?\ K]F_]"K8K'\#_P#((E_Z_9O_ $*MB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#'\2_\A?1_
M^OT_^@FMBL?Q+_R%]'_Z_3_Z":V* "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH \7^.?['?A7XA/+XH\!/%HFNY\P^6NVWN
M7ZY95_U;9_C7\02<UQ7P_P#VGOB5\$==3X;?M%Z)>2PQ86'4V7=/&G0-N'%P
MG^T#NZ\L>*^G:POB!\-_!GQ/T)O#WC71(KR Y,3D8DA;^\CCE3].O0Y'% %_
MPWXF\/\ C#1X?$'AC5X+ZRN%S%<6[[E/M[$=P>1WKEO@?\1_#?Q TW5X= N@
M[:7K4UO,-P.X9RL@_P!EN<'OM-?.'Q8^'_Q*_9&O9+KP)\07.BZ\LMNB&0"4
M_(0=\9X+*#Q*O0X^[D ^>?"CXN>._A-J5Y<>!+N..?4[46SB6,. =P*N >-X
M.<$Y'S'CF@#[@^*'QD\ ?"#2O[2\9ZTL<CJ3;6,.'N+C_<3/3_:.%'<BOGO5
M?B%^T%^UWJ4OASX?:8^B>&@^RYF\PI&5_P"FTP&7./\ EF@[\@]:Z'X7_L::
MQXDU7_A/OVB=;GO[V=A(VEBZ+LQ])I0>?38AP./F[5]":5I.EZ%IT.D:+IT%
MI:VZ;(+>VB")&OH .!0!YU\%?V6?AY\'TCU1H!JNM*,MJ=W&/W1_Z9)R(_KR
MWOCBO3:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ K-\8_P#(L7O_ %P-:59OC'_D6+W_ *X&@"YIW_(/@_ZXK_(5-4.G?\@^
M#_KBO\A4U !1110 4444 %%%% !1110 4444 %4/%7B72?!GAC4O&&OSF*QT
MFPFO+V4+DI#$A=SCOA5-7ZH>*_#6D^-/"^I>#M>A,ECJUA-9WL:M@M%*A1P#
MVRK&@#\]M;_::_X*'^-H?A-^UIJ/Q-TKP7\.?B%\7-"T;1?ASI>E0S7<VE7=
MRP6:[NI$+;I(HS\J$ B0, AXKZ!^&_QT_:0^&W[=>I_LO?M#7NDZSX<\;VFH
MZ]\*]=TRV$,UK;P39?3+A0 ':.)E(DY)V@EFWXC^8/BS\%/^"E7P;^'_ ,/_
M -F:R_9YM?BAX2^%WQ(TKQ#X/\7Z#K45M<WMC8RR/%8W,#DM$^V0)Y@4J@4
M>9C=7T-^S+\(OVM/C5^U!%^V?^V-X,TSP4- \/3Z/X \ :=J*W<MFMPRF>[N
M9D)4NR@( ,$@\JFP;@#ZPHHHH **_//]JS_@N&_@WXIQ_#C]ECX-:CXOM] \
M:VFF>)]=>!VMM0):57T^S\L,1-*8W$<K9R87*QR+\U?5?[$_[:WPI_;F^$S?
M%#X907=E)9WAL]:T740HN+"X"AMI*DAT92"KCAAD$!@R@ ]AHKY:_P""@?\
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M (L?\+2^*US_ &?<[]+TC-GIVTY5]I_>2#_>;.#W55KS*OIK_AW1_P!5B_\
M+>_^Z*IZ'_P3^_MFT:Z_X6UY>V9X]O\ 8.<[3C/^O% 'K/[*'Q8_X6E\*;;^
MT+G?JFD8L]1W'+/M'[N0_P"\N,GNRM7IM>/_  #_ &6=6^!7BN?7[3XG?VA:
MW=J8;S3SH_E"3G*,&\YL%3['@L.^:]@H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K-\8_P#(L7O_ %P-:59OC'_D6+W_
M *X&@"YIW_(/@_ZXK_(5-4.G?\@^#_KBO\A4U !1110 4444 %%%% !1110
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M8^&/^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0H
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M_OT* *?_  F/AC_H-0?]]4?\)CX8_P"@U!_WU5S^SM/_ .?&'_OT*/[.T_\
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MV+<&M3_A,?#'_0:@_P"^JJ>"[*SETJ1I;2)C]LE&6C!XW5K_ -G:?_SXP_\
M?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C
M#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\
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M<_L[3_\ GQA_[]"C^SM/_P"?&'_OT* *?_"8^&/^@U!_WU1_PF/AC_H-0?\
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M\)CX8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*
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M_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\
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MHH **** "BBB@ HHHH Q_ __ "")?^OV;_T*MBL?P/\ \@B7_K]F_P#0JV*
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M /:A^)_B_P )Z3JVJZ7+:2^ _AIH;V6B6X<AMV78&0KC &P '^(T ?9%%%%
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M-P12ZBMG*;"*<X1Y@AV!N1P6QGD<=Z +-M;6]G;QVEI D442!(HHU"JB@8
M'  ':GU\O_ ;_@I]\*_$$>K> /VL;*/X/_$3PM:--XD\.>*;@0P31H,FXLIF
M^6XC8#<JJ2Y!^7S%PYM?LS?MJ_$_]L+XV2:G\'_@S>6'P5TVSN4;QYX@A:WG
MUZ]!"QBSA8@B '>2V&)P WEG*$ ^EJ*** "BBB@ HHHH **** "BBB@ HHHH
M *\%_P""=7_)#]7_ .Q[UC_T?7O5>"_\$ZO^2'ZO_P!CWK'_ */H ]ZHHHH
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MN/\ :?[S?B36S10 4444 %%%% !6/XE_Y"^C_P#7Z?\ T$UL5C^)?^0OH_\
MU^G_ -!- &Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!C^!_^01+_P!?LW_H5;%8_@?_ )!$O_7[-_Z%6Q0
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M>H>*OC!^R5\9_B#+XSM?AAK:6.E:_<7#7&5\^ZMY(A*^6>)OLX>-6)*C<.F
M.;_;1_X(E>']>^+6A?%;]EC4O$&C/XB^(5BWB_2M-O($@T6SD>1[C5+8NR,K
M1-AEB4N09#L"@;1]@?L<_L6?!?\ 8A^&TOP[^$%G=RM?7(N=:UK5)5DN]1G
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MC@L]PN(JNT(5(2;[)23?X(\CB#"UL;D.+P]%7G.E4BEW<H-+\6?G3\+/#_\
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M-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\
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M!$O_ %^S?^A5L4 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\
M8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B
M\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%%
M&/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\
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M&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\
M]!NR_P# 8_XUL44 8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q10!C
M_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_ /0;LO\ P&/^
M-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C
M_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_ /0;
MLO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\ ]!NR_P# 8_XT?8O&_P#T
M&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%% &/]
MB\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\ ]!NR_P# 8_XT
M?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C5'Q':^*X]"NGU#5;62
M$0G>D<!!/T-=-6;XQ_Y%B]_ZX&@"YIW_ "#X/^N*_P A4U0Z=_R#X/\ KBO\
MA4U !1110 4444 %%%% !1110 4444 %>+?'C]N3]C#X0^(=2^#'QS^.>EZ)
MJCV 2_TNY6<2+#/'D'=&A W(V00<C->TUQGC/]G#]GGXCZ])XJ^(?P&\&:]J
MDR*DNI:UX7M+JX=5&%!DEC9B   !G@4 ?GE+\&O^#=>>0S3_ !0MW=CEF?Q/
MK!)_&O9OV"_AO_P2&\+_ ![35/V+/&<%]XU&CW*)!'K.H3G[*=OFG;/\G]WG
MKZ5])?\ #&W[(/\ T:I\-O\ PAM/_P#C-:_@C]G?]G_X9ZX/$_PW^!G@[P_J
M0B:(:AHGABTM)PC8W)YD4:MM.!D9P<4 =C1110 4444 %%%% !1110 4444
M%%%% !7@O_!.K_DA^K_]CWK'_H^O>J\%_P""=7_)#]7_ .Q[UC_T?0![U111
M0 4444 %-DBCFC:*:-71AAE89!'H13J*&DT!QGBC]GOX,>,-SZS\/=/$C=9K
M.,V[D^I:(J2?KFO.?%'[!7@2^+3>$?%^HZ:YY5+I%N(P?08V,/Q)KWFBOF<Q
MX-X6S:[Q.$@V^J7++_P*-G^)R5<!@ZWQP7Y?BCYI_P"%%_M=_#/Y_A_\1CJ4
M"?ZNVCU$]/\ KE<#RQ^!-'_#3?[2WPW/E_$[X5_:8(_OW+V,D&[_ +:IF/\
M):^EJ.O6O#_U#J8'7*<QKT.T7+VD%_VY+_,YO[-=/^!5E'RO=?<SQ'PO^W;\
M+]5VQ>)M$U/29#]YPBSQ+^*D-_XY7H.A_%WX,_$. 6>F>--'OA+TM+F15=O^
MV<N&/Y5+XH^"OPG\9[F\1^ -,GD?[TZ6PBE/_ TPWZUYSXH_83^%VJ[I?#6M
M:GI,A^ZGF">)?P;#?^/TT_$O*W=>PQ<5ZTJC_P#;$#6:TU9\M1?<_P#([S7O
MV=_@)XH!;7?@UX8N7;K,VB0"3_OL*&_6N*U__@GU^R9K^YV^%JV<A_Y:6&J7
M,6/HHDV_I7(']F/]I3X;GS/AA\5/M$"?<MDO9+?=Z?NGW1G\6H_X7E^UY\,_
MD\?_  Z.I6\?^LN7TXXQ_P!=;<^6/Q!KU</XM<09+ICZ&+PUMY1<ITU_V]!_
MH>3B<%D>(_W[ 1]73C)??8@U[_@E/^S_ *ANDT/Q5XGTYS]U1>0RQC\&BW?^
M/5R&H_\ !)O4=+N#?^!/C_-;RC_5K<:.48?]M(YL_P#CM>I^&/V]O M\5A\7
M>#]1TYSP7M9%N$!]3G8P_ &O1O"_[0WP7\7[5T?XAZ>LC](;R0V[D^@$H7)^
MF:^YR;QTQ&.2CA<VC._V9\MW\JD>8\B7!/ &/=XX>*?]V4H/[E)?D?+_ /PQ
MM_P4 \#_ #>"/VD/M4*?<MQXGO4S_P!LY$*?K09_^"L_@+[\3:S;IT^73;G=
M^6):^T8I8IXUFAD5T895E.01Z@TZOKO]?\;77^U83#UO.5)7^]-%?\0^P-'_
M '3&8FC_ (:KM]S3/BO_ (;4_;U\$?+X\_9K\^%/O7!\,WT6?^VBN4_(5:TS
M_@K1+83_ &'QO\ [BVE7_6-;:SAA_P!LY(01_P!]5]E56U/1M(UJ#[+K.E6U
MW%_SSN8%D7\F!I_ZR\*XC_><HAZPJ3A^"NA_ZL<68;_=<XG;M4IPG^+LSYOT
M#_@JI^SSJ6V/6O#OB?37/WFDL898Q^*2EC_WS7:Z#^W]^R9X@VI%\6(K60]8
M[_3KF''U9H]OZUU6O?LQ_L[^)MS:S\$_##NWWI8M&BB<_P# D4-^M<5K_P#P
M3K_9,US<T/P[FT^1NLEAJ]ROY*SLH_*E[;PXQ/QTL12?]V4)+_R;4/8>)6%^
M"KAJR_O1G!_^2Z'H&@_M ? OQ1M'A_XQ>&+MVZ11:Y!O_P"^=VX?E75VMW:W
ML*W-E<QS1M]V2)PRGZ$5\O:__P $G_@=>Y?P]XZ\36#'HLTL$Z#Z#RU/_CU<
MI<_\$J/&/AZ9KSX>?M$-!(>5$NF26[#ZO%,V?RH_L7@;$_P<SE3?:=&3_&+L
M']M\>8;^-E<:B[TZT5^$E<\4_P""AO\ R>%XO_[A_P#Z;[:O%J[3]H;P#XU^
M&'QAUCP+\1/%/]M:Q8?9Q=:G]IDF\X/;QR)\\H#'$;(O/3;@< 5Q=?TWD%*G
M0R+"TJ<U.,:<$I+:244DUY/<_ESB"M4Q&?8NK4@X2E5J-Q>\6YMN+\UL%?IW
M_P $\O\ DSWPA_W$/_3A<U^8E?H=_P $^?CQ\'+/]GCPW\,M1^(^E6FO6+7B
MW&F7UR(),R7D\B!/,P),HZGY">N.H-?!^+F&Q&)X9IJC!RY:L6[)NRY)J[ML
MKM:^9]_X/8G#8;BBHZTU'FI22NTKOGINRON[)Z;Z,^EJ*165E#*001D$=Z6O
MYE/ZB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH Q_ __((E_P"OV;_T*MBL?P/_ ,@B7_K]F_\ 0JV* "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***\P^(?[97[-OPI
M\8WG@'Q]\1_L&K6'E_:[3^Q[R7R]\:R+\T<+*<HZG@GK@\Y%=>#P&.S&JZ>$
MI2J22O:,7)VVO9)NUVM?,X\;F& RVDJN+JQIQ;LG.2BKZNUVTKV3T\F=OXE_
MY"^C_P#7Z?\ T$UL5X)KG[?O[)%YJ.FSVWQ9W);W)>8_V#?C:-N,\P<_A6E_
MP\-_8]_Z*_\ ^6_J'_R/7I_ZK<3_ /0#6_\ !4__ )$\S_6OA;_H/H_^#8?_
M "1[316+\//B'X.^*W@ZS\?> =8^WZ3?^9]DN_L\D7F;)&C;Y9%5AAT8<@=,
MCC!K:KQ:M*K0JRIU(N,HMIIJS36C33U33W1[=*K2KTHU:4E*,DFFG=-/5--:
M--;-!11169H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !6/X'_Y!$O\ U^S?^A5L5C^!_P#D$2_]?LW_ *%0!L4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5F^,?^18O?
M^N!K2K-\8_\ (L7O_7 T 7-._P"0?!_UQ7^0J:H=._Y!\'_7%?Y"IJ "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ KP7_@G5_P D/U?_ +'O6/\ T?7O5>"_\$ZO^2'ZO_V/>L?^CZ />J**
M* "BBB@ HHHH **** "BBB@ HHHH **** ,+Q/\ #'X>>- Q\4^"M-OG;K-/
M:*9!]'QN'X&O.?%'[$'P<UO=+H;:EI$A^ZMM=>9&#[K*&/Y,*]CHKP\RX9X?
MS>[QF%A-OJXKF_\  E:7XG/5PF%K_'!/Y:_>?-<O[(/QK\!2-=?"CXN?*#GR
MO/ELV;VPI96_$@4W_A9'[:_PP^7Q1X.;6K:/K(]@MP OKOMB"/JWXU]+45\R
M_#S!8/7*L76PWE&HY0^<97O]YQ_V73A_!G*'H]/N9\^^'?V]M#\W['XZ^'U]
M92*=LCV,ZRX/NC["OTR:]$\+_M/? [Q7M2T\>VMK*W6'4@UN0?3=( I_ FNJ
M\1>"?!WBZ+R?%/A;3]07&!]LLTD(^A89'X5YWXH_8P^"'B'=)I^EWFDRMSNT
M^\.W/^[)O 'L,4?5/$C+/X6(HXJ*_GBZ<_DX>[?U'R9K1^&49KS5G^&AZG97
MUCJ5LMYIUY%<0O\ <EAD#JWT(X-2U\W7O[$WQ!\)W+:C\*OBVT$O55E,MJX]
MM\1;/Y"HO[=_;E^%_P#Q_P"DOK]K'TS;I>;A]8B)?SH_UTS; :9KE5:FOYJ=
MJT?5N-K+[Q?VA6I?QJ,EYKWE^!]+45\ZZ+^W?<:9<_V;\1_AA<6LR?ZUK*8A
MA_VRE (_[ZKT'PO^UK\"_$^V/_A+O[.E;_EEJENT6/J_*?\ CU>IE_'G"69/
MEI8N,9=IW@[]K3MKZ7-J698*KHIJ_GI^9\&_\%#?^3PO%_\ W#__ $WVU>+5
M^GG[2?[4%EX!T*VTGX;:O97VJ:G$72]@E2:.UASC?P2&8G(4'(X)/8'Y3U[Q
M9XG\47[:IXC\0WE]<,V?-NKEG(^F3Q]!7Z%FWTLLIX*H4,HH9:\34HPA&359
M1CI%):^RGJUJTKI7M>]S\(XB\-J&)SBOB8XW6I.4VO9Z1YI.5K^TUM?>R/F^
MOL3]GC_@G_\ "CX_?LS^'?B#<:]JNCZ]?+>"XNK:1989"EY/$I:)QV5%'RLO
M3U-3?!C]IGQ[\+=7@@U#5;G4]%+A;K3[J4N43NT18Y1AZ9VGN.X^TM(U73]=
MTJVUO2KE9K6\@2:WE7HZ, 5/Y&O5RWZ1R\0\MY<KHRPE>E)2DO:*;M:2M\$5
M*+;O=[-:QV9Z_"/ACD]'$5*F,JK$1<7'DE#ELVTU)24V^C6EGJ]>_P 6-^R1
M^W?^SN3<? ?XN'6=/AYCT^WOO+R!W-K<YA_)B:L:7_P47_:"^$5]'H/[2/P)
MD!SM%U';RV$SCNP#AHY?^ [17VG5?5-)TK7+&32]:TRWO+:48EMKJ%9(W'H5
M8$&O5_UVP^8Z9S@:=?O.*]G4_P# H[^ED?6_ZCXG+=<EQ]6AVA)^UI^G++;U
MNSQGX;?\%"?V8OB+Y=M/XS?P_=O@?9O$,'D '_KJ"T0'U<5[-I>K:5KEC'JF
MB:G;WEM*,Q7%K,LD;CU#*2#7C7Q*_P"">_[,7Q%\RYA\%OH%W)D_:O#T_P!G
M /\ UR(:(#Z(/K7C.J_\$Y_V@?A%?2:_^S=\=I V=WV62XEL)G_V24+1R_\
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M^S?^A5L5C^!_^01+_P!?LW_H5;% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 44C,JJ69@ !DDGI7!>.OVI/V>?AOOC\7?%[18)
MH_OVMO=BXG7ZQ0[G'Y5TX7!XS&U/9X>G*<NT4V_N5SFQ6-P>!I^TQ-2,(]Y-
M17WNQWU?F)_P4-_Y/"\7_P#</_\ 3?;5],>.?^"K'P3T/?!X&\(:WKTJ_=DE
M5+2!OHS%G_..OC']H/XK:C\;OB]J_P 4=5\/+I4VJ_9V-@LA<1*EO'$OS$ G
M*H&S@?>K]N\+>&,^RC.:F+QM!TX2IN*YK)W<H/X;\VR>Z/POQ6XIR#.,EIX/
M!5U4J1JJ3Y;M649KXK<N[6S.,HHHK]U/P0_3O_@GE_R9[X0_[B'_ *<+FO::
M^+_V)OVZ_@E\,_A!HOP;^(LFH:5<Z8UP/[4:T,MK();F68?ZO+J1Y@!RN.,Y
MKZX\&?$'P+\1=,&L^ _%^G:O:D#,VG7B2A2>S;22I]C@U_(?&>3YK@<_Q=>O
M1E&$ZLY1DT^5IR;5GMJGM>Y_8W!.<Y3CN'L)0P]>,JD*5.,HIKF3C!)W6^C6
M]K&Q1117QY]D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M $?0![U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !6/XE_Y"^C_P#7Z?\ T$UL5C^)?^0OH_\ U^G_ -!- &Q1110
M4444 %%%% %#6_"OA?Q+'Y7B+PW87ZXQMO;-)1C_ ($#7%Z_^RI\!_$&YY?
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M;XXOEUKX\?M R7=QUD6U$U[(<]1YUPRX_P"^#7JG@7_@FY^R[X.V3:EX;O\
M7YTY$NM:BQ&?]R+RT(]B#7O5%<&-X[XJQT>1XEPCVA:"7E[J3^]GH8'@'A/
MSYUAE.7652\VWW]YM?<D8WA'X<_#_P  6WV3P-X)TG1X]N"NFZ?'#N^NP#/X
MULT45\K5JU:TW.I)R;ZMW?WGUE*E2H04*<5%+HE9?<@HHHK,T"BBB@ HHHH
M***"0H+,< =2: ,?Q+_R%]'_ .OT_P#H)K8KS3QU^T+\&-'\0:?:7GQ LV>U
MNR;C[*KSB/@CDQJPZ]LUVGA'QYX-\>V1U'P=XEM-1B7'F&VE!:,GH&7JI]B!
M7G8?.,HQ>(="AB(3FMXQG%R7R3N91KT)RY8R3?:Z->BBBO1-0HHHH *;)''-
M&T,T:NCJ0RL,@@]013J*-@W/(?BE^PQ^S5\5O,N=1\ 1:3>R9_XF'A\BTDR>
MI**#&Q]V0FO"M;_X)V?'_P"#FHR>)?V9/C=,6!W&SEN7L9W Z(64F*;_ ('L
M'M7VG17U>6\:\1Y93]E&M[2GUA47/%KM:5VEZ-'R69\#\-9I4]K*C[.ITG3?
M))/O>-DWZIGQ-:?MP_M?_L]W2:/^TI\'7U&V5MG]H26OV1Y#T^6>(-!)]%7G
MUKV?X6_\%#?V:OB5Y=I?>*9/#E\^!]E\01B%,]\3 F+'^\RGVKVZ\L[34+62
MQO[6.>&52LL,R!E<'J"#P17B_P 4O^"?O[-'Q.\R[C\''P_?29/VSP[(+<9]
MXL&+KUP@)]:]/^U^"LYTQ^#>&F_MT'[OSIRT2_PW9Y?]C\;Y+KE^,CB::^Q7
M7O6\JD=6_P#%9'LVGZCI^K64>I:5?0W-O,NZ&>WE#HZ^H8<$?2IJ^)]0_8-_
M:L^ E[)KG[,_QF>\A#;S8+=&RED] T;EH)?JQ'TI^D_\%!?VE/@E?Q>'OVF_
M@I+,N=HOA:M8S2>K X,,W_  H]Z4N!O[0CSY)BZ>)7\M^2I_X!+_ #^0X\=_
MV?)0SS!U,*_YK>TI_P#@</\ +YGVK17C?PM_;T_9I^*?EVMOXY71+Z3'^@^(
M4%JV?02$F)C[!\^U>PV]Q!=0)<VLZ21R*&CDC8%6!Z$$=17R./RO,<KJ^SQE
M&5.7]Y-7]+[_ "/L<OS7+<UI>UP=:-2/>+3MZVV]&/HHHK@.\**** "BBB@
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MN?\ ^"<_B;6&^!.IR-X.O07\::H[(67*%I Q4^ZDE3[B@#Z4HK'_ .$EU?\
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MZ[C/^@=_>CZFHKY8/[,7Q^E^2X^(NH%3U_TF<_H7H_X97^-W_10=0_[[E_\
MCE'^M7%;VR6I_P"#:8?7<;_T#O[T?4]%?*Y_9.^,4WS7/CZ_+#@<2-Q^,E'_
M  R3\6?^A\O_ /OV_P#\=H_UHXOZ9)/_ ,'4_P#(/KF._P"@=_\ @2/JBBOE
M;_ACGXAGEO&]]D]?]";_ ./4?\,:^/)?DG\;7Q7O_H!/Z&:C_67C3IDDO_!]
M/_(/K>/_ .@?_P F1]4T5\K?\,5^+?\ H=+[_P %7_V^D/[$.OS'?<^,+TMT
MR=%#<?C<4?ZQ\<O;(W_X4TO\@^MYC_T#_P#DZ/JJH_MEG_S]1_\ ?P5\L_\
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MDK6DNO?0_,2O:?\ @GE_R>%X0_[B'_ION:^P/"O[ 7[)&I:=)/>_";>ZW,B
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M_K]/_H)K8K\^P'A+PC@<<L3RSG9W49R3BNVB2;])-KO<\NGDF!IU.>S?DWH
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MS[?^WOX2_P!?9G4H4Z?N[.?/_?&'_.C_ (:G_:3\+_+XT^"P*)UD.E74&?\
M@1+*?P%?2=%3_J3F>&_W/-\1'_&XU%]S2#^SZT/X=>2]=3YXTO\ ;_T<MY7B
M'X9W=N0<.;74%D/Y,B8_.NGTC]M_X):C@7K:M8$]?M5@& _[],]>J:IX=\/Z
MXNS6M"L[P8QBZM4D'_CP-<QJ_P"SQ\$-;S]M^&6E+NZFUM_(/_D(K1_9?B-A
M/X684JW_ %\I<G_IMA['-8?#5C+UC;\B+2/VD_@7K>/L?Q+TY,]/MC-;_P#H
MT+BNHTGQ;X4U_']A>)M/O<]/LE[')G_ODFO--7_8G^!FI9^QV&I:?GI]DU%F
MQ_W]#UR^K?\ !/\ \,2DG0/B+?VW]W[79)-_Z"4H_M+Q(PG\7 T:W_7NJX?^
MG$'M<UA\5.,O1V_,^@Z*^;/^&1OC[X8Y\#?&H(%^ZHO[FUS^";A1_P (Y^WI
MX2_Y!^NG4HTZ_P"E6L^1_P!M@&/X<T?ZZ9OAO]\R?$1_Z]\M7_TEH/K]>'\2
MA)>EF?2=97B[P/X,\?:6=$\;^%=/U>T.?]'U&S290?4!@<'W'-> _P#"^OVP
M?"GR^(_A)]L1?ORG1)C_ ./0MM'Y5):?MZ:KILPM/%WPE>*3^(Q7[1D?\ >/
M^M:4O$_AO#5%*O*KAY+;GISBT_6*=B*F99?4@X5DTGNI1=OGHR'XI?\ !+WX
M$^,?,O? &H:AX5NWR52!S<VN?>.0[A]%< >E>;?\*5_X*)_LN?O/AAXRD\4Z
M+;_=LK:X^U*$'\/V:X^9,^D.3[U[CI'[=WPEO<)JFAZW9,>K&WCD0?BKY_2N
MITC]J[X!ZQA8_'T4#GJEW:318_%DV_K7Z5E/CA@*]%4*^.HXFG_)7<7]SE:=
M_F[=CY/$\'\)XFM[?!3>&J_S49^S?_@/PV^2N>!>!O\ @J5=Z%J/_",_M#?!
M^]TJ]B(6YN-+1E9#_M6TY#+_ -]D^U?0WPN_::^!7QC6./P!\2-.NKJ0<:=-
M)Y%UGT\J3:Y^H!'O3O$9_9T^-FG#2?$]SX4\10D8CBN9X)GCS_=YW(?<8->*
M?$[_ ()9_!WQ/OU3X5^*-0\-7#?-% [?;+7/48#$2+]=YQZ5]70Q_ASQ''FC
MS86;ZP?M:7JU\2]%H*-/C[)]:-2GCJ:Z2M3J?*2]Q^KU9]245\0_\(7_ ,%)
MOV6OF\,:S+XRT2WZ012'44V#HOE28N$&.T? ]:Y[XY_\% [GXQ? 7Q#\&/'_
M ,+I]&U^\^RJL]K*3"'BNH9F#QR8>+Y8V &7YQTZCKH>'>.QV(I_4<13KT92
MBG.$DW!-I.4H-IZ+6R9&(\2,!@,-4^OX>I0K1C)QA4BTIR2;48S2:U>EVOD?
M?]8_@?\ Y!$O_7[-_P"A5^.=%?9_\04_ZC__ "E_]T/B?^(X?]2__P J_P#W
M,_:2BOS$_P"">7_)X7A#_N(?^F^YK].Z_->,>%_]4LSA@_;>TYH*=^7EWE)6
MMS2_EO>_78_3>"^*O];\KGC/8^RY9N%N;FVC&5[\L?YK6MTW"BBBODSZ\***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LWQC_ ,BQ
M>_\ 7 UI5F^,?^18O?\ K@: +FG?\@^#_KBO\A4U0Z=_R#X/^N*_R%34 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !7@O\ P3J_Y(?J_P#V/>L?^CZ]ZKP7_@G5_P D/U?_ +'O6/\ T?0!
M[U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ77QF^'-C.EM]G"Z]+I%LT]IFXC V3P_<#$[3V(8CO7W17BW_!0W_DSWQ?\
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M^$]>FP<G;X;AF_\ 0$-9RX(S7_EWB,-4_P %>+_]*427XAX:'\7+\5#UHO\
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MBN+?6#:M@#^(>2X)^@6OK;]GCXO_ /"^O@]H_P 6/^$>_LK^U?M'^@?:_/\
M*\JXDA^_L3=GR]WW1C..<9K\CZ_3O_@GE_R9[X0_[B'_ *<+FOF/$3@KAKAC
MAVC4RVBX2]HHW=2I-\KC-V;J3DWJEJ]?,^X\+^,.(\_SVIA<?7YX1I2DERP6
MJG!7NHI[-[NQ[31117XJ?NP4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5X+_P3J_Y(?J__8]ZQ_Z/KWJO!?\ @G5_
MR0_5_P#L>]8_]'T >]4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5C^)?^0OH__7Z?_036Q6/XE_Y"^C_]?I_]!- &
MQ1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!C^!_\ D$2_]?LW_H5;%8_@?_D$2_\ 7[-_Z%6Q0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!C^)?\
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MG"YKQ.W_ ."1'VBWCG_X:$QO0-C_ (1/ID9_Y^Z^H?V>/A!_PH7X/:/\)_\
MA(?[5_LK[1_I_P!D\CS?-N))ON;WVX\S;]XYQGC.*^2\2N+^'>(,BIX? 5^>
M:J*37+-:*,U>\HI;M>9]AX8\&\2</9]5Q.84.2#I2BGS0EJYP=K1DWLGTL=I
M1117X@?N@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5X+_P $ZO\ DA^K_P#8]ZQ_Z/KWJO!?^"=7_)#]7_['O6/_
M $?0![U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !6/XE_Y"^C_P#7Z?\ T$UL5C^)?^0OH_\ U^G_ -!- &Q1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!C^!_^01+_P!?LW_H5;%8_@?_ )!$O_7[-_Z%6Q0 4444 %%%% !1110
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M_P#0JV*Q_ __ "")?^OV;_T*MB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#'\2_\A?1_P#K]/\ Z":V*Q_$O_(7
MT?\ Z_3_ .@FMB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ K'\#_P#((E_Z_9O_ $*MBL?P/_R")?\ K]F_]"H
MV**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *S?&/\ R+%[_P!<#6E6;XQ_Y%B]_P"N!H N:=_R#X/^N*_R%35#IW_(
M/@_ZXK_(5-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_B*/^&[OV0_^B\:)_P!]2?\ Q%=U_P *F^%?_1-/#_\ X)H/_B*/^%3?"O\
MZ)IX?_\ !-!_\10!PO\ PW=^R'_T7C1/^^I/_B*/^&[OV0_^B\:)_P!]2?\
MQ%=U_P *F^%?_1-/#_\ X)H/_B*/^%3?"O\ Z)IX?_\ !-!_\10!PO\ PW=^
MR'_T7C1/^^I/_B*/^&[OV0_^B\:)_P!]2?\ Q%=U_P *F^%?_1-/#_\ X)H/
M_B*/^%3?"O\ Z)IX?_\ !-!_\10!PO\ PW=^R'_T7C1/^^I/_B*/^&[OV0_^
MB\:)_P!]2?\ Q%=U_P *F^%?_1-/#_\ X)H/_B*/^%3?"O\ Z)IX?_\ !-!_
M\10!PO\ PW=^R'_T7C1/^^I/_B*/^&[OV0_^B\:)_P!]2?\ Q%=U_P *F^%?
M_1-/#_\ X)H/_B*/^%3?"O\ Z)IX?_\ !-!_\10!PO\ PW=^R'_T7C1/^^I/
M_B*/^&[OV0_^B\:)_P!]2?\ Q%=U_P *F^%?_1-/#_\ X)H/_B*/^%3?"O\
MZ)IX?_\ !-!_\10!PO\ PW=^R'_T7C1/^^I/_B*/^&[OV0_^B\:)_P!]2?\
MQ%=U_P *F^%?_1-/#_\ X)H/_B*/^%3?"O\ Z)IX?_\ !-!_\10!PO\ PW=^
MR'_T7C1/^^I/_B*/^&[OV0_^B\:)_P!]2?\ Q%=U_P *F^%?_1-/#_\ X)H/
M_B*/^%3?"O\ Z)IX?_\ !-!_\10!PO\ PW=^R'_T7C1/^^I/_B*/^&[OV0_^
MB\:)_P!]2?\ Q%=U_P *F^%?_1-/#_\ X)H/_B*/^%3?"O\ Z)IX?_\ !-!_
M\10!PO\ PW=^R'_T7C1/^^I/_B*/^&[OV0_^B\:)_P!]2?\ Q%=U_P *F^%?
M_1-/#_\ X)H/_B*/^%3?"O\ Z)IX?_\ !-!_\10!PO\ PW=^R'_T7C1/^^I/
M_B*/^&[OV0_^B\:)_P!]2?\ Q%=U_P *F^%?_1-/#_\ X)H/_B*/^%3?"O\
MZ)IX?_\ !-!_\10!PO\ PW=^R'_T7C1/^^I/_B*/^&[OV0_^B\:)_P!]2?\
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M\-W?LA_]%XT3_OJ3_P"(KNO^%3?"O_HFGA__ ,$T'_Q%'_"IOA7_ -$T\/\
M_@F@_P#B* .%_P"&[OV0_P#HO&B?]]2?_$4?\-W?LA_]%XT3_OJ3_P"(KNO^
M%3?"O_HFGA__ ,$T'_Q%'_"IOA7_ -$T\/\ _@F@_P#B* .%_P"&[OV0_P#H
MO&B?]]2?_$4?\-W?LA_]%XT3_OJ3_P"(KNO^%3?"O_HFGA__ ,$T'_Q%'_"I
MOA7_ -$T\/\ _@F@_P#B* .%_P"&[OV0_P#HO&B?]]2?_$4?\-W?LA_]%XT3
M_OJ3_P"(KNO^%3?"O_HFGA__ ,$T'_Q%'_"IOA7_ -$T\/\ _@F@_P#B* .%
M_P"&[OV0_P#HO&B?]]2?_$4?\-W?LA_]%XT3_OJ3_P"(KNO^%3?"O_HFGA__
M ,$T'_Q%'_"IOA7_ -$T\/\ _@F@_P#B* .%_P"&[OV0_P#HO&B?]]2?_$4?
M\-W?LA_]%XT3_OJ3_P"(KNO^%3?"O_HFGA__ ,$T'_Q%'_"IOA7_ -$T\/\
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M]%XT3_OJ3_XBNZ_X5-\*_P#HFGA__P $T'_Q%'_"IOA7_P!$T\/_ /@F@_\
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M_P"(H X7_AN[]D/_ *+QHG_?4G_Q%'_#=W[(?_1>-$_[ZD_^(KNO^%3?"O\
MZ)IX?_\ !-!_\11_PJ;X5_\ 1-/#_P#X)H/_ (B@#A?^&[OV0_\ HO&B?]]2
M?_$4?\-W?LA_]%XT3_OJ3_XBNZ_X5-\*_P#HFGA__P $T'_Q%'_"IOA7_P!$
MT\/_ /@F@_\ B* /+_$/[<W[)<VJ:5)#\<=(=8[LF1D$I"C;U.$X%:W_  W=
M^R'_ -%XT3_OJ3_XBN-_:D^'G@#3OC)\%[73_ VCP17?C>6.ZCATR)5F3[,Q
MVN N&&>QKVS_ (5-\*_^B:>'_P#P30?_ !% '"_\-W?LA_\ 1>-$_P"^I/\
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MO&B?]]2?_$5W7_"IOA7_ -$T\/\ _@F@_P#B*/\ A4WPK_Z)IX?_ /!-!_\
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MJ;X5_P#1-/#_ /X)H/\ XBC_ (5-\*_^B:>'_P#P30?_ !% '"_\-W?LA_\
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MA_\ 1>-$_P"^I/\ XBLGP;^W-^R7;:7)'<_''2(V-W*0L@E4D%N#RG2O4/\
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MN_9#_P"B\:)_WU)_\17=?\*F^%?_ $33P_\ ^":#_P"(H_X5-\*_^B:>'_\
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M (BC_A4WPK_Z)IX?_P#!-!_\10!PO_#=W[(?_1>-$_[ZD_\ B*/^&[OV0_\
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M%4:5\$J7*MM15=CMR0 02W]A[_@J!\&_VU/$NI_#&#PKJ_@WQMH\;RW?A;Q
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MX436/$OCZ?6LQ1L8H96A-N(?E"I)*2_F'F!AMYX^?[__ (. _A%'JDVOZ/\
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MXWU/X/7?@76_ _CG2H'FG\,^(5&Z:-"!)Y;X4ET)&Y'1& .0" Q4 ^GJ***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#@OVG_@_P"(_C[\!_$7P>\)
M_$>\\(WVO6T=NGB&P5S-:)YT;2%0CH3NC5TQN (<@\9%?ESXT_9#^%_[$_\
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MW[-'@O\ 9Y?6_AFFHW=@?BQ%HUVMM';2W?FR,RE-N[>^ [$% ZJ5W 5^J/\
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M;G6=0TSS YT\S+&B0$@XW!(D9@. SL.<9(!\-:E^R9\,/V+_ /@L3\"O@O\
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M4_;(3]H3]HO]COQ]XT\':1=R+X;^'WV2\L+>&T5LPQR.+67.2%>7"@R-QD*
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MK"TDLTC6L@5%502S$\  9- 'A/\ P05_Y1\Z;_V-.I_^C%K!_8QT33?VF?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP5<?#N]TZRN-/O;WSKD74RW N(I,*%_=RV[*K+]]2&PN<4 ?2-%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD_%&$=? 3O;22:M*+Z77GT:NGK9Z,VPN,H8R'-3?^:"BBODO_@I#^T)^T_\
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M0ZK#]K(QG/D[M_3GITH VZ*JW>MZ+87L6G7^KVL%Q.CO!!-<*KR*@RQ52<D
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M\!PI@(XO%QE*,I*"Y$F[M2?645:T7U[:'W917YB?\/#?VPO^BO\ _EOZ?_\
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MZ*^1?V</VL/VJ? O[8*_L,_MLV/AC4=8UGPZ^L^#/&/A*&2&'48H]Y>*6)\
M-MBF.0J;3$1A@ZM72?LC_M)?%GXS?M;_ +1'P:\::U;MHOP]UG2[7PLMM8QQ
MRVR7"79D+-@^8<Q(1NSC'O0!]+45\I_LM_M:_&3PY^U/XH_8<_;+U&QD\5HS
M:I\._$MI8+:0>(]*()VA%^43($9B!G[LJ_\ +++6HOVI_B[^T;^VV?@-^R_J
MUI:> _AS)N^*WC"2Q2X%W>$_+I5H7!4."K*[CD?O.GEKY@!]14444 %%%% !
M1110 445Y;^T9^T3:?!*]T#3H8EGGO[Y9+^+&62R4X=@.S$G"_[K4 >I45%9
M7MIJ5E#J-A<++!<1+)#*ARKHPR&!]""#4M !117Q=_P5J_;B_:#_ &,O%?PF
M?X&6%KJ%OKUSJ]QXBT>?3Q,U];60LI"BM@M%^[DGRR\@<_PT ?:-%<E\"/C9
MX"_:+^$>A?&GX::G]JT;7[%;BV8XWQ-T>&0 G;)&X9&'9E/6O'_^"<'[1_Q3
M_:2\+?$W5?BIJ=M=3>&/BYJV@:0;6R2$1V,"0&-6"CYF!D;+'DYH ^C:*^)?
M^"EG[='[1GP7^*UK\+/V3H=.NK[PGX(NO&GQ"CO+%9P-+CGBC6($@^4=OFNQ
MZ[60C'?ZZ^%'Q*\,_&3X9:!\5_!MSYNE>(](M]1L7)&1'+&'"MZ,,X([$$=J
M .@HKXNN?CI^W)^VA^T!\1?AI^R1\3?#7PT\&_#+7WT#4?$VIZ$FIZCJ6I1E
MEF"0R@QK&K(P&0#C:<MN*I:\$?'G]M_]E;]IOP5^S_\ MB>)-#^(?A?XC336
MGAWQYH&B"QNK*^0+B*Z@B41A6+HO _Y:;@YVLM 'V/17Q=^U#\=?VW==_P""
MAEA^R#^R[\5/#7AFTN/APGB"2?Q!H*W2F07,T;C<%9N0J8'3@^M5/B;XL_X+
M"?LI>$;OXW>+O$WPU^*GAS0HC=>(O#VEZ3-8WRV:?-++ RHHRJ L2=V ,[&P
M10!]N45Q_P  /C=X)_:0^#7A[XX?#NX=](\1Z>MS;+, )(6R4DA<#(#QR*\;
M8)&Y#@D<U\;?M,?\%+?C7\,?VP]3_P"$'%A+\&OAKXCT'0/B;.UBLDOVC4//
M,LZ2XRH@VJA4$?O$ /#T ??-%1O>6B6AOWNHQ (_,,Y<; F,[L],8YS7Q1X5
M_:0_;H_X*$^)M;U?]B[Q3H'PR^%FBZG+IUAX]UW1%U'4->GC.'DM[>4&-81Q
M]X \CYBVY$ /MNBOB+QI^T9^W=_P3PU_1_$?[8_BS0?BG\*M6U.*PU+QQH>A
M+IVI:#+(<)+/;0@1M%U^Z&)QC<K%5?[9L[RTU&TBU"PN8YH)XUDAFB<,LB,,
MA@1P0000: )**\'_ &[/VRKO]E/POX>\._#[P3_PE?Q$\>:N-)\"^&#+L2YN
M"5#32L""(8R\>[!!)=1E1N=?-YO@K_P64FT=O'(_;1\ 0ZUY7G+X%B\!PG3"
M_7R/MK(;C'\.['X]Z /L"BO"_P!@?]KK6?VM/A=J=Y\0/ C>%_&WA'79M#\:
M:$ QB@O83AGB+$GRV(8;2259'7+ !F]5O_BO\+=*\4Q^!M4^)6@6VMRD"+1[
MC68$NG)QC$1;><Y';O0!OT57U35M*T2T.H:UJ=O9VZL%:>ZF6- 2< ;F(')X
MK,;XE_#A/%P^'[?$#1!KS+E=$.JP_;",9SY.[?TYZ=* -NBL2?XE?#JU\6Q^
M ;KQ_HD>NRJ#%HLFJPB[<8SD0EMYXYZ5I7>LZ/87D&G7^JVT%Q=!S:P33JKS
M;!EMJDY; Y..@ZT 6:*Q/"GQ*^'/CRXN;/P/X_T369;)MMY%I.JPW#0'T<1L
M2OXXJ]X@\1^'O">E2Z[XIUZRTRQ@ ,UYJ%TD,4>>!N=R /Q- %VBLSPIXT\'
M>.]*&N^!_%FF:S8EBHO-*OX[B(GTWQDC/XU6\8?$_P"&OP]D@B\??$/0]#:Z
M_P"/9=8U:&V,W;Y?,8;OPH W**YKXG7OBK4?A#X@U#X2>)]'L];F\/73^&]9
MU24-8071A8P3S,%<&%7VLQ ;Y0>#TKP;]I3]K_XG?L>_LD^"O&/C>_\ "?BC
MQYK.HZ7I.IW5G>E=/>6?(FO8554:2)=IP,(/F!)&,$ ^GJ*J6FNZ'J&D_P!O
M6&LVD]CL9_ML-PK1;5)#'>#C P<G/&#6=X1^)OPW^($D\7@/X@Z'K;VIQ=+I
M&K0W)A[?,(V.W\: -RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7@W]@3_@HC\&-:_9KTP>'/#GQ?N[[0/&G@_3Y&6PGDB2(P720Y*QNK3 Y4
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M_.XLSACN)KTB#PQ_P4Q_9H^)/C"V^&6D:-\9?!?B77Y=5\/_ /"5^-);/4M
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MWPY^(_Q[\#?M&^()]27Q!\/HK^/04M[I5MV%W"89?-0H2_RGC#+@^M>AT44
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
)110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289105392912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 08, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CUMBERLAND PHARMACEUTICALS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">TN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">62-1765329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001087294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1600 West End Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Nashville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">37203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-0068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.00 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CPIX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,061,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,176,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain information required in Part III of Form 10-K is incorporated by reference from the registrant&#8217;s Proxy Statement for its 2024 annual meeting of shareholders.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289105353712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_AuditorInformationAbstract', window );"><strong>Auditor Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Carr, Riggs & Ingram, LLC<span></span>
</td>
<td class="text">FORVIS, LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Nashville, Tennessee<span></span>
</td>
<td class="text">Nashville, Tennessee<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">213<span></span>
</td>
<td class="text">686<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_AuditorInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Auditor Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_AuditorInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289100424784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 18,321,624<span></span>
</td>
<td class="nump">$ 19,757,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">9,758,176<span></span>
</td>
<td class="nump">13,163,681<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">4,609,362<span></span>
</td>
<td class="nump">9,863,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">3,025,248<span></span>
</td>
<td class="nump">3,084,978<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">35,714,410<span></span>
</td>
<td class="nump">45,870,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">12,804,529<span></span>
</td>
<td class="nump">7,527,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">367,903<span></span>
</td>
<td class="nump">284,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">22,607,918<span></span>
</td>
<td class="nump">30,590,678<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">914,000<span></span>
</td>
<td class="nump">914,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">6,674,394<span></span>
</td>
<td class="nump">5,218,403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,692,921<span></span>
</td>
<td class="nump">2,520,661<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">81,776,075<span></span>
</td>
<td class="nump">92,925,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">14,037,629<span></span>
</td>
<td class="nump">10,819,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease current liabilities</a></td>
<td class="nump">348,092<span></span>
</td>
<td class="nump">172,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">13,596,528<span></span>
</td>
<td class="nump">17,587,911<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">27,982,249<span></span>
</td>
<td class="nump">28,579,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="nump">12,784,144<span></span>
</td>
<td class="nump">16,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease non-current liabilities</a></td>
<td class="nump">5,296,247<span></span>
</td>
<td class="nump">4,586,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Total other long-term liabilities</a></td>
<td class="nump">6,453,566<span></span>
</td>
<td class="nump">7,585,019<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">52,516,206<span></span>
</td>
<td class="nump">56,951,152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock &#8211; no par value; 100,000,000 shares authorized; 14,121,833 and 14,366,316 shares issued and outstanding as of December&#160;31, 2023 and 2022, respectively</a></td>
<td class="nump">47,091,602<span></span>
</td>
<td class="nump">47,474,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(17,488,161)<span></span>
</td>
<td class="num">(11,208,841)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">29,603,441<span></span>
</td>
<td class="nump">36,266,132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(343,572)<span></span>
</td>
<td class="num">(292,126)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">29,259,869<span></span>
</td>
<td class="nump">35,974,006<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 81,776,075<span></span>
</td>
<td class="nump">$ 92,925,158<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481573/470-10-45-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481573/470-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289100624864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">14,121,833<span></span>
</td>
<td class="nump">14,366,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">14,121,833<span></span>
</td>
<td class="nump">14,366,316<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289106624592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">$ 39,552,507<span></span>
</td>
<td class="nump">$ 42,010,949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">6,066,611<span></span>
</td>
<td class="nump">9,118,521<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing</a></td>
<td class="nump">18,451,765<span></span>
</td>
<td class="nump">16,660,945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">5,834,229<span></span>
</td>
<td class="nump">6,688,924<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">10,651,915<span></span>
</td>
<td class="nump">10,180,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization and impairment</a></td>
<td class="nump">8,102,648<span></span>
</td>
<td class="nump">5,067,368<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">49,107,168<span></span>
</td>
<td class="nump">47,715,878<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(9,554,661)<span></span>
</td>
<td class="num">(5,704,929)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">286,854<span></span>
</td>
<td class="nump">98,405<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income</a></td>
<td class="nump">2,828,871<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Other income - settlement</a></td>
<td class="nump">475,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuredEventGainLoss', window );">Other income - gain on insurance proceeds</a></td>
<td class="nump">346,800<span></span>
</td>
<td class="nump">611,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(667,861)<span></span>
</td>
<td class="num">(585,995)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(6,284,997)<span></span>
</td>
<td class="num">(5,581,189)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(45,769)<span></span>
</td>
<td class="num">(68,850)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(6,330,766)<span></span>
</td>
<td class="num">(5,650,039)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="nump">51,446<span></span>
</td>
<td class="nump">79,798<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to common shareholders</a></td>
<td class="num">$ (6,279,320)<span></span>
</td>
<td class="num">$ (5,570,241)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per share attributable to common shareholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in USD per share)</a></td>
<td class="num">$ (0.44)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in USD per share)</a></td>
<td class="num">$ (0.44)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">14,298,774<span></span>
</td>
<td class="nump">14,563,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">14,298,774<span></span>
</td>
<td class="nump">14,563,592<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">$ 37,513,492<span></span>
</td>
<td class="nump">$ 40,681,182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ManufacturedProductOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">$ 2,039,015<span></span>
</td>
<td class="nump">$ 1,329,767<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuredEventGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess (deficiency) of insurance recovery over the loss incurred from an insured event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483049/450-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuredEventGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ManufacturedProductOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ManufacturedProductOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289100678064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (6,330,766)<span></span>
</td>
<td class="num">$ (5,650,039)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash flows provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">4,935,954<span></span>
</td>
<td class="nump">5,328,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment loss on intangible assets</a></td>
<td class="nump">3,343,842<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating lease right-of-use asset</a></td>
<td class="nump">834,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Disposal of assets</a></td>
<td class="nump">20,256<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">365,040<span></span>
</td>
<td class="nump">447,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Decrease in non-cash contingent consideration</a></td>
<td class="num">(1,253,840)<span></span>
</td>
<td class="num">(2,088,296)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy', window );">Decrease (increase) in cash surrender value of life insurance policies over premiums paid</a></td>
<td class="num">(124,736)<span></span>
</td>
<td class="nump">613,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Noncash interest expense</a></td>
<td class="nump">15,523<span></span>
</td>
<td class="nump">11,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_NoncashOrPartNoncashGainOnTransaction', window );">Noncash gain on RediTrex transaction</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(37,882)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingGainsLosses', window );">Gain on receipt of life insurance policies</a></td>
<td class="num">(346,800)<span></span>
</td>
<td class="num">(611,330)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in assets and liabilities affecting operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">3,404,949<span></span>
</td>
<td class="num">(6,115,640)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories, net</a></td>
<td class="num">(23,143)<span></span>
</td>
<td class="nump">911,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other current assets and other assets</a></td>
<td class="nump">65,684<span></span>
</td>
<td class="nump">689,260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(1,405,363)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and other current liabilities</a></td>
<td class="nump">3,724,174<span></span>
</td>
<td class="nump">14,536,076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="num">(1,131,453)<span></span>
</td>
<td class="nump">419,659<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">6,093,821<span></span>
</td>
<td class="nump">8,453,396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property and equipment</a></td>
<td class="num">(281,268)<span></span>
</td>
<td class="num">(102,148)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Additions to intangible assets</a></td>
<td class="num">(171,783)<span></span>
</td>
<td class="num">(1,971,662)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ProceedsFromCollaborativeArrangement', window );">Return of RediTrex</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLifeInsurancePolicies', window );">Life insurance policy proceeds received</a></td>
<td class="nump">347,356<span></span>
</td>
<td class="nump">877,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ProceedsFromSettlementOfPatentLitigation', window );">Settlement of patent litigation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21,757<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for acquisition</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(13,500,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(105,695)<span></span>
</td>
<td class="num">(13,674,456)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit', window );">Borrowings on line of credit</a></td>
<td class="nump">31,475,000<span></span>
</td>
<td class="nump">52,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payments on line of credit</a></td>
<td class="num">(34,890,856)<span></span>
</td>
<td class="num">(51,700,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments made in connection with repurchase of common shares</a></td>
<td class="num">(740,533)<span></span>
</td>
<td class="num">(1,053,042)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Cash settlement of contingent consideration</a></td>
<td class="num">(3,268,083)<span></span>
</td>
<td class="num">(2,208,744)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(7,424,472)<span></span>
</td>
<td class="num">(2,061,786)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(1,436,346)<span></span>
</td>
<td class="num">(7,282,846)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">19,757,970<span></span>
</td>
<td class="nump">27,040,816<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">18,321,624<span></span>
</td>
<td class="nump">19,757,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CashPaidDuringYearAbstract', window );"><strong>Net cash paid during the year for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">647,137<span></span>
</td>
<td class="nump">523,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="nump">108,823<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CashPaymentIncludedInMeasurementOfLeaseLiability', window );">Total cash paid included in measurement of lease liability</a></td>
<td class="nump">804,818<span></span>
</td>
<td class="nump">1,011,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid', window );">Change in unpaid invoices for intangible asset additions</a></td>
<td class="num">(51,895)<span></span>
</td>
<td class="num">(1,803,403)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ChangeInUnpaidInvoicesForOfferingCosts', window );">Change in unpaid invoices for offering costs</a></td>
<td class="nump">69,001<span></span>
</td>
<td class="num">(94,689)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Lease liability obtained from right-of-use assets</a></td>
<td class="nump">1,158,367<span></span>
</td>
<td class="nump">4,590,978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CreditIssuedForMilestonePayable', window );">RediTrex forgiveness of milestone payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Return of shares related to RediTrex</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 399,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CashPaidDuringYearAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Paid During Year For [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CashPaidDuringYearAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CashPaymentIncludedInMeasurementOfLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Payment Included In Measurement Of Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CashPaymentIncludedInMeasurementOfLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ChangeInUnpaidInvoicesForOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Unpaid Invoices For Offering Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ChangeInUnpaidInvoicesForOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CreditIssuedForMilestonePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Credit Issued for Milestone Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CreditIssuedForMilestonePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_NoncashOrPartNoncashGainOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash or Part Noncash, Gain on Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_NoncashOrPartNoncashGainOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ProceedsFromCollaborativeArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Collaborative Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ProceedsFromCollaborativeArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ProceedsFromSettlementOfPatentLitigation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Settlement of Patent Litigation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ProceedsFromSettlementOfPatentLitigation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases of Intangible Assets Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7,9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLifeInsurancePolicies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow for proceeds from settlement of corporate-owned life insurance policy, classified as investing activities. Includes, but is not limited to, bank-owned life insurance policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21C<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-21C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLifeInsurancePolicies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289101273888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Non-controlling interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,742,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 42,601,978<span></span>
</td>
<td class="nump">$ 48,452,906<span></span>
</td>
<td class="num">$ (5,638,600)<span></span>
</td>
<td class="num">$ (212,328)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(5,650,039)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,570,241)<span></span>
</td>
<td class="num">(79,798)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares', window );">Return of common stock - Methotrexate (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(180,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Return of common stock - Methotrexate</a></td>
<td class="num">(399,600)<span></span>
</td>
<td class="num">$ (399,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">447,503<span></span>
</td>
<td class="nump">$ 447,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(367,793)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">$ (1,025,836)<span></span>
</td>
<td class="num">$ (1,025,836)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">14,366,316<span></span>
</td>
<td class="nump">14,366,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 35,974,006<span></span>
</td>
<td class="nump">$ 47,474,973<span></span>
</td>
<td class="num">(11,208,841)<span></span>
</td>
<td class="num">(292,126)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(6,330,766)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,279,320)<span></span>
</td>
<td class="num">(51,446)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Return of common stock - Methotrexate</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">365,040<span></span>
</td>
<td class="nump">$ 365,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(402,143)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">$ (748,411)<span></span>
</td>
<td class="num">$ (748,411)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">14,121,833<span></span>
</td>
<td class="nump">14,121,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 29,259,869<span></span>
</td>
<td class="nump">$ 47,091,602<span></span>
</td>
<td class="num">$ (17,488,161)<span></span>
</td>
<td class="num">$ (343,572)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289104566032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Valuation and Qualifying Accounts<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsAbstract', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">Valuation and Qualifying Accounts</a></td>
<td class="text"><div style="margin-top:8pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Schedule II</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation and Qualifying Accounts</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Years ended December&#160;31, 2023 and 2022.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.470%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.406%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">beginning&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">period</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Charged to</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">costs and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">expenses</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Charged&#160;to</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">accounts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">end&#160;of&#160;period</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for uncollectible amounts, cash discounts, chargebacks, and credits issued for damaged products:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the years ended </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340,964&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,673,104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,417,977)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;text-align:center"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596,091&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596,091&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,953,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,969,671)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the years ended </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,761,922&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,795,862&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,557,784&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,557,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,869,328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Composed of actual returns and credits for chargebacks and cash discounts.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289103643232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization</a></td>
<td class="text">Organization<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company&#8217;s primary target markets are hospital acute care, gastroenterology  and oncology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs. The Company promotes its approved products through its hospital, field and oncology sales forces in the United States and is establishing a network of international partners to bring its medicines to patients in their countries.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#8217;s products are manufactured by third parties, which are overseen by Cumberland&#8217;s quality and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to build a pipeline of early-stage product candidates, the Company formed a subsidiary, Cumberland Emerging Technologies, Inc. ("CET"), which teams with universities and other research organizations to help advance scientific discoveries from the laboratory to the marketplace. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April, 2019, CET entered into an agreement with HongKong WinHealth Pharma Group Co. Limited ("WinHealth") whereby WinHealth made a $1.0&#160;million investment through the purchase of shares of CET stock. As part of the agreement, WinHealth obtained a board position at CET and the first opportunity to license CET products for the Chinese market. In connection with WinHealth's investment in CET, Cumberland also made an additional $1.0 million investment in CET. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ownership in CET is now 85% while the remaining interest is owned by WinHealth, Vanderbilt University and the Tennessee Technology Development Corporation. The operating results of CET allocated to noncontrolling interests in the consolidated statements of operations were  $51,446 and $79,798 for the years ended December&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January&#160;1, 2007, the Company formed a wholly-owned subsidiary, Cumberland Pharma Sales Corp. ("CPSC"). CPSC is the subsidiary that employs the Company's hospital and field sales force personnel.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Company formed the Cumberland Pharma Foundation (the "Foundation") to serve as a vehicle to facilitate the ongoing philanthropic endeavors of Cumberland Pharmaceuticals Inc. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Foundation was formed as a nonprofit corporation designed to qualify as a tax-exempt organization pursuant to Section 501(a) of the Internal Revenue Code. The Foundation&#8217;s Board of Directors is comprised of Cumberland Pharmaceuticals executives who are responsible for overseeing the Foundation&#8217;s ongoing activities including charitable contributions. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, Cumberland provided a grant of 50,000 shares of the Company&#8217;s common stock to the Foundation. The shares will address the ongoing financial needs of the Foundation. The organization also plans to hold a portion of the shares for long-term appreciation. The Foundation maintains separate financial statements and its ongoing operations do not impact the financial statements of Cumberland Pharmaceuticals. Initial annual grants by the Foundation have been and are expected to remain consistent with the historic level of contributions made by Cumberland Pharmaceuticals.  Since 2019, Cumberland has made annual cash contributions to the Foundation. During the years 2023 and 2022,  the Company made cash contributions of $40,000 and $25,000, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289110228656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text">Significant Accounting Policies<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements of the Company are stated in U.S. dollars and are prepared using U.S. generally accepted accounting principles. These financial statements include the accounts of the Company and its wholly and majority-owned subsidiaries. All significant intercompany transactions and accounts have been eliminated in consolidation.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates under different assumptions and conditions. The Company&#8217;s most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory, (3) valuation of contingent consideration liability associated with business combinations and (4) evaluation of continuing utility of intangible assets.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, evaluated that our specialty pharmaceutical products compete in similar economic markets and similar circumstances. Substantially all of the Company&#8217;s assets are located in the United States. Total revenues are primarily attributable to U.S.&#160;customers. Net revenues from customers outside the United States were approximately $1.1 million and $1.5 million for the years ended December&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of financial assets and liabilities is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date. The Company&#8217;s fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements. It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 -   Quoted prices for identical instruments in active markets.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 -  Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 -    Significant inputs to the valuation model are unobservable.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain policies and procedures to value instruments using the best and most relevant data available. The following section describes the valuation methodologies we use to measure different financial instruments at fair value on a recurring basis.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, contingent consideration liability and a revolving line of credit. The carrying values for cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to their short-term nature. The revolving line of credit has a variable interest rate, which approximates the current market rate.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s contingent consideration liability is a Level 3 fair value measurement that is updated on a recurring basis at each reporting period using a valuation model. Consistent with Level 3 fair value measurements, there are significant inputs to the valuation model that are unobservable. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include highly liquid investments with original maturities of three months or less. As of December&#160;31, 2023 and 2022, cash equivalents consist primarily of money market funds.  The Company monitors concentration of credit risk with the financial institutions in which it conducts business.  The Company has cash deposits which fluctuate in excess of federally insured limits throughout the year.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable are recorded at the invoiced amount. The Company records allowances for amounts that could become uncollectible in the future based on historical experience, as well as amounts related to chargebacks and cash discounts. The Company reviews each customer balance to assess collection status.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s products are distributed through independent pharmaceutical wholesalers. The allowances against accounts receivable for chargebacks and discounts are determined on a product-by-product basis, and established by management as the Company&#8217;s best estimate at the time of sale based on each product&#8217;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks and discounts. The allowances in accounts receivable for chargebacks and cash discounts were $0.6 million at December&#160;31, 2023 and 2022. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#8217;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, revenues are reduced and accrued liabilities are increased by the Company&#8217;s estimate of the rebate that may be claimed. Cash discounts are reductions to invoiced amounts offered to customers for payment within a specified period of time from the date of the invoice.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company works closely with third parties to manufacture and package finished goods for sale. Based on the customer relationship with the manufacturer or packager, the Company will either take title to finished goods at the time of shipment or at the time of arrival from the manufacturer. The Company then warehouses such goods until distribution and sale at third party facilities located in the U.S. and international locations. Periodic inventory counts are made by the warehouse teams and by the Company on a regular basis. In addition, the Company re-tests API inventory prior to use to confirm product expiration. Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually evaluates inventories for potential losses due to expired, short-dated or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates the carrying value of a product may not be recoverable, a charge is recorded to reduce the inventory to its current net realizable value.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current inventories consist of active pharmaceutical ingredients which typically has an extended life and selected finished good products with extended life longer than one year. </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid and Other Current Assets</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid and other current assets consist of deferred offering costs, prepaid insurance premiums, prepaid consulting services, deposits and annual fees paid to the U.S. Food and Drug Administration ("FDA"). The Company expenses all prepaid and other current asset amounts as used or over the period of benefit primarily on a straight-line basis, as applicable.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, the Company filed its Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100&#160;million in corporate securities. The Shelf Registration was declared effective in January 2018. It also included an At the Market ("ATM") feature that allows the Company to sell common shares at market prices.  The Company filed an updated Form S-3 with the SEC in December 2020 (the &#8220;Prior Registration Statement&#8221;), which was declared effective in January 2021. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 27, 2021, the Company filed a related prospectus supplement in connection with the sale and issuance of shares having an aggregate gross sales price of up to $19&#160;million. The Company amended the ATM Sales Agreement on December 27, 2021, in order to allow the Company to continue using its ATM feature to sell shares at market prices.  This ATM program was under the Prior Registration Statement and is no longer active.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company filed an updated Form S-3 with the SEC on December 14, 2023, which was declared effective on December 26, 2023 (the &#8220;Current Registration Statement&#8221;).  The Company intends to enter into an agreement with H.C. Wainwright &amp; Co., LLC to establish a new ATM program under the Current Registration Statement.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recorded deferred offering costs for payments directly related to the current Shelf Registration on Form S-3 that was completed during December 2021 and December 2023. These costs consist of legal and accounting fees that the Company has capitalized. Deferred costs associated with the Shelf Registration will be reclassified to additional paid in capital on a pro-rata basis as the Company completes sales of shares under the Shelf Registration. The Company did not issue any shares under this ATM during the year ended December&#160;31, 2023. </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, including leasehold improvements, are stated at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the initial lease term plus renewal options, if reasonably assured, or the remaining useful life of the asset. Upon retirement or disposal of assets, any gain or loss is reflected as a component of operating loss in the consolidated statement of operations. Improvements that extend an asset&#8217;s useful life are capitalized. Repairs and maintenance costs are expensed as incurred.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible assets and goodwill consist of capitalized costs related to product and license rights, patents, trademarks and goodwill obtained in the Vibativ and Sancuso acquisitions. Goodwill is not amortized for financial reporting purposes, but is subject to impairment analysis at least annually.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of acquiring product and license rights are capitalized at fair value at the date of acquisition for products that are approved by the FDA for commercial use. These costs are amortized ratably over the estimated economic life of the product. The economic life is estimated based upon several factors. This includes the term of the license agreement, the patent life or market exclusivity of the product and as well as  management&#8217;s expectations of continued involvement with the product and the assessment of future sales, the future periods under which the product will be sold and the profitability of the product. This estimate is evaluated on a regular basis during the amortization period and adjusted if appropriate. If there are any changes made to the useful life of the product and license rights, the costs associated with such a change, if any, will be capitalized and amortized over the revised useful life.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Given the delay in identifying a packager for Omeclamox-Pak, the Company has taken a non-cash write down of the related intangible asset of $3.3 million. The financial statements reflect this adjustment as efforts to identify a packager continue.   </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized patent costs consist of outside legal costs associated with obtaining and protecting patents on products that have been approved for marketing by the FDA. If it becomes probable that a patent will not be issued or a patent has been declared invalid, related costs associated with the patent application are expensed at the time such determination is made. All costs associated with obtaining patents for products that have not been approved for marketing by the FDA are expensed as incurred. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense is recognized ratably over the following periods:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.141%"><tr><td style="width:1.0%"></td><td style="width:46.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated economic life</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License rights</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term of license agreement</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life of patent</span></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade and Note Receivables</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current Expected Credit Losses (&#8220;CECL&#8221;) is applicable to all financial assets measured at amortized cost. All financial instruments are evaluated, which principally relates to trade receivables and two notes receivable. CECL requires the measurement of expected credit losses on a collective (pool) basis when similar risk characteristics exist. This may include, either individually or in combination, some of the following characteristics of Accounting Standards Codification ("ASC") 326-20-55-5:</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Internal or external credit score/rating</span></div><div style="margin-top:2pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Risk ratings or classification</span></div><div style="margin-top:2pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Financial asset type</span></div><div style="margin-top:2pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Size</span></div><div style="margin-top:2pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Effective interest rate</span></div><div style="margin-top:2pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Term</span></div><div style="margin-top:2pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Geographical location</span></div><div style="margin-top:2pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Historical or expected credit loss patterns</span></div><div style="margin-top:2pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Reasonable and supportable forecast periods</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The standard requires entities to pool financial assets but allows them to choose which risk characteristics to use. Under the requirements of the guidance, the Company reassesses at the end of each reporting period whether the pool of assets continue to display similar risk characteristics.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With twenty years of experience, Cumberland has experienced virtually no write downs of receivables as most of our receivables are due from large successful pharmaceutical, healthcare or government customers, consistently making payments on account. Although the payment behaviors of all of our customers are consistently reliable, for the sake of transparency, we have separated our customer base into seven separate pools. The Company performs a monthly analysis of aged accounts receivable to determine how much, if any, of the accounts receivable balance should be reserved as potential bad debt. The Company reviews all balances over 90 days past due for a possible reserve and considers any specific factors or information for balances aged under 90 days if there are indicators that the balance should be reserved, such as other aged balances with the customer or bankruptcy as well as any economic issues with a customer, industry or region. The adoption of ASC 326 did not result in a material impact to the Company.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, such as property and equipment, operating lease right-of-use assets and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If events or circumstances arise that require a long-lived asset to be tested for potential impairment, the Company first compares undiscounted cash flows expected to be generated by the asset to its carrying value. If the carrying amount of the long-lived asset is not recoverable on an undiscounted cash flow basis, an impairment charge is recognized to the extent that the carrying value exceeds the fair value. Fair value is determined through various valuation techniques including quoted market prices, third-party independent appraisals and discounted cash flow models.   </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and other indefinite lived intangible assets that are not subject to amortization are tested at least annually for impairment. The impairment analysis for goodwill requires a comparison of fair value to the carrying value of the reporting unit. The Company&#8217;s goodwill was acquired in November 2018 with the Vibativ acquisition and in January 2022 with the Sancuso acquisition. As a result, the Vibativ and Sancuso components of the Company are the reporting units evaluated for goodwill impairment. Cumberland determined the fair value of the reporting units through current and future estimated revenue and profitability of the product. The Company recorded no impairment charges during 2022.  In 2023, given the delay in identifying a packager for Omeclamox-Pak the Company has taken a non-cash write down of the related intangible assets of $3.3 million, which is included in amortization expense in the statement operations.  These intangible assets consisted of product and license rights and trademarks.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Joint Venture Agreement</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, Cumberland entered into an agreement with WinHealth Investment (Singapore) Ltd creating WHC Biopharmaceuticals, Pte. Ltd. The joint venture, as a limited liability company, focuses on acquiring, developing, registering, and commercializing development stage and commercial stage biopharmaceuticals for China, Hong Kong and other Asian markets. The agreement provided for initial investment from WinHealth in the form of a $0.2&#160;million equity contribution and an initial investment from Cumberland in the form of $0.2&#160;million convertible note. The joint venture will seek additional future capital from additional investors and has entered into exclusive option agreements to license intellectual property from both Cumberland Pharmaceuticals Inc. and Cumberland Emerging Technologies.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recognized in the amount that reflects the consideration that we expect to receive for these goods. Depending upon the shipping terms of the transaction, the revenue is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation. This occurs upon either shipment of the product or arrival at its ship to destination. Payment terms typically range from 30 to 60 days from date of shipment. The Company&#8217;s net product revenue reflects the reduction from gross product revenue for estimated allowances for chargebacks, discounts and damaged goods, and reflects sales related accruals for rebates, coupons, product returns, and certain administrative and service fees. Significant judgments must be made in determining the transaction price for our sales of products related to these adjustments. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company revised its estimate for rebates related to Sancuso revenues based on additional information related to actual product activities.  As a result, the Company recognized additional revenue allowances of $0.6 million for rebates as a change of estimate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Rebates and Discounts</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowances against accounts receivable and accrued liabilities for chargebacks, discounts, service fees and expired product returns are determined on a product-by-product basis, and established by management as the Company&#8217;s best estimate at the time of sale based on each product&#8217;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and returns of expired product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#8217;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, sales revenues are reduced and accrued liabilities are increased by the Company&#8217;s estimate of the rebate that may be claimed.</span></div><div style="margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Returns</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, the Company maintains a return policy that allows customers to return product within a specified period prior to and subsequent to the expiration date. The Company&#8217;s estimate of the provision for returns is based upon historical experience, expiration date by product as well as any other factor </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expected to impact future returns. Any changes in the assumptions used to estimate the provision for returns are recognized in the period those assumptions are changed.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Revenues</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues primarily consist of income from grant funding programs, licensing agreements, leases and contract services. Revenue related to grants is recognized when all conditions related to such grants have been met. All other revenue is recognized when earned.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Products Sold</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold consists principally of the cost to acquire each unit of product sold, including in-bound freight expense as well as any adjustment in the net realizable value of inventory acquired in acquisitions. Cost of products sold also includes expenses associated with the reduction in the net realizable value of slow-moving or expired product.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling and Marketing Expense</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling and marketing expense consists primarily of expenses relating to the advertising, promotion, distribution and sale of products, including royalty expense, salaries and related costs.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distribution Costs</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distribution costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations. Distribution costs were as follows for the years ended December 31:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:65.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.790%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.792%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881,829&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857,842&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Costs</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations. Advertising costs were as follows for the years ended December 31:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:65.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.790%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.792%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advertising costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,903,741&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,927,041&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed in the period incurred. Research and development costs are comprised mainly of clinical trial expenses, salaries, wages and other related costs such as materials and supplies. Research and development expense includes activities performed by third-party providers participating in the Company&#8217;s clinical studies. The Company accounts for these costs based on estimates of work performed, patients enrolled or fixed fees for services over the period of time the clinical trials are performed.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for deferred taxes using the asset and liability approach. Under this method, deferred tax assets and liabilities are recognized for future tax consequences attributable to operating loss and tax credit carryforwards, as well as differences between the carrying amounts of existing assets and liabilities and their respective tax bases. The Company&#8217;s principal differences are related to the timing of deductibility of certain items, such as inventory, depreciation, amortization and share-based compensation. Deferred tax assets and liabilities are measured using enacted statutory tax rates that are expected to apply to taxable income in the years such temporary differences are anticipated to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. The Company only recognizes income tax benefits </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">associated with an income tax position in which it is &#8220;more likely than not&#8221; that the position would be sustained upon examination by the taxing authorities.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, management considers whether some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of existing temporary differences, projected future taxable income and tax planning strategies in making this assessment. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounting policy with respect to interest and penalties arising from income tax settlements is to recognize them as part of the provision for income taxes.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss per Share</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share is calculated by dividing net loss attributable to common shareholders by the weighted-average number of shares outstanding. Except where the result would be antidilutive, diluted loss per share is calculated by assuming the vesting of unvested restricted stock and the exercise of stock options and warrants and unrecognized compensation costs.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Payments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation cost for all share-based payments issued, modified, repurchased or canceled. Depending on the nature of the vesting provisions, restricted stock awards are measured using either the fair value on the grant date or the fair value of common stock on the date the vesting provisions lapse. Prior to the lapse for those equity grants not valued on the grant date, the fair value is measured on the last day of the reporting period.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Agreements</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment discussed in Note 3, related to the Vibativ and Sancuso contingent consideration payments, do not meet the criteria for accounting under ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The agreements do not specifically designate each party&#8217;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party. Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the consolidated statements of operations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Related Party Transactions</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, Cumberland named Martin S. Brown Jr. to our Board of Directors. Mr. Brown is an attorney with over 30 years of corporate law experience who brings significant legal, public company, health care and civic experience to our board. The Company relies on several law firms for legal advice, including the firm with which Mr. Brown is affiliated.  In 2023 and 2022, the Company paid Mr. Brown&#8217;s law firm $0.05 million and $0.04 million, respectively.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Adopted</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies are required to use a new forward-looking &#8220;expected loss&#8221; model that generally results in an earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies measure credit losses in a manner similar with previous guidance, except that the losses are recognized as </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allowances rather than as reductions in the amortized cost of the securities. Companies have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies apply the ASU&#8217;s provisions as a cumulative-effect adjustment, if any, to the accumulated deficit as of the beginning of the first reporting period in which the guidance is adopted.</span></div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. </span>The Company adopted both ASU 2016-13 and ASU 2019-05 on January 1, 2023<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289105007392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Vibativ&#174;, Sancuso&#174; and RediTrex&#174; Products<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Vibativ&#174;, Sancuso&#174; and RediTrex&#174; Products</a></td>
<td class="text">Vibativ<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Sancuso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">and RediTrex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Products</span><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vibativ</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2018, the Company executed an agreement with Theravance Biopharma ("Theravance") to acquire the assets and global rights to Vibativ including responsibility for the marketing, distribution, manufacturing and regulatory activities associated with the brand. Vibativ is a patented, FDA approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $20&#160;million at the closing of the transaction and a $5&#160;million milestone payment in early April 2019. In addition, Cumberland has agreed to pay royalties of up to 20% of on-going net sales of the product in the U.S. after a $2.5&#160;million threshold is met. The future royalty payments were recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland prepared the valuations of the contingent consideration liability utilizing significant unobservable inputs. As a result, the valuation is classified as Level 3 fair value measurement.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis. The contingent consideration earned and accrued in operating expenses is paid to Theravance annually.</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent Consideration Liability</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,515,627&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,133,113)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,104,690)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876,999&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,154,823&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,018,451)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(270,485)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,167,486&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,033,373&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current portion of the contingent consideration liability is $1.7&#160;million and the non-current portion is $2.3&#160;million, as of December&#160;31, 2023. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sancuso</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 3, 2022, Cumberland acquired the U.S. rights to the FDA-approved oncology-supportive care medicine Sancuso from Kyowa Kirin, Inc. ("Kyowa Kirin"), the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sancuso is the first and only FDA-approved prescription patch for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment. The active drug in Sancuso, granisetron, slowly dissolves in the thin layer of adhesive that sticks to the patient&#8217;s skin and is released into their bloodstream over several days, working continuously to prevent chemotherapy-induced nausea and vomiting (&#8220;CINV&#8221;). It is applied 24 to 48 hours before receiving chemotherapy and can prevent CINV for up to five consecutive days. Alternative oral treatments must be taken several times (day and night) to deliver the same therapeutic doses.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland acquired U.S. rights to Sancuso and assumed full commercial responsibility for the product in the U.S. &#8211; including its marketing, promotion, distribution, manufacturing and medical support activities. The product&#8217;s FDA registration was subsequently transferred from Kyowa Kirin to Cumberland in August 2023. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $13.5&#160;million at the closing of the transaction. The Agreement calls for milestone payments of up to $3.5&#160;million based on the attainment of various approvals and sales performance. In January 2023, Cumberland made a $1.0&#160;million milestone payment to Kwoya Kirin based on the FDA approval of a manufacturing site for the product. In October 2023, Cumberland made a $0.5&#160;million milestone payment based on the successful transfer of the product&#8217;s FDA registration from Kyowa Kirin to Cumberland.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining $2&#160;million in milestone payments are tied to achievement of certain annual sales levels for the product.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Cumberland has agreed to pay a royalty of up to 10% of on-going net sales of the product. The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland has prepared a valuation of the contingent consideration liability utilizing significant unobservable inputs. As a result, the valuation is classified as Level 3 fair value measurement. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition was funded by cash and the Company's revolving credit facility. The fair value for the assets and liabilities assumed using Level 3 fair value inputs were as follows: prepaid expenses of  $1.8&#160;million, inventory $2.6&#160;million, goodwill $0.03&#160;million, intangible assets $14.1&#160;million, milestone payable $1.7&#160;million and contingent liability $3.4&#160;million.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.271%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.215%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent Consideration Liability</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent Consideration Liability Including Milestone</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Balance at January 3, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3,384,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3,946,716&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash payment of royalty during the period</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1,075,631)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1,075,631)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Change in fair value</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">16,394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,210,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Contingent consideration earned and accrued</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">675,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">675,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Balance at December 31, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4,757,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash payment of royalty during the period</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(790,632)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(2,249,632)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Change in fair value</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(685,355)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(983,355)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Contingent consideration earned and accrued</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">781,987&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">781,987&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Balance at December 31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,306,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,306,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current portion of the contingent consideration liability is $1.3 million and the non-current portion is $1.0 million, as of December&#160;31, 2023. </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RediTrex</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the Company announced an agreement with the Nordic Group B.V. ("Nordic") to acquire the exclusive U.S. rights to Nordic&#8217;s injectable methotrexate product line designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the license Cumberland paid a deposit of $0.1 million at closing. The Company provided $0.9 million in consideration through a grant of 180,000 restricted shares of Cumberland common stock to be vested upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments tied to the products&#8217; FDA approval, launch and achievement of certain sales milestones. Under the terms of the agreement, Cumberland is responsible for the product registration and commercialization in the U.S. Nordic is responsible for product manufacturing and supply. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2019, Cumberland received FDA approval for the first Nordic injectable product and authorization to market them under the RediTrex brand name. The 180,000 shares of restricted Cumberland common stock previously provided to Nordic vested upon approval and were valued at $0.9 million on the vesting date. The FDA approval also resulted in a $1.0&#160;million milestone payment due to Nordic. This milestone payment was paid in July 2020. During December 2020, Cumberland began distributing RediTrex which also resulted in a $1.0&#160;million milestone payment due to Nordic. The full launch of RediTrex occurred in October 2021.</span></div>Effective July 12, 2022, the Company entered into an amendment to our agreement with Nordic whereby they may assume responsibility for RediTrex marketing authorization in the U.S. and the opportunity to commercialize the product in the U.S. after June 30, 2023.  In accordance with the terms of the amendment, Nordic a) returned the 180,000 restricted Cumberland shares we previously issued to Nordic which were cancelled; b) refunded to Cumberland the milestone payment of $1.0&#160;million we made associated with the brand&#8217;s U.S. approval; and c) issued a credit note in favor of the Company in the amount of $1.0&#160;million for the unpaid milestone payment due from us for launch of the product line all in 2023.  Cumberland will receive a long-term royalty on any Nordic sales of the product.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289202299152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text">Revenues<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenue</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net product revenues consisted of the following for the years ended December&#160;31:</span></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.085%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.088%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,981,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,205,155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,812,692&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,487,462&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,096,788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,205,603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,333,923&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,827,200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458,759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,030&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,145&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(447,697)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(341,886)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126,726)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,513,492&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,681,182&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with international partners for commercialization of the Company&#8217;s products with associated payments included in other revenues. Those agreements provide that each of the partners is responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner&#8217;s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies. The contractual payments associated with the partner&#8217;s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2023, the Company received $1 million relating to a litigation settlement based on two $500,000 milestone payments due to us for the license associated with our Vibativ product that is included in other revenue for the year ended  December&#160;31, 2023.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues includes funding from federal grant programs including those secured from the FDA and from those secured by CET through the Small Business Administration. Grant revenue from these federal grant programs totaled approximately $0.4 million and $0.2 million for the year ended December&#160;31, 2023 and 2022,respectively.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues also includes lease income generated by CET&#8217;s Life Sciences Center. It is a research facility that provides scientists with access to flexible lab space and other resources to develop biomedical products. This lease income, as noted in Footnote 15 - Leases, was approximately $0.5&#160;million for the years ended December&#160;31, 2023 and 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289195370080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories, Net</a></td>
<td class="text">Inventories, Net<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's net inventories consisted of the following as of December 31:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.265%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.178%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,619,092&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,899,659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods, net of reserve</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,645,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,322,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,413,891&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,390,748&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,804,529)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,527,167)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,609,362&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,863,581&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's non-current inventories consisted of the following as of December 31:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.178%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ - raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,611,426&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,138,936&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ - finished goods</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810,454&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose - raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,263,515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol - raw materials</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170,641&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor - finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso - raw materials</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574,502&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Study drug - raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,383&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Study drug - finished goods</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,757&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,804,529&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,527,167&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company purchases the active pharmaceutical ingredient (&#8220;API&#8221;) for Kristalose and maintains the inventory of that raw material.  API for the Company's Vaprisol and Vibativ brands were included in the assets associated with the acquisition of those brands and are also included in the raw materials inventory.  As part of the Vibativ acquisition, the Company acquired API and work in process inventories of $15.6 million that were all initially classified as non-current inventories at the date of acquisition.  Consigned inventory represents Authorized Generic inventory stored with Padagis until shipment.  </span></div>At December&#160;31, 2023, there were no cumulative obsolescence or discontinuance losses necessary to recognize.  At December 31, 2022, the Company had recognized and maintained cumulative net realizable value charges for potential obsolescence and discontinuance losses of approximately $0.5 million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289110811536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following at December&#160;31:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">useful lives</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;&#8211;&#160;5 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;&#8211;&#160;15 years&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771,667&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746,602&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;&#8211;&#160;15 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369,365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;&#8211;&#160;15 years,&#160;or remaining&#160;lease&#160;term</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800,974&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787,749&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">equipment, gross</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,605,976&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,369,224&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and amortization</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,238,073)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,085,185)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">equipment, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,903&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,039&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense, including amortization expense related to leasehold improvements, is included in general and administrative expense in the consolidated statements of operations. Depreciation expense was as follows for the years ended December 31:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.819%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,148&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,745&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289195566080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text">Intangible Assets and Goodwill<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets and Goodwill consisted of the following at December&#160;31, 2023 and 2022. </span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:51.387%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.692%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product and license rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,250,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,668,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,755,543)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,891,974)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product and license rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,494,798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,776,167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,712,405&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,610,228&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,819,287)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,051,018)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,893,118&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,559,210&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397,974&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(193,773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142,673)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,002&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,301&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,607,918&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,590,678&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product and license rights include assets associated with the Company&#8217;s acquired products, including those discussed in Note 3, Vibativ and Sancuso. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023 and 2022, the Company recorded an additional $0.1 million and $0.2 million, respectively, in intangible assets for patents, trademarks and capitalized patent costs, including amounts incurred in the protection of the Company's intellectual property. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to product and license rights, trademarks and patents were as follows for the years ended December 31:</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:51.387%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.692%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.695%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization and impairment expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,102,648&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,067,368&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected amortization expense for the Company's current balance of intangible assets are as follows:</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:73.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,304,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,245,825&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,859,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,452,780&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,745,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,607,918&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289105226992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current and Other Long-term Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrentAbstract', window );"><strong>Other Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">Other Current and Other Long-term Liabilities</a></td>
<td class="text">Other Current and Other Long-term Liabilities<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities consisted of the following at December&#160;31:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.697%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates, product returns, administrative fees </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and service fees</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,579,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,347,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee wages and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,197,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,440,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso related liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827,813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,226,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of accrued contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,424,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,006,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Studies accrual</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued inventory purchases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current deferred charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">961,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941,929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,596,528&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,587,911&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities consisted of the following at December 31:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.697%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of accrued contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,284,672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,931,513&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,894,894&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,522,506&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,453,566&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,585,019&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20,24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289110171584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 5, 2023, the Company entered into a new Revolving Credit Loan Agreement with Pinnacle Bank. This facility provides for an aggregate principal funding amount of up to $25&#160;million. The initial revolving line of credit is up to $20&#160;million, with the ability for Cumberland to increase the amount to $25&#160;million, under certain conditions. It has a three year term expiring on October 1, 2026. The interest rate is based on a benchmark (Term SOFR) plus a spread of 2.75%. Cumberland is subject to one financial covenant, the maintenance of a Funded Debt Ratio, determined on a quarterly basis. Borrowings under the line of credit are collateralized by substantially all of our assets.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 and December&#160;31, 2022, the Company had $12.8 million and $16.2 million, respectively, in borrowings outstanding under its revolving credit facility. The applicable interest rate under the Pinnacle Agreement was 8.125% at December&#160;31, 2023.  In 2022, under a previous agreement with Pinnacle Bank, the applicable interest rate was based on LIBOR plus an interest rate spread and was 6.75% at December 31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289105041744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text">Shareholders&#8217; Equity<div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Initial Public Offering</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;10, 2009, the Company completed its initial public offering of 5,000,000 shares of common stock at a price of $17.00 per share, raising gross proceeds of $85.0 million. After deducting underwriting discounts of approximately $6.0 million and offering costs incurred of approximately $4.2 million, the net proceeds to the Company were approximately $74.8 million. </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Preferred Stock</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue 20,000,000&#160;shares of preferred stock. The Board of Directors is authorized to divide these shares into classes or series, and to fix and determine the relative rights, preferences, qualifications and limitations of the shares of any class or series so established. At December&#160;31, 2023 and 2022, there was no preferred stock outstanding.</span></div><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Common Stock</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023 and 2022, the Company issued 157,360 shares and 171,655  shares of common stock, respectively, as a result of restricted shares vesting as well as other common share issuances. There were no option exercise transactions during 2023 and  2022.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Share Repurchases</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has a share repurchase program available to repurchase up to $10&#160;million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934.  The Company repurchased 402,143 shares and 367,793 shares of common stock for approximately $0.7 million and $1.0 million during the years ended December&#160;31, 2023 and 2022, respectively.  There remains approximately $3 million  available under the current repurchase program available for share repurchases at December&#160;31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289105226992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss Per Share</a></td>
<td class="text">Loss Per Share <div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the computation of the numerator and the denominator used to calculate diluted loss per share for the years ended December 31:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.791%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.412%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.415%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,330,766)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,650,039)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss at subsidiary attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,279,320)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,570,241)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,298,774&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,563,592&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,298,774&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,563,592&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's anti-dilutive restricted shares and stock options outstanding were as follows for the years ended December 31:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.791%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.412%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.415%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive shares and options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452,224&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,050&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289110211584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company's net deferred tax assets at December&#160;31 are as follows:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.573%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.575%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss and tax credits</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,427,801&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,164,754&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment and intangibles</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,307,178&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121,800&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,337,091&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866,942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,208,093&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481,455&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for expired product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616,979&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654,148&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">937,935&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,156,150&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative compensation costs incurred on deductible equity awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635,989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,417,101&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,708,719&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,547,773)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,150,935)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets, before valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,869,328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,557,784&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: deferred tax asset valuation allowance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,869,328)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,557,784)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amount and year of expiration of the Company's federal and state net operating loss carryforwards as of December&#160;31, 2023:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:55.561%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.606%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years of expiration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Federal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">State</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,756,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025-2042</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,709,390&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,333,628&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,405,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total federal and state net operating loss carryforwards</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,115,225&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,563,210&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense includes the following components for the years ended December 31:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.201%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.370%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,769&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,850&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,769&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,850&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective income tax rate for 2023 and 2022 reconciles with the federal statutory tax rate as follows: </span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:62.302%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.235%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.237%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal tax expense at statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax expense (net of federal income tax benefit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.58)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences associated with general business credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.96)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.76)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiring tax credits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.32)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred True-ups</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss tax expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.73)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.23)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that it is not more likely than not that its net deferred tax assets will be realized.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As such, the net deferred tax assets are fully offset with a valuation allowance as of the periods ended December&#160;31, 2023 and  2022.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company has general business credit carryforwards of $1.3&#160;million. These credit carryforwards will expire in years 2024 through 2044. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:64.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.925%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.341%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years of expiration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Federal</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,370&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025-2044</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,322,531&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total federal and state credit carryforwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340,901&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects it will continue to pay minimal taxes in future periods through the continued utilization of net operating loss carryforwards, as it is able to achieve taxable income through its operations.</span></div>The Company is no longer subject to U.S. federal tax examinations for tax years before 2020, and with few exceptions, the Company is not subject to examination by state tax authorities for tax years which ended before 2020. Loss carryforwards and credit carryforwards generated or utilized in years earlier than 2020 remain subject to examination and adjustment. The Company has no unrecognized tax benefits in 2023 and 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289104971248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation Plans</a></td>
<td class="text">Stock-Based Compensation Plans<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has grants outstanding under two equity compensation plans. The 2007 Long-Term Incentive Compensation Plan (the "2007 Plan") and the 2007 Directors&#8217; Incentive Plan (the "Directors&#8217; Plan"), which were approved by shareholders, superseded the 1999 Stock Option Plan. Both plans are available for future grants of equity compensation awards to employees, consultants and directors. The 2007 Plan and the Directors&#8217; Plan provide for the issuance of stock options, stock appreciation rights and restricted stock. Vesting is determined on a grant-by-grant basis in accordance with the terms of the plans and the related grant agreements. The Company has reserved 3.2 million shares of common stock for issuance under the 2007 Plan and 250,000 shares for issuance under the Directors&#8217; Plan.  As of December&#160;31, 2023, the Company had 933,517 shares available for future grants under the 2007 Plan and 130,507 shares available under the Directors&#8217; Plan.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price of stock options is generally 100% of the fair market value of the underlying common stock on the grant date, except for incentive stock options granted to 10% shareholders, which the exercise price is no less than 110% of the fair market value.  The maximum contractual term of stock options is ten years from the grant date, except for incentive stock options granted to 10% shareholders, which is no more than five years.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2011, the Company began issuing shares of restricted stock with no exercise price to employees and directors. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the grant date. Restricted stock issued to directors vests on the one year anniversary of the grant date.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock compensation expense is presented as a component of general and administrative expense in the consolidated statements of operations. Stock compensation expense was $0.4&#160;million for the years ended December&#160;31, 2023 and 2022.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023, there was approximately $0.5 million of unrecognized compensation cost related to share-based payments, which is expected to be recognized over a weighted-average period of 1.85 years. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options activity was as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:35.176%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.286%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">of option shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">exercise price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-average remaining contractual term</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/canceled</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,900)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.98&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,650&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.15</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.06&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/canceled</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,150)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.55&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487,250&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.65&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.59</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The weighted-average grant-date fair value of options granted during  the years 2023 and 2022 was 1.16 and  1.29, respectively.  No options were vested and exercisable at December&#160;31, 2023.  The aggregate intrinsic value of options outstanding was minimal.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options is calculated using the Black-Scholes (&#8220;Black-Scholes-Merton&#8221;, or &#8220;BSM&#8221;) option-pricing model on the grant date. Since 2012, the Company had been issuing Restricted Share Awards where the grant date Fair Value (&#8220;FV&#8221;) equaled the closing share price. The assumptions used in the Black-Scholes valuation to determine the FV of stock options were as follows at December 31: </span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.470%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.311%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.71</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.88</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Term - The Company has estimated the expected life of its stock options using the simplified method, whereby the expected life equals the average of the vesting term and the original contractual term of the option. </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company&#8217;s historical stock price volatility.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk Free rate - The Company bases the risk-free interest rate assumption for equity awards on the rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expected dividend yield - The Company&#8217;s expected dividend yield assumption is zero as it has never paid dividends and has no present intention to do so in the future.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock activity was as follows:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.117%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.312%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-average grant-date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">fair value</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,225&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested/released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171,655)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/canceled</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395,751&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,250&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.93&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested/released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157,360)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/canceled</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,075)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,566&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.14&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of restricted stock granted was based on the closing market price of the Company&#8217;s common stock on the grant date. The fair value of restricted stock awards that vested during the years 2023 and 2022 was $0.3 million and $0.5 million, respectively.  At December&#160;31, 2023, there was approximately $0.2&#160;million of unrecognized compensation costs related to restricted stock awards, which is expected to be recognized over a weighted-average period of less than a year.  The restricted stock grants are included in the diluted weighted shares outstanding computation until they cliff-vest. Once vested they are included in the basic weighted shares outstanding computation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289110164384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsAbstract', window );"><strong>Postemployment Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text">Employee Benefit Plans<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors an employee benefit plan that was established on January&#160;1, 2006, the Cumberland Pharmaceuticals 401(k) Plan (the&#160;"Plan"), under Section&#160;401(k) of the Internal Revenue Code of 1986, as amended, for the benefit of all employees over the age of 21, having been employed by the Company for at least six months. The Plan provides that participants may contribute up to the maximum amount of their compensation as set forth by the Internal Revenue Service each year. Employee contributions are invested in various investment funds based upon elections made by the employees. During 2023 and 2022, the Company contributed approximately $0.08 million and $0.06 million, respectively, in each year to the Plan as an employer match of participant contributions.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012 and 2013, the Company established non-qualified unfunded deferred compensation plans that allow participants to defer receipt of a portion of their compensation. The liability under the plans, reflected in other long term liabilities in the consolidated balance sheets, was $2.9 million and $2.5 million as of December&#160;31, 2023 and 2022, respectively. The Company had assets consisting of company-owned life insurance contracts generally designated to pay benefits of the deferred compensation plans reflected in other assets in the consolidated balance sheet of $2.4 million and $2.3 million as of December&#160;31, 2023 and 2022, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289104933168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 15, 2021, Cumberland entered into a lease, pursuant to which the Company leases approximately 16,903 rentable square feet of space at the new development Broadwest located in Nashville, Tennessee with 1600 West End Avenue Partners, LLC. The leased premise serves as the Company's new corporate headquarters. The initial term of the lease is one hundred fifty-seven (157) months, with two consecutive options to renew for a period of five years each, with the commencement date of October 25, 2022. This lease currently expires in November 2035.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for paying rent to the Landlord under the lease beginning three months after the commencement date. The Company pays a base rent of $33.06 per square foot of rentable space with a gradual rental rate increase of 2.5% for each year period thereafter of the prior year's base rental. In addition to the monthly base rent, the Company is responsible for its percentage share of the operating expenses of the building. The lease also provides for a tenant improvement allowance for the space. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 24, 2022, the CET lease with The Gateway to Nashville, LLC provided the notice of exercise to extend the lease for five years.  The lease is for approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee where CET operates the CET Life Sciences Center.The wet laboratory and office space is leased through April 2028. The Company also subleases a portion of the space under this lease.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also included within the right-of-use assets are start up expenditures related to a new supply agreement with Nephron Pharmaceuticals Corporation (&#8220;Nephron&#8221;).   These expenditures are classified as an embedded lease resulting in a right-of-use asset to be amortized over the life of the Nephron contract.  As of December&#160;31, 2023, the value of this asset was $1.0 million.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense is recognized over the expected term of the lease on a straight-line basis as a component of general and administrative expense. Rent expense and sublease income  as follows for the years ended December 31:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.210%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304,865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,159,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544,138&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529,411&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the FASB issued ASU 2016-02. ASU 2016-02&#8217;s core principle is to increase transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information. The primary effect of adopting ASU 2016-02 to the Company was to record right-of-use assets and obligations for the leases currently classified as operating leases. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities were recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As the Company&#8217;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at October 25, 2022 and May 1, 2023. Incremental borrowing rates reflect the Company&#8217;s estimated interest rates for collateralized borrowings over similar lease terms. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average remaining lease term for the Broadwest and Gateway leases is 10.42 years and 12.69 years for the years ended December 31, 2023 and 2022, respectively.. The weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments of both leases is 9.40% and 9.24% for the years ended December 31, 2023 and 2023, respectively.</span></div><div style="margin-top:8pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    Lease Position</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023 and 2022, the Company recorded the following on the Consolidated Balance Sheet: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-Use Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,674,394&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,218,403&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348,092&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,910&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,296,247&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,586,301&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,644,339&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,759,211&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $0.3 million and will be paid through the leases ending in April 2024. Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.132%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of Leases Liabilities at December&#160;31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863,320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836,100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934,180&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,847,400&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,131,702&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,487,363)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,644,339&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289110146496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Market Concentrations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">Market Concentrations</a></td>
<td class="text">Market Concentrations<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s principal financial instruments subject to potential concentration of credit risk are accounts receivable, which are unsecured, and cash equivalents. The Company&#8217;s cash equivalents consist primarily of money market funds. Certain bank deposits may be in excess of the insurance limits provided by the Federal Deposit Insurance Corporation.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s primary customers are wholesale pharmaceutical distributors in the U.S. &#160;Total revenues by customer for each customer representing 10% or more of consolidated revenues are summarized below for the years ended December 31: </span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.594%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts receivable, net of allowances, due from the customers representing 10% or more of consolidated revenue was 62.3% and 51.8% at December&#160;31, 2023 and 2022, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289105071632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Manufacturing and Supply Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ManufacturingAndSupplyAgreementsAbstract', window );"><strong>Manufacturing and Supply Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ManufacturingAndSupplyAgreementsTextBlock', window );">Manufacturing and Supply Agreements</a></td>
<td class="text">Manufacturing and Supply Agreements<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes one or two primary suppliers to manufacture each of its products and product candidates. Although there are a limited number of manufacturers of pharmaceutical products, the Company believes it could utilize other suppliers to manufacture its prescription products on comparable terms. A change in suppliers, problems with its third-party manufacturing operations or related production capacity, or contract disputes with suppliers could cause a delay in manufacturing or shipment of finished goods and possible loss of sales, which could adversely affect operating results.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ManufacturingAndSupplyAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Manufacturing and Supply Agreements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ManufacturingAndSupplyAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ManufacturingAndSupplyAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Manufacturing and Supply Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ManufacturingAndSupplyAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289104406688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employment Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_EmploymentAgreementsAbstract', window );"><strong>Employment Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_EmploymentAgreementsTextBlock', window );">Employment Agreements</a></td>
<td class="text">Employment Agreements<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment agreements with all its full-time employees. Each employment agreement provides for a salary for services performed, a potential annual bonus and, if applicable, a grant of restricted common shares pursuant to a restricted stock and incentive stock option agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_EmploymentAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employment Agreements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_EmploymentAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_EmploymentAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employment Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_EmploymentAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289105226992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its licensing agreements for Caldolor,  the Company is required to pay royalties based on net sales over the life of the product. Royalty expense is recognized as a component of selling and marketing expense in the period that revenue is recognized. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Vibativ, the Company is required to pay royalties based on net sales of the product. At the purchase date, Cumberland recorded the fair value of this liability and will continue to evaluate the liability each period and the royalty expense is recognized as a component of selling and marketing expense in the period that the change in fair value is recognized. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Sancuso, the Company is required to pay up to $3.5&#160;million in milestones and tiered royalties ranging from 10% to 5% on U.S. net product sales for ten years.   </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has a number of patents issued through the United States Patent and Trademark Office (the &#8220;USPTO&#8221;) including U.S. Patent number 8,148,356 (the &#8220;356 Acetadote Patent&#8221;) which is assigned to the Company. The claims of the 356 Acetadote Patent encompass the new Acetadote formulation and include composition of matter claims. Following its issuance, the 356 Acetadote Patent was listed in the FDA Orange Book. The 356 Acetadote Patent is scheduled to expire in May 2026, which time period includes a 270-day patent term adjustment granted by the USPTO.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2012, Cumberland has continued to vigorously defend and protect its Acetadote product and related intellectual property rights including the use of all its legal options. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Melinta Litigation</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2022, the Company filed an action for breach of contract against Melinta Therapeutics, LLC and Targanta Therapeutics Corporation (collectively, the &#8220;Defendants&#8221;) in the United States District Court for the Southern District of New York (Case No. 1:22-cv-00915-VM). The Company and the Defendants are parties to an agreement (the &#8220;Agreement&#8221;), pursuant to which the Defendants have a license to develop and commercialize products under certain Company patents, in exchange for the Defendants paying the Company certain milestone payments and royalties on net sales of the licensed products. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, the Agreement requires the Defendants to, among other things, make a $500,000 payment to the Company within 30 days following the first filing of an sNDA in relation to the Product (as defined by the Agreement) and a $500,000 payment to the Company following the approval of the first sNDA in relation to the Product. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After Defendants disclosed the domiciles of its limited partners to the Company, as required by the Court, on October 24, 2022, the action for breach of contract was refiled in the Supreme Court of the State of New York, County of New York (Index No. 654234/2022) on November 7, 2022.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The complaint alleges that, despite the Defendants filing an NDA and sNDA for the Product and receiving FDA approval for both applications, the Defendants failed to make the required total of $1&#160;million in milestone payments to the Company. The Company was seeking damages in the amount of no less than $1&#160;million, pre- and post-judgment interest under N.Y. C.P.L.R. &#167; 5001, costs, and such further relief as the court deems just and proper.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     On April 18, 2023 the state court ruled in favor of the Company.  On June 16, 2023, the Company received consideration related to the breach of contract action with the Defendants that finalized a settlement agreement that was entered into by the Company and the Defendants to close the case.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289105075056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Information (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Financial Information (Unaudited)</a></td>
<td class="text">Quarterly Financial Information (Unaudited)<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the unaudited operating results for each fiscal quarter of 2023 and 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.605%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">First</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Second</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Third</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fourth</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,224,638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,888,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,085,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,353,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,552,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,531,678)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,866,603)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,179,239)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,554,661)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">862,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,063,219)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,301,987)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,330,766)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">872,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,049,298)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,294,406)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,279,320)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share attributable to common shareholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,175,045&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,299,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,413,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,123,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,010,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,291,999)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,846,538)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(288,588)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,277,804)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,704,929)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,402,433)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,364,666)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(423,226)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,459,714)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,650,039)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,385,253)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,335,620)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(408,639)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,440,729)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,570,241)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share attributable to common shareholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Due to the nature of interim earnings per share calculations, the sum of the quarterly earnings (loss) per share amounts may not equal the reported earnings (loss) per share for the full year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482964/270-10-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 270<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//270/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289105239728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to common shareholders</a></td>
<td class="num">$ (6,294,406)<span></span>
</td>
<td class="num">$ (1,049,298)<span></span>
</td>
<td class="nump">$ 872,200<span></span>
</td>
<td class="nump">$ 192,184<span></span>
</td>
<td class="num">$ (2,440,729)<span></span>
</td>
<td class="num">$ (408,639)<span></span>
</td>
<td class="num">$ (1,335,620)<span></span>
</td>
<td class="num">$ (1,385,253)<span></span>
</td>
<td class="num">$ (6,279,320)<span></span>
</td>
<td class="num">$ (5,570,241)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289105164240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289100646832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements of the Company are stated in U.S. dollars and are prepared using U.S. generally accepted accounting principles. These financial statements include the accounts of the Company and its wholly and majority-owned subsidiaries. All significant intercompany transactions and accounts have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates under different assumptions and conditions. The Company&#8217;s most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory, (3) valuation of contingent consideration liability associated with business combinations and (4) evaluation of continuing utility of intangible assets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div>The Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, evaluated that our specialty pharmaceutical products compete in similar economic markets and similar circumstances. Substantially all of the Company&#8217;s assets are located in the United States. Total revenues are primarily attributable to U.S.&#160;customers.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of financial assets and liabilities is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date. The Company&#8217;s fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements. It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 -   Quoted prices for identical instruments in active markets.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 -  Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 -    Significant inputs to the valuation model are unobservable.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain policies and procedures to value instruments using the best and most relevant data available. The following section describes the valuation methodologies we use to measure different financial instruments at fair value on a recurring basis.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, contingent consideration liability and a revolving line of credit. The carrying values for cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to their short-term nature. The revolving line of credit has a variable interest rate, which approximates the current market rate.</span></div>The Company&#8217;s contingent consideration liability is a Level 3 fair value measurement that is updated on a recurring basis at each reporting period using a valuation model. Consistent with Level 3 fair value measurements, there are significant inputs to the valuation model that are unobservable.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include highly liquid investments with original maturities of three months or less. As of December&#160;31, 2023 and 2022, cash equivalents consist primarily of money market funds.  The Company monitors concentration of credit risk with the financial institutions in which it conducts business.  The Company has cash deposits which fluctuate in excess of federally insured limits throughout the year.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable are recorded at the invoiced amount. The Company records allowances for amounts that could become uncollectible in the future based on historical experience, as well as amounts related to chargebacks and cash discounts. The Company reviews each customer balance to assess collection status.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s products are distributed through independent pharmaceutical wholesalers. The allowances against accounts receivable for chargebacks and discounts are determined on a product-by-product basis, and established by management as the Company&#8217;s best estimate at the time of sale based on each product&#8217;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks and discounts. The allowances in accounts receivable for chargebacks and cash discounts were $0.6 million at December&#160;31, 2023 and 2022. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#8217;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, revenues are reduced and accrued liabilities are increased by the Company&#8217;s estimate of the rebate that may be claimed. Cash discounts are reductions to invoiced amounts offered to customers for payment within a specified period of time from the date of the invoice.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company works closely with third parties to manufacture and package finished goods for sale. Based on the customer relationship with the manufacturer or packager, the Company will either take title to finished goods at the time of shipment or at the time of arrival from the manufacturer. The Company then warehouses such goods until distribution and sale at third party facilities located in the U.S. and international locations. Periodic inventory counts are made by the warehouse teams and by the Company on a regular basis. In addition, the Company re-tests API inventory prior to use to confirm product expiration. Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually evaluates inventories for potential losses due to expired, short-dated or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates the carrying value of a product may not be recoverable, a charge is recorded to reduce the inventory to its current net realizable value.</span></div>Non-current inventories consist of active pharmaceutical ingredients which typically has an extended life and selected finished good products with extended life longer than one year.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock', window );">Prepaid and Other Current Assets</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid and Other Current Assets</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid and other current assets consist of deferred offering costs, prepaid insurance premiums, prepaid consulting services, deposits and annual fees paid to the U.S. Food and Drug Administration ("FDA"). The Company expenses all prepaid and other current asset amounts as used or over the period of benefit primarily on a straight-line basis, as applicable.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, including leasehold improvements, are stated at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the initial lease term plus renewal options, if reasonably assured, or the remaining useful life of the asset. Upon retirement or disposal of assets, any gain or loss is reflected as a component of operating loss in the consolidated statement of operations. Improvements that extend an asset&#8217;s useful life are capitalized. Repairs and maintenance costs are expensed as incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible assets and goodwill consist of capitalized costs related to product and license rights, patents, trademarks and goodwill obtained in the Vibativ and Sancuso acquisitions. Goodwill is not amortized for financial reporting purposes, but is subject to impairment analysis at least annually.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of acquiring product and license rights are capitalized at fair value at the date of acquisition for products that are approved by the FDA for commercial use. These costs are amortized ratably over the estimated economic life of the product. The economic life is estimated based upon several factors. This includes the term of the license agreement, the patent life or market exclusivity of the product and as well as  management&#8217;s expectations of continued involvement with the product and the assessment of future sales, the future periods under which the product will be sold and the profitability of the product. This estimate is evaluated on a regular basis during the amortization period and adjusted if appropriate. If there are any changes made to the useful life of the product and license rights, the costs associated with such a change, if any, will be capitalized and amortized over the revised useful life.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Given the delay in identifying a packager for Omeclamox-Pak, the Company has taken a non-cash write down of the related intangible asset of $3.3 million. The financial statements reflect this adjustment as efforts to identify a packager continue.   </span></div>Capitalized patent costs consist of outside legal costs associated with obtaining and protecting patents on products that have been approved for marketing by the FDA. If it becomes probable that a patent will not be issued or a patent has been declared invalid, related costs associated with the patent application are expensed at the time such determination is made. All costs associated with obtaining patents for products that have not been approved for marketing by the FDA are expensed as incurred.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Trade and Note Receivables</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade and Note Receivables</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current Expected Credit Losses (&#8220;CECL&#8221;) is applicable to all financial assets measured at amortized cost. All financial instruments are evaluated, which principally relates to trade receivables and two notes receivable. CECL requires the measurement of expected credit losses on a collective (pool) basis when similar risk characteristics exist. This may include, either individually or in combination, some of the following characteristics of Accounting Standards Codification ("ASC") 326-20-55-5:</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Internal or external credit score/rating</span></div><div style="margin-top:2pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Risk ratings or classification</span></div><div style="margin-top:2pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Financial asset type</span></div><div style="margin-top:2pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Size</span></div><div style="margin-top:2pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Effective interest rate</span></div><div style="margin-top:2pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Term</span></div><div style="margin-top:2pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Geographical location</span></div><div style="margin-top:2pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Historical or expected credit loss patterns</span></div><div style="margin-top:2pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Reasonable and supportable forecast periods</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The standard requires entities to pool financial assets but allows them to choose which risk characteristics to use. Under the requirements of the guidance, the Company reassesses at the end of each reporting period whether the pool of assets continue to display similar risk characteristics.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With twenty years of experience, Cumberland has experienced virtually no write downs of receivables as most of our receivables are due from large successful pharmaceutical, healthcare or government customers, consistently making payments on account. Although the payment behaviors of all of our customers are consistently reliable, for the sake of transparency, we have separated our customer base into seven separate pools. The Company performs a monthly analysis of aged accounts receivable to determine how much, if any, of the accounts receivable balance should be reserved as potential bad debt. The Company reviews all balances over 90 days past due for a possible reserve and considers any specific factors or information for balances aged under 90 days if there are indicators that the balance should be reserved, such as other aged balances with the customer or bankruptcy as well as any economic issues with a customer, industry or region. The adoption of ASC 326 did not result in a material impact to the Company.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div>Long-lived assets, such as property and equipment, operating lease right-of-use assets and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If events or circumstances arise that require a long-lived asset to be tested for potential impairment, the Company first compares undiscounted cash flows expected to be generated by the asset to its carrying value. If the carrying amount of the long-lived asset is not recoverable on an undiscounted cash flow basis, an impairment charge is recognized to the extent that the carrying value exceeds the fair value. Fair value is determined through various valuation techniques including quoted market prices, third-party independent appraisals and discounted cash flow models.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recognized in the amount that reflects the consideration that we expect to receive for these goods. Depending upon the shipping terms of the transaction, the revenue is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation. This occurs upon either shipment of the product or arrival at its ship to destination. Payment terms typically range from 30 to 60 days from date of shipment. The Company&#8217;s net product revenue reflects the reduction from gross product revenue for estimated allowances for chargebacks, discounts and damaged goods, and reflects sales related accruals for rebates, coupons, product returns, and certain administrative and service fees. Significant judgments must be made in determining the transaction price for our sales of products related to these adjustments. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company revised its estimate for rebates related to Sancuso revenues based on additional information related to actual product activities.  As a result, the Company recognized additional revenue allowances of $0.6 million for rebates as a change of estimate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Rebates and Discounts</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowances against accounts receivable and accrued liabilities for chargebacks, discounts, service fees and expired product returns are determined on a product-by-product basis, and established by management as the Company&#8217;s best estimate at the time of sale based on each product&#8217;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and returns of expired product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#8217;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, sales revenues are reduced and accrued liabilities are increased by the Company&#8217;s estimate of the rebate that may be claimed.</span></div><div style="margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Returns</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, the Company maintains a return policy that allows customers to return product within a specified period prior to and subsequent to the expiration date. The Company&#8217;s estimate of the provision for returns is based upon historical experience, expiration date by product as well as any other factor </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expected to impact future returns. Any changes in the assumptions used to estimate the provision for returns are recognized in the period those assumptions are changed.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Revenues</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues primarily consist of income from grant funding programs, licensing agreements, leases and contract services. Revenue related to grants is recognized when all conditions related to such grants have been met. All other revenue is recognized when earned.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Products Sold</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Products Sold</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold consists principally of the cost to acquire each unit of product sold, including in-bound freight expense as well as any adjustment in the net realizable value of inventory acquired in acquisitions. Cost of products sold also includes expenses associated with the reduction in the net realizable value of slow-moving or expired product.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling and Marketing Expense</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling and marketing expense consists primarily of expenses relating to the advertising, promotion, distribution and sale of products, including royalty expense, salaries and related costs.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distribution Costs</span></div>Distribution costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Costs</span></div>Advertising costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed in the period incurred. Research and development costs are comprised mainly of clinical trial expenses, salaries, wages and other related costs such as materials and supplies. Research and development expense includes activities performed by third-party providers participating in the Company&#8217;s clinical studies. The Company accounts for these costs based on estimates of work performed, patients enrolled or fixed fees for services over the period of time the clinical trials are performed.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for deferred taxes using the asset and liability approach. Under this method, deferred tax assets and liabilities are recognized for future tax consequences attributable to operating loss and tax credit carryforwards, as well as differences between the carrying amounts of existing assets and liabilities and their respective tax bases. The Company&#8217;s principal differences are related to the timing of deductibility of certain items, such as inventory, depreciation, amortization and share-based compensation. Deferred tax assets and liabilities are measured using enacted statutory tax rates that are expected to apply to taxable income in the years such temporary differences are anticipated to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. The Company only recognizes income tax benefits </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">associated with an income tax position in which it is &#8220;more likely than not&#8221; that the position would be sustained upon examination by the taxing authorities.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, management considers whether some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of existing temporary differences, projected future taxable income and tax planning strategies in making this assessment. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounting policy with respect to interest and penalties arising from income tax settlements is to recognize them as part of the provision for income taxes.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (Loss) Per Share</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss per Share</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share is calculated by dividing net loss attributable to common shareholders by the weighted-average number of shares outstanding. Except where the result would be antidilutive, diluted loss per share is calculated by assuming the vesting of unvested restricted stock and the exercise of stock options and warrants and unrecognized compensation costs.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Payments</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Payments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation cost for all share-based payments issued, modified, repurchased or canceled. Depending on the nature of the vesting provisions, restricted stock awards are measured using either the fair value on the grant date or the fair value of common stock on the date the vesting provisions lapse. Prior to the lapse for those equity grants not valued on the grant date, the fair value is measured on the last day of the reporting period.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Agreements</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Agreements</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment discussed in Note 3, related to the Vibativ and Sancuso contingent consideration payments, do not meet the criteria for accounting under ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The agreements do not specifically designate each party&#8217;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party. Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the consolidated statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Guidance</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Adopted</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies are required to use a new forward-looking &#8220;expected loss&#8221; model that generally results in an earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies measure credit losses in a manner similar with previous guidance, except that the losses are recognized as </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allowances rather than as reductions in the amortized cost of the securities. Companies have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies apply the ASU&#8217;s provisions as a cumulative-effect adjustment, if any, to the accumulated deficit as of the beginning of the first reporting period in which the guidance is adopted.</span></div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. </span>The Company adopted both ASU 2016-13 and ASU 2019-05 on January 1, 2023<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaids and Other Current Assets, Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org//705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289105230016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of intangible assets</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense is recognized ratably over the following periods:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.141%"><tr><td style="width:1.0%"></td><td style="width:46.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated economic life</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License rights</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term of license agreement</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life of patent</span></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets and Goodwill consisted of the following at December&#160;31, 2023 and 2022. </span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:51.387%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.692%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product and license rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,250,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,668,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,755,543)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,891,974)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product and license rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,494,798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,776,167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,712,405&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,610,228&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,819,287)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,051,018)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,893,118&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,559,210&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397,974&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(193,773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142,673)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,002&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,301&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,607,918&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,590,678&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ScheduleOfDistributionCostsTableTextBlock', window );">Schedule of Distribution Costs</a></td>
<td class="text">Distribution costs were as follows for the years ended December 31:<div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:65.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.790%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.792%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881,829&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857,842&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ScheduleOfAdvertisingCostsTableTextBlock', window );">Schedule of Advertising Costs</a></td>
<td class="text">Advertising costs were as follows for the years ended December 31:<div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:65.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.790%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.792%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advertising costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,903,741&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,927,041&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ScheduleOfAdvertisingCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Advertising Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ScheduleOfAdvertisingCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ScheduleOfDistributionCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Distribution Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ScheduleOfDistributionCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289104933168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Vibativ&#174;, Sancuso&#174; and RediTrex&#174; Products (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Schedule of Business Acquisitions by Acquisition, Contingent Consideration</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis. The contingent consideration earned and accrued in operating expenses is paid to Theravance annually.</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent Consideration Liability</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,515,627&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,133,113)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,104,690)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876,999&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,154,823&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,018,451)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(270,485)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,167,486&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,033,373&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.271%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.215%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent Consideration Liability</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent Consideration Liability Including Milestone</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Balance at January 3, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3,384,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3,946,716&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash payment of royalty during the period</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1,075,631)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1,075,631)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Change in fair value</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">16,394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,210,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Contingent consideration earned and accrued</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">675,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">675,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Balance at December 31, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4,757,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash payment of royalty during the period</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(790,632)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(2,249,632)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Change in fair value</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(685,355)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(983,355)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Contingent consideration earned and accrued</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">781,987&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">781,987&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Balance at December 31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,306,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,306,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289110211584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of net product revenues by product</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net product revenues consisted of the following for the years ended December&#160;31:</span></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.085%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.088%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,981,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,205,155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,812,692&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,487,462&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,096,788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,205,603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,333,923&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,827,200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458,759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,030&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,145&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(447,697)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(341,886)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126,726)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,513,492&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,681,182&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289100591888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's net inventories consisted of the following as of December 31:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.265%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.178%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,619,092&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,899,659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods, net of reserve</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,645,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,322,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,413,891&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,390,748&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,804,529)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,527,167)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,609,362&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,863,581&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock', window );">Schedule of Inventory, Noncurrent</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's non-current inventories consisted of the following as of December 31:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.178%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ - raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,611,426&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,138,936&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ - finished goods</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810,454&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose - raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,263,515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol - raw materials</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170,641&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor - finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso - raw materials</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574,502&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Study drug - raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,383&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Study drug - finished goods</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,757&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,804,529&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,527,167&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle including inventoried costs relating to long-term contracts or programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289100586640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following at December&#160;31:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">useful lives</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;&#8211;&#160;5 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;&#8211;&#160;15 years&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771,667&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746,602&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;&#8211;&#160;15 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369,365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;&#8211;&#160;15 years,&#160;or remaining&#160;lease&#160;term</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800,974&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787,749&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">equipment, gross</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,605,976&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,369,224&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and amortization</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,238,073)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,085,185)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">equipment, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,903&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,039&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ScheduleofDepreciationExpenseTableTextBlock', window );">Schedule of depreciation expense</a></td>
<td class="text">Depreciation expense was as follows for the years ended December 31:<div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.819%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,148&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,745&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ScheduleofDepreciationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Depreciation Expense [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ScheduleofDepreciationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289105316512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of intangible assets</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense is recognized ratably over the following periods:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.141%"><tr><td style="width:1.0%"></td><td style="width:46.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated economic life</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License rights</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term of license agreement</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life of patent</span></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets and Goodwill consisted of the following at December&#160;31, 2023 and 2022. </span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:51.387%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.692%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product and license rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,250,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,668,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,755,543)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,891,974)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product and license rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,494,798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,776,167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,712,405&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,610,228&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,819,287)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,051,018)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,893,118&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,559,210&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397,974&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(193,773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142,673)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,002&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,301&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,607,918&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,590,678&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of expected amortization expense of intangible assets</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to product and license rights, trademarks and patents were as follows for the years ended December 31:</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:51.387%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.692%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.695%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization and impairment expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,102,648&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,067,368&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected amortization expense for the Company's current balance of intangible assets are as follows:</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:73.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,304,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,245,825&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,859,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,452,780&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,745,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,607,918&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289105170464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current and Other Long-term Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrentAbstract', window );"><strong>Other Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued liabilities</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities consisted of the following at December&#160;31:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.697%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates, product returns, administrative fees </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and service fees</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,579,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,347,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee wages and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,197,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,440,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso related liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827,813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,226,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of accrued contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,424,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,006,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Studies accrual</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued inventory purchases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current deferred charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">961,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941,929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,596,528&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,587,911&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock', window );">Schedule of other long-term liabilities</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities consisted of the following at December 31:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.697%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of accrued contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,284,672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,931,513&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,894,894&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,522,506&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,453,566&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,585,019&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other noncurrent liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289103630032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of calculation of numerator and denominator in earnings per share</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the computation of the numerator and the denominator used to calculate diluted loss per share for the years ended December 31:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.791%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.412%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.415%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,330,766)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,650,039)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss at subsidiary attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,279,320)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,570,241)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,298,774&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,563,592&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,298,774&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,563,592&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of anti-dilutive securities excluded from computation of earnings per share</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's anti-dilutive restricted shares and stock options outstanding were as follows for the years ended December 31:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.791%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.412%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.415%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive shares and options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452,224&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,050&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289098131008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities, net</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company's net deferred tax assets at December&#160;31 are as follows:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.573%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.575%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss and tax credits</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,427,801&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,164,754&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment and intangibles</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,307,178&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121,800&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,337,091&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866,942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,208,093&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481,455&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for expired product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616,979&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654,148&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">937,935&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,156,150&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative compensation costs incurred on deductible equity awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635,989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,417,101&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,708,719&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,547,773)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,150,935)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets, before valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,869,328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,557,784&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: deferred tax asset valuation allowance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,869,328)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,557,784)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock', window );">Schedule of federal and state net operating loss carryforwards</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amount and year of expiration of the Company's federal and state net operating loss carryforwards as of December&#160;31, 2023:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:55.561%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.606%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years of expiration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Federal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">State</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,756,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025-2042</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,709,390&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,333,628&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,405,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total federal and state net operating loss carryforwards</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,115,225&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,563,210&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of the components of income tax benefit (expense)</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense includes the following components for the years ended December 31:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.201%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.370%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,769&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,850&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,769&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,850&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of effective tax rate reconciliation</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective income tax rate for 2023 and 2022 reconciles with the federal statutory tax rate as follows: </span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:62.302%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.235%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.237%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal tax expense at statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax expense (net of federal income tax benefit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.58)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences associated with general business credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.96)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.76)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiring tax credits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.32)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred True-ups</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss tax expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.73)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.23)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock', window );">Summary of tax credit carryforwards</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:64.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.925%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.341%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years of expiration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Federal</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,370&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025-2044</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,322,531&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total federal and state credit carryforwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340,901&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of tax credit carryforwards available to reduce future taxable income, including amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289100432000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-Based Payment Arrangement, Option, Activity</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options activity was as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:35.176%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.286%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">of option shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">exercise price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-average remaining contractual term</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/canceled</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,900)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.98&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,650&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.15</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.06&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/canceled</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,150)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.55&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487,250&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.65&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.59</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text">The assumptions used in the Black-Scholes valuation to determine the FV of stock options were as follows at December 31: <div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.470%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.311%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.71</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.88</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock activity was as follows:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.117%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.312%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-average grant-date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">fair value</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,225&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested/released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171,655)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/canceled</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395,751&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,250&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.93&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested/released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157,360)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/canceled</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,075)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,566&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.14&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289105122128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock', window );">Schedule of rent expense and sublease income</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense is recognized over the expected term of the lease on a straight-line basis as a component of general and administrative expense. Rent expense and sublease income  as follows for the years ended December 31:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.210%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304,865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,159,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544,138&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529,411&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of balance sheet classification</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023 and 2022, the Company recorded the following on the Consolidated Balance Sheet: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-Use Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,674,394&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,218,403&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348,092&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,910&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,296,247&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,586,301&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,644,339&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,759,211&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of operating lease liability maturities</a></td>
<td class="text"><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.132%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of Leases Liabilities at December&#160;31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863,320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836,100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934,180&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,847,400&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,131,702&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,487,363)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,644,339&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets and Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Rent Expense and Sublease Income [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289098458080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Market Concentrations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of revenues concentration from major customers</a></td>
<td class="text">Total revenues by customer for each customer representing 10% or more of consolidated revenues are summarized below for the years ended December 31: <div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.594%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-16<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289195636560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Information (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Schedule of quarterly financial information</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the unaudited operating results for each fiscal quarter of 2023 and 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.605%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">First</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Second</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Third</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fourth</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,224,638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,888,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,085,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,353,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,552,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,531,678)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,866,603)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,179,239)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,554,661)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">862,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,063,219)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,301,987)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,330,766)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">872,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,049,298)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,294,406)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,279,320)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share attributable to common shareholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,175,045&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,299,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,413,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,123,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,010,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,291,999)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,846,538)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(288,588)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,277,804)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,704,929)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,402,433)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,364,666)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(423,226)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,459,714)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,650,039)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,385,253)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,335,620)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(408,639)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,440,729)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,570,241)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share attributable to common shareholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Due to the nature of interim earnings per share calculations, the sum of the quarterly earnings (loss) per share amounts may not equal the reported earnings (loss) per share for the full year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482964/270-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289105430912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="nump">$ 51,446<span></span>
</td>
<td class="nump">$ 79,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_SharebasedCompensationCharitableContributionofSharesShares', window );">Charitable contribution of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions', window );">Cash contributions</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=cpix_CumberlandEmergingTechnologiesIncMember', window );">Cumberland Emerging Technologies, Inc (CET)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Noncontrolling interest, ownership percentage by parent</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_HongKongWinHealthPharmaGroupCoLimitedMember', window );">HongKong WinHealth Pharma Group Co. Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_SubsidiaryInvestmentPurchaseOfShares', window );">Investment in CET</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation, Charitable Contribution of Shares, Cash Contributions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_SharebasedCompensationCharitableContributionofSharesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation, Charitable Contribution of Shares, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_SharebasedCompensationCharitableContributionofSharesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_SubsidiaryInvestmentPurchaseOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subsidiary Investment, Purchase Of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_SubsidiaryInvestmentPurchaseOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=cpix_CumberlandEmergingTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=cpix_CumberlandEmergingTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_HongKongWinHealthPharmaGroupCoLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_HongKongWinHealthPharmaGroupCoLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289100161024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 27, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,353,066<span></span>
</td>
<td class="nump">$ 10,085,926<span></span>
</td>
<td class="nump">$ 10,888,877<span></span>
</td>
<td class="nump">$ 9,224,638<span></span>
</td>
<td class="nump">$ 9,123,680<span></span>
</td>
<td class="nump">$ 11,413,072<span></span>
</td>
<td class="nump">$ 10,299,152<span></span>
</td>
<td class="nump">$ 11,175,045<span></span>
</td>
<td class="nump">$ 39,552,507<span></span>
</td>
<td class="nump">$ 42,010,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities', window );">Shelf Registration, sale of corporate securities (up to)</a></td>
<td class="nump">$ 19,000,000<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment loss on intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,343,842<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,107,168<span></span>
</td>
<td class="nump">47,715,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_AccountsReceivableAllowancesByComponentAxis=cpix_ChargebacksCashDiscountsAndDamagedGoodsMember', window );">Product Sales Related Allowances - Chargebacks, Cash Discounts and Damaged Goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts receivable, allowances, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_WinHealthInvestmentSingaporeLtdMember', window );">WinHealth Investment (Singapore) Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Initial investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_MartinS.BrownJr.sLawFirmMember', window );">Martin S. Brown Jr.'s Law Firm | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000.00<span></span>
</td>
<td class="nump">$ 40,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shelf Registration, Proceeds From Sale of Corporate Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_AccountsReceivableAllowancesByComponentAxis=cpix_ChargebacksCashDiscountsAndDamagedGoodsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_AccountsReceivableAllowancesByComponentAxis=cpix_ChargebacksCashDiscountsAndDamagedGoodsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_WinHealthInvestmentSingaporeLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_WinHealthInvestmentSingaporeLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_MartinS.BrownJr.sLawFirmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_MartinS.BrownJr.sLawFirmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289104566032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Schedule of Distribution Costs) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductionAndDistributionCosts', window );">Distribution costs</a></td>
<td class="nump">$ 881,829<span></span>
</td>
<td class="nump">$ 857,842<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductionAndDistributionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to the production and distribution of goods or services to customers and clients.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductionAndDistributionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289107084880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Schedule of Advertising Costs) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising costs</a></td>
<td class="nump">$ 2,903,741<span></span>
</td>
<td class="nump">$ 2,927,041<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289099067584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Vibativ&#174;, Sancuso&#174; and RediTrex&#174; Products - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 12, 2022</div></th>
<th class="th"><div>Jan. 03, 2022</div></th>
<th class="th"><div>Nov. 27, 2019</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Nov. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business upon closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Non-current portion of accrued contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,284,672<span></span>
</td>
<td class="nump">4,931,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">914,000<span></span>
</td>
<td class="nump">$ 914,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_NordicGroupBVMember', window );">Nordic Group B.V. | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsMilestonePayment', window );">Milestone payment</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue', window );">Milestone payment credit due</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_NordicGroupBVMember', window );">Nordic Group B.V. | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationCancelledAndRefunded', window );">Shares cancelled and refunded</a></td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_NordicGroupBVMember', window );">Nordic Group B.V. | Methotrexate | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsDepositPayment', window );">Deposit payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationValue', window );">Share consideration, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationVestedValue', window );">Share consideration vested, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsMilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_NordicGroupBVMember', window );">Nordic Group B.V. | Methotrexate | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationShares', window );">Share consideration (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_ProductAssetsAndGlobalRightsVibativMember', window );">Product Assets And Global Rights - Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business upon closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_PaymentsToAcquireBusinessMilestonePayment', window );">MIlestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold', window );">Tiered royalty payments, threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of accrued contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Non-current portion of accrued contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_ProductAssetsAndGlobalRightsVibativMember', window );">Product Assets And Global Rights - Vibativ | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage', window );">Tiered royalty payments (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_U.S.ProductAssetRightsSancusoMember', window );">U.S. Product Asset Rights - Sancuso</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business upon closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_PaymentsToAcquireBusinessMilestonePayment', window );">MIlestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold', window );">Tiered royalty payments, threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of accrued contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Non-current portion of accrued contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_PaymentsToAcquireBusinessMilestonePaymentRemaining', window );">Milestone payment remaining</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability', window );">Contingent liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expense and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets, other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMilestonePayable', window );">Milestone payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_U.S.ProductAssetRightsSancusoMember', window );">U.S. Product Asset Rights - Sancuso | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage', window );">Tiered royalty payments (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMilestonePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Milestone Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMilestonePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsDepositPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Deposit Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsDepositPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Milestone Payment, Credit Due</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationCancelledAndRefunded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Stock Consideration, Cancelled And Refunded</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationCancelledAndRefunded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Stock Consideration, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Stock Consideration, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationVestedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Stock Consideration Vested, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationVestedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_PaymentsToAcquireBusinessMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Business, Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_PaymentsToAcquireBusinessMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_PaymentsToAcquireBusinessMilestonePaymentRemaining">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Business, Milestone Payment Remaining</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_PaymentsToAcquireBusinessMilestonePaymentRemaining</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Business, Tiered Royalty Payments, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Business, Tiered Royalty Payments, Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_NordicGroupBVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_NordicGroupBVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_MethotrexateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_MethotrexateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_ProductAssetsAndGlobalRightsVibativMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_ProductAssetsAndGlobalRightsVibativMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_U.S.ProductAssetRightsSancusoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_U.S.ProductAssetRightsSancusoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289098976592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Vibativ&#174;, Sancuso&#174; and RediTrex&#174; Products - Changes In Fair Value Of Contingent Consideration Liability (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_BusinessCombinationContingentConsiderationLiabilityRollForward', window );"><strong>Business Combination, Contingent Consideration, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value</a></td>
<td class="num">$ (1,253,840)<span></span>
</td>
<td class="num">$ (2,088,296)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_ProductAssetsAndGlobalRightsVibativMember', window );">Product Assets And Global Rights - Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_BusinessCombinationContingentConsiderationLiabilityRollForward', window );"><strong>Business Combination, Contingent Consideration, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Beginning balance</a></td>
<td class="nump">4,154,823<span></span>
</td>
<td class="nump">6,515,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Cash payment of royalty during the period</a></td>
<td class="num">(1,018,451)<span></span>
</td>
<td class="num">(1,133,113)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value</a></td>
<td class="num">(270,485)<span></span>
</td>
<td class="num">(2,104,690)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses', window );">Contingent consideration earned and accrued</a></td>
<td class="nump">1,167,486<span></span>
</td>
<td class="nump">876,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance</a></td>
<td class="nump">4,033,373<span></span>
</td>
<td class="nump">4,154,823<span></span>
</td>
<td class="nump">$ 4,154,823<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_U.S.ProductAssetRightsSancusoMember', window );">U.S. Product Asset Rights - Sancuso</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_BusinessCombinationContingentConsiderationLiabilityRollForward', window );"><strong>Business Combination, Contingent Consideration, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Beginning balance</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,384,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Cash payment of royalty during the period</a></td>
<td class="num">(790,632)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,075,631)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value</a></td>
<td class="num">(685,355)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses', window );">Contingent consideration earned and accrued</a></td>
<td class="nump">781,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">675,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance</a></td>
<td class="nump">$ 2,306,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationContingentConsiderationLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationContingentConsiderationLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_ProductAssetsAndGlobalRightsVibativMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_ProductAssetsAndGlobalRightsVibativMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_U.S.ProductAssetRightsSancusoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_U.S.ProductAssetRightsSancusoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289101005376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Schedule of Net Product Revenues by Product) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 9,353,066<span></span>
</td>
<td class="nump">$ 10,085,926<span></span>
</td>
<td class="nump">$ 10,888,877<span></span>
</td>
<td class="nump">$ 9,224,638<span></span>
</td>
<td class="nump">$ 9,123,680<span></span>
</td>
<td class="nump">$ 11,413,072<span></span>
</td>
<td class="nump">$ 10,299,152<span></span>
</td>
<td class="nump">$ 11,175,045<span></span>
</td>
<td class="nump">$ 39,552,507<span></span>
</td>
<td class="nump">$ 42,010,949<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,513,492<span></span>
</td>
<td class="nump">40,681,182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_ProductKristaloseMember', window );">Kristalose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,981,850<span></span>
</td>
<td class="nump">15,205,155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_ProductVibativMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,812,692<span></span>
</td>
<td class="nump">7,487,462<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_ProductSancusoMember', window );">Sancuso</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,096,788<span></span>
</td>
<td class="nump">13,205,603<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_ProductCaldolorMember', window );">Caldolor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,333,923<span></span>
</td>
<td class="nump">4,827,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_ProductAcetadoteMember', window );">Acetadote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">458,759<span></span>
</td>
<td class="nump">501,040<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_ProductOmeclamoxPakMember', window );">Omeclamox-Pak</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,030<span></span>
</td>
<td class="nump">29,145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_ProductVaprisolMember', window );">Vaprisol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,336<span></span>
</td>
<td class="num">(447,697)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_ProductRediTrexMember', window );">RediTrex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (341,886)<span></span>
</td>
<td class="num">$ (126,726)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_ProductKristaloseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_ProductKristaloseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_ProductVibativMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_ProductVibativMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_ProductSancusoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_ProductSancusoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_ProductCaldolorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_ProductCaldolorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_ProductAcetadoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_ProductAcetadoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_ProductOmeclamoxPakMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_ProductOmeclamoxPakMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_ProductVaprisolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_ProductVaprisolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_ProductRediTrexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_ProductRediTrexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289100979232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>payment</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLegalSettlements', window );">Proceeds from litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 9,353,066<span></span>
</td>
<td class="nump">$ 10,085,926<span></span>
</td>
<td class="nump">$ 10,888,877<span></span>
</td>
<td class="nump">$ 9,224,638<span></span>
</td>
<td class="nump">$ 9,123,680<span></span>
</td>
<td class="nump">$ 11,413,072<span></span>
</td>
<td class="nump">$ 10,299,152<span></span>
</td>
<td class="nump">$ 11,175,045<span></span>
</td>
<td class="nump">$ 39,552,507<span></span>
</td>
<td class="nump">$ 42,010,949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">544,138<span></span>
</td>
<td class="nump">529,411<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_VibativMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivableNumberOfPayments', window );">Milestone payments receivable, number of payments | payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentOne', window );">Milestone payments receivable, payment one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentTwo', window );">Milestone payments receivable, payment two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant | Federal Grant Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivableNumberOfPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Legal Settlements, Milestone Payments Receivable, Number of Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivableNumberOfPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Legal Settlements, Milestone Payments Receivable, Payment One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Legal Settlements, Milestone Payments Receivable, Payment Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for the settlement of litigation during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_VibativMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_VibativMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_FederalGrantProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_FederalGrantProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289107082608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories, Net - Schedule of Inventories (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 12,619,092<span></span>
</td>
<td class="nump">$ 12,899,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment', window );">Consigned inventory</a></td>
<td class="nump">149,701<span></span>
</td>
<td class="nump">168,923<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods, net of reserve</a></td>
<td class="nump">4,645,098<span></span>
</td>
<td class="nump">4,322,167<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total inventories</a></td>
<td class="nump">17,413,891<span></span>
</td>
<td class="nump">17,390,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">less non-current inventories</a></td>
<td class="num">(12,804,529)<span></span>
</td>
<td class="num">(7,527,167)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 4,609,362<span></span>
</td>
<td class="nump">$ 9,863,581<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289101236576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories, Net - Schedule of Non-Current Inventories (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_InventoryNoncurrentLineItems', window );"><strong>Inventory, Noncurrent [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">$ 12,804,529<span></span>
</td>
<td class="nump">$ 7,527,167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=cpix_OtherProductsMember', window );">Other Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_InventoryNoncurrentLineItems', window );"><strong>Inventory, Noncurrent [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">103,300<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_VibativMember', window );">Vibativ | Raw Materials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_InventoryNoncurrentLineItems', window );"><strong>Inventory, Noncurrent [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">6,611,426<span></span>
</td>
<td class="nump">7,138,936<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_VibativMember', window );">Vibativ | Finished Goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_InventoryNoncurrentLineItems', window );"><strong>Inventory, Noncurrent [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">810,454<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_KristaloseMember', window );">Kristalose | Raw Materials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_InventoryNoncurrentLineItems', window );"><strong>Inventory, Noncurrent [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">3,263,515<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_VaprisolMember', window );">Vaprisol | Raw Materials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_InventoryNoncurrentLineItems', window );"><strong>Inventory, Noncurrent [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">1,170,641<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_CaldolorMember', window );">Caldolor | Finished Goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_InventoryNoncurrentLineItems', window );"><strong>Inventory, Noncurrent [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">67,307<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_SancusoMember', window );">Sancuso | Raw Materials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_InventoryNoncurrentLineItems', window );"><strong>Inventory, Noncurrent [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">574,502<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_StudyDrugMember', window );">Study Drug | Raw Materials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_InventoryNoncurrentLineItems', window );"><strong>Inventory, Noncurrent [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">203,383<span></span>
</td>
<td class="nump">256,474<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_StudyDrugMember', window );">Study Drug | Finished Goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_InventoryNoncurrentLineItems', window );"><strong>Inventory, Noncurrent [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 131,757<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_InventoryNoncurrentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory, Noncurrent [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_InventoryNoncurrentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=cpix_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=cpix_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_VibativMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_VibativMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=us-gaap_PublicUtilitiesInventoryRawMaterialsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=us-gaap_PublicUtilitiesInventoryRawMaterialsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=cpix_FinishedGoodsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=cpix_FinishedGoodsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_KristaloseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_KristaloseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_VaprisolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_VaprisolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_CaldolorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_CaldolorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_SancusoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_SancusoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_StudyDrugMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_StudyDrugMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289109415744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories, Net - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">$ 12,804,529<span></span>
</td>
<td class="nump">$ 7,527,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory reserves, obsolescence and discontinuance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_VibativMember', window );">Vibativ | Active Pharmaceutical Ingredient ("API") And Work In Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,600,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_VibativMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_VibativMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=cpix_ActivePharmaceuticalIngredientAPIAndWorkInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=cpix_ActivePharmaceuticalIngredientAPIAndWorkInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289103691360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Schedule of Property and Equipment) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 2,605,976<span></span>
</td>
<td class="nump">$ 2,369,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(2,238,073)<span></span>
</td>
<td class="num">(2,085,185)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">367,903<span></span>
</td>
<td class="nump">284,039<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 499,557<span></span>
</td>
<td class="nump">465,508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 771,667<span></span>
</td>
<td class="nump">746,602<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 533,778<span></span>
</td>
<td class="nump">369,365<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 800,974<span></span>
</td>
<td class="nump">$ 787,749<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289197753808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Depreciation Expense) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements', window );">Depreciation, including amortization related to leasehold improvements</a></td>
<td class="nump">$ 177,148<span></span>
</td>
<td class="nump">$ 260,745<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation, Including Amortization Related to Leasehold Improvements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289098493408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Schedule of Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">$ 22,607,918<span></span>
</td>
<td class="nump">$ 30,590,678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">914,000<span></span>
</td>
<td class="nump">914,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cpix_ProductAndLicenseRightsMember', window );">Product and License Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">43,250,341<span></span>
</td>
<td class="nump">49,668,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(22,755,543)<span></span>
</td>
<td class="num">(21,891,974)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">20,494,798<span></span>
</td>
<td class="nump">27,776,167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">10,712,405<span></span>
</td>
<td class="nump">10,610,228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(8,819,287)<span></span>
</td>
<td class="num">(8,051,018)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">1,893,118<span></span>
</td>
<td class="nump">2,559,210<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">413,775<span></span>
</td>
<td class="nump">397,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(193,773)<span></span>
</td>
<td class="num">(142,673)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">$ 220,002<span></span>
</td>
<td class="nump">$ 255,301<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cpix_ProductAndLicenseRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cpix_ProductAndLicenseRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289110512528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Additions to intangible assets</a></td>
<td class="nump">$ 171,783<span></span>
</td>
<td class="nump">$ 1,971,662<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Additions to intangible assets</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289106962176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Amortization Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization and impairment expense</a></td>
<td class="nump">$ 8,102,648<span></span>
</td>
<td class="nump">$ 5,067,368<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289098206688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Future Amortization Expense (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 4,304,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">4,245,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">3,859,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">3,452,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFourAndAfter', window );">2028 and thereafter</a></td>
<td class="nump">6,745,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">$ 22,607,918<span></span>
</td>
<td class="nump">$ 30,590,678<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFourAndAfter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Amortization Expense, Year Four and After</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFourAndAfter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289106647488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Current and Other Long-term Liabilities (Schedule of Other Current Liabilities) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrentAbstract', window );"><strong>Other Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ProductSalesRelatedLiabilitiesCurrent', window );">Rebates, product returns, administrative fees and service fees</a></td>
<td class="nump">$ 7,579,783<span></span>
</td>
<td class="nump">$ 8,347,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee wages and benefits</a></td>
<td class="nump">1,197,832<span></span>
</td>
<td class="nump">1,440,859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_AccruedLiabilitiesStockPayable', window );">Sancuso related liabilities</a></td>
<td class="nump">827,813<span></span>
</td>
<td class="nump">2,226,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent', window );">Current portion of accrued contingent consideration</a></td>
<td class="nump">2,424,000<span></span>
</td>
<td class="nump">3,006,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_AccruedLiabilitiesStudies', window );">Studies accrual</a></td>
<td class="nump">385,266<span></span>
</td>
<td class="nump">400,702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_AccruedLiabilitiesInventoryPurchases', window );">Accrued inventory purchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">609,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current deferred charges</a></td>
<td class="nump">220,402<span></span>
</td>
<td class="nump">614,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">961,432<span></span>
</td>
<td class="nump">941,929<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total other current liabilities</a></td>
<td class="nump">$ 13,596,528<span></span>
</td>
<td class="nump">$ 17,587,911<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_AccruedLiabilitiesInventoryPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities, Inventory Purchases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_AccruedLiabilitiesInventoryPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_AccruedLiabilitiesStockPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities, Stock Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_AccruedLiabilitiesStockPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_AccruedLiabilitiesStudies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities, Studies</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_AccruedLiabilitiesStudies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Liability, Accrued, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ProductSalesRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Product Sales-Related Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ProductSalesRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289105412736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Current and Other Long-term Liabilities (Schedule of Noncurrent Liabilities) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Non-current portion of accrued contingent consideration</a></td>
<td class="nump">$ 3,284,672<span></span>
</td>
<td class="nump">$ 4,931,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent', window );">Deferred compensation</a></td>
<td class="nump">2,894,894<span></span>
</td>
<td class="nump">2,522,506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent', window );">Other</a></td>
<td class="nump">274,000<span></span>
</td>
<td class="nump">131,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Total other long-term liabilities</a></td>
<td class="nump">$ 6,453,566<span></span>
</td>
<td class="nump">$ 7,585,019<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer), including liabilities for compensation costs, fringe benefits other than pension and postretirement obligations, rent, contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289100999600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 05, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Borrowings outstanding under revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,784,144<span></span>
</td>
<td class="nump">$ 16,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Line of Credit | Pinnacle Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit, maximum borrowing capacity</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity', window );">Maximum increase to line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Expiration period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Borrowings outstanding under revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,800,000<span></span>
</td>
<td class="nump">$ 16,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.125%<span></span>
</td>
<td class="nump">675.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Line of Credit | Pinnacle Bank | Maximum | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate (in percent)</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Additional Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LineOfCreditFacilityAdditionalBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481573/470-10-45-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481573/470-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289101135632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 10, 2009</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>May 13, 2010</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (748,411)<span></span>
</td>
<td class="num">$ (1,025,836)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Amount available under current repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,360<span></span>
</td>
<td class="nump">171,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Share repurchase program, number of shares authorized to be repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402,143<span></span>
</td>
<td class="nump">367,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (748,411)<span></span>
</td>
<td class="num">$ (1,025,836)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockTransactionDate', window );">Initial public offering, effective date</a></td>
<td class="text">Aug. 10,  2009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Initial public offering, shares issued</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_StockIssuedDuringPeriodPricePerShareNewIssues', window );">Initial public offering, price per share</a></td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering', window );">Initial public offering, gross proceeds</a></td>
<td class="nump">$ 85,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts', window );">Initial public offering, underwriting discounts</a></td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Initial public offering, issuance costs</a></td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Initial public offering, net proceeds</a></td>
<td class="nump">$ 74,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Gross Proceeds from Initial Public Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, New Shares, Underwriting Discounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_StockIssuedDuringPeriodPricePerShareNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Price Per Share, New Issues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_StockIssuedDuringPeriodPricePerShareNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockTransactionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the subsidiary or equity investee issued or sold stock, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockTransactionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289098756784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share - Schedule of Computation of Numerator and Denominator in Earnings Per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (6,301,987)<span></span>
</td>
<td class="num">$ (1,063,219)<span></span>
</td>
<td class="nump">$ 862,154<span></span>
</td>
<td class="nump">$ 172,286<span></span>
</td>
<td class="num">$ (2,459,714)<span></span>
</td>
<td class="num">$ (423,226)<span></span>
</td>
<td class="num">$ (1,364,666)<span></span>
</td>
<td class="num">$ (1,402,433)<span></span>
</td>
<td class="num">$ (6,330,766)<span></span>
</td>
<td class="num">$ (5,650,039)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,446<span></span>
</td>
<td class="nump">79,798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to common shareholders</a></td>
<td class="num">$ (6,294,406)<span></span>
</td>
<td class="num">$ (1,049,298)<span></span>
</td>
<td class="nump">$ 872,200<span></span>
</td>
<td class="nump">$ 192,184<span></span>
</td>
<td class="num">$ (2,440,729)<span></span>
</td>
<td class="num">$ (408,639)<span></span>
</td>
<td class="num">$ (1,335,620)<span></span>
</td>
<td class="num">$ (1,385,253)<span></span>
</td>
<td class="num">$ (6,279,320)<span></span>
</td>
<td class="num">$ (5,570,241)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding &#8211; basic (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,298,774<span></span>
</td>
<td class="nump">14,563,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding &#8211; diluted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,298,774<span></span>
</td>
<td class="nump">14,563,592<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289098458080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share - Schedule of Anti-dilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares and options (in shares)</a></td>
<td class="nump">452,224<span></span>
</td>
<td class="nump">227,050<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289100980512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities, Net (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred Tax Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards', window );">Net operating loss and tax credits</a></td>
<td class="nump">$ 15,427,801<span></span>
</td>
<td class="nump">$ 16,164,754<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles', window );">Property and equipment and intangibles</a></td>
<td class="nump">71,990<span></span>
</td>
<td class="nump">264,653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_DeferredTaxAssetOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">1,307,178<span></span>
</td>
<td class="nump">1,121,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">2,337,091<span></span>
</td>
<td class="nump">866,942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research cost</a></td>
<td class="nump">2,208,093<span></span>
</td>
<td class="nump">1,481,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Allowance for accounts receivable</a></td>
<td class="nump">147,919<span></span>
</td>
<td class="nump">145,803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct', window );">Reserve for expired product</a></td>
<td class="nump">616,979<span></span>
</td>
<td class="nump">654,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory</a></td>
<td class="nump">185,189<span></span>
</td>
<td class="nump">217,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_DeferredTaxAssetsDeferredCharges', window );">Deferred charges</a></td>
<td class="nump">937,935<span></span>
</td>
<td class="nump">1,156,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Cumulative compensation costs incurred on deductible equity awards</a></td>
<td class="nump">176,926<span></span>
</td>
<td class="nump">635,989<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">23,417,101<span></span>
</td>
<td class="nump">22,708,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred Tax Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="num">(1,547,773)<span></span>
</td>
<td class="num">(1,150,935)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_NetDeferredTaxAssetsGross', window );">Net deferred tax assets, before valuation allowance</a></td>
<td class="nump">21,869,328<span></span>
</td>
<td class="nump">21,557,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: deferred tax asset valuation allowance</a></td>
<td class="num">(21,869,328)<span></span>
</td>
<td class="num">(21,557,784)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DeferredTaxAssetOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset, Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DeferredTaxAssetOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DeferredTaxAssetsDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Deferred Charges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DeferredTaxAssetsDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Loss Carryforwards and Tax Credit Carryforwards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Property and Equipment and Intangibles</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves for Expired Product</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liability, Operating Lease Right-of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_NetDeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Deferred Tax Assets, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_NetDeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289101026256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Net Operating Loss Carryforwards (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 52,115,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,563,210<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermOneMember', window );">2024 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermOneMember', window );">2024 | State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,756,304<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermTwoMember', window );">2025-2042 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">45,709,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermTwoMember', window );">2025-2042 | State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,333,628<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_IndefiniteMember', window );">Indefinite Period | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 6,405,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_IndefiniteMember', window );">Indefinite Period | State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 473,278<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ExpirationTimePeriodAxis=cpix_IndefiniteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ExpirationTimePeriodAxis=cpix_IndefiniteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289098185040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of the Components of Income Tax Benefit (Expense) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State and other</a></td>
<td class="nump">45,769<span></span>
</td>
<td class="nump">68,850<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current income tax expense</a></td>
<td class="nump">45,769<span></span>
</td>
<td class="nump">68,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOtherTaxExpenseBenefit', window );">Total deferred income tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense</a></td>
<td class="nump">$ 45,769<span></span>
</td>
<td class="nump">$ 68,850<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOtherTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. For example, but not limited to, acquisition-date income tax benefits or expenses recognized from changes in the acquirer's valuation allowance for its previously existing deferred tax assets resulting from a business combination and adjustments to beginning-of-year balance of a valuation allowance because of a change in circumstance causing a change in judgment about the realizability of the related deferred tax asset in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOtherTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289109423760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal tax expense at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax expense (net of federal income tax benefit)</a></td>
<td class="num">(0.58%)<span></span>
</td>
<td class="nump">2.11%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Permanent differences associated with general business credits</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(4.96%)<span></span>
</td>
<td class="num">(21.76%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Other permanent differences</a></td>
<td class="num">(6.51%)<span></span>
</td>
<td class="num">(2.58%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Expiring tax credits</a></td>
<td class="num">(3.32%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_EffectiveIncomeTaxRateReconciliationDeferredTrueUpsPercent', window );">Deferred True-ups</a></td>
<td class="num">(7.16%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Net loss tax expense</a></td>
<td class="num">(0.73%)<span></span>
</td>
<td class="num">(1.23%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_EffectiveIncomeTaxRateReconciliationDeferredTrueUpsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Deferred True-Ups, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_EffectiveIncomeTaxRateReconciliationDeferredTrueUpsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289098157120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule Of Tax Credit Carryforwards (Details) - Federal And State<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Total federal and state credit carryforwards</a></td>
<td class="nump">$ 1,340,901<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermOneMember', window );">2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Total federal and state credit carryforwards</a></td>
<td class="nump">18,370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermTwoMember', window );">2025-2042</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Total federal and state credit carryforwards</a></td>
<td class="nump">$ 1,322,531<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=cpix_FederalAndStateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=cpix_FederalAndStateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289100817056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>plan </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants', window );">Number of equity compensation plans available for future grants | plan</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent', window );">Shareholder, percent</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense | $</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to share-based payments | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost related to share-based payments, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 10 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 1.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Options vested (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend', window );">Expected dividend yield | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of vested awards | $</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation costs | $</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue', window );">Stock options, exercise price as percent of weighted-average grant date fair value</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cpix_NonprincipalOwnerMember', window );">NonPrincipal Owner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue', window );">Stock options, exercise price as percent of weighted-average grant date fair value</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cpix_NonprincipalOwnerMember', window );">NonPrincipal Owner | Maximum | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options, expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=us-gaap_PrincipalOwnerMember', window );">Principal Owner | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options, expiration period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cpix_LongTermIncentiveCompensationPlan2007Member', window );">Long-Term Incentive Compensation Plan 2007</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares reserved for issuance under equity compensation plans</a></td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for future grants (in shares)</a></td>
<td class="nump">933,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cpix_DirectorsIncentivePlan2007Member', window );">Directors&#8217; Incentive Plan 2007</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares reserved for issuance under equity compensation plans</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for future grants (in shares)</a></td>
<td class="nump">130,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans Available for Future Grants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price as Percent of Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Shareholder, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cpix_NonprincipalOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cpix_NonprincipalOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=us-gaap_PrincipalOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=us-gaap_PrincipalOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cpix_LongTermIncentiveCompensationPlan2007Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cpix_LongTermIncentiveCompensationPlan2007Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cpix_DirectorsIncentivePlan2007Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cpix_DirectorsIncentivePlan2007Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289105141776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans - Stock Options Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of option shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="nump">319,650<span></span>
</td>
<td class="nump">170,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">192,750<span></span>
</td>
<td class="nump">178,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited/cancelled (in shares)</a></td>
<td class="num">(25,150)<span></span>
</td>
<td class="num">(29,900)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, end of period (in shares)</a></td>
<td class="nump">487,250<span></span>
</td>
<td class="nump">319,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning of period (in USD per share)</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="nump">$ 3.33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in USD per share)</a></td>
<td class="nump">2.06<span></span>
</td>
<td class="nump">2.68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in USD per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited/cancelled (in USD per share)</a></td>
<td class="nump">2.55<span></span>
</td>
<td class="nump">2.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, end of period (in USD per share)</a></td>
<td class="nump">$ 2.65<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual term</a></td>
<td class="text">5 years 7 months 2 days<span></span>
</td>
<td class="text">6 years 1 month 24 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289107075792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans - Valuation Assumptions (Details) - Stock Options - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 8 months 15 days<span></span>
</td>
<td class="text">5 years 10 months 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">65.87%<span></span>
</td>
<td class="nump">54.38%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">3.45%<span></span>
</td>
<td class="nump">2.29%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend', window );">Expected dividend yield</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289104342912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans - Restricted Stock Activity (Details) - Restricted Stock - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, beginning of period (in shares)</a></td>
<td class="nump">395,751<span></span>
</td>
<td class="nump">568,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">34,250<span></span>
</td>
<td class="nump">65,225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(157,360)<span></span>
</td>
<td class="num">(171,655)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(12,075)<span></span>
</td>
<td class="num">(66,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, end of period (in shares)</a></td>
<td class="nump">260,566<span></span>
</td>
<td class="nump">395,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-average grant-date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested, beginning of period (in USD per share)</a></td>
<td class="nump">$ 4.29<span></span>
</td>
<td class="nump">$ 5.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in USD per share)</a></td>
<td class="nump">1.93<span></span>
</td>
<td class="nump">2.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in USD per share)</a></td>
<td class="nump">5.73<span></span>
</td>
<td class="nump">6.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in USD per share)</a></td>
<td class="nump">3.63<span></span>
</td>
<td class="nump">4.67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested, end of period (in USD per share)</a></td>
<td class="nump">$ 3.14<span></span>
</td>
<td class="nump">$ 4.29<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289104312064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsAbstract', window );"><strong>Postemployment Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge', window );">Defined contribution plan, eligibiilty, minimum employee age</a></td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility', window );">Defined contribution plan, eligibility, minimum employee service time for participation eligibility</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined contribution plan, employer discretionary contribution amount</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent', window );">Deferred compensation liability</a></td>
<td class="nump">2,900<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationPlanAssets', window );">Deferred compensation assets</a></td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Eligibility, Minimum Employee Age</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Eligibility, Minimum Employee Service Time for Participation Eligibility</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements. Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of assets held under deferred compensation agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289100814272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Oct. 24, 2022</div></th>
<th class="th">
<div>Nov. 15, 2021 </div>
<div>ft&#178; </div>
<div>renewalTerm </div>
<div>$ / ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_LesseeOperatingLeaseRentIncrease', window );">Rent increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 6,674,394<span></span>
</td>
<td class="nump">$ 5,218,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Future minimum sublease income under noncancelable operating subleases</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_A1600WestEndAvenuePartnersLLCMember', window );">1600 West End Avenue Partners, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">10 years 5 months 1 day<span></span>
</td>
<td class="text">12 years 8 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average incremental borrowing rate</a></td>
<td class="nump">9.40%<span></span>
</td>
<td class="nump">9.24%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_NephronPharmaceuticalsCorporationNephronMember', window );">Nephron Pharmaceuticals Corporation (&#8220;Nephron&#8221;)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=srt_OfficeBuildingMember', window );">Office Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_LesseeOperatingLeaseLeasedArea', window );">Leased area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">157 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_LesseeOperatingLeaseBaseRent', window );">Lessee, Operating Lease, Base Rent | $ / ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.06<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of real estate property | ft&#178;</a></td>
<td class="nump">14,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=srt_OfficeBuildingMember', window );">Office Building | Broadwest Lease, Five Year Renewal Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_LesseeOperatingLeaseNumberOfRenewalTerms', window );">Number of renewal terms | renewalTerm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LesseeOperatingLeaseBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Base Rent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LesseeOperatingLeaseBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LesseeOperatingLeaseLeasedArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Leased Area</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LesseeOperatingLeaseLeasedArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LesseeOperatingLeaseNumberOfRenewalTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Renewal Terms</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LesseeOperatingLeaseNumberOfRenewalTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LesseeOperatingLeaseRentIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Rent Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LesseeOperatingLeaseRentIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_A1600WestEndAvenuePartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_A1600WestEndAvenuePartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_NephronPharmaceuticalsCorporationNephronMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_NephronPharmaceuticalsCorporationNephronMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=srt_OfficeBuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=srt_OfficeBuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=cpix_BroadwestLeaseFiveYearRenewalOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=cpix_BroadwestLeaseFiveYearRenewalOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289101042512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Rent Expense and Sublease Income (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="nump">$ 1,304,865<span></span>
</td>
<td class="nump">$ 1,159,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease Income</a></td>
<td class="nump">$ 544,138<span></span>
</td>
<td class="nump">$ 529,411<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289098485600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Lease Position (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 6,674,394<span></span>
</td>
<td class="nump">$ 5,218,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease current liabilities</a></td>
<td class="nump">348,092<span></span>
</td>
<td class="nump">172,910<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease non-current liabilities</a></td>
<td class="nump">5,296,247<span></span>
</td>
<td class="nump">4,586,301<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 5,644,339<span></span>
</td>
<td class="nump">$ 4,759,211<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289100656800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Lease Liability Maturities and Future Minimum Payments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Lease Liabilities, Payments Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 863,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">836,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">909,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">934,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">740,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">After 2028</a></td>
<td class="nump">4,847,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">9,131,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="num">(3,487,363)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 5,644,339<span></span>
</td>
<td class="nump">$ 4,759,211<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289100898800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Market Concentrations (Schedule of Revenues Concentration from Major Customers and Narrative) (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Sales Revenue, Goods, Gross | Customer 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">29.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Sales Revenue, Goods, Gross | Customer 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Sales Revenue, Goods, Gross | Customer 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts Receivable | Customer 1, 2, and 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">62.30%<span></span>
</td>
<td class="nump">51.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481027/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=cpix_SalesRevenueGoodsGrossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=cpix_SalesRevenueGoodsGrossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cpix_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cpix_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cpix_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cpix_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cpix_CustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cpix_CustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cpix_Customer12And3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cpix_Customer12And3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289195550048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Manufacturing and Supply Agreements Manufacturing and Supply Agreements (Narrative) (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>supplier</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ManufacturingandSupplyAgreementLineItems', window );"><strong>Manufacturing and Supply Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct', window );">Manufacturing agreements, number of primary suppliers for each product</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ManufacturingandSupplyAgreementLineItems', window );"><strong>Manufacturing and Supply Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct', window );">Manufacturing agreements, number of primary suppliers for each product</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Manufacturing agreements, number of primary suppliers for each product</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ManufacturingandSupplyAgreementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Manufacturing and Supply Agreement [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ManufacturingandSupplyAgreementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289098477520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Nov. 07, 2022</div></th>
<th class="th"><div>Feb. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLegalSettlements', window );">Proceeds from litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember', window );">Melinta Therapeutics, LLC and Targanta Therapeutics Corporation | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable', window );">Sales milestone payments, receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember', window );">Melinta Therapeutics, LLC and Targanta Therapeutics Corporation | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Within 30 Days Of First sNDA Filing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable', window );">Sales milestone payments, receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember', window );">Melinta Therapeutics, LLC and Targanta Therapeutics Corporation | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Following Approval Of First sNDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable', window );">Sales milestone payments, receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_U.S.ProductAssetRightsSancusoMember', window );">U.S. Product Asset Rights - Sancuso</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold', window );">Tiered royalty payments, threshold</a></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsTerm', window );">Tiered royalty payments term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_U.S.ProductAssetRightsSancusoMember', window );">U.S. Product Asset Rights - Sancuso | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage', window );">Tiered royalty payments (percentage)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_U.S.ProductAssetRightsSancusoMember', window );">U.S. Product Asset Rights - Sancuso | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage', window );">Tiered royalty payments (percentage)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Business, Tiered Royalty Payments, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Business, Tiered Royalty Payments, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Business, Tiered Royalty Payments, Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for the settlement of litigation during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementMilestonePaymentThresholdAxis=cpix_Within30DaysOfFirstSNDAFilingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementMilestonePaymentThresholdAxis=cpix_Within30DaysOfFirstSNDAFilingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementMilestonePaymentThresholdAxis=cpix_FollowingApprovalOfFirstSNDAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementMilestonePaymentThresholdAxis=cpix_FollowingApprovalOfFirstSNDAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_U.S.ProductAssetRightsSancusoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_U.S.ProductAssetRightsSancusoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289099299680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Information (Schedule of Quarterly Financial Information (Unaudited)) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 9,353,066<span></span>
</td>
<td class="nump">$ 10,085,926<span></span>
</td>
<td class="nump">$ 10,888,877<span></span>
</td>
<td class="nump">$ 9,224,638<span></span>
</td>
<td class="nump">$ 9,123,680<span></span>
</td>
<td class="nump">$ 11,413,072<span></span>
</td>
<td class="nump">$ 10,299,152<span></span>
</td>
<td class="nump">$ 11,175,045<span></span>
</td>
<td class="nump">$ 39,552,507<span></span>
</td>
<td class="nump">$ 42,010,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">(6,179,239)<span></span>
</td>
<td class="num">(1,866,603)<span></span>
</td>
<td class="nump">22,859<span></span>
</td>
<td class="num">(1,531,678)<span></span>
</td>
<td class="num">(2,277,804)<span></span>
</td>
<td class="num">(288,588)<span></span>
</td>
<td class="num">(1,846,538)<span></span>
</td>
<td class="num">(1,291,999)<span></span>
</td>
<td class="num">(9,554,661)<span></span>
</td>
<td class="num">(5,704,929)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(6,301,987)<span></span>
</td>
<td class="num">(1,063,219)<span></span>
</td>
<td class="nump">862,154<span></span>
</td>
<td class="nump">172,286<span></span>
</td>
<td class="num">(2,459,714)<span></span>
</td>
<td class="num">(423,226)<span></span>
</td>
<td class="num">(1,364,666)<span></span>
</td>
<td class="num">(1,402,433)<span></span>
</td>
<td class="num">(6,330,766)<span></span>
</td>
<td class="num">(5,650,039)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to common shareholders</a></td>
<td class="num">$ (6,294,406)<span></span>
</td>
<td class="num">$ (1,049,298)<span></span>
</td>
<td class="nump">$ 872,200<span></span>
</td>
<td class="nump">$ 192,184<span></span>
</td>
<td class="num">$ (2,440,729)<span></span>
</td>
<td class="num">$ (408,639)<span></span>
</td>
<td class="num">$ (1,335,620)<span></span>
</td>
<td class="num">$ (1,385,253)<span></span>
</td>
<td class="num">$ (6,279,320)<span></span>
</td>
<td class="num">$ (5,570,241)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per share attributable to common shareholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in USD per share)</a></td>
<td class="num">$ (0.44)<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.44)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in USD per share)</a></td>
<td class="num">$ (0.44)<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.44)<span></span>
</td>
<td class="num">(0.38)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Continuing operations - basic (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.38)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Continuing operations - diluted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289101137840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Valuation and Qualifying Accounts (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember', window );">Allowance for uncollectible amounts, cash discounts, chargebacks, and credits issued for damaged products:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">$ 596,091<span></span>
</td>
<td class="nump">$ 340,964<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Charged to costs and expenses</a></td>
<td class="nump">5,953,142<span></span>
</td>
<td class="nump">6,673,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Charged to other accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Deductions</a></td>
<td class="num">(5,969,671)<span></span>
</td>
<td class="num">(6,417,977)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">579,562<span></span>
</td>
<td class="nump">596,091<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember', window );">Valuation allowance for deferred tax assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">21,557,784<span></span>
</td>
<td class="nump">19,761,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Charged to costs and expenses</a></td>
<td class="nump">311,544<span></span>
</td>
<td class="nump">1,795,862<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Charged to other accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Deductions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">$ 21,869,328<span></span>
</td>
<td class="nump">$ 21,557,784<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>107
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MU7US<&MJEM3JU"HCX!JSY9&?<:Y>J(^1"(#:-TJX,14Y(]?MNKCKN5IL5CV
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MB#9L6QYK^54\_).-"B5JOTK4O?X_>AAEXT54'7LIFG$Q(&AX._PMOX^&.%N
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M,2>+>).Q.[K]@^P'Y B]A&95_=?8[F*=P#223<5HOD_F/<C38O<:/^]!'"5
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MH0^0?L>Y.@G:P7F<3_\'4$L#!!0    ( ,.I;%BFRE>#L @  +@4   8
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MO5Z:2#?N;(MUW![DT[YZ0ES#EAB3)/E6DDY9<9<*_7@R?2WW.A'ZW/7N+Z@
MTU(8"_4<7E^I'UB2</1:.Y@C7Y%C&L.=Y@'\1<>!$ .QIN$3_.+V32P%[36U
M1V)X:N?=Z+(#0A=[?LR/+4F;O&IYWJ0Y60=NMER+J4/'+@NJG&X1.,ZIS/>E
MHR@!_O%D-)E,!OH==@@6S36(),MZU[0V4&/TDH65IIDJ#;%#[BSZ!U >7[NK
MGIO92B>++OIBZK(VS@IH .DQ)FSNI6!6N&L?Z:UY J8GBHW= ?=(5JGI>) ?
M_8E(O@$W$"J>=,,F P/5*DC^>*I'6E)[VF'A17I0CC3/IM) HJJ8$Q^GORW
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M$@_3BRNX4Q3P,G#,:#6/WF'?V7FRY\<>AA#Q#Q= %I9 NQK4'4F3C7*9CD)
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M;$<3U5#V@ZAU4ISJ!C)#";(W+W5^X$CRT@OBATXB37AS50V('H@GX#XMX5T
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M>T:5&JI$6KW8U%F;9EK-87PD=-::"0O\'"XLJ_(="HIO+%[&95CX3.$G_V"
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MD_+96_RK(.?//\D;6=;2G8X\M/':*&LE+QO)]!'))*4/IO0;1V_*7.;W%8P
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;)56;6_;. S^*X17##?
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MD2THF"FYZBV:/6E*>N@6[J+2V K3"K=*56G,*B1GPJ8<CNBZ#K<-6,('L?M
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MQ9KF.VJG0.<[I>QAX1PL_Q@V_P!02P,$%     @ PZEL6 *I8D !!   VP@
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M%-HJ6T_Z'T<?^L=^B,;5Z3_4R]B#H0BMI184; I=9K9([SX</7=BS^.LB:*
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M;%X+DHZ6%]#WM3'^,. -NO\SLQ]02P,$%     @ PZEL6(%]F56O!   [0H
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M8V^/2SIFL#\?C (T5E#.40=,* ,L4./ ?$%YL&L>#ID&H0L016 M#!3JV#]
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M6]D"/ZPLPJ_E(;8IX-&Z"5S?O+@#@J_UT,*56J^)Z%T]^"3"?-Q9;1Q93;!
M\+2%71!3Q!J<4C9K8/F%%GC&:;!U%H<IC@=MB^!" A1 3\HZ1/R.@WK&\Y9C
M:]MH-3PT>,BR\%6*WY-[#,HNHY'.,]IL8=G/L6=\B9XG0SHCQ0SK.K8-IZU
M#5/3)L7ZJ#'W8/4!<Z78AN_H-"0[/\2"MC(HF:7-_:$.AX2LVP=[W14;++8?
M?XZ+Y+<6C( *[-O0+<+PS>N&6I3\NE>':=^[HW[<6U2]":?.!/.3\UHGL'.C
M4RD<TX+NCV[CV_'@>^O/>T=Q?VK^!1L_V1OLH-90Q6#E,[^/.CQ8M7&GOZ6R
M.$NZVP:'=Z%) -_72MG# SD8_QUP\S]02P,$%     @ PZEL6,R_%=8R"0
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MM 2RBL(;$095=.G9PT@H-43ER.RXM<#0"6]34"_%3NHM?'B(OZ#LT ;3:12
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MEIF2(I-*^D/7+8%K/"I(M DI:C-J\,*2,D@(JJ0:_"2'+$>W/'2\DH4(+ID
M"&HG?D@ %AK]33K^<)J3='SVM.$"3PQI#JT^#.JCU!_G;'PR;4J! G"H:!=9
M2.=#Y0 N;PW>F[T&*2@=ZM0U-G*+B<.<=K1%:UO(>H"*3FYU# &:UFBRK)_K
MW>1X+3W/2-;1^D^- CST6/Q3H/FW"O3<]V)R]%VOV&[C[25HADG1?N*'W>&"
M=-W>"Y[,V]O5%V&WD!+3:P/7Z?@'W$=L>V-I'[RIXRTA,QYWCK@L<<EC&PSP
M?F.,[Q_" <.U<?4W4$L#!!0    ( ,.I;%A6B34#70D  +46   9    >&PO
M=V]R:W-H965T<R]S:&5E=#(S+GAM;)U8VW+<N!']%=2LO+&KJ!%O<Y-E54G:
M=;)5LE=EV=F'5!XP)&8&,4EP"5 CY>MSND'.32,YR8LT!-'HT[?3#5ZL3?/=
MKI1RXK$L*OMAL'*N/C\[L]E*E=(.3:TJO%F8II0.C\WRS-:-DCD+E<59'(;C
MLU+J:G!YP6MWS>6%:5VA*W77"-N6I6R>KE5AUA\&T:!?^**7*T<+9Y<7M5RJ
M>^6^U7<-GLXVI^2Z5)75IA*-6GP87$7GURGMYPU_UVIM=WX+LF1NS'=Z^"W_
M, @)D"I4YN@$B7\/ZD85!1T$&']V9PXV*DEP]W=_^D>V';;,I54WIOA#YV[U
M83 =B%PM9%NX+V;]-]79,Z+S,E-8_BO6?F^$S5EKG2D[82 H=>7_R\?.#SL"
MT_ %@;@3B!FW5\0H?Y%.7EXT9BT:VHW3Z >;RM( IRL*RKUK\%9#SEW>*IAD
M+\X<SJ*5LZR3N_9R\0MR42P^F<JMK/BURE6^?\ 90&R0Q#V2Z_C5$W]1V5 D
M42#B,$Y>.2_96);P><FKEHE_7,VM:Q#\?QXSTA^1'C^""N+<UC)3'P;(>*N:
M!S6X_/FG:!R^?P5@N@&8OG;Z*ZY_5>XXJL[:WROQV3RH<JX:$8W8E_#H34L+
MA:QRH2JG&I4+73DCI"A(+!!UV]A65DY@<;W2V4JXE1(WIJQE]>0W62'KNC&/
M&I6@BB<1C8-9F* N*R?GA4(YM;)18D%$8A:" 0KI^* *Q9FK!S! C7IVXKHQ
M,E\KZT1A,AQ'<,1G:5</NB@ YZNJ*F6M4B@&MX*J,!1_T';DFKAZ4%6KQ)UL
M7*4:&XC;VYNA^ HUC#,7<$JI+1"19P#;[AKS%\MH,M/4IH%JL0*3$72XQ?IC
M=*6=EH7 2DFFN/YHH:TP%43:*B<?+O3"/9U:&%:)M]%H\DZ47!*!A^W6!GHJ
MJ[*6F$>8FGC(DH_A-8  I2($M6JTR4G1@G8]*=E8H62VZH^!^LR4<%RFV'LY
MP<;VWS-G*,ZQCW-,Z('00\W:AD*#0*G'6B--V,5]:L1A,O+&]C&&(#;5P*<I
MF@2MED^Z6G*$"3/AN$4*%:;)!3R 8[:>F:NEKBK:[E8-XN8=(>3"==N>6;"O
M'KJPF_G5*X1])TDR#,?DGTUR&<-OMDG'6<9NDF+9R+Q%W/@M_I&;=)4U#!!2
M\7#TA@TCY[*?>]\#('8QUB[>-=8;WH.$V:"2Q5#\ADZ2YYI;2N<5-A:>WNP+
M]LKGB&NULZ0[HS.7,&-%UG6JT6\!G5R)R*'[(73=FWFKBQPO=K)=R,(:H#4/
M.L=&GU%.553+NJ1U[W%9H/M*^)^WT&'LNB$1QB:/4I]''?I?OW8JV+VD\:_P
MZ%H^D=D[Q8KRZP'DOMJ-TQF;HQYA(Y4B)-0C8.4[*4- MAF_:Y/N#-GGFS3
MH'%(,VO\*^2<2MDT3X(8SBP6I-ZGQHN\0A%G&[V[E=T8?:L72MQGFK+5BALF
MS"&!^Z$NVS,0:L"TRY6X0AH5Y-/I?K9ST&P[[XE5@(LXH;I ^_/Z&NO/'8HK
MDD-*%RWYFN("^TB@H=GCU"Q.6TH)6(C\(C=9!V(3;>U3"5G;$A,TJF#2Y0Y
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MV$ IB,.*7FYT[$#K&TMU?)SP!L-_@=5?4$L#!!0    ( ,.I;%B>X26!) ,
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M$6W+C6AUMQ+&HK0&AHJARC,2$I@8^%A7 9W6##-21!E\SR@Y06^X41"\/?!
M-B+HJQ@G$/$%M[*!G))3DL:/S_ $OA!4$!@[$JYD-_@N>K5!;)RO2IZFD/X<
MPLMCF6E=0W)I/&$IU+FDH>8IS7!1$9 9Q00T:U8?U=P'[?-$:ZA"78>R5ZR
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M'0PK06QA.A3&*\#Y6FMW6'B"<=Y<_ -02P,$%     @ PZEL6";;Q PQ P
M.PT  !D   !X;"]W;W)K<VAE971S+W-H965T,CDN>&ULK9==;]HP%(;_BI5-
MTR:M3>)\ !U$:DMIH>J$6G6[-N% HB8QLPVT_WYV$C*@)HJZW)#8>9_7/K$/
M.>YO*7OA$8! KVF2\8$1";&Z,$T>1I 2?DY7D,DG"\I2(F23+4V^8D#F.90F
M)K8LWTQ)G!E!/^^;LJ!/UR*),Y@RQ-=I2MC;%21T.S!L8]?Q&"\CH3K,H+\B
M2W@"\;R:,MDR*Y=YG$+&8YHA!HN!<6E?W+M*GPM^Q;#E>_=(13*C]$4UQO.!
M8:D)00*A4 Y$7C9P#4FBC.0T_I2>1C6D O?O=^ZC/'89RXQPN*;)[W@NHH'1
M-= <%F2=B$>ZO8,R'D_YA33A^2_:%EK7,U"XYH*F)2QGD,99<26OY7O8 ^Q3
M "X!? RX)P"G!)RF@%L";E/ *P&O*>"7@-\4Z)1 IRG0+8%N4Z!7 KUCP#^U
M<-9NY:RF8]C58A>;KM@E^18;$D&"/J-;Q)1>^JF;?)_FO-Q9<:8RZDDP^326
MG BFY UM.)H"R[,S"P$-8QXFE*\9H#/T_#1$7S]_ZYM"#J80,RR-KPIC?,+8
M00\T$Q%'-]D<YAI^4L_;N,; E%%6H>)=J%>XUG$(X3ER[.\(6]C13.BZ'G^"
ME<2MD_BP'I^LLUK\IAY_(*QV\J/FL6,-?ML\=AU^USQV'3YN'KL.G_S?NM]_
M^-4=;$.GRC@G]W,^DG&Z/"OL7+V=^N)>\!4)86#(3RH'M@$C^/+)]JT?NCW>
MIMFP3;.;-LU&;9K=MFEVUZ;9N$VS29MF]RV9'6286V686^<>_)2%J$PGCH@0
M+)ZM!9DE@ 1%(4U36<;QB#"(:#('QG4)5[A[N;NJ2#?!F8][KFOY?7.SGTP:
MH6VY/=SK'@J'[X7=#I9%[Z'LYKW,[F&[ZQ[*1IIAL9Q=!_<.A;<:H6MU?>=(
M=Z>+PW$\'Q]-<*P5=CWL.8?"B?85=GK.L>.]1NAY'0N[=B4L]H"Y5^.DP)9Y
M&<[EDJXS4?SY5KU5I7^9%[A'_5?VQ=C6]$_DR:"HJ?[9%\<*^?U9QAE'"2SD
M4-9Y1TZ7%:5ZT1!TE5=8,RIDQ9;?1O)T TP)Y/,%I6+74 -4YZ7@+U!+ P04
M    " ##J6Q89#JB:T,"  "*!@  &0   'AL+W=O<FMS:&5E=',O<VAE970S
M,"YX;6R=E5MOFS 4@/^*Q:0]M>&6RY8!4M)N6AXZ16FW/3MP *O&9K8)[;^O
M;0C+IH1*>0';G//Y.T8<HI:+9UD"*/12429CIU2J7KJN3$NHL)SP&IA^DG-1
M8:6GHG!E+0!G-JFB;N!Y<[?"A#E)9->V(HEXHRAAL!5(-E6%Q>L:*&]CQW>.
M"SM2E,HLN$E4XP(>0?VLMT+/W(&2D0J8))PA 7GLK/SE>F'B;< O JT\&2-3
MR9[S9S/99+'C&2&@D"I#P/IV@#N@U("TQI^>Z0Q;FL33\9'^S=:N:]EC"7><
M_B:9*F/GDX,RR'%#U8ZWWZ&O9V9X*:?27E';Q8:?'90V4O&J3]8&%6'=';_T
MYW"2H#GG$X(^(;#>W4;6\AXKG$2"MTB8:$TS UNJS=9RA)F7\JB$?DITGDHV
M^G@S$.A)X(RP JV$P*P ?>Q*1J[2.Y@X-^UIZXX67*"%Z($S54KTE660_9OO
M:K-!+SCJK8-1X#VD$Q3Z-RCP@G"$%P[EAI877N"=*_,&[5_1AF7D0+(&TW-5
M=]#I>:CY;I:RQBG$COXP)(@#.,G'#_[<^S*B/!V4IV/T9-=00+ZWG]WZI]IH
ME?%:_7_(G>XX,,=4PHC8;!";C7)^<'9[A=PX]#VY^2 WO^K4GD#HKPA?<!MG
MON>V&-P65Q_<N-\X]Z*?>](?*A"%[8(2I;QAJFL5P^K0:%==?_D;WG7I!RP*
MPB2BD.M4;[+0KU-TG:^;*%[;;K/G2O<N.RSUSP*$"=#/<\[5<6(V&'X_R1M0
M2P,$%     @ PZEL6$VNV!G['@   6,  !D   !X;"]W;W)K<VAE971S+W-H
M965T,S$N>&UL[5U;<]M&LOXK*.W6EE5%RKK$3F(GKI(5.^NM9-?'<C8/I\X#
M"(S(B4" F0$D<W_]Z:^[YP(*I"\Y56<?]L4F"<RMIR]?7V;TW7WG;OW*F+[X
ML&Y:__W1JN\WSQX_]M7*K$M_TFU,2T]N.K<N>_KJEH_]QIFRYD;KYO'YZ>G3
MQ^O2MD<OON/?WKH7WW5#W]C6O'6%'];KTFU?FJ:[__[H["C\\,XN5SU^>/SB
MNTVY-->F_V7SUM&WQ[&7VJY-ZVW7%L[<?']T>?;LY?E7:,!O_-.:>Y]]+K"4
M1=?=XLN;^ONC4\S(-*;JT45)_]V9*],TZ(GF\;MV>A3'1,/\<^C]-2^>%K,H
MO;GJFE]MW:^^/_KFJ*C-33DT_;ON_J]&%_0$_55=X_G?XE[>_>KBJ*@&WW=K
M;4PS6-M6_B\_*"&R!M^<[FEPK@W.>=XR$,_RA[(O7WSGNOO"X6WJ#1]XJ=R:
M)F=;[,IU[^BII7;]BVN[;.V-K<JV+RZKJAO:WK;+XFW7V,H:7SP*GXZ_>]S3
M>&CUN-*^7TK?YWOZ/CLO?N[:?N6+5VUMZG$'CVFB<;;G8;8OSP_V^(.I3HJ+
MLUEQ?GI^<:"_B[CZ"^[O8D]_4RO^[\N%[QUQR_],K5CZ^VJZ/XC0,[\I*_/]
M$<F(-^[.'+WXRY_.GIX^/S#;K^)LOSK4^XNWSK:5W30TR>ZFN.I:3W.N2W#W
MU%2_N+/B_<H45?S%U,6-;4MZNVP*W],/))4]-^OIQ:MNO2G;;5$Z(T_KPK;%
M+R?7)T7=-4WI?%&V-3\FFFSH_[H8/$C.[RQ-:US9--1!59D-FI=I5S9QEB>8
ME3?34Z&7FJ$V/!]M_7!^- E+/]^O.AZ-OJ[+WSIG^^V\NV]I7#\LO*UMZ2R&
MNVQHB$PZ;-L;5VEGQ""M+UFQZ/+"J*ORSA0+8]K"-)8$-A"DRBE\<H ;GD1N
M>')P W\A8M 27_G>DG(R?HH%/J\'WG?9(^$#I>#'64'6!QM!U"0-UJ\^;W-)
MO_\^6)(8VI*6C %ZW=V_OJ.'MZ8P<;I,=T_V9"/[T*_*OBAO;DCA<TM:2>=X
MS'7D"'K?]-*TL>7"-K:WVE5M?=5T?G!,%5H/)HF)C%Z4KD&+3R</>M\W(6?N
M3#OH%,P'LK:>OM2# X70:&.<[6KBQZH?J%LB$AD<3Z,.#>9,RW7%C>O6]'+G
M<_(,I'2=OH%EY*3"8#3OVO)7EJU Z+_\Z9OSLZ^?TU9TOA])0.I:Y>U9\>CL
MF(6*]KB[IX73,^*"HEJ5;FD6974;I</1Y.6AHP=A^S:NJP?:+F?ZP;5^5CPZ
M/Q8I'G?8+8C$QE?,%XZ61A#BUO3EHC$T&:)@W[DMM;XX+N[*9HCLF^TBMLD2
M1>19V-,MR-+1AF%;F'$74$[&@\+K!>0W$NS15\>%F>A^P%8-O71'OY*F*-NE
MQ=R$W0Z)^],H[D\/"NNU6;)4O&,>HA&GY/T/=3&:UM=Q6E\?[/-U:5WQ3Z()
MB\/KR/UO6C*B [/_U$3_<*<%OW,7WDEBMT? K1=A<K8R([5RSW+D3&4('4+)
M$&*D7EKI",RV*5GYL,J'L)49\Y#BHU<[1WS5C*R"\%)9")]2'T1PTG40(U4A
M:U-"U_".0'=,"^%-6F;6 $(! 1%1V9 4T<*@DMP ;5J2E>-5R**S/E:6!,!5
MJZTH2VH% VC_9>1-VPK.QP(&3Q)!ZZY)037=9G?.I#3>]!B[ 7GO5Z3I[X@X
M';WFBN5 ZI"$-^GU1R"D@7WPQV&/Z*=\BVBL11RB!IFRB6,_E[1#,L\586W2
M1F'^O#]#6]:_$6"FIK\/'?[CS6;C)-A?-T,T"JD"DMTJ<<S.;![]A'479Z,U
M'T=53L1_. '24@3Y5"EMAC[V<C'NA91Y<(."$?FT/<H&P$2F1@S;I@/F'9->
M(C9>.4, Q74E"0@FQ[)1DVYU=D%-%W#4GA5A]?/BOT;$')/.9@+Y@,PGVLGY
M9">>P!&!P\-=/-_9RO'H^WL)&RV(@*C0=KUV_5R07U>;9DY22[_4R60P.O21
MEFB949C&D\>Y4132UNC([;8(%+@@"ER/H"1WS[MA,H/%L^(^\IT]*7X%06!5
M:&F;X*>H^:P,8061GK#+B12"LS'( MPJ*_<PM[3UI2B>LBCO2B(BCP05)*H%
M#;VZSH$[_.Y\#6$. OG=DG6  ?/EO)>P1]+/^?3&(@X?'8IX<(Q]R->V>Y#)
M=&_!":A*OQ* @P]00-0_WI@EE"[Z'FO.?B1%'W]Q@QD9D-DG00E '2"ZKKG#
M$F#7&":0/K.]K*4JG=OB(2]:X=(?G''"6&8'UL(T?&#0AJTC4B=Z V0:Y4'Z
MS:\($\S)Q5D7A'EH]V2Z^Q9#?@YU3SV1W1'M0TW!8T04FN']RE:K?'AA'>PM
M"*A6$>\>PD;?1!#RS4&\<!7HQQ]>)?I-08\O[*JXVK=)D?%@E0@%-):>U0Q+
M?2^LR6" M/B2&+>AU1-]98-8^T,AKR50 B-$V),,!#_[@39]O2"#&F(>/ 'Z
M<#Y[. WF2K%)1%_;L&VA?LTVT/N&7(*Q2.&Y)>S,K8&ND^>G^^RLOY7YLYD:
M29[M!]&:I)=DQRT+!R"]CT!Z/"#XAJ=>$PKUXI"CY4TSP,'IP4KD!U5 X !V
MIE8/D@9D7 "OFE6[ZX;EJAL$36U-Z0ZQTK>1E;X]N/^70;3>17F;8J+/[J1X
M[\K:3(DSZWOZ"A!9!W!(S-.1Q0N>XIB$\O(#IRLXE6STQ#U<T)MK6).*=#J4
MN8BJ;.4 *>>09@W=NR+>(1:%884;ZJRAGF<YE@P#D/5@=XETQZZC)SM+CC2_
MN3OM.\14"U/2=DMHTR"DVC!2I,X Q-CO:D+,%C[TH-V$8,U.7" :!74EQ0;3
M%'JR6 -/4SB%UDTL9UK AV)#\UZ7E1D$22 F9#S)D=/!,M*6RQ*\/KEU4[YN
M7+U,Q$"EVE9H7(99SA?;>?!]V=#-Q/_W<&FM7P&(;?-@B$+YW46S60]^>6 >
M^L::&@M*^\MDUS%C^\E-+R*0IDUQY@:[4=RVW7V+Q9()])&'"%-!>3#+69H:
MO>@':/Y(OQ"WRRGJS'BE88H:3>'H*V(=()TJSYJ\B$H0#.VC? D\I#$&4JU;
M+SHU6Y9B7"BT?1OU8,L9AW[:;H\9GD2%UO;GTY.G!>'2AM,._0$M?E+\@_VE
MSBW+UOY+,.A,21B"81B$@Z?='4 '/5?NW=+VM^;&]CFC2(0R ,1E1["T%0XB
MZ%(QDEF7V^CPAF",1I"2M":^L3S%UBR[7L(D88L8=#*>.2R0'/.QZ\7@?/1>
M"8D0@1C9,[C<I$ 4@E@$M03 .!/1EIG<^K$V(*>40Y&_D<I+;C@4)J'O?P'&
ME"(64#>9V,^R.!RK8YHYM.\^7.6@1LE",I$6T^N/8JE3%%*+K& +R-FMFI)D
MM3X1<#'6'#P'#6QVNP8!Z[YADF +(C%N)%S!^XV5@Y$+OS$5>1Z@-8<2>3Y0
M$7'/\VBF#G3(EIZ=IN32Z4%#^$9#<W8Z//WIK4>&A%.6!6*UIMD&;&)=+5$6
M\85((@9H)Y@X]I1(8DD" &!$Z2R[KE9/M(3G\W*DA()U8E.'/5C934)!6>=.
M(D3<.7'1*+)$#!ZDIT?DFGA:.&]G$KMJF\9::Z!SYQ')&N!>VKE\)F-K2T^)
M^XF1"")!*[).D?$0?F^2B60M121BN> ! RVW4/"!YYNN"KD,C,SQ?5''I*8E
M3 IUB[=$E-\RM]DJ!6B+C+W7@$,J.7&:I/'+M6BNL5 %YW YP-M7UY!$O:PE
MA#VFO#/DR'@:Z/+MFVQTCJ1PI$;<5*0L+/D[P1"3!;2"?]%WXKTLLZ7[@>B/
MDP"PYWUJX<V8LB$=#DLA#BWS"[^1H8#DDM/8OI];FKM\ I05CWJ\DQID9A"L
MX6>V46F"+/9=#ZW)6^!]\NYX4::>J8,G60IP/:UAON[8M4LD6FS%@+ '#H8(
M$&$;6805^V\FJ2;5&MH#D"2]>E+\"@8T,%F %-#<5?(#1TXP<W;<!:A&A&L6
M@HK)?JG3J[87X:H(EQF@0%?OS (:$RZ1^IM3VW-0PV7I\[./I%'-IK1B*<26
M7^F8EQQ6G%1[?ZS+(G]!XJUAG1K*#)X@T;4V9"9@)]A>@.1@2& ([83=*D;@
M],O:#NOL&?H9FEY"0>X.(;A9\ML$=($QR4L#6Z")\@-KA]>D;?BM']RP+"[K
M-=1>\# ?';W^X?+H>,SJ,?]%S!YGL6>9T1*6&O1$F@@AZ)0T P$"1,J\8C:*
M- \4;,PYK!$@N)> =L7!L$/\<9[XX_PCF]G17#0VA' "J_9)KOB2CHK1SR;\
M/-.8!,=M %((Z-0 Z(0A!8+-=K0:N.*$D"H1'<DP[)#*&8#32&^-22<:*U$^
MH!ZT,#<#J2..VBNZT'Q8\=/DI'A.M*VNYR%CGZRZ1.&*F%M1=.B$G81BTPR8
M;6ON$1?>*(ZV2*^6G@S3HN%$W\":L'.*QQ!4Y=Q=F.F-&4WTI/AEP\5'O=5$
M38>$JB<!P# AFPS?;5O 3>3X#:E?H1T[3B O(F50JUVK>6WL6<ER)6]'UR<E
MDF/Z.'N?S>J;G& ,)LT'4OUUS%E% )HOBX%TN;$]E" 0YSL(E[I.'%PV+6L!
M5@_BHHDP\OR)G2![]4&A2%4W9P?+9 C8Q03I94K7_4CJ IAI4CB^H.[F\"B3
M@>4'F5MUHK1)IE<S6BK)LJA(,&62A*Q Q<)!9*!;RU[DKT= "(&YG4&Z!>+\
M"6C]TY+;8._XI6O:HL&3ZU*1I/N0O(]+(J[C1$>4(/&S0LC.A;QOL1D<\3"T
M.>$_-//#XC<NF^C8C2=4Q'J676K+"!7"UJN^;[8:R^Z$&#P=)R4=^U:^RX&[
M^;UQ746V0$$WP9>,&1V.+=\E[XNLB3CHW9J .Z^7^#\XE(FK$W%(HE@O3*@N
M4GMMMR;HFJL$G8,L??R&]5EC\9P': Z/G"CLH\1)T-3&>+% (59?.D*@6+ET
MQH@>YX&9970N+@1SS0?JQ=N[+"264S^+VZ7H0/)-2;:K7G->J9"!N0X!?Q-=
MR <=!^WH?=!.&DED<#C+8XMBA4,EBL1Y\^Z8:0GG>1B"T#<])'L=4BH/:9_1
MFNFNB+B><!'R,AK==S%M"@^83B'61<8BRZ23GN61G:A.QN$:^V+/17'.A.4X
M)/S]*K+B3M6)A'QT#+9<-.0L4F@D.&T]92017O6YV;VA1?Q(QE?42$WJB>L5
M)']ZLY5@2'!=67;^L3950UU_F+\M;\<N%<+V<&)!X[9KYQSWNG>6-J%&8##&
M.!IU$L>*%,__?'%R$<)BFFF<*I8* <<>.RV[$R*@YH9F*6&GL(I\"8&)3XI#
M5BI56YX=KI#4B#U1^^_D6V6Q_&E0_Z6=173_BF62B'<EF9>?Q(][!*$]/WU^
M]>KJ)_YX]OP8C)^0*@>SB$\>%,'DM12)8P3J78X:C+*RL/U!JD(J3VOUV F5
M3?9:%%.;+$:JM6[W'0R1R:.G)P46D I"=DM@B$%,(("FGM219;D.28$[4SS:
M=%USK!*.PI-8!<"Y*GB)I&Y)PDE+5%!UU@?%L6818.T["Z$9>*;DI8I_C?J"
M-J_\(K^Y6T?93JGQW5'HA:R8^)JXORZ1H[GJ:L[ZJ\]S>7UU=%Q<G#^=GY_.
MGSR9/WE6\)X^?5Z\D3@*ES4 T?%GI80G=]<\5L@8&KS#:N4WCK&2Z'J?!@NO
MO1YS1=%O-R8^O":.B%]><>DD2#S*YL;G[V&JPI<?3;=TY68E0?9N9]"_I@ \
M+^?AQL*J89$^K2= =9$3/VP 5T+DW53 '\&BO&<_1(B<>"J&C8'!B$D>2@3@
M#@?ZF0'7DL+J4-,A;#[)01(Q(F> S9BH.1YQ5 <=:IYV0U%B*U/I** ZF!WI
MF R1B44B=I9X(0P)5I!*5H-VXYHL\D&@S@\Q_DGQ*YOO>YKDEO.C/@A9R.U=
M#4A+-* V]'MZ5!=WUO4B$FV7Z7DM6<W$7>M$X:0,;OP(Z:]!P\P-AV[(RB&Q
M"_LTSL#-BI4IFW[%F0[BF"QO$:/;LX"_Z=<&R;%;)IR$NT5-B 1"N9%3BIR?
MP"<)B"_,JKRSG9 !^E+GG*610K8AC$&:SDKTZ4:=1H] +G8<I7XH9F\KF&DC
M==]>:J=AEK..&1%*]14 81M?XRW>R9+2%J &#RXCUP1PJ;K"<,Q[F6JH1\DI
MKM33*&.Q(ENW)D21@$1P:R=:A@PL>=F2,R[4A6(0F>**B[*F(18/DM&2U05!
MM2<OH.3;4X+S6P@Z(J"#Y,_(7)/P,S#044(M,N=X/",MS5A4,;_(:CF5)J*C
M.!931!!F&-'FT$TCCS%-R=50>Y><DF\2<N+>XU@1$,>MY9FTMV[8]-5VE"Q'
M."LX"=;[(30O8V-$:6KZ[+:2(EM&8%36$L-@LW)]!8-!,E^S=R<%X)RC1"4)
M22SLM^1>%96&9-@A&)2.&9P=/B7P)OF#-)N?NG8Y_XFKY@X$./\/>QS/.E5+
MGQVN=7XGZ3P +42P]IV1^4@O?S<<86,\GWK41"'KM8#V)3(>2CDT9J8>O 0J
MA?L4W?H8\$EU9/S\WJBUE-"V)&E5^9 2X00.Q^G(C'#H:J,I*V2--NSL<-)<
MY3VK2)X%+X%7,0[NJ5AL.@NOCT5GS.4<DQ ;Y,0JL<F3]!7)[STT8V\] 7)H
M/E5B+&/=HK%+S:HP".NJ:B!AY)DK!DLIK[$/!86A*2\4&!#9.!''NHZ,7*O=
MOE4-+TLG@ .3 O4-9TKVZ>(4K9ZJ@N"?0JPA##Y=:XC403JE(,0;;6+,TTJO
M2\?@9J<%=C!%"/:?EICE26#4*)1KUD!,::D1B8,+RP6/:^J(!2PFR,PA_9V#
M%JQUC>.:TC(+S:M"UG@_1_9/1L6KOPWU4BSNFMB#2[;A ]@VVI_@<N?E\%)X
MST<Y!J=3)]K'N$X6/1-.3YX?^#WY\0 RP%#T[H.ZBEWH)0XQV"9&#/(#*-F8
M(; 6JP!B^4/(,+*3E$Q0UE:+5:+?#PC-,)2K^$I5V+MS2[*7!@C<DO$'_.:\
MG&1T@,;'B $C.UTC;1>3]UUVSN:'R%6?4=VTK_IA/\_.1GP3CC0A_[C+@/\I
MCOJW+8[:U4%AQ\1YR#?S/^5+_S;E2\$8_'\6,06U(^QR%1TI647$NAL0W^XZ
MRN& @VA,="%''?04C#KMB7 L??):C";O*WB*A1\25UAX<M\9+PA<3G4?!PYB
M[1*"^=DGE2R+MCX/_^\IJ=T9#Z2/QF/L0(@/(HHD15$T25/U(<ZNHY.]R<+4
M 7QFIS[#V:"XEOT+F4:R2D\Y:3HZ3PI&YX'KH!0B3I:OD353(CY+IQ$?=J$B
M;>D ,U"KKADE^@%5"1),9R$(^1'\"O:-!UI9L&.QPDD$[9FYYN[]#@#F,&(I
M*3X]%)NWD>(I:9@.>*^-QE&[?(53/1-F:3^2/$T'+L\.'XZ\TG#+VZ"?KKNF
MGO1MOJ"?(OP:M1_G9G2G_"@,'(\_^UY@$,?$Q)0.Y')EW7 O>5&";><+LC U
M[3C?FQ&2S;L"D,7_E04G*ZV8@T+MCTZDEC+>/%$ZO3@"S5W*R:42E)T,S1CK
M?V0V>765B.[8;E[3&IF3B00_<SX/WUXI$?*GZ_@TD"C?C'30(\Y;2A:!ED6[
ME3794'+-Z"=V ]:=>(/3]7\9=?+]<MVV;/I8H,/VIG3!3 =)X=36"<!FZADT
M/^C2IT,^9X>/YERFA4SUJDS_A_H8SRR=&3D[?-[C'1E]G-@4J"WG9?>6^7Q9
M5\7H09T]F"C8&&OK6+OQ*7T ?SEVFV"0A;4JFB0;L9YC38'3$A/,BOMRJ;P0
M=&'&$1D@E'"5CP'^QHJ6WC.OP/)1.I-S%6(, ;I85\^E9C4BS73JNA>=,XEP
MXNI\3[QN=L*QT2]*,1A94P*8\58$(A5*D]/,N-K#,F0TK>L8,#)T_(#:#!-.
MPJJUFJI>8V^%M>QH#V2OXCB'#,MY*M8^_UBY-=O@]^6'Z0SG9S0?1[1E/V2Q
ML1ZQY_=259G6]&7']K>2CR=SDE(OR.%QP=ELU-/>:SW&*(9QNT F-((B923(
M?E<O.BL$TW=*M#BMB3:2P6*W@;J[1Y)O=$@JG'E%GPO3WQO-O\>2U^SN#TY-
M\F_[;R7I^70F>1D;S<UA%F"^/6=CHX4>S40(D8=8P%ILG5 CRE8M55R$N)#M
MS3KSY[*+-NJL4' VKJU@T28/S\Q%1*!12(@U5/?#)^Y:3%T+AYBVK$)5W" 5
MOM3>:4&QE@3E !G9<;FVH?R@!U29/54)2#J,%T9KW'0.1_%W"5:VJCVDRU20
MK!74IN\;H\7:1JZ=X</2'U\A%SQKY 8SBFL98T=LP6C:23$P01Y$+6G\)@LN
M^="<>4:<[8? IFSSU[BX5Q%./--I-4M[^IQV&G5*MSAY081OD9+0JH247HE]
MW(?TBB<4)U5M$O;]4*XU>AL<3QJ;)6$@Z78:/GO3:J514!(!:D5.G2#V;!Q.
M"'FED%GE=#YG73LNU]1$H)3(/-PY+L")Y>BA>!(D1V$T.U$ZJ9"OF>J%;U@(
M9P]CR%YN1PKMDF+*^?7!14#985MQPZ;Y5T]^!M%&_<7/4V3AU$&UHM=@G.#"
M.*UMC<II<H!9. 4 M3HY\Z Q-TW9<DB8X\N&KPK@*QIN96'69^5DTSHMOS-*
M8@(:%_$A4Q(+%OBL#PE'HYI$H![[E1F3B^CJM0$:2U"9D;J 4L##M+.?.C('
MK_8Y3Z<(S@^7_+\B_Y#+.!ZAZ.<81V>*:^C023M\N*^?./\0.L"Y)E0IAA]9
M,V/-A"6J00S" CM+)AJ4@D,C!F_''J*N$A6-*SZKTS#SA.,[[,*9>EZBVI%4
M6LMU!9);*5&8T0T]5VO0""?DY> JL"S-I!G-J"R@=VO;##!W\%,:/L;[L25P
M."+(RIT1WJ4I#'P.GYD;;HF:D:ZZC16'Y@,*1N4R-'G29==DD8D7QU]N7,G4
M<V[9U/<YQ WIS,#YX5)_WKBY'$C3U-8T(/O\;AZ<(U<[\6 IDJS'%7B9*8^U
M%IS/)@RVYNHF?')F,Q""+_4@1H5@-AO'E*I4K2>W2P3)"AL5)<S/)C:*8=8D
M+K"Q7&9\DPCK5Z=7G)A0\G\SNC0JL+1L>9L*D*<G5C3E!F5 ;T,T$:_Q;^H<
M\/5KOP\P31HK@N'@X>J'<YKMSLAF!7OZ=L.E$^4V15_']4('^2V5XY\?+L>_
MPC6-BTZS?Y<QN#;)<U_6U8COH/'U?*&6Q*!&NAHU9:%;FNSZ#!><Q-'-$Z-2
M4.C^P1%K<IQ#5/_.2?\0D*J@C; -"J-#N#&Y>2'PB.FF2(LZ,^E6@==R045Q
MO8:TO R7Q^V>=KI^^>;=X^OW[]\=9UZR,(-P]\-;,K+L6$!6['V.R)1%0F.4
MRK""'5W@F+<)]5#(\@Q>XP5<E7HQVW42I@X?[+T()Z@'TME<_TGL; 005B@@
M(\=5M$JRYE*V@PJ7]]V&S-0WI]_,BKT\I+4QZ0<=)I0+<522'$V[Q*V;FM,#
MFT4@$8XB8 =B60(S$;\LNS+$,K_]+!FMF)RXYBP'@%\;X@.S%) +\1<8J:XU
MROGA5BHM)4P>AF::8D9&)L6-3D*$,.LTSO8 ;X14#V(HO-ON(P$7(5&0"4VV
MU5EX/KG6<FN)UTBHQO@/'FCR.R>:#NFP5*Q]?KB^&@75XRN,?]1ZS$DM=K"S
MZ>-$^T<H'CYZZ[J6/E>ZX$O4<Q$-R*'YVT L<'YZ]E3T?ZK.G2P??MFAP/71
MT>O+ZY='QVIWIU_]9<.V"S7&O]"K?^].>)CY&4FU.F^3-RG.1^7FL^#,B8L1
MDDF8:G8P2"XJ ^]S\>?D[8LAB"#\FQ68XV"HT\KQ/&(8*T=1#-K4\[Z;ZTU)
M6ZX[Q'5D>F_2C-!@V>8!QZS_69Y$=F8D83CY71*OWA<:O)DW77<;JZI/G\<8
M N!FH(4LEY5PNM$V7,0J5T"2.#56EA'JS;3,-*_TD8IV(4"\=6U.3^8<?-]9
MI6AT0$X]^2'-\_6%F];&%?-:&]BV)MV0QWUM4!/3#3XK5A9CD7QW[6(G<E:.
M;ALBR174Q4<.\YLJ4L5;=M@@F*&TLA,U=%@"Y].DIIFO=-A3<3/.'J5"'.IX
M&P[T(_MW&VCQ^U!RE& AQ<^L=.0&KEA#FC-OU'/,@OD$-91$"R#)RLL# BZ4
M.IQA#5^$].1<8T$I=Y7*<$-.IM+7#=0OF2[+J5^ETX*<9'&9P[$#W _PL%@\
M"P2D\G-&5Z)N$%B/UISFGNN$S/J3Q8"?1;W]3$B3GG^KJHET3M0XU!I/YJ=/
M9L71)^B1XI%8](OSI\?/BO<H+L%$WJ,D3*2#YF;-S5$\7Z)!XCZ]X?@-WBD=
MGV>^""A, H-])BO@QT:OHQ"NL@XWV%5\T,\TX6;HW _81':@X>3(TF<<I)%H
M3EZO*VG!^QV1#(<5B+%4+\IH$LD:G2>(974F';B+?\4@/)2+5Z5NJLVT'VJG
MTK?\$L7813@E&O2/K%T<J0FE1 \_IHZG#UP]SOXJP=H0 ^!O+WBY T3^0$'\
MM0A_W^%2_JI!>EW^.,3/Q#\H#6G,#34]/?GZR9%@N?"E[S;\-PX67=]W:_ZX
M,F1@'%Z@YS<=X5O]@@'B7[UX\;]02P,$%     @ PZEL6!8(^;KZ P  [0D
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MB^=>,04E&P0"!)4J#/C.X)O.I])3/9.  A.["P@#%N>4?9J]=L(%Y#PBL.!
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M<*#UM:'C.RAA@^/O8_$/4$L#!!0    ( ,.I;%A9B((KK ,  .,(   9
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MX0K_A0CC ?A^H;7;3?P&X_^:V;]02P,$%     @ PZEL6 &J\ZUI P   0@
M !D   !X;"]W;W)K<VAE971S+W-H965T,S8N>&ULC55M;]LV$/XK!S4H&D"(
MWE_LV@;RTJ(#5LQ(NNW#L ^T=+*)4J)*4G&R7[^C9"L.IK@#!.E(\9Y[CO>V
MV$OU7>\0#3S5HM%+9V=,._<\7>RP9OI*MMC0GTJJFAE:JJVG6X6L[)5JX86^
MGWHUXXVS6O1[:[5:R,X(WN!:@>[JFJGG&Q1ROW0"Y[AQS[<[8S>\U:)E6WQ
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MF0:LG$^B2S:Z2H-_Z_"'DANWMX:@9&;,YV"\KR81#82DEJ4/" )_'N6UU#H
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METN\YDD;'/!\;HS?&2%!?W&<_@=02P,$%     @ PZEL6&&Z7SRX P  NP@
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MZ?3TV"K'B57=T)XVRE*S&X8[^G>!VFV@[UNE[&'B',S_5U;_ E!+ P04
M" ##J6Q8'562UH<#  !]"   &0   'AL+W=O<FMS:&5E=',O<VAE970S.2YX
M;6R55EUOVS@0_"N$6K0QH$82)=FQ:QM(TA[N@+8(FM[UH>@#+:TM(A2IDE2<
M_/M;4K)B%XZ1OMC\VMF9Y9#4?*OTG:D +'FHA32+H+*VF461*2JHF3E7#4B<
M62M=,XM=O8E,HX&5/J@6$8WC<50S+H/EW(_=Z.5<M59P"3>:F+:NF7Z\ J&V
MBR )=@-?^::R;B!:SANV@5NP_S8W&GO1@%+R&J3A2A(-ZT5PF<RN<K?>+_B/
MP];LM8E3LE+JSG7^*1=![ B!@,(Z!(9_]W -0C@@I/&KQPR&E"YPO[U#_\MK
M1RTK9N!:B>^\M-4BN A("6O6"OM5;?^&7H\G6"AA_"_9]FOC@!2ML:KN@Y%!
MS67WSQ[Z.KPD@/8!U//N$GF6'YAER[E66Z+=:D1S#2_51R,Y+MVFW%J-LQSC
M[/*3,H;<@":W%=- SKZQE0 SFD<6P=V2J.B!KCH@^@Q00LEG)6UER$=90GD(
M$"&K@1K=4;NB)Q$_0'%.TB0D-*;I";QTD)IZO/09O(],2RXW^W)_7*Z,U>B,
MG\<$=W#9<3AW6F:F804L CP.!O0]!,LWKY)Q_/X$V6P@FYU"7][BZ2M; 42M
M2<%$T0KF78Q=V=:@F56:,%FB Z5"7_@^EP1V(AL4:9S(8\I.YCZN[%L%9*T$
M'F*$)];9!/'5UA"+,X6JF]8.%-W0(4TWLD^U-8"#:M"&LURT%@>%<^3 'G-J
M'_R(R@P!YRV"SH!ZA4O29.;=X7XH^;++."-?\#KS0&?C,$WC<#(>C\A9'H[S
M.(S3Z>AI ;-X(:T,+SG>2=BSFJ_:3A[2DTH6Z&J-PIUL+BU@1:PA>1)FV9A,
MIN%D>K&/=AB/=:FQ)%Y*I40)J.&U(T4Q,J7QR/7R,)_$(<V2$2H;2C0CW_V5
M N4[=H^Z-M#!&()WJ[%85,?HS:L+FB3OW<W$"Y)D(9U>A)-)YIKY. WS*?TC
MG-TN'$<Z8>Q\,';^8F,S:?D[GQ%O9F*@:#6W')G!0R%:M]-KK>K?S?4RBY]D
M\;S%KS$7DX]OS6_DW*YK7KC2]-5SKL;KN;@CJG'4#NNY19\09OHC8_[$QI>'
M57G*MLN3Y32D-".43L(XCX_N2K3W)."IV/B'SV I6VF[UV$8'=[6R^Y)>5K>
M/<R?F=YP3"M@C:'Q^01+J[O'KNM8U?@'9J4L/E>^6>'W 6BW .?72ME=QR48
MOCB6_P-02P,$%     @ PZEL6*4IYKQ4!@  QQ   !D   !X;"]W;W)K<VAE
M971S+W-H965T-# N>&ULG5AK;]LV%/TKA!MT,:#8$O5TF@1(TQ8+T$?09!N&
M81]HB8Z%RJ)+4G&R7[]S*5MV$L7M]B'6BSSW?>YE3E9*?S-S*2V[7U2U.1W,
MK5T>C\<FG\N%,".UE#6^S)1>"(M'?3LV2RU%X38MJC'W_62\$&4].#MQ[Z[T
MV8EJ;%76\DHSTRP60C^\E95:G0Z"P>;%U_)V;NG%^.QD*6[EM;2_+:\TGL8=
M2E$N9&U*53,M9Z>#\^#X;4;KW8+?2[DR._>,+)DJ]8T>+HO3@4\*R4KFEA $
M+G?R0E85 4&-[VO,02>2-N[>;] _.-MARU08>:&J/\K"SD\'V8 5<B::RGY5
MJU_EVIZ8\')5&??+5NW:)!RPO#%6+=:;H<&BK-NKN%_[86=#YK^P@:\W<*=W
M*\AI^4Y8<7:BU8II6@TTNG&FNMU0KJPI*-=6XVN)??;LLL[50K(;<2\-.[P1
MTTJ:X<G8 IH6C/,US-L6AK\ $W#V2=5V;MC[NI#%8X Q=.H4XQO%WO*]B.]D
M/F)AX#'N\W /7M@9&CJ\\(>&LG>ER2ME&BW97^=38S52X^\^FUO$J!^1RN78
M+$4N3P>H!R/UG1R<O7X5)/Z;/?I&G;[1/O2S:Y1?T522J1EEF=1:%LQ">V&,
MM(:)NF!5*:9E5=I2&H_5TO;9L%=*OPTW<\G@K*6J90U)4,#BS07>B/KA%T.2
M^E6R#%&3BZG4B!P3\*\P;*8J5+XY=H&D'XY5Z\T4C?-V\V> @FJTL&5]RQ">
MUD2"S[&TQ)(#%L1>Q%,O\P-Z2+P@B;PTCMB5IJWVP6V1WYMR"=ZP[JFLK:AO
M2\IKE@;>9.(SCEU)'+(O6W$2A;WK3A9XH9]Z09KA+N !1/KLLH/:6,R],$P]
M?Q*P+$F\2<39A5B65E3E/[".'"IT/H<SC<5:[F=8&P(QRO 7Q^R<7"/J7,)+
M&@R5JX8\KN'%\HYJD051ZDV"":XQ= C9US9(;KV\7Y;DQ:5619-;EL CDW3"
MDCCR@BB#OG?P@M(/+,AB+\@FC ?0EL?; .1SH6]A[@1F3,*8C(WAUMAG%\VB
MJ011ILL%T+!P-$JV&'@U;QP WJ#>(=VYA5Q/45@)7<"'*?3A"4O"V)M ^HV"
M9WHSAX=>!-4"Q)5S+X6?4MC\*$T^[@3G:> T4>^1FATUI@O-8>#%\%V:AD.Z
MATEDX+ GB*]?93S@;[KKY_[T]MA4PNN2W8FJ:7TANO!1AB03+^09W<8Q!&<1
M^R@-\OXY5B_$X19CZ![6*,.7%$();%3>WNUAGKACGOBGF6<F"[BZ<I5DK+#2
M%?^3.LV%U@]PC8MZ'P?ME?<R![7,06*LJX5V<$!I&4=(8D'5XE1[0)V1NJXB
M6L<^8ZW_;@JQ%V!V.*WM1L?L3\@S3P1^6.-?.VRLBQX%*/3!5 E8):)O\1'W
MP18HZM1'R(F4,G!)Z"6<ZA;1+NL2,%=2EZI@B1?YJ'\4:)2&'@<KM;7T/VPZ
M8#'W A I!P_@8>+%"2 #?U_J)%WJ)#^=.O99%RG;%DP9/)4U3+3L$ X$M<C>
MD6.OK/ZTN=R*6".3U*HIUCFS3:D=U8A+Z>.#BZJD 68WZ+N=ZX)8K[;'7;3[
M:K#- (J) JQV44Y RYF7@5C;R.4MT*Y/-@H_7KXAP:W(IWS5BGOZ]@G9]LCI
MW]&S\&"CTL%&J3VIDG:IDOYTJLC93+KIW(G59 Y:H*IS$+XKKK[LV ]_LZU]
M9U_ZQNR(V3'22:,,<$&FH+E ;^0C;U:EG;?)LPX 55KC^FH'T#_G;"*VZTP,
M2=O];N\!6L8(X\7FVL:S)PZ'KKBWI/R\GM X_%&,_L%'04#DL1"4XJPH83KR
M+9=$:D;E<"N2PEEVBZV$-FT,?$A\L1ZW_%'F=\EQ,4?7)*WZ>U<TFB2N:XU2
M7+^XM%_VBC],1G% 2YV>[XD_6X;?SGF'X2CDPT[T=@S0C3QJEEB0CH)D^*AA
M.Z9[G+1P!35_W 0C'@[WY&S6Y6RV/V?;DZMCMT[?'[>_O:#]/+:OP:Q;2X"&
MD?I=,XEH9,7P%&/R?JDY]"E,2%X883K"\-7GH_'.X7(A,2W2$1I90LVW/6=V
M;[M3^GE[.-TN;X_XGS!LEK7!U#;#5H0'@X%NC\WM@U5+=U2=*HN#K[N=2P$S
M: &^SY2RFP<2T/WOXNQ?4$L#!!0    ( ,.I;%BYC^C+6P0  .H*   9
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M]MA0\.(>"F?#)"+;CXC$&9E'T3"-$$;)V X,#8HW@LB))@,RBSJ91<,:H'^
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M] ':7W.NCA/MH&MOY_\!4$L#!!0    ( ,.I;%@!QE]N%00  /D)   9
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M< 3]@'BNM6(/9+1$A48T/A91DX(EVW$K'OQ?P<-_!,VP"]W0 <+/CMT.A;&
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M@>DN&MW$Z;7_N,^UHZN"'Z[H;H:&-]#[A=;N,&$'Q]O>]!]02P,$%     @
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MZ>ZN)_?>)SQ'RU513NC/;C=TR>:L^+%YROB[_D%91&N6Y%&:D(R]WO7NY9M
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MAVH&5#.AF@75;*CF0#47JGE0S8=J 4IK)I!CB: \P%ZN(,N>'J&:!M5TJ&9
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M'_<<GW/M>^,#%\^R!%#HI:),SIU2J7KFNC(MH<)RQ&M@>B?GHL)*3T7AREH
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MMUD0)D#OYYRKX\0<T#?NY ]02P,$%     @ PZEL6'<VPR-> @  Q 4  !D
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MMLJ<K15%FB9*'HBRT8;-+EQN'-JX8<+^Q0TJ<\L,#M,-*P4K6$8%DGF6R9U
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M^I[!VWB/)_8GK.DBA88Z4OC=+_;OF3Y2;_;080+5+%2S4<U!-1?5/%3S42U
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M<(H70D$@^>\)SW":*B09Q[\5J%&OJ1SWKU_1/Q;)RV3FB.,93?\BB5B/C=
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M '%\12D_[N05U$O+I]\!4$L#!!0    ( ,.I;%B[$#Z6XP(  %H(   9
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M_X-6A *%MV1I4;Z"_2$V"ARPW!:"956RK"!+\L,[^58UXB@!^F<24)6 +DW
M50(NB1XJ*VG=$D%F$\[V@*MHB:8.RMZ4V9)-DJME7 @NOTUDGIC=Y3N:"\83
M6ER!SU(V[\!"2B7>IA2P%?C,\G?S+><R!AR%@C>W5) D+=[*^"^+6_#FY[<3
M5\AZ%*J[K*[]_G!M=.;:MW1Y#3"\ LA#N"-]?GDZTM-=V86Z%:AN!2KQ\ ]:
M\7*E:"\KUO]\E&'@3M"L^+>+X@'3[\94/\*;8D.6=.K(7UE!^8XZLU]^@J'W
M:Q=A2V :?5S3QR;TF5KJ5]))L]1=G ] 00FD[A.[&40CSP_0>.+NCOFT Z,
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M&N.'S;/#B6";<O_IB0G!LO)P34E,N0J0WZ\8$Z\G:DNKWL*<?0=02P,$%
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M+@C" /3])>?JY<3LZ]OO.(O_ %!+ P04    " ##J6Q8B*(R5:<"  !C"
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MVT[;0!#]E95;52"U^!8"HHZE7"CE 0F!:!^J/FSL2;QBO>ON3F+:K^]>')-
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MCYFN><#W)BAC@/,[*?53Q[QHQA?LZE]02P,$%     @ PZEL6/FLDA?$ @
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M9N7EGF#YEE (Y.]/E(J70E%!<X(X_@=02P,$%     @ PZEL6&82%Y!^ @
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MJ'8?H?,S\GR%XB9\T:[+C3$J&F.5Z,!.@6"R_=/GK@X'@.'X!(!T /(:D)X
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MTKGJ*R9>="W%0++<'/PO3*HVPMPFJM,#K@/4\Y@QN1OH%U2]8_ /4$L#!!0
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M986-E:;=7HR]4.US(BI;GJ3$[;??279--IP,"GD32_(]CWYW%T6):ZF>]!K
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M-2YX;6RM5M]OVC 0_E=.V32UTFA"0H!U$(D?G59IU5!1NX=I#R8YP,*),]M
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M H&R!C@_E])L.C9 _:@:_@902P,$%     @ PZEL6-FLL"_#!0  +R8  !D
M  !X;"]W;W)K<VAE971S+W-H965T-S@N>&ULM9IA;YLX&,>_BI5-4R>M 3LA
M2;<TTAJ8;M*NJ[K;3:?3O7#!:=  9[9)5FD?_FR@$%K'O9R>]D43@I\?^/G#
M8_\Q\QT7W^6:,85^YEDASP=KI39O/4_&:Y93.>0;5N@]*RYRJO2FN/7D1C":
M5$%YYA'?GW@Y38O!8E[]=B46<UZJ+"W8E4"RS',J[BY8QG?G SRX_^$ZO5TK
M\X.WF&_H+?O"U-?-E=!;7DM)TIP5,N4%$FQU/GB/WT9D9 *J%G^F;"?WOB/3
ME1O.OYN-C\GYP#=GQ#(6*X.@^F/+EBS+#$F?QX\&.FB/:0+WO]_3/U2=UYVY
MH9(M>?8M3=3Z?# ;H(2M:)FI:[[[C34="@POYIFL_J-=W7:JCQB74O&\"=;;
M>5K4G_1GDXB] #(Y$$": /(P(#@0,&H"1@\"\/A P+@)&#\(&,T.! 1-0-5U
MK^Y[E;B0*KJ8"[Y#PK36-/.ERGX5K?.5%N9"^:*$WIOJ.+7XQ'26)3I%EU0(
M:D1#)R%3-,WDZ[FG]!%,.R]N:!<UC1R@A2P>HA%^@XA/1NCKEQ"=O'R-5NK5
M"SR=O;/PEO^=1^YY%DSHQGR.U1"1<8VQA$?N\$N^'2(<5.&X[8V^30JVH]D?
M3.3H)?(.=-/3@K2JD%854AUQ=% 5*1E[@RIUWJ"0R5BDF^K.^ON3;HL^*I;+
M?VP"U>"Q'6S*SENYH3$['^BZ(IG8LL%"G_;$MZH#"0LA81$0K*?.J%5GY*(O
MKEFA4%K$PJACT\ 9?JP&D+ 0$A;5,.Q7-#,B;1?^T"?!W-M:LCMNLSMV9O?S
MAIE"5-RBS.07"5/J3_GJM-0;5-\72MIR7D.#O7.93*;CT=FX/9LZG8_;!03/
MQOZHWRYTGN2QF0*"]?(9M/D,G/G\4*I2,#-VI'F9ZQG!39U7?0'SG*&R2)A
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M, WT_A7GZG[#O-'3OB.V^!=02P,$%     @ PZEL6/CO:N1X @  2 8  !D
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MB+J;JP>*E[8AFG.EVRM[N-$=, @S05]?<:X>!J;':GOJ["]02P,$%     @
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M>BN!WHIZ*X'>BGHK@=Z*>BN!W@GU3@1Z)]0[$>B=4.]$H'="O1.!WFGRLIM
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M_CQQ\PM02P$"% ,4    " ##J6Q8!T%-8H$   "Q    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( ,.I;%C/Z+H#[@
M "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( ,.I;%B97)PC$ 8  )PG   3              "  <P!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ PZEL6*\?=:"Q!P  23   !@
M             ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( ,.I;%@XZ +4>0(  %0'   8              " @?0/  !X;"]W
M;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " ##J6Q89+]-%48&  !N
M&0  &               @(&C$@  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
M4$L! A0#%     @ PZEL6*#L#JN9 @  8 <  !@              ("!'QD
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( ,.I;%A5N&37
M]P4  /\8   8              " @>X;  !X;"]W;W)K<VAE971S+W-H965T
M-2YX;6Q02P$"% ,4    " ##J6Q8@Y:I3TT)   '*0  &
M@($;(@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ PZEL
M6+*:# ]O!0  EB   !@              ("!GBL  'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;%!+ 0(4 Q0    ( ,.I;%@H*N-5?P,  -H'   8
M      " @4,Q  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M" ##J6Q8ILI7@[ (  "X%   &               @('X-   >&PO=V]R:W-H
M965T<R]S:&5E=#DN>&UL4$L! A0#%     @ PZEL6'GXH8P&)@  $W8  !D
M             ("!WCT  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"
M% ,4    " ##J6Q8[JI$!R$,  "L(P  &0              @($;9   >&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( ,.I;%A&CQ3LG08
M &H/   9              " @7-P  !X;"]W;W)K<VAE971S+W-H965T,3(N
M>&UL4$L! A0#%     @ PZEL6)N\:S^$!   G@H  !D              ("!
M1W<  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " ##J6Q8
M5($/((\#   1"   &0              @($"?   >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;%!+ 0(4 Q0    ( ,.I;%B^=[2]B00  (8*   9
M      " @<A_  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%
M  @ PZEL6,.,RKB0 P  /0@  !D              ("!B(0  'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " ##J6Q8 JEB0 $$  #;"
M&0              @(%/B   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+
M 0(4 Q0    ( ,.I;%B!?9E5KP0  .T*   9              " @8>,  !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ PZEL6,K;LRE+
M P  :0<  !D              ("!;9$  'AL+W=O<FMS:&5E=',O<VAE970Q
M.2YX;6Q02P$"% ,4    " ##J6Q8CN=82J\&   :$   &0
M@('OE   >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( ,.I
M;%C,OQ76,@D  *\9   9              " @=6;  !X;"]W;W)K<VAE971S
M+W-H965T,C$N>&UL4$L! A0#%     @ PZEL6*_U,DME!   0@H  !D
M         ("!/J4  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
M    " ##J6Q85HDU UT)  "U%@  &0              @(':J0  >&PO=V]R
M:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( ,.I;%AS7PM#G0,  !<(
M   9              " @6ZS  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL
M4$L! A0#%     @ PZEL6)[A)8$D P  .@<  !D              ("!0K<
M 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " ##J6Q8.H;<
MG9("  #A!0  &0              @(&=N@  >&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;%!+ 0(4 Q0    ( ,.I;%@!E6%3T@<  !\3   9
M  " @6:]  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @
MPZEL6#FMEK]J!   >PH  !D              ("!;\4  'AL+W=O<FMS:&5E
M=',O<VAE970R."YX;6Q02P$"% ,4    " ##J6Q8)MO$##$#   [#0  &0
M            @($0R@  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4
M Q0    ( ,.I;%AD.J)K0P(  (H&   9              " @7C-  !X;"]W
M;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ PZEL6$VNV!G['@
M 6,  !D              ("!\L\  'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6Q02P$"% ,4    " ##J6Q8%@CYNOH#  #M"0  &0              @($D
M[P  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( ,.I;%AZ
M)1!6Z0,  )H*   9              " @57S  !X;"]W;W)K<VAE971S+W-H
M965T,S,N>&UL4$L! A0#%     @ PZEL6$6_=NL- P  2@8  !D
M     ("!=?<  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,.I;%@=59+6AP,  'T(   9              "
M@:$* 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ PZEL
M6*4IYKQ4!@  QQ   !D              ("!7PX! 'AL+W=O<FMS:&5E=',O
M<VAE970T,"YX;6Q02P$"% ,4    " ##J6Q8N8_HRUL$  #J"@  &0
M        @('J% $ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0
M   ( ,.I;%@!QE]N%00  /D)   9              " @7P9 0!X;"]W;W)K
M<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ PZEL6.,N2%.1 @  G04
M !D              ("!R!T! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q0
M2P$"% ,4    " ##J6Q8H#"O''\$  !8"@  &0              @(&0( $
M>&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( ,.I;%@89B63
M" 0   D4   9              " @48E 0!X;"]W;W)K<VAE971S+W-H965T
M-#4N>&UL4$L! A0#%     @ PZEL6!53O\$0"   /5@  !D
M ("!A2D! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " ##
MJ6Q8$E6..& "  #$!0  &0              @(',,0$ >&PO=V]R:W-H965T
M<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( ,.I;%AW-L,C7@(  ,0%   9
M          " @6,T 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#
M%     @ PZEL6"J'$O$M#0  V,,  !D              ("!^#8! 'AL+W=O
M<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " ##J6Q8?HSSZ+@$  !J
M%@  &0              @(%<1 $ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM
M;%!+ 0(4 Q0    ( ,.I;%@IE3E9\P<  !9F   9              " @4M)
M 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ PZEL6(AE
M&?16!0  9BX  !D              ("!=5$! 'AL+W=O<FMS:&5E=',O<VAE
M970U,BYX;6Q02P$"% ,4    " ##J6Q8NQ ^EN,"  !:"   &0
M    @($"5P$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    (
M ,.I;%@SY+5U@@0  ,X<   9              " @1Q: 0!X;"]W;W)K<VAE
M971S+W-H965T-30N>&UL4$L! A0#%     @ PZEL6.[?!!3H @  WPH  !D
M             ("!U5X! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"
M% ,4    " ##J6Q8_,O !6\%  !-*0  &0              @('T80$ >&PO
M=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( ,.I;%A(F4[U?P(
M .\%   9              " @9IG 0!X;"]W;W)K<VAE971S+W-H965T-3<N
M>&UL4$L! A0#%     @ PZEL6+BW*J_@ P  TQ$  !D              ("!
M4&H! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4    " ##J6Q8
MB*(R5:<"  !C"   &0              @(%G;@$ >&PO=V]R:W-H965T<R]S
M:&5E=#4Y+GAM;%!+ 0(4 Q0    ( ,.I;%C.=Q=O<P(  .(%   9
M      " @45Q 0!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%
M  @ PZEL6/=^/H'& @  ] @  !D              ("![W,! 'AL+W=O<FMS
M:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    " ##J6Q8R@7==)8#  #-"@
M&0              @('L=@$ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+
M 0(4 Q0    ( ,.I;%CYK)(7Q (  %,'   9              " @;EZ 0!X
M;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ PZEL6-/'O2<9
M!   B18  !D              ("!M'T! 'AL+W=O<FMS:&5E=',O<VAE970V
M-"YX;6Q02P$"% ,4    " ##J6Q8CK0A+EX%  !7(@  &0
M@($$@@$ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( ,.I
M;%BUMA_0UP0  $T<   9              " @9F' 0!X;"]W;W)K<VAE971S
M+W-H965T-C8N>&UL4$L! A0#%     @ PZEL6&82%Y!^ @   08  !D
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M=#<Q+GAM;%!+ 0(4 Q0    ( ,.I;%@'$:33@0(  "((   9
M  " @3Z? 0!X;"]W;W)K<VAE971S+W-H965T-S(N>&UL4$L! A0#%     @
MPZEL6+R$_M _!P  1#<  !D              ("!]J$! 'AL+W=O<FMS:&5E
M=',O<VAE970W,RYX;6Q02P$"% ,4    " ##J6Q8:S'='\<#   ##@  &0
M            @(%LJ0$ >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4
M Q0    ( ,.I;%B=[M@O^ (  #4(   9              " @6JM 0!X;"]W
M;W)K<VAE971S+W-H965T-S4N>&UL4$L! A0#%     @ PZEL6!RBH=>> P
M"@T  !D              ("!F; ! 'AL+W=O<FMS:&5E=',O<VAE970W-BYX
M;6Q02P$"% ,4    " ##J6Q8_JM_  T#  !@"0  &0              @(%N
MM $ >&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    ( ,.I;%C9
MK+ OPP4  "\F   9              " @;*W 0!X;"]W;W)K<VAE971S+W-H
M965T-S@N>&UL4$L! A0#%     @ PZEL6/CO:N1X @  2 8  !D
M     ("!K+T! 'AL+W=O<FMS:&5E=',O<VAE970W.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,.I;%A)*G7:2P4  "LG   9              "
M@:?, 0!X;"]W;W)K<VAE971S+W-H965T.#0N>&UL4$L! A0#%     @ PZEL
M6#B9,7/A!0  8R$  !D              ("!*=(! 'AL+W=O<FMS:&5E=',O
M<VAE970X-2YX;6Q02P$"% ,4    " ##J6Q8%-@ ( X$  !7#P  &0
M        @(%!V $ >&PO=V]R:W-H965T<R]S:&5E=#@V+GAM;%!+ 0(4 Q0
M   ( ,.I;%CJ9!Q@+@,  - 2   -              "  8;< 0!X;"]S='EL
M97,N>&UL4$L! A0#%     @ PZEL6)>*NQS     $P(   L
M ( !W]\! %]R96QS+RYR96QS4$L! A0#%     @ PZEL6(),E;),!@  8#@
M  \              ( !R. ! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M ,.I;%A2-<:CB@(  +DR   :              "  4'G 0!X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( ,.I;%B#T:P!+@(  $0Q   3
M              "  0/J 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !>
- %X R1D  &+L 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>199</ContextCount>
  <ElementCount>393</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>80</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity</Role>
      <ShortName>Consolidated Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Valuation and Qualifying Accounts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ValuationandQualifyingAccounts</Role>
      <ShortName>Valuation and Qualifying Accounts</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Vibativ??, Sancuso?? and RediTrex?? Products</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProducts</Role>
      <ShortName>Vibativ??, Sancuso?? and RediTrex?? Products</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Inventories, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesNet</Role>
      <ShortName>Inventories, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Other Current and Other Long-term Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities</Role>
      <ShortName>Other Current and Other Long-term Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LossPerShare</Role>
      <ShortName>Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Stock-Based Compensation Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/StockBasedCompensationPlans</Role>
      <ShortName>Stock-Based Compensation Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Market Concentrations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/MarketConcentrations</Role>
      <ShortName>Market Concentrations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Manufacturing and Supply Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreements</Role>
      <ShortName>Manufacturing and Supply Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Employment Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EmploymentAgreements</Role>
      <ShortName>Employment Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Quarterly Financial Information (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited</Role>
      <ShortName>Quarterly Financial Information (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Vibativ??, Sancuso?? and RediTrex?? Products (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsTables</Role>
      <ShortName>Vibativ??, Sancuso?? and RediTrex?? Products (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProducts</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Revenues</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Inventories, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesNetTables</Role>
      <ShortName>Inventories, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/InventoriesNet</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/PropertyandEquipment</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwill</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Other Current and Other Long-term Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables</Role>
      <ShortName>Other Current and Other Long-term Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LossPerShareTables</Role>
      <ShortName>Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LossPerShare</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IncomeTaxes</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Stock-Based Compensation Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables</Role>
      <ShortName>Stock-Based Compensation Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/StockBasedCompensationPlans</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Leases</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Market Concentrations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/MarketConcentrationsTables</Role>
      <ShortName>Market Concentrations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/MarketConcentrations</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Quarterly Financial Information (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables</Role>
      <ShortName>Quarterly Financial Information (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Organization (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails</Role>
      <ShortName>Organization (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Organization</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Significant Accounting Policies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Significant Accounting Policies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Significant Accounting Policies (Schedule of Distribution Costs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofDistributionCostsDetails</Role>
      <ShortName>Significant Accounting Policies (Schedule of Distribution Costs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Significant Accounting Policies (Schedule of Advertising Costs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofAdvertisingCostsDetails</Role>
      <ShortName>Significant Accounting Policies (Schedule of Advertising Costs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Vibativ??, Sancuso?? and RediTrex?? Products - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails</Role>
      <ShortName>Vibativ??, Sancuso?? and RediTrex?? Products - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Vibativ??, Sancuso?? and RediTrex?? Products - Changes In Fair Value Of Contingent Consideration Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsChangesInFairValueOfContingentConsiderationLiabilityDetails</Role>
      <ShortName>Vibativ??, Sancuso?? and RediTrex?? Products - Changes In Fair Value Of Contingent Consideration Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Revenues (Schedule of Net Product Revenues by Product) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails</Role>
      <ShortName>Revenues (Schedule of Net Product Revenues by Product) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/RevenuesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Revenues (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails</Role>
      <ShortName>Revenues (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/RevenuesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Inventories, Net - Schedule of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesNetScheduleofInventoriesDetails</Role>
      <ShortName>Inventories, Net - Schedule of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Inventories, Net - Schedule of Non-Current Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesNetScheduleofNonCurrentInventoriesDetails</Role>
      <ShortName>Inventories, Net - Schedule of Non-Current Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Inventories, Net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesNetNarrativeDetails</Role>
      <ShortName>Inventories, Net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Schedule of Property and Equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Property and Equipment (Depreciation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/PropertyandEquipmentDepreciationExpenseDetails</Role>
      <ShortName>Property and Equipment (Depreciation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Intangible Assets and Goodwill - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillNarrativeDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Intangible Assets and Goodwill - Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillAmortizationExpenseDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Intangible Assets and Goodwill - Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Other Current and Other Long-term Liabilities (Schedule of Other Current Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Other Current and Other Long-term Liabilities (Schedule of Other Current Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Other Current and Other Long-term Liabilities (Schedule of Noncurrent Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofNoncurrentLiabilitiesDetails</Role>
      <ShortName>Other Current and Other Long-term Liabilities (Schedule of Noncurrent Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/DebtDetails</Role>
      <ShortName>Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Debt</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Shareholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/ShareholdersEquity</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Loss Per Share - Schedule of Computation of Numerator and Denominator in Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails</Role>
      <ShortName>Loss Per Share - Schedule of Computation of Numerator and Denominator in Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - Loss Per Share - Schedule of Anti-dilutive Securities Excluded From Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails</Role>
      <ShortName>Loss Per Share - Schedule of Anti-dilutive Securities Excluded From Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - Income Taxes - Schedule of Net Operating Loss Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails</Role>
      <ShortName>Income Taxes - Schedule of Net Operating Loss Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - Income Taxes - Schedule of the Components of Income Tax Benefit (Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails</Role>
      <ShortName>Income Taxes - Schedule of the Components of Income Tax Benefit (Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - Income Taxes - Schedule Of Tax Credit Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxesScheduleOfTaxCreditCarryforwardsDetails</Role>
      <ShortName>Income Taxes - Schedule Of Tax Credit Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9954513 - Disclosure - Stock-Based Compensation Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9954514 - Disclosure - Stock-Based Compensation Plans - Stock Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/StockBasedCompensationPlansStockOptionsActivityDetails</Role>
      <ShortName>Stock-Based Compensation Plans - Stock Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9954515 - Disclosure - Stock-Based Compensation Plans - Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/StockBasedCompensationPlansValuationAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation Plans - Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9954516 - Disclosure - Stock-Based Compensation Plans - Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/StockBasedCompensationPlansRestrictedStockActivityDetails</Role>
      <ShortName>Stock-Based Compensation Plans - Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9954517 - Disclosure - Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EmployeeBenefitPlansDetails</Role>
      <ShortName>Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9954518 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9954519 - Disclosure - Leases - Schedule of Rent Expense and Sublease Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails</Role>
      <ShortName>Leases - Schedule of Rent Expense and Sublease Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9954520 - Disclosure - Leases - Lease Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails</Role>
      <ShortName>Leases - Lease Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9954521 - Disclosure - Leases - Schedule of Lease Liability Maturities and Future Minimum Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails</Role>
      <ShortName>Leases - Schedule of Lease Liability Maturities and Future Minimum Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9954522 - Disclosure - Market Concentrations (Schedule of Revenues Concentration from Major Customers and Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails</Role>
      <ShortName>Market Concentrations (Schedule of Revenues Concentration from Major Customers and Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/MarketConcentrationsTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9954523 - Disclosure - Manufacturing and Supply Agreements Manufacturing and Supply Agreements (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails</Role>
      <ShortName>Manufacturing and Supply Agreements Manufacturing and Supply Agreements (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9954524 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/CommitmentsandContingencies</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9954525 - Disclosure - Quarterly Financial Information (Schedule of Quarterly Financial Information (Unaudited)) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails</Role>
      <ShortName>Quarterly Financial Information (Schedule of Quarterly Financial Information (Unaudited)) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="cpix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>9954526 - Disclosure - Valuation and Qualifying Accounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails</Role>
      <ShortName>Valuation and Qualifying Accounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="cpix-20231231.htm">cpix-20231231.htm</File>
    <File>cpix-20231231.xsd</File>
    <File>cpix-20231231_cal.xml</File>
    <File>cpix-20231231_def.xml</File>
    <File>cpix-20231231_lab.xml</File>
    <File>cpix-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cpix-20231231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2023</BaseTaxonomy>
    <BaseTaxonomy items="727">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="42">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>114
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cpix-20231231.htm": {
   "nsprefix": "cpix",
   "nsuri": "http://www.cumberlandpharma.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "cpix-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "cpix-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "cpix-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cpix-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cpix-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cpix-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 326,
   "keyCustom": 67,
   "axisStandard": 26,
   "axisCustom": 3,
   "memberStandard": 32,
   "memberCustom": 47,
   "hidden": {
    "total": 16,
    "http://xbrl.sec.gov/dei/2023": 16
   },
   "contextCount": 199,
   "entityCount": 1,
   "segmentCount": 80,
   "elementCount": 722,
   "unitCount": 11,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 727,
    "http://xbrl.sec.gov/dei/2023": 42,
    "http://xbrl.sec.gov/ecd/2023": 4,
    "http://fasb.org/srt/2023": 1
   },
   "report": {
    "R1": {
     "role": "http://www.cumberlandpharma.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.cumberlandpharma.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
     "longName": "0000003 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "0000004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:CommonStockNoParValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:CommonStockNoParValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations",
     "longName": "0000005 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "0000006 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
     "longName": "0000007 - Statement - Consolidated Statements of Equity",
     "shortName": "Consolidated Statements of Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccounts",
     "longName": "0000008 - Statement - Valuation and Qualifying Accounts",
     "shortName": "Valuation and Qualifying Accounts",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.cumberlandpharma.com/role/Organization",
     "longName": "0000009 - Disclosure - Organization",
     "shortName": "Organization",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.cumberlandpharma.com/role/SignificantAccountingPolicies",
     "longName": "0000010 - Disclosure - Significant Accounting Policies",
     "shortName": "Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProducts",
     "longName": "0000011 - Disclosure - Vibativ\u00ae, Sancuso\u00ae and RediTrex\u00ae Products",
     "shortName": "Vibativ\u00ae, Sancuso\u00ae and RediTrex\u00ae Products",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.cumberlandpharma.com/role/Revenues",
     "longName": "0000012 - Disclosure - Revenues",
     "shortName": "Revenues",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.cumberlandpharma.com/role/InventoriesNet",
     "longName": "0000013 - Disclosure - Inventories, Net",
     "shortName": "Inventories, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.cumberlandpharma.com/role/PropertyandEquipment",
     "longName": "0000014 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwill",
     "longName": "0000015 - Disclosure - Intangible Assets and Goodwill",
     "shortName": "Intangible Assets and Goodwill",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities",
     "longName": "0000016 - Disclosure - Other Current and Other Long-term Liabilities",
     "shortName": "Other Current and Other Long-term Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.cumberlandpharma.com/role/Debt",
     "longName": "0000017 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquity",
     "longName": "0000018 - Disclosure - Shareholders' Equity",
     "shortName": "Shareholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.cumberlandpharma.com/role/LossPerShare",
     "longName": "0000019 - Disclosure - Loss Per Share",
     "shortName": "Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxes",
     "longName": "0000020 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.cumberlandpharma.com/role/StockBasedCompensationPlans",
     "longName": "0000021 - Disclosure - Stock-Based Compensation Plans",
     "shortName": "Stock-Based Compensation Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.cumberlandpharma.com/role/EmployeeBenefitPlans",
     "longName": "0000022 - Disclosure - Employee Benefit Plans",
     "shortName": "Employee Benefit Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.cumberlandpharma.com/role/Leases",
     "longName": "0000023 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.cumberlandpharma.com/role/MarketConcentrations",
     "longName": "0000024 - Disclosure - Market Concentrations",
     "shortName": "Market Concentrations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreements",
     "longName": "0000025 - Disclosure - Manufacturing and Supply Agreements",
     "shortName": "Manufacturing and Supply Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cpix:ManufacturingAndSupplyAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cpix:ManufacturingAndSupplyAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.cumberlandpharma.com/role/EmploymentAgreements",
     "longName": "0000026 - Disclosure - Employment Agreements",
     "shortName": "Employment Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cpix:EmploymentAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cpix:EmploymentAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.cumberlandpharma.com/role/CommitmentsandContingencies",
     "longName": "0000027 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited",
     "longName": "0000028 - Disclosure - Quarterly Financial Information (Unaudited)",
     "shortName": "Quarterly Financial Information (Unaudited)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R30": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Significant Accounting Policies (Policies)",
     "shortName": "Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables",
     "longName": "9954472 - Disclosure - Significant Accounting Policies (Tables)",
     "shortName": "Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cpix:ScheduleOfDistributionCostsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsTables",
     "longName": "9954473 - Disclosure - Vibativ\u00ae, Sancuso\u00ae and RediTrex\u00ae Products (Tables)",
     "shortName": "Vibativ\u00ae, Sancuso\u00ae and RediTrex\u00ae Products (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.cumberlandpharma.com/role/RevenuesTables",
     "longName": "9954474 - Disclosure - Revenues (Tables)",
     "shortName": "Revenues (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.cumberlandpharma.com/role/InventoriesNetTables",
     "longName": "9954475 - Disclosure - Inventories, Net (Tables)",
     "shortName": "Inventories, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.cumberlandpharma.com/role/PropertyandEquipmentTables",
     "longName": "9954476 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillTables",
     "longName": "9954477 - Disclosure - Intangible Assets and Goodwill (Tables)",
     "shortName": "Intangible Assets and Goodwill (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables",
     "longName": "9954478 - Disclosure - Other Current and Other Long-term Liabilities (Tables)",
     "shortName": "Other Current and Other Long-term Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.cumberlandpharma.com/role/LossPerShareTables",
     "longName": "9954479 - Disclosure - Loss Per Share (Tables)",
     "shortName": "Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxesTables",
     "longName": "9954480 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables",
     "longName": "9954481 - Disclosure - Stock-Based Compensation Plans (Tables)",
     "shortName": "Stock-Based Compensation Plans (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.cumberlandpharma.com/role/LeasesTables",
     "longName": "9954482 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.cumberlandpharma.com/role/MarketConcentrationsTables",
     "longName": "9954483 - Disclosure - Market Concentrations (Tables)",
     "shortName": "Market Concentrations (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables",
     "longName": "9954484 - Disclosure - Quarterly Financial Information (Unaudited) (Tables)",
     "shortName": "Quarterly Financial Information (Unaudited) (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails",
     "longName": "9954485 - Disclosure - Organization (Narrative) (Details)",
     "shortName": "Organization (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLossAttributableToNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-30",
      "name": "cpix:SharebasedCompensationCharitableContributionofSharesShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails",
     "longName": "9954486 - Disclosure - Significant Accounting Policies (Narrative) (Details)",
     "shortName": "Significant Accounting Policies (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofDistributionCostsDetails",
     "longName": "9954487 - Disclosure - Significant Accounting Policies (Schedule of Distribution Costs) (Details)",
     "shortName": "Significant Accounting Policies (Schedule of Distribution Costs) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProductionAndDistributionCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProductionAndDistributionCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofAdvertisingCostsDetails",
     "longName": "9954488 - Disclosure - Significant Accounting Policies (Schedule of Advertising Costs) (Details)",
     "shortName": "Significant Accounting Policies (Schedule of Advertising Costs) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AdvertisingExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AdvertisingExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails",
     "longName": "9954489 - Disclosure - Vibativ\u00ae, Sancuso\u00ae and RediTrex\u00ae Products - Narrative (Details)",
     "shortName": "Vibativ\u00ae, Sancuso\u00ae and RediTrex\u00ae Products - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-63",
      "name": "cpix:CollaborativeArrangementRightsAndObligationsMilestonePayment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsChangesInFairValueOfContingentConsiderationLiabilityDetails",
     "longName": "9954490 - Disclosure - Vibativ\u00ae, Sancuso\u00ae and RediTrex\u00ae Products - Changes In Fair Value Of Contingent Consideration Liability (Details)",
     "shortName": "Vibativ\u00ae, Sancuso\u00ae and RediTrex\u00ae Products - Changes In Fair Value Of Contingent Consideration Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-42",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails",
     "longName": "9954491 - Disclosure - Revenues (Schedule of Net Product Revenues by Product) (Details)",
     "shortName": "Revenues (Schedule of Net Product Revenues by Product) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-64",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails",
     "longName": "9954492 - Disclosure - Revenues (Narrative) (Details)",
     "shortName": "Revenues (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-80",
      "name": "us-gaap:ProceedsFromLegalSettlements",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-81",
      "name": "cpix:ProceedsFromLegalSettlementsMilestonePaymentsReceivableNumberOfPayments",
      "unitRef": "payment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.cumberlandpharma.com/role/InventoriesNetScheduleofInventoriesDetails",
     "longName": "9954493 - Disclosure - Inventories, Net - Schedule of Inventories (Details)",
     "shortName": "Inventories, Net - Schedule of Inventories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.cumberlandpharma.com/role/InventoriesNetScheduleofNonCurrentInventoriesDetails",
     "longName": "9954494 - Disclosure - Inventories, Net - Schedule of Non-Current Inventories (Details)",
     "shortName": "Inventories, Net - Schedule of Non-Current Inventories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:InventoryNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-100",
      "name": "us-gaap:InventoryNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.cumberlandpharma.com/role/InventoriesNetNarrativeDetails",
     "longName": "9954495 - Disclosure - Inventories, Net - Narrative (Details)",
     "shortName": "Inventories, Net - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:InventoryNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:InventoryValuationReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails",
     "longName": "9954496 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)",
     "shortName": "Property and Equipment (Schedule of Property and Equipment) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.cumberlandpharma.com/role/PropertyandEquipmentDepreciationExpenseDetails",
     "longName": "9954497 - Disclosure - Property and Equipment (Depreciation Expense) (Details)",
     "shortName": "Property and Equipment (Depreciation Expense) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails",
     "longName": "9954498 - Disclosure - Intangible Assets and Goodwill - Schedule of Intangible Assets (Details)",
     "shortName": "Intangible Assets and Goodwill - Schedule of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-119",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
     "longName": "9954499 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)",
     "shortName": "Intangible Assets and Goodwill - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-125",
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillAmortizationExpenseDetails",
     "longName": "9954500 - Disclosure - Intangible Assets and Goodwill - Amortization Expense (Details)",
     "shortName": "Intangible Assets and Goodwill - Amortization Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R61": {
     "role": "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails",
     "longName": "9954501 - Disclosure - Intangible Assets and Goodwill - Future Amortization Expense (Details)",
     "shortName": "Intangible Assets and Goodwill - Future Amortization Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails",
     "longName": "9954502 - Disclosure - Other Current and Other Long-term Liabilities (Schedule of Other Current Liabilities) (Details)",
     "shortName": "Other Current and Other Long-term Liabilities (Schedule of Other Current Liabilities) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "cpix:ProductSalesRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "cpix:ProductSalesRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofNoncurrentLiabilitiesDetails",
     "longName": "9954503 - Disclosure - Other Current and Other Long-term Liabilities (Schedule of Noncurrent Liabilities) (Details)",
     "shortName": "Other Current and Other Long-term Liabilities (Schedule of Noncurrent Liabilities) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.cumberlandpharma.com/role/DebtDetails",
     "longName": "9954504 - Disclosure - Debt (Details)",
     "shortName": "Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:LongTermLineOfCredit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-127",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityDetails",
     "longName": "9954505 - Disclosure - Shareholders' Equity (Details)",
     "shortName": "Shareholders' Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.cumberlandpharma.com/role/LossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails",
     "longName": "9954506 - Disclosure - Loss Per Share - Schedule of Computation of Numerator and Denominator in Earnings Per Share (Details)",
     "shortName": "Loss Per Share - Schedule of Computation of Numerator and Denominator in Earnings Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R67": {
     "role": "http://www.cumberlandpharma.com/role/LossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails",
     "longName": "9954507 - Disclosure - Loss Per Share - Schedule of Anti-dilutive Securities Excluded From Computation of Earnings Per Share (Details)",
     "shortName": "Loss Per Share - Schedule of Anti-dilutive Securities Excluded From Computation of Earnings Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails",
     "longName": "9954508 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities, Net (Details)",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "cpix:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "cpix:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails",
     "longName": "9954509 - Disclosure - Income Taxes - Schedule of Net Operating Loss Carryforwards (Details)",
     "shortName": "Income Taxes - Schedule of Net Operating Loss Carryforwards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-141",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-141",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails",
     "longName": "9954510 - Disclosure - Income Taxes - Schedule of the Components of Income Tax Benefit (Expense) (Details)",
     "shortName": "Income Taxes - Schedule of the Components of Income Tax Benefit (Expense) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails",
     "longName": "9954511 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleOfTaxCreditCarryforwardsDetails",
     "longName": "9954512 - Disclosure - Income Taxes - Schedule Of Tax Credit Carryforwards (Details)",
     "shortName": "Income Taxes - Schedule Of Tax Credit Carryforwards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-143",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-143",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
     "longName": "9954513 - Disclosure - Stock-Based Compensation Plans - Narrative (Details)",
     "shortName": "Stock-Based Compensation Plans - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants",
      "unitRef": "plan",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants",
      "unitRef": "plan",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansStockOptionsActivityDetails",
     "longName": "9954514 - Disclosure - Stock-Based Compensation Plans - Stock Options Activity (Details)",
     "shortName": "Stock-Based Compensation Plans - Stock Options Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansValuationAssumptionsDetails",
     "longName": "9954515 - Disclosure - Stock-Based Compensation Plans - Valuation Assumptions (Details)",
     "shortName": "Stock-Based Compensation Plans - Valuation Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-155",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-155",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansRestrictedStockActivityDetails",
     "longName": "9954516 - Disclosure - Stock-Based Compensation Plans - Restricted Stock Activity (Details)",
     "shortName": "Stock-Based Compensation Plans - Restricted Stock Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-159",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-157",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.cumberlandpharma.com/role/EmployeeBenefitPlansDetails",
     "longName": "9954517 - Disclosure - Employee Benefit Plans (Details)",
     "shortName": "Employee Benefit Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cpix:DefinedContributionPlanEligibilityMinimumEmployeeAge",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cpix:DefinedContributionPlanEligibilityMinimumEmployeeAge",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails",
     "longName": "9954518 - Disclosure - Leases - Narrative (Details)",
     "shortName": "Leases - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-164",
      "name": "cpix:LesseeOperatingLeaseRentIncrease",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-164",
      "name": "cpix:LesseeOperatingLeaseRentIncrease",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails",
     "longName": "9954519 - Disclosure - Leases - Schedule of Rent Expense and Sublease Income (Details)",
     "shortName": "Leases - Schedule of Rent Expense and Sublease Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails",
     "longName": "9954520 - Disclosure - Leases - Lease Position (Details)",
     "shortName": "Leases - Lease Position (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R81": {
     "role": "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails",
     "longName": "9954521 - Disclosure - Leases - Schedule of Lease Liability Maturities and Future Minimum Payments (Details)",
     "shortName": "Leases - Schedule of Lease Liability Maturities and Future Minimum Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails",
     "longName": "9954522 - Disclosure - Market Concentrations (Schedule of Revenues Concentration from Major Customers and Narrative) (Details)",
     "shortName": "Market Concentrations (Schedule of Revenues Concentration from Major Customers and Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-170",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-170",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails",
     "longName": "9954523 - Disclosure - Manufacturing and Supply Agreements Manufacturing and Supply Agreements (Narrative) (Details)",
     "shortName": "Manufacturing and Supply Agreements Manufacturing and Supply Agreements (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-178",
      "name": "cpix:ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct",
      "unitRef": "supplier",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-178",
      "name": "cpix:ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct",
      "unitRef": "supplier",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails",
     "longName": "9954524 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-80",
      "name": "us-gaap:ProceedsFromLegalSettlements",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-183",
      "name": "cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails",
     "longName": "9954525 - Disclosure - Quarterly Financial Information (Schedule of Quarterly Financial Information (Unaudited)) (Details)",
     "shortName": "Quarterly Financial Information (Schedule of Quarterly Financial Information (Unaudited)) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OperatingIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails",
     "longName": "9954526 - Disclosure - Valuation and Qualifying Accounts (Details)",
     "shortName": "Valuation and Qualifying Accounts (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c-192",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-190",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "cpix_A1600WestEndAvenuePartnersLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "A1600WestEndAvenuePartnersLLCMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1600 West End Avenue Partners, LLC",
        "label": "1600 West End Avenue Partners, LLC [Member]",
        "documentation": "1600 West End Avenue Partners, LLC"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofNoncurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofNoncurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Accounts Payable and Accrued Liabilities, Noncurrent",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer), including liabilities for compensation costs, fringe benefits other than pension and postretirement obligations, rent, contractual rights and obligations, and statutory obligations."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r725"
     ]
    },
    "cpix_AccountsReceivableAllowancesByComponentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "AccountsReceivableAllowancesByComponentAxis",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable, Allowances by Component [Axis]",
        "label": "Accounts Receivable, Allowances by Component [Axis]",
        "documentation": "Accounts Receivable, Allowances by Component [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_AccountsReceivableAllowancesByComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "AccountsReceivableAllowancesByComponentDomain",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable, Allowances by Component [Domain]",
        "label": "Accounts Receivable, Allowances by Component [Domain]",
        "documentation": "[Domain] for Accounts Receivable, Allowances by Component [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r296"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other current liabilities",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "cpix_AccruedLiabilitiesInventoryPurchases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "AccruedLiabilitiesInventoryPurchases",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued inventory purchases",
        "label": "Accrued Liabilities, Inventory Purchases",
        "documentation": "Accrued Liabilities, Inventory Purchases"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_AccruedLiabilitiesStockPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "AccruedLiabilitiesStockPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sancuso related liabilities",
        "label": "Accrued Liabilities, Stock Payable",
        "documentation": "Accrued Liabilities, Stock Payable"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_AccruedLiabilitiesStudies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "AccruedLiabilitiesStudies",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Studies accrual",
        "label": "Accrued Liabilities, Studies",
        "documentation": "Accrued Liabilities, Studies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r196",
      "r546"
     ]
    },
    "cpix_ActivePharmaceuticalIngredientAPIAndWorkInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "ActivePharmaceuticalIngredientAPIAndWorkInProgressMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Active Pharmaceutical Ingredient (\"API\") And Work In Progress",
        "label": "Active Pharmaceutical Ingredient (\"API\") And Work In Progress [Member]",
        "documentation": "Active Pharmaceutical Ingredient (\"API\") And Work In Progress"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Adjustments to reconcile net loss to net cash flows provided by operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdvertisingCostsPolicyTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advertising Costs",
        "label": "Advertising Cost [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for advertising cost."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "us-gaap_AdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdvertisingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofAdvertisingCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advertising costs",
        "label": "Advertising Expense",
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line."
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r749",
      "r761",
      "r771",
      "r797"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r752",
      "r764",
      "r774",
      "r800"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r756",
      "r765",
      "r775",
      "r792",
      "r801",
      "r805",
      "r813"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r455"
     ]
    },
    "us-gaap_AllowanceForCreditLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForCreditLossMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for uncollectible amounts, cash discounts, chargebacks, and credits issued for damaged products:",
        "label": "SEC Schedule, 12-09, Allowance, Credit Loss [Member]",
        "documentation": "Allowance for credit loss from right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r841",
      "r842",
      "r843",
      "r844",
      "r845"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, allowances, current",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r299",
      "r304"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Noncash interest expense",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r353",
      "r513",
      "r836"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Amortization and impairment",
        "terseLabel": "Amortization and impairment expense",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r56",
      "r59"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Anti-dilutive shares and options (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Area of real estate property",
        "label": "Area of Real Estate Property",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r200",
      "r225",
      "r270",
      "r285",
      "r289",
      "r301",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r489",
      "r493",
      "r505",
      "r540",
      "r617",
      "r725",
      "r738",
      "r867",
      "r868",
      "r915"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of balance sheet classification",
        "label": "Assets and Liabilities, Lessee [Table Text Block]",
        "documentation": "Assets and Liabilities, Lessee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r207",
      "r225",
      "r301",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r489",
      "r493",
      "r505",
      "r725",
      "r867",
      "r868",
      "r915"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r743",
      "r744",
      "r757"
     ]
    },
    "cpix_AuditorInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "AuditorInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Information [Abstract]",
        "documentation": "Auditor Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r743",
      "r744",
      "r757"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r743",
      "r744",
      "r757"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansRestrictedStockActivityDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansValuationAssumptionsDetails",
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r415",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "cpix_BroadwestLeaseFiveYearRenewalOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "BroadwestLeaseFiveYearRenewalOptionMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Broadwest Lease, Five Year Renewal Option",
        "label": "Broadwest Lease, Five Year Renewal Option [Member]",
        "documentation": "Broadwest Lease, Five Year Renewal Option"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsChangesInFairValueOfContingentConsiderationLiabilityDetails",
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree [Domain]",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r716",
      "r717"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsChangesInFairValueOfContingentConsiderationLiabilityDetails",
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Axis]",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77",
      "r482",
      "r716",
      "r717"
     ]
    },
    "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionContingentConsiderationLineItems",
     "presentation": [
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsChangesInFairValueOfContingentConsiderationLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]",
        "label": "Business Acquisition, Contingent Consideration [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Line Items]",
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsChangesInFairValueOfContingentConsiderationLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Decrease in non-cash contingent consideration",
        "terseLabel": "Change in fair value",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r835"
     ]
    },
    "cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses",
     "crdr": "credit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsChangesInFairValueOfContingentConsiderationLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration earned and accrued",
        "label": "Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses",
        "documentation": "Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsChangesInFairValueOfContingentConsiderationLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Business Combination, Contingent Consideration, Liability",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r81",
      "r485"
     ]
    },
    "cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "BusinessCombinationContingentConsiderationLiabilityAccruedCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of accrued contingent consideration",
        "label": "Business Combination, Contingent Consideration, Liability, Accrued, Current",
        "documentation": "Business Combination, Contingent Consideration, Liability, Accrued, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of accrued contingent consideration",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r81"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofNoncurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofNoncurrentLiabilitiesDetails",
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current portion of accrued contingent consideration",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r81"
     ]
    },
    "cpix_BusinessCombinationContingentConsiderationLiabilityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "BusinessCombinationContingentConsiderationLiabilityRollForward",
     "presentation": [
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsChangesInFairValueOfContingentConsiderationLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination, Contingent Consideration, Liability [Roll Forward]",
        "label": "Business Combination, Contingent Consideration, Liability [Roll Forward]",
        "documentation": "Business Combination, Contingent Consideration, Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProducts"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vibativ\u00ae, Sancuso\u00ae and RediTrex\u00ae Products",
        "label": "Business Combination Disclosure [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r483"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent liability",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability",
        "documentation": "The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r79"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expense and other assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, other than goodwill",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "crdr": "debit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "documentation": "The amount of inventory recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r79"
     ]
    },
    "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMilestonePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMilestonePayable",
     "crdr": "credit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payable",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Milestone Payable",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Milestone Payable"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_CaldolorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "CaldolorMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNetScheduleofNonCurrentInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Caldolor",
        "label": "Caldolor [Member]",
        "documentation": "Caldolor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r194",
      "r687"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents, beginning of year",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r115",
      "r221"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r115"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncash investing and financing activities:",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_CashPaidDuringYearAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "CashPaidDuringYearAbstract",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net cash paid during the year for:",
        "label": "Cash Paid During Year [Abstract]",
        "documentation": "Cash Paid During Year For [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_CashPaymentIncludedInMeasurementOfLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "CashPaymentIncludedInMeasurementOfLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total cash paid included in measurement of lease liability",
        "label": "Cash Payment Included In Measurement Of Lease Liability",
        "documentation": "Cash Payment Included In Measurement Of Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_ChangeInUnpaidInvoicesForOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "ChangeInUnpaidInvoicesForOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in unpaid invoices for offering costs",
        "label": "Change In Unpaid Invoices For Offering Costs",
        "documentation": "Change In Unpaid Invoices For Offering Costs"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "cpix_ChargebacksCashDiscountsAndDamagedGoodsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "ChargebacksCashDiscountsAndDamagedGoodsMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product Sales Related Allowances - Chargebacks, Cash Discounts and Damaged Goods",
        "label": "Chargebacks, Cash Discounts and Damaged Goods [Member]",
        "documentation": "Chargebacks, Cash Discounts and Damaged Goods [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r201",
      "r202",
      "r203",
      "r225",
      "r256",
      "r257",
      "r259",
      "r261",
      "r268",
      "r269",
      "r301",
      "r322",
      "r324",
      "r325",
      "r326",
      "r329",
      "r330",
      "r358",
      "r359",
      "r362",
      "r365",
      "r372",
      "r505",
      "r572",
      "r573",
      "r574",
      "r575",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r605",
      "r626",
      "r645",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r820",
      "r837",
      "r849"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r202",
      "r203",
      "r268",
      "r358",
      "r359",
      "r360",
      "r362",
      "r365",
      "r370",
      "r372",
      "r572",
      "r573",
      "r574",
      "r575",
      "r707",
      "r820",
      "r837"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementAccountingPolicy",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Agreements",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for collaborative arrangements."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "cpix_CollaborativeArrangementMilestonePaymentThresholdAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "CollaborativeArrangementMilestonePaymentThresholdAxis",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement, Milestone Payment, Threshold [Axis]",
        "label": "Collaborative Arrangement, Milestone Payment, Threshold [Axis]",
        "documentation": "Collaborative Arrangement, Milestone Payment, Threshold"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_CollaborativeArrangementMilestonePaymentThresholdDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "CollaborativeArrangementMilestonePaymentThresholdDomain",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement, Milestone Payment, Threshold [Domain]",
        "label": "Collaborative Arrangement, Milestone Payment, Threshold [Domain]",
        "documentation": "Collaborative Arrangement, Milestone Payment, Threshold [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_CollaborativeArrangementRightsAndObligationsDepositPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "CollaborativeArrangementRightsAndObligationsDepositPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposit payment",
        "label": "Collaborative Arrangement, Rights And Obligations, Deposit Payment",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Deposit Payment"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_CollaborativeArrangementRightsAndObligationsMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "CollaborativeArrangementRightsAndObligationsMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment",
        "label": "Collaborative Arrangement, Rights and Obligations, Milestone Payment",
        "documentation": "Collaborative Arrangement, Rights and Obligations, Milestone Payment"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue",
     "crdr": "credit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment credit due",
        "label": "Collaborative Arrangement, Rights and Obligations, Milestone Payment, Credit Due",
        "documentation": "Collaborative Arrangement, Rights and Obligations, Milestone Payment, Credit Due"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales milestone payments, receivable",
        "label": "Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Receivable",
        "documentation": "Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationCancelledAndRefunded": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "CollaborativeArrangementRightsAndObligationsStockConsiderationCancelledAndRefunded",
     "presentation": [
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares cancelled and refunded",
        "label": "Collaborative Arrangement, Rights And Obligations, Stock Consideration, Cancelled And Refunded",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Stock Consideration, Cancelled And Refunded"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "CollaborativeArrangementRightsAndObligationsStockConsiderationShares",
     "presentation": [
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share consideration (in shares)",
        "label": "Collaborative Arrangement, Rights And Obligations, Stock Consideration, Shares",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Stock Consideration, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "CollaborativeArrangementRightsAndObligationsStockConsiderationValue",
     "crdr": "credit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share consideration, value",
        "label": "Collaborative Arrangement, Rights And Obligations, Stock Consideration, Value",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Stock Consideration, Value"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_CollaborativeArrangementRightsAndObligationsStockConsiderationVestedValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "CollaborativeArrangementRightsAndObligationsStockConsiderationVestedValue",
     "crdr": "credit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share consideration vested, value",
        "label": "Collaborative Arrangement, Rights And Obligations, Stock Consideration Vested, Value",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Stock Consideration Vested, Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement."
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r90",
      "r541",
      "r604"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r316",
      "r317",
      "r672",
      "r862"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for future grants (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock",
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r728",
      "r729",
      "r730",
      "r732",
      "r733",
      "r734",
      "r735",
      "r846",
      "r847",
      "r907",
      "r927",
      "r930"
     ]
    },
    "us-gaap_CommonStockNoParValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockNoParValue",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, No Par Value",
        "documentation": "Face amount per share of no-par value common stock."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r605"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r96",
      "r605",
      "r623",
      "r930",
      "r931"
     ]
    },
    "us-gaap_CommonStockValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValueOutstanding",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock \u2013 no par value; 100,000,000 shares authorized; 14,121,833 and 14,366,316 shares issued and outstanding as of December\u00a031, 2023 and 2022, respectively",
        "label": "Common Stock, Value, Outstanding",
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r605"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r48",
      "r87",
      "r88",
      "r294",
      "r671"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r48",
      "r87",
      "r88",
      "r294",
      "r567",
      "r671"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r48",
      "r87",
      "r88",
      "r294",
      "r671",
      "r821"
     ]
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market Concentrations",
        "label": "Concentration Risk Disclosure [Text Block]",
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Line Items]",
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk, percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r48",
      "r87",
      "r88",
      "r294"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Table]",
        "label": "Concentration Risk [Table]",
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r48",
      "r49",
      "r87",
      "r147",
      "r671"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r48",
      "r87",
      "r88",
      "r294",
      "r671"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r694"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current deferred charges",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r375",
      "r394"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cost of products sold",
        "label": "Cost of Goods and Services Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r533"
     ]
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Products Sold",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total costs and expenses",
        "terseLabel": "Expenses",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Costs and expenses:",
        "label": "Costs and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]",
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r229",
      "r230",
      "r335",
      "r360",
      "r529",
      "r691",
      "r693"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "cpix_CreditIssuedForMilestonePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "CreditIssuedForMilestonePayable",
     "crdr": "credit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RediTrex forgiveness of milestone payable",
        "label": "Credit Issued for Milestone Payable",
        "documentation": "Credit Issued for Milestone Payable"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_CumberlandEmergingTechnologiesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "CumberlandEmergingTechnologiesIncMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumberland Emerging Technologies, Inc (CET)",
        "label": "Cumberland Emerging Technologies, Inc [Member]",
        "documentation": "Cumberland Emerging Technologies, Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r825",
      "r840",
      "r903"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current income tax expense",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r472",
      "r477",
      "r840"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current:",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and other",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r825",
      "r840",
      "r903"
     ]
    },
    "cpix_Customer12And3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "Customer12And3Member",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer 1, 2, and 3",
        "label": "Customer 1, 2, and 3 [Member]",
        "documentation": "Customer 1, 2, and 3"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r294"
     ]
    },
    "cpix_CustomerOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "CustomerOneMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer 1",
        "label": "Customer One [Member]",
        "documentation": "Customer One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_CustomerThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "CustomerThreeMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer 3",
        "label": "Customer Three [Member]",
        "documentation": "Customer Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_CustomerTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "CustomerTwoMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer 2",
        "label": "Customer Two [Member]",
        "documentation": "Customer Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r223",
      "r331",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r347",
      "r354",
      "r355",
      "r356"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r93",
      "r94",
      "r149",
      "r150",
      "r231",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r338",
      "r343",
      "r344",
      "r345",
      "r346",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r514",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r838"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis spread on variable rate (in percent)",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r333"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r231",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r338",
      "r343",
      "r344",
      "r345",
      "r346",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r514",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r838"
     ]
    },
    "us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCompensationLiabilityClassifiedNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofNoncurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofNoncurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred compensation",
        "label": "Deferred Compensation Liability, Classified, Noncurrent",
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCompensationLiabilityCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred compensation liability",
        "label": "Deferred Compensation Liability, Current and Noncurrent",
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements. Represents currently earned compensation under compensation arrangements that is not actually paid until a later date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCompensationPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCompensationPlanAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred compensation assets",
        "label": "Deferred Compensation Plan Assets",
        "documentation": "Carrying amount as of the balance sheet date of assets held under deferred compensation agreements."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails": {
       "parentTag": "us-gaap_DeferredOtherTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r840",
      "r902",
      "r903"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred:",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredOtherTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredOtherTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred income tax expense",
        "label": "Deferred Other Tax Expense (Benefit)",
        "documentation": "Amount of other deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. For example, but not limited to, acquisition-date income tax benefits or expenses recognized from changes in the acquirer's valuation allowance for its previously existing deferred tax assets resulting from a business combination and adjustments to beginning-of-year balance of a valuation allowance because of a change in circumstance causing a change in judgment about the realizability of the related deferred tax asset in future periods."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r140",
      "r840"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails": {
       "parentTag": "us-gaap_DeferredOtherTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r840",
      "r902",
      "r903"
     ]
    },
    "cpix_DeferredTaxAssetOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "DeferredTaxAssetOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Deferred Tax Asset, Operating Lease Liabilities",
        "documentation": "Deferred Tax Asset, Operating Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_DeferredTaxAssetsDeferredCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "DeferredTaxAssetsDeferredCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred charges",
        "label": "Deferred Tax Assets, Deferred Charges",
        "documentation": "Deferred Tax Assets, Deferred Charges"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "parentTag": "cpix_NetDeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Tax Assets",
        "label": "Deferred Tax Assets, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research cost",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r901"
     ]
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInventory",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Deferred Tax Assets, Inventory",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r901"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss and tax credits",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards and Tax Credit Carryforwards",
        "documentation": "Deferred Tax Assets, Operating Loss Carryforwards and Tax Credit Carryforwards"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "DeferredTaxAssetsPropertyAndEquipmentAndIntangibles",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment and intangibles",
        "label": "Deferred Tax Assets, Property and Equipment and Intangibles",
        "documentation": "Deferred Tax Assets, Property and Equipment and Intangibles"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative compensation costs incurred on deductible equity awards",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r901"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for accounts receivable",
        "label": "Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r901"
     ]
    },
    "cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserve for expired product",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves for Expired Product",
        "documentation": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves for Expired Product"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: deferred tax asset valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Tax Liabilities",
        "label": "Deferred Tax Liabilities, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "parentTag": "cpix_NetDeferredTaxAssetsGross",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Intangible assets",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r901"
     ]
    },
    "cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "DeferredTaxLiabilityOperatingLeaseRightOfUseAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "parentTag": "cpix_NetDeferredTaxAssetsGross",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Operating lease right-of-use assets",
        "label": "Deferred Tax Liability, Operating Lease Right-of-Use Assets",
        "documentation": "Deferred Tax Liability, Operating Lease Right-of-Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "DefinedContributionPlanEligibilityMinimumEmployeeAge",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined contribution plan, eligibiilty, minimum employee age",
        "label": "Defined Contribution Plan, Eligibility, Minimum Employee Age",
        "documentation": "Defined Contribution Plan, Eligibility, Minimum Employee Age"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined contribution plan, eligibility, minimum employee service time for participation eligibility",
        "label": "Defined Contribution Plan, Eligibility, Minimum Employee Service Time for Participation Eligibility",
        "documentation": "Defined Contribution Plan, Eligibility, Minimum Employee Service Time for Participation Eligibility"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined contribution plan, employer discretionary contribution amount",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation and amortization expense",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r275"
     ]
    },
    "cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "DepreciationIncludingAmortizationRelatedToLeaseholdImprovements",
     "crdr": "debit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentDepreciationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation, including amortization related to leasehold improvements",
        "label": "Depreciation, Including Amortization Related to Leasehold Improvements",
        "documentation": "Depreciation, Including Amortization Related to Leasehold Improvements"
       }
      }
     },
     "auth_ref": []
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "DirectorMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Director",
        "label": "Director [Member]",
        "documentation": "Person serving on board of directors."
       }
      }
     },
     "auth_ref": [
      "r852",
      "r928"
     ]
    },
    "cpix_DirectorsIncentivePlan2007Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "DirectorsIncentivePlan2007Member",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Directors\u2019 Incentive Plan 2007",
        "label": "Directors\u2019 Incentive Plan 2007 [Member]",
        "documentation": "Directors\u2019 Incentive Plan 2007 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation Plans",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r413",
      "r444",
      "r445",
      "r447",
      "r719"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r743",
      "r744",
      "r757"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r743",
      "r744",
      "r757",
      "r793"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Loss per share attributable to common shareholders:",
        "terseLabel": "Earnings per share attributable to common shareholders",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in USD per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r254",
      "r256",
      "r259",
      "r260",
      "r261",
      "r265",
      "r503",
      "r504",
      "r537",
      "r552",
      "r696"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in USD per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r256",
      "r259",
      "r260",
      "r261",
      "r265",
      "r503",
      "r504",
      "r537",
      "r552",
      "r696"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings (Loss) Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r262",
      "r263",
      "r264"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss tax expense",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal tax expense at statutory rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r463",
      "r478"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r899",
      "r904"
     ]
    },
    "cpix_EffectiveIncomeTaxRateReconciliationDeferredTrueUpsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationDeferredTrueUpsPercent",
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred True-ups",
        "label": "Effective Income Tax Rate Reconciliation, Deferred True-Ups, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Deferred True-Ups, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other permanent differences",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r899",
      "r904"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income tax expense (net of federal income tax benefit)",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r899",
      "r904"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiring tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r899",
      "r904"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Permanent differences associated with general business credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r899",
      "r904"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee wages and benefits",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost related to share-based payments",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost related to share-based payments, period for recognition",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation costs",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansValuationAssumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "cpix_EmploymentAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "EmploymentAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Employment Agreements [Abstract]",
        "documentation": "Employment Agreements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_EmploymentAgreementsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "EmploymentAgreementsTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EmploymentAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employment Agreements",
        "label": "Employment Agreements [Text Block]",
        "documentation": "Employment Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitiesTable",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entities [Table]",
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Information [Line Items]",
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from External Customer [Line Items]",
        "label": "Revenue from External Customer [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r188",
      "r211",
      "r212",
      "r213",
      "r240",
      "r241",
      "r242",
      "r244",
      "r250",
      "r252",
      "r267",
      "r302",
      "r303",
      "r373",
      "r448",
      "r449",
      "r450",
      "r473",
      "r474",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r502",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r525",
      "r562",
      "r563",
      "r564",
      "r580",
      "r645"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r749",
      "r761",
      "r771",
      "r797"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r746",
      "r758",
      "r768",
      "r794"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "cpix_ExpirationTermOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "ExpirationTermOneMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleOfTaxCreditCarryforwardsDetails",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Expiration, Term One [Member]",
        "documentation": "Expiration, Term One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_ExpirationTermTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "ExpirationTermTwoMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleOfTaxCreditCarryforwardsDetails",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025-2042",
        "label": "Expiration, Term Two [Member]",
        "documentation": "Expiration, Term Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_ExpirationTimePeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "ExpirationTimePeriodAxis",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleOfTaxCreditCarryforwardsDetails",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Time Period [Axis]",
        "label": "Expiration Time Period [Axis]",
        "documentation": "Expiration Time Period [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_ExpirationTimePeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "ExpirationTimePeriodDomain",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleOfTaxCreditCarryforwardsDetails",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Time Period [Domain]",
        "label": "Expiration Time Period [Domain]",
        "documentation": "[Domain] for Expiration Time Period [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r18"
     ]
    },
    "cpix_FederalAndStateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "FederalAndStateMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleOfTaxCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal And State",
        "label": "Federal And State [Member]",
        "documentation": "Federal And State"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_FederalGrantProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "FederalGrantProgramsMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal Grant Programs",
        "label": "Federal Grant Programs [Member]",
        "documentation": "Collaborative Arrangement, Federal Small Business Grant Programs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_FinishedGoodsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "FinishedGoodsMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNetScheduleofNonCurrentInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished Goods",
        "label": "Finished Goods [Member]",
        "documentation": "Finished Goods"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accumulated amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r314"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFourAndAfter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFourAndAfter",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028 and thereafter",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four and After",
        "documentation": "Finite-Lived Intangible Assets, Amortization Expense, Year Four and After"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r313",
      "r314",
      "r315",
      "r534",
      "r535"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, gross",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r535"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r534"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible assets, net",
        "totalLabel": "Intangible assets, net",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r534"
     ]
    },
    "cpix_FollowingApprovalOfFirstSNDAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "FollowingApprovalOfFirstSNDAMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Following Approval Of First sNDA",
        "label": "Following Approval Of First sNDA [Member]",
        "documentation": "Following Approval Of First sNDA"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r765",
      "r775",
      "r801"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r765",
      "r775",
      "r801"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r765",
      "r775",
      "r801"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r765",
      "r775",
      "r801"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r765",
      "r775",
      "r801"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnDispositionOfAssets1",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Disposal of assets",
        "label": "Gain (Loss) on Disposition of Assets",
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossRelatedToLitigationSettlement",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income - settlement",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process."
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r629"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails",
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r308",
      "r536",
      "r701",
      "r725",
      "r858",
      "r859"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwill"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets and Goodwill",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets and Goodwill",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r55"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill, impairment loss",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r309",
      "r310",
      "r311",
      "r701"
     ]
    },
    "us-gaap_GrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrantMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant",
        "label": "Grant [Member]",
        "documentation": "Award of money not required to be repaid."
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "cpix_HongKongWinHealthPharmaGroupCoLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "HongKongWinHealthPharmaGroupCoLimitedMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "HongKong WinHealth Pharma Group Co. Limited",
        "label": "HongKong WinHealth Pharma Group Co. Limited [Member]",
        "documentation": "HongKong WinHealth Pharma Group Co. Limited"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment loss on intangible assets",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r836",
      "r860"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r128"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r106",
      "r154",
      "r270",
      "r284",
      "r288",
      "r290",
      "r538",
      "r548",
      "r698"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "presentation": [
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Continuing operations - basic (in dollars per share)",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r153",
      "r155",
      "r215",
      "r243",
      "r245",
      "r246",
      "r247",
      "r248",
      "r256",
      "r259",
      "r260",
      "r504",
      "r537",
      "r924"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "presentation": [
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Continuing operations - diluted (in dollars per share)",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r215",
      "r243",
      "r245",
      "r246",
      "r247",
      "r248",
      "r256",
      "r259",
      "r260",
      "r261",
      "r504",
      "r537",
      "r924"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleOfTaxCreditCarryforwardsDetails",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Axis]",
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleOfTaxCreditCarryforwardsDetails",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Domain]",
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r459",
      "r464",
      "r465",
      "r470",
      "r475",
      "r479",
      "r480",
      "r481",
      "r577"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax expense",
        "totalLabel": "Total income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r173",
      "r251",
      "r252",
      "r276",
      "r462",
      "r476",
      "r554"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r460",
      "r461",
      "r465",
      "r466",
      "r469",
      "r471",
      "r571"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Income Taxes Paid, Net",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and other current liabilities",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Decrease (increase) in cash surrender value of life insurance policies over premiums paid",
        "label": "Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy",
        "documentation": "Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventories, net",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net changes in assets and liabilities affecting operating activities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r823",
      "r835"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other current assets and other assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Shareholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "cpix_IndefiniteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "IndefiniteMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite Period",
        "label": "Indefinite [Member]",
        "documentation": "Indefinite"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r756",
      "r765",
      "r775",
      "r792",
      "r801",
      "r805",
      "r813"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r745",
      "r817"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r745",
      "r817"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r745",
      "r817"
     ]
    },
    "us-gaap_InsuredEventGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InsuredEventGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income - gain on insurance proceeds",
        "label": "Insured Event, Gain (Loss)",
        "documentation": "Amount of excess (deficiency) of insurance recovery over the loss incurred from an insured event."
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r157",
      "r214",
      "r274",
      "r512",
      "r630",
      "r736",
      "r929"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r219",
      "r220"
     ]
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InternalRevenueServiceIRSMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Internal Revenue Service (IRS) [Member]",
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryCurrentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryCurrentTable",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory, Current [Table]",
        "label": "Inventory, Current [Table]",
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories, Net",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesNetScheduleofInventoriesDetails": {
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNetScheduleofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Finished goods, net of reserve",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r689"
     ]
    },
    "us-gaap_InventoryGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryGross",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesNetScheduleofInventoriesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNetScheduleofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total inventories",
        "label": "Inventory, Gross",
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_InventoryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryLineItems",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory [Line Items]",
        "label": "Inventory [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/InventoriesNetScheduleofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventories, net",
        "terseLabel": "Total inventories",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r688",
      "r725"
     ]
    },
    "us-gaap_InventoryNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/InventoriesNetNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNetScheduleofInventoriesDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNetScheduleofNonCurrentInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current inventories",
        "negatedLabel": "less non-current inventories",
        "label": "Inventory, Noncurrent",
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "cpix_InventoryNoncurrentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "InventoryNoncurrentLineItems",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNetScheduleofNonCurrentInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory, Noncurrent [Line Items]",
        "label": "Inventory, Noncurrent [Line Items]",
        "documentation": "Inventory, Noncurrent [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_InventoryNoncurrentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "InventoryNoncurrentTable",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNetScheduleofNonCurrentInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory, Noncurrent [Table]",
        "label": "Inventory, Noncurrent [Table]",
        "documentation": "Inventory, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r193",
      "r205",
      "r305",
      "r306",
      "r307",
      "r532",
      "r695"
     ]
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryRawMaterialsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesNetScheduleofInventoriesDetails": {
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNetScheduleofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r690"
     ]
    },
    "us-gaap_InventoryValuationReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryValuationReserves",
     "crdr": "credit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory reserves, obsolescence and discontinuance",
        "label": "Inventory Valuation Reserves",
        "documentation": "Amount of valuation reserve for inventory."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r832"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r273"
     ]
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "crdr": "debit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial investment amount",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "cpix_KristaloseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "KristaloseMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNetScheduleofNonCurrentInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kristalose",
        "label": "Kristalose [Member]",
        "documentation": "Kristalose."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Contractual Term [Axis]",
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Contractual Term [Domain]",
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold Improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "cpix_LesseeOperatingLeaseBaseRent": {
     "xbrltype": "perUnitItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "LesseeOperatingLeaseBaseRent",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Operating Lease, Base Rent",
        "label": "Lessee, Operating Lease, Base Rent",
        "documentation": "Lessee, Operating Lease, Base Rent"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_LesseeOperatingLeaseLeasedArea": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "LesseeOperatingLeaseLeasedArea",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leased area",
        "label": "Lessee, Operating Lease, Leased Area",
        "documentation": "Lessee, Operating Lease, Leased Area"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of operating lease liability maturities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total minimum lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After 2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "cpix_LesseeOperatingLeaseNumberOfRenewalTerms": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "LesseeOperatingLeaseNumberOfRenewalTerms",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of renewal terms",
        "label": "Lessee, Operating Lease, Number Of Renewal Terms",
        "documentation": "Lessee, Operating Lease, Number Of Renewal Terms"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining lease term (in years)",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Renewal term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "cpix_LesseeOperatingLeaseRentIncrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "LesseeOperatingLeaseRentIncrease",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent increase",
        "label": "Lessee, Operating Lease, Rent Increase",
        "documentation": "Lessee, Operating Lease, Rent Increase"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of contract",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future minimum sublease income under noncancelable operating subleases",
        "label": "Lessor, Operating Lease, Payment to be Received",
        "documentation": "Amount of lease payments to be received by lessor for operating lease."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r225",
      "r301",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r490",
      "r493",
      "r494",
      "r505",
      "r603",
      "r697",
      "r738",
      "r867",
      "r915",
      "r916"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r152",
      "r544",
      "r725",
      "r839",
      "r857",
      "r908"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "LIABILITIES AND EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r192",
      "r225",
      "r301",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r490",
      "r493",
      "r494",
      "r505",
      "r725",
      "r867",
      "r915",
      "r916"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_LineOfCreditFacilityAdditionalBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "LineOfCreditFacilityAdditionalBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum increase to line of credit",
        "label": "Line Of Credit Facility, Additional Borrowing Capacity",
        "documentation": "Line Of Credit Facility, Additional Borrowing Capacity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityAxis",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lender Name [Axis]",
        "label": "Lender Name [Axis]",
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r838"
     ]
    },
    "us-gaap_LineOfCreditFacilityExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityExpirationPeriod",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration period (in years)",
        "label": "Line of Credit Facility, Expiration Period",
        "documentation": "Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityLenderDomain",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility, Lender [Domain]",
        "label": "Line of Credit Facility, Lender [Domain]",
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r838"
     ]
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityLineItems",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility [Line Items]",
        "label": "Line of Credit Facility [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit, maximum borrowing capacity",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityTable",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility [Table]",
        "label": "Line of Credit Facility [Table]",
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r838"
     ]
    },
    "us-gaap_LineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit",
        "label": "Line of Credit [Member]",
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "cpix_LongTermIncentiveCompensationPlan2007Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "LongTermIncentiveCompensationPlan2007Member",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Incentive Compensation Plan 2007",
        "label": "Long-Term Incentive Compensation Plan 2007 [Member]",
        "documentation": "Long-Term Incentive Compensation Plan 2007 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermLineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermLineOfCredit",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revolving line of credit",
        "terseLabel": "Borrowings outstanding under revolving credit facility",
        "label": "Long-Term Line of Credit, Noncurrent",
        "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r61",
      "r62"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major Customers [Axis]",
        "label": "Customer [Axis]",
        "documentation": "Information by name or description of a single external customer or a group of external customers."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r710",
      "r870",
      "r925",
      "r926"
     ]
    },
    "us-gaap_ManufacturedProductOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ManufacturedProductOtherMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Manufactured Product, Other [Member]",
        "documentation": "Article or substance produced by labor or machinery, classified as other."
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Manufacturing agreements, number of primary suppliers for each product",
        "label": "Manufacturing agreements, number of primary suppliers for each product",
        "documentation": "Manufacturing agreements, number of primary suppliers for each product"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_ManufacturingAndSupplyAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "ManufacturingAndSupplyAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Manufacturing and Supply Agreements [Abstract]",
        "documentation": "Manufacturing and Supply Agreements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_ManufacturingAndSupplyAgreementsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "ManufacturingAndSupplyAgreementsTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Manufacturing and Supply Agreements",
        "label": "Manufacturing and Supply Agreements [Text Block]",
        "documentation": "Manufacturing and Supply Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_ManufacturingandSupplyAgreementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "ManufacturingandSupplyAgreementLineItems",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Manufacturing and Supply Agreement [Line Items]",
        "label": "Manufacturing and Supply Agreement [Line Items]",
        "documentation": "[Line Items] for Manufacturing and Supply Agreement [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_ManufacturingandSupplyAgreementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "ManufacturingandSupplyAgreementTable",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Manufacturing and Supply Agreement [Table]",
        "label": "Manufacturing and Supply Agreement [Table]",
        "documentation": "Manufacturing and Supply Agreement [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_MartinS.BrownJr.sLawFirmMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "MartinS.BrownJr.sLawFirmMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Martin S. Brown Jr.'s Law Firm",
        "label": "Martin S. Brown Jr.'s Law Firm [Member]",
        "documentation": "Martin S. Brown Jr.'s Law Firm"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.cumberlandpharma.com/role/DebtDetails",
      "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r321",
      "r409",
      "r531",
      "r561",
      "r595",
      "r596",
      "r651",
      "r653",
      "r655",
      "r656",
      "r658",
      "r682",
      "r683",
      "r700",
      "r707",
      "r718",
      "r727",
      "r869",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Melinta Therapeutics, LLC and Targanta Therapeutics Corporation",
        "label": "Melinta Therapeutics, LLC and Targanta Therapeutics Corporation [Member]",
        "documentation": "Melinta Therapeutics, LLC and Targanta Therapeutics Corporation"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_MethotrexateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "MethotrexateMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Methotrexate",
        "label": "Methotrexate [Member]",
        "documentation": "Methotrexate [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r321",
      "r409",
      "r531",
      "r561",
      "r595",
      "r596",
      "r651",
      "r653",
      "r655",
      "r656",
      "r658",
      "r682",
      "r683",
      "r700",
      "r707",
      "r718",
      "r727",
      "r869",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interests",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r151",
      "r225",
      "r301",
      "r322",
      "r324",
      "r325",
      "r326",
      "r329",
      "r330",
      "r505",
      "r543",
      "r607"
     ]
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interest, ownership percentage by parent",
        "label": "Subsidiary, Ownership Percentage, Parent",
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name of Major Customer [Domain]",
        "label": "Customer [Domain]",
        "documentation": "Single external customer or group of external customers."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r710",
      "r870",
      "r925",
      "r926"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "cpix_NephronPharmaceuticalsCorporationNephronMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "NephronPharmaceuticalsCorporationNephronMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nephron Pharmaceuticals Corporation (\u201cNephron\u201d)",
        "label": "Nephron Pharmaceuticals Corporation (\u201cNephron\u201d) [Member]",
        "documentation": "Nephron Pharmaceuticals Corporation (\u201cNephron\u201d)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116",
      "r117"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_NetDeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "NetDeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets, before valuation allowance",
        "label": "Net Deferred Tax Assets, Gross",
        "documentation": "Net Deferred Tax Assets, Gross"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/LossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails",
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss attributable to common shareholders",
        "terseLabel": "Net loss attributable to common shareholders",
        "verboseLabel": "Net loss attributable to common shareholders",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r117",
      "r156",
      "r190",
      "r208",
      "r209",
      "r213",
      "r225",
      "r243",
      "r245",
      "r246",
      "r247",
      "r248",
      "r251",
      "r252",
      "r258",
      "r270",
      "r284",
      "r288",
      "r290",
      "r301",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r504",
      "r505",
      "r551",
      "r625",
      "r643",
      "r644",
      "r698",
      "r736",
      "r867"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/LossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails",
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net loss at subsidiary attributable to noncontrolling interests",
        "negatedTerseLabel": "Net loss at subsidiary attributable to noncontrolling interests",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r146",
      "r208",
      "r209",
      "r251",
      "r252",
      "r550",
      "r834"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Numerator:",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Guidance",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r765",
      "r775",
      "r792",
      "r801"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "us-gaap_NonUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonUsMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-US",
        "label": "Non-US [Member]",
        "documentation": "Countries excluding the United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r932",
      "r933",
      "r934",
      "r935"
     ]
    },
    "cpix_NoncashOrPartNoncashGainOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "NoncashOrPartNoncashGainOnTransaction",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Noncash gain on RediTrex transaction",
        "label": "Noncash or Part Noncash, Gain on Transaction",
        "documentation": "Noncash or Part Noncash, Gain on Transaction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestAbstract",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interest [Abstract]",
        "label": "Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-controlling interest",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r373",
      "r846",
      "r847",
      "r848",
      "r930"
     ]
    },
    "cpix_NonprincipalOwnerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "NonprincipalOwnerMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NonPrincipal Owner",
        "label": "NonPrincipal Owner [Member]",
        "documentation": "NonPrincipal Owner [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_NordicGroupBVMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "NordicGroupBVMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nordic Group B.V.",
        "label": "Nordic Group B.V. [Member]",
        "documentation": "Nordic Group B.V."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "srt_OfficeBuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OfficeBuildingMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office Building",
        "label": "Office Building [Member]",
        "documentation": "Building designed primarily for the conduct of business, for example, but not limited to, administration, clerical services, and consultation."
       }
      }
     },
     "auth_ref": [
      "r827",
      "r828",
      "r936",
      "r937"
     ]
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office equipment",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "terseLabel": "Operating income (loss)",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r284",
      "r288",
      "r290",
      "r698"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease Liabilities, Payments Due [Abstract]",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails",
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Present value of lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease current liabilities",
        "verboseLabel": "Operating lease current liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease non-current liabilities",
        "verboseLabel": "Operating lease non-current liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails",
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of operating lease right-of-use asset",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average incremental borrowing rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r724"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r521",
      "r724"
     ]
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasedAssetsLineItems",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leased Assets [Line Items]",
        "label": "Operating Leased Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Line Items]",
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Organization"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r145",
      "r568",
      "r569"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r199"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Line Items]",
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Table]",
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income",
        "label": "Other Income",
        "documentation": "Amount of revenue and income classified as other."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r627",
      "r659",
      "r660",
      "r661"
     ]
    },
    "us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesNetScheduleofInventoriesDetails": {
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNetScheduleofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consigned inventory",
        "label": "Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross",
        "documentation": "Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other current liabilities",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r725"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Current and Other Long-term Liabilities",
        "label": "Other Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for other liabilities."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofNoncurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofNoncurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total other long-term liabilities",
        "totalLabel": "Total other long-term liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of other long-term liabilities",
        "label": "Other Noncurrent Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of other noncurrent liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingGainsLosses",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gain on receipt of life insurance policies",
        "label": "Other Nonoperating Gains (Losses)",
        "documentation": "Amount of gain (loss) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "cpix_OtherProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "OtherProductsMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNetScheduleofNonCurrentInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Products",
        "label": "Other Products [Member]",
        "documentation": "Other Products"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r751",
      "r763",
      "r773",
      "r799"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r754",
      "r766",
      "r776",
      "r802"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r754",
      "r766",
      "r776",
      "r802"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Axis]",
        "label": "Ownership [Axis]",
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Domain]",
        "label": "Ownership [Domain]",
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PatentsMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patents",
        "label": "Patents [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cash settlement of contingent consideration",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments made in connection with repurchase of common shares",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_PaymentsForRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsChangesInFairValueOfContingentConsiderationLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cash payment of royalty during the period",
        "label": "Payments for Royalties",
        "documentation": "The amount of cash paid for royalties during the current period."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial public offering, issuance costs",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "cpix_PaymentsToAcquireBusinessMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "PaymentsToAcquireBusinessMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MIlestone payment",
        "label": "Payments To Acquire Business, Milestone Payment",
        "documentation": "Payments To Acquire Business, Milestone Payment"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_PaymentsToAcquireBusinessMilestonePaymentRemaining": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "PaymentsToAcquireBusinessMilestonePaymentRemaining",
     "crdr": "credit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment remaining",
        "label": "Payments To Acquire Business, Milestone Payment Remaining",
        "documentation": "Payments To Acquire Business, Milestone Payment Remaining"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tiered royalty payments (percentage)",
        "label": "Payments To Acquire Business, Tiered Royalty Payments, Percentage",
        "documentation": "Payments To Acquire Business, Tiered Royalty Payments, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "PaymentsToAcquireBusinessTieredRoyaltyPaymentsTerm",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tiered royalty payments term (in years)",
        "label": "Payments To Acquire Business, Tiered Royalty Payments, Term",
        "documentation": "Payments To Acquire Business, Tiered Royalty Payments, Term"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold",
     "crdr": "credit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tiered royalty payments, threshold",
        "label": "Payments To Acquire Business, Tiered Royalty Payments, Threshold",
        "documentation": "Payments To Acquire Business, Tiered Royalty Payments, Threshold"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cash paid for acquisition",
        "terseLabel": "Payment to acquire business upon closing",
        "label": "Payments to Acquire Businesses, Gross",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r484"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Additions to intangible assets",
        "terseLabel": "Additions to intangible assets",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Additions to property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EmployeeBenefitPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Benefit Plans",
        "label": "Retirement Benefits [Text Block]",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r715"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "cpix_PinnacleBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "PinnacleBankMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pinnacle Bank",
        "label": "Pinnacle Bank [Member]",
        "documentation": "Pinnacle Bank [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897"
     ]
    },
    "us-gaap_PostemploymentBenefitsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PostemploymentBenefitsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Postemployment Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r605"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r605",
      "r623",
      "r930",
      "r931"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid and Other Current Assets",
        "label": "Prepaids and Other Current Assets, Policy [Policy Text Block]",
        "documentation": "Prepaids and Other Current Assets, Policy [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrincipalOwnerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrincipalOwnerMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal Owner",
        "label": "Principal Owner [Member]",
        "documentation": "Owner of record or known beneficial owner of more than 10 percent of the voting interests of the entity."
       }
      }
     },
     "auth_ref": []
    },
    "cpix_ProceedsFromCollaborativeArrangement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "ProceedsFromCollaborativeArrangement",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Return of RediTrex",
        "label": "Proceeds from Collaborative Arrangement",
        "documentation": "Proceeds from Collaborative Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial public offering, net proceeds",
        "label": "Proceeds from Issuance Initial Public Offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ProceedsFromLegalSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromLegalSettlements",
     "crdr": "debit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from litigation settlement",
        "label": "Proceeds from Legal Settlements",
        "documentation": "Cash received for the settlement of litigation during the current period."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivableNumberOfPayments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "ProceedsFromLegalSettlementsMilestonePaymentsReceivableNumberOfPayments",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payments receivable, number of payments",
        "label": "Proceeds from Legal Settlements, Milestone Payments Receivable, Number of Payments",
        "documentation": "Proceeds from Legal Settlements, Milestone Payments Receivable, Number of Payments"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentOne",
     "crdr": "credit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payments receivable, payment one",
        "label": "Proceeds from Legal Settlements, Milestone Payments Receivable, Payment One",
        "documentation": "Proceeds from Legal Settlements, Milestone Payments Receivable, Payment One"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payments receivable, payment two",
        "label": "Proceeds from Legal Settlements, Milestone Payments Receivable, Payment Two",
        "documentation": "Proceeds from Legal Settlements, Milestone Payments Receivable, Payment Two"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromLifeInsurancePolicies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromLifeInsurancePolicies",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Life insurance policy proceeds received",
        "label": "Proceeds from Life Insurance Policy",
        "documentation": "Amount of cash inflow for proceeds from settlement of corporate-owned life insurance policy, classified as investing activities. Includes, but is not limited to, bank-owned life insurance policy."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r34"
     ]
    },
    "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromRepaymentsOfLinesOfCredit",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings on line of credit",
        "label": "Proceeds from (Repayments of) Lines of Credit",
        "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets)."
       }
      }
     },
     "auth_ref": []
    },
    "cpix_ProceedsFromSettlementOfPatentLitigation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "ProceedsFromSettlementOfPatentLitigation",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement of patent litigation",
        "label": "Proceeds from Settlement of Patent Litigation",
        "documentation": "Proceeds from Settlement of Patent Litigation"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_ProductAcetadoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "ProductAcetadoteMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acetadote",
        "label": "Product - Acetadote [Member]",
        "documentation": "Product - Acetadote"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_ProductAndLicenseRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "ProductAndLicenseRightsMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and License Rights",
        "label": "Product and License Rights [Member]",
        "documentation": "Product and License Rights [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_ProductAssetsAndGlobalRightsVibativMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "ProductAssetsAndGlobalRightsVibativMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsChangesInFairValueOfContingentConsiderationLiabilityDetails",
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product Assets And Global Rights - Vibativ",
        "label": "Product Assets And Global Rights - Vibativ [Member]",
        "documentation": "Product Assets And Global Rights - Vibativ"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_ProductCaldolorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "ProductCaldolorMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Caldolor",
        "label": "Product - Caldolor [Member]",
        "documentation": "Product - Caldolor"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_ProductKristaloseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "ProductKristaloseMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kristalose",
        "label": "Product - Kristalose [Member]",
        "documentation": "Product - Kristalose"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product",
        "label": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "cpix_ProductOmeclamoxPakMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "ProductOmeclamoxPakMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Omeclamox-Pak",
        "label": "Product - Omeclamox-Pak [Member]",
        "documentation": "Product - Omeclamox-Pak"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/InventoriesNetNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNetScheduleofNonCurrentInventoriesDetails",
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails",
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r533",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r685",
      "r708",
      "r726",
      "r824",
      "r864",
      "r865",
      "r870",
      "r925"
     ]
    },
    "cpix_ProductRediTrexMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "ProductRediTrexMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RediTrex",
        "label": "Product - RediTrex [Member]",
        "documentation": "Product - RediTrex"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_ProductSalesRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "ProductSalesRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rebates, product returns, administrative fees and service fees",
        "label": "Product Sales-Related Liabilities, Current",
        "documentation": "Product Sales-Related Liabilities, Current"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_ProductSancusoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "ProductSancusoMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sancuso",
        "label": "Product - Sancuso [Member]",
        "documentation": "Product - Sancuso"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_ProductVaprisolMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "ProductVaprisolMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vaprisol",
        "label": "Product - Vaprisol [Member]",
        "documentation": "Product - Vaprisol"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_ProductVibativMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "ProductVibativMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vibativ",
        "label": "Product - Vibativ [Member]",
        "documentation": "Product - Vibativ"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductionAndDistributionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductionAndDistributionCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofDistributionCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Distribution costs",
        "label": "Production and Distribution Costs",
        "documentation": "Amount of expense related to the production and distribution of goods or services to customers and clients."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/InventoriesNetNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNetScheduleofNonCurrentInventoriesDetails",
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails",
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r533",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r685",
      "r708",
      "r726",
      "r824",
      "r864",
      "r865",
      "r870",
      "r925"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/LossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails",
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "verboseLabel": "Net income (loss)",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r208",
      "r209",
      "r217",
      "r225",
      "r243",
      "r251",
      "r252",
      "r270",
      "r284",
      "r288",
      "r290",
      "r301",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r488",
      "r491",
      "r492",
      "r504",
      "r505",
      "r538",
      "r549",
      "r579",
      "r625",
      "r643",
      "r644",
      "r698",
      "r722",
      "r723",
      "r737",
      "r834",
      "r867"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r168",
      "r171",
      "r172"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total property and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r195",
      "r547"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r539",
      "r547",
      "r725"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r168",
      "r171",
      "r545"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of property and equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PublicUtilitiesInventoryAxis",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNetNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNetScheduleofNonCurrentInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory [Axis]",
        "label": "Inventory [Axis]",
        "documentation": "Information by type of inventory held."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "us-gaap_PublicUtilitiesInventoryRawMaterialsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PublicUtilitiesInventoryRawMaterialsMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNetScheduleofNonCurrentInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw Materials",
        "label": "Raw Materials [Member]",
        "documentation": "Basic goods that are to be consumed directly or indirectly in the production of finished goods or services."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNetNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNetScheduleofNonCurrentInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory [Domain]",
        "label": "Inventory [Domain]",
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "PurchasesOfIntangibleAssetsIncurredButNotYetPaid",
     "crdr": "debit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in unpaid invoices for intangible asset additions",
        "label": "Purchases of Intangible Assets Incurred But Not Yet Paid",
        "documentation": "Purchases of Intangible Assets Incurred But Not Yet Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "QuarterlyFinancialInformationTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quarterly Financial Information (Unaudited)",
        "label": "Quarterly Financial Information [Text Block]",
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r266"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.cumberlandpharma.com/role/DebtDetails",
      "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [Axis]",
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r321",
      "r397",
      "r409",
      "r439",
      "r440",
      "r441",
      "r530",
      "r531",
      "r561",
      "r595",
      "r596",
      "r651",
      "r653",
      "r655",
      "r656",
      "r658",
      "r682",
      "r683",
      "r700",
      "r707",
      "r718",
      "r727",
      "r730",
      "r861",
      "r869",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.cumberlandpharma.com/role/DebtDetails",
      "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [Domain]",
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r321",
      "r397",
      "r409",
      "r439",
      "r440",
      "r441",
      "r530",
      "r531",
      "r561",
      "r595",
      "r596",
      "r651",
      "r653",
      "r655",
      "r656",
      "r658",
      "r682",
      "r683",
      "r700",
      "r707",
      "r718",
      "r727",
      "r730",
      "r861",
      "r869",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922"
     ]
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesPolicyTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade and Note Receivables",
        "label": "Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable."
       }
      }
     },
     "auth_ref": [
      "r853",
      "r854",
      "r855",
      "r856"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r746",
      "r758",
      "r768",
      "r794"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r228",
      "r526",
      "r527",
      "r528",
      "r529",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r622",
      "r624",
      "r650"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Axis]",
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r527",
      "r914"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Domain]",
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments on line of credit",
        "label": "Repayments of Notes Payable",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]",
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r230",
      "r335",
      "r360",
      "r529",
      "r692",
      "r693"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r458",
      "r923"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r747",
      "r759",
      "r769",
      "r795"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r748",
      "r760",
      "r770",
      "r796"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r755",
      "r767",
      "r777",
      "r803"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansRestrictedStockActivityDetails",
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r134",
      "r542",
      "r565",
      "r566",
      "r576",
      "r606",
      "r725"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r240",
      "r241",
      "r242",
      "r244",
      "r250",
      "r252",
      "r302",
      "r303",
      "r448",
      "r449",
      "r450",
      "r473",
      "r474",
      "r495",
      "r497",
      "r498",
      "r500",
      "r502",
      "r562",
      "r564",
      "r580",
      "r930"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails",
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net revenues",
        "terseLabel": "Revenues",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272",
      "r283",
      "r286",
      "r287",
      "r291",
      "r292",
      "r294",
      "r392",
      "r393",
      "r533"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r684"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Revenues"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r395"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving Credit Facility",
        "label": "Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability obtained from right-of-use assets",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r724"
     ]
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RisksAndUncertaintiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "us-gaap_SaleOfStockTransactionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockTransactionDate",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial public offering, effective date",
        "label": "Sale of Stock, Transaction Date",
        "documentation": "Date the subsidiary or equity investee issued or sold stock, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "cpix_SalesRevenueGoodsGrossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "SalesRevenueGoodsGrossMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales Revenue, Goods, Gross",
        "label": "Sales Revenue, Goods, Gross [Member]",
        "documentation": "Sales Revenue, Goods, Gross [Member] [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_SancusoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "SancusoMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNetScheduleofNonCurrentInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sancuso",
        "label": "Sancuso [Member]",
        "documentation": "Sancuso"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of accrued liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "cpix_ScheduleOfAdvertisingCostsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "ScheduleOfAdvertisingCostsTableTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Advertising Costs",
        "label": "Schedule of Advertising Costs [Table Text Block]",
        "documentation": "Schedule of Advertising Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of anti-dilutive securities excluded from computation of earnings per share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable",
     "presentation": [
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsChangesInFairValueOfContingentConsiderationLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]",
        "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]",
        "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77",
      "r482"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of the components of income tax benefit (expense)",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of deferred tax assets and liabilities, net",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "cpix_ScheduleOfDistributionCostsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "ScheduleOfDistributionCostsTableTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Distribution Costs",
        "label": "Schedule of Distribution Costs [Table Text Block]",
        "documentation": "Schedule of Distribution Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of calculation of numerator and denominator in earnings per share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of effective tax rate reconciliation",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenue from External Customers by Products and Services [Table]",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of net product revenues by product",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r534"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillTables",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of intangible assets",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory, Current",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r102",
      "r103",
      "r104"
     ]
    },
    "us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInventoryNoncurrentTableTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory, Noncurrent",
        "label": "Schedule of Inventory, Noncurrent [Table Text Block]",
        "documentation": "Tabular disclosure of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle including inventoried costs relating to long-term contracts or programs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Leased Assets [Table]",
        "label": "Schedule of Operating Leased Assets [Table]",
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of quarterly financial information",
        "label": "Quarterly Financial Information [Table Text Block]",
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansRestrictedStockActivityDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r412",
      "r414",
      "r415",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Option, Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r70"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r65",
      "r66",
      "r67",
      "r68",
      "r69",
      "r132",
      "r133",
      "r134",
      "r201",
      "r202",
      "r203",
      "r268",
      "r358",
      "r359",
      "r360",
      "r362",
      "r365",
      "r370",
      "r372",
      "r572",
      "r573",
      "r574",
      "r575",
      "r707",
      "r820",
      "r837"
     ]
    },
    "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccounts"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation and Qualifying Accounts",
        "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]",
        "documentation": "The entire disclosure for valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r239"
     ]
    },
    "cpix_ScheduleofDepreciationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "ScheduleofDepreciationExpenseTableTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of depreciation expense",
        "label": "Schedule of Depreciation Expense [Table Text Block]",
        "documentation": "Schedule of Depreciation Expense [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of expected amortization expense of intangible assets",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "ScheduleofRentExpenseandSubleaseIncomeTableTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of rent expense and sublease income",
        "label": "Schedule of Rent Expense and Sublease Income [Table Text Block]",
        "documentation": "Schedule of Rent Expense and Sublease Income [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of revenues concentration from major customers",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r48",
      "r49",
      "r87",
      "r147"
     ]
    },
    "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate",
        "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]",
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg."
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]",
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r292",
      "r293",
      "r592",
      "r593",
      "r594",
      "r652",
      "r654",
      "r657",
      "r662",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r686",
      "r709",
      "r730",
      "r870",
      "r925"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingAbstract",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting [Abstract]",
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r292",
      "r699"
     ]
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Selling and marketing",
        "label": "Selling and Marketing Expense",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Nonvested, beginning of period (in shares)",
        "periodEndLabel": "Nonvested, end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r427"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Nonvested, beginning of period (in USD per share)",
        "periodEndLabel": "Nonvested, end of period (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r427"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average grant-date fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of vested awards",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend",
     "crdr": "debit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend",
        "documentation": "Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansRestrictedStockActivityDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r412",
      "r414",
      "r415",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442"
     ]
    },
    "cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of equity compensation plans available for future grants",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans Available for Future Grants",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans Available for Future Grants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares reserved for issuance under equity compensation plans",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options, exercise price as percent of weighted-average grant date fair value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price as Percent of Weighted Average Grant Date Fair Value",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price as Percent of Weighted Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited/cancelled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited/cancelled (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning of period (in shares)",
        "periodEndLabel": "Outstanding, end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r419"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of option shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning of period (in USD per share)",
        "periodEndLabel": "Outstanding, end of period (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r419"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- average exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholder, percent",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shareholder, Percent",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Shareholder, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansRestrictedStockActivityDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansValuationAssumptionsDetails",
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Award [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r415",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in USD per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in USD per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "ShareBasedCompensationCharitableContributionOfSharesCashContributions",
     "crdr": "credit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash contributions",
        "label": "Share-based Compensation, Charitable Contribution of Shares, Cash Contributions",
        "documentation": "Share-based Compensation, Charitable Contribution of Shares, Cash Contributions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payments",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r417",
      "r436",
      "r437",
      "r438",
      "r439",
      "r442",
      "r451",
      "r452",
      "r453",
      "r454"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options, expiration period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining contractual term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "cpix_SharebasedCompensationCharitableContributionofSharesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "SharebasedCompensationCharitableContributionofSharesShares",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Charitable contribution of shares (in shares)",
        "label": "Share-based Compensation, Charitable Contribution of Shares, Shares",
        "documentation": "Share-based Compensation, Charitable Contribution of Shares, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r222"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r201",
      "r202",
      "r203",
      "r225",
      "r256",
      "r257",
      "r259",
      "r261",
      "r268",
      "r269",
      "r301",
      "r322",
      "r324",
      "r325",
      "r326",
      "r329",
      "r330",
      "r358",
      "r359",
      "r362",
      "r365",
      "r372",
      "r505",
      "r572",
      "r573",
      "r574",
      "r575",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r605",
      "r626",
      "r645",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r820",
      "r837",
      "r849"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r32",
      "r188",
      "r211",
      "r212",
      "r213",
      "r240",
      "r241",
      "r242",
      "r244",
      "r250",
      "r252",
      "r267",
      "r302",
      "r303",
      "r373",
      "r448",
      "r449",
      "r450",
      "r473",
      "r474",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r502",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r525",
      "r562",
      "r563",
      "r564",
      "r580",
      "r645"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r186",
      "r292",
      "r293",
      "r592",
      "r593",
      "r594",
      "r652",
      "r654",
      "r657",
      "r662",
      "r670",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r686",
      "r709",
      "r730",
      "r870",
      "r925"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r267",
      "r533",
      "r570",
      "r591",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r605",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r624",
      "r628",
      "r629",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r645",
      "r731"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r267",
      "r533",
      "r570",
      "r591",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r605",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r624",
      "r628",
      "r629",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r645",
      "r731"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r750",
      "r762",
      "r772",
      "r798"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial public offering, gross proceeds",
        "label": "Stock Issued During Period, Gross Proceeds from Initial Public Offering",
        "documentation": "Stock Issued During Period, Gross Proceeds from Initial Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "StockIssuedDuringPeriodNewSharesUnderwritingDiscounts",
     "crdr": "credit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial public offering, underwriting discounts",
        "label": "Stock Issued During Period, New Shares, Underwriting Discounts",
        "documentation": "Stock Issued During Period, New Shares, Underwriting Discounts"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_StockIssuedDuringPeriodPricePerShareNewIssues": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "StockIssuedDuringPeriodPricePerShareNewIssues",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial public offering, price per share",
        "label": "Stock Issued During Period, Price Per Share, New Issues",
        "documentation": "Stock Issued During Period, Price Per Share, New Issues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial public offering, shares issued",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r95",
      "r96",
      "r134",
      "r572",
      "r645",
      "r664"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r95",
      "r96",
      "r134"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r95",
      "r96",
      "r134",
      "r423"
     ]
    },
    "cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shelf Registration, sale of corporate securities (up to)",
        "label": "Stock Issued During Period, Shelf Registration, Proceeds From Sale of Corporate Securities",
        "documentation": "Stock Issued During Period, Shelf Registration, Proceeds From Sale of Corporate Securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r95",
      "r96",
      "r134"
     ]
    },
    "us-gaap_StockRedeemedOrCalledDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRedeemedOrCalledDuringPeriodShares",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Return of common stock - Methotrexate (in shares)",
        "label": "Stock Redeemed or Called During Period, Shares",
        "documentation": "Number of stock bought back by the entity at the exercise price or redemption price."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_StockRedeemedOrCalledDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRedeemedOrCalledDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Return of shares related to RediTrex",
        "negatedTerseLabel": "Return of common stock - Methotrexate",
        "label": "Stock Redeemed or Called During Period, Value",
        "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share repurchase program, number of shares authorized to be repurchased",
        "label": "Stock Repurchase Program, Authorized Amount",
        "documentation": "Amount of stock repurchase plan authorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount available under current repurchase program",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "documentation": "Amount remaining of a stock repurchase plan authorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repurchase of common shares (in shares)",
        "terseLabel": "Repurchase of common shares (in shares)",
        "label": "Stock Repurchased During Period, Shares",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r95",
      "r96",
      "r134",
      "r575",
      "r645",
      "r666"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repurchase of common shares",
        "label": "Stock Repurchased During Period, Value",
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r95",
      "r96",
      "r134",
      "r580",
      "r645",
      "r666",
      "r737"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total shareholders\u2019 equity",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r98",
      "r99",
      "r121",
      "r607",
      "r623",
      "r646",
      "r647",
      "r725",
      "r738",
      "r839",
      "r857",
      "r908",
      "r930"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shareholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r83",
      "r85",
      "r188",
      "r189",
      "r212",
      "r240",
      "r241",
      "r242",
      "r244",
      "r250",
      "r302",
      "r303",
      "r373",
      "r448",
      "r449",
      "r450",
      "r473",
      "r474",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r502",
      "r506",
      "r507",
      "r511",
      "r525",
      "r563",
      "r564",
      "r578",
      "r607",
      "r623",
      "r646",
      "r647",
      "r668",
      "r737",
      "r839",
      "r857",
      "r908",
      "r930"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity:",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shareholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r224",
      "r357",
      "r359",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r373",
      "r501",
      "r648",
      "r649",
      "r669"
     ]
    },
    "cpix_StudyDrugMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "StudyDrugMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNetScheduleofNonCurrentInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Study Drug",
        "label": "Study Drug [Member]",
        "documentation": "Study Drug"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublease Income",
        "label": "Sublease Income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r519",
      "r724"
     ]
    },
    "cpix_SubsidiaryInvestmentPurchaseOfShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "SubsidiaryInvestmentPurchaseOfShares",
     "crdr": "debit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in CET",
        "label": "Subsidiary Investment, Purchase Of Shares",
        "documentation": "Subsidiary Investment, Purchase Of Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SummaryOfOperatingLossCarryforwardsTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of federal and state net operating loss carryforwards",
        "label": "Summary of Operating Loss Carryforwards [Table Text Block]",
        "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SummaryOfTaxCreditCarryforwardsTextBlock",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of tax credit carryforwards",
        "label": "Summary of Tax Credit Carryforwards [Table Text Block]",
        "documentation": "Tabular disclosure of tax credit carryforwards available to reduce future taxable income, including amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleOfTaxCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total federal and state credit carryforwards",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardLineItems",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleOfTaxCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Line Items]",
        "label": "Tax Credit Carryforward [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardTable",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleOfTaxCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Table]",
        "label": "Tax Credit Carryforward [Table]",
        "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_TextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Text Block [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Axis]",
        "label": "Title of Individual [Axis]",
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals."
       }
      }
     },
     "auth_ref": [
      "r852",
      "r913"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual with Relationship to Entity [Domain]",
        "label": "Title of Individual [Domain]",
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r297",
      "r298",
      "r300"
     ]
    },
    "us-gaap_TrademarksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TrademarksMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trademarks",
        "label": "Trademarks [Member]",
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "cpix_U.S.ProductAssetRightsSancusoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "U.S.ProductAssetRightsSancusoMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsChangesInFairValueOfContingentConsiderationLiabilityDetails",
      "http://www.cumberlandpharma.com/role/VibativSancusoandRediTrexProductsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Product Asset Rights - Sancuso",
        "label": "U.S. Product Asset Rights - Sancuso [Member]",
        "documentation": "U.S. Product Asset Rights - Sancuso"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r52",
      "r165",
      "r166",
      "r169",
      "r170"
     ]
    },
    "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceOfDeferredTaxAssetsMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance for deferred tax assets:",
        "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]",
        "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward."
       }
      }
     },
     "auth_ref": [
      "r841",
      "r842",
      "r843",
      "r844",
      "r845"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesBalance",
     "crdr": "credit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of period",
        "periodEndLabel": "Balance at end of period",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "documentation": "Amount of valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r238"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Charged to costs and expenses",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense",
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense."
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesChargedToOtherAccounts",
     "crdr": "credit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Charged to other accounts",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account",
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesDeductions",
     "crdr": "debit",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deductions",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesDomain",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "documentation": "Valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r237",
      "r238"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "documentation": "Information by valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r237",
      "r238"
     ]
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r232",
      "r233",
      "r234",
      "r237",
      "r238"
     ]
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "documentation": "Disclosure of valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r232",
      "r233",
      "r234",
      "r237",
      "r238"
     ]
    },
    "cpix_VaprisolMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "VaprisolMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNetScheduleofNonCurrentInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vaprisol",
        "label": "Vaprisol [Member]",
        "documentation": "Vaprisol [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Axis]",
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Domain]",
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "cpix_VibativMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "VibativMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNetNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNetScheduleofNonCurrentInventoriesDetails",
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vibativ",
        "label": "Vibativ [Member]",
        "documentation": "Vibativ"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/LossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Diluted (in shares)",
        "terseLabel": "Weighted-average shares outstanding \u2013 diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r261"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average shares outstanding",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/LossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic (in shares)",
        "terseLabel": "Weighted-average shares outstanding \u2013 basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r261"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_WinHealthInvestmentSingaporeLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "WinHealthInvestmentSingaporeLtdMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "WinHealth Investment (Singapore) Ltd",
        "label": "WinHealth Investment (Singapore) Ltd [Member]",
        "documentation": "WinHealth Investment (Singapore) Ltd"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_Within30DaysOfFirstSNDAFilingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cumberlandpharma.com/20231231",
     "localname": "Within30DaysOfFirstSNDAFilingMember",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Within 30 Days Of First sNDA Filing",
        "label": "Within 30 Days Of First sNDA Filing [Member]",
        "documentation": "Within 30 Days Of First sNDA Filing"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "b",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(f)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21C",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21C"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20,24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "330",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-13"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-14"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7,9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "270",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//270/tableOfContent"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350/tableOfContent"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//805/tableOfContent"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "c",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482964/270-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Publisher": "SEC"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "4",
   "Subsection": "08",
   "Paragraph": "(m)",
   "Subparagraph": "(1)(iii)",
   "Publisher": "SEC"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482964/270-10-50-1B"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-12"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//705/tableOfContent"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-4"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483049/450-30-50-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480682/815-20-25-6A"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>115
<FILENAME>0001628280-24-010725-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-24-010725-xbrl.zip
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MA13V:+3FJ<NS1=L;NS?UQ+_EOP!02P,$%     @ PZEL6)I-(E,D"   >C$
M !@   !A,C R,RTQ,&MX97AH:6)I=#,Q,2YH=&WM6VUSV[@1_MY?@=K37#(C
MR:1>_"([F7%\RISOVOC&<7K73QV06)JH28('@)*57]]=@)1DRR^*VYREB3,3
M621V@5WL@V<7('64VCQ[=Y0"%^_^<O37=IO]J.(JA\*R6 .W(%AE9'')?A-@
MKEB[74N=J'*JY65J63?H]MEO2E_),??M5MH,WC7]'.WXZZ,=-\A1I,3TW9&0
M8R;%VRT9Q4E_$(;1H-?=[?>BF/,]?B""WNY!/]X''OX[W$)5%/<ZQDXS>+N5
MRZ*= HT_['<[>X/2'DZDL.DP#(*_;3G1=T>)*BR.IU'??_7=+'5FX=JV>28O
MBZ%S:<NK-LVQRI0>;@?NWR&UM!.>RVPZ_.%"YF#81YBP<Y7SXH>6X85I&] R
M\8)&?@&T"<USEQ-O\A[VD\D"&A?"+AD]NDYE)"WKA9WPIL6+CG-]B;Y;50[)
MZ0738YQKT,]D^\GH_.+TP^G)\<7IV4=V]H&=_'0Z^L!&OX]./E^<_G.$M[!U
M='ZO7^OBR*^?SS]]/OYXP2[.V*?1";GS:CO<#0Y[01>=6'O[+WX:L4_'Y^^/
M/XX^M<]^__OH7^SXY((BT@V"[BJPVB^__0+HWVG[:8L==W[NL%_X%YG+%HM!
M6YE,F4VY?;4]V#]<,O]Y[/2 N'<N2RX$,F8[@\0.>T&GO]\L5%D(Q,:P'3[?
M'(>=QNX_?_3#&S,3!IT!3<,I2_D8F(:QA FF&YM*PSXHG;,P:/_"5,).JCP"
MG?%"L%]3KG,>0V5ES#/#3HNX@] XV-!H=-<N&N^YP1BH@N53=E6H20;B$EH^
M*!I*I2T3"DTH%!8(. *7!>/%E%6%U16@!U@RN.H!X\99CE=:\HPE/,9;FJD<
M$YQ57FY)H( 8C.%Z2B(YOP(<=Z%/@_<$&H-#9J[TP#%(()8:2PT4*U =+1&@
MV225<<I,11]S_0EHJ#LA!W)I,JQ)J+R92)NB@Z:$V!E(_99HFA+HYAC5!(NF
MB].PP:CK;0[J@"6RP+@21.9Q;#'B H7->J%=%@FR!K<2^Y%%G%4"^T2L+ 2M
MA3B3.INR$D--*"7T9MD<AC4"S*VA$>E"4L<MDJ@R%$#L*02(&\XX>V)N4I9D
M:F(:8&JXE,9JC@-QNNGM1BM;"_@RC3%+UFXPQ/IK![&+&_%XM;W?#?<.30VB
MNM(@(E!)(O'21>J4<0T.$QAC&65 L6. 0(PR:5(2)[$<29"(D*Z%-'&F3(5Z
M1(]:91X<I58Q"+QMV&O$@@ $EP_XZ#I.>7$)[!B9Y[S*4"+L\78X> UOG&HX
M$/[*7TJJ+@L/2NJ?$3TM8-5CAVQ9>:#DQD )#D1^WD8P2E"FOKL2VPA4\O5!
M9=@)]F@>?@2#>P8,D$M5CZ.G15DTYI597872602(A'HDGR!5I;$#I*"Q-([8
M4 H*UP_5VW-*7*15#1EWT*HSY!P>K9IRJ5$B/:(M1F52N!,$4T5&"LFU) >D
MS^..Z OJJ3*46]U*-"X1.QI4!M @B[1+2B5'3,=5QHF]T2UGQ#Q'HX;/^(N%
M"GZ+@ 218%$?Q 83:K0^T*T)]29R5V:E)0"OSF<KXQBQ/Y:"X,F-*C@1-S<(
M;2H0";-<BP8_B&C)(YE).Z6L?=>PM)H<U!R*_$*X(;I08+K\<%T[5%:Z1!0;
M5V7$L=+"&>!*S4LHL'C($,S8 B6M$A+!,MH#%E>3+)&B-QBR\?I MF';T9AG
ME:,D"B@D"=9Z<HRA,'?4;+,:806*]9=WEW$.HJB(]&A\L1BIRMYOP2I)@,^D
M@2KAY/']"HN:&MNM.O S@?8XA-$ FXDRL3XH:XC1QV\9![1/KDLPUW(GV+Z"
M#BE-JSBN-$5[(2?>T6NNC,7[=#2)?9D8._JCPI2*7;^^1R5!V")1W9*N#<>]
M#K@M/NW^BVIFUQMO5<K-K( @BG,P!^&XW\U'S<M3W,A?05;O]V_)M_[G*?+0
MWDQ<#]8.UT_;0;G#/=$LB=:<AH@5%V$Y9R0"UE?4$TNUZ,PTCO6H5=K,4KB[
M@5WFN;06X '.CQ06"=0N)-KG.GF-X$6*-43A^)>JXF;%P1^51//=ZJJ*V)T)
MO-G@C=+NVH'O.,,Z"^L^B=BBW2CM:V,)"(8Z^\[V*Q/@5Y1.?=WE$JJK&-WQ
M8W-B\U40J[<6_BS@#N;B A4-S(CK7CC6=2:J(*:P'&SYG&XPH9LJSW%_] 6<
M,W7"N/-L:\/S]1KNP8\Q+R<:N:&%D09'9X@5=T!<@ZKETYHLQBH; ^6V@E_6
MY]RZ9D#(RTQ- 5LGJ?*TQV] %B'V?TG\LPFT;F=3SV"$> +=QHG,>&E@V'PY
M1.XM,SX=RL)-AU,ZK)_W1<I:E;LGR6,B<,ST]4-,!Q??7#]9/SCH],,!/5RW
M&O^+9N#ZN7O'/7??L6*YK1]T#@;[]S8'G?!);=U.+[A_T(<T'S*VUPG"O6]@
MZU[_:9H/V]H+G];KP[;V^T^;@4= T.WNKM3MC@.8;@2:!>SR "DBM$W)B[=;
MO:U;E#<,6.BDFC%FHKO/(5H[\IC1W?*:M!9?YB""NKTD_6K\\VG;+;)_<(TI
M,.RVW/L^L]1S>T(VT[E;#_0?=^I>0'PG_J_HE%7E,WGT?GJS^GZ)TWK&Z=5V
M'VL?][GX[L\-%U=DT>]]3;[X_WWZ7Q?^].H>^L3<4S?6V+<Q1/"R^%_ _^+_
MMT[TS^K422HA8:-KB"MZY,7._#GQ\G+?<6<4#[]D_9_*T'GSUKUO^2^HW?JA
M0*F,>Y=KZ-]F&,/23P?FU.J.1X*Y"H^07RN[K/+(KPWJ3__;AQWWFXO_ E!+
M P04    " ##J6Q8_,[#8= '  !J+P  &    &$R,#(S+3$P:WAE>&AI8FET
M,S$R+FAT;>U:;7/;-A+^?K\"Y\RER8PDDWJQ9<GQC*+*$_5:.^.X[=VG&Y!<
MFCB3  N DG6_OKL@]6;9CI)<:CEQ9^J(Q.YB%WCP[ +$<6*S].0X 1Z=_.WX
M[_4Z^U&%10;2LE #MQ"QP@AYQ7Z/P%RS>KV2&JI\IL558EG3:[;9[TI?BPDO
MVZVP*9S,[1SOE\_'^ZZ3XT!%LY/C2$R8B-[L"?_@\*A]='C0:OOM-N^TNT&W
M>^AUVI''H=N&YG_\/51%\5+'V%D*;_8R(>L)4/^]=K-QV,EM?RHBF_1\S_O'
MGA,].8Z5M-B?1OWR9VEFTQC75VC/JKS714,6;FR=I^)*]ER$>Z6EN72H4J5[
M+SSW7Y]:ZC'/1#KK_7 I,C#L#*;L0F5<_E S7)JZ 2WB4M"(_P&ZB)VXQVD9
MP2':286$>41^DV(8W20B$):U_$9S/8"[7>^LNQ[BT(-^)-^'HXO+\>EX.+@<
MGY^Q\U,V?#<>G;+3\=G@;#@>_(ROL'5T<6]<NQ+(^U\O/OPZ.+MDE^?LPVA(
MX;Q\X1]X_9;7Q"!VWO_+=R/V87#Q=G V^E __]?/HW^SP?"29J3I>5O!"E?$
M5_>]?:?OXQK[2262_=)@[WB6U5@(VHIXQFS"[<L7G6Y_P__'<;1$Q):#V<]Y
M%"&AUE.(;:_E-=H+SA$R0JSTZO[CC;G?F(?QU_>^/C*^U^C0,(Q9PB? -$P$
M3#$;V408=JITQGRO_D^F8C8LL@!TRF7$WB=<9SR$PHJ0IX:-9=A I!SUOZ$I
M:N[<%+WE!B=&29;-V+54TQ2B*ZB5,Z4A5]JR2*$+4F%1@3UP(1F7,U9(JPO
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M:R/F)(AJOQBDCP1)OC.0;+4;G2,:AQ_!8 6(L^,XY>/0J1'=A;PPVZL0[P2
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M"W73Y!MO_*O/\O>'/?.[QS]02P,$%     @ PZEL6-F*X+6P @  50@  !X
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MG:-6%F9SL<F+$EO8##GE#&EYE]5/QS5S0MV78V!@4VUC1(&+$78=N9F0#M$
ME<1V7_ZD^ZI 5FRHH[+:E[4%.*7-A_><UX;.M/78B!;XWL?>*_?K7VP\MTVW
MM^)DI-Q(3CY/OYQ>=LG9V<5_P/R<JF*)90E=<@6<@U( _P@UU_<D"%U_Q2\Z
MF7Z]!A="H=WDJ832[/8E/'DQ9D)K4:7^'81F9E_5^B'D21+WQO9:WW>_$S\
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M07>/!@]CJ<?8+1H)=+5JD%29]6*_WR;&A@)M(1T_,@WXJ#@O,C0UR^)(.BP
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M?/@,XU.<6FQ-*<CRLWHM@.W;=S[/(OFV:EDFSA7'*6;>B8"H*'4E5I5#M(Z
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M5]\Q7]^UQ[_PF]E_H3?"_PM02P,$%     @ PZEL6);R/&:X$P  O'   !4
M  !A,C R,W$T97AH:6)I=#0Q,2YH=&WM'6ESW+;U>W\%ZC1M.K-2)-F)'=GU
MC"*KCJ:-[9'DIM\Z6!+<1002# 'N>OOK^PX )/>PY"9I*%4>V]+N@C@>WGWM
MB[DOS<L7<R7SE[][\?N]/?'*9FVI*B^R1DFO<M$Z7<W$#[ERUV)O+XPZM?6J
MT;.Y%T<'1T_$#[:YU@O)GWOMC7H9YWGQ);]^\24M\F)J\]7+%[E>")W_Y9%^
M]N2KHZ^?JF=/GQQ\_>1IEC_+'Q?JF^DWAX?PQM<J^]?A(W@4AO,SSJ^,^LNC
M4E=[<X7K'S_^NO;/ESKW\^/#@X//']&XER\*6WE8K(&'^5>>8V,FKS[X/6GT
MK#JF\SSB1^/'F36V.?[L@/X\QT_V"EEJLSK^TY4NE1-OU%)<V%)6?YHX6;D]
MIQI=\$"G_ZV.#X]@>_1RR?M]"O,87:FX_\/#KV#39Q_F>JJ]>+)_>#C<\<=.
M,[+/ML T PQ0S6\$U%=GEZ<7Y^^NSM^^$6__*JZ^.Q,79Z_/+Z\N3MY<_?&S
M9T>'3Y]?BM.WWW\/ RZOWI[^38S^3'R LXNS5^+=^XO+]W 2<?567)Z=TC$/
MC\))1W\0V/'[B_.K\[-+<?;/T^].WKP^$R>G5[C]PV\>/_FYB/=CZ[PN5K_X
MX0[6#O=DZ^&NYDIDMBQM!2O;[%K80IRVY50U1E:Y>#>732DSU7J=2>,FXKS*
M]L47 G'RZ.#Y4DWHM\/G\1W;-NMOM2Z^81OA8;WP_JDM:UFMPH=_%MJ)1LVT
M@YM&9E[EJA&7*O,:]@;8 AO#A^&=MM%> PC./F1S6<V4.,D\?HRW,1'2"0GL
M/%?Y?@3_KXLUVP$K-BGT%T&,J<RN9XT%\.R%HQ3TY_G_ZF"(,84UQBY1VH*P
MS1I=TR7!%<#U#]$)+E4*UY:E;%8",2JWL)7*>E&W36T;+[P54\+!VBBO]L6Y
MQX=<._T1[AX_Q:=^:@$FA0:\T)70W@E@"+I1?B6F*\": E"FRA2.1AR1F8?Q
M A"I=/1XW=B%=K!'!PM57L*A:";<[M5<-[DX892AT1?*>5(H3@'[89(^3HDO
M^AC,GT<,GM#3."<@J:UV3/KMRLBE&\S#;W739+9&_ 9XR@: K0W.@2<1*DA?
M.BB Z:2J\*07BD )4/^K;4IQ>+#W-UH4']=59A'2M/@< *4KWF@$5ET;(.ZI
M47TPP=I7JJJ4<TH)V-V^^$$!T#,XG02*6]D6GP?%BP\<($'SA@/2$K>>'U *
MGLYSC9@$)](5O%%*?+5_YPEINUPY:?W<-O  ()JLM8=3W_F3;F<9@#J(B;([
M,.".=JY5HJWQ]\.C@PEL ?\)!ZC$R)\%J! GF> [R[G.YH#>W>A2KI!]]![J
M<9^)J&4C%M+ 0G\XV(?A-> HC642./K(1#6Q%11%-\VU+Y G!G$F0#P!,_)F
M)>82.=WZ1'SP// *#URARH&3[HL38Z*0ZXE&T/Q<?]R.HS*G: TL6TO-LU=
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M.$Z<P@AXLT+?TR4A13KL'S][_.PYO(3])8>/=H0!/HZ1"2!- L@6SG]OW9H
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M4F^(KC@=.0M1(;XH6M]BRQ\@]*7BMI:#TEQ,$DIKKI'R!/W5.VM4(TL*%B%
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MH&,'IJ'B.[^F;I2EIO)GSB_%UZ@'D$Y\7CG@KZ'!HQR B7S(BJU4%#KUJFN
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M1GC0TV?]A%;IGK;;#VD 9S$]KWB(?F:J\H3^(D/J1+\JK1Y?U7PNB9CFKS#
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M4<:\_I"'<-]XL2,/&SA:J/&-O>DV;Y7^U<TF\E9YEIS@%^;'+TA;'52V<("
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M7@&62$@4"K\O0410?KS[OH1+3,&:4664$V4[:X*OX$Y^E =\-/'/M'76I0
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M@ZN!]",Q4 \;;?#RF'#]6GQ=IN#5JJ:.U$ .$_$?%8&< ULE(<9S!B,_1(4
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MQ+$1J:9)9!U(VSR'1V!9>B/,U99<$G8S6EPZD6(R*8]8@'N*RR#![Y#LVID
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M'D=EQT7%2([>R!8XW4E.E)#M#>^DW4C'I@"W3Z7CS71K$;DU9)RM=<V%KL[
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MC)1@LC%TM ;R9.D>II.A]S& ,&/-@)TE!R[H6V$&FVJN(CR=V#855$:P"[9
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M&=]M<E7N>Z!&8G";&_P'MPEA2SC6,'/U?AT)JCM?6?QUR!(QS\5Z)'__I$K
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MIC,PP2:; DGS2CF"!B=YD'(MEGS0 XTY?>0%8D"%@Z?E+=)US?A#!F[7(?)
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M.E,.3A.50,4DBT&8^N$0;[ETU:%EA/";2!)X,GGAS@UEG')ZAJQ?+H?*:3B
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M5D&&0-;+<_QYI&X[MYB+K3N<C/O&"J2$=ZXJH'>A_/[]3$K*S:I\UJHX/WX
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MG>Z\#(Q0CO8Q*V(MW7WV25S^-CG)M8WK%FZ':IS#-GX./I^4C*_FUJ^\N:7
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MZI*'*8*#=,N<>;N@Z)-XX;M>>3(+4&^D%9CMD>GOYVW!<[#'2C!Y";W+):)
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MVZ>(O& RM1,$SS_0_1"\'UOU\I\&L2RVW9$^R:MK6SR0%[0%R4V&.Z(!+W7
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MX;SGQ$PPN_F80TB(!RYLS$9?9A(P;W+LD<^2U$N_<P6AVJY386:^2CEQX)M
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MK;@%N-:PTX5B\Z+VY!85,\4A?>5HJ 9J)&DG'KN^B(8D97Q-8H(KP.S%__#
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M"MU?9FP)\4)NAA75[NY4H%5#9GX[>K50JAS:E TXA3B;?FL^#4V]K*J;[Z3
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M,\^9E7"8"J3)*:$X 1=A^O+.T@[MTMR:B"E7M&1E7&1U$,8V>5C4'?850D8
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MR"]*WN-C.S"J04&PQP0;TM<S/)HY !41"DH^-&?5%''"2\]O>AB6%^FS!.L
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M:NLYP;_1V6R3/<%:U^LBZ26)9)3P[MHA1_Y4I =9G+F@%V*G+;F3 AKSZ3G
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M[]EN6BP#6AR+G$E@I_D*36IZ 5W%83H)6#@ON7"84U2Q)N[%R;QLEKQ&$86
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MBI(71"&>3YL:5*T."A]7JRAE! /X42CA0*>Q+JJT6=<7,AGSD:7O7J<(>(U
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M=;=V@B0N4 %DU5U4J&]456&F:7)ZM!0.G#A<P#@ *.&NY9YI1(_E9CP&1&)
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M&0GY@JIK8EEXJBX1QB!GCI(BN#(TM^)>)6V2L8.1E$R0<"O;<]GQL7:2? W
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MVFV8PC'U]Q!,2]ZW!6-FM5YD@SF@=G-GR%I !QD9'48CAFT57>\N8C\4YK[
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MY/9S=GE9.I'#8+Q'3J9ST!,P'@.HX*+M'T)SD( )9.:F(/S!8:C@.1&]BO&
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MW9E]I%?VY-(71O8X\N+0/TYSTFAB1;V6,GW6:OHTVGIK=D$61<\5S?-N%\R
MS3I]7X\]><-<[RYB/UZ9*7EB-0R]TUD]LU=9*AO?&L-LZ6U3;<T>;HUI-'6
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M"NRW&+?T>KVK6\W&?$E> R$V:]4IGGT]/-O0ZT8'SNWS2^'N%\^^0#D]O^C
MNO>G63.7N!.?=5HV:YT%3N#-G/$[RU4?H/C]J21^S+O!O.*?#(SWIIAO$>F-
MT3*%7 U:*8^AL8MQX_9]Q/B_PD%%N/@+PG /:V_-G>XMQFA(^R@/A\[RJF3"
M,04K%;)AR>U42/<4N9H4/XO!JQC.A)L_MCT>/=Z?%'D"XV;M*,M^+,:[BH\H
M?RLO$6%TUA\'=7SA,")^6(7#J' 8%0[S\G"81<U=53B,"H=1X3 J'.90_&"%
M2)AUN]S5[?XA>0F6:^R]SS<(BM\.B=\,2V\V%[<\?[67(BJ<9(M1DL<;^&#H
MIH$MLE4?M/52M=FP +MVT5A7&;(JG&33Q+1TJ]T$U-@KW:PVJ'BG!\=>O;X
MUE^M\;2++9&%.E1$B;J=7RTRM=[2C461>WMU.Z]X]G7S;%OOU+MZM[V@J]%>
M\>P&(TI6*;YY6'$(NXTQN2N4O]KC. 33/,KR<+T1UG'ZAU>>H7*E(Z!8A&$)
MN^U[,F=B>9&?K(X5+ZQM\Z"&E%>RHB)0]IA(\0]Q4F(']QYU)XECEL2%"FO%
M8L&R-B4!$)9;LQ,,TM"U)+)=A@7=8L%9^#D5\0E$>4*LC#5GWLB&%%&58-]!
M9-!R?Y9.S2@7LN.UZ;RGI>FL0KL64:3+QD_SBNQY74-)BZS6[5-*'"5K7P1.
M.,)^-#]RS\ N6+FF%6>2[?U/C:;>;G57*52%[/13JZ-WFO55FO0<X^;RHK4>
M$;:VT_*Y%T%61@SPR GO T(;$$>ST-X@8KS:W" KHI?M(-=<I-P(''"7<>-0
MJ/N$9BZO5A?1FJG^7-::0E3=@^,^P,ZF6E4M8WP 9.]Z&]"B3*@&HJP\/;TE
M][87B"*'>0L7H"T/3H4'8!KIP'82KO713DP3WG:J]&.KU$/&QM!5K$4.>Q'P
MTH8VKR 73#0 8-(]<0KVA .[#2:P,ZD 7,_]GS>>U34[MM4PFP,V:!B=1J?>
M:AJ&;36-UF!@]XW_9YCM-R^(C%45X*8JP+6/I@+<AHX>B^-S2/R^7/SKV\6G
MB[M_:[W+3]I9[_KBKO=%NSF_O?IV<W9^>Q J:+["(=C%BK\3.'NDD<,[3O@>
M'!Q<+#J-W24<.QYJ S]\I+X##Y[+^W90C=$LOI<WC>!]AF(-3LA1^"@.*Z**
M-=JPU$X ?TAU1K'+081E]_/RI_@J>(G#F%OH9,$KE_K:&,[@GH-]\%@D^LM@
MFP0LX)Z$SG<8PD[HL(0XY5/'/4"W7GH/5 ?LK'>I6FH?CHCL@?&G^?#4H\8'
M:_6>BG#B#_-5ZV":>S'=R3R&T7>J=LDM\*P-Q]1R'@%'4<N!9?UWBOV74--1
M1";+7J;= X62H9Y]T4]C&"6.2X5F"S5;N:5$"E>^GHX,\,(T*FA>^%]0H(P(
M/DCQNT(I_L-EU5XRPX(DLLSJ&@>;*K88*,B;R5"[CA#.01[N IQ20"U2]PMD
M?*0_\$6@!3 !X'\7$%$31^NL(#:55H531QQ[ X_1=\0ML-G> YC!&^YOM,T
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MY QQ>^*A'7%J4N'40K&HA=5!#Q%4>C%P8R)[[%+U1KX17)R6(HR.=7OR;KU
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M!"E5@Q?$"?NP2%O(UO*Y:;,.!IN\U5Z1'\[@B0B))$O]%99Z^&RP1-ZB,X<
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M:MKO]C_>R)MOH--90(3T[BY2:YZ@\U5HY_FB>W+1NPPM$R'/;W7M-V^D_<H
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M)@>6_S,34@2>6%-X8II&HV[.P9/,#69T$5*,U2#EV;;-FMQ",Z\?MU8LKK*
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ML&1(%X=1>)_Z\??CO3M4"*P0>.;ZMR,)"H,5!C^]KX[9>*B=U;1?;!^+VB@
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M+8..S9;8_XL )O.=LRQ(+I_-B)*1O$1+Y<2<R(.7>K86LP1%&G95E,&@ KS
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MJKD)C\5GK#I$M^S<=[F_8AXYC04'1J^A.6SL3FTO^I]&6WHSYE'SWK9G[Y'
MSGT'_[I,J>L\QAY3F,. &<>LH5'4.083]U?\WI]/FTY *<KX5* W6!5&SQ;N
MD$'CS!CHEFGH/>SCDQWL&;<,=MD=R;L;[])^CK*:1TZ51_JOSR-#X)&AWN_V
M]6&_71(>>>%<E<8X#)2M9JGC7[4GW; "ZL'Y,BR9KODL/IBV:!9;Q5PI6&U1
ML?XXE1MRD^S'-Q8+5;Z@A.BV&V<H( :ZT>_M*B#64/@A#M&:E'8_=?9)2@8<
M-I9N]"R]-S!*0DMOQXB3Y7:4<K6M=-[$Q;*.I3;54:O-4NNE<U+W")Q4E(7,
MQEE'[[6'NM4S2Z*NU:3S>M)X%]*Q\" ?@/#M[BY\7T?3/R$5F=+J7$>IUQIG
M/*NUJGPD82PVYO+7C/D1 _OZ.^X.+U/?4LWI-,XLO6UV=;,S*(F64U/4Z\GH
M U!4ERAJT-&'_;)0U#[U9JM?9M%]1]A3>Q#7>U* 5H8GU0CEB7+>"VZ/77BL
M!SS6U?M&1^\8^_*$;KQ5%="[WS+9O> BV87L^F#0=?5!OZV;U2"[DT]Y^!;X
M32GMW=1G4FOH1W>7),U!BC(91H)-?=#NZ%US6!(%JB:A8[A-MB:A8>.L#]33
MUXU>OR04=$))BJN<)L&,A:)C 68=S7A7AMIY?4Q_"=^3:\_V8S!N+^6V%/=(
M]MJ@<O?Z^K!ME<0?61/2:[I)]D=(1N/,''3TMK7SX5XNQW9Y1?/5,E)'G?!Q
M/*G\V85;V1?WD3GISG"[= MV,H&=3+W7!M%LE,7?6%/3ZXGF_5*3!:=\6^\.
MVWKOU+S7Y97/?PC VUI//I)$EAM0E%LZC;.A :I,NRS9N#71O)[@W99HNF4C
MFI/7?[_/"-K(O]<\AA"=M![-8-)$=.@ZI>.HHC?9FR^X-3?XCN^3'Q'78(JR
M5J]QU@/%I:-;PYUKB&I5N(2TM%XB[Y66^HVSKFX: [VSN\>K5H0W%-24;'?\
MK(T3YZ(7)'*: ;5U!*8W:)R9>F]HZD.S+/FK-0V]HB3>!PT-D8:Z9EOO]<I"
M0_O,@:Y"(MUAE..7[MDM>ZG"%=.%YW\Z\F239,&" J3?;IP-#+W?[^GM?G=/
M.EPIL@1KWJIY:\\9D45YRVB<D7;7U8WNO@(%KY$**0<A%K-'N-&OC%FU1\PK
M:X9]9N88VEU<J(J,[H2\C_GH;5^NSC]>?;FZN[J\)=#1R__WX^KN'S4XU_[!
MN<I  ^N1V90F>MO!LY5$ NW]_K=37)K@K\SL9T1H>&WCZ@WH>">JQFT&(W/-
MR6J["I>^V3C#V*35UWNGE'Q?,\6I,L5F@#B[,84%3-'6!\90;QLU%,ZQH_?C
M95VJCA65(GK_1385WI+/$(NA,]#;PQHMYQ1)J4CP?E=2ZH+([IOZ<&]ENF6*
M')5<7F<0<W:5TG5>S)XB^E_2C=B2IWJ$"-@=]O2N69;<\)J,7CFHOSL9]5$T
MZ]T!%JR<HC9=A;A^R73HMPQ7LEYT[\YNF(D%K#8P=;.SKXK+4@3!:]H[L+S?
MG?8P@VN@=_M#?6#MRZ:K\7)VH8X;]AAXC^1,@=^P#? X9(Y;%P,?3< '_OT=
M"Z=?X!W?)Q>T&079;- FQ)S^H*,;G;KNX11IZ 5!O0<:0KCWGFZVV_LH3"N7
M5EY>:;SHVO85-+.2J.8GSEA;N;>W3FD?F%14- 1&Z^P,3%7[N$M(3UOYN+>G
M)PL[#'0'/=UJGUB)1(F%-OFW/3ASFS$<NK6'NPR">L$UN3U'=;"$N-.U]&ZO
M[J!TBH14S,>]/2%U"8-RT-7;1ED2J=Z:E[LD*O1;]C!N[-TNREX]T*1-O4LV
MZ\Z"NG9KGQ31;>S6+DITB G1TX==0S>ZM3^[#(+^(IA.W1B12"/>\QSN@($S
M?WQ(=7R#^S?:5O[PH@+U5^2^]UWO?QIQB#V$%QH/IPN"_8?5Y4C(> "O7"3>
MDUJD_AX6:;ARD4[>+8GHOO%S7:#T-@N4;A_LD#T$'G!F]-__W\ T^A\(SWU;
MBMB3K"C=_:\J!ASW\7@';(!O#<8_-2('XX.V3A9?LY HJ)@EP%]SBV_Y%ES;
MX=]L#\6VJIY-W%_,:?Z'A<&R9C9LKS\@5@UJO::XZZ",QID?Y!PB"U]H,SO4
M'O'9:U8VPN%':\=_]>WSFAG0_*/S>?P0A+#_3D'==VBN6>'\P?5>;W!4H4.A
MR]SPY?*2\Q%K=O+&PDM?>';?YW$4@XX*O%]T>IW#K_U5%,V+KWN7R@4-T] '
MUC)*WO*RHXI^:!+?89U[A=>Y\.BV6^<^K;/5Z^F6L>SM6$G>+KV,][%-5T6S
M(TS\^<3&;#IB(3=;+4/7S+9IT<7PP=0U>,*,P0,?F?><G/QT$-6!Z%=VE"ED
M1(?0#C0.QE^GK[>'AMYKUW56ITA*&RLUNY+2D$BIT\=6MV7I"K1/.\WLEME.
M.Q^/Y].Y9\<@X1TV<<=U%F?!%?QM%P$=P?#_I]%<9*\;%MOP(N?2#GU8CDC9
MI4]\DPIR&0R5"F8Z@X%NY !AOJO#T96FJT5I_7ITA2F?AFZV!_J@4P*Z>FO1
MZ6BEGZT.5I=1!R>52>P7]Y 7YCCLU34$O=O2.SD<5\+X84U\)=':]T!\V-JK
MIYN]GFZ\J6*L"H1<,,L,+@H#ST/_C MT$;*H[DI3 GW^J^L'(;#;E=B3PFQ'
MH#:6WNTO\URMNE>;A#94W7<FH2ZJ#:9NF,NNWUI+/["67FOD5=+(K_RQ-\<%
MN0Y"?/AY'(?N:!XC^-]=D#UFMV;''FGQ9G>H#WHUHD)-L+MH\:]"L'U00;KZ
ML(]-)RN1*[U/S;\S+/\AHQ0J4/QUAT-GC>JV838FWX8\[/ZZ=\C>%NAT)-[&
M%1[GOK,'+\;@<#U]]K"O)86WKCF[YNP#EM'LA[.'A^LH="3.)C7F=]+E9.84
M_"$'/;7#>]>78QO ]HEO<#"#+(>-&>I^"S2S<M:O0$PF98HSIMGC<3"%03VC
MX](/8GAZ'" AT5)2<L+$]6U_[&+(*X8OJ.RBE4TH6[LLJ];A["^C$%?YT \2
M<^Z;\(A9$+E(C^]#YMF8&O?AR77B!\E=REWBO>WT%GL$:S*/5]_RTH:_UKY^
M;@X6\OV4/W&\R+*N-30'MM4QNQ,VZ1B#SJ#=ZQJ&;76-WF1BCXQ_&GTJ-**[
M'I+&6S/[GC5'(;-_-NT)S/&][3W9SQ'RB[IYL'/JNA==LKPM744AR&^=#?AM
M_\N_U#"*EO_BQ]>/ES=?L%?4]9_G-U_/+RY_W%U=G'^YU:Z^7;2HB=3MCX^W
M5Y^NSF^N+F]?XH#CS2^?O"Y4X7";B 3,214 *7!!U2;U#V:'D<9\!^;T0F:M
M)N=&)T,J+^@D@O%Z]BQB[^6'#XX;S3S[^;WKTUOII@]9X89Y:HLF+:X+_UDP
MSW#8ZAI#Y!]A68L7"]9JP2Q^7_Z^9[0&/3/WIW;+*/A]O]<K=,>J01F]5J=;
MRD%U7GI4CJHO-QC4';;Y5;OZ2(Y=1Y5C1W &?AU]>;A1[S[DVS(4O55EL<P-
M%NN5R'TT89TJ%=W>L$?FS[?M"[@PV\+T)NY?:0[M_.2CC^PX4K9".2@LUF9A
MX,S'L19R6JQ;$^[=T72BKJ+!6E>1$&V?PV"*6 OXP+^[\</%/(+9L?#REXB!
M82=J^+]S9_\JZCTRVHTSJZ]W#4OO[-X^JCSI-C7+G"K+#(_.,D;CK-/6>P-#
M-P;E9IFCJHP5.+LY).DNI_8F6MJZU(^<I3O![ XX98[-M%A"H+<M;$6Z<_AS
M#;T?XIBK:6PC&C..3F.(IJ%;YE#O]W9&*3\HC1W?IK-*[5- FTZ<"D>M)7C+
M&8''9V>L0!CJ781+;>_,ST5WM )E"F^9.KM'I\XN6"&@T1AM?;A[?[KC46?M
MU5X!'Q<)9%;V:\;\J*S^[5*[N&LO]U[I$1,-A*<[PE5VZC++(VD_N!O?)W\$
M@4,YA"Q\=,<LNH4M*7R,]+!O1[O7TWNE:2I<4]+K:2I[I*1^XVRH&\9 [YKE
MIJ3:*_H"D#'CY?2H?4SM\"=#E._:.WHD62]V [CSJ]R+2ZX2%N;00>,,V+/3
M-?1^KW:"GB(IK1?V>R2E(;4][?70^BPW*=6:_4OY4Q&SP_$#B7N'/3(OF&%>
M<:W<'\VUR3<$V/13NAU;,JK9QLZI ZNCFV99VJG5Q/2:GLA]$I.!QF)O,-"'
M9KG[I=<J_GH"^X/Y++0]DOFV,W5]-XI#JLNJ]?PCB7VQ)<"HYYD-V99736SM
MH/= V1_6&0\G24_K)?^^Z8E:A>C& /XSESN%E(F>:HW_!0#T*6+F_(?J!>D$
M<*<SVPUKI?^(TE_=D^^3*S^V_7MWY#&,$,=%^VT:9J=Q-M"-MJGW.ON"!*BU
M_C)1TWK9OV=JZJ(-V>[U=:M7;FHZOMI?[KPVCIHU7LHM.*;2_Y:SB%Z.\F)4
M3FALQ?FVUSCK#.$8Z.O&[HQ;=+LJ8!^\9=)[.2R\$^GUJ<51W^CJ@WZ%2>^H
MID1YSQ$!-^+?:UX0U1G2Q\+17CP^5N!H)[MUY8^#*?L"6U:8GP>8W-'M=O3>
M/EHIE>(0J2EP=PI</$4.2(%#-$+Z[8X^S ED58$"ZTSG7'J3Z,R:2[11QQ^.
M9&U<^8^P"^@$Y$RZ+6JVU6Z<F8.>/NCN'"*LHPXEI*+UAL/>J,@ A6.@=]KE
M#EW5]L&:NOH=!'KM!-Y=H-,F<"XLS'U4+3\P!V"]ESN7NR:=0TCQE:0S<7\Q
MI_D?%@9Y5&,USJ@AI_FAU#13*^(O"FVMJ44LCCVV=5"X5J;VD!)DNS[:RC>,
M^A7?!5_<V+VGJ-YMLCN%97L'7;-='1:AU*I535('R0HJ3E+K97YW;S*_5M2/
M+O/O@3HTH"_7C^:A[8\9UON.&7/JCJK'<\O 5C#G\A'X4C)O89'?PUZJ/7VP
MN\BOE?D24M!++ID]4%"_<=8S#-VRRDU!M6J_WL<N$GYJC?[U@K*+S,AW8LLL
M;&L ?-CKZX.=HK"UWEY&PGE)BN]&.!@^'73UX7#9H5X2PCE^VK[9+;,0QW-;
M&S'8=R8U]MC^50,4ED;2KTA^2',>)!Z<Z\]A7=*>31]I4_EU=[BEE[_BT(:E
M=7T[?+Z*V33:3T?C3AL+.,U!!^3 ,J)A%9(H:DH^8AI/F2C9P'2@+F&PU^E
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MW'+5WP4\.)3E?+*CA/YQ]4"0S BT$.1><MR R$,YQ\\3,H4GS_SRV/[59+^
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M>26%%)#/MAL2M*U2CG3E1Z!'D'CDFD@Z%W-9 1F:)ZN X.)HM#HH)U+7I+)
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MDDUX:"FR5\_F>L&[YG2&K_)T8':A#VHP+=(H?_Z);!1#Y$O-!19NP0BFYME
M3$Z+6T99\4UC2&J@%]0*G/>$E@2W(%D,CD3ZG"#"H33AZ7>4!2D,;QP/RNED
MS]5$>?&B?>K+5S+W>Z7EFP.!/,R!0"YM8*^@FBP7Q#V5>I0U&)X9#%%>'Y*
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MN^#_GP,PGVZ;5FH:WUY>+)71$_8A&I>P]O,9TD,Q!W(GXT#N96'C$.CQ*HI
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M4,NT,-'#CJK*N+D5B8X%#E-0-D0/N"?JR\Y4_(V6AA-(T?KC+-8_\E#235V
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MZ+9<^;:DB"5EH;QK"\+#<]2F^^UK#?=9:AA5I=9PL+[64.8[I27/)!OLW$H
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MY=[R=(%E%[2 )WW;!0$?>R_(K[1-Z95_/IG (F/2Y.U\%+F.:R.V_[DL(4-
M:^(%P0I%,1ZM]A [@9DO8+6B/A;SCA69WBAH^*]8+85P%Y:KNHMEM#=9+)@
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MHHWR1]1^KD<7) 0VS0Q"_OB:^==UNOWK[.[S(1"Y8+ZF7#!?LY>:G%(^';Y
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M <&W$01?M3,(OIJ&G<+YWG*N#?#>%K9].'BOM@/L*MEY4[B],0]=H;*A%%[
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M".ASGEW?A][LKPUA_R<F&FIOW\3MYV=@IMNWW6THJB5P^^,2;AZQF>F][SR
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MMF<D*+A=<_L>NWH)>XL#8KLO-2%Q!L<ZYLN(DR44:!@LB86G&*N)Y?1*+#\
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MN0NX8P0*3;^0O.+%BYPY@BTRF0 */DC0>(/H(2#_C.C,&3IG?-Q_Q7'#.">
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M.C,=WB+(M;(;Y+HZ1+"$DG: QAZ@L?>3W)F@L<\%1JTV!$9]XX(RP\C()SO
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M@?508#T46%>;/,Y=<?Y0:CV4?IX(4+1\G$T#<2M)&$TT7A-%7BD 1NY:K>?
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MFJIU;U&&6(X746QV)#<,)$:J?ZHKV!.G;-G?#UMTN7 %U?<N5=C[4327_'K
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M&EJ4HC2XJ/*3&FI0WU8-JGE8"6IQV:AV_K+1L]:,GK3.DPKO<QC%=^3!"DG
MI[T8/@DCWX4?6/,G,'.#T*>]F]R"P$MSRN8\BT;S!;[Z;,_8NK8:XH9<\I!+
M/C3P$K=AWX./%MRQ3J6,31K;S[4]/&TTT7E5-WG=R"/3GB>^,C#(P" UX29:
M9! =ZZYE1><EL2F0_HX =78WV/_Y:>5XKX1P+]8C85V6#\0E"_N\ [O>9- _
M"8@D=](<9^&\4UXT==Z0C\9I'G#W.TA0Y=! S1.4B02E* )6*'2$H"Z^)2^&
MXDE[YYULK';(SY[>3<B'J^]#;_;7=^L5XZ5U>4K$*:42B&CQ@KR#@9"JF-,-
M$Y*(@P\E2>/UNC68@QU]*"4D2;45UF4PT!F+W6J<F7MD\#5N8,^)/PRY.IO0
M_A@%\.@@N/:>'FR77L1U>D'7V?M)V/$U9L\#;261SB%5I"81%@?CNTO45B+9
M3T]M,E9("H+&RXU-O1TL\WV6>1C-,6M/);YU&/;V8$2U8(W3:ZG-0C@JU%!Y
M2>M*X?U 0V<TQ ^C(74T@97R>F-ST08+?!]B46QNV^XSZ$W/?^56D3];6L&!
MX9'!]FE<(-\D5_,]N9E-OEK8O\C\ZE_$]XI82AM-*+2U]%M'[)J!DLXFEO=1
M4@4)K8\FFF#RFG3TQ,#!3*X7(YF3!:%8O7!S_N,0O3Y;HA%=47S*W^UP>1T%
ML*5UR?GKH0ZHP2;"*IVQ? :*.EVFL16*,D%2BPJOJDW-=AULZ3T$01L3!JOY
M3&*9GG[>YCF0?21A-#$UD5>&TH^+I*5R@=PP+>%,-D7D3>G"JCYZ,TG;V]4R
MUCDTYK?2.7V" [H<856N^)J34])H(LJ\:FJ\*IT,0[;5-NN!I0>6[B1+E]L?
MS;&T#"RM\ZJ!  E-.8*=1TZH#QGPS7-CZV!_&[VDU&VC[TK/O),B%M3OFJ\Q
M$6IHF#^V-WUHF+^LIO&A7[ZT7UX]?[]\5C-=?,O\.8PCT+!7LQ.5^PZ-MY6W
M>#D6=;F3?$!)Z=HFK&UUJUA.*AD*K^D7E,\;>.=2>:?<&STM[VB(A6[*(J]V
MIJ7K4F:R?$I+2+PG1#^MJF$'*.?]"B8YV^O,T:YS^(X5!/;")O,C&$/'CAC#
M5/"_TZ(X#U1QJ.ALGRJP<(A7)?BO+N)]1Y*(W167A]=S#$51C:2UX$C"(.[G
M18#N7%3\"+XQ@6_T1KH+NV.@#[15/;_2(FW) N91Q0[1UB$S2'I3UE&8U3C0
MJMV,W15GN':GMR[) V[B!"Y'G%0H/6Q&=(@X3D)195ZMW4?9P(VUZQP,S#4P
MUX&UF,TPET2Q1 V5%\2ZE9AG8J[6QT0H^\=$Q!0T^<\'_S\F.TL XMO7)2"/
ME1?8N)0/%'3+?B;K//W?-JLEX@,5UE^Q'N#XHG#W5W()SS.55'RYRHQ!8S>3
M^7/IKR7A([EZ\(GUUQ6="O7!<EZLUP!O-WOD<-[9(ZR[^SVW<_I#*Q[T<?WS
MCX^?[[Y.OWWBOO_7].Z/Z?7GGS]NKJ=?[[F;;]=C#G]Q__/C_<VGF^G=S>?[
MVAOJW#D4$\\W+X2'A1Z'X7,4%Q2;[HOM6N[,!LOV/H0?/,$* XY[QX+MX)V\
M+Z*W?7Q[ZBM^9S8TR^43>0C+YK?(<GY^BRSGY[?@<PX:RT(?UM,9*2YW3U8A
MJ]Q2>0YK4'A:W(612,M]Y2CUT\9_H$*+<_&]Y-ESGK'NZQI^8X?<5P]6/GWT
M"25%[L4.E]QWVW6M&6B^CY;[UYC[L;0#;F'-:$ 3D?"?[3EL Q0S!]^U'N'+
MCT#*\!L;*'L%I+V(V%!XZPE=<*P!B%;("?]6QV00I0VCX4K=)IZO<"2W"[:/
M+_'R_K!^V4_1TT?/]VEYV[6U@M^$K]7L"&U->* T=V+$P64Z\"\\&<+AL"MD
M9S\]6;PJW/.,G3 <WD&[-\ZX>Q7K>LIWSS-:07J+8]V4(JXCI$>'3DGTX'#@
M$*R L(\Q:FCL)&@'?-$Q3,$@P\=:SO$GH>VG QZ6/\?>$[#P+-O%Y;/W!V/N
M)N265@#,5RX7);/*]7[^M;)9$O8[/,2;;VP&Q,CLPSSR7\!0#8B[WH$^FH0X
M:)=[)9:_+20Y&E0A^& D7;B*VUGHH401J431$B)'21*$G(^,#A3] )<ZQX];
MB(H]6X+4_(M[]P,?=G_[Y>X]MW(BW':P@ONG5:<[K]RE%).[=5G(WOK-MR]%
MNN/&#4 !H.3Z: 5V<$_?=NO^:?DVVM-WL%HQO=4K:7THF%(9Z_F+_=LX2\&P
MT2!Z^%\RHU3K 5LO4O4]\YX)_#UD(O?)PB/"WU'6M[@O2!-S#A?)W>&=\; ;
M/&RXU_C@_AE9/OS$><73M(%84FH-8HK")V])$\LG'"VNA6^"6OH7/.SA%5<9
MA+ 86!@\#O[ ;W@1"&@Z=F_,Y6>3]$[?30/<U/:$+Z;W*#Q[X:^D396X!&*L
M)WUD<8\<]MQ'I/LLP]:6,H@:+8WS_3A<+&+H_FJN6VI_W0I&P;5QOOZ)2T4C
M2(T5\ \XB,XK#W*$>U@3N1>%2+745& $;X,QO%:D,<DGI@<31=9JY8 ?C8[Y
MIE1:LTQJOV3L&A#"M2606$L"W<2K0:%#;?LY2&GT0, Y+))!"AB>QE@LT"Y_
M*QIEQP@=./G&C>F:;=@"NXL\VQZ*VQ(SCK'!SL/#\TEE^M>;C[=WL01WMSX8
M"W2DQX/.5&KP3$N)-3EE'-Y;*.FW.A^8M!AON5]'!5[T@^9S;LC;*V6LGL_-
M$X6&_#R*VKST'"#8X/,_(UH]%I(RST\I\/R4 L_O?@D:,7XR!<'2?^/8&P[R
M!Y5]_F <[;O"0#35AB>=L$J?^,$.X76S*A=H[;R_F]AM^1X]P+.XV\6"H 78
M?S,!W.)RVL28PA9U6CACE=+H#Q]>S23$)Q WFS(&(SA73_"T)7[_:FZ]7J%-
M?96QMA7P&Z?1(QP).V910+DBF-O$N&F58*V>0S \A HP\2A7[&J\^&I*C>@
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M0X-%>V)YFJ0T<W;'[YXW?[$=9\/68+^JS4HJ&!R\+.N\8-8,APP&;2]HJUA
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M(.9E$E2IX#7.)'B/QK/118J.IM:L6&M9R%[0R R&4_,?/G&(538XXS+-F-H
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M9L:G<DD29/4"?+&L<6H'U&Y NQ3%"]XQV)5HH.(Y)&[K5Q# L+9YQAUBY_5
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MX(-TA%"R4XK@36=#I#]))S]@::8H_ WKP)]PBA%R1%;HI\_#PPJB)R17.KV
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M /\>AV,#X+>[ OX>%484X\7X%^K#NO:Q$Y$GO%@O=UL[A1<K@5G1AN8(/Y;
M_CEAOZ(?:S?T-5EXL@3TS\N:>:XG:P\7*,*7)1C@7!C@F;ZL/?!7NV+0"_@+
M^!_)F[4'_EI7X"_\66)\7\?W_H396O-2T5=#C&]]_(LH "/Z:HB"M-5.@)EM
MEZ35L.2-0A3+(+)N]*=ZB6"9OK*,U3K+\,X:JN,0Q5 %RPB6Z3K+V*VSC,EV
M&5W1B&P)EA$LTWF6<5IG&=9;0U$U8MJUZS\(CA$<<UR.:;UYDV8/1KI*9-#,
M'+UV-?>&&*;WCL95;PT\8RYJ5!VQ6,RFJ^!XM:,UUE)#=13B.*($>>^ M&E
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MV>M\ N@,H+V,I)G[),V#I41AT)2-#NDB@.'>GL&3(&273N+I5'J"ZX8;:9?
M8V/.IFR*HY3K/L<S>*/Q&@@3^EBXYMM+^LOWEH]I5<[<*,Y/;^35$/<^"E $
M[!R2@_*8(FE/[[%C&/AP@6)HC5ZYGSAAE%F^YJBVJ^FJ,:$37;%U6S8-17$U
M0S$G$_=>^5\5<ZF348^9]W[A/M"+^Y"Z/R[<";SD&W?ZRWV*4/+D.1_8/D_X
M39KM%A_\Y]IR;BH\J?R.PN6;N_$C]>(IO9W\Z4XY&B[GWK\ ;"!* %V7XS$#
MXK4?C0%F@/QO<*=WTV#\8R6[]8%$0:(O<!'#F [V";%-05Q^D2]#WYV675JK
M<&G3MY5N;LH(77U]OB="9?'4K[Y_>O?^Z\?+S]?2E_^Y_/KI\NK]]V\W5Y<?
M[Z2;SU=#";^X^_[N[N;ZYO+KS?N[[KY?,==E\)/<N2>M "BE""SY0BU-_R^0
MLI%$8=?UI&LZIK-[&O*M0U.(I,JJQMX+VU]EPIAG]V<",_1HB+K,U%U$]$WZ
MR]OTW+4_9T]E@]XF[YQ(V8*D>[:L_.N5\!C*7( D\9;DR<G70_CJC^V_:_)0
MMXJ_ D.FXM\ML]J(79-2E*&J.=V;E&PU-2E';692SM QK([-"0BER]4@M>M6
MZM"PC>8F9>Z]U8%8Y9Z0))>L[=B#6]L)DP'7L&&'_@(%;HD09,FP;XU35R=3
M LN1YYT[=>=C/(>U<]OIR$SO*6P$: ?PW2:8='W"8*;X@;>AM KHK1(&P(1[
M "UB&71])<=!!!8JJ#5=GRC]O:#SB$8"= = QV5(]Y$7+!]IV/5)NH6&RU%1
MUT4]PXN9([=,B:07QW;GHV: 99LJ&/S_G=MX<;:JLR];E9N^:,"CPSX*IKXG
MI6]4$1.'$A/%HWKZJ-XGDEY.I\$O)BW0O1_/T4%$0;2B#RF)%A!I[$:/DN='
MX_0SV]?QY>$#.J#&(?5\T-K\*(I!R<1;>>[,185S$08HJR/1GEV,[\[XYSM=
M=K/OYO::!$L5M0WW,6/N#TG$[BGG1MZO$K0_Y]3-+6G*FV/IN.*RFI>)@KIG
M<U4U2<?R6E2CRQH+!KOJ6GUJX?NW7=RM) $JU0=TY+V-2E?A^50/C"[GWE<*
M4_M)H\20K%KMS30&(TV7B6-N5X[?VY?T.-F' @D<"4H-)"2>O&_!51 MX>_O
MN>^S,C+,P<@DIJ41I: AF<#&>6/C%OVG:6+%.C0F_F_J7?P?#8,B5%B8(F>K
MBOI68.*8F*A66K86*%8>VLHRPD89H2L6<:SR&>VG2EPO/'%<E#B4)-&H>Y*A
M"A/M-C6:LP9<-;RI+:@JSF!D.":1G>VRM$<5/4V6A^R\OJZ)1A;]8AM+?B;;
M=/G@D0!5#E1:^\:"I6#1<,< 8T%7!<P$S)JV.RSUF7:'@->YF#!U\/5\$\9B
M[0X<TR&FU8%V!\>-71<EPI2W@1K#3\LM!OK);=6836]!$=6!TRR'&&97-(3J
MB4K=".F)RUY:ZD_N;-Q:$I!')S0,,5?<_2VY441%\HX8WZ7Q(GE').^(RT3R
M3O^O$LD[?0O!5K.H-GLSGL*B,@8CQ2&6J1!'K6A4B7C\,<&PV;"\#9>\B<VH
M+<<@=E6#6V"C\]AXMA]=Y._T#1.[?-_[<6 +''00!U8+2H0#JIY"#,,BEGWB
M1$^162/"A^?+.;;\?,[I6@!1X&H'KNSV-7E;&8PT!8"F"Y )D#5N$M@BM4;
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MEYPM5 I9SD][CA]([EF>#^!$J+"*7SCS%Y_V9')'G#F 2CWX^EK@^9XEE&
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M$:GJ>C4 ,*+"NEN5NA/(]>5?>_<W7+E\0PL8&YE;:YFSFMB$N2[GZHB^D)?
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M. FLUBMD![>@'$<]DH3<<\:Y>F5F@!;P8P73C7%,[>XM;HW=,]>]"H(>ENY
MK8GZVOLT<1ALL-YK1C#*)#5"UZ.2'1W#8'Q2KQ;9M$94H_%EJ'Y%_)=V8*]_
M;4ISP;5RR[Z>K#G;]ZWM;_6M]+5A/M(\Y[#1/,RPVJ-3<38,_0[3+=K+4ANQ
MJ2+?RF0\]8*F[@1 E<1KSR69-_MB,T&>4!987DT7H6^]EK%1#6#J'93ZRX%+
MQ*G:KPFOIE_3>.<R-*#+SQ9L.!=CE^9QN#:UVE:1/U.FEBY,0$UI4]>K7_<?
M]M/G?X--JEJWBFN)FC#^E<3P4-94>C"XEH^[(G?DCUUB1S%/FT8&J8MJZM@R
MXEA&?U7[E/+1K5"#PW>)5*#NX-]ZST4;*%-\&&I=,JX7DYN%P2MU\2_7@'SU
M6]GAV;D&UPE,C*)1]"ZL;BU4+?/JJZ'HV97A9/65FNO@0+%S[HL[)OZ.A8PJ
M6]Y9&P.9.H(5G="Z#UR(ZD&"1D>[LH);O"-2WS I>H *UNN-GNV))4Q=EPSB
M9^HOYYA/B8ST8<\H<]E4O3IDZ_PO-<5_[K"D7G[W[!F>H\^__#]02P,$%
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MV11]ZW$B#Z'O";B/W2.J$?LZ!-B-@2FUY#:EZ3GFJ[1Z)\GL%70$>*:M8,)
M#(6#X5XS[KPE@CN'VBZ4/@&WM'O0-6=I,_C]@I^FF(:+W:-_CW#!&J+O2D7O
MH#!;)SMJ8#:2@9?)W8JLMAL7*FIA)9>\=;[,+G3UZ3+Z2-!JSJXVT; J3VGU
M;Z9OPW2^^J+:>V_&'Z:!W(2TI"L:)7(=;1!TG7CB%3BA$XB<35#*RXPW7+<M
MX;"=7O? T:E/VH#JB D=-6IX-1R'<:)5+PI?!RQYL9@BE8VJ(1R5:.G*@PS>
MI,"D;)^#?Q<]N^#&?5]2I1E[F@%F'8D[F9Q%(J<2MDSP^4@V6TW\H.V8KKAR
M&>V=G9S6?Y*Z/:O:]DW9\BN7G:WY@#$1%:][)41M:R,-[9I$*,;HE*R6NGEQ
MPY&6M@N,_?<%XSZ"IDM'='.[]H'G=9JBYL#1.W*6:RL>YA@4G[R5RI;0?&#/
MSL3M%#1EWQ<LN^%<\TSG-^-?AK-/D]EPJ066J1U\H)W6TB,'Z1,YQ<$S<#XH
ML")A3*P@;SXB]6Z*=H+0T=HG' E##9G41<.0X%A4,C/(LO:IX:) U,R )O1Z
M0F_2\5@-0[8 XEB%7$?"PYY[WTX;G7T*P^DR&^-F.AC9C[1'H^$%YH'/V<I$
MBRI%ULY?7H./6 ?D!(,Y12E<\VX9NY&V$VJ.U<CQ6)JH ZX=(1#Z;7SJ@*@J
M1A#.BRB>!!TY(\[+VH"C#MU+.6O;0?>5>^G:"4SJ.]-)S1G6)A9UFZRZ&>\7
MX7YBQ&* XIMR.Q/ZZX KS:1 4INZIAHZY8C,X"&9H'E0S-&6[!2?VIN$G7"D
MOQ,<'9%;'0V0?U>Y\*;0MBQDZ-4PRKK6U3"FT1G:"1\-**84>8W:U0ZI@GMN
MK&P^8_FA-.X$NN\LCMXI'[N^?/ZV&:OT>ZT)\G4B%SHB,,0 WB<-!94QM!O1
MNN[O C=1MA.ROI<8?(=,ZSJW\#+B>V4+A++<UPI(HH4 ;S."*Y&3(2B1I9"=
M;%Y]LSMUAW?0_;3*_7Q3_IC,<7TQ.Q ,1>9DI BL$Q'JK+M0="*EHCW9*S)K
MT3JC<ALMO>H2V1%P;O?(;<"7UGG<KR;3^V+"F_8A1"U9$1Y,;=VJD GRGQS6
M$N+@')/&-=?\!Q'\%)(46^/M>!QN&76[+'NX>EQ>UZN/RW&=+IGB2%,!DRFL
MFCY9)8'[@I+S5$)N7CNY"V%]FIYQ+(PU9UCS0A7"/U%V/DVG9*_4&["SL\EX
M,>ULH# KZ9.%8+RN?:T]>$9FBN+9!XX"D755.KF=J@<F,GY/HJH5K]IUBZ>U
MU_]KQ>9%&.$B_#.;3X=ICKG^X.4X7__&E4^^Q>EPDF];S*M6^+]^28O+V7=A
MCK^6@FD^R"1::W83B%+[CA5OP'''P#$>)'*OR4QHC,?CKO"(Y4,8K4\RD5'%
M@R>C*G&(*A;@B<RM%+WWNK6%LF_YT"//8^LOQC?T=.V"_8_A@2H9$;D1($/)
MH(0L$(0D=SRZ4@(7&7WK6/^^'N@C3X=[\O \E/U=PW-3Y:GV-G,, HKB@K1M
MJ2ZIQ5HWH#.=(-E^NM2^W7T>>4K=DX?GH>P_2D>O*Z52M(SWZ13S^0@GY<KW
M?\%Y&([V:NWU@*>W[/&U[Z(:-?M:O^;KJAZ<^<*3KC';LDB%+4"&M03+C?11
ML>!+^T#[50H:-4%=/?)W.C3381C-WI]_^C2BK:PC0;%Z%N,\G.&?]0)N$0WY
M.%XT4T#CF#72012U0"47#V'1(X]L!\^C%+:KMJG[$=PG$_( )&WIC7H$)C9M
M![Z@]EWX?$DP'>@WI4X=G9)T'12EZIZ0\YI2)'6_&!E$.Q(Y;9'+0639NI7J
M_53UR<IKB*#&[&@/DYJ,-"-9OYA:?9VP$*U(I&)!6ED'C>9$T/4:I'$<?4HJ
MJ-9=!7<@JT_V5A= :<20HQA"ZUYBX4H;L6^6PZ:?'F 7[?^REF92HR4WLIJV
M-G,CX R*(>-<, 521'+KB@PU736"21AXK$76IK41<1<]#:YC-C][>?A*$<8G
MXP!5G9V=.1T.0>ZL(Y]6B.*"=\T[/=U)49]LHF8XV7#ETHHI[4H@$QW?\T6K
M\5V*>+<W1/2.G-@Z1]DS4Z>XA  N^P0J.(9<*U&:'Z!6M/?JBKDS]#T*IX\4
M8KB>,TX?J0;!Y^%H=-4UO_ZA@X(.![RO;1BBU<(;J=AEMO[KFJU_\[45OMES
MI0Q#8*[.?)+>@L_,@O#!96.98<UO=NZFZ%#I><?3ES*=1#D=DLB QT16+B*"
MC[4>IB1T06:C2NLQ@O?1U"=5VQ O-\5=4]8T4[=W4'5%/E]KF\%L"EF3H^2]
MK)$14\#I4F\=0I1><R?C$0_-%BI[I4(?!U4M^/?8ZO+5^?Q\BAL2S;O1EO>^
M[DC*\F'+/HZNU)SYDE,!%@."8A@AY-KZBPO!N?'!R]9!_4?3E1MV_G\P3#]\
MG@R*LU+FJ*"H>MU:J_^\(BG-.8M)6!]]\_E">Q'ZA+3J0Y#U$/G7AHE'4;6;
M27TU.9\.8M ENY+ )B5J60UYX=YQ*"QH>HFSG+<.^.]':9\N 7J%N >S\1$A
M]X$@A(/@;3+D5 ,9I+7!1@JT/[E 5H6Q:%A*MG6KJ3U)[=.%0J] ]W!&MBDK
MWN]XU%A/F>-TP)QUJ>:BH#8:5) "7"D"ZL:5('PNB=]GX#6@HT\M8#N U;$Y
M]4@"[0^RC#]\QM$%_CX9ST]G QNB9IEG$);37DD2QSX)46.6LE:M2A%;ITH>
M1G&?NL+V1KP=Q-:C>+2+U).39>=D^O'BR]>3\4<Z-V=76ME^BXE>_84K'SC
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M^I[%K/GA!0ZD-LE(Q>F,TV%3P3"(20O0HOC(@@Y"M^YE\% :GZ1R?@C&'B1
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MW"L*>B1-]V"0O?@S3'*=N_/IFI*,'&,&\A,(C#,:@A(:C+5>JNQ0\-8A-+<
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M/#%L,'%>UB:TP^$\:^H=ELO:K^FL"",UB@26E4@N6TV+*I9!\0+)Y\J6AG2
M57$=MN_T/(J66Q=8VF>VO9Q@'LQ^II7>YB@4%@XZJP3*N 0^"YJ%(J?H9#:V
M= M%:@+G.S4/I<N-E9R.T^?OY<<ZY.GKT:LPF,QMD'JM]7"ALSY; NZ#YY#=
M YO)K;]&@QOAK&:-8C8+32YXX+R01ZYIYS>L5@B744M.#E+S/-$=8!ZP+>$&
M*!^62=?1"\8SH)#U&%C/FQMY<(&SJ.E_/+:^[FX$_8A-#)MR<(_>ALTT>^HM
M#WF1+J=<"TIE!0HY@^!BK/$J4M-NA%CZJKKW]%H>MF-%QTZ(VVCG*(WMN@#\
MW@EQ:U5NW>%N%ST<A3"V!*D=$R!YLHNFV8%A!)%M236H28L#]# ^X4Z(_?)D
M&_$?KQ.B-IJ7'!4P0:Z1LBR#3X4654PI.V4EQXX5]Y]R)\2M=+5;)\1M!'V,
M3HA1!RZ]2:"9KF>-1D+P5M4,I22--SEZV8D(3[03XLX4:"W<UFO!#N72WXV'
MPU?C28V[.0O1$T]EA*P0014;@(RO CDS-%ERK57HQ(O]<)P$97IQF0ZMI!Z"
MSW= ?R9]%%BKJQN):M$<-#H9H&@6(V>T,?/4DW6R!<S#T>[@--B_J\)6.NS!
M!%X5]J?A+SK:#&H @?+<H*S-ANM2F]  _8 @YFQ$+B85'AKS:AV.;X<X>VNA
M81C']F2^>;VQ.#A^/7IQ48NQ/'YHS,^L%<6R1+0G?P&44@D"[>=09(HF>F6M
M.EX7F+V&]NWP]Q2YTCI^I/L8?PF3T?P^]T5*D\M:E??-I_FO1N?+@OG3L\B"
M9*%6(4J*9CA*"RY(A)+(DLU"\12[A7TVA?7\&7MD59Y&#ZXSLBD036V\RVGV
MT#Y#CEH@E\V[4+0NRDES@&8&W0S'7BZ.W^%G'%WB='6:/BY_X&SI@:Y^%[\N
M?[#'A?!.[VEXT;O_.!M=X/Y"JIY]_0<I^?6HC EC'=,2P2M:%7ZAUTQ&8?CR
M<CH;7^#DVA_DM1]#(H8FEVF61TZSG)Q]$(F3862L$MBZQL#.8-M=YFX+8?K3
MUS5%<Q97/8D5[7@P8!3/9$UZ!"<B@RQ%BAI]"<VK-/0RD$-=]!Z&JYNO>X^E
M^V-?_FXLW*6#3247DB,-ALP^@V0 1@F.-EC-:HY/MS;J3[+(X='8\%B=PVVT
M<K!*=UU ?4-U#K?24:>2=[L(^&#:1\2HK"-P* .H' 1$FP7DDIF5S)N4.K6H
M.RVM;UOGL+W2MY%K'X>4"V#+BZ"$B7F) HRH)7BC"^!S]."9U3R3MR5-ZU/O
M6P!.I13B5DJY>^"XLT1;WZLND?SOR6 Z"]7(6&(J+G)R[SVD5)U[Z1@X+C4(
M[RU95ZY8TRW]:\,+#G\9MH?,UUR7[R6PGF(E;M_6.Y,$_=] 3O-2G3[1X%($
M+4MPG!N.KEM"Z;JG/W7U[2ZJUAF;2T!W+MNC,MX'1;M'S68NM3%44::V"1.1
MFQ!0=\MW6_?TIZZ[W475^DQZ">AE&.;Q<#Q9(LK$I6*4A53K>"B,!H(D7A7%
M6$Y($%VW3FAK'__4M;>'L%KG!ZY"7A+.0AY?UR4.Q<@0.$11NTMKC!!01,C&
M"JN,BR5LM?7=>?Y35^ ^XFJ=++>ROR\P#</%^,O;L"J"$Y-7*1L!RCM/HV0>
MHM<::*U(UH7 5.H6"[;Q%4]=CWL*;6.FV9XV3/A$EM5X>%4C/*2BK(02D1,L
MP\!+:R$8KS2/*GA7MC)B;CW^J:MP#V'=5Y]MH;Y5(MO** ZR%,L+.!7(%6:,
M7&$K(R2&@45K;+Z;U?2P^FX__JFK;P]AW5??WGW;;YQIUIO!24BS6CIV=:[Y
MRY<TO,R#T7F-$*5_\H?PI1YUL))1 [(2%B7\HX@6G%&%=FXIM>ATX+-5+;BM
M81Z>)\>YPNA;@QO/'GJ](_ZC5D^N"=0-[H'O/:N'N]Z'\3:ZS_UY, WGYQ-<
M)(^_*<N77_,(:ZDA423H&K!/K!$0+"<S6WEOBR'G*+2.(7P,T[X+U(;G+ZY6
M@I7HM>4@M*]Q%=* 5S2->&:%99YST*U/)1_"<ZB[TJ8\N+N>-!/XR=YLVN 3
M][1E6T\R48[5I ;NR 5EQ053+.9.L^0)W6RV4^IC%Y3;"/=@5U1=0'U#%Y1;
MZ:C37=4N CZ8]IUGI7@6@0=+_%;<@TN^ ',"F3?!&=>B#^N)7U"V5_HV<FU]
M^7'[*)\5$Z24M=%HK)F)-0<N" 52<N\]4P%=-X_S2-<=#>4\;B*D'G*M?IV$
MJYXCY'HX5^IF@S:!*JSV/<D&:+N)40=I4;2V4V^\_BGK=5]I-EYTUW9X1NE"
MXCI"5([89FK3D60$.!DUEI)"[)8A]\AZN^[=S\J^VENXC1O==N_^W 5D0WOK
MR!W0'[*_]M?A3BW0=U% XZ6A.UB?A79<.L@Z<5!:8"U02XBCTI$)JQ!;-,H]
M,DL>L->.1))MY-[:?GN%-?-D.-_&:(<\GX2+56>TY'/@B8;KZY&%2D8!;9+U
M1+P477(0T9M.QMSF=QS6 NA)(^/VXNS![",T"3%/Z_GT;[0_#M_C;+8XX9F>
M9<VM=MF""$74VB(6O"X2HA4I5@O5E-8I40_A.?R50:\G><U$WT/XX49@=RNB
M3M]APL'G:DC],3^%?U-6OSE33C!=4JZLIC$H;<%5OS8)QY QGZ7I''/3 M S
MX<_1=-1#A.0N8UC^Y,T(SZP+4;! P)&1^+QV$!#)=(^J!*69X+9;1>6]H7SG
MUJYZZ2%V<P_T'_X<G[$HB[#1@8WD!JK"$P0G!1BT,O#"=<+. 1+[0?G.JEWU
MTC"J=)^;?&,MBSP+L*FV?9-9@;,ED@%IN8C&:RE;WX ^B5B,7@VKOA751Q/=
M2Z(Z>2"O1XD@G@EIA1<Y #I1=V7C(82,8)@GHD<M ^.-:7,;P3-CQ![BW1@=
MVTM\S>L1C9JH,L#I'SB[4:%@/'IY.9G0[VY\8H_8FYW>TS N9_]Q[AFS,]^2
M5N_X6KM/+%Y[S3=OB05&)RC,(BBNR(;Q(D+45AO!4BDV=;("'GK+7I;.F@<O
M3K21&14B%\ X^NH\&HA"%_ A<6]9+DJX7:$?))*FK79NF2%-A':RL3/,:>=<
ML:"BE[2R>=K&L!A@ 4T6V6;#.Q4.>P*Q,PVU^5C0S#92/5C81!=0WU#0S%8Z
MZA0_L8N #Z;]Z'AFK%);6;7,L M80"A1LE"I1->P_,>I!LVT5_HV<NTW:(:K
M(F3!"+J8#"H[2V-#"2;*VL99&%:ZV1\G&32SE9PW!\UL(Z36Q^3WLLT#]THR
MVFD$^2DT)F\@* S@9,+"7*XYL9TT=KR\_)Z4MI>HFD^SVPE:114>E=/@5(V[
MHD4#7!(:3([!TZ\,RFZ="HZ5QM;71-M=3,T;*-].3S;<>845BJ^K?N*F]M=P
MX&K-2YMTT*%;_N&QDKA[TM@>8FJ=A'^['$!BY*FEHLCZ+EBY(\&Y:"&G6&0(
MT92[QLH&A1VI9$)/^MI=2*V3[M_/+O/7GR>7YRLLBCSH:"2@<(0%0ZY59!$T
M*MI05='6=2MU<>?!3U]E>PBJ89[]50C!91P.TM]FM33LH+:F7'K#"^.89:9+
MC1XHHA:&SK1B9_J6@-5;W62$[A2WM4WTQ@-XGO[Y0'.I]U"A?A.V#_3W5WYM
M!X0]-7Q['-UQ.KZUTVA'JNRICC[JR3V.-,>H="H>O*^Y\)'38F>T S( >7 !
ME0S-P\&.1)A'.K\=DR_;:.& /'D7_OP]S' R",-5:&/(V0<> M!RJD&YI,AY
M(">/#)E$?IY12A^*+_?1':%.16/==J3.GHII?6KRBN0\_8CYU_$XK_ P:5'Q
M$B$5VH)5+!8\9C)]1:RC+D[Q;L6=UCS\V>BYB?1:GZ6\F7W$R<K.7K'+>&-I
M3,"3HO4O,TE6E=10$BLUE(),XFX!XFL>_KRTN:_T>K ?UQC,9Z%H%T-*P,EF
M!B6D@!AK<3^3= I&6V-:-XU? ^/ ?5B:WSZWDO!A"[[<#M1H4?;ED2?V%F1R
MD!(P5\J]Y@I-65UBXL"0T?(<G(184 "FPK2Q,C/>V^SYK569EZLGOKSI1$MA
M,:;H(+%:HI5E R[07)#(10[69!-M7T-[><!PE$;:W;@2["S4TXU#*3G:K#R(
MQ&I3!5L@HM40.&HIDD.;._4(?P)Q* VU^6@<RA92/5P<2@=0WU(<RC8ZZA:'
MLH. #Z9]\C3JH8:!(CA90BK6/H16092>T'(47C8,.#O9.)3F2M]&KOW&H3B=
M+-H*PA1.#DG.X*40P*0K23.?6>KFSIUD',I6<MX<A[*-D/K(XGWH/%)I+8*M
M _-%DG.AR3U%31:+1RF4TD[;UE;:*=T#M=^?FTO]./= 71!^OP?:4:/;G^OO
MHH[CW ,)J:TK*D*VM3V["0H"9@1K=79%JFP,>R:$V><>J&>^;*.%UA;"BU0/
M4M[.SUL27LX&*0Q?C\XGF >$\\7;U[31_F,\^>?KT;S:!4Y7IYM<YI(S#X"!
MT69I/=E(F@PEP35&*Q-A5IV,B5T1G.0!\E:J'!]:#SW8*^O.0(W-W&+FD',-
MZ$YH:Y\#3R:42LI;3#:TSGD\ZBESWX=*.XJV3VW_/0POEU77IV2&(ZV1!8OB
M00(OM3N"JK7Q/)G1FLE@D_::^]:UZC>C>3ZZWT_0&W>+7FX8:&4B*W[VE7[U
MRW]=#C[5\\CKA-!UO]WC\F'WES6\EV@TXD97%JOWO26HLQ<W7GK-2:%HNV".
MG*1<"R]D)<B[90:R$UD8CRRE'NI /8*J75_QC>]:N(B9^]IF!R'Q.&\BJ&E&
M9@5"AV*=U6A$:W.W*[9#77PTYLCF-M\-57'LNY%'9??3W 1<G!\&)5D.M82@
M=.0J.'(5LF T+JMHZ2HRFX--L&M8Q^_SW9(.]ZNO-55+'Z[XQM'?B![M +&O
M0YS'X1WI%*>U:KM29T^]'(E"*@7D*2>0/,D:M&K!)1/!H"A&E^*EP>="G<?.
M<TZ .=NHHP?&O!Q??+J<X>0*VO+$0&).,5@-)9N::AUJ_E\Q8!67F#2+B*XQ
M2S9 .4J'N;9J&[>7>0]^^YM2!@GO@M+9D,>("(B,#+U$.V_04A#&J VFQ*UK
M[;*O!?+\:+"_O'M8#UY=3DBNEQ.D ;\:?*E?K0X1HR CR\M2ESY")A."XSF"
ME<ZFR)4CBZPQ$S:C>7YT:"3Y'BX7?ZNUU#Z.A_GUQ:?)^/.RAN-RS>*&E>P2
M:.=K'QN5:^'B#,6+E)DT5O).W7RV(,4#<)X?*UK)OF'&][R(>AB=+^RCG*-"
MRS($3E:1BD1+KW5M?&(,D]8E7CJ=XS_6+F#UPF?II>XNTH;3_0K$JI%-!Q@M
MVX9<O_KPL7T["O^N^O:07.,0OIMP4%JE<RJ SKI:GIF#CR40+36W,B>C5*>-
M^]@*?"!,KZW^MA%88[W]3I*ZN+Q856&107*>&-2B$ 1$2B!;@-,?243%C;"F
M16_,6R\]<#>.7<4^;B&SAE[4'$CX<@,(&NE,I-<S;FE[-L:!\[5:F6>&11DY
M\ZJ%\FZ^] DJ;V>9'?+\[-?)>#H]BVB,*82)VWI92W0"YP*#+$PN-,082R>-
MMC@ZFR,Z(7NWS=500P7T<$+R(J7+B\MAF&'^&3]-, WFM^[T]1#G8A_E%Q?C
MR6SPW_.?;QS,63)!*2D*2!\B318,$)BB)<L:(7ED*G7KR;<%D5IA?W:4.XI2
M#[EV_8&S,Z^E,8'6Y) *87,V@6-9UPX=DB%ME.ENU;O^5B["\^Q(U$SX?<2&
M;\+VMRF6R^%O@X)G-IHDC$M0'-+N+6E-I6T\D.F<$07C0<;F,;Z/P_IV:+*C
M*C:>ZO24'#XC@V\0AUA;:<RF])%:F.+/P7!X'<]T]T-[I8[O\;ZFB>6MQMTH
MAJN6!9GA;X//F.^^]IJGJ13,MKI JBCZ XFG0FCPJ(1AS$;!.^7D;G-<WP%7
MNSBN!]ZV.(DSV9#O(*N-J,F9P!3!6^$!0ZVLD8O(S0M9=$=WJ%BNYES9',W5
M5"&G$L_UP*!^^OI[^/_'DY?#,)W.SYZ\J><+R4-)M<6>"Z[V"O40N59*&0RV
M>0/-+> =_^2\+4'NWI_UI*@^+EDW0[T&>K,1;0>X/45];0GU.!%@O:F^.\6:
MZ>T4Z,9<Q" E2')<086:)"N=A:*#( ,T%92M4W-.@F:/1(N=+,NV4%?KS,!E
MICVY,K\-$LD1WPW./\ZNT\X,#TX88%K77'E!7DQMXY@D(8N6N70W%7US9\W-
MKSF\E]BKAL:]B+>/*@1A=B,800>7+9.<MFZ90%G.(!2G(='H- M)%M8Z3NP6
M@.?)@OUEW<-^\F$2,EZ$R3]7>%!9RVUVP),DLXW&1PL=$Q!84%99TMO=WC5[
MZ_XNAN>M_KTDWL.1X@-C7US4:,R,&>F@>%?+6@9#AGSAD M:I61DF%HSXC%,
M)\60-JYW4S7TL$,\@._&K<O-VY4SU+2IY1PAFOGIIW!$;)HJRGL=;7$&L5/$
M0QOB;$#Y;5&IA:H.Z]742Q=ZOT,3)6#1&E12M5482X"T3AICA*)M\G!$.LJ=
MUS%)LZT*>MBD5F?T9Y@RD3%XH/6OGBH%24.,M7";5Y$<-%U2ZXRGU;N?H=)W
M$NO)7%2U*6G<_?&'N88Z2+'C3LSRF)W+/H&TVM3:-@5\K$6NN0M"1RET;AUH
M<&*W3D*E')1BX),EFXO3TA<-UV DAI)UPJ ZM6I]_K=.VW!ECUNG;13R%&^=
MN.591N> Z5A/ \@.\_5<($DEO;>H>6X=N_&\;IVV(L@>MT[;*.H$K@&ZP/U^
MZ]2#ZO>\#]A%;R= -\M30L4R:$66J+)D2884YCTWI%48B\,#6@Y/\M;ID"S;
M1EU]1+O>.A#GR%1-A*6!8TT;X.3/!/HV.JERY(ZST/JX\8E=/FREK@<O'[:1
M=2^W3E_G.; ?QB_2?UT.)GAW^&<Y.RZRCB"LBZ $IUD@K ##-'EPW/,DFS="
M?0S421&DC07>5A&';7/T,\9]R@K>_.L-'?R-J!HY\%7O;\K+6BYV]BJD6J'V
MZS47:!$PO@:HQ["(4F?@9)%@:SYERLJ[T+J\PX. ]JY:L.;A"WN?9S2T6"G
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MQY3.D+FH)BPH\")%PJHS"B9S-JV;-XU-BBUNP]B<V$7B#;E0S[(NWLRZD/_
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M>"\N[+;NR=%B0+&W-A&W+M4[<L((V/1RZ5LM_\EG,PSD5:$E$4A(ILZB2%Q
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MW"-3=1B:QL2RQCQ$"5(?;*=%H4$T\@QU^(!%C;^&V;]Q<=Y-*\=OKX'FZU%
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MB\Q:G^ _N$HPSJ%GQ,242JA#[QP]24@0#.,LTF;@V2E=O^RKO+UEUOC->W8
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MZQ7A8R#7S^X8:&1%_J;SE"7!P8*APK&$WXWS+6N5]PT;L3SIKHT^457NL)%
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MT0H;0-F#TP-9W_/?OON'FFS\-33X]<)5&*+9K-/(?#9@/U; !M)GN,?>O8D
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MO;1]*" 7(P>CBJ8NEC7Y"Z?24(;DFGBA,'S[_K'6K[S#@M48?6'C3N\U73/
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M8#\@E/*<B\29GE_0[%G!YU&X2ZAZ>WSLAJ ^&_"_W+% @K)^_%P'UB#VE\.
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MM,_C=_L[GWX7(_-/'[#[+SH#B8V+]7(.H\1\OU\@PX)*QN9=BF&/LZ]N(5W
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M[/EUC+<@KJ),;O6SBR:0NG<G?->1(>J6J$O5NV0ES 0I7>Y06+N%?]9V+N?
MQ+28Z<PHA$7Z7H12UDA"M!>7M(=.P:H@G0>_$9@@IQNO&.K]4_1RU$G?1S8(
M,GB*'+P9PN)Y=Z!3%_/L%U/WM%,T:H0,E6J[.,2=SK>?#OIEYU 1$V14W 6F
M16SZ]VY\RC3S#Q@2&KAPB47'K/6'^M01O]&K(+\N!=@.>=+A!AX[J19V21>
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M[?O-E^XP0?7[8_PI"B%XDB%T))[(F^P<2,RE7?$&P/;#J[2L'O3DN\?U.X_
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M+MN?OS'5'*O][=KE\6N%LQ.Q&]@6,"#)NVI%Y45]%8**UO!3O8!HO"7I1.Z
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M5OS8:YB@^#7Z$U;CK7ZHG5$4S01"FIFK@=!%4@48>UE,4&+5,D-(MQ.S=[(
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M/=_D"([3_WK82?="(.;4=_; [?6I',H?@#M5%B[Q#:$!MQD['C_5LY^Z'[7
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M!@,*R)5Y*K2[S/ID!O[%6JMWU<5C/C'J_)3E8SV:S9]R(%MS!7R@,&2=&DT
M9D9_R>"!J]#SM2')N;T)K1(X_0.!]95JQAPZ#4^FL8+F70W=4YX^LXO'.+^
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M[V@4QZR;B#;:/GZ\S\+KV-T2!WH$U?O_>6#@1?,9,CH)]V"EG9A8 _7"W3L
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M :UOO%O BC?+WWCENDAN)K\MVH6'6#<T/SV8&:$R?5_7@;4_%B[\'<U/QZ7
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M5&%=<.%$2/R6E7)TQNBGRTQQ3KGN-L1_+?XR2.B$"^>T>V@#S&IX\JR$8'M
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MI7\*]];(JD6)KD(2+D0[:T7-(D"=MR4O\8EUVQ!!KO1"XYN,F/QF=",;%ZB
MT"/O&<Z.H:);=WOW ]+K8R> =JY(-!4JANE4U>-D-8?,:N?[7 43UA=5#1BI
MG<_+C9V\,RT>.ID=VEW9U?,!X[GWA;PII ^,XEER&B<M7&\"[P!HI6+V3OK!
MU4;"3.=&8*%'RLFEBS)=*JN#=R>?)HMX.S3$\DD\P3_%'&+[@H4,?Z[P8]PL
M<;<#EJXGC+Y4!ZS[#_9<<\57394DW KM-?B0U(33ZA7(M--:P$F,8TDW8(+
M6PKSS@!;!)B\U%@QE)!5Q+Z:UU&UOS/@O?HCNJNA0D;Q%=)G07O=,_46)>Q_
MX-035?^O#U. +Z(23U+Q['4<"T1;^Y;ZD>O*].OLEW"PWA ]&[*9:.H7<HJ(
MED9LU-R_.C>F(J> Z(T<SX ;HN6!-[G..!B4L!#IU&*6LG[YO?NT98_&DWY]
MSYL1/@:A [&3L?J7L22[;<@-AXDE9A@G+AACBCX&O,G&2[$U8UXO2H%;*T,F
M)5$QFK^;0]WZ#<U\5<C.3PKD*JZ(B_[UXHKZLXZQ;3D?$#=5HJGXMKCKX9]L
MN&W^(27N>V],2GR]"W<[1"(7*X>7$*FOH=7$#@09RSS,L&T-3MC1L42N9P9/
M["P,_]'.2EV*HH129W\D5W9K[8B%\3/70?MB[A"^/GBY&YCL4LP?:7E. */=
M\Y"N8L5QJV67!@_]JIMZ<-0N2_PLG]#-=%OV;EDJM TQ[C%'RUF)8>F@%-M)
M]T:39U<0-J,!S9:2$V6_RW1_F&;/H)Z(J4./2'0$_4G6R#I9NPVAOO10 K]C
M@R@3D2= %8+OM<BTY9ISX9LEM0\CJK)=C@S:Z?R:V!!^>WIFC_</$3OEE%7>
M0['0.L)*-<.6=(D[AA$&BF-YN5RR0]^_"A5\<NQ\<3A=Q4;JE.8/41F+D.P>
M?-ZN=H&*FY!?RRT*H"N3P=/I2_0%@+(B<9.\%H\16[CFB$^ J41KQR2OKNW;
MN-F4K78\JRI3,D^M)$UY60[:@7OH(<&)0U!?(78:$R8(9U65@;E.5M,*?U>!
MY- /[XJ"TYGJ@H-6F96--:T_CT-LXW#Z&_-(1>(M)-F+IK?B^XY+1E2^4(6.
MZ:*OOB85H[8AK1B-%O]3P^*B)1(CS8NB;]XGI5A1Q?7_U#_61IMP<A%^6+(0
MLQSH7_%A^2QP58"1G':6Q3.>[;+:&U.1>X/*Y0/J(YT%!&^UN@E0G\V:NB=^
MA?R9[&X4^M?X TH.IA/3>#/["EHQE\35G)\YP@C8FE$"\V[P()S_M7%?B8S@
MVQ>?Z1">/A,2A]Z'['/$O41=DYS([.>*Z#':QIAGP;'W*$*;C*_Y]$A!3FFU
M"-K$.SZ2>>]-2M4;_ZT$]NJ1OKVK!S[MEQ3'DLYB;^&2X4?K0.\WMRD*:'FZ
M.\;=N7T; F2!@ZZ6]L=EJ$H&&SN=ZL]"4@H>MESJ]!>BK;%EMV8Q62PC[G<D
MD.N.\H:KH\,?+?J&!?+-Z&C9>^TN%1!=;M *ZW-G]-G.D#SYZ)0ZH39LPG^O
M> [G?E$U'F/+WX@L=2@!H58Y%W*EO&/, ^&VV</X/[^^OLSZ+3>()9TQ=N #
MQ68C2=CQH%Z:3THQ:"?Q<.83'<&'UA_\D;OD?"KJ[)ZV@]-[VZI>-\6V[[ )
M;GYG6XKYO@VIE.\.3D("#L@'1'ZV8'AA\2.N_!?:)[O 6K&W>R(CKX47WC]]
MZKWA??<D#4C$K/:+5*02]I8#>6PV(0,@,BN_>P+U\2V6:%@VT/OJTU2.(ORU
MCV&CY9.>ACN*RE+MA;G6G_^X'X=?!R?H_8EP&89>/,: VXH''+#I%,GF<!I6
MRK5VUAIHH_>T.P^>M_Y6U&.EGGQ,XJ-GPU+?'=O%3^C4]R@$5S28=1'5WZXH
MWS'I#J42XL,L/76L.B)5Q1DOZJ^5-ZKW_SUR]^1N:[$?">*HS\$OWEW^/?(?
MFUQ1DBO2K!@0P42!&7KM,?ZMBMFO84XA;DIYKL\&A!_+[%0JT$>*8H:@\D9K
MCXA*X<24QO,9E@];2IG!NH,_V\VCG 9.WG6.?Z* L$*^_XN/1^\KFU9:\6EK
M#)SZ>?)Y^0>OC,\J.UUDD;G0^E]YQ;[0VOI4HY4#;6*N*"[I)RE8ZI3;N.N3
MAQ<@7S0XYS +-!L]]=+GYBYHPX?AUAOGOM7JW9.OB7".P#C57P:0>X"HWT<J
MG3KH5^;->S-%14Q9U;4_FZH:-S[U*[]*T=Z*!V27H!-XKJ@6E1B'%*AQ>'BM
MOKWL$G?V#,OA>61@N.+K/_4&7X\J9<2I02\BW3%]VQ#E&CP92FM&RABYB\Z>
MO^_:$-A9.YRR*GYSQ]WFT-R-_G%)$EQ\9!MR$R^R:%[_(*RI-!E.^>40<D.I
MR9-+%:\^I 7AVY1;S;V5470[^U6WS9#.BIJXBY6_:%=L0;$HA/!SETG7'8Y;
MKYR]Q,.GVN^'?N7E^3D];?@T>=5]Z6<E)Z1U7'=_4?8-;<^0D'PA&^6**\-N
MP7O79YR;JH;Z0^EKY%6C1*Z8!,O0 U6:KGA.R0WG8(@M9:'J/G89LEW)8XQ)
M9,!8(G<:6=F!J)UKGSZ@)P'V.(B!%-+?1G]50<85_57SF$6IB KE9Q0_'^7[
M2>.!3:X]1)H)SW?(G878-@A&%+TOQW&].6YV@/!9)W0+\STPE!C)\+K%8P$[
MX== ]4W^*0P,;0>&S^K%4O:P=:B\29O_6U!,VX8(+5;XDR/P[SJ/_ TK\]87
M@?EUOO*Z?_RZ8?RC+(8S6_8)W8>]>^TD)Q4M^8:]DY/; EUJD4D87;[]M[R:
M'E'?\/%R]!VW9L\3]3+R%[NMA3[%J+!@F-:_^&462P=]"M"92\OIA/+PJHN?
M,UR'83WJ9;]B0Y^Y8BV0EI11%"!C</;1N%(=P9\'')B@W"QAHIAI 3BW;D.2
M3W[USY6H'42FBN%,E+]$P7IK </USY\:?\7"FIB^G,QMB%_P7LQH-W.6\]$8
M+^ZZ]!>9B+0!@A^@U08MZW+$<C8T,NT,&SYG7HSMQQOE]\A=\.0!8!CBYSYB
M[18G[:\D-PZ+O#WV%5^-6QYC-%$1*_M8MNSPA@&C,AMH4B0Y9N[^LOI(A''O
MI&T$K&&\>)7/][522\".;J&]:JH7>2#JF;ES1[\TVA"4!A V+43P]X%&8X3
M]'SDJYDYZ^KC9S>^Z0&GNHX>UXQZT((Y2>"A?)("^P;@<YF#"^!"V6; CT9H
M$EL;JX/O<%=D;T/>OJW.U/R8IZ8OL]R3";^0H/?G9D@#2QC3C9!JD05?=^)K
MUE;L2L?]L?+-D?>V(>3(;!D%G9I\2Q?A@,#GL?N.OG.HLFE>GII RF&]^M.P
M$L1 #I3YC?-XS/X*8T=,(GWLP=I:^@?SVA9G^8M219COD'[3/[.7G_RR?RQ9
M^A\\^C/7 #.FJ@R:S3H#3L4T)1Z/)INE >=3WIA^W@L;*W?47I, (Z]\/'8M
M.\X[Y!!$0:O6-F#7A+H1'Y4" /T[L0.P$01PV/S/W*Q6QXHM?:M#>TT)>6I
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M5SR'OW[MD6D@ZH#[DP;5]1GI+7E5;$K:GGL"!7GFMUC]QQ8X:*&#%CSX32(
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MA!9+Q@7?(C?T!%V'$> WB8L%8T"16J/F&F/K+M9@0X&X89,-E<<-TZO\7NJ
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M(AASQPLQ"N*(:;61L8[A[ =U Q;P'=Q7F!9P=GO4#NY79;J>!K/0_7_;WW^
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MVS(&5$ N:P=H,.'(!-!YU[!$(\O%\OLC:SYNBXS2.(DP0Q@Z"78A2CB"A/
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M%TVG)N5R3%?;N.Y+5OW^<5MV$>$@C&D<PSAQ$$0^0S )Y>0D'E'&9*]WM?C
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MBVH#%:(/-8#2._I&]EV)F^%E9?GFY2;OIMPH6MJGWIWYS.] #H-QXJLDLGJ
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MKY\_?/GSX/<-CD BV3R@Z=5>M#&*#NQ2[-8,G5[*Z1DNMUEAE2VW]")<EO5
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M2KEF17@S2^8'+CB#SX^9-V*1:AS.&N&Z@;D6,.@@]R<I^$D __,,8JM(J;4
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M;S?"C7KDY<=MQC_U/ >SA,/(1RY$/N&0$,QADL8L3<,(Q7K%O<:8S*R,.Q2
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M6\L9/6<QWC-VSC]EV(\#5P_"U9-_O/^O32;\$NG\W1;KC+[LCEA,7413Q&'
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MSG)E=LX/?QK2:CG)BS+6?K#2&Y!B",>8():K$JDL+1@O:(EQ IF(?$@ M$_
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MEY:'YH"\\+._.N)NI_#AT829A0T_T2\;COZBCT71%M^''KX=7_V]W&<?O6N
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M7N:E/CDW; &J\BU0&C8E 0""60Y;;"#-V6#5^_;2NQ7Q6ZP_7BV_O;![)?V
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MI)*""YHD^FQ5F%&GHD(DRS(4\R0F..59R>P39=WY"&S<=BQ$HL>#N2]NIS[
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MH6_W6C;,192YTA,-)Y'HLP)MQV<)J.7]70"8@'=U.X2,:](R$>UQ$?9J#HB
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MG1X:8Q_AM]0 \>\%95@$^=>+"#R1-_0"%.Q(N@3\%P0&1/W7"^X6^I]1@*?
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MLHCV1%9MT=BX+-)$9HCCV%Q=TM" U%.D8A;2.$]E'MIG#,\0&-G1-(4]6Y*
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M+_TFZD-:F&4Z"&IME$/2]-FB?K=CA_IO>QN\N.PDIC<DU-;B!I\;(TO\9O5
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MVM-K%$9,"1T;I85*S!%!!ZLT*U"N3 L75L9)0+S ,,F1O<".HN.%NX7.[/R
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MN<2%?4WE93IC'S<:PD%->;M-06Z?>C1D<5OG1V[@*>*LR"XXN3VR V[8_.C
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M/6M'7A^=6P8\_I"MA?6'BCE ;VI@3#OQSV!C6KYX18]H9SKFF[+BBU7UM);
M7_/P0N/]G)L6Q [Q8$]]E%^SO; ^.PC["4[?)FBE@+.]@'9ONOVB;\0_GZI-
MG?>_6WV11J!R(3_)S?LE7SU(@P]UMWJM3UC:M+Z70HI7SW]44KQ?[GJQ;_1Y
MZWO-W,X&.(Y,=8A D8HSA!-6(*)$@2A+$R4+'>HE#%8V,@:;H]>;=)@.-BMS
MC=RP'2SEID$;U/_6_+G.*JC%ZD=EBN=K_DUZ=@]-2'?,_PT61([R>>U<W$M_
M,N!]P^&WVO%K9E,'#<?!;X;GOYC_;-@.;CN?ZC?#>E N_](!E]BS/XI7'5._
MGOSP*"Q.ZKG'5/*QKQ^5E@-DV&+1UJ)WZCVW=:NVR&$]:XQ]Y;I8!&=JZ2UK
ME@<5T.\#?<H.]&,7Q/98@6LKG!NF6-_"TT&+68AW@#!F\[S#Y=U_K,MJ0W6H
M(-N?G<2,9XIFB(1*F(+<&#&:IHCG7"4JBG$>VG<3'*\^LD7NR0'NDDXT8'&K
M=HU<,&O;4W+I"SB1#7 E=HV,;K=?>XI_]72Y=4F&WGNLDY>FN[*ZQ._![=3%
MAYQV8!T3Z#U_]? (WG>/WIQ@MST*H0UMN:R \\3/R&RUU5XA+GR#[9'4_SY[
M03+7W?5XN2GWU NB'.VDEYZZNKVE@1%XVFC[7)J]>AY',L51GJ*(2I.GB/2^
MFA7ZKT4N*2DH)PF#3:2[2&MD^^NVM@3__F\DCJ*_!\M5\$C7P7?#RM^#* QG
M8?/_I[TO^C_C611',Y(D=7Y;_S7)LIE6R?;ALJJ>]!G7_,?57JZ UB/PWDA>
M?ZQ__[<H"_^>1+/ _.[JA_4?XEF@5WB4YG@B%T"PN+X/:)>)\/198'[BL+FF
MICL+.I1'Z:ZY))[_[IH32B_577-)Y)[NFHNON.-JF[SLAW(IWV_DPU"1[<7W
M1MRTNA#3^QRR/A4:XD%-W3/,]%G)KH*9/EQQ<ICILP*=@YD^_R#LMU6M-_.[
M<F. M-[KW^CW4CS1Q3_*S;=ZEK+!TOI6/MZMFLJ-MAY GPC32$4YRK(D0;B0
M#-$LE"@D+ IQ+'"AK(8O.M >>7>KN3';S)Z?X(=F*.AR9"*QMB (5G#AHNM^
M"Q]9@S#;/Z<\?Z475XC:MRGI93L;DO[;WB6X4)S$65RABJT;N68)^.;5V0)-
MNOF[7-=EYS</&]MSYN45QH]W]T>N 3 DB-S#.[<?D6$FW*$9;(D&$!6 =O!A
M"9VV\9YE)]O+AT7K;N@63[M@Q93+LOHFQ>^KE=C>)N!(;]<%SLQ4]!CA,$Y-
MYX7)[899KG">%H45>O@E B-;XY9B4).$(*.<T85%@O=*"6'&=RB<$_[+&2DA
MP"_72>N6[;7\I$#8ELN2]..UG'EO0J"6RUP?(K3T/.>(2VDR+Z]H)477V7>N
MF%X][Q]IFW7K4XBI>]L\=V RZSJBNV]T^?FQ#B/^4U8;<W5\*]?E2MRM-G2Q
M ]K4!XF$8A$IE/#"I,62##%&<A13Q5-<8,H3J[%L+RO&V#[/@,Q^WX+,?J\9
M"2A@:N4+?V2[U-FO_^E@SKQF%M7<'@50';@]]AQTG]O"'M1RS8)&LBZ8<-!4
M5&ZT<$$KW2QHY O*9=!(. OVL,0><3M?]/OXPOQ\&2&FQ0M]T0]U@C7ZLMRX
M@$C4(WYNEJ)3#/M!ZG\I:QSY_=SZ-".)*"*.XHP5")M_D# K4)*&),H$X8FP
M&D@!HCKR7M.=GL#HPK2(!SK2,)6C"UI5I2HYX)H5ID^+<'P,+0'SVS4']753
MAP?3:62X:&=)6&&\7Z$I"%#$"!IS1(GHU9PO0 B@N/UH$+:+30@% 93O$ <"
M^K)C'U;=WOG'IJ6PFR]48YQD4L1%HB12,L<(&Y@W4L02Y84J"B)PRA1H>ED?
ML9%]Y8X6"!7&2DMV(;,OV6$>T%IL>"^:A3R^VM#Z2$W;@68A]$GSF<T[OUHB
MX-UJK62Y,9?!_Y!FH*(4-]_EFM[+&FG6 &/OSXQ8A1E/,H:H+!*$%4L0RY((
MI6DBDRQB"2U@P[Y^";'&3A0TK+3XLG]\?1,\ZL-B750#A)G]-=3UXIF#L;[M
MKYI)Z,@["[82!ZW(+="V$?I_6(+!Y3/^\@D'D%#_ER0@7#[D= D))^X<>VE;
M1#?-7PWGMA3ZWZR?9#>R-WA%S<BD.0N31,4L0E1@CC"F&:(13E#*XA0789[$
M%(2" B,_\JY7?P9@KRI,?7;;T'A* 68HMFB,+2/UB;MEY?#DO>?&8Z^HDQ9\
M=8'"B$_;W^FDF)/.3;=57 O:.[,X.AZR9:)<WK>S&D.,62JQ1)PKBC A(6)<
M4I1F9AZYU$=[:M4K!B4\>NG/P2R2^[6$-':"M6CG9L;0#<S!](QHV3,QR=1+
MJ"Z\%:=;DIVX4AVFC-.R=>#[#G<K;\JUY/J;5N^U2$M#R.#G:&GSMEB%1CS/
M!2^0)$HBG&0YHFF>H2)4)%94I2D/K>]4AJB-[#YVY.LNF?SOP8Z-&MTI,(P
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MSS M X'F@"YY:>9XZ9BVN7.JV0GV_-BCO5NHL=\W^%<.\#@#T4OPIV'&0TP
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MJ?/<\SEKQJL$!ZRVR(NS 22$,3\'P)F_R&=Q<_R3?A[83N%=B[V[BC]JT^U
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MQ]WJ-1]@K@"L8COW,*;B8"ZCDZ8RU&;!EIF@Y2;8L=,\4:,1^/,CKIKPY%O
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M/ H)]RRZ'Q!&'VT\G)&CP,&;4UR<D$K[ZV+^Y^K+J_GIUS"C;<BB34(-C!A
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M<'-_Q%7H9IC?A,6,R%^^2.GL]&Q:^RF\QM*E;C7Q+!.KG">/VM1"SV@@<(W
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M_/A.'_-=VVFN*#;0N8 *M9"L]B*L_48@H&)"!1%<\RXN[;GHHP[BI _K)@%
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M>>VV$WJ#7BL%%!YH4-IJ\,%8B"D9VER6%][Z%FQ/$J<-]1N XF'?NA$UU $
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MY=>O%[2-WRSR/[%FT!=YOL;_HLV[VO;C^K383O&TQ5FM2WU_C;:^T2#&E?;
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M[2/;/K#Q1$5_=#R3Q^5KKRZUZ]45L("@W9.%2B6ZAIUWNW_JM)=.!SUUVD?
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M1Y%1<XSI0(Z:K^TNR/0%MYW/&)/VI63F6[^G>9VJ8VWC 1'RK6YF3C"=+&K
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M?79_:#A<<<MV4IP0!.O59O8A+#[A=EN(;$LP=9",%=N9CQ1(&DWRJ.6F:&Q
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M52!H]]B<M/*B=4#X$CW3EHNT=[V:R;X''-VUO3M&GK;!A<4DL]6@4-:[ F'
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M*(50MDT*=/;@:]M.[3R36><D5>N'UF/P,7'#B6D]Q7&UWB/RM^*=)8RR3OH
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M4F^^+"\7FQGS*GMEZ_C?Z&IOU@2!80;A L]1D1!SZPN!%\CI,'ERH-:' .H
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M\;0)KA' /($B^X#M=MF[SO5O\W"U!]]>KJHRWBPR^<KIZHN9TUS82&YP2-&
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M-K;_?O\*W/9N:\_07LMY.]G,N$FZ3;=-.TEZ>_MI!R(A"0U)< %2COK7W_,
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M>6LL*N'7$=M'-J/9Z5*W&QJWGR$^*:QA"2/;1*!)6!UY!1YJCF<N&G "V(4
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M)I$-81H0Z:I!^*FK.4 ^U6?/X)Y$.7,^F>NK803E"= C4)3$8DU(<Q1=]#H
M4\=%B$B-@.DX6;8C1>V?.IHM:?+--.9+L;.MET: '62=BV2"_3&@Q<):6:\$
M#4R8&^NLXO*IN&9>:3*K-%-220GE8*D:RW46(5>8E\:I+;'D41IW;X7]SDT3
M]B2)VXJ?09JN&/V^'@:@X$-MVF%B&MF2,L/XRSR"4*P;\RE+F$B-0--Y.XB:
M!!$"YB<V0:V$M#; U[9SVR1UC!2.(PS&&A9_>X!1,/=GFK+2)$MVH"804 2
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M(B5X#VMV*(OAC5222ET-3-OPPBGD"F=&XOGQL'7!(O-N54K6$R1#=468.J*
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MDU5(9)MAIBI+4U51OX0\%9],Q.8GDPERIQ<@02: O-QGAK&;E^;!U9BNLFI
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MO^4#>U^J!1=5]J7M'+0?790H"G2QL!ASFH!G)1^CX8Q80J>_M#93^X9ZX5A
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M? VYXC+&&("P6]O1W"[D_)^8Z/#-67\L)OK7N2DV\->JK<K'_P]02P,$%
M  @ PZEL6$VS3[V^'0  2YT  !P   !E>"TQ,#$R:FEM:&5R;6%N>#(P,C,Q
M,&LN:'1M[5U;D]NVDG[?7X%U]B0S59PYH_$U8Q]7C2\Y<39Q7+:SV3RE(!*2
MD"$)!2 E*[]^^P* ('6Q-[$S(R6N5&Q)) @T^OIUH_EHUE3EXT<S)8O'__'H
M/T].Q#.3MY6J&Y%;)1M5B-;I>BI^+)2[$B<G_JJG9KZR>CIKQ/G9^1WQH[%7
M>B'Y]T8WI7H<QGGT3_[\Z)_TD$=C4ZP>/RKT0NCB7[?T[0=WU/G963&^??[E
MG?/Q^,O[,L_'\IZ\?^?VZ,[=!S_?.[\%]\+U?)-K5J7ZUZU*UR<SA1.XN'\^
M;QXN==',+D9G9_^X1=<]?C0Q=0-/LW S_Y/'6!NI4>^:$UGJ:7U!"[K%MX:?
M<U,:>_'9&?UYB+^<3&2ER]7%%V]UI9QXJ9;BM:ED_47F9.U.G+)ZPA<Z_9NZ
M&.'TZ..2YWL'QBEUK<+\>=+/W\WT6#=B='8Z.N]/>?-D?VE=HR>K6UM7^@EO
M^WC$&;V/..=$G,E$Y8U>*/&-K%MI5V*4$>,=XHJ)';Z1.-CGGSTX/S][^(VN
MZ%^CA^)K96'LFS__.[?/Q!,+XK\TIA#?RRLGGEG8P)L_\Y?2S1:Z+%4FWKX4
MM^^?CT8?F\OFLBA IYZ4:M)<W+X'TUH?B+_2=0$TO#C!BZZ)'J_5YY_=??#P
M\\]&]\XV_/]Y-2_-B@R&F0AF6V;2+*S_$\V:1KS0#9 M_X!UB.?O5-XV"0]>
M!S7%S2+*_^A<B5=6.8U\)E[*1IM:EN(RSTU;-RX33V=:3<#<PS9K6</5WT\F
M<)/]-,R])]KYF9)6@%;.Q,$:H*TF-Q/-3#LAIU8I$ONC9J:"I;H,WWI[=2R6
MH$J%6B!_ ?/@I0UH![B_+D1NZD(CQSG1 B]8L9SI?"96IN7;QDHH4B_@A8Y7
MXFE;C94M\<Y7,PDJ)E<@S[DLG7A1YZ>]B2##RGH5IG$*5^#CD,\M,3EJ*WB0
M%7(^-[IN:"G2W3#YC#I+_'%)O19U!U3&7?';D=&V&_C&BBDZ!OAQ(<M6CDO5
MWY^,[K,J5WK>T'6NQ?5HX*,5#LN\ IP(@RG@#IE?U699JF*J"KYY+FVCE6=5
MW-N)*4NS=&3/#E9P1Z?;3/7U,0+K^T+EAC?W@L0=K[KU&%E#U8Z^__RS._<?
M/E&UFNC&G5XKXXJW'=LR!SG1&.!1/UM%:NJOPE1'\G@;5Z5T(JT]ERNF30W_
M@>DHA9,E&I")L0*>OP"EY,1<6?A<@68G%8$2.@.NL/!%HVKXQK0.I;X \DKK
MQ-%_W1Z=9;#*T[.SXTQH&!PTGRU(TRUU,TOU#*K]T?V'#N=B#<[)2C!F\-Q3
M 6;$8F!2@C;RU@5UA$5]H0L<6/V*DZZ *+-R!5\XT-8EV@<:CU05/AY&P8F9
MFIX\^B3<>O]T=/=#Y&MN'!G2"ZM*B?;B86/FX%F=/L#;%\J2G?2L-)9.L>RY
MYEIEK)"DR94$10[34W4!;A71';;I*^ 6^F6%SA8J>;B4A+% 6>#] (ED(]YC
MM. \% I]#7@NN0\)?^#^@881SL!>%MKE5K'ZN?OE0^ 5@^X*&)&962J@'5H3
MV="SS1@HR/X#/+J25\@U*YX+NS#D'+U!UPFN&8'<\&QR!407*CI5[1R'H-GU
MW1'5Q5,H+_A0X#-G:B#)2],@IP,_UNABTXK@(C4%!V::B1H,*WZMZPVSD"4\
M#;C5HLD$?P>(C:)F^ <:2L)^X5QA1BV(PX89@;HK%%!+CQ5)2GC";19B&#DZ
M@##=2U8&Z4ZE1(J7"C>3O&&UHB@2%]W(=SA9]A5D13X.4.+75EN>]YC%?J;*
MM=WEAX!C!TX6B6LIES"?P]7.XZW:^:?4EX:I:B0'4(]\HUS/T9"A,@.J>>H!
M#Q31[U9P'UMC5+EYV1+?+63.3(L*>F9*C8+<P(HRY!"@.TA0)W-/C+2DY9_!
MUN6-L:B$W\9 (+(9S4Z7NEG1N-T,\4EA#5,8V28"3<+J*(3PKN9PYF(.$0/'
M&Z"R93U5S) P4]>">N&?4=327RM8$3Q.5BPG$VLJ6B'2CO[6K/8[Y3%P=;]P
MFQ9^N"R8_V$6C.([-G7K<&>G5E9'#H*W)_B-M])HO0K6GQ+=L?%0@WK/@AP#
M&+=2L#W M&PGG -:P?T02,TQW""&HR ! Y/Q+ZR>^>,FAP+9#Y75EH>@4?&V
MJ!LL8[T9;1&QXGN%9,!/J$^!-L2R3*!HY2(+HNW#P<,OKJ4Y$,^F\D;*OM..
M/7IG_4LYRO*_!:FH3*$G.H@%V6=4[_BW%XN!81VL)5)SHVI(-YM<,E.#&T9K
M,*Z/"*1*W_MAJ(K&Z0C>FA^PZ!4[18^Y09;.<#0-SH<4L)L,V.[ 5$"VP!>#
MU9C\*A/SUKH6;T*7@;\49LY6H(."//KRYOO+#GD1;Y!GP<:#S&UC3;@ABASS
MGE/D (%?[UD*S \\ J>?)Q$CJ>\>>@37KFCGY1*8"S9>""0#L"[(8;.1#0?<
MFG6$*AB? G&FT4@D L.A+]+ H/S8S0O3%ATFX!'*I$9"=?IEQZK<[F4=+#^?
M[QF \:H$H4'&2%(AUQE6>8;G6)S-%!N_HB5+M]$%GUO@1+#%):A:TNJF5D%K
M,\*!YNTHGRF0>W;RO/DX)N3C@+UK<8V[N8OOQ/]>+T 6%2'6=?S:@C>' 29H
MZS2#JNI:.0?>N-F>,=IW!OD9_HC7JC*-"M)#\C8S%9D0L'M@8V9F":9R;'Y/
M#GPW(=(ZF'4@:%@9$^X:FZ8QU<59=XL<@R%LF_5;WE-,P_^?V2X#.%4G8ZOD
MU8F< %-<R'(I5Z[_^$]2P'.]?/!3P#<(H&'0R!);B*6Q5P&]0!BCU!Y&;#":
M;1#+!";)!+BM!("$Z"#U->:HJ'UF(XD^X/((JE)DL9"ZE#Z0+EJ+>GN,-5S(
MA3/@2XQ'!(RG*#3.*1;#^7%R1A8(M=7\-48Z6USW.83]>0B<(KP*SHJJ:31\
MK/4R<;B^RNT]\U6>M3'8?6KJ"6QA0S[M"V1$=;UP<.JWS.1"<:Q;=#->B]F;
MU1Q#%5"Z$->;7).33;D !@*\8F.^[C"=@ &L@SKC%=_IVCF*E#/63PH=[QDA
MCS'5T$DZ0[']V )15AX*8PL?LUJ:24QO^] 4I''2EN4)S8 4A9I@Y'/:D:.
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MZH(2-YV3H"F5<)&#(VV=9@DI<.U"A?3A.K*C?>O]_(8.:S<W(0GYU0;8[W=
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MO4K;+!SJB"=:YPB:-"U\$=NHI2<!9BL7G"4ZO+%^C >^E;KV]G7'R:J ,DZ
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M#SG\Y]@4*_AKUE3EX_\#4$L#!!0    ( ,.I;%A5</.SH1T   >;   >
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M:B7FM0&^^LYMD]0Q4CA),!@K7,+M$4;!VE]H2DN3+-F!FD! $0&"VIB'PQ2
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M@]Y\"Y?!$J<;(#GSW+$V9\DH'NXHV4$L8YV.M\!H"R[#FNN:@X$KM3L60K;
M$B4287"7FG17&_B$2$2Z=7/;3%16RN!?Q]@[;#@/OT\4/9\\FT E.31R:3H@
M=,V..A9]L%6.\12VR5:'VBUDCI+.E<KH#>\F'9(?"$VU,[ AH)Q&'H]^YC:^
MV<$V=!KF0WAG3#?^>@GF+OE#Z&4O-:B'P$Q3A4X.F&-,-Q+CU*:4=9XA"-%<
MGP(VH-$H,9M#A%W3,.^XC\\\^2E_)E,J.QB$WK.J $ ;QV9ZO##E%3S_5$^0
MUTF,*;AQ1 _(UKN70]66GV)FL_/HD#.A9Z=[9FZIKX?77X!1/5RFN*8M!W9(
M<&S548.^)U(>HS$)*9.F)*&.U3THBN!%'9W=YL.<O1KE]@5\ZOY#Q\\5+EB1
MH@<U2KQ5%O0?ZL)-=ZO8D3,$%P8+4_N -SJ#?8L +E1='Q]'GP8&-JL6VS?0
M:<6YJ2O\@)$K^M:P!T6XWW6UEZT?!N*/C[E"DZP*9Q(:B2<'0L \IA,P^$]:
M-T5GS4*WUQQ[W9%+H_I4X<#2UGRB=MND^9PFSU0B.52UX0(?C1_+;=KC!./3
M<'E6.C!!WY&-13S2,!XL]QTS_[UGG]S<ZN#";7].N%?XH@UQZF!2UF1$2A];
M/(#KI0IV9%'/+%,9G=R(/FZP]^&JA-WM'EYR"F'6ZKS^'-"JK,1,8<)J 0PC
M (LMM@0GJM1#07+V.! ^!"H&5U,Q(?X#T4TH6QY$XG]J"3"^013D8JLO+BH@
M0[_1I>0T5*;W!6"$&$='$+-=2&2;8=*JR+-62<G$E!6?5,1N*!L+Y-8O0()"
M 'FY\0P#N"#2@ZLQ<V75@![8S:YCQL7C_,E=VXQR->M!N?C+*95W=];W/0(B
MB!MHRK[S"IVK(W!54YT8[@C%R9B>Q$M%M.BC]7V;M"UC#S)I2%>!A3I\R#^;
M9W*;UAM+?S97G!VAXJ?3<.(T+9JJ7CYXG7$:]+HX \@>9*-]OU($P@Q'_3SP
MCT^N<,9=P7IARK?L:WA!U<ZHEK[$.A*N$H91#[=@X9I.'6\_0$;[ A\L^DVA
M ([!QEJ><3@C2Z%29A!^0L/3"BQ4=H-8P<!D)&-!Z4*<(I2K5%2=7).>R@;G
MPRS7A$MQ>M8CN&CBG @IMDX\\(K>9[\#;?@TUZ@!!F:=HZRDO#?Y0AM[93^+
MK64Z2A7.BK@>$;@$"5P.1/)3/AF4^-#;,B2!%>-#^W\B?D! 1=6K(8H/<D9M
MV@ "E-0!XMX?"&#46:P=@^'QY%AH X'A76XA$2(P\>0G%XT=Z=L@Y1Q3QD+T
M-O:\Q,B-Y8- ZETYQWX]M(LC#7< X8G#/![IP3!,UE+N")C_=@X$7<;)5+%$
M\#F:CNS"&%#.T"M&E2GW, VZ%#4[*#NL:$LR [I,DJ4*O<QP-;M0-?' B-C]
ML0<NI]N*?1/3T#JXTQBIZL#>P&WP,P&K5/30U]31N->A^8&SL!X4T^ %@R+%
MO):&5L/YDG'L7@12X#FF0>(%O;A7HPYFB8;A8?6:/^0%"#MB %-M9':DU8["
M^KN\"5(6' C+\.4 P<;L1)];H17$>E..GV4-B3#1"N.14("(:<RW5QTV"6FT
MHT,F"ZO#W?RTIYYQUG9"7I-:^)=+A6^^$.#?J? ;:BOTS3ID$QG:;A[6RAKU
M]F9EW"Q@PR,8M?P9^0;MH./@V=F6;,?8?PB)QZT^>"H@"H=R=Y<0]CE*O&Y4
M4(C+@E$DI7WQ2%DX)-)7HQ?A>!4>D:+B\?X(".?)L4LR)W!C75 &TSD)FE,)
M-SDZTM9KEI@"URY62!\ND#W;MS;(;^BPMO\2DI#?;@G[_8Z0'P67TJ<LQ-1S
M,?JFB#,0VO/^=UODE.1,)_E-R-ZEXC J+94UF_O%H&-97\>:8A.<Y4=;VW=.
M9]3+2<K48)QR^YS&W#PU/@=H-U'@HG+%25KEYI4P,LV=6G;U"5WIXOX#1DUE
MSK'P)3M73B-) !&VR2)\5RUFF;#>I0H:@*I.,5>YT9 !YZ.VL!GA^Y7GTZ=G
M75W_L-D5RE319HNV!7IG#/,1*6!VY[.XBRX3K-_I*G[(P8:1K[@Q*P:.QJP.
MB[ =_F-.QZH,]RQP*7,,7P=/@O@U]B[=G#RY".'08?00F9,+XA6,E(+2MST/
MI2=.F;B4K2'6'4=>:WVEN-$BQUVWWY-SQ.&:EGWK01?;VR O/0NZ[*:/<_Q"
MI6#Q[ %5,U.+72\&!SM08E"%A:;-PVIC/)-7]_(: JW<4&38LK>(A29#@2 O
M-9.)I/$!U6%!LO/!J'"JFGML!,4^P)8F-F)<48<,V-:29B6'D.;1(!3:#HYC
MS(<] OJ8"2G\/.T]*G [7,G:MQY2KY7O+&52XLO\;EJN!I6V13S4D4ZT+C!H
MXCOX(K51RT\"S-<N@B4ZO+%YC >^E;H-]O6:DU4QRC@%^K#S$XKZMT22^+S4
MH/YW5VW(]8>(MQY$>?_1GUC/0L]R?,0E'K2!G2FL3(K=E,)X>87<MK;]V8*Q
M9'1!:HM*8L>4V&CH_TN>(,?EX8XB*?I2H+BP>'R-MVF#.EQ0QH0;<US?FNAP
MM<J^M=YY'8*67X")WHC5!*$B^X9<U <U1R8Q'5$LL2@/]$\#\'@CWMNW*4=@
M#=:<,KNR+K$:3A6;U^)+H##C8:E\D((<Z.<5(D6.@HGE%3;@NZ[3Y&R=247
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M_,&C[-&]L].SL^-,:'AL#HQ62#0H*]W.4PV$"G_R\+'#65J#L[42S!C,Z%2
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MHGHG 24)'PI\YDP#)'EM6N1TX,<&X36M""Y2,X NLTPT8'+Q:]ULF86LX&G
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MM;XFY[)=+R4!!QBDS[QP;-U2&(7CXYML<2I>-C,Y\\%M''')_&>Z%I/)%*G
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M6'RPSNUW>Z8.OP>IFO7NW)L^*/?<(%:]#8KR%TJS(W/.,([RF@+\8]CM4W
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MS]8^F\C0=O.P5M(YN#<KXV8!&Q[!J W1R#=H!ET0)Y,MV8ZQ_^ 3CUM]\%A
MY _E[BXA['.4>-VHH)!:J3K4L-K-\4B9/R325Z-G_G@5'I&BXO'^" CGR;%M
M,R=P0UU0 M,Y"9I2"1<Y.M+6:Y:0 M<N5$@?+I"=[%M?YK=T6+N]#4G(/VT)
M^_V&D!\%E^*G),34<S'ZIH@S$-KS^G=;Y)CDC"?YC<_>Q>(P*BVEGNPPZ\6@
MBUI?QQIC$YSE1UL[ \3VC][R^B1E['A.N7U.8VZ>&I\#M)LJ<%&YXB3.<O-*
M&)F>'=N(]0E=Z<+Z/4:-9<ZA\"4Y5TXC20 1MDXB?%<-9IFPWJ7P&H"J3C%7
MN=&0 9]'K6H3PO<S3Q\?][JX?K/9%4I4T6;;N 5Z9PSS$2E@=N>KN(LN$:S?
MZ"I^RL&&D:^X\50,'(U9'29A._S'G(Y5&>Y9X&+F&+[VG@3Q:^BGNOGPZ"+X
M0X?!0V1.SHA7,%(*2M_V/!1WG#)Q,5M#K#N.O%;Z2G'S1XZ[;K\GY8C#-2W[
MUA<OM+=!7GKN==E-'^?XA4K!PMD#JF:FMK^M&!SL0(E!%>8;20^KC?%,7M7+
MJP^T<D.181OA+!2:# 6"O-1$)J+&!U2'!<FN]4:%4]7<8\,K]@&V-*$YY(HZ
M9,"REO14<@CI.1J$0MO!<8SYL$= 'S,AA9^FO4<%;H<K6?O60^J-:CM+F93P
MKL";EJM!I6T6#G7$$ZT+#)JT'7P1VZBE)P'F:Q? $AW>V#S& ]]*W7C[>LW)
MJA!E+($^[/SXHOXMD20^+S6H_]U5&W+](>*M!U$^?O0GU+/07HZ/N(2#-K R
MA95)H9N2'R^MD-OV*H%DPE@RNB"U126Q8TILO&3@ES1!CM/#%052]*5 86+A
M^!HOTWIUN*","3?FN+XUT>%JE7UKO?/&!RUO@8G>B-5XH2+[AES4!S5')C$>
M4<RQ* _T3PWP>"/>V[=.1V -UIPRN[+*L1I.99O7XENI,.-AJ7R0@ASHYV4B
M1HZ\B>49UN"[KN/#V3J3BH#+XOD["A+W LB=W6E=7$MN%;[;(QM'7TA]A7PG
M/$UBN1U5O%+Q1 A3]23QY:$^><K=^F+&T2?(X;9?NX9?38*],57)E99]O3M'
M[D<7)8H"_2RLT-Q,R+.2CR%Q1BRA$V!:L*E]P[UP5B -.7$/,"KY@SN2DXV1
M&'AN4&/.*#FJNDF-+.@HQ$)+;;CF==Q!;Z/J<+/'$Y4!4#F_::@38NHK#M]4
M I3'''X?LY-M:RQPB/.1/U%2,PARYVA?PH(&K[88O%WE<-7FOC4Q>J&FH GH
M?<TWKC<_XMI0"(*+IS%RA!.G3BJN(Q;%S"8;<PJ 4(ET6!S^HCZ0A/NVG</W
MLWCU%^N+?<5Q?'-$/+B"G/TG8^"I+VPW\WU070T.?2XN\[8_88I=ALI1B7^"
M>C#49GQ'#IZ_\S7)A79^TK]!2KYZIZ';/\7)OC5#XN,K-^T1 ;]RHZRDJZOE
M)B9MK"6D\S;-1]Z*Y7SCOA FG"):GV&8P ^:X_O=J"ZJ]L:1#ZCS"T/]29&1
M@^&+E7QO=./M9*6P&Q!VD\_$9=MRH127J.V(21ZP)=JW-BH_2]@72]V?7G)?
MXN1%O/#E);[,ZC9$"S!HOZ+)(B_[^AJT)^L0=([89PO$[S%G."N#065^L6QK
M.U7XHSO\ #^@ZZ8.'6!T$3S&'C7[\Q":D9SOZ]R_V2: 3"X&W+AY]+JPT.Y/
M*__V(CR'%H_1]J/Z3L&AP57#!]9$T57KM+U2-.M42+'9C_-P17#?SK[_F5Y/
MAX'5&Q>Q[;9D_/Z\2JYBE=);!F]E_\H0;\< 42WHF#:7+V'QW$ZYI.9OCGI(
M7_^^)7YY5(83H8):A]VF6U]IM>W])7TM HFV#\O_ZH-U(>\&YK3[_ 4&_W*5
M3?<.I;+IJZNL?3N?_I)##KY/^PVKK5=IG"^&NSZ.!D#KA!?!AH,+C*^[1H7U
MH3+A-W[&X>)K*6,XC%%R+3_HNJO#&=C0>9"&"-WE.=:/^@K[66T/T\08/Z4%
MX'\Z!\TA'JK2H@;!APNASW>?'MTO(7G;V:5>RION3SU^ 33585R;7\FV<Z2C
M]0R25OWK-[;TB*<J0WSA"%?<I%EB>*8O@'3B028>9N)1)L1WF9B<95@2B8^8
MG(^>&\X>)1._KBVUL=M>,+T=@WM,K1OAFQ36AEI"=&A-$;]C%M(G#S@6G?22
M@^OU3(>WN/B30\D+'I,.;#AZT 5.4FD*NA_7QYT6^$;)9G92J;*].)\\@(V_
M-<+Z%M]%:3&VMJ9W5'V615ROJ&XS.<3SGWYX]O+-]Y>O7X@?_W+YYH?+YR]_
M>O?J^>7W;\6KU\\_SQY_/O+L+Z&?K2G ]/[]%U:N-.*%;F'-^3]E#"B8XNA/
M<7GZUU/QW_(?NM8W:1O>;_WO_VM[D\5DN^)]7PVK?-W;OO:&7=+13HY5^9:@
M_$(O?@=7P^\==K=_(3*&#QZV9%-_D!:LY?G9^3T2ZW]O_-C*SAIJLKK'2N_Y
MW +R>H;13*PBO'V*[_W!LL^/5L-#&\";G)5Y_\4YZ+=6_^XOCPS TMWM6(F_
MT@V6(=(U_PXC;GTCU6\+(_YA:HHU_#5OZ^KI_P%02P,$%     @ PZEL6(.>
MQ9"<'0  ]9H  !L   !E>"TQ,#$U:F]H;FAA;6UX,C R,S$P:RYH=&WM7>MS
MVS:V_W[_"MST;FO/T*[MO)UL9O+J-MTVS23I[>VG#D1"$FJ2X *D%/6OO^<!
M@" E.=EN$EMJ,[M-))$@<' >O_/ X<-Y6Y6/'LZ5+![]U\/_/CH2STS>5:IN
M16Z5;%4A.J?KF?BY4.Y"'!WYJYZ:9F7U;-Z*LY.S6^)G8R_T0O+OK6Y+]2B,
M\_!K_OSP:WK(PXDI5H\>%GHA=/'W&_KV_?MW[IW<OCV9JINW)L7->W?O%C?/
M[N4W;^:GD]O%Z:^W3F[ O7 ]W^3:5:G^?J/2]=%<X03.[YXU[8.E+MKY^>G)
MR=]NT'6/'DY-W<+3+-S,_^0QUD9JU;OV2)9Z5I_3@F[PK>'GW)3&GG]Q0G\>
MX"]'4UGI<G7^U5M=*2=>JJ5X;2I9?Y4Y6;LCIZR>\H5._Z[.3W%Z]'')\[T%
MXY2Z5F'^/.GG[^9ZHEMQ>G)\>GLXY<V3_:USK9ZN;FQ=Z2>\[>,1Y_3#B#.=
MJKS5"R6^DW4G[4J<9L1X>[OB[\R\%M_*JKK^4SV]<_N^^*>V%TMC"O&JE+FZ
M_I-^8D$UX80S\?:EN'GW[.3N-1&Z1A8%*-RC4DW;\YMW8#7K _%7NBY@$>='
M>-$5D?&U^O*+V_<>?/G%Z9V3#?]]7C6E69$U,5,1>3H+B_]$4Z81SW4+-,L_
M8!'B?W6NQ"NKG$:"9N+I7*NI^$;7LLZU+,6/TRE<83_-ENV(0GJFI*4=S,3>
M*MVM9B83[5P[(6=6*>+F@W:NQ)=?W#L[.WGP.'Q+GT\?'(JE+DNA%LA-P%AX
M::ML!??7A<A-7>A6F]J)#IC!BN5<YW.Q,AW?-E%"D=0 \IJLQ-.NFBA;XIVO
MYM)6H%R[5N>R=.)%G1\/)O+45(VL5V$:QW %/@ZYVDI\) HA/,@*V31&URTM
M13IQO<3QWY3&JV 4)"02WE,\HYTU\(T5,S2"^'$ARTY.2C7<@HSNLRI7NFGI
M.M?A>C2PR@J'978 9H/!%#" S"]JLRQ5,5,%W]Q(VVKEN1&W;VK*TBP=:>*]
ME<W3XVU&YNH8@75ZH7+#FWM.$HU7W7B$K*%J1]]_^<6MNP^>J%I-=>N.KY1Q
MQ=N>;9F#G&@-\*B?K2)-]&=AJ@-YN(VK4CJ18F[DBFE3P__ .I3"R1)MQ-18
M <]?@%)RHE$6/E>@O%%%+(V8 T]8^ C?MBN8W#N08=,YE/RUGT4!1)?6B8/_
M.;MU)SN[=7)\<G*8"0V/S(')"HGV9*G;>:I]4-^?WGW@<(;6X$RM!"L&LSD6
M8#\L(MT2=)0W*Z@Y+&H17># ZE^XE I(-2]7\(4#-5VB8:#Q2('AXV$4G!C8
M$'SRZ2?AX;O@^7Z(U#7&D04]MZJ4:*X?M*8!3'5\#V]?*$L&TC/81#K%$NG:
M*Y6\0I)^5Q+4.TQ/U04 *J([;-,WP$/TRPIA%JI^N)1$M$ )X?T .67K/6"_
M@!H*A2 #GDNX(>$/W#_0.\(9V,M"N]PJ5DJW[S\ 7C&(4\"TS,U2 >W0QLB6
MGFTF0$$&#O#H2EX@UZQX+HQ="!6]0<P$UYR"-/%L<@5$%RJBJ:[!(6AV0QRB
M>O\ I0@?"GSF3 TD>6E:Y'3@QQK!-:T(+E(S0"ZS3-1@;O%K76^8A2SA:<"M
M%@TI !T@-I %%D$_T% 2]@OG"C/J0!PVS B48*& 6GJB2%+"$VZR]8>1(_*#
MZ3YF%9'N5$JD>*EP<\D;5BORBG#1K7R'DV4$(2O3X2 61%-;GO>$Q7ZNRK7=
MY8< H@-T1>):RB7,9W]U]F2KSOXE!=$P58WD .H18LIU@^8-E1E0S5,/>*"(
M@%O!?6RC4>7F94=\MY Y,RVJ[+DI-0IR"RO*D$. [B!!O<P],=*2[G\&6Y>W
MQJ(2?AL]@,AF-#M=:E#Z.&X_0WQ26,,,1K:)0).P.O(=/  =SUPTX"JPHP$J
M6]8SQ0P),W4=J!?^&44M_;6"%<'C9,5R,K6FHA4B[>AOS6J_5QXC /R5V[3P
M_67!_#]FP2B^$U-W#G=V9F5UX,!K>X+?>"N-UJM@_2D1I$W&&M3C#0(&,&ZE
M8'N :=E.. >T@OO!EVK0"2&&(]<!W97);ZR>^>,F0('LA\IJRT/0J'A;U ^6
ML=Z,MHA8\;U",N(GU*= &V)9)E"T<I$%T?;AX.$7U]$<B&=3>2-EWVO' ;VS
MX:7L>_G?@E14IM!3'<2"[#.J=_S;B\7(L([6$JFY436DFTV0S-0 PV@-Q@U#
M :G2]S@,5=$D'<%;\ST6O>)2T6-ND*4S[&,#^) "=I,#D)<$4T"V (O!:DQ^
MD8FFLZ[#FQ R\)?"-&P%^AB0#[N\^?%Q'W(1;Y!GP<:#S&UC3;@ABASSGE,$
M@ #7>Y8"\P./P.GGB1])ZGL0-H)K5[3S<@G,!1LO!)(!6!?DL-W(AB-NS7I"
M%1R8 G&FT4@D L,A%FEA4'[LYH5IBX )>(32AI%0O7ZY9%7N\F7M+3^?[5A8
M@]([R!A):/\JW2K/\.RALYEBXU=T9.DV0O#& B>"+2Y!U9)6-[4*6IOC'FC>
M#O*Y KEGD.?-QR'%0_8870LA_@_^'\0>4_;_Z@"[H#L%NNFE=/,%T!K [UM5
MU\HYP)YF>V9DU\GQ*_P1KU5E6A5XA;AK;BI2F*#E0:."ZPR&80(0YV,3(BUQ
M6 ][C(L>PET3T[:F.C_I;Y$34/M=NW[+>^HD^+]SVV>Z9NIH C[ZQ9&< E.<
MRW(I5V[X^$]2FW&U?/!+\.8I',$A$DML(9;&7@1?'9WV4ON@68N^6XN1.V"2
M3 !((W<_8.'4LC8593K(QTNP-EP> XN$HQ=2E]*[C45G44M-L#P'N7 .?(GH
M6\!XBAS!G#P/G!\G*&2!@:6:OT9<OP6H-N#DYL%-B,%$,,VJIM'PL=;+Q/Y:
MYIL[9IF?==&U>VKJ*6QA2PCN!3*BNMK@9VJEYW*AV+,K^AFO>:CMJD%@#DH7
MO%B3:X*4%/EFM]<K-N;K/H(1/-[U$,9DQ7>ZKD&1<L;Z22',G%.<+0;6>TGG
MP.,026-,D8=").T]-$LSB5E<[XB!-$Z[LCRB&9"B4%/$^<<].0I8\8PB] ">
M%X83,%8@3F:';@K"[5$Y/"&(^Q$9 0P.XM#T"^RQ']X%3R-JCQA+Y+A!<"?5
MNX8L&-ZO*P0YNDT]YQ0U96%0CM"2DD, [Z8RW^#V#J+.G/B&!Z@V]3V8#)S'
M]$FH<G5)?F.S7DJ<>QBDSW)P'-M2R()CT>ML<2R>US,Y\X%D'''!_&>Z%I.V
M%!7 ?:/!N"*2(C$L8/BS]O*585BM4"W.*T$*05UC#"C%IY%5+Y,"&!&#+:,[
M9@8]UE$,9TRU#-E4(@,!82JZ&H6D!$"'<\%-T$ W#J/P!G8-&0;DA1C]O#QJ
M#R+TPC,4V#VU4$RGE1>K!M@9^)C$6-<+4RXXD@XNM6X[GUD@PIJN+"XG+TLZ
M;^.8L++ +!9!M &-?S,3H@NK[0%Q<(J V_"QNJI4H?EV72<>!(5I$H6Q-4[V
M;0<:$F"B@]N0(Y\I#/<1@?;6/-[:,?/X_!T&')2[6C/XC$%;B/QLTK+!AG (
MN:;B:1+9$*<!D:X:A)^ZF@#D4WWZ#.Y)E#-R:^&+L&$$Y0G0(U"4Q&)!2',4
M7O0Z '/'10A)C8#I.%NV)4?MGSJ:+6GRU7K0EX)G&R^- #O(.M?.!/MC["JN
ME?5*T,"$N;$<*RZ?:FXFE2:S2C,EE910#I:JL8IG&I*%>6F<VA!,'N5Q]U;8
M;^^:L"=9W%;\#-)TQ>CW[3  !1]JTPXST\B6E!K&7R81A&(YF<]9PD1J!)K.
MVT'4)(@0,$&Q"FHEY+4!OK:=VR2I8Z1P'&$PEK;XVP.,@KD_UY26)EFR S6!
M@"( !+7V' Y3 )Z9ZT;XD@(&PC@!& K_!IP%4D2^L<65 Z+;Y^2UN+-CDH2N
M)-5A HH#M'7%8H1%%K$<TELI,DJ<R4#)D24H\F(58B7L%)#]ZB:@MK.DWE;F
M9%,R=DG]IR)CUL0T$G\3#&". 9:-MF\L4?P%HODDZS,&C<&32VL-)B -N(A2
M5YJ<.Y.):2Q\':PU!SXVE<*0SP*4B,%_P/K0QF$2EIR62H& %?"ID*W,R PV
MLJ%[8')@+%WF_0XTW$X<]#-!7ZQ#\^=_.\0+J8[1X'>S#F0;C2Y,IZ4!8_E*
MKQSHE]X-:_UYLC'6<(3W Y-1<0+<9<'0@_^*GB*,'HMFK)HJZXMBX+*#6/J<
MC/"BIU,LR>[5ZV0P$U_MZ%H+_@8X .E4 B#9-GBBKQ7K2'898!BL/*KC)]3F
M#CD+O2Z$$LQD%2Z1PX.A3  (@KD(/[%0$]5TMH&[,@ QN6K:P)"P+^R_]9QY
M&:/Y7$BN+> DC&Z@JP)#)0*!-J #GK$@ED1BKYC#O#END_#AR(-'4HQOV4J]
MQ,7F9/?F*5#=F5\Q,QX[8AM6/TS\E"&RT<&S2QJ]A] :A=QJ8-$:X5Y @X&$
M5'+^_)W*.TI7^I+S<8@CS(ZC6;S@SJK]Q8%W=\QZ/8,]P2*6$&!Y49'K0UGI
M*S9EJ2=( :DT<+*E[(-5^#:!RL9*$U@<E@N\KEJ4DT1L.9B"&0"OMB*9T!HM
M<&S ;:!VS;1=^L(2K(F!K^!?J+#P2F]>0O0P4K97^:!-2>!0]:F%*DWC51\]
M=ZE!;$D)LK[#Y5$FUGJ(B!>Y+&1;RJ1\;RE7V^PJ1C3IP)FEP@(JGPL:D"E2
M=!@:/X#-+CEZ5C*5O2UYQC.EI03[@;!!$:T8I@HLY )7$]4VEG_W=1!Y/!@-
M3VI]R2C5*0T' !O6Y:SA0!5SG1C%GLB^QM]"F#,Q@;'D"#=78=GXV(\>Z.2H
MB/'V=&T^D("EX1BD#EX_J45B33/RS@?#7BC5^*@BN#&28@F)9YYSW3DB#U\$
M!EM*^>(BZMT .[R'3EHTG6 6U#[398IT0[YS%ZK-Y_BOPDI,U3.O6]5@[#L@
MO#!ZI%M8+GO_;>N)/PI[Q,L9&.'J0NWE)F*38P,WH R[,8TX8LL8RQ_G*?IO
M$=P-1BI+MF#$/O ;1G[\IO@8:#NWIIN1TX1W L@KO7=8A)Q>2L#A?.9^J@,>
MX.7B$25X' "^( 1XH-\1 /D64(P7 W$0ZDA1N LUI0J_4&*AQ$_';XZ3S@#?
MRR7C1M)KX3P3K7Y$^:ROY%-D=$,JA^!U".Q$3HDRAOJ(!-$E)[!2G<=7T?/1
M626@[U7(@ S!%1V5O?LR.XSF;K#]>"+$FI4L0ZR>[J8Y#(_=^7)P.B@R9O+M
M8.&3Y_XWP NLSU+VJFJAUDBQH]4).X+F[NT8FGM%'CQ]?0WB$+U6ZE6/-YW.
MHXS>Q2S6X_ZC($)OM@CG^,*-B @+XZ-]I,(*A$G3433.V*!5>[PS'5^!*=G'
MX,V4F/!RI-"#'I^ 3EH>1@,(4&P= \2T-6$@W \W'SIRJ37U%=P!4 0ER^8T
M]<!07?HF ;W[!>-4RJ9'?OOG9W&P:6>]QNTK2K/>BB1AQX,1 @ND!1'L YYC
MR'U(!J??:\Q#@"7N,^FLD'M2):@/RW<HH>%-59)5G0\,W/#"=> 5SH_$$^=A
M X-=YCVKE*S7\ R5&&$6B6(;+1X0I/-3X0.MF/"3#P]P(;3_>4.P>&^=V_L[
MI@Z_!ZF:]>[<ZSXH]]0@5KT.BO(72K,C<\XPCO*2 OQCV.U3< !N :8>W#SL
M]5<!UGM0C!]/^=U>3YT*/8TR71N!^DO97J[92TU2_=,/TP#IA2@5X(_Q-129
M P?5U ,E@%_GI=3DR97)'LTDGJX=B;8/ W!Q0\MIEJ%96$42YGY;E??7UL+.
MX9B6FE+.E;U=1T$L5D=Q;@Q7<^Y#49LEU<B\TZ#8*+UKV5OP5543<CIBV'':
MT8G)L![TYFNX#*8X70/)B>>.M3D+1O%P1\X.8A[J=%H+C-9P&=9<EQP,7*KM
ML1"R!98H$0F#J]2DNVK/)T0BTJWKRV:BLE(&_SK$WF'!:?A]HFA_TFP"E>30
MR+GI@- E.^I8],%6.<13V"9;[6NWD#ER.E<J@S>\G71(?B TU<[ @H!R&GD\
M^)F;^&8+V]!IF _AG3'=^.L%F+OH#Z&7O="@'CPS314Z.6".,=U(C%.:7)9I
MAL!'<]L8L &-1HG9%")L>PSSCOOXS),>[V<RQ;*#0>@]J0H M'%DID>-R2]@
M_V,]05HG,:;@VA$](%OO7@Y56WJ*F<W._7W.A)Z>[)BYI88>K;X&1G5_F>*2
M?AS8(<&Q54<-^IY(>8C&1*1,FI*$.E3WH"B"%W5P>LB'.7LURNT+^-3]AXZ?
M*ERP(ED/:I1XJRSH/]2%Z^Y6MB5G""X,%J;V 6]T!OL6 5RHNCHZ"CX-#&R6
M-;9OH-.*<U,6^ $C5_2M80^*<+_KRE;6[3 0?W3$%9ID53B34$D\.> #YB&=
M@,%_TKHQ.FL:75]R['5++HWJ4X4#2UORB=I-#TV?:=),)9*#NZ8,=N5@O"V'
MM,8)QJ?A\J1T8(*^(QN+<*1A/%CJ.R;^>\\^J;G5WH7;O$^X5OBB]G%J;U)6
M9$3R-K1X -=+9>S(HIY9Q#(ZN19]7&/O_54)V]L]O. 4PJS6:?TYH%59B)G"
MA%4##", BS4;@A-%[*$@.7OL">\#%8.KJ9@0_X'HQI<M#R+Q/]4$&-\@"G*A
MQQ<7%9"A7^M2<N(KT_L",$*,HR.(R2HDLLTP:96E6:NH9$+*BD\J8C>4M0ER
MZQ<@02: O-QXA@&<%^G!U9BYLFI #VQBUS'CXG'^Z*ZM1[FJU:!<_,64RKL[
MV_8] @*(&VC*OO,*G:LC<%52G1BN",7)F)[$"T6TZ*/U?7^T#6,/,FE(5X&%
M.GS(/WG.Y)#F&TI_UF><'*'BW:DX<1HG354O'SS/\!CTNC@#R!YDI=M^I@B$
M&8ZV<\\_;72%$^[RU@M3OGE?PPNJ=D:U]#G6D7"5,(RZOP4+EW3J>/L!,MH7
M^&#1;PP%< PVU/*,PQE)"I4R@_ 3&IY:8*&R&\0*!B8C&@M*%^(C?+E*0=7)
M)>FI9' ^S'))N!0?SWH$)TV<$R#%Q@</O*+WV6]/&S[--6J @5GG("LQ[TV^
MT-I:V<]B:QF/4OFS(JY'!"Y" I<"D?243P(E/O2V!$E@Q?C0_A^+'Q%04?6J
MC^*#G$VI? CH3!T@;O^- $:9Q-HQ&!Y.CODV$!C>Y182/@(33GYRT=B!/@0I
MYY@R%J+S:1ML\ 4DMWP02+W+Y]BOAU9QH.$.(#QQ6(M'>C , Z0.S>0.@/D/
M4R#H$DZFBB6"S\%T)!>&@'*"7C&J3+F'J=>EJ-E!V6%%6Y09T&62+)7O98:S
MV8:JB0=&Q.Z//7 YW4;L&YF&YL&=QDA5>_8&;H.?"5C%HH>^IH[&O0S-#YR%
MU:"8!B\8%"FFM30T&\Z7C&/WPI,"SS$-$B_HQ;T<=3"+-/2;U6M^GQ<@[(@!
M3+66V9%6.PKK;_,F2%EP("S!EP,$&[(3?6Z%9A#J33E^EC0DPD0KC$=" 2*F
M,=]>=-@DI-*.#IDT5ON[>;>G+>.LS82\)+7PITN%W_PK%7Y=V@H]6?EL(D/;
M]<-:28?>WJR,FP6L>02CEC\CWZ >=!P\/=V0[1C[#S[QN-$'CP5$_E#N]A+"
M/D>)UXT*"G%:,(JDM"\>*?.'1/IJ],P?K\(C4E0\WA\!X3PYMD?F!&ZH"TI@
M.B=!4RKA(D='VGK-$E+@VH4*Z?T%LJ>[UO_X#1W6;J]#$O*;#6&_/Q#RH^!2
M_)2$F'HN1M\4<09">U[_=HL<DYSQ)+_QV;M8'$:EI;)D<]\,.I;U=:PQ-L%9
M?K2U,T!LO_>6UR<I8V=QRNUS&G/]U/@<H-U$@8O*%2=QENM7PLCT[-BRJT_H
M2A?6[S%J+',.A2_)N7(:20*(L%42X;NH,<N$]2Z%UP!4=8JYRK6&#/@\:@N;
M$+Z?>?KXN-?%Y9O-KE"BBM9;M#7HG3',1Z2 V9W/XBZZ1+#^H*OX(0<;1K[B
MVE,Q<#1F=9B$[? ?<SI69;AG@8N98_C:>Q+$KZ%WZ?K#HXO@#QT&#Y$Y.2->
MP4@I*'W;\U#<<<K$Q6P-L>XX\EKJ"\6-%CGNNOF>E"/VU[3L6@^ZT-X&>>FI
MUV57?9SC%RH%"V</J)J96NRV8G"P R4&59AOVCRL-L8S>64OKS[0R@U%ABU[
MLU!H,A0(\E(3F8@:'U =%B2[UAL53E5SCPVOV ?8TH1&C$OJD '+6M!3R2&D
MYV@0"FT'QS'FPQX!?<R$%'Z:]AX5N.VO9.U:#ZG7JNTL95+"V_NN6JX&E;99
M.-013[0V&#1I._@BME%+3P+,5RZ )3J\L7Z,![Z5NO;V]9*352'*. 7ZL//C
MB_HW1)+XO-2@_G=;;<CEAX@W'D1Y_]&?4,]">SD^XA(.VL#*%%8FA6Y*?KRT
M0FY3V_YDPE@RVI#:HI+8,276&OK_DB;(<7JXHD"*OA0H3"P<7^-E6J\.&\J8
M<&..RUL3[:]6V;76.Z]]T/(:F.BU6(T7*K)OR$5]4'-D$N,1Q1R+\D#_5 "/
MU^*]?9MR!-9@S2FS*\L<J^%4MGXMOOT),QZ6R@<IR(%^7B9BY,B;6)YA!;[K
M*CZ<K3.I"+@LGK^C('$O@-Q%G=;%M>16X7LTLG'TA=17R'?"TR26VU'%*Q5/
MA#!53Q)?'NJ3I]RM+V8<?8(<;ONMJ_DU(-@;4TVYTK*O=^?(_>BB1%&@GX45
MFNL)>5;R,23.B"5T DP+-K5ON!?."J0A)^X!1B5_<$=RLC$2 \\-:LP9)4=5
MUZF1!1V%6&BA#=>\CCOHK54=KO=XHC( *N<W-75"3'W%X5M!@/*8P^]C=K)M
MC04.<3[R)Z;4#(+<.=J7L*#!:R0&;S+97[6Y:TV,GJD): )Z@_*5Z\WWN#84
M@N#B:8P<X<2IDXKKB$4QL\G&G (@5"(=%H>_J'<DX;YMY_!=*%[]Q?IB7W$<
MW](0#ZX@9W]#+W1]9KN9[X/J*G#H<_$X;_L3IMAE:#HJ\4]0#X;:C._(P?-W
MOB:YT,Y/^@](R6?O-'3]IWBZ:\V0^/C*57M$P*_<*"OIZFJYB4D;:PGIO$W]
MGC=0.=^X+X0))XC69Q@F\(/F^"XUJHNJO''D ^K\;DY_4F3D8/AB)=\;W7@[
M62KL!H3MY#/QN&VY4(I+U+;$)/?8$NU:&Y6?)>R+I>Y/S[DO<?+.6_CR,;XX
MZCI$"S!HOZ3)(B_[^AJT)ZL0=([89P/$[S%G."N#065^@6MK.U7XHSO\ #^@
MZR8.'6!T$3S&'C7[\Q":D9SOZ]R_12: 3"X&7+MY]&JNT.Y/*_^F(#R'%H_1
M]J/Z3L&AP57-!]9$T96KM+U2-.M42+'>CW-_17#7SK[_@UX%AX'5*Q>QS;9D
M_*ZZ4BYCE=(;!F_3_ITAWHX!HFKHF#:7+V'QW%:YI.9OCGI(7_YN(WY14X83
MH8):A]VF6U]IM>D%)GTM HFV#\O_YH-U(>\&YK3[^ 4&?[K*IEO[4MGTV576
MKIU/?\XA!]^G_8K5UHLTSA?#7>]' Z!UPDM7P\$%QM==K<+Z4)GPVS7C</$5
MD#$<QBBYDN]TU57A#&SH/$A#A.[R'.M'?87]K#:':6*,G]("\#\Z!\TA'JK2
MH@;!^PNAS[:?'MTM(7G3V85>R*ON3SU^V3+585R:7\DV<Z2C]0R25OWK-S;T
MB*<J0WSA"%?<I%EB>*8O@'3B3B;N9N)>)L3]3)R>9%@2B8\X/1L]-YP]2B9^
M65MJ8S>]S'DS!O>86M?"-RFL#+6$Z-":(G['+*1/'G L.NDE!]?KF0YO<?$G
MAY*7*28=V'#TH N<I-(4=#\NCSLU^/;&>G94JFE[?G9Z!S;^V@CK&WSOH\78
MVHK>4?51%G&YHKK.Y!!/?_KAR?/7WS]^^4R\^O;QZQ\>/WW^T]L73Q]__T:\
M>/GTX^SQQR//[A+ZR8H"3+_^^HF5*XUXKEM8<_X?&0,*IC@.J1Q_=RS^*7_7
ME;Y*T_#KQC__KNE-%I-M"_=]-JCR>6_[W!OVF$YV<JC*=P3E]WGQ*[AJ?L6O
MN_X+D3%Z<+<ED_J#M& LST[.;I%4_[7Q8R,[JZG'ZN[J//&=F=?B6UE5UT_E
MX9^]Y9U75L-#:\":G)'Y]9.SSQ]DEEUED %*NKD9)/%7NL;Z0[KFK_CAQE=1
M_;'XX=<34ZS@KWE;E8_^'U!+ 0(4 Q0    ( ,.I;%A#UJ@SIP(  -('   ?
M              "  0    !A,C R,RTQ,&MX97@R,S%C;VYS96YT;V9C<FDN
M:'1M4$L! A0#%     @ PZEL6)I-(E,D"   >C$  !@              ( !
MY (  &$R,#(S+3$P:WAE>&AI8FET,S$Q+FAT;5!+ 0(4 Q0    ( ,.I;%C\
MSL-AT <  &HO   8              "  3X+  !A,C R,RTQ,&MX97AH:6)I
M=#,Q,BYH=&U02P$"% ,4    " ##J6Q8LUI/K]D$  #^&   &
M    @ %$$P  83(P,C,M,3!K>&5X:&EB:70S,C$N:'1M4$L! A0#%     @
MPZEL6-F*X+6P @  50@  !X              ( !4Q@  &$R,#(S+7AE>#(S
M,F-O;G-E;G1O9F9O<G9I+FAT;5!+ 0(4 Q0    ( ,.I;%A:UYVJ6!,  !A^
M   >              "  3\;  !A,C R,RUX97@Y-S%C;VUP96YS871I;VYR
M92YH=&U02P$"% ,4    " ##J6Q8EO(\9K@3  "\<   %0
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M+3(P,C,Q,C,Q7V1E9BYX;6Q02P$"% ,4    " ##J6Q8]NKZIIH] 0 OJP$
M%               @ %0G@, 8W!I>"TR,#(S,3(S,5]G,2YJ<&=02P$"% ,4
M    " ##J6Q8RF7/5L0Y 0#N=PP %0              @ $<W 0 8W!I>"TR
M,#(S,3(S,5]L86(N>&UL4$L! A0#%     @ PZEL6'B9DZ"AO0  &Z(( !4
M             ( !$Q8& &-P:7@M,C R,S$R,S%?<')E+GAM;%!+ 0(4 Q0
M   ( ,.I;%@0[/]0LQT  '^;   ;              "  >?3!@!E>"TQ,#$Q
M86IK87II;6EX,C R,S$P:RYH=&U02P$"% ,4    " ##J6Q83;-/O;X=  !+
MG0  '               @ '3\08 97@M,3 Q,FII;6AE<FUA;G@R,#(S,3!K
M+FAT;5!+ 0(4 Q0    ( ,.I;%A5</.SH1T   >;   >              "
M <L/!P!E>"TQ,#$S=&]D9&%N=&AO;GEX,C R,S$P:RYH=&U02P$"% ,4
M" ##J6Q82,'+";D=  !JFP  '@              @ &H+0< 97@M,3 Q-&-H
M<FES8FET=&5R;6%N>#(P,C,N:'1M4$L! A0#%     @ PZEL6(.>Q9"<'0
M]9H  !L              ( !G4L' &5X+3$P,35J;VAN:&%M;7@R,#(S,3!K
:+FAT;5!+!08     $P 3 #H%  !R:0<    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>cpix-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cpix="http://www.cumberlandpharma.com/20231231"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cpix-20231231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2024-03-08</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManufacturedProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManufacturedProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:HongKongWinHealthPharmaGroupCoLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">cpix:CumberlandEmergingTechnologiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cpix:AccountsReceivableAllowancesByComponentAxis">cpix:ChargebacksCashDiscountsAndDamagedGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2021-12-27</startDate>
            <endDate>2021-12-27</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:WinHealthInvestmentSingaporeLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:MartinS.BrownJr.sLawFirmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:MartinS.BrownJr.sLawFirmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:ProductAssetsAndGlobalRightsVibativMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:ProductAssetsAndGlobalRightsVibativMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:ProductAssetsAndGlobalRightsVibativMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:ProductAssetsAndGlobalRightsVibativMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:ProductAssetsAndGlobalRightsVibativMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:ProductAssetsAndGlobalRightsVibativMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:ProductAssetsAndGlobalRightsVibativMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:ProductAssetsAndGlobalRightsVibativMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:U.S.ProductAssetRightsSancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-01-03</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:U.S.ProductAssetRightsSancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:U.S.ProductAssetRightsSancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:U.S.ProductAssetRightsSancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:U.S.ProductAssetRightsSancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-01-03</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:U.S.ProductAssetRightsSancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-03</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:U.S.ProductAssetRightsSancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:U.S.ProductAssetRightsSancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:U.S.ProductAssetRightsSancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:U.S.ProductAssetRightsSancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicGroupBVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicGroupBVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicGroupBVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-27</startDate>
            <endDate>2019-11-27</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicGroupBVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicGroupBVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicGroupBVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-12</startDate>
            <endDate>2022-07-12</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicGroupBVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-12</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductKristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductKristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductVibativMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductVibativMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductSancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductSancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductCaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductCaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductAcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductAcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductOmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductOmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductVaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductVaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductRediTrexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductRediTrexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VibativMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:FederalGrantProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:FederalGrantProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VibativMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:PublicUtilitiesInventoryRawMaterialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VibativMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:PublicUtilitiesInventoryRawMaterialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VibativMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:FinishedGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VibativMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:FinishedGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:PublicUtilitiesInventoryRawMaterialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:PublicUtilitiesInventoryRawMaterialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:PublicUtilitiesInventoryRawMaterialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:PublicUtilitiesInventoryRawMaterialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:FinishedGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:FinishedGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:SancusoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:PublicUtilitiesInventoryRawMaterialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:SancusoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:PublicUtilitiesInventoryRawMaterialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:StudyDrugMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:PublicUtilitiesInventoryRawMaterialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:StudyDrugMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:PublicUtilitiesInventoryRawMaterialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:StudyDrugMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:FinishedGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:StudyDrugMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:FinishedGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VibativMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:ActivePharmaceuticalIngredientAPIAndWorkInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cpix:ProductAndLicenseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cpix:ProductAndLicenseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-05</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-05</startDate>
            <endDate>2023-09-05</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-05</startDate>
            <endDate>2023-09-05</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-08-09</startDate>
            <endDate>2009-08-10</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2010-05-13</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:IndefiniteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:IndefiniteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cpix:FederalAndStateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cpix:FederalAndStateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cpix:FederalAndStateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cpix:LongTermIncentiveCompensationPlan2007Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cpix:DirectorsIncentivePlan2007Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:NonprincipalOwnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:NonprincipalOwnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-15</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cpix:BroadwestLeaseFiveYearRenewalOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-15</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2021-11-15</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-24</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NephronPharmaceuticalsCorporationNephronMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:A1600WestEndAvenuePartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:A1600WestEndAvenuePartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:Customer12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:Customer12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:U.S.ProductAssetRightsSancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-01-03</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:CollaborativeArrangementMilestonePaymentThresholdAxis">cpix:Within30DaysOfFirstSNDAFilingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-02</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:CollaborativeArrangementMilestonePaymentThresholdAxis">cpix:FollowingApprovalOfFirstSNDAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-02</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-07</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>cpix:segment</measure>
    </unit>
    <unit id="payment">
        <measure>cpix:payment</measure>
    </unit>
    <unit id="plan">
        <measure>cpix:plan</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="renewalterm">
        <measure>cpix:renewalTerm</measure>
    </unit>
    <unit id="usdPerSqft">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>utr:sqft</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="supplier">
        <measure>cpix:supplier</measure>
    </unit>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-21">true</dei:DocumentAnnualReport>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-22">false</dei:DocumentTransitionReport>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-23">0001087294</dei:EntityCentralIndexKey>
    <dei:EntityFilerCategory contextRef="c-1" id="f-24">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-25">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-26">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-27">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-28">false</dei:AmendmentFlag>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-29">false</dei:EntityEmergingGrowthCompany>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-30">true</dei:EntitySmallBusiness>
    <dei:EntityShellCompany contextRef="c-1" id="f-31">false</dei:EntityShellCompany>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-32">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-33">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-34">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-35">Yes</dei:EntityInteractiveDataCurrent>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-36">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">CUMBERLAND PHARMACEUTICALS INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">TN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-5">62-1765329</dei:EntityTaxIdentificationNumber>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-33637</dei:EntityFileNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">1600 West End Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">Suite 1300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">Nashville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">TN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">37203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">615</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">255-0068</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-14">Common Stock, $0.00 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-15">CPIX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-16">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityPublicFloat contextRef="c-2" decimals="0" id="f-17" unitRef="usd">12061328</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-18" unitRef="shares">14176529</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-19">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-20">&lt;div style="margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain information required in Part III of Form 10-K is incorporated by reference from the registrant&#x2019;s Proxy Statement for its 2024 annual meeting of shareholders.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-1" decimals="-5" id="f-37" unitRef="usd">3300000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-4" id="f-38">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-4" id="f-39">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-4" id="f-40">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-4" id="f-41">false</ecd:NonRule10b51ArrTrmntdFlag>
    <dei:AuditorFirmId contextRef="c-1" id="f-42">213</dei:AuditorFirmId>
    <dei:AuditorFirmId contextRef="c-5" id="f-43">686</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-44">Carr, Riggs &amp; Ingram, LLC</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-45">Nashville, Tennessee</dei:AuditorLocation>
    <dei:AuditorName contextRef="c-5" id="f-46">FORVIS, LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-5" id="f-47">Nashville, Tennessee</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-6" decimals="0" id="f-48" unitRef="usd">18321624</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-7" decimals="0" id="f-49" unitRef="usd">19757970</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-6" decimals="0" id="f-50" unitRef="usd">9758176</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-7" decimals="0" id="f-51" unitRef="usd">13163681</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-6" decimals="0" id="f-52" unitRef="usd">4609362</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-7" decimals="0" id="f-53" unitRef="usd">9863581</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-6" decimals="0" id="f-54" unitRef="usd">3025248</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-7" decimals="0" id="f-55" unitRef="usd">3084978</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-6" decimals="0" id="f-56" unitRef="usd">35714410</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-7" decimals="0" id="f-57" unitRef="usd">45870210</us-gaap:AssetsCurrent>
    <us-gaap:InventoryNoncurrent contextRef="c-6" decimals="0" id="f-58" unitRef="usd">12804529</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent contextRef="c-7" decimals="0" id="f-59" unitRef="usd">7527167</us-gaap:InventoryNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-6" decimals="0" id="f-60" unitRef="usd">367903</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-7" decimals="0" id="f-61" unitRef="usd">284039</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-6" decimals="0" id="f-62" unitRef="usd">22607918</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-7" decimals="0" id="f-63" unitRef="usd">30590678</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill contextRef="c-6" decimals="0" id="f-64" unitRef="usd">914000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-7" decimals="0" id="f-65" unitRef="usd">914000</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-6" decimals="0" id="f-66" unitRef="usd">6674394</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-7" decimals="0" id="f-67" unitRef="usd">5218403</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-6" decimals="0" id="f-68" unitRef="usd">2692921</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-7" decimals="0" id="f-69" unitRef="usd">2520661</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-6" decimals="0" id="f-70" unitRef="usd">81776075</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-7" decimals="0" id="f-71" unitRef="usd">92925158</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-6" decimals="0" id="f-72" unitRef="usd">14037629</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-7" decimals="0" id="f-73" unitRef="usd">10819011</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-6" decimals="0" id="f-74" unitRef="usd">348092</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-7" decimals="0" id="f-75" unitRef="usd">172910</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-6" decimals="0" id="f-76" unitRef="usd">13596528</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-7" decimals="0" id="f-77" unitRef="usd">17587911</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-6" decimals="0" id="f-78" unitRef="usd">27982249</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-7" decimals="0" id="f-79" unitRef="usd">28579832</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermLineOfCredit contextRef="c-6" decimals="0" id="f-80" unitRef="usd">12784144</us-gaap:LongTermLineOfCredit>
    <us-gaap:LongTermLineOfCredit contextRef="c-7" decimals="0" id="f-81" unitRef="usd">16200000</us-gaap:LongTermLineOfCredit>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-6" decimals="0" id="f-82" unitRef="usd">5296247</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-7" decimals="0" id="f-83" unitRef="usd">4586301</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-6" decimals="0" id="f-84" unitRef="usd">6453566</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-7" decimals="0" id="f-85" unitRef="usd">7585019</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-6" decimals="0" id="f-86" unitRef="usd">52516206</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-7" decimals="0" id="f-87" unitRef="usd">56951152</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-6" id="f-88" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-7" id="f-89" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommonStockNoParValue
      contextRef="c-6"
      decimals="0"
      id="f-90"
      unitRef="usdPerShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="c-7"
      decimals="0"
      id="f-91"
      unitRef="usdPerShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-7" decimals="INF" id="f-92" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-6" decimals="INF" id="f-93" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-6" decimals="INF" id="f-94" unitRef="shares">14121833</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-6" decimals="INF" id="f-95" unitRef="shares">14121833</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-7" decimals="INF" id="f-96" unitRef="shares">14366316</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-7" decimals="INF" id="f-97" unitRef="shares">14366316</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValueOutstanding contextRef="c-6" decimals="0" id="f-98" unitRef="usd">47091602</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding contextRef="c-7" decimals="0" id="f-99" unitRef="usd">47474973</us-gaap:CommonStockValueOutstanding>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-6" decimals="0" id="f-100" unitRef="usd">-17488161</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-7" decimals="0" id="f-101" unitRef="usd">-11208841</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="0" id="f-102" unitRef="usd">29603441</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-7" decimals="0" id="f-103" unitRef="usd">36266132</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c-6" decimals="0" id="f-104" unitRef="usd">-343572</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c-7" decimals="0" id="f-105" unitRef="usd">-292126</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-6" decimals="0" id="f-106" unitRef="usd">29259869</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-7" decimals="0" id="f-107" unitRef="usd">35974006</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-6" decimals="0" id="f-108" unitRef="usd">81776075</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-7" decimals="0" id="f-109" unitRef="usd">92925158</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-8" decimals="0" id="f-110" unitRef="usd">37513492</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-9" decimals="0" id="f-111" unitRef="usd">40681182</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-10" decimals="0" id="f-112" unitRef="usd">2039015</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-11" decimals="0" id="f-113" unitRef="usd">1329767</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="0" id="f-114" unitRef="usd">39552507</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="0" id="f-115" unitRef="usd">42010949</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="0" id="f-116" unitRef="usd">6066611</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-5" decimals="0" id="f-117" unitRef="usd">9118521</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingAndMarketingExpense contextRef="c-1" decimals="0" id="f-118" unitRef="usd">18451765</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c-5" decimals="0" id="f-119" unitRef="usd">16660945</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="0" id="f-120" unitRef="usd">5834229</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-5" decimals="0" id="f-121" unitRef="usd">6688924</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="0" id="f-122" unitRef="usd">10651915</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-5" decimals="0" id="f-123" unitRef="usd">10180120</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="0" id="f-124" unitRef="usd">8102648</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-5" decimals="0" id="f-125" unitRef="usd">5067368</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:CostsAndExpenses contextRef="c-1" decimals="0" id="f-126" unitRef="usd">49107168</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-5" decimals="0" id="f-127" unitRef="usd">47715878</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="0" id="f-128" unitRef="usd">-9554661</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="0" id="f-129" unitRef="usd">-5704929</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="0" id="f-130" unitRef="usd">286854</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-5" decimals="0" id="f-131" unitRef="usd">98405</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherIncome contextRef="c-1" decimals="0" id="f-132" unitRef="usd">2828871</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-5" decimals="0" id="f-133" unitRef="usd">0</us-gaap:OtherIncome>
    <us-gaap:GainLossRelatedToLitigationSettlement contextRef="c-1" decimals="0" id="f-134" unitRef="usd">475000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement contextRef="c-5" decimals="0" id="f-135" unitRef="usd">0</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:InsuredEventGainLoss contextRef="c-1" decimals="0" id="f-136" unitRef="usd">346800</us-gaap:InsuredEventGainLoss>
    <us-gaap:InsuredEventGainLoss contextRef="c-5" decimals="0" id="f-137" unitRef="usd">611330</us-gaap:InsuredEventGainLoss>
    <us-gaap:InterestExpense contextRef="c-1" decimals="0" id="f-138" unitRef="usd">667861</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-5" decimals="0" id="f-139" unitRef="usd">585995</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="0" id="f-140" unitRef="usd">-6284997</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-5" decimals="0" id="f-141" unitRef="usd">-5581189</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="0" id="f-142" unitRef="usd">45769</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-5" decimals="0" id="f-143" unitRef="usd">68850</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="0" id="f-144" unitRef="usd">-6330766</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-5" decimals="0" id="f-145" unitRef="usd">-5650039</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="0" id="f-146" unitRef="usd">-51446</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-5" decimals="0" id="f-147" unitRef="usd">-79798</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="0" id="f-148" unitRef="usd">-6279320</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="0" id="f-149" unitRef="usd">-5570241</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-150"
      unitRef="usdPerShare">-0.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-151"
      unitRef="usdPerShare">-0.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-152"
      unitRef="usdPerShare">-0.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-153"
      unitRef="usdPerShare">-0.38</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-154" unitRef="shares">14298774</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="0" id="f-155" unitRef="shares">14563592</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-156" unitRef="shares">14298774</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="0" id="f-157" unitRef="shares">14563592</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="0" id="f-158" unitRef="usd">-6330766</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-5" decimals="0" id="f-159" unitRef="usd">-5650039</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="0" id="f-160" unitRef="usd">4935954</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-5" decimals="0" id="f-161" unitRef="usd">5328113</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-1" decimals="0" id="f-162" unitRef="usd">3343842</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-5" decimals="0" id="f-163" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="0" id="f-164" unitRef="usd">834500</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-5" decimals="0" id="f-165" unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c-1" decimals="0" id="f-166" unitRef="usd">-20256</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c-5" decimals="0" id="f-167" unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="0" id="f-168" unitRef="usd">365040</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-5" decimals="0" id="f-169" unitRef="usd">447503</us-gaap:ShareBasedCompensation>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-1" decimals="0" id="f-170" unitRef="usd">-1253840</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-5" decimals="0" id="f-171" unitRef="usd">-2088296</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy contextRef="c-1" decimals="0" id="f-172" unitRef="usd">124736</cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy>
    <cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy contextRef="c-5" decimals="0" id="f-173" unitRef="usd">-613657</cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-1" decimals="0" id="f-174" unitRef="usd">15523</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-5" decimals="0" id="f-175" unitRef="usd">11237</us-gaap:AmortizationOfFinancingCosts>
    <cpix:NoncashOrPartNoncashGainOnTransaction contextRef="c-1" decimals="0" id="f-176" unitRef="usd">0</cpix:NoncashOrPartNoncashGainOnTransaction>
    <cpix:NoncashOrPartNoncashGainOnTransaction contextRef="c-5" decimals="0" id="f-177" unitRef="usd">37882</cpix:NoncashOrPartNoncashGainOnTransaction>
    <us-gaap:OtherNonoperatingGainsLosses contextRef="c-1" decimals="0" id="f-178" unitRef="usd">346800</us-gaap:OtherNonoperatingGainsLosses>
    <us-gaap:OtherNonoperatingGainsLosses contextRef="c-5" decimals="0" id="f-179" unitRef="usd">611330</us-gaap:OtherNonoperatingGainsLosses>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="0" id="f-180" unitRef="usd">-3404949</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-5" decimals="0" id="f-181" unitRef="usd">6115640</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="0" id="f-182" unitRef="usd">23143</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-5" decimals="0" id="f-183" unitRef="usd">-911078</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-1" decimals="0" id="f-184" unitRef="usd">-65684</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-5" decimals="0" id="f-185" unitRef="usd">-689260</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="0" id="f-186" unitRef="usd">-1405363</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-5" decimals="0" id="f-187" unitRef="usd">0</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="0" id="f-188" unitRef="usd">3724174</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-5" decimals="0" id="f-189" unitRef="usd">14536076</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c-1" decimals="0" id="f-190" unitRef="usd">-1131453</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c-5" decimals="0" id="f-191" unitRef="usd">419659</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="0" id="f-192" unitRef="usd">6093821</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-5" decimals="0" id="f-193" unitRef="usd">8453396</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="0" id="f-194" unitRef="usd">281268</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-5" decimals="0" id="f-195" unitRef="usd">102148</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-1" decimals="0" id="f-196" unitRef="usd">171783</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-5" decimals="0" id="f-197" unitRef="usd">1971662</us-gaap:PaymentsToAcquireIntangibleAssets>
    <cpix:ProceedsFromCollaborativeArrangement contextRef="c-1" decimals="0" id="f-198" unitRef="usd">0</cpix:ProceedsFromCollaborativeArrangement>
    <cpix:ProceedsFromCollaborativeArrangement contextRef="c-5" decimals="0" id="f-199" unitRef="usd">1000000</cpix:ProceedsFromCollaborativeArrangement>
    <us-gaap:ProceedsFromLifeInsurancePolicies contextRef="c-1" decimals="0" id="f-200" unitRef="usd">347356</us-gaap:ProceedsFromLifeInsurancePolicies>
    <us-gaap:ProceedsFromLifeInsurancePolicies contextRef="c-5" decimals="0" id="f-201" unitRef="usd">877597</us-gaap:ProceedsFromLifeInsurancePolicies>
    <cpix:ProceedsFromSettlementOfPatentLitigation contextRef="c-1" decimals="0" id="f-202" unitRef="usd">0</cpix:ProceedsFromSettlementOfPatentLitigation>
    <cpix:ProceedsFromSettlementOfPatentLitigation contextRef="c-5" decimals="0" id="f-203" unitRef="usd">21757</cpix:ProceedsFromSettlementOfPatentLitigation>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-1" decimals="0" id="f-204" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-5" decimals="0" id="f-205" unitRef="usd">13500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="0" id="f-206" unitRef="usd">-105695</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-5" decimals="0" id="f-207" unitRef="usd">-13674456</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit contextRef="c-1" decimals="0" id="f-208" unitRef="usd">31475000</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit contextRef="c-5" decimals="0" id="f-209" unitRef="usd">52900000</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c-1" decimals="0" id="f-210" unitRef="usd">34890856</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c-5" decimals="0" id="f-211" unitRef="usd">51700000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-1" decimals="0" id="f-212" unitRef="usd">740533</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-5" decimals="0" id="f-213" unitRef="usd">1053042</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-1" decimals="0" id="f-214" unitRef="usd">3268083</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-5" decimals="0" id="f-215" unitRef="usd">2208744</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="0" id="f-216" unitRef="usd">-7424472</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-5" decimals="0" id="f-217" unitRef="usd">-2061786</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="0" id="f-218" unitRef="usd">-1436346</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-5" decimals="0" id="f-219" unitRef="usd">-7282846</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="0" id="f-220" unitRef="usd">19757970</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-12" decimals="0" id="f-221" unitRef="usd">27040816</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-6" decimals="0" id="f-222" unitRef="usd">18321624</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="0" id="f-223" unitRef="usd">19757970</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="0" id="f-224" unitRef="usd">647137</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-5" decimals="0" id="f-225" unitRef="usd">523161</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="0" id="f-226" unitRef="usd">108823</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-5" decimals="0" id="f-227" unitRef="usd">3300</us-gaap:IncomeTaxesPaidNet>
    <cpix:CashPaymentIncludedInMeasurementOfLeaseLiability contextRef="c-1" decimals="0" id="f-228" unitRef="usd">804818</cpix:CashPaymentIncludedInMeasurementOfLeaseLiability>
    <cpix:CashPaymentIncludedInMeasurementOfLeaseLiability contextRef="c-5" decimals="0" id="f-229" unitRef="usd">1011313</cpix:CashPaymentIncludedInMeasurementOfLeaseLiability>
    <cpix:PurchasesOfIntangibleAssetsIncurredButNotYetPaid contextRef="c-1" decimals="0" id="f-230" unitRef="usd">-51895</cpix:PurchasesOfIntangibleAssetsIncurredButNotYetPaid>
    <cpix:PurchasesOfIntangibleAssetsIncurredButNotYetPaid contextRef="c-5" decimals="0" id="f-231" unitRef="usd">-1803403</cpix:PurchasesOfIntangibleAssetsIncurredButNotYetPaid>
    <cpix:ChangeInUnpaidInvoicesForOfferingCosts contextRef="c-1" decimals="0" id="f-232" unitRef="usd">69001</cpix:ChangeInUnpaidInvoicesForOfferingCosts>
    <cpix:ChangeInUnpaidInvoicesForOfferingCosts contextRef="c-5" decimals="0" id="f-233" unitRef="usd">-94689</cpix:ChangeInUnpaidInvoicesForOfferingCosts>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="0" id="f-234" unitRef="usd">1158367</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-5" decimals="0" id="f-235" unitRef="usd">4590978</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <cpix:CreditIssuedForMilestonePayable contextRef="c-1" decimals="0" id="f-236" unitRef="usd">0</cpix:CreditIssuedForMilestonePayable>
    <cpix:CreditIssuedForMilestonePayable contextRef="c-5" decimals="0" id="f-237" unitRef="usd">-1000000</cpix:CreditIssuedForMilestonePayable>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue contextRef="c-1" decimals="0" id="f-238" unitRef="usd">0</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue contextRef="c-5" decimals="0" id="f-239" unitRef="usd">399600</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-13"
      decimals="INF"
      id="f-240"
      unitRef="shares">14742754</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-13" decimals="0" id="f-241" unitRef="usd">48452906</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-14" decimals="0" id="f-242" unitRef="usd">-5638600</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-15" decimals="0" id="f-243" unitRef="usd">-212328</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-12" decimals="0" id="f-244" unitRef="usd">42601978</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-16" decimals="0" id="f-245" unitRef="usd">-5570241</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-17" decimals="0" id="f-246" unitRef="usd">-79798</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-5" decimals="0" id="f-247" unitRef="usd">-5650039</us-gaap:ProfitLoss>
    <us-gaap:StockRedeemedOrCalledDuringPeriodShares
      contextRef="c-18"
      decimals="INF"
      id="f-248"
      unitRef="shares">180000</us-gaap:StockRedeemedOrCalledDuringPeriodShares>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue contextRef="c-18" decimals="0" id="f-249" unitRef="usd">399600</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue contextRef="c-5" decimals="0" id="f-250" unitRef="usd">399600</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-18"
      decimals="INF"
      id="f-251"
      unitRef="shares">171655</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-18" decimals="0" id="f-252" unitRef="usd">447503</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-5" decimals="0" id="f-253" unitRef="usd">447503</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="c-18"
      decimals="INF"
      id="f-254"
      unitRef="shares">367793</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c-18" decimals="0" id="f-255" unitRef="usd">1025836</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c-5" decimals="0" id="f-256" unitRef="usd">1025836</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-19"
      decimals="INF"
      id="f-257"
      unitRef="shares">14366616</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-19" decimals="0" id="f-258" unitRef="usd">47474973</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-20" decimals="0" id="f-259" unitRef="usd">-11208841</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-21" decimals="0" id="f-260" unitRef="usd">-292126</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-7" decimals="0" id="f-261" unitRef="usd">35974006</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-22" decimals="0" id="f-262" unitRef="usd">-6279320</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-23" decimals="0" id="f-263" unitRef="usd">-51446</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="0" id="f-264" unitRef="usd">-6330766</us-gaap:ProfitLoss>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-24"
      decimals="INF"
      id="f-265"
      unitRef="shares">157360</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-24" decimals="0" id="f-266" unitRef="usd">365040</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-1" decimals="0" id="f-267" unitRef="usd">365040</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="c-24"
      decimals="INF"
      id="f-268"
      unitRef="shares">402143</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c-24" decimals="0" id="f-269" unitRef="usd">748411</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c-1" decimals="0" id="f-270" unitRef="usd">748411</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-25"
      decimals="INF"
      id="f-271"
      unitRef="shares">14121833</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-25" decimals="0" id="f-272" unitRef="usd">47091602</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-26" decimals="0" id="f-273" unitRef="usd">-17488161</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-27" decimals="0" id="f-274" unitRef="usd">-343572</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-6" decimals="0" id="f-275" unitRef="usd">29259869</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-276">Organization&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland Pharmaceuticals Inc. (&#x201c;Cumberland,&#x201d; the &#x201c;Company,&#x201d; or as used in the context of &#x201c;we,&#x201d; &#x201c;us,&#x201d; or &#x201c;our&#x201d;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company&#x2019;s primary target markets are hospital acute care, gastroenterology  and oncology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs. The Company promotes its approved products through its hospital, field and oncology sales forces in the United States and is establishing a network of international partners to bring its medicines to patients in their countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#x2019;s products are manufactured by third parties, which are overseen by Cumberland&#x2019;s quality and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to build a pipeline of early-stage product candidates, the Company formed a subsidiary, Cumberland Emerging Technologies, Inc. ("CET"), which teams with universities and other research organizations to help advance scientific discoveries from the laboratory to the marketplace. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April, 2019, CET entered into an agreement with HongKong WinHealth Pharma Group Co. Limited ("WinHealth") whereby WinHealth made a $1.0&#160;million investment through the purchase of shares of CET stock. As part of the agreement, WinHealth obtained a board position at CET and the first opportunity to license CET products for the Chinese market. In connection with WinHealth's investment in CET, Cumberland also made an additional $1.0 million investment in CET. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s ownership in CET is now 85% while the remaining interest is owned by WinHealth, Vanderbilt University and the Tennessee Technology Development Corporation. The operating results of CET allocated to noncontrolling interests in the consolidated statements of operations were  $51,446 and $79,798 for the years ended December&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January&#160;1, 2007, the Company formed a wholly-owned subsidiary, Cumberland Pharma Sales Corp. ("CPSC"). CPSC is the subsidiary that employs the Company's hospital and field sales force personnel.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2017, the Company formed the Cumberland Pharma Foundation (the "Foundation") to serve as a vehicle to facilitate the ongoing philanthropic endeavors of Cumberland Pharmaceuticals Inc. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Foundation was formed as a nonprofit corporation designed to qualify as a tax-exempt organization pursuant to Section 501(a) of the Internal Revenue Code. The Foundation&#x2019;s Board of Directors is comprised of Cumberland Pharmaceuticals executives who are responsible for overseeing the Foundation&#x2019;s ongoing activities including charitable contributions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, Cumberland provided a grant of 50,000 shares of the Company&#x2019;s common stock to the Foundation. The shares will address the ongoing financial needs of the Foundation. The organization also plans to hold a portion of the shares for long-term appreciation. The Foundation maintains separate financial statements and its ongoing operations do not impact the financial statements of Cumberland Pharmaceuticals. Initial annual grants by the Foundation have been and are expected to remain consistent with the historic level of contributions made by Cumberland Pharmaceuticals.  Since 2019, Cumberland has made annual cash contributions to the Foundation. During the years 2023 and 2022,  the Company made cash contributions of $40,000 and $25,000, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <cpix:SubsidiaryInvestmentPurchaseOfShares contextRef="c-28" decimals="-5" id="f-277" unitRef="usd">1000000</cpix:SubsidiaryInvestmentPurchaseOfShares>
    <cpix:SubsidiaryInvestmentPurchaseOfShares contextRef="c-28" decimals="-5" id="f-278" unitRef="usd">1000000</cpix:SubsidiaryInvestmentPurchaseOfShares>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c-29" decimals="2" id="f-279" unitRef="number">0.85</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="0" id="f-280" unitRef="usd">-51446</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-5" decimals="0" id="f-281" unitRef="usd">-79798</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <cpix:SharebasedCompensationCharitableContributionofSharesShares
      contextRef="c-30"
      decimals="INF"
      id="f-282"
      unitRef="shares">50000</cpix:SharebasedCompensationCharitableContributionofSharesShares>
    <cpix:ShareBasedCompensationCharitableContributionOfSharesCashContributions contextRef="c-1" decimals="-3" id="f-283" unitRef="usd">40000</cpix:ShareBasedCompensationCharitableContributionOfSharesCashContributions>
    <cpix:ShareBasedCompensationCharitableContributionOfSharesCashContributions contextRef="c-5" decimals="-3" id="f-284" unitRef="usd">25000</cpix:ShareBasedCompensationCharitableContributionOfSharesCashContributions>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-285">Significant Accounting Policies&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements of the Company are stated in U.S. dollars and are prepared using U.S. generally accepted accounting principles. These financial statements include the accounts of the Company and its wholly and majority-owned subsidiaries. All significant intercompany transactions and accounts have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates under different assumptions and conditions. The Company&#x2019;s most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory, (3) valuation of contingent consideration liability associated with business combinations and (4) evaluation of continuing utility of intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, evaluated that our specialty pharmaceutical products compete in similar economic markets and similar circumstances. Substantially all of the Company&#x2019;s assets are located in the United States. Total revenues are primarily attributable to U.S.&#160;customers. Net revenues from customers outside the United States were approximately $1.1 million and $1.5 million for the years ended December&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of financial assets and liabilities is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date. The Company&#x2019;s fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements. It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 -   Quoted prices for identical instruments in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 -  Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 -    Significant inputs to the valuation model are unobservable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain policies and procedures to value instruments using the best and most relevant data available. The following section describes the valuation methodologies we use to measure different financial instruments at fair value on a recurring basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, contingent consideration liability and a revolving line of credit. The carrying values for cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to their short-term nature. The revolving line of credit has a variable interest rate, which approximates the current market rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s contingent consideration liability is a Level 3 fair value measurement that is updated on a recurring basis at each reporting period using a valuation model. Consistent with Level 3 fair value measurements, there are significant inputs to the valuation model that are unobservable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents include highly liquid investments with original maturities of three months or less. As of December&#160;31, 2023 and 2022, cash equivalents consist primarily of money market funds.  The Company monitors concentration of credit risk with the financial institutions in which it conducts business.  The Company has cash deposits which fluctuate in excess of federally insured limits throughout the year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade accounts receivable are recorded at the invoiced amount. The Company records allowances for amounts that could become uncollectible in the future based on historical experience, as well as amounts related to chargebacks and cash discounts. The Company reviews each customer balance to assess collection status.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the Company&#x2019;s products are distributed through independent pharmaceutical wholesalers. The allowances against accounts receivable for chargebacks and discounts are determined on a product-by-product basis, and established by management as the Company&#x2019;s best estimate at the time of sale based on each product&#x2019;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks and discounts. The allowances in accounts receivable for chargebacks and cash discounts were $0.6 million at December&#160;31, 2023 and 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#x2019;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, revenues are reduced and accrued liabilities are increased by the Company&#x2019;s estimate of the rebate that may be claimed. Cash discounts are reductions to invoiced amounts offered to customers for payment within a specified period of time from the date of the invoice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company works closely with third parties to manufacture and package finished goods for sale. Based on the customer relationship with the manufacturer or packager, the Company will either take title to finished goods at the time of shipment or at the time of arrival from the manufacturer. The Company then warehouses such goods until distribution and sale at third party facilities located in the U.S. and international locations. Periodic inventory counts are made by the warehouse teams and by the Company on a regular basis. In addition, the Company re-tests API inventory prior to use to confirm product expiration. Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually evaluates inventories for potential losses due to expired, short-dated or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates the carrying value of a product may not be recoverable, a charge is recorded to reduce the inventory to its current net realizable value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current inventories consist of active pharmaceutical ingredients which typically has an extended life and selected finished good products with extended life longer than one year. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid and other current assets consist of deferred offering costs, prepaid insurance premiums, prepaid consulting services, deposits and annual fees paid to the U.S. Food and Drug Administration ("FDA"). The Company expenses all prepaid and other current asset amounts as used or over the period of benefit primarily on a straight-line basis, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2017, the Company filed its Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100&#160;million in corporate securities. The Shelf Registration was declared effective in January 2018. It also included an At the Market ("ATM") feature that allows the Company to sell common shares at market prices.  The Company filed an updated Form S-3 with the SEC in December 2020 (the &#x201c;Prior Registration Statement&#x201d;), which was declared effective in January 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 27, 2021, the Company filed a related prospectus supplement in connection with the sale and issuance of shares having an aggregate gross sales price of up to $19&#160;million. The Company amended the ATM Sales Agreement on December 27, 2021, in order to allow the Company to continue using its ATM feature to sell shares at market prices.  This ATM program was under the Prior Registration Statement and is no longer active.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company filed an updated Form S-3 with the SEC on December 14, 2023, which was declared effective on December 26, 2023 (the &#x201c;Current Registration Statement&#x201d;).  The Company intends to enter into an agreement with H.C. Wainwright &amp;amp; Co., LLC to establish a new ATM program under the Current Registration Statement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has recorded deferred offering costs for payments directly related to the current Shelf Registration on Form S-3 that was completed during December 2021 and December 2023. These costs consist of legal and accounting fees that the Company has capitalized. Deferred costs associated with the Shelf Registration will be reclassified to additional paid in capital on a pro-rata basis as the Company completes sales of shares under the Shelf Registration. The Company did not issue any shares under this ATM during the year ended December&#160;31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, including leasehold improvements, are stated at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the initial lease term plus renewal options, if reasonably assured, or the remaining useful life of the asset. Upon retirement or disposal of assets, any gain or loss is reflected as a component of operating loss in the consolidated statement of operations. Improvements that extend an asset&#x2019;s useful life are capitalized. Repairs and maintenance costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets and Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s intangible assets and goodwill consist of capitalized costs related to product and license rights, patents, trademarks and goodwill obtained in the Vibativ and Sancuso acquisitions. Goodwill is not amortized for financial reporting purposes, but is subject to impairment analysis at least annually.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cost of acquiring product and license rights are capitalized at fair value at the date of acquisition for products that are approved by the FDA for commercial use. These costs are amortized ratably over the estimated economic life of the product. The economic life is estimated based upon several factors. This includes the term of the license agreement, the patent life or market exclusivity of the product and as well as  management&#x2019;s expectations of continued involvement with the product and the assessment of future sales, the future periods under which the product will be sold and the profitability of the product. This estimate is evaluated on a regular basis during the amortization period and adjusted if appropriate. If there are any changes made to the useful life of the product and license rights, the costs associated with such a change, if any, will be capitalized and amortized over the revised useful life.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Given the delay in identifying a packager for Omeclamox-Pak, the Company has taken a non-cash write down of the related intangible asset of $3.3 million. The financial statements reflect this adjustment as efforts to identify a packager continue.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitalized patent costs consist of outside legal costs associated with obtaining and protecting patents on products that have been approved for marketing by the FDA. If it becomes probable that a patent will not be issued or a patent has been declared invalid, related costs associated with the patent application are expensed at the time such determination is made. All costs associated with obtaining patents for products that have not been approved for marketing by the FDA are expensed as incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense is recognized ratably over the following periods:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.141%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.871%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated economic life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term of license agreement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Life of patent&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Trade and Note Receivables&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current Expected Credit Losses (&#x201c;CECL&#x201d;) is applicable to all financial assets measured at amortized cost. All financial instruments are evaluated, which principally relates to trade receivables and two notes receivable. CECL requires the measurement of expected credit losses on a collective (pool) basis when similar risk characteristics exist. This may include, either individually or in combination, some of the following characteristics of Accounting Standards Codification ("ASC") 326-20-55-5:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Internal or external credit score/rating&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Risk ratings or classification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Financial asset type&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Size&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Effective interest rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Geographical location&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Historical or expected credit loss patterns&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Reasonable and supportable forecast periods&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The standard requires entities to pool financial assets but allows them to choose which risk characteristics to use. Under the requirements of the guidance, the Company reassesses at the end of each reporting period whether the pool of assets continue to display similar risk characteristics.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With twenty years of experience, Cumberland has experienced virtually no write downs of receivables as most of our receivables are due from large successful pharmaceutical, healthcare or government customers, consistently making payments on account. Although the payment behaviors of all of our customers are consistently reliable, for the sake of transparency, we have separated our customer base into seven separate pools. The Company performs a monthly analysis of aged accounts receivable to determine how much, if any, of the accounts receivable balance should be reserved as potential bad debt. The Company reviews all balances over 90 days past due for a possible reserve and considers any specific factors or information for balances aged under 90 days if there are indicators that the balance should be reserved, such as other aged balances with the customer or bankruptcy as well as any economic issues with a customer, industry or region. The adoption of ASC 326 did not result in a material impact to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets, such as property and equipment, operating lease right-of-use assets and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If events or circumstances arise that require a long-lived asset to be tested for potential impairment, the Company first compares undiscounted cash flows expected to be generated by the asset to its carrying value. If the carrying amount of the long-lived asset is not recoverable on an undiscounted cash flow basis, an impairment charge is recognized to the extent that the carrying value exceeds the fair value. Fair value is determined through various valuation techniques including quoted market prices, third-party independent appraisals and discounted cash flow models.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill and other indefinite lived intangible assets that are not subject to amortization are tested at least annually for impairment. The impairment analysis for goodwill requires a comparison of fair value to the carrying value of the reporting unit. The Company&#x2019;s goodwill was acquired in November 2018 with the Vibativ acquisition and in January 2022 with the Sancuso acquisition. As a result, the Vibativ and Sancuso components of the Company are the reporting units evaluated for goodwill impairment. Cumberland determined the fair value of the reporting units through current and future estimated revenue and profitability of the product. The Company recorded no impairment charges during 2022.  In 2023, given the delay in identifying a packager for Omeclamox-Pak the Company has taken a non-cash write down of the related intangible assets of $3.3 million, which is included in amortization expense in the statement operations.  These intangible assets consisted of product and license rights and trademarks.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Joint Venture Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, Cumberland entered into an agreement with WinHealth Investment (Singapore) Ltd creating WHC Biopharmaceuticals, Pte. Ltd. The joint venture, as a limited liability company, focuses on acquiring, developing, registering, and commercializing development stage and commercial stage biopharmaceuticals for China, Hong Kong and other Asian markets. The agreement provided for initial investment from WinHealth in the form of a $0.2&#160;million equity contribution and an initial investment from Cumberland in the form of $0.2&#160;million convertible note. The joint venture will seek additional future capital from additional investors and has entered into exclusive option agreements to license intellectual property from both Cumberland Pharmaceuticals Inc. and Cumberland Emerging Technologies.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from product sales are recognized in the amount that reflects the consideration that we expect to receive for these goods. Depending upon the shipping terms of the transaction, the revenue is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation. This occurs upon either shipment of the product or arrival at its ship to destination. Payment terms typically range from 30 to 60 days from date of shipment. The Company&#x2019;s net product revenue reflects the reduction from gross product revenue for estimated allowances for chargebacks, discounts and damaged goods, and reflects sales related accruals for rebates, coupons, product returns, and certain administrative and service fees. Significant judgments must be made in determining the transaction price for our sales of products related to these adjustments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2023, the Company revised its estimate for rebates related to Sancuso revenues based on additional information related to actual product activities.  As a result, the Company recognized additional revenue allowances of $0.6 million for rebates as a change of estimate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sales Rebates and Discounts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allowances against accounts receivable and accrued liabilities for chargebacks, discounts, service fees and expired product returns are determined on a product-by-product basis, and established by management as the Company&#x2019;s best estimate at the time of sale based on each product&#x2019;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and returns of expired product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#x2019;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, sales revenues are reduced and accrued liabilities are increased by the Company&#x2019;s estimate of the rebate that may be claimed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sales Returns&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with industry practice, the Company maintains a return policy that allows customers to return product within a specified period prior to and subsequent to the expiration date. The Company&#x2019;s estimate of the provision for returns is based upon historical experience, expiration date by product as well as any other factor &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;expected to impact future returns. Any changes in the assumptions used to estimate the provision for returns are recognized in the period those assumptions are changed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenues primarily consist of income from grant funding programs, licensing agreements, leases and contract services. Revenue related to grants is recognized when all conditions related to such grants have been met. All other revenue is recognized when earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of products sold consists principally of the cost to acquire each unit of product sold, including in-bound freight expense as well as any adjustment in the net realizable value of inventory acquired in acquisitions. Cost of products sold also includes expenses associated with the reduction in the net realizable value of slow-moving or expired product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Selling and Marketing Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling and marketing expense consists primarily of expenses relating to the advertising, promotion, distribution and sale of products, including royalty expense, salaries and related costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Distribution Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Distribution costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations. Distribution costs were as follows for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.192%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.792%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distribution costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;857,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advertising costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations. Advertising costs were as follows for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.192%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.792%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Advertising costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,903,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,927,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed in the period incurred. Research and development costs are comprised mainly of clinical trial expenses, salaries, wages and other related costs such as materials and supplies. Research and development expense includes activities performed by third-party providers participating in the Company&#x2019;s clinical studies. The Company accounts for these costs based on estimates of work performed, patients enrolled or fixed fees for services over the period of time the clinical trials are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides for deferred taxes using the asset and liability approach. Under this method, deferred tax assets and liabilities are recognized for future tax consequences attributable to operating loss and tax credit carryforwards, as well as differences between the carrying amounts of existing assets and liabilities and their respective tax bases. The Company&#x2019;s principal differences are related to the timing of deductibility of certain items, such as inventory, depreciation, amortization and share-based compensation. Deferred tax assets and liabilities are measured using enacted statutory tax rates that are expected to apply to taxable income in the years such temporary differences are anticipated to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. The Company only recognizes income tax benefits &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;associated with an income tax position in which it is &#x201c;more likely than not&#x201d; that the position would be sustained upon examination by the taxing authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In assessing the realizability of deferred tax assets, management considers whether some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of existing temporary differences, projected future taxable income and tax planning strategies in making this assessment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounting policy with respect to interest and penalties arising from income tax settlements is to recognize them as part of the provision for income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Loss per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic loss per share is calculated by dividing net loss attributable to common shareholders by the weighted-average number of shares outstanding. Except where the result would be antidilutive, diluted loss per share is calculated by assuming the vesting of unvested restricted stock and the exercise of stock options and warrants and unrecognized compensation costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes compensation cost for all share-based payments issued, modified, repurchased or canceled. Depending on the nature of the vesting provisions, restricted stock awards are measured using either the fair value on the grant date or the fair value of common stock on the date the vesting provisions lapse. Prior to the lapse for those equity grants not valued on the grant date, the fair value is measured on the last day of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaborative Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment discussed in Note 3, related to the Vibativ and Sancuso contingent consideration payments, do not meet the criteria for accounting under ASC Topic 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The agreements do not specifically designate each party&#x2019;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party. Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Related Party Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2023, Cumberland named Martin S. Brown Jr. to our Board of Directors. Mr. Brown is an attorney with over 30 years of corporate law experience who brings significant legal, public company, health care and civic experience to our board. The Company relies on several law firms for legal advice, including the firm with which Mr. Brown is affiliated.  In 2023 and 2022, the Company paid Mr. Brown&#x2019;s law firm $0.05 million and $0.04 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Guidance &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-13, &#x201c;Financial Instruments-Credit Losses,&#x201d; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies are required to use a new forward-looking &#x201c;expected loss&#x201d; model that generally results in an earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies measure credit losses in a manner similar with previous guidance, except that the losses are recognized as &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;allowances rather than as reductions in the amortized cost of the securities. Companies have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies apply the ASU&#x2019;s provisions as a cumulative-effect adjustment, if any, to the accumulated deficit as of the beginning of the first reporting period in which the guidance is adopted.&lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. &lt;/span&gt;The Company adopted both ASU 2016-13 and ASU 2019-05 on January 1, 2023</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-286">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements of the Company are stated in U.S. dollars and are prepared using U.S. generally accepted accounting principles. These financial statements include the accounts of the Company and its wholly and majority-owned subsidiaries. All significant intercompany transactions and accounts have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-287">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates under different assumptions and conditions. The Company&#x2019;s most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory, (3) valuation of contingent consideration liability associated with business combinations and (4) evaluation of continuing utility of intangible assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-288">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;The Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, evaluated that our specialty pharmaceutical products compete in similar economic markets and similar circumstances. Substantially all of the Company&#x2019;s assets are located in the United States. Total revenues are primarily attributable to U.S.&#160;customers.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-289"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-31" decimals="-5" id="f-290" unitRef="usd">1100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-32" decimals="-5" id="f-291" unitRef="usd">1500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c-1" id="f-292">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of financial assets and liabilities is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date. The Company&#x2019;s fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements. It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 -   Quoted prices for identical instruments in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 -  Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 -    Significant inputs to the valuation model are unobservable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain policies and procedures to value instruments using the best and most relevant data available. The following section describes the valuation methodologies we use to measure different financial instruments at fair value on a recurring basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, contingent consideration liability and a revolving line of credit. The carrying values for cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to their short-term nature. The revolving line of credit has a variable interest rate, which approximates the current market rate.&lt;/span&gt;&lt;/div&gt;The Company&#x2019;s contingent consideration liability is a Level 3 fair value measurement that is updated on a recurring basis at each reporting period using a valuation model. Consistent with Level 3 fair value measurements, there are significant inputs to the valuation model that are unobservable.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-293">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents include highly liquid investments with original maturities of three months or less. As of December&#160;31, 2023 and 2022, cash equivalents consist primarily of money market funds.  The Company monitors concentration of credit risk with the financial institutions in which it conducts business.  The Company has cash deposits which fluctuate in excess of federally insured limits throughout the year.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c-1" id="f-294">&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade accounts receivable are recorded at the invoiced amount. The Company records allowances for amounts that could become uncollectible in the future based on historical experience, as well as amounts related to chargebacks and cash discounts. The Company reviews each customer balance to assess collection status.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the Company&#x2019;s products are distributed through independent pharmaceutical wholesalers. The allowances against accounts receivable for chargebacks and discounts are determined on a product-by-product basis, and established by management as the Company&#x2019;s best estimate at the time of sale based on each product&#x2019;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks and discounts. The allowances in accounts receivable for chargebacks and cash discounts were $0.6 million at December&#160;31, 2023 and 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#x2019;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, revenues are reduced and accrued liabilities are increased by the Company&#x2019;s estimate of the rebate that may be claimed. Cash discounts are reductions to invoiced amounts offered to customers for payment within a specified period of time from the date of the invoice.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-33" decimals="-5" id="f-295" unitRef="usd">600000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:InventoryPolicyTextBlock contextRef="c-1" id="f-296">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company works closely with third parties to manufacture and package finished goods for sale. Based on the customer relationship with the manufacturer or packager, the Company will either take title to finished goods at the time of shipment or at the time of arrival from the manufacturer. The Company then warehouses such goods until distribution and sale at third party facilities located in the U.S. and international locations. Periodic inventory counts are made by the warehouse teams and by the Company on a regular basis. In addition, the Company re-tests API inventory prior to use to confirm product expiration. Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually evaluates inventories for potential losses due to expired, short-dated or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates the carrying value of a product may not be recoverable, a charge is recorded to reduce the inventory to its current net realizable value.&lt;/span&gt;&lt;/div&gt;Non-current inventories consist of active pharmaceutical ingredients which typically has an extended life and selected finished good products with extended life longer than one year.</us-gaap:InventoryPolicyTextBlock>
    <cpix:PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock contextRef="c-1" id="f-297">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid and other current assets consist of deferred offering costs, prepaid insurance premiums, prepaid consulting services, deposits and annual fees paid to the U.S. Food and Drug Administration ("FDA"). The Company expenses all prepaid and other current asset amounts as used or over the period of benefit primarily on a straight-line basis, as applicable.&lt;/span&gt;&lt;/div&gt;</cpix:PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock>
    <cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities contextRef="c-34" decimals="-6" id="f-298" unitRef="usd">100000000</cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities>
    <cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities contextRef="c-35" decimals="-6" id="f-299" unitRef="usd">19000000</cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-300">&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, including leasehold improvements, are stated at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the initial lease term plus renewal options, if reasonably assured, or the remaining useful life of the asset. Upon retirement or disposal of assets, any gain or loss is reflected as a component of operating loss in the consolidated statement of operations. Improvements that extend an asset&#x2019;s useful life are capitalized. Repairs and maintenance costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="c-1" id="f-301">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets and Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s intangible assets and goodwill consist of capitalized costs related to product and license rights, patents, trademarks and goodwill obtained in the Vibativ and Sancuso acquisitions. Goodwill is not amortized for financial reporting purposes, but is subject to impairment analysis at least annually.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cost of acquiring product and license rights are capitalized at fair value at the date of acquisition for products that are approved by the FDA for commercial use. These costs are amortized ratably over the estimated economic life of the product. The economic life is estimated based upon several factors. This includes the term of the license agreement, the patent life or market exclusivity of the product and as well as  management&#x2019;s expectations of continued involvement with the product and the assessment of future sales, the future periods under which the product will be sold and the profitability of the product. This estimate is evaluated on a regular basis during the amortization period and adjusted if appropriate. If there are any changes made to the useful life of the product and license rights, the costs associated with such a change, if any, will be capitalized and amortized over the revised useful life.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Given the delay in identifying a packager for Omeclamox-Pak, the Company has taken a non-cash write down of the related intangible asset of $3.3 million. The financial statements reflect this adjustment as efforts to identify a packager continue.   &lt;/span&gt;&lt;/div&gt;Capitalized patent costs consist of outside legal costs associated with obtaining and protecting patents on products that have been approved for marketing by the FDA. If it becomes probable that a patent will not be issued or a patent has been declared invalid, related costs associated with the patent application are expensed at the time such determination is made. All costs associated with obtaining patents for products that have not been approved for marketing by the FDA are expensed as incurred.</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-1" decimals="-5" id="f-302" unitRef="usd">3300000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c-1" id="f-303">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense is recognized ratably over the following periods:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.141%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.871%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated economic life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term of license agreement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Life of patent&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets and Goodwill consisted of the following at December&#160;31, 2023 and 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product and license rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,250,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,668,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,755,543)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,891,974)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product and license rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,494,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,776,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,712,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,610,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,819,287)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,051,018)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,893,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,559,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(193,773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142,673)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,607,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,590,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;914,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;914,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="c-1" id="f-304">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Trade and Note Receivables&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current Expected Credit Losses (&#x201c;CECL&#x201d;) is applicable to all financial assets measured at amortized cost. All financial instruments are evaluated, which principally relates to trade receivables and two notes receivable. CECL requires the measurement of expected credit losses on a collective (pool) basis when similar risk characteristics exist. This may include, either individually or in combination, some of the following characteristics of Accounting Standards Codification ("ASC") 326-20-55-5:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Internal or external credit score/rating&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Risk ratings or classification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Financial asset type&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Size&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Effective interest rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Geographical location&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Historical or expected credit loss patterns&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Reasonable and supportable forecast periods&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The standard requires entities to pool financial assets but allows them to choose which risk characteristics to use. Under the requirements of the guidance, the Company reassesses at the end of each reporting period whether the pool of assets continue to display similar risk characteristics.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With twenty years of experience, Cumberland has experienced virtually no write downs of receivables as most of our receivables are due from large successful pharmaceutical, healthcare or government customers, consistently making payments on account. Although the payment behaviors of all of our customers are consistently reliable, for the sake of transparency, we have separated our customer base into seven separate pools. The Company performs a monthly analysis of aged accounts receivable to determine how much, if any, of the accounts receivable balance should be reserved as potential bad debt. The Company reviews all balances over 90 days past due for a possible reserve and considers any specific factors or information for balances aged under 90 days if there are indicators that the balance should be reserved, such as other aged balances with the customer or bankruptcy as well as any economic issues with a customer, industry or region. The adoption of ASC 326 did not result in a material impact to the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c-1" id="f-305">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;Long-lived assets, such as property and equipment, operating lease right-of-use assets and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If events or circumstances arise that require a long-lived asset to be tested for potential impairment, the Company first compares undiscounted cash flows expected to be generated by the asset to its carrying value. If the carrying amount of the long-lived asset is not recoverable on an undiscounted cash flow basis, an impairment charge is recognized to the extent that the carrying value exceeds the fair value. Fair value is determined through various valuation techniques including quoted market prices, third-party independent appraisals and discounted cash flow models.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="INF" id="f-306" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-5" decimals="INF" id="f-307" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-1" decimals="-5" id="f-308" unitRef="usd">3300000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c-36" decimals="-5" id="f-309" unitRef="usd">200000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c-36" decimals="-5" id="f-310" unitRef="usd">200000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-311">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from product sales are recognized in the amount that reflects the consideration that we expect to receive for these goods. Depending upon the shipping terms of the transaction, the revenue is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation. This occurs upon either shipment of the product or arrival at its ship to destination. Payment terms typically range from 30 to 60 days from date of shipment. The Company&#x2019;s net product revenue reflects the reduction from gross product revenue for estimated allowances for chargebacks, discounts and damaged goods, and reflects sales related accruals for rebates, coupons, product returns, and certain administrative and service fees. Significant judgments must be made in determining the transaction price for our sales of products related to these adjustments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2023, the Company revised its estimate for rebates related to Sancuso revenues based on additional information related to actual product activities.  As a result, the Company recognized additional revenue allowances of $0.6 million for rebates as a change of estimate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sales Rebates and Discounts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allowances against accounts receivable and accrued liabilities for chargebacks, discounts, service fees and expired product returns are determined on a product-by-product basis, and established by management as the Company&#x2019;s best estimate at the time of sale based on each product&#x2019;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and returns of expired product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#x2019;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, sales revenues are reduced and accrued liabilities are increased by the Company&#x2019;s estimate of the rebate that may be claimed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sales Returns&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with industry practice, the Company maintains a return policy that allows customers to return product within a specified period prior to and subsequent to the expiration date. The Company&#x2019;s estimate of the provision for returns is based upon historical experience, expiration date by product as well as any other factor &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;expected to impact future returns. Any changes in the assumptions used to estimate the provision for returns are recognized in the period those assumptions are changed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenues primarily consist of income from grant funding programs, licensing agreements, leases and contract services. Revenue related to grants is recognized when all conditions related to such grants have been met. All other revenue is recognized when earned.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="c-1" id="f-312">&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of products sold consists principally of the cost to acquire each unit of product sold, including in-bound freight expense as well as any adjustment in the net realizable value of inventory acquired in acquisitions. Cost of products sold also includes expenses associated with the reduction in the net realizable value of slow-moving or expired product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Selling and Marketing Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling and marketing expense consists primarily of expenses relating to the advertising, promotion, distribution and sale of products, including royalty expense, salaries and related costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Distribution Costs&lt;/span&gt;&lt;/div&gt;Distribution costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations.</us-gaap:CostOfSalesPolicyTextBlock>
    <cpix:ScheduleOfDistributionCostsTableTextBlock contextRef="c-1" id="f-313">Distribution costs were as follows for the years ended December 31:&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.192%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.792%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distribution costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;857,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cpix:ScheduleOfDistributionCostsTableTextBlock>
    <us-gaap:ProductionAndDistributionCosts contextRef="c-1" decimals="0" id="f-314" unitRef="usd">881829</us-gaap:ProductionAndDistributionCosts>
    <us-gaap:ProductionAndDistributionCosts contextRef="c-5" decimals="0" id="f-315" unitRef="usd">857842</us-gaap:ProductionAndDistributionCosts>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="c-1" id="f-316">&lt;div style="margin-top:8pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising Costs&lt;/span&gt;&lt;/div&gt;Advertising costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations.</us-gaap:AdvertisingCostsPolicyTextBlock>
    <cpix:ScheduleOfAdvertisingCostsTableTextBlock contextRef="c-1" id="f-317">Advertising costs were as follows for the years ended December 31:&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.192%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.792%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Advertising costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,903,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,927,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cpix:ScheduleOfAdvertisingCostsTableTextBlock>
    <us-gaap:AdvertisingExpense contextRef="c-1" decimals="0" id="f-318" unitRef="usd">2903741</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="c-5" decimals="0" id="f-319" unitRef="usd">2927041</us-gaap:AdvertisingExpense>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-320">&lt;div style="margin-top:8pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed in the period incurred. Research and development costs are comprised mainly of clinical trial expenses, salaries, wages and other related costs such as materials and supplies. Research and development expense includes activities performed by third-party providers participating in the Company&#x2019;s clinical studies. The Company accounts for these costs based on estimates of work performed, patients enrolled or fixed fees for services over the period of time the clinical trials are performed.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-321">&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides for deferred taxes using the asset and liability approach. Under this method, deferred tax assets and liabilities are recognized for future tax consequences attributable to operating loss and tax credit carryforwards, as well as differences between the carrying amounts of existing assets and liabilities and their respective tax bases. The Company&#x2019;s principal differences are related to the timing of deductibility of certain items, such as inventory, depreciation, amortization and share-based compensation. Deferred tax assets and liabilities are measured using enacted statutory tax rates that are expected to apply to taxable income in the years such temporary differences are anticipated to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. The Company only recognizes income tax benefits &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;associated with an income tax position in which it is &#x201c;more likely than not&#x201d; that the position would be sustained upon examination by the taxing authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In assessing the realizability of deferred tax assets, management considers whether some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of existing temporary differences, projected future taxable income and tax planning strategies in making this assessment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounting policy with respect to interest and penalties arising from income tax settlements is to recognize them as part of the provision for income taxes.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-322">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Loss per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic loss per share is calculated by dividing net loss attributable to common shareholders by the weighted-average number of shares outstanding. Except where the result would be antidilutive, diluted loss per share is calculated by assuming the vesting of unvested restricted stock and the exercise of stock options and warrants and unrecognized compensation costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-323">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes compensation cost for all share-based payments issued, modified, repurchased or canceled. Depending on the nature of the vesting provisions, restricted stock awards are measured using either the fair value on the grant date or the fair value of common stock on the date the vesting provisions lapse. Prior to the lapse for those equity grants not valued on the grant date, the fair value is measured on the last day of the reporting period.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:CollaborativeArrangementAccountingPolicy contextRef="c-1" id="f-324">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaborative Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment discussed in Note 3, related to the Vibativ and Sancuso contingent consideration payments, do not meet the criteria for accounting under ASC Topic 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The agreements do not specifically designate each party&#x2019;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party. Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:CostsAndExpenses contextRef="c-37" decimals="-4" id="f-325" unitRef="usd">50000.00</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-38" decimals="-4" id="f-326" unitRef="usd">40000.00</us-gaap:CostsAndExpenses>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-327">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Guidance &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-13, &#x201c;Financial Instruments-Credit Losses,&#x201d; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies are required to use a new forward-looking &#x201c;expected loss&#x201d; model that generally results in an earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies measure credit losses in a manner similar with previous guidance, except that the losses are recognized as &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;allowances rather than as reductions in the amortized cost of the securities. Companies have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies apply the ASU&#x2019;s provisions as a cumulative-effect adjustment, if any, to the accumulated deficit as of the beginning of the first reporting period in which the guidance is adopted.&lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. &lt;/span&gt;The Company adopted both ASU 2016-13 and ASU 2019-05 on January 1, 2023</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c-1" id="f-328">Vibativ&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; Sancuso&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;and RediTrex&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Products&lt;/span&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Vibativ&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During November 2018, the Company executed an agreement with Theravance Biopharma ("Theravance") to acquire the assets and global rights to Vibativ including responsibility for the marketing, distribution, manufacturing and regulatory activities associated with the brand. Vibativ is a patented, FDA approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $20&#160;million at the closing of the transaction and a $5&#160;million milestone payment in early April 2019. In addition, Cumberland has agreed to pay royalties of up to 20% of on-going net sales of the product in the U.S. after a $2.5&#160;million threshold is met. The future royalty payments were recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland prepared the valuations of the contingent consideration liability utilizing significant unobservable inputs. As a result, the valuation is classified as Level 3 fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis. The contingent consideration earned and accrued in operating expenses is paid to Theravance annually.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.265%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contingent Consideration Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,515,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,133,113)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,104,690)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration earned and accrued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,154,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,018,451)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(270,485)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration earned and accrued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,167,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,033,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The current portion of the contingent consideration liability is $1.7&#160;million and the non-current portion is $2.3&#160;million, as of December&#160;31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sancuso&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 3, 2022, Cumberland acquired the U.S. rights to the FDA-approved oncology-supportive care medicine Sancuso from Kyowa Kirin, Inc. ("Kyowa Kirin"), the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sancuso is the first and only FDA-approved prescription patch for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment. The active drug in Sancuso, granisetron, slowly dissolves in the thin layer of adhesive that sticks to the patient&#x2019;s skin and is released into their bloodstream over several days, working continuously to prevent chemotherapy-induced nausea and vomiting (&#x201c;CINV&#x201d;). It is applied 24 to 48 hours before receiving chemotherapy and can prevent CINV for up to five consecutive days. Alternative oral treatments must be taken several times (day and night) to deliver the same therapeutic doses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland acquired U.S. rights to Sancuso and assumed full commercial responsibility for the product in the U.S. &#x2013; including its marketing, promotion, distribution, manufacturing and medical support activities. The product&#x2019;s FDA registration was subsequently transferred from Kyowa Kirin to Cumberland in August 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $13.5&#160;million at the closing of the transaction. The Agreement calls for milestone payments of up to $3.5&#160;million based on the attainment of various approvals and sales performance. In January 2023, Cumberland made a $1.0&#160;million milestone payment to Kwoya Kirin based on the FDA approval of a manufacturing site for the product. In October 2023, Cumberland made a $0.5&#160;million milestone payment based on the successful transfer of the product&#x2019;s FDA registration from Kyowa Kirin to Cumberland.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The remaining $2&#160;million in milestone payments are tied to achievement of certain annual sales levels for the product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, Cumberland has agreed to pay a royalty of up to 10% of on-going net sales of the product. The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland has prepared a valuation of the contingent consideration liability utilizing significant unobservable inputs. As a result, the valuation is classified as Level 3 fair value measurement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition was funded by cash and the Company's revolving credit facility. The fair value for the assets and liabilities assumed using Level 3 fair value inputs were as follows: prepaid expenses of  $1.8&#160;million, inventory $2.6&#160;million, goodwill $0.03&#160;million, intangible assets $14.1&#160;million, milestone payable $1.7&#160;million and contingent liability $3.4&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.271%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.214%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.215%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contingent Consideration Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contingent Consideration Liability Including Milestone&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Balance at January 3, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;3,384,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;3,946,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(1,075,631)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(1,075,631)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Change in fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;16,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;1,210,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Contingent consideration earned and accrued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;675,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;675,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;3,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;4,757,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(790,632)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(2,249,632)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Change in fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(685,355)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(983,355)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Contingent consideration earned and accrued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;781,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;781,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,306,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,306,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The current portion of the contingent consideration liability is $1.3 million and the non-current portion is $1.0 million, as of December&#160;31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;RediTrex&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2016, the Company announced an agreement with the Nordic Group B.V. ("Nordic") to acquire the exclusive U.S. rights to Nordic&#x2019;s injectable methotrexate product line designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As consideration for the license Cumberland paid a deposit of $0.1 million at closing. The Company provided $0.9 million in consideration through a grant of 180,000 restricted shares of Cumberland common stock to be vested upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments tied to the products&#x2019; FDA approval, launch and achievement of certain sales milestones. Under the terms of the agreement, Cumberland is responsible for the product registration and commercialization in the U.S. Nordic is responsible for product manufacturing and supply. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 27, 2019, Cumberland received FDA approval for the first Nordic injectable product and authorization to market them under the RediTrex brand name. The 180,000 shares of restricted Cumberland common stock previously provided to Nordic vested upon approval and were valued at $0.9 million on the vesting date. The FDA approval also resulted in a $1.0&#160;million milestone payment due to Nordic. This milestone payment was paid in July 2020. During December 2020, Cumberland began distributing RediTrex which also resulted in a $1.0&#160;million milestone payment due to Nordic. The full launch of RediTrex occurred in October 2021.&lt;/span&gt;&lt;/div&gt;Effective July 12, 2022, the Company entered into an amendment to our agreement with Nordic whereby they may assume responsibility for RediTrex marketing authorization in the U.S. and the opportunity to commercialize the product in the U.S. after June 30, 2023.  In accordance with the terms of the amendment, Nordic a) returned the 180,000 restricted Cumberland shares we previously issued to Nordic which were cancelled; b) refunded to Cumberland the milestone payment of $1.0&#160;million we made associated with the brand&#x2019;s U.S. approval; and c) issued a credit note in favor of the Company in the amount of $1.0&#160;million for the unpaid milestone payment due from us for launch of the product line all in 2023.  Cumberland will receive a long-term royalty on any Nordic sales of the product.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-39" decimals="-5" id="f-329" unitRef="usd">20000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <cpix:PaymentsToAcquireBusinessMilestonePayment contextRef="c-40" decimals="-5" id="f-330" unitRef="usd">5000000</cpix:PaymentsToAcquireBusinessMilestonePayment>
    <cpix:PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage contextRef="c-41" decimals="2" id="f-331" unitRef="number">0.20</cpix:PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage>
    <cpix:PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold contextRef="c-39" decimals="-5" id="f-332" unitRef="usd">2500000</cpix:PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock contextRef="c-1" id="f-333">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis. The contingent consideration earned and accrued in operating expenses is paid to Theravance annually.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.265%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contingent Consideration Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,515,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,133,113)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,104,690)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration earned and accrued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,154,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,018,451)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(270,485)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration earned and accrued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,167,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,033,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.271%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.214%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.215%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contingent Consideration Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contingent Consideration Liability Including Milestone&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Balance at January 3, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;3,384,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;3,946,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(1,075,631)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(1,075,631)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Change in fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;16,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;1,210,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Contingent consideration earned and accrued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;675,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;675,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;3,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;4,757,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(790,632)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(2,249,632)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Change in fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(685,355)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(983,355)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Contingent consideration earned and accrued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;781,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;781,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,306,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,306,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-42" decimals="0" id="f-334" unitRef="usd">6515627</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentsForRoyalties contextRef="c-43" decimals="0" id="f-335" unitRef="usd">1133113</us-gaap:PaymentsForRoyalties>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-43" decimals="0" id="f-336" unitRef="usd">-2104690</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses contextRef="c-43" decimals="0" id="f-337" unitRef="usd">876999</cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-44" decimals="0" id="f-338" unitRef="usd">4154823</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentsForRoyalties contextRef="c-45" decimals="0" id="f-339" unitRef="usd">1018451</us-gaap:PaymentsForRoyalties>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-45" decimals="0" id="f-340" unitRef="usd">-270485</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses contextRef="c-45" decimals="0" id="f-341" unitRef="usd">1167486</cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-46" decimals="0" id="f-342" unitRef="usd">4033373</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-46" decimals="-5" id="f-343" unitRef="usd">1700000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-46" decimals="-5" id="f-344" unitRef="usd">2300000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-47" decimals="-5" id="f-345" unitRef="usd">13500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <cpix:PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold contextRef="c-47" decimals="-5" id="f-346" unitRef="usd">3500000</cpix:PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold>
    <cpix:PaymentsToAcquireBusinessMilestonePayment contextRef="c-48" decimals="-5" id="f-347" unitRef="usd">1000000</cpix:PaymentsToAcquireBusinessMilestonePayment>
    <cpix:PaymentsToAcquireBusinessMilestonePayment contextRef="c-49" decimals="-5" id="f-348" unitRef="usd">500000</cpix:PaymentsToAcquireBusinessMilestonePayment>
    <cpix:PaymentsToAcquireBusinessMilestonePaymentRemaining contextRef="c-50" decimals="-5" id="f-349" unitRef="usd">2000000</cpix:PaymentsToAcquireBusinessMilestonePaymentRemaining>
    <cpix:PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage contextRef="c-51" decimals="2" id="f-350" unitRef="number">0.10</cpix:PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets contextRef="c-52" decimals="0" id="f-351" unitRef="usd">1800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory contextRef="c-52" decimals="0" id="f-352" unitRef="usd">2600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:Goodwill contextRef="c-52" decimals="0" id="f-353" unitRef="usd">30000.00</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-52" decimals="0" id="f-354" unitRef="usd">14100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMilestonePayable contextRef="c-47" decimals="-5" id="f-355" unitRef="usd">1700000</cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMilestonePayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability contextRef="c-52" decimals="-5" id="f-356" unitRef="usd">3400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-53" decimals="0" id="f-357" unitRef="usd">3384000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentsForRoyalties contextRef="c-54" decimals="0" id="f-358" unitRef="usd">1075631</us-gaap:PaymentsForRoyalties>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-54" decimals="0" id="f-359" unitRef="usd">16394</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses contextRef="c-54" decimals="0" id="f-360" unitRef="usd">675237</cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-55" decimals="0" id="f-361" unitRef="usd">3000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentsForRoyalties contextRef="c-50" decimals="0" id="f-362" unitRef="usd">790632</us-gaap:PaymentsForRoyalties>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-50" decimals="0" id="f-363" unitRef="usd">-685355</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses contextRef="c-50" decimals="0" id="f-364" unitRef="usd">781987</cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-56" decimals="0" id="f-365" unitRef="usd">2306000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-56" decimals="-5" id="f-366" unitRef="usd">1300000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-56" decimals="-5" id="f-367" unitRef="usd">1000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <cpix:CollaborativeArrangementRightsAndObligationsDepositPayment contextRef="c-57" decimals="-5" id="f-368" unitRef="usd">100000</cpix:CollaborativeArrangementRightsAndObligationsDepositPayment>
    <cpix:CollaborativeArrangementRightsAndObligationsStockConsiderationValue contextRef="c-57" decimals="-5" id="f-369" unitRef="usd">900000</cpix:CollaborativeArrangementRightsAndObligationsStockConsiderationValue>
    <cpix:CollaborativeArrangementRightsAndObligationsStockConsiderationShares
      contextRef="c-58"
      decimals="INF"
      id="f-370"
      unitRef="shares">180000</cpix:CollaborativeArrangementRightsAndObligationsStockConsiderationShares>
    <cpix:CollaborativeArrangementRightsAndObligationsStockConsiderationShares
      contextRef="c-58"
      decimals="INF"
      id="f-371"
      unitRef="shares">180000</cpix:CollaborativeArrangementRightsAndObligationsStockConsiderationShares>
    <cpix:CollaborativeArrangementRightsAndObligationsStockConsiderationVestedValue contextRef="c-59" decimals="-5" id="f-372" unitRef="usd">900000</cpix:CollaborativeArrangementRightsAndObligationsStockConsiderationVestedValue>
    <cpix:CollaborativeArrangementRightsAndObligationsMilestonePayment contextRef="c-60" decimals="-5" id="f-373" unitRef="usd">1000000</cpix:CollaborativeArrangementRightsAndObligationsMilestonePayment>
    <cpix:CollaborativeArrangementRightsAndObligationsMilestonePayment contextRef="c-61" decimals="-5" id="f-374" unitRef="usd">1000000</cpix:CollaborativeArrangementRightsAndObligationsMilestonePayment>
    <cpix:CollaborativeArrangementRightsAndObligationsStockConsiderationCancelledAndRefunded contextRef="c-62" decimals="0" id="f-375" unitRef="shares">180000</cpix:CollaborativeArrangementRightsAndObligationsStockConsiderationCancelledAndRefunded>
    <cpix:CollaborativeArrangementRightsAndObligationsMilestonePayment contextRef="c-63" decimals="-5" id="f-376" unitRef="usd">1000000</cpix:CollaborativeArrangementRightsAndObligationsMilestonePayment>
    <cpix:CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue contextRef="c-63" decimals="-5" id="f-377" unitRef="usd">1000000</cpix:CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-378">Revenues&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s net product revenues consisted of the following for the years ended December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.605%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kristalose&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,981,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,205,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vibativ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,812,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,487,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sancuso&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,096,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,205,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Caldolor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,333,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,827,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acetadote&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Omeclamox-Pak&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vaprisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(447,697)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RediTrex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(341,886)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126,726)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,513,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,681,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has agreements with international partners for commercialization of the Company&#x2019;s products with associated payments included in other revenues. Those agreements provide that each of the partners is responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner&#x2019;s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies. The contractual payments associated with the partner&#x2019;s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the second quarter of 2023, the Company received $1 million relating to a litigation settlement based on two $500,000 milestone payments due to us for the license associated with our Vibativ product that is included in other revenue for the year ended  December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenues includes funding from federal grant programs including those secured from the FDA and from those secured by CET through the Small Business Administration. Grant revenue from these federal grant programs totaled approximately $0.4 million and $0.2 million for the year ended December&#160;31, 2023 and 2022,respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenues also includes lease income generated by CET&#x2019;s Life Sciences Center. It is a research facility that provides scientists with access to flexible lab space and other resources to develop biomedical products. This lease income, as noted in Footnote 15 - Leases, was approximately $0.5&#160;million for the years ended December&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock contextRef="c-1" id="f-379">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s net product revenues consisted of the following for the years ended December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.605%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kristalose&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,981,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,205,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vibativ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,812,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,487,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sancuso&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,096,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,205,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Caldolor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,333,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,827,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acetadote&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Omeclamox-Pak&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vaprisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(447,697)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RediTrex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(341,886)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126,726)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,513,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,681,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-64" decimals="0" id="f-380" unitRef="usd">15981850</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-65" decimals="0" id="f-381" unitRef="usd">15205155</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-66" decimals="0" id="f-382" unitRef="usd">8812692</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-67" decimals="0" id="f-383" unitRef="usd">7487462</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-68" decimals="0" id="f-384" unitRef="usd">8096788</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-69" decimals="0" id="f-385" unitRef="usd">13205603</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-70" decimals="0" id="f-386" unitRef="usd">4333923</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-71" decimals="0" id="f-387" unitRef="usd">4827200</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-72" decimals="0" id="f-388" unitRef="usd">458759</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-73" decimals="0" id="f-389" unitRef="usd">501040</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-74" decimals="0" id="f-390" unitRef="usd">20030</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-75" decimals="0" id="f-391" unitRef="usd">29145</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-76" decimals="0" id="f-392" unitRef="usd">151336</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-77" decimals="0" id="f-393" unitRef="usd">-447697</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-78" decimals="0" id="f-394" unitRef="usd">-341886</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-79" decimals="0" id="f-395" unitRef="usd">-126726</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-8" decimals="0" id="f-396" unitRef="usd">37513492</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-9" decimals="0" id="f-397" unitRef="usd">40681182</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ProceedsFromLegalSettlements contextRef="c-80" decimals="-5" id="f-398" unitRef="usd">1000000</us-gaap:ProceedsFromLegalSettlements>
    <cpix:ProceedsFromLegalSettlementsMilestonePaymentsReceivableNumberOfPayments
      contextRef="c-81"
      decimals="INF"
      id="f-399"
      unitRef="payment">2</cpix:ProceedsFromLegalSettlementsMilestonePaymentsReceivableNumberOfPayments>
    <cpix:ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentTwo contextRef="c-81" decimals="INF" id="f-400" unitRef="usd">500000</cpix:ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentTwo>
    <cpix:ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentOne contextRef="c-81" decimals="INF" id="f-401" unitRef="usd">500000</cpix:ProceedsFromLegalSettlementsMilestonePaymentsReceivablePaymentOne>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-82" decimals="-5" id="f-402" unitRef="usd">400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-83" decimals="-5" id="f-403" unitRef="usd">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SubleaseIncome contextRef="c-1" decimals="-5" id="f-404" unitRef="usd">500000</us-gaap:SubleaseIncome>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c-1" id="f-405">Inventories, Net&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's net inventories consisted of the following as of December 31:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.265%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.175%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.921%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.178%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,619,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,899,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consigned inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods, net of reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,645,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,322,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,413,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,390,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;less non-current inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,804,529)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,527,167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories classified as current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,609,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,863,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's non-current inventories consisted of the following as of December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.921%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.175%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.921%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.178%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vibativ - raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,611,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,138,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vibativ - finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;810,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kristalose - raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,263,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vaprisol - raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,170,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Caldolor - finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sancuso - raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;574,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Study drug - raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Study drug - finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,804,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,527,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company purchases the active pharmaceutical ingredient (&#x201c;API&#x201d;) for Kristalose and maintains the inventory of that raw material.  API for the Company's Vaprisol and Vibativ brands were included in the assets associated with the acquisition of those brands and are also included in the raw materials inventory.  As part of the Vibativ acquisition, the Company acquired API and work in process inventories of $15.6 million that were all initially classified as non-current inventories at the date of acquisition.  Consigned inventory represents Authorized Generic inventory stored with Padagis until shipment.  &lt;/span&gt;&lt;/div&gt;At December&#160;31, 2023, there were no cumulative obsolescence or discontinuance losses necessary to recognize.  At December 31, 2022, the Company had recognized and maintained cumulative net realizable value charges for potential obsolescence and discontinuance losses of approximately $0.5 million.</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-406">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's net inventories consisted of the following as of December 31:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.265%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.175%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.921%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.178%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,619,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,899,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consigned inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods, net of reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,645,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,322,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,413,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,390,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;less non-current inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,804,529)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,527,167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories classified as current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,609,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,863,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-6" decimals="0" id="f-407" unitRef="usd">12619092</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-7" decimals="0" id="f-408" unitRef="usd">12899659</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment contextRef="c-6" decimals="0" id="f-409" unitRef="usd">149701</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment contextRef="c-7" decimals="0" id="f-410" unitRef="usd">168923</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-6" decimals="0" id="f-411" unitRef="usd">4645098</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-7" decimals="0" id="f-412" unitRef="usd">4322167</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryGross contextRef="c-6" decimals="0" id="f-413" unitRef="usd">17413891</us-gaap:InventoryGross>
    <us-gaap:InventoryGross contextRef="c-7" decimals="0" id="f-414" unitRef="usd">17390748</us-gaap:InventoryGross>
    <us-gaap:InventoryNoncurrent contextRef="c-6" decimals="0" id="f-415" unitRef="usd">12804529</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent contextRef="c-7" decimals="0" id="f-416" unitRef="usd">7527167</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNet contextRef="c-6" decimals="0" id="f-417" unitRef="usd">4609362</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-7" decimals="0" id="f-418" unitRef="usd">9863581</us-gaap:InventoryNet>
    <us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock contextRef="c-1" id="f-419">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's non-current inventories consisted of the following as of December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.921%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.175%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.921%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.178%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vibativ - raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,611,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,138,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vibativ - finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;810,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kristalose - raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,263,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vaprisol - raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,170,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Caldolor - finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sancuso - raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;574,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Study drug - raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Study drug - finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,804,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,527,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock>
    <us-gaap:InventoryNoncurrent contextRef="c-84" decimals="0" id="f-420" unitRef="usd">6611426</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent contextRef="c-85" decimals="0" id="f-421" unitRef="usd">7138936</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent contextRef="c-86" decimals="0" id="f-422" unitRef="usd">810454</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent contextRef="c-87" decimals="0" id="f-423" unitRef="usd">0</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent contextRef="c-88" decimals="0" id="f-424" unitRef="usd">3263515</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent contextRef="c-89" decimals="0" id="f-425" unitRef="usd">0</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent contextRef="c-90" decimals="0" id="f-426" unitRef="usd">1170641</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent contextRef="c-91" decimals="0" id="f-427" unitRef="usd">0</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent contextRef="c-92" decimals="0" id="f-428" unitRef="usd">67307</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent contextRef="c-93" decimals="0" id="f-429" unitRef="usd">0</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent contextRef="c-94" decimals="0" id="f-430" unitRef="usd">574502</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent contextRef="c-95" decimals="0" id="f-431" unitRef="usd">0</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent contextRef="c-96" decimals="0" id="f-432" unitRef="usd">203383</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent contextRef="c-97" decimals="0" id="f-433" unitRef="usd">256474</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent contextRef="c-98" decimals="0" id="f-434" unitRef="usd">0</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent contextRef="c-99" decimals="0" id="f-435" unitRef="usd">131757</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent contextRef="c-100" decimals="0" id="f-436" unitRef="usd">103300</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent contextRef="c-101" decimals="0" id="f-437" unitRef="usd">0</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent contextRef="c-6" decimals="0" id="f-438" unitRef="usd">12804529</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent contextRef="c-7" decimals="0" id="f-439" unitRef="usd">7527167</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent contextRef="c-102" decimals="-5" id="f-440" unitRef="usd">15600000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryValuationReserves contextRef="c-6" decimals="INF" id="f-441" unitRef="usd">0</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves contextRef="c-7" decimals="-5" id="f-442" unitRef="usd">500000</us-gaap:InventoryValuationReserves>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-443">Property and Equipment&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following at December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.694%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.694%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.699%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Range of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;useful lives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&#x2013;&#160;5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&#x2013;&#160;15 years&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;771,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;746,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&#x2013;&#160;15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&#x2013;&#160;15 years,&#160;or remaining&#160;lease&#160;term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;equipment, gross&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,605,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,369,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,238,073)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,085,185)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense, including amortization expense related to leasehold improvements, is included in general and administrative expense in the consolidated statements of operations. Depreciation expense was as follows for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.656%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.819%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-444">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following at December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.694%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.694%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.699%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Range of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;useful lives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&#x2013;&#160;5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&#x2013;&#160;15 years&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;771,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;746,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&#x2013;&#160;15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&#x2013;&#160;15 years,&#160;or remaining&#160;lease&#160;term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;equipment, gross&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,605,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,369,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,238,073)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,085,185)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-103" id="f-445">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-104" id="f-446">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-105" decimals="0" id="f-447" unitRef="usd">499557</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-106" decimals="0" id="f-448" unitRef="usd">465508</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-107" id="f-449">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-108" id="f-450">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-109" decimals="0" id="f-451" unitRef="usd">771667</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-110" decimals="0" id="f-452" unitRef="usd">746602</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-111" id="f-453">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-112" id="f-454">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-113" decimals="0" id="f-455" unitRef="usd">533778</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-114" decimals="0" id="f-456" unitRef="usd">369365</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-115" id="f-457">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-116" id="f-458">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-117" decimals="0" id="f-459" unitRef="usd">800974</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-118" decimals="0" id="f-460" unitRef="usd">787749</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-6" decimals="0" id="f-461" unitRef="usd">2605976</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-7" decimals="0" id="f-462" unitRef="usd">2369224</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-6" decimals="0" id="f-463" unitRef="usd">2238073</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-7" decimals="0" id="f-464" unitRef="usd">2085185</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-6" decimals="0" id="f-465" unitRef="usd">367903</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-7" decimals="0" id="f-466" unitRef="usd">284039</us-gaap:PropertyPlantAndEquipmentNet>
    <cpix:ScheduleofDepreciationExpenseTableTextBlock contextRef="c-1" id="f-467">Depreciation expense was as follows for the years ended December 31:&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.656%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.819%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cpix:ScheduleofDepreciationExpenseTableTextBlock>
    <cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements contextRef="c-1" decimals="0" id="f-468" unitRef="usd">177148</cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements>
    <cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements contextRef="c-5" decimals="0" id="f-469" unitRef="usd">260745</cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-470">Intangible Assets and Goodwill&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets and Goodwill consisted of the following at December&#160;31, 2023 and 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product and license rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,250,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,668,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,755,543)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,891,974)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product and license rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,494,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,776,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,712,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,610,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,819,287)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,051,018)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,893,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,559,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(193,773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142,673)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,607,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,590,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;914,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;914,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product and license rights include assets associated with the Company&#x2019;s acquired products, including those discussed in Note 3, Vibativ and Sancuso. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2023 and 2022, the Company recorded an additional $0.1 million and $0.2 million, respectively, in intangible assets for patents, trademarks and capitalized patent costs, including amounts incurred in the protection of the Company's intellectual property. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense related to product and license rights, trademarks and patents were as follows for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization and impairment expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,102,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,067,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected amortization expense for the Company's current balance of intangible assets are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.780%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,304,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,245,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,859,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,452,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,745,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,607,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-119" decimals="0" id="f-471" unitRef="usd">43250341</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-120" decimals="0" id="f-472" unitRef="usd">49668141</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-119" decimals="0" id="f-473" unitRef="usd">22755543</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-120" decimals="0" id="f-474" unitRef="usd">21891974</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-119" decimals="0" id="f-475" unitRef="usd">20494798</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-120" decimals="0" id="f-476" unitRef="usd">27776167</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-121" decimals="0" id="f-477" unitRef="usd">10712405</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-122" decimals="0" id="f-478" unitRef="usd">10610228</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-121" decimals="0" id="f-479" unitRef="usd">8819287</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-122" decimals="0" id="f-480" unitRef="usd">8051018</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-121" decimals="0" id="f-481" unitRef="usd">1893118</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-122" decimals="0" id="f-482" unitRef="usd">2559210</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-123" decimals="0" id="f-483" unitRef="usd">413775</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-124" decimals="0" id="f-484" unitRef="usd">397974</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-123" decimals="0" id="f-485" unitRef="usd">193773</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-124" decimals="0" id="f-486" unitRef="usd">142673</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-123" decimals="0" id="f-487" unitRef="usd">220002</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-124" decimals="0" id="f-488" unitRef="usd">255301</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-6" decimals="0" id="f-489" unitRef="usd">22607918</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-7" decimals="0" id="f-490" unitRef="usd">30590678</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill contextRef="c-6" decimals="0" id="f-491" unitRef="usd">914000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-7" decimals="0" id="f-492" unitRef="usd">914000</us-gaap:Goodwill>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-125" decimals="-5" id="f-493" unitRef="usd">100000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-126" decimals="-5" id="f-494" unitRef="usd">200000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c-1" id="f-495">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense related to product and license rights, trademarks and patents were as follows for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization and impairment expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,102,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,067,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected amortization expense for the Company's current balance of intangible assets are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.780%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,304,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,245,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,859,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,452,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,745,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,607,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="0" id="f-496" unitRef="usd">8102648</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-5" decimals="0" id="f-497" unitRef="usd">5067368</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-6" decimals="0" id="f-498" unitRef="usd">4304157</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-6" decimals="0" id="f-499" unitRef="usd">4245825</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-6" decimals="0" id="f-500" unitRef="usd">3859206</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-6" decimals="0" id="f-501" unitRef="usd">3452780</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <cpix:FiniteLivedIntangibleAssetsAmortizationExpenseYearFourAndAfter contextRef="c-6" decimals="0" id="f-502" unitRef="usd">6745950</cpix:FiniteLivedIntangibleAssetsAmortizationExpenseYearFourAndAfter>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-6" decimals="0" id="f-503" unitRef="usd">22607918</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock contextRef="c-1" id="f-504">Other Current and Other Long-term Liabilities&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liabilities consisted of the following at December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.867%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.694%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.697%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rebates, product returns, administrative fees &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;and service fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,579,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,347,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee wages and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,197,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,440,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sancuso related liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,226,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of accrued contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,424,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,006,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Studies accrual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued inventory purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;609,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current deferred charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;614,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;961,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;941,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,596,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,587,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other long-term liabilities consisted of the following at December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.867%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.694%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.697%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion of accrued contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,284,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,931,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,894,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,522,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,453,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,585,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-505">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liabilities consisted of the following at December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.867%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.694%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.697%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rebates, product returns, administrative fees &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;and service fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,579,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,347,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee wages and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,197,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,440,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sancuso related liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,226,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of accrued contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,424,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,006,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Studies accrual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued inventory purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;609,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current deferred charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;614,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;961,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;941,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,596,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,587,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <cpix:ProductSalesRelatedLiabilitiesCurrent contextRef="c-6" decimals="0" id="f-506" unitRef="usd">7579783</cpix:ProductSalesRelatedLiabilitiesCurrent>
    <cpix:ProductSalesRelatedLiabilitiesCurrent contextRef="c-7" decimals="0" id="f-507" unitRef="usd">8347214</cpix:ProductSalesRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-6" decimals="0" id="f-508" unitRef="usd">1197832</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-7" decimals="0" id="f-509" unitRef="usd">1440859</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <cpix:AccruedLiabilitiesStockPayable contextRef="c-6" decimals="0" id="f-510" unitRef="usd">827813</cpix:AccruedLiabilitiesStockPayable>
    <cpix:AccruedLiabilitiesStockPayable contextRef="c-7" decimals="0" id="f-511" unitRef="usd">2226725</cpix:AccruedLiabilitiesStockPayable>
    <cpix:BusinessCombinationContingentConsiderationLiabilityAccruedCurrent contextRef="c-6" decimals="0" id="f-512" unitRef="usd">2424000</cpix:BusinessCombinationContingentConsiderationLiabilityAccruedCurrent>
    <cpix:BusinessCombinationContingentConsiderationLiabilityAccruedCurrent contextRef="c-7" decimals="0" id="f-513" unitRef="usd">3006310</cpix:BusinessCombinationContingentConsiderationLiabilityAccruedCurrent>
    <cpix:AccruedLiabilitiesStudies contextRef="c-6" decimals="0" id="f-514" unitRef="usd">385266</cpix:AccruedLiabilitiesStudies>
    <cpix:AccruedLiabilitiesStudies contextRef="c-7" decimals="0" id="f-515" unitRef="usd">400702</cpix:AccruedLiabilitiesStudies>
    <cpix:AccruedLiabilitiesInventoryPurchases contextRef="c-6" decimals="0" id="f-516" unitRef="usd">0</cpix:AccruedLiabilitiesInventoryPurchases>
    <cpix:AccruedLiabilitiesInventoryPurchases contextRef="c-7" decimals="0" id="f-517" unitRef="usd">609621</cpix:AccruedLiabilitiesInventoryPurchases>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-6" decimals="0" id="f-518" unitRef="usd">220402</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-7" decimals="0" id="f-519" unitRef="usd">614551</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-6" decimals="0" id="f-520" unitRef="usd">961432</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-7" decimals="0" id="f-521" unitRef="usd">941929</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-6" decimals="0" id="f-522" unitRef="usd">13596528</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-7" decimals="0" id="f-523" unitRef="usd">17587911</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherNoncurrentLiabilitiesTableTextBlock contextRef="c-1" id="f-524">&lt;div style="margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other long-term liabilities consisted of the following at December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.867%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.694%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.697%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion of accrued contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,284,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,931,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,894,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,522,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,453,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,585,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherNoncurrentLiabilitiesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-6" decimals="0" id="f-525" unitRef="usd">3284672</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-7" decimals="0" id="f-526" unitRef="usd">4931513</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent contextRef="c-6" decimals="0" id="f-527" unitRef="usd">2894894</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent contextRef="c-7" decimals="0" id="f-528" unitRef="usd">2522506</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent contextRef="c-6" decimals="0" id="f-529" unitRef="usd">274000</us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent contextRef="c-7" decimals="0" id="f-530" unitRef="usd">131000</us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-6" decimals="0" id="f-531" unitRef="usd">6453566</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-7" decimals="0" id="f-532" unitRef="usd">7585019</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-533">Debt&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 5, 2023, the Company entered into a new Revolving Credit Loan Agreement with Pinnacle Bank. This facility provides for an aggregate principal funding amount of up to $25&#160;million. The initial revolving line of credit is up to $20&#160;million, with the ability for Cumberland to increase the amount to $25&#160;million, under certain conditions. It has a three year term expiring on October 1, 2026. The interest rate is based on a benchmark (Term SOFR) plus a spread of 2.75%. Cumberland is subject to one financial covenant, the maintenance of a Funded Debt Ratio, determined on a quarterly basis. Borrowings under the line of credit are collateralized by substantially all of our assets.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023 and December&#160;31, 2022, the Company had $12.8 million and $16.2 million, respectively, in borrowings outstanding under its revolving credit facility. The applicable interest rate under the Pinnacle Agreement was 8.125% at December&#160;31, 2023.  In 2022, under a previous agreement with Pinnacle Bank, the applicable interest rate was based on LIBOR plus an interest rate spread and was 6.75% at December 31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-127" decimals="-5" id="f-534" unitRef="usd">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-128" decimals="-5" id="f-535" unitRef="usd">20000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <cpix:LineOfCreditFacilityAdditionalBorrowingCapacity contextRef="c-128" decimals="-5" id="f-536" unitRef="usd">25000000</cpix:LineOfCreditFacilityAdditionalBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityExpirationPeriod contextRef="c-129" id="f-537">P3Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-130"
      decimals="INF"
      id="f-538"
      unitRef="number">0.0275</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LongTermLineOfCredit contextRef="c-131" decimals="-5" id="f-539" unitRef="usd">12800000</us-gaap:LongTermLineOfCredit>
    <us-gaap:LongTermLineOfCredit contextRef="c-132" decimals="-5" id="f-540" unitRef="usd">16200000</us-gaap:LongTermLineOfCredit>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-131"
      decimals="INF"
      id="f-541"
      unitRef="number">0.08125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-132"
      decimals="INF"
      id="f-542"
      unitRef="number">6.75</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-543">Shareholders&#x2019; Equity&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Initial Public Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August&#160;10, 2009, the Company completed its initial public offering of 5,000,000 shares of common stock at a price of $17.00 per share, raising gross proceeds of $85.0 million. After deducting underwriting discounts of approximately $6.0 million and offering costs incurred of approximately $4.2 million, the net proceeds to the Company were approximately $74.8 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is authorized to issue 20,000,000&#160;shares of preferred stock. The Board of Directors is authorized to divide these shares into classes or series, and to fix and determine the relative rights, preferences, qualifications and limitations of the shares of any class or series so established. At December&#160;31, 2023 and 2022, there was no preferred stock outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2023 and 2022, the Company issued 157,360 shares and 171,655  shares of common stock, respectively, as a result of restricted shares vesting as well as other common share issuances. There were no option exercise transactions during 2023 and  2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(d)&#160;&#160;&#160;&#160;Share Repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently has a share repurchase program available to repurchase up to $10&#160;million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934.  The Company repurchased 402,143 shares and 367,793 shares of common stock for approximately $0.7 million and $1.0 million during the years ended December&#160;31, 2023 and 2022, respectively.  There remains approximately $3 million  available under the current repurchase program available for share repurchases at December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockTransactionDate contextRef="c-133" id="f-544">2009-08-10</us-gaap:SaleOfStockTransactionDate>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-133"
      decimals="INF"
      id="f-545"
      unitRef="shares">5000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <cpix:StockIssuedDuringPeriodPricePerShareNewIssues
      contextRef="c-133"
      decimals="INF"
      id="f-546"
      unitRef="usdPerShare">17.00</cpix:StockIssuedDuringPeriodPricePerShareNewIssues>
    <cpix:StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering contextRef="c-133" decimals="-5" id="f-547" unitRef="usd">85000000</cpix:StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering>
    <cpix:StockIssuedDuringPeriodNewSharesUnderwritingDiscounts contextRef="c-133" decimals="-5" id="f-548" unitRef="usd">6000000</cpix:StockIssuedDuringPeriodNewSharesUnderwritingDiscounts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-133" decimals="-5" id="f-549" unitRef="usd">4200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c-133" decimals="-5" id="f-550" unitRef="usd">74800000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-6" decimals="INF" id="f-551" unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-6" decimals="INF" id="f-552" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-7" decimals="INF" id="f-553" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-24"
      decimals="INF"
      id="f-554"
      unitRef="shares">157360</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-18"
      decimals="INF"
      id="f-555"
      unitRef="shares">171655</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-134" decimals="INF" id="f-556" unitRef="usd">10000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="c-24"
      decimals="INF"
      id="f-557"
      unitRef="shares">402143</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="c-18"
      decimals="INF"
      id="f-558"
      unitRef="shares">367793</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c-24" decimals="-5" id="f-559" unitRef="usd">700000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c-18" decimals="-5" id="f-560" unitRef="usd">1000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 contextRef="c-6" decimals="-5" id="f-561" unitRef="usd">3000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-562">Loss Per Share &lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the computation of the numerator and the denominator used to calculate diluted loss per share for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.791%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.921%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,330,766)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,650,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss at subsidiary attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,279,320)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,570,241)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,298,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,563,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,298,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,563,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's anti-dilutive restricted shares and stock options outstanding were as follows for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.791%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.921%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive shares and options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-563">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the computation of the numerator and the denominator used to calculate diluted loss per share for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.791%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.921%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,330,766)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,650,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss at subsidiary attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,279,320)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,570,241)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,298,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,563,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,298,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,563,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="0" id="f-564" unitRef="usd">-6330766</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-5" decimals="0" id="f-565" unitRef="usd">-5650039</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="0" id="f-566" unitRef="usd">-51446</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-5" decimals="0" id="f-567" unitRef="usd">-79798</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="0" id="f-568" unitRef="usd">-6279320</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="0" id="f-569" unitRef="usd">-5570241</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-570" unitRef="shares">14298774</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="0" id="f-571" unitRef="shares">14563592</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-572" unitRef="shares">14298774</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="0" id="f-573" unitRef="shares">14563592</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-574">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's anti-dilutive restricted shares and stock options outstanding were as follows for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.791%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.921%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive shares and options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-575" unitRef="shares">452224</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-5" decimals="0" id="f-576" unitRef="shares">227050</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-577">Income Taxes&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the Company's net deferred tax assets at December&#160;31 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.573%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.575%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Tax Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss and tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,427,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,164,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment and intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,307,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,121,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,337,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;866,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,208,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve for expired product&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;937,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,156,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cumulative compensation costs incurred on deductible equity awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;635,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,417,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,708,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Tax Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,547,773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,150,935)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets, before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,869,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,557,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: deferred tax asset valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,869,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,557,784)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amount and year of expiration of the Company's federal and state net operating loss carryforwards as of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.561%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.606%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.607%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years of expiration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,756,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025-2042&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,709,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,333,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,405,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total federal and state net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,115,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,563,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax expense includes the following components for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.201%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.207%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.370%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s effective income tax rate for 2023 and 2022 reconciles with the federal statutory tax rate as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.302%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.235%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.237%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal tax expense at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income tax expense (net of federal income tax benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.58)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent differences associated with general business credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.96)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.76)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expiring tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.32)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred True-ups&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.73)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.23)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that it is not more likely than not that its net deferred tax assets will be realized.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As such, the net deferred tax assets are fully offset with a valuation allowance as of the periods ended December&#160;31, 2023 and  2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the Company has general business credit carryforwards of $1.3&#160;million. These credit carryforwards will expire in years 2024 through 2044. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.334%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.341%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years of expiration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025-2044&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,322,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total federal and state credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expects it will continue to pay minimal taxes in future periods through the continued utilization of net operating loss carryforwards, as it is able to achieve taxable income through its operations.&lt;/span&gt;&lt;/div&gt;The Company is no longer subject to U.S. federal tax examinations for tax years before 2020, and with few exceptions, the Company is not subject to examination by state tax authorities for tax years which ended before 2020. Loss carryforwards and credit carryforwards generated or utilized in years earlier than 2020 remain subject to examination and adjustment. The Company has no unrecognized tax benefits in 2023 and 2022.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-578">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the Company's net deferred tax assets at December&#160;31 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.573%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.575%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Tax Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss and tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,427,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,164,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment and intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,307,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,121,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,337,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;866,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,208,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve for expired product&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;937,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,156,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cumulative compensation costs incurred on deductible equity awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;635,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,417,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,708,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Tax Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,547,773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,150,935)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets, before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,869,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,557,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: deferred tax asset valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,869,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,557,784)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <cpix:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards contextRef="c-6" decimals="0" id="f-579" unitRef="usd">15427801</cpix:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards>
    <cpix:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards contextRef="c-7" decimals="0" id="f-580" unitRef="usd">16164754</cpix:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards>
    <cpix:DeferredTaxAssetsPropertyAndEquipmentAndIntangibles contextRef="c-6" decimals="0" id="f-581" unitRef="usd">71990</cpix:DeferredTaxAssetsPropertyAndEquipmentAndIntangibles>
    <cpix:DeferredTaxAssetsPropertyAndEquipmentAndIntangibles contextRef="c-7" decimals="0" id="f-582" unitRef="usd">264653</cpix:DeferredTaxAssetsPropertyAndEquipmentAndIntangibles>
    <cpix:DeferredTaxAssetOperatingLeaseLiabilities contextRef="c-6" decimals="0" id="f-583" unitRef="usd">1307178</cpix:DeferredTaxAssetOperatingLeaseLiabilities>
    <cpix:DeferredTaxAssetOperatingLeaseLiabilities contextRef="c-7" decimals="0" id="f-584" unitRef="usd">1121800</cpix:DeferredTaxAssetOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-6" decimals="0" id="f-585" unitRef="usd">2337091</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-7" decimals="0" id="f-586" unitRef="usd">866942</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-6" decimals="0" id="f-587" unitRef="usd">2208093</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-7" decimals="0" id="f-588" unitRef="usd">1481455</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts contextRef="c-6" decimals="0" id="f-589" unitRef="usd">147919</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts contextRef="c-7" decimals="0" id="f-590" unitRef="usd">145803</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <cpix:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct contextRef="c-6" decimals="0" id="f-591" unitRef="usd">616979</cpix:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct>
    <cpix:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct contextRef="c-7" decimals="0" id="f-592" unitRef="usd">654148</cpix:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct>
    <us-gaap:DeferredTaxAssetsInventory contextRef="c-6" decimals="0" id="f-593" unitRef="usd">185189</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory contextRef="c-7" decimals="0" id="f-594" unitRef="usd">217025</us-gaap:DeferredTaxAssetsInventory>
    <cpix:DeferredTaxAssetsDeferredCharges contextRef="c-6" decimals="0" id="f-595" unitRef="usd">937935</cpix:DeferredTaxAssetsDeferredCharges>
    <cpix:DeferredTaxAssetsDeferredCharges contextRef="c-7" decimals="0" id="f-596" unitRef="usd">1156150</cpix:DeferredTaxAssetsDeferredCharges>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-6" decimals="0" id="f-597" unitRef="usd">176926</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-7" decimals="0" id="f-598" unitRef="usd">635989</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-6" decimals="0" id="f-599" unitRef="usd">23417101</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-7" decimals="0" id="f-600" unitRef="usd">22708719</us-gaap:DeferredTaxAssetsGross>
    <cpix:DeferredTaxLiabilityOperatingLeaseRightOfUseAssets contextRef="c-6" decimals="0" id="f-601" unitRef="usd">1547773</cpix:DeferredTaxLiabilityOperatingLeaseRightOfUseAssets>
    <cpix:DeferredTaxLiabilityOperatingLeaseRightOfUseAssets contextRef="c-7" decimals="0" id="f-602" unitRef="usd">1150935</cpix:DeferredTaxLiabilityOperatingLeaseRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-6" decimals="0" id="f-603" unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-7" decimals="0" id="f-604" unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <cpix:NetDeferredTaxAssetsGross contextRef="c-6" decimals="0" id="f-605" unitRef="usd">21869328</cpix:NetDeferredTaxAssetsGross>
    <cpix:NetDeferredTaxAssetsGross contextRef="c-7" decimals="0" id="f-606" unitRef="usd">21557784</cpix:NetDeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-6" decimals="0" id="f-607" unitRef="usd">21869328</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-7" decimals="0" id="f-608" unitRef="usd">21557784</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-6" decimals="0" id="f-609" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-7" decimals="0" id="f-610" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock contextRef="c-1" id="f-611">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amount and year of expiration of the Company's federal and state net operating loss carryforwards as of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.561%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.606%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.607%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years of expiration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,756,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025-2042&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,709,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,333,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,405,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total federal and state net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,115,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,563,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
    <us-gaap:OperatingLossCarryforwards contextRef="c-135" decimals="0" id="f-612" unitRef="usd">0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-136" decimals="0" id="f-613" unitRef="usd">30756304</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-137" decimals="0" id="f-614" unitRef="usd">45709390</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-138" decimals="0" id="f-615" unitRef="usd">28333628</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-139" decimals="0" id="f-616" unitRef="usd">6405835</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-140" decimals="0" id="f-617" unitRef="usd">473278</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-141" decimals="0" id="f-618" unitRef="usd">52115225</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-142" decimals="0" id="f-619" unitRef="usd">59563210</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-620">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax expense includes the following components for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.201%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.207%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.370%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-1" decimals="0" id="f-621" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-5" decimals="0" id="f-622" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="0" id="f-623" unitRef="usd">45769</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-5" decimals="0" id="f-624" unitRef="usd">68850</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="0" id="f-625" unitRef="usd">45769</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-5" decimals="0" id="f-626" unitRef="usd">68850</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-1" decimals="0" id="f-627" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-5" decimals="0" id="f-628" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-1" decimals="0" id="f-629" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-5" decimals="0" id="f-630" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredOtherTaxExpenseBenefit contextRef="c-1" decimals="0" id="f-631" unitRef="usd">0</us-gaap:DeferredOtherTaxExpenseBenefit>
    <us-gaap:DeferredOtherTaxExpenseBenefit contextRef="c-5" decimals="0" id="f-632" unitRef="usd">0</us-gaap:DeferredOtherTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="0" id="f-633" unitRef="usd">45769</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-5" decimals="0" id="f-634" unitRef="usd">68850</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-635">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s effective income tax rate for 2023 and 2022 reconciles with the federal statutory tax rate as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.302%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.235%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.237%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal tax expense at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income tax expense (net of federal income tax benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.58)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent differences associated with general business credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.96)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.76)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expiring tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.32)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred True-ups&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.73)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.23)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="4" id="f-636" unitRef="number">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-5" decimals="4" id="f-637" unitRef="number">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="4" id="f-638" unitRef="number">-0.0058</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-5" decimals="4" id="f-639" unitRef="number">0.0211</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-1" decimals="4" id="f-640" unitRef="number">-0.0080</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-5" decimals="4" id="f-641" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="4" id="f-642" unitRef="number">-0.0496</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="4" id="f-643" unitRef="number">-0.2176</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="c-1" decimals="4" id="f-644" unitRef="number">-0.0651</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="c-5" decimals="4" id="f-645" unitRef="number">-0.0258</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-1" decimals="4" id="f-646" unitRef="number">-0.0332</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-5" decimals="4" id="f-647" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <cpix:EffectiveIncomeTaxRateReconciliationDeferredTrueUpsPercent contextRef="c-1" decimals="4" id="f-648" unitRef="number">-0.0716</cpix:EffectiveIncomeTaxRateReconciliationDeferredTrueUpsPercent>
    <cpix:EffectiveIncomeTaxRateReconciliationDeferredTrueUpsPercent contextRef="c-5" decimals="4" id="f-649" unitRef="number">0</cpix:EffectiveIncomeTaxRateReconciliationDeferredTrueUpsPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="4" id="f-650" unitRef="number">-0.0073</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-5" decimals="4" id="f-651" unitRef="number">-0.0123</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-143" decimals="-5" id="f-652" unitRef="usd">1300000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock contextRef="c-1" id="f-653">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.334%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.341%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years of expiration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025-2044&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,322,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total federal and state credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-144" decimals="0" id="f-654" unitRef="usd">18370</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-145" decimals="0" id="f-655" unitRef="usd">1322531</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-143" decimals="0" id="f-656" unitRef="usd">1340901</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-657">Stock-Based Compensation Plans&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has grants outstanding under two equity compensation plans. The 2007 Long-Term Incentive Compensation Plan (the "2007 Plan") and the 2007 Directors&#x2019; Incentive Plan (the "Directors&#x2019; Plan"), which were approved by shareholders, superseded the 1999 Stock Option Plan. Both plans are available for future grants of equity compensation awards to employees, consultants and directors. The 2007 Plan and the Directors&#x2019; Plan provide for the issuance of stock options, stock appreciation rights and restricted stock. Vesting is determined on a grant-by-grant basis in accordance with the terms of the plans and the related grant agreements. The Company has reserved 3.2 million shares of common stock for issuance under the 2007 Plan and 250,000 shares for issuance under the Directors&#x2019; Plan.  As of December&#160;31, 2023, the Company had 933,517 shares available for future grants under the 2007 Plan and 130,507 shares available under the Directors&#x2019; Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The exercise price of stock options is generally 100% of the fair market value of the underlying common stock on the grant date, except for incentive stock options granted to 10% shareholders, which the exercise price is no less than 110% of the fair market value.  The maximum contractual term of stock options is ten years from the grant date, except for incentive stock options granted to 10% shareholders, which is no more than five years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2011, the Company began issuing shares of restricted stock with no exercise price to employees and directors. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the grant date. Restricted stock issued to directors vests on the one year anniversary of the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock compensation expense is presented as a component of general and administrative expense in the consolidated statements of operations. Stock compensation expense was $0.4&#160;million for the years ended December&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2023, there was approximately $0.5 million of unrecognized compensation cost related to share-based payments, which is expected to be recognized over a weighted-average period of 1.85 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.176%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.442%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.286%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;of option shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;exercise price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-average remaining contractual term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,150)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The weighted-average grant-date fair value of options granted during  the years 2023 and 2022 was 1.16 and  1.29, respectively.  No options were vested and exercisable at December&#160;31, 2023.  The aggregate intrinsic value of options outstanding was minimal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options is calculated using the Black-Scholes (&#x201c;Black-Scholes-Merton&#x201d;, or &#x201c;BSM&#x201d;) option-pricing model on the grant date. Since 2012, the Company had been issuing Restricted Share Awards where the grant date Fair Value (&#x201c;FV&#x201d;) equaled the closing share price. The assumptions used in the Black-Scholes valuation to determine the FV of stock options were as follows at December 31: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.311%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.88&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Expected Term - The Company has estimated the expected life of its stock options using the simplified method, whereby the expected life equals the average of the vesting term and the original contractual term of the option. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Expected volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the Company&#x2019;s historical stock price volatility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Risk Free rate - The Company bases the risk-free interest rate assumption for equity awards on the rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Expected dividend yield - The Company&#x2019;s expected dividend yield assumption is zero as it has never paid dividends and has no present intention to do so in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.117%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.310%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.312%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-average grant-date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested, December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;568,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested/released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(171,655)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested, December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested/released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(157,360)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested, December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of restricted stock granted was based on the closing market price of the Company&#x2019;s common stock on the grant date. The fair value of restricted stock awards that vested during the years 2023 and 2022 was $0.3 million and $0.5 million, respectively.  At December&#160;31, 2023, there was approximately $0.2&#160;million of unrecognized compensation costs related to restricted stock awards, which is expected to be recognized over a weighted-average period of less than a year.  The restricted stock grants are included in the diluted weighted shares outstanding computation until they cliff-vest. Once vested they are included in the basic weighted shares outstanding computation.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants contextRef="c-1" decimals="INF" id="f-658" unitRef="plan">2</cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-146"
      decimals="-5"
      id="f-659"
      unitRef="shares">3200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-147"
      decimals="INF"
      id="f-660"
      unitRef="shares">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-146"
      decimals="INF"
      id="f-661"
      unitRef="shares">933517</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-147"
      decimals="INF"
      id="f-662"
      unitRef="shares">130507</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue
      contextRef="c-148"
      decimals="INF"
      id="f-663"
      unitRef="number">1</cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue>
    <cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent contextRef="c-1" decimals="2" id="f-664" unitRef="number">0.10</cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent>
    <cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue
      contextRef="c-149"
      decimals="INF"
      id="f-665"
      unitRef="number">1.10</cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-150" id="f-666">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent contextRef="c-1" decimals="2" id="f-667" unitRef="number">0.10</cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-151" id="f-668">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-152" id="f-669">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="0" id="f-670" unitRef="usd">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="0" id="f-671" unitRef="usd">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-153" decimals="-5" id="f-672" unitRef="usd">500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-154" id="f-673">P1Y10M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-674">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.176%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.442%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.286%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;of option shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;exercise price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-average remaining contractual term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,150)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-12"
      decimals="INF"
      id="f-675"
      unitRef="shares">170600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-12"
      decimals="2"
      id="f-676"
      unitRef="usdPerShare">3.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-5" decimals="INF" id="f-677" unitRef="shares">178950</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-678"
      unitRef="usdPerShare">2.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-5" decimals="INF" id="f-679" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-680"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="c-5" decimals="INF" id="f-681" unitRef="shares">29900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-682"
      unitRef="usdPerShare">2.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-7" decimals="INF" id="f-683" unitRef="shares">319650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-7"
      decimals="2"
      id="f-684"
      unitRef="usdPerShare">3.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-5" id="f-685">P6Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-686" unitRef="shares">192750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-687"
      unitRef="usdPerShare">2.06</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-688" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-689"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="c-1" decimals="INF" id="f-690" unitRef="shares">25150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-691"
      unitRef="usdPerShare">2.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-6" decimals="INF" id="f-692" unitRef="shares">487250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-6"
      decimals="2"
      id="f-693"
      unitRef="usdPerShare">2.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-694">P5Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-695"
      unitRef="usdPerShare">1.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-5"
      decimals="2"
      id="f-696"
      unitRef="usdPerShare">1.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-6" decimals="INF" id="f-697" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="c-1" decimals="INF" id="f-698" unitRef="shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-699">The assumptions used in the Black-Scholes valuation to determine the FV of stock options were as follows at December 31: &lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.311%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.88&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-155" id="f-700">P5Y8M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-156" id="f-701">P5Y10M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="c-155" decimals="4" id="f-702" unitRef="number">0.6587</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="c-156" decimals="4" id="f-703" unitRef="number">0.5438</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-155" decimals="4" id="f-704" unitRef="number">0.0345</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-156" decimals="4" id="f-705" unitRef="number">0.0229</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend contextRef="c-155" decimals="INF" id="f-706" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend contextRef="c-156" decimals="INF" id="f-707" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend contextRef="c-155" decimals="INF" id="f-708" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="c-1" id="f-709">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.117%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.310%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.312%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-average grant-date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested, December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;568,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested/released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(171,655)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested, December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested/released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(157,360)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested, December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-157"
      decimals="INF"
      id="f-710"
      unitRef="shares">568181</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-157"
      decimals="2"
      id="f-711"
      unitRef="usdPerShare">5.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-158"
      decimals="INF"
      id="f-712"
      unitRef="shares">65225</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-158"
      decimals="2"
      id="f-713"
      unitRef="usdPerShare">2.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-158"
      decimals="INF"
      id="f-714"
      unitRef="shares">171655</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-158"
      decimals="2"
      id="f-715"
      unitRef="usdPerShare">6.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-158"
      decimals="INF"
      id="f-716"
      unitRef="shares">66000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-158"
      decimals="2"
      id="f-717"
      unitRef="usdPerShare">4.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-159"
      decimals="INF"
      id="f-718"
      unitRef="shares">395751</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-159"
      decimals="2"
      id="f-719"
      unitRef="usdPerShare">4.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-160"
      decimals="INF"
      id="f-720"
      unitRef="shares">34250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-160"
      decimals="2"
      id="f-721"
      unitRef="usdPerShare">1.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-160"
      decimals="INF"
      id="f-722"
      unitRef="shares">157360</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-160"
      decimals="2"
      id="f-723"
      unitRef="usdPerShare">5.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-160"
      decimals="INF"
      id="f-724"
      unitRef="shares">12075</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-160"
      decimals="2"
      id="f-725"
      unitRef="usdPerShare">3.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-161"
      decimals="INF"
      id="f-726"
      unitRef="shares">260566</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-161"
      decimals="2"
      id="f-727"
      unitRef="usdPerShare">3.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-160" decimals="-5" id="f-728" unitRef="usd">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-158" decimals="-5" id="f-729" unitRef="usd">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-161" decimals="-5" id="f-730" unitRef="usd">200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="c-1" id="f-731">Employee Benefit Plans&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sponsors an employee benefit plan that was established on January&#160;1, 2006, the Cumberland Pharmaceuticals 401(k) Plan (the&#160;"Plan"), under Section&#160;401(k) of the Internal Revenue Code of 1986, as amended, for the benefit of all employees over the age of 21, having been employed by the Company for at least six months. The Plan provides that participants may contribute up to the maximum amount of their compensation as set forth by the Internal Revenue Service each year. Employee contributions are invested in various investment funds based upon elections made by the employees. During 2023 and 2022, the Company contributed approximately $0.08 million and $0.06 million, respectively, in each year to the Plan as an employer match of participant contributions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2012 and 2013, the Company established non-qualified unfunded deferred compensation plans that allow participants to defer receipt of a portion of their compensation. The liability under the plans, reflected in other long term liabilities in the consolidated balance sheets, was $2.9 million and $2.5 million as of December&#160;31, 2023 and 2022, respectively. The Company had assets consisting of company-owned life insurance contracts generally designated to pay benefits of the deferred compensation plans reflected in other assets in the consolidated balance sheet of $2.4 million and $2.3 million as of December&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <cpix:DefinedContributionPlanEligibilityMinimumEmployeeAge contextRef="c-1" id="f-732">P21Y</cpix:DefinedContributionPlanEligibilityMinimumEmployeeAge>
    <cpix:DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility contextRef="c-1" id="f-733">P6M</cpix:DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="c-1" decimals="-4" id="f-734" unitRef="usd">80000.00</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="c-5" decimals="-4" id="f-735" unitRef="usd">60000.00</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent contextRef="c-6" decimals="-5" id="f-736" unitRef="usd">2900000</us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent contextRef="c-7" decimals="-5" id="f-737" unitRef="usd">2500000</us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationPlanAssets contextRef="c-6" decimals="-5" id="f-738" unitRef="usd">2400000</us-gaap:DeferredCompensationPlanAssets>
    <us-gaap:DeferredCompensationPlanAssets contextRef="c-7" decimals="-5" id="f-739" unitRef="usd">2300000</us-gaap:DeferredCompensationPlanAssets>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-740">Leases&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 15, 2021, Cumberland entered into a lease, pursuant to which the Company leases approximately 16,903 rentable square feet of space at the new development Broadwest located in Nashville, Tennessee with 1600 West End Avenue Partners, LLC. The leased premise serves as the Company's new corporate headquarters. The initial term of the lease is one hundred fifty-seven (157) months, with two consecutive options to renew for a period of five years each, with the commencement date of October 25, 2022. This lease currently expires in November 2035.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is responsible for paying rent to the Landlord under the lease beginning three months after the commencement date. The Company pays a base rent of $33.06 per square foot of rentable space with a gradual rental rate increase of 2.5% for each year period thereafter of the prior year's base rental. In addition to the monthly base rent, the Company is responsible for its percentage share of the operating expenses of the building. The lease also provides for a tenant improvement allowance for the space. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 24, 2022, the CET lease with The Gateway to Nashville, LLC provided the notice of exercise to extend the lease for five years.  The lease is for approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee where CET operates the CET Life Sciences Center.The wet laboratory and office space is leased through April 2028. The Company also subleases a portion of the space under this lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also included within the right-of-use assets are start up expenditures related to a new supply agreement with Nephron Pharmaceuticals Corporation (&#x201c;Nephron&#x201d;).   These expenditures are classified as an embedded lease resulting in a right-of-use asset to be amortized over the life of the Nephron contract.  As of December&#160;31, 2023, the value of this asset was $1.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense is recognized over the expected term of the lease on a straight-line basis as a component of general and administrative expense. Rent expense and sublease income  as follows for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.361%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.207%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.210%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rent expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,304,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,159,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2016, the FASB issued ASU 2016-02. ASU 2016-02&#x2019;s core principle is to increase transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information. The primary effect of adopting ASU 2016-02 to the Company was to record right-of-use assets and obligations for the leases currently classified as operating leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities were recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As the Company&#x2019;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at October 25, 2022 and May 1, 2023. Incremental borrowing rates reflect the Company&#x2019;s estimated interest rates for collateralized borrowings over similar lease terms. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average remaining lease term for the Broadwest and Gateway leases is 10.42 years and 12.69 years for the years ended December 31, 2023 and 2022, respectively.. The weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments of both leases is 9.40% and 9.24% for the years ended December 31, 2023 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;    Lease Position&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2023 and 2022, the Company recorded the following on the Consolidated Balance Sheet: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.271%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.883%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.130%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.883%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,674,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,218,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.271%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.883%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.130%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.883%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,296,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,586,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,644,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,759,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $0.3 million and will be paid through the leases ending in April 2024. Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.585%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.883%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.132%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Maturity of Leases Liabilities at December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;863,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;909,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;740,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,847,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,131,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,487,363)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,644,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <cpix:LesseeOperatingLeaseLeasedArea contextRef="c-162" decimals="0" id="f-741" unitRef="sqft">16903</cpix:LesseeOperatingLeaseLeasedArea>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-162" id="f-742">P157M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <cpix:LesseeOperatingLeaseNumberOfRenewalTerms
      contextRef="c-163"
      decimals="INF"
      id="f-743"
      unitRef="renewalterm">2</cpix:LesseeOperatingLeaseNumberOfRenewalTerms>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-163" id="f-744">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <cpix:LesseeOperatingLeaseBaseRent
      contextRef="c-162"
      decimals="2"
      id="f-745"
      unitRef="usdPerSqft">33.06</cpix:LesseeOperatingLeaseBaseRent>
    <cpix:LesseeOperatingLeaseRentIncrease contextRef="c-164" decimals="3" id="f-746" unitRef="number">0.025</cpix:LesseeOperatingLeaseRentIncrease>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c-165" id="f-747">P5Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:AreaOfRealEstateProperty contextRef="c-166" decimals="0" id="f-748" unitRef="sqft">14200</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-167" decimals="-5" id="f-749" unitRef="usd">1000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock contextRef="c-1" id="f-750">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense is recognized over the expected term of the lease on a straight-line basis as a component of general and administrative expense. Rent expense and sublease income  as follows for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.361%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.207%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.210%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rent expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,304,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,159,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock>
    <us-gaap:OperatingLeaseExpense contextRef="c-1" decimals="0" id="f-751" unitRef="usd">1304865</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-5" decimals="0" id="f-752" unitRef="usd">1159695</us-gaap:OperatingLeaseExpense>
    <us-gaap:SubleaseIncome contextRef="c-1" decimals="0" id="f-753" unitRef="usd">544138</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-5" decimals="0" id="f-754" unitRef="usd">529411</us-gaap:SubleaseIncome>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-168" id="f-755">P10Y5M1D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-169" id="f-756">P12Y8M8D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="c-168"
      decimals="INF"
      id="f-757"
      unitRef="number">0.0940</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="c-169"
      decimals="INF"
      id="f-758"
      unitRef="number">0.0924</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <cpix:AssetsAndLiabilitiesLesseeTableTextBlock contextRef="c-1" id="f-759">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2023 and 2022, the Company recorded the following on the Consolidated Balance Sheet: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.271%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.883%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.130%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.883%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,674,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,218,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.271%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.883%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.130%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.883%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,296,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,586,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,644,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,759,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cpix:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-6" decimals="0" id="f-760" unitRef="usd">6674394</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-7" decimals="0" id="f-761" unitRef="usd">5218403</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-6" decimals="0" id="f-762" unitRef="usd">348092</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-7" decimals="0" id="f-763" unitRef="usd">172910</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-6" decimals="0" id="f-764" unitRef="usd">5296247</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-7" decimals="0" id="f-765" unitRef="usd">4586301</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c-6" decimals="0" id="f-766" unitRef="usd">5644339</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="c-7" decimals="0" id="f-767" unitRef="usd">4759211</us-gaap:OperatingLeaseLiability>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived contextRef="c-6" decimals="-5" id="f-768" unitRef="usd">300000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-769">&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.585%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.883%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.132%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Maturity of Leases Liabilities at December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;863,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;909,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;740,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,847,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,131,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,487,363)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,644,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-6" decimals="0" id="f-770" unitRef="usd">863320</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-6" decimals="0" id="f-771" unitRef="usd">836100</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-6" decimals="0" id="f-772" unitRef="usd">909911</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-6" decimals="0" id="f-773" unitRef="usd">934180</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-6" decimals="0" id="f-774" unitRef="usd">740791</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-6" decimals="0" id="f-775" unitRef="usd">4847400</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-6" decimals="0" id="f-776" unitRef="usd">9131702</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-6" decimals="0" id="f-777" unitRef="usd">3487363</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-6" decimals="0" id="f-778" unitRef="usd">5644339</us-gaap:OperatingLeaseLiability>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="c-1" id="f-779">Market Concentrations&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s principal financial instruments subject to potential concentration of credit risk are accounts receivable, which are unsecured, and cash equivalents. The Company&#x2019;s cash equivalents consist primarily of money market funds. Certain bank deposits may be in excess of the insurance limits provided by the Federal Deposit Insurance Corporation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s primary customers are wholesale pharmaceutical distributors in the U.S. &#160;Total revenues by customer for each customer representing 10% or more of consolidated revenues are summarized below for the years ended December 31: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.592%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.592%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.594%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounts receivable, net of allowances, due from the customers representing 10% or more of consolidated revenue was 62.3% and 51.8% at December&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="c-1" id="f-780">Total revenues by customer for each customer representing 10% or more of consolidated revenues are summarized below for the years ended December 31: &lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.592%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.592%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.594%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-170" decimals="2" id="f-781" unitRef="number">0.29</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-171" decimals="2" id="f-782" unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-172" decimals="2" id="f-783" unitRef="number">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-173" decimals="2" id="f-784" unitRef="number">0.29</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-174" decimals="2" id="f-785" unitRef="number">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-175" decimals="2" id="f-786" unitRef="number">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-176" decimals="4" id="f-787" unitRef="number">0.623</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-177" decimals="4" id="f-788" unitRef="number">0.518</us-gaap:ConcentrationRiskPercentage1>
    <cpix:ManufacturingAndSupplyAgreementsTextBlock contextRef="c-1" id="f-789">Manufacturing and Supply Agreements&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes one or two primary suppliers to manufacture each of its products and product candidates. Although there are a limited number of manufacturers of pharmaceutical products, the Company believes it could utilize other suppliers to manufacture its prescription products on comparable terms. A change in suppliers, problems with its third-party manufacturing operations or related production capacity, or contract disputes with suppliers could cause a delay in manufacturing or shipment of finished goods and possible loss of sales, which could adversely affect operating results.&lt;/span&gt;&lt;/div&gt;</cpix:ManufacturingAndSupplyAgreementsTextBlock>
    <cpix:ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct
      contextRef="c-178"
      decimals="INF"
      id="f-790"
      unitRef="supplier">1</cpix:ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct>
    <cpix:ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct
      contextRef="c-179"
      decimals="INF"
      id="f-791"
      unitRef="supplier">2</cpix:ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct>
    <cpix:EmploymentAgreementsTextBlock contextRef="c-1" id="f-792">Employment Agreements&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into employment agreements with all its full-time employees. Each employment agreement provides for a salary for services performed, a potential annual bonus and, if applicable, a grant of restricted common shares pursuant to a restricted stock and incentive stock option agreement.&lt;/span&gt;&lt;/div&gt;</cpix:EmploymentAgreementsTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-793">Commitments and Contingencies&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with its licensing agreements for Caldolor,  the Company is required to pay royalties based on net sales over the life of the product. Royalty expense is recognized as a component of selling and marketing expense in the period that revenue is recognized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of Vibativ, the Company is required to pay royalties based on net sales of the product. At the purchase date, Cumberland recorded the fair value of this liability and will continue to evaluate the liability each period and the royalty expense is recognized as a component of selling and marketing expense in the period that the change in fair value is recognized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of Sancuso, the Company is required to pay up to $3.5&#160;million in milestones and tiered royalties ranging from 10% to 5% on U.S. net product sales for ten years.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland has a number of patents issued through the United States Patent and Trademark Office (the &#x201c;USPTO&#x201d;) including U.S. Patent number 8,148,356 (the &#x201c;356 Acetadote Patent&#x201d;) which is assigned to the Company. The claims of the 356 Acetadote Patent encompass the new Acetadote formulation and include composition of matter claims. Following its issuance, the 356 Acetadote Patent was listed in the FDA Orange Book. The 356 Acetadote Patent is scheduled to expire in May 2026, which time period includes a 270-day patent term adjustment granted by the USPTO.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since 2012, Cumberland has continued to vigorously defend and protect its Acetadote product and related intellectual property rights including the use of all its legal options. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Melinta Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 2, 2022, the Company filed an action for breach of contract against Melinta Therapeutics, LLC and Targanta Therapeutics Corporation (collectively, the &#x201c;Defendants&#x201d;) in the United States District Court for the Southern District of New York (Case No. 1:22-cv-00915-VM). The Company and the Defendants are parties to an agreement (the &#x201c;Agreement&#x201d;), pursuant to which the Defendants have a license to develop and commercialize products under certain Company patents, in exchange for the Defendants paying the Company certain milestone payments and royalties on net sales of the licensed products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Specifically, the Agreement requires the Defendants to, among other things, make a $500,000 payment to the Company within 30 days following the first filing of an sNDA in relation to the Product (as defined by the Agreement) and a $500,000 payment to the Company following the approval of the first sNDA in relation to the Product. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;After Defendants disclosed the domiciles of its limited partners to the Company, as required by the Court, on October 24, 2022, the action for breach of contract was refiled in the Supreme Court of the State of New York, County of New York (Index No. 654234/2022) on November 7, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The complaint alleges that, despite the Defendants filing an NDA and sNDA for the Product and receiving FDA approval for both applications, the Defendants failed to make the required total of $1&#160;million in milestone payments to the Company. The Company was seeking damages in the amount of no less than $1&#160;million, pre- and post-judgment interest under N.Y. C.P.L.R. &#xa7; 5001, costs, and such further relief as the court deems just and proper.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;     On April 18, 2023 the state court ruled in favor of the Company.  On June 16, 2023, the Company received consideration related to the breach of contract action with the Defendants that finalized a settlement agreement that was entered into by the Company and the Defendants to close the case.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <cpix:PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold contextRef="c-47" decimals="-5" id="f-794" unitRef="usd">3500000</cpix:PaymentsToAcquireBusinessTieredRoyaltyPaymentsThreshold>
    <cpix:PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage contextRef="c-51" decimals="2" id="f-795" unitRef="number">0.10</cpix:PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage>
    <cpix:PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage contextRef="c-180" decimals="2" id="f-796" unitRef="number">0.05</cpix:PaymentsToAcquireBusinessTieredRoyaltyPaymentsPercentage>
    <cpix:PaymentsToAcquireBusinessTieredRoyaltyPaymentsTerm contextRef="c-47" id="f-797">P10Y</cpix:PaymentsToAcquireBusinessTieredRoyaltyPaymentsTerm>
    <cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable contextRef="c-181" decimals="-3" id="f-798" unitRef="usd">500000</cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable>
    <cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable contextRef="c-182" decimals="-3" id="f-799" unitRef="usd">500000</cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable>
    <cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable contextRef="c-183" decimals="-6" id="f-800" unitRef="usd">1000000</cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable>
    <us-gaap:ProceedsFromLegalSettlements contextRef="c-80" decimals="-6" id="f-801" unitRef="usd">1000000</us-gaap:ProceedsFromLegalSettlements>
    <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="c-1" id="f-802">Quarterly Financial Information (Unaudited)&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the unaudited operating results for each fiscal quarter of 2023 and 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.605%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;First&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Second&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Third&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fourth&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,224,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,888,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,085,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,353,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,552,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,531,678)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,866,603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,179,239)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,554,661)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;862,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,063,219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,301,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,330,766)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;192,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;872,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,049,298)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,294,406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,279,320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings (loss) per share attributable to common shareholders &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,175,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,299,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,413,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,123,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,010,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,291,999)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,846,538)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(288,588)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,277,804)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,704,929)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,402,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,364,666)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(423,226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,459,714)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,650,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,385,253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,335,620)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(408,639)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,440,729)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,570,241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss per share attributable to common shareholders &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Due to the nature of interim earnings per share calculations, the sum of the quarterly earnings (loss) per share amounts may not equal the reported earnings (loss) per share for the full year.&lt;/span&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="c-1" id="f-803">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the unaudited operating results for each fiscal quarter of 2023 and 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.605%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;First&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Second&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Third&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fourth&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,224,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,888,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,085,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,353,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,552,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,531,678)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,866,603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,179,239)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,554,661)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;862,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,063,219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,301,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,330,766)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;192,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;872,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,049,298)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,294,406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,279,320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings (loss) per share attributable to common shareholders &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,175,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,299,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,413,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,123,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,010,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,291,999)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,846,538)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(288,588)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,277,804)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,704,929)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,402,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,364,666)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(423,226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,459,714)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,650,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,385,253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,335,620)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(408,639)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,440,729)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,570,241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss per share attributable to common shareholders &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Due to the nature of interim earnings per share calculations, the sum of the quarterly earnings (loss) per share amounts may not equal the reported earnings (loss) per share for the full year.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-184" decimals="0" id="f-804" unitRef="usd">9224638</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-80" decimals="0" id="f-805" unitRef="usd">10888877</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-185" decimals="0" id="f-806" unitRef="usd">10085926</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-4" decimals="0" id="f-807" unitRef="usd">9353066</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="0" id="f-808" unitRef="usd">39552507</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss contextRef="c-184" decimals="0" id="f-809" unitRef="usd">-1531678</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-80" decimals="0" id="f-810" unitRef="usd">22859</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-185" decimals="0" id="f-811" unitRef="usd">-1866603</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-4" decimals="0" id="f-812" unitRef="usd">-6179239</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="0" id="f-813" unitRef="usd">-9554661</us-gaap:OperatingIncomeLoss>
    <us-gaap:ProfitLoss contextRef="c-184" decimals="0" id="f-814" unitRef="usd">172286</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-80" decimals="0" id="f-815" unitRef="usd">862154</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-185" decimals="0" id="f-816" unitRef="usd">-1063219</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-4" decimals="0" id="f-817" unitRef="usd">-6301987</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="0" id="f-818" unitRef="usd">-6330766</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLoss contextRef="c-184" decimals="0" id="f-819" unitRef="usd">192184</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-80" decimals="0" id="f-820" unitRef="usd">872200</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-185" decimals="0" id="f-821" unitRef="usd">-1049298</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-4" decimals="0" id="f-822" unitRef="usd">-6294406</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="0" id="f-823" unitRef="usd">-6279320</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-184"
      decimals="2"
      id="f-824"
      unitRef="usdPerShare">0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-80"
      decimals="2"
      id="f-825"
      unitRef="usdPerShare">0.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-185"
      decimals="2"
      id="f-826"
      unitRef="usdPerShare">-0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-4"
      decimals="2"
      id="f-827"
      unitRef="usdPerShare">-0.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-828"
      unitRef="usdPerShare">-0.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-184"
      decimals="2"
      id="f-829"
      unitRef="usdPerShare">0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-80"
      decimals="2"
      id="f-830"
      unitRef="usdPerShare">0.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-185"
      decimals="2"
      id="f-831"
      unitRef="usdPerShare">-0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-4"
      decimals="2"
      id="f-832"
      unitRef="usdPerShare">-0.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-833"
      unitRef="usdPerShare">-0.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-186" decimals="0" id="f-834" unitRef="usd">11175045</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-187" decimals="0" id="f-835" unitRef="usd">10299152</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-188" decimals="0" id="f-836" unitRef="usd">11413072</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-189" decimals="0" id="f-837" unitRef="usd">9123680</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="0" id="f-838" unitRef="usd">42010949</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss contextRef="c-186" decimals="0" id="f-839" unitRef="usd">-1291999</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-187" decimals="0" id="f-840" unitRef="usd">-1846538</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-188" decimals="0" id="f-841" unitRef="usd">-288588</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-189" decimals="0" id="f-842" unitRef="usd">-2277804</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="0" id="f-843" unitRef="usd">-5704929</us-gaap:OperatingIncomeLoss>
    <us-gaap:ProfitLoss contextRef="c-186" decimals="0" id="f-844" unitRef="usd">-1402433</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-187" decimals="0" id="f-845" unitRef="usd">-1364666</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-188" decimals="0" id="f-846" unitRef="usd">-423226</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-189" decimals="0" id="f-847" unitRef="usd">-2459714</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-5" decimals="0" id="f-848" unitRef="usd">-5650039</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLoss contextRef="c-186" decimals="0" id="f-849" unitRef="usd">-1385253</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-187" decimals="0" id="f-850" unitRef="usd">-1335620</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-188" decimals="0" id="f-851" unitRef="usd">-408639</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-189" decimals="0" id="f-852" unitRef="usd">-2440729</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="0" id="f-853" unitRef="usd">-5570241</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-186"
      decimals="2"
      id="f-854"
      unitRef="usdPerShare">-0.09</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-187"
      decimals="2"
      id="f-855"
      unitRef="usdPerShare">-0.09</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-188"
      decimals="2"
      id="f-856"
      unitRef="usdPerShare">-0.03</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-189"
      decimals="2"
      id="f-857"
      unitRef="usdPerShare">-0.17</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-5"
      decimals="2"
      id="f-858"
      unitRef="usdPerShare">-0.38</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-186"
      decimals="2"
      id="f-859"
      unitRef="usdPerShare">-0.09</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-187"
      decimals="2"
      id="f-860"
      unitRef="usdPerShare">-0.09</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-188"
      decimals="2"
      id="f-861"
      unitRef="usdPerShare">-0.03</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-189"
      decimals="2"
      id="f-862"
      unitRef="usdPerShare">-0.17</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-5"
      decimals="2"
      id="f-863"
      unitRef="usdPerShare">-0.38</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock contextRef="c-1" id="f-864">&lt;div style="margin-top:8pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Schedule II&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation and Qualifying Accounts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Years ended December&#160;31, 2023 and 2022.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.921%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.957%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.921%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.585%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;beginning&#160;of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Charged to&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;costs and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Charged&#160;to&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;accounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;end&#160;of&#160;period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for uncollectible amounts, cash discounts, chargebacks, and credits issued for damaged products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;For the years ended &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,673,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,417,977)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;596,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;596,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,953,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,969,671)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;579,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance for deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;For the years ended &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,761,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,795,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,557,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,557,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,869,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Composed of actual returns and credits for chargebacks and cash discounts.&lt;/span&gt;&lt;/div&gt;</srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-190" decimals="0" id="f-865" unitRef="usd">340964</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-191" decimals="0" id="f-866" unitRef="usd">6673104</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts contextRef="c-191" decimals="0" id="f-867" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-191" decimals="0" id="f-868" unitRef="usd">6417977</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-192" decimals="0" id="f-869" unitRef="usd">596091</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-192" decimals="0" id="f-870" unitRef="usd">596091</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-193" decimals="0" id="f-871" unitRef="usd">5953142</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts contextRef="c-193" decimals="0" id="f-872" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-193" decimals="0" id="f-873" unitRef="usd">5969671</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-194" decimals="0" id="f-874" unitRef="usd">579562</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-195" decimals="0" id="f-875" unitRef="usd">19761922</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-196" decimals="0" id="f-876" unitRef="usd">1795862</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts contextRef="c-196" decimals="0" id="f-877" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-196" decimals="0" id="f-878" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-197" decimals="0" id="f-879" unitRef="usd">21557784</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-197" decimals="0" id="f-880" unitRef="usd">21557784</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-198" decimals="0" id="f-881" unitRef="usd">311544</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts contextRef="c-198" decimals="0" id="f-882" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-198" decimals="0" id="f-883" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-199" decimals="0" id="f-884" unitRef="usd">21869328</us-gaap:ValuationAllowancesAndReservesBalance>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
